<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22236802</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>379</Volume><Issue>9815</Issue><PubDate><Year>2012</Year><Month>Feb</Month><Day>11</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial.</ArticleTitle><Pagination><StartPage>528</StartPage><EndPage>536</EndPage><MedlinePgn>528-36</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(11)61676-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Prevalence of Alzheimer's disease in people with Down's syndrome is very high, and many such individuals who are older than 40 years have pathological changes characteristic of Alzheimer's disease. Evidence to support treatment with Alzheimer's drugs is inadequate, although memantine is beneficial in transgenic mice. We aimed to assess safety and efficacy of memantine on cognition and function in individuals with Down's syndrome.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In our prospective randomised double-blind trial, we enrolled adults (&gt;40 years) with karyotypic or clinically diagnosed Down's syndrome, with and without dementia, at four learning disability centres in the UK and Norway. We randomly allocated participants (1:1) to receive memantine or placebo for 52 weeks by use of a computer-generated sequence and a minimisation algorithm to ensure balanced allocation for five prognostic factors (sex, dementia, age group, total Down's syndrome attention, memory, and executive function scales [DAMES] score, and centre). The primary outcome was change in cognition and function, measured with DAMES scores and the adaptive behaviour scale (ABS) parts I and II. We analysed differences in DAMES and ABS scores between groups with analyses of covariance or quantile regression in all patients who completed the 52 week assessment and had available follow-up data. This study is registered, number ISRCTN47562898.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">We randomly allocated 88 patients to receive memantine (72 [82%] had DAMES data and 75 [85%] had ABS data at 52 weeks) and 85 to receive placebo (74 [87%] and 73 [86%]). Both groups declined in cognition and function but rates did not differ between groups for any outcomes. After adjustment for baseline score, there were non-significant differences between groups of -4&#xb7;1 (95% CI -13&#xb7;1 to 4&#xb7;8) in DAMES scores, -8&#xb7;5 (-20&#xb7;1 to 3&#xb7;1) in ABS I scores, and 2&#xb7;0 (-7&#xb7;2 to 11&#xb7;3) in ABS II scores, all in favour of controls. 10 (11%) of 88 participants in the memantine group and six (7%) of 85 controls had serious adverse events (p=0&#xb7;33). Five participants in the memantine group and four controls died from serious adverse events (p=0&#xb7;77).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">There is a striking absence of evidence about pharmacological treatment of cognitive impairment and dementia in people older than 40 years with Down's syndrome. Despite promising indications, memantine is not an effective treatment. Therapies that are effective for Alzheimer's disease are not necessarily effective in this group of patients.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Lundbeck.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hanney</LastName><ForeName>Marisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Wolfson Centre for Age-Related Diseases, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prasher</LastName><ForeName>Vee</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Emma L</ForeName><Initials>EL</Initials></Author><Author ValidYN="Y"><LastName>Aarsland</LastName><ForeName>Dag</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Corbett</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lawrence</LastName><ForeName>Dale</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Ly-Mee</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Tyrer</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Francis</LastName><ForeName>Paul T</ForeName><Initials>PT</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Tony</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Bullock</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Clive</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><CollectiveName>MEADOWS trial researchers</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ISRCTN</DataBankName><AccessionNumberList><AccessionNumber>ISRCTN47562898</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>6384-92-5</RegistryNumber><NameOfSubstance UI="D016202">N-Methylaspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2012 Feb 11;379(9815):498-500. doi: 10.1016/S0140-6736(11)61929-6.</RefSource><PMID Version="1">22236803</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016202" MajorTopicYN="N">N-Methylaspartate</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Fryer</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bakala</LastName><ForeName>Alina</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adams</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sikabofori</LastName><ForeName>Tonye</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilkinson</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mollinson</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kossakowski</LastName><ForeName>Katja</ForeName><Initials>K</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22236802</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(11)61676-0</ArticleId><ArticleId IdType="pii">S0140-6736(11)61676-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22213792</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3636</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Cerebrospinal fluid levels of &#x3b2;-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.</ArticleTitle><Pagination><StartPage>98</StartPage><EndPage>106</EndPage><MedlinePgn>98-106</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archgenpsychiatry.2011.155</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Early detection of prodromal Alzheimer disease (AD) is important because new disease-modifying therapies are most likely to be effective when initiated during the early stages of disease.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess the ability of the cerebrospinal fluid (CSF) biomarkers total tau (T-tau), phosphorylated tau (P-tau), and &#x3b2;-amyloid 1-42 (A&#x3b2;42) to predict future development of AD dementia within 9.2 years in patients with mild cognitive impairment (MCI) and to compare CSF biomarkers between early and late converters to AD.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">A clinical study with a median follow-up of 9.2 years (range, 4.1-11.8 years).</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Memory disorder clinic. Patients A total of 137 patients with MCI who underwent lumbar puncture at baseline. MAIN OUTCOME MEASURE Conversion to AD dementia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During follow-up, 72 patients (53.7%) developed AD and 21 (15.7%) progressed to other forms of dementia. At baseline, CSF A&#x3b2;42 levels were reduced and T-tau and P-tau levels were elevated in patients who converted to AD during follow-up compared with nonconverters (P &lt; .001). Baseline CSF A&#x3b2;42 levels were equally reduced in patients with MCI who converted to AD within 0 to 5 years (early converters) compared with those who converted between 5 and 10 years (late converters). However, CSF T-tau and P-tau levels were significantly higher in early converters vs late converters. A baseline A&#x3b2;42:P-tau ratio predicted the development of AD within 9.2 years with a sensitivity of 88%, specificity of 90%, positive predictive value of 91%, and negative predictive value of 86%.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Approximately 90% of patients with MCI and pathologic CSF biomarker levels at baseline develop AD within 9 to 10 years. Levels of A&#x3b2;42 are already fully decreased at least 5 to 10 years before conversion to AD dementia, whereas T-tau and P-tau seem to be later markers. These results provide direct support in humans for the hypothesis that altered A&#x3b2; metabolism precedes tau-related pathology and neuronal degeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Buchhave</LastName><ForeName>Peder</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Neuropsychiatric Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minthon</LastName><ForeName>Lennart</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Wallin</LastName><ForeName>Asa K</ForeName><Initials>AK</Initials></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22213792</ArticleId><ArticleId IdType="doi">10.1001/archgenpsychiatry.2011.155</ArticleId><ArticleId IdType="pii">69/1/98</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22232050</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Jan</Month><Day>10</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial.</ArticleTitle><Pagination><StartPage>91</StartPage><EndPage>101</EndPage><MedlinePgn>91-101</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0b013e31823efcbb</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To preliminarily assess the safety and efficacy of transdermal nicotine therapy on cognitive performance and clinical status in subjects with mild cognitive impairment (MCI).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Nonsmoking subjects with amnestic MCI were randomized to transdermal nicotine (15 mg per day or placebo) for 6 months. Primary outcome variables were attentional improvement assessed with Connors Continuous Performance Test (CPT), clinical improvement as measured by clinical global impression, and safety measures. Secondary measures included computerized cognitive testing and patient and observer ratings.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 74 subjects enrolled, 39 were randomized to nicotine and 35 to placebo. 67 subjects completed (34 nicotine, 33 placebo). The primary cognitive outcome measure (CPT) showed a significant nicotine-induced improvement. There was no statistically significant effect on clinician-rated global improvement. The secondary outcome measures showed significant nicotine-associated improvements in attention, memory, and psychomotor speed, and improvements were seen in patient/informant ratings of cognitive impairment. Safety and tolerability for transdermal nicotine were excellent.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study demonstrated that transdermal nicotine can be safely administered to nonsmoking subjects with MCI over 6 months with improvement in primary and secondary cognitive measures of attention, memory, and mental processing, but not in ratings of clinician-rated global impression. We conclude that this initial study provides evidence for nicotine-induced cognitive improvement in subjects with MCI; however, whether these effects are clinically important will require larger studies.</AbstractText><AbstractText Label="CLASSIFICATION OF EVIDENCE" NlmCategory="METHODS">This study provides Class I evidence that 6 months of transdermal nicotine (15 mg/day) improves cognitive test performance, but not clinical global impression of change, in nonsmoking subjects with amnestic MCI.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Newhouse</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinical Neuroscience Research Unit, Department of Psychiatry, University of Vermont College of Medicine, Burlington, USA. Paul.Newhouse@vanderbilt.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kellar</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Wesnes</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Coderre</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Pfaff</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Wilkins</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Howard</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>E D</ForeName><Initials>ED</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>M01 RR00109</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG22462</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018722">Nicotinic Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>6M3C89ZY6R</RegistryNumber><NameOfSubstance UI="D009538">Nicotine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Expert Rev Neurother. 2012 May;12(5):531-3. doi: 10.1586/ern.12.36.</RefSource><PMID Version="1">22550981</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000279" MajorTopicYN="N">Administration, Cutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001835" MajorTopicYN="N">Body Weight</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011939" MajorTopicYN="N">Mental Recall</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009538" MajorTopicYN="N">Nicotine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018722" MajorTopicYN="N">Nicotinic Agonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055986" MajorTopicYN="N">Vital Signs</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>1</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22232050</ArticleId><ArticleId IdType="pmc">PMC3466669</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e31823efcbb</ArticleId><ArticleId IdType="pii">78/2/91</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Crook T, Bartus T, Ferris S, Whitehouse P. Age associated memory impairment: proposed diagnostic criteria and measures of clinical change: report of a National Institute of Mental Health Work Group. Dev Neurobiol 1986; 2: 261&#x2013; 276</Citation></Reference><Reference><Citation>Dawe B, Procter A, Philpot M. Concepts of mild memory impairment in the elderly and their relationship to dementia: a review. Int J Geriatr Psychiatry 1992; 7: 473&#x2013; 479</Citation></Reference><Reference><Citation>Petersen RC. Normal aging, mild cognitive impairment, and early Alzheimer's disease. Neurologist 1995; 1: 326&#x2013; 344</Citation></Reference><Reference><Citation>Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58: 1985&#x2013; 1992</Citation><ArticleIdList><ArticleId IdType="pubmed">11735772</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin ED. Nicotinic receptor subtypes and cognitive function. J Neurobiol 2002; 53: 633&#x2013; 640</Citation><ArticleIdList><ArticleId IdType="pubmed">12436426</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehouse PJ, Martino AM, Antuono PG, et al. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res 1986; 371: 146&#x2013; 151</Citation><ArticleIdList><ArticleId IdType="pubmed">3708340</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry E. Cholinergic signaling in Alzheimer disease: therapeutic strategies. Alzheimer Dis Assoc Disord 1995; 9: 1&#x2013; 2</Citation><ArticleIdList><ArticleId IdType="pubmed">8534417</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordberg A. Imaging of nicotinic receptors in human brain. In: Domino EF, ed. Brain Imaging of Nicotine and Tobacco Smoking. Ann Arbor, MI: Npp Books; 1995: 45&#x2013;57</Citation></Reference><Reference><Citation>Nordberg A. Clinical studies in Alzheimer patients with positron emission tomography. Behav Brain Res 1993; 57: 215&#x2013; 224</Citation><ArticleIdList><ArticleId IdType="pubmed">7906947</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordberg A. In vivo detection of neurotransmitter changes in Alzheimer's disease. Ann NY Acad Sci 1993; 695: 27&#x2013; 33</Citation><ArticleIdList><ArticleId IdType="pubmed">7902055</ArticleId></ArticleIdList></Reference><Reference><Citation>Heishman SJ, Kleykamp BA, Singleton EG. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology 2010; 210: 453&#x2013; 469</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3151730</ArticleId><ArticleId IdType="pubmed">20414766</ArticleId></ArticleIdList></Reference><Reference><Citation>Provost SC, Woodward R. Effects of nicotine gum on repeated administration of the Stroop test. Psychopharmacology 1991; 104: 536&#x2013; 540</Citation><ArticleIdList><ArticleId IdType="pubmed">1780425</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusted J, Graupner L, O'Connell N, Nicholls C. Does nicotine improve cognitive function? Psychopharmacology 1994; 115: 547&#x2013; 549</Citation><ArticleIdList><ArticleId IdType="pubmed">7871101</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesnes K, Revell A. The separate and combined effects of scopolamine and nicotine on human information processing. Psychopharmacology 1984; 84: 5&#x2013; 11</Citation><ArticleIdList><ArticleId IdType="pubmed">6436890</ArticleId></ArticleIdList></Reference><Reference><Citation>Newhouse PA, Sunderland T, Tariot PN, et al. Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology 1988; 95: 171&#x2013; 175</Citation><ArticleIdList><ArticleId IdType="pubmed">3137593</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones GMM, Sahakian BJ, Levy R, Warburton DM, Gray JA. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology 1992; 108: 485&#x2013; 494</Citation><ArticleIdList><ArticleId IdType="pubmed">1410164</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahakian BJ, Jones GMM. The effects of nicotine on attention, information processing, and working memory in patients with dementia of the Alzheimer type. In: Adlkofer F, Thruau K, eds. Effects of Nicotine on Biological Systems. Basel: Birkhauser Verlag; 1991: 623&#x2013; 230</Citation></Reference><Reference><Citation>White HK, Levin ED. Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. Psychopharmacology 1999; 143: 158&#x2013; 165</Citation><ArticleIdList><ArticleId IdType="pubmed">10326778</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson AL, Langley LK, Monley J, et al. Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety. Pharmacol Biochem Behav 1995; 51: 509&#x2013; 514</Citation><ArticleIdList><ArticleId IdType="pubmed">7667377</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352: 2379&#x2013; 2388</Citation><ArticleIdList><ArticleId IdType="pubmed">15829527</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L. Clinical Dementia Rating (CDR). Psychopharmacol Bull 1988; 24: 637&#x2013; 639</Citation><ArticleIdList><ArticleId IdType="pubmed">3249765</ArticleId></ArticleIdList></Reference><Reference><Citation>Robins LN, Helzer JE, Croughan J, Ratcliff KS. National Institute of Mental Health Diagnostic Interview Schedule: history, diagnostics, and validity. Arch Gen Psychiatry 1981; 38: 381&#x2013; 389</Citation><ArticleIdList><ArticleId IdType="pubmed">6260053</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher D, Nies G, Thompson LW. Reliability of the Beck Depression Inventory with older adults. J Consult Clin Psychol 1982; 50: 152&#x2013; 153</Citation><ArticleIdList><ArticleId IdType="pubmed">7056913</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams JBW. A structured interview guide for the Hamilton depression rating scale. Arch Gen Psychiatry 1988; 45: 742&#x2013; 747</Citation><ArticleIdList><ArticleId IdType="pubmed">3395203</ArticleId></ArticleIdList></Reference><Reference><Citation>Conners CK. The Continuous Performance Test (CPT): Use as a Diagnostic Tool and Measure of Treatment Outcome. Los Angeles, CA: 1994.</Citation></Reference><Reference><Citation>Conners CK, ed. The Continuous Performance Test, V30. Toronto: Multi-Health Systems; 1995.</Citation></Reference><Reference><Citation>Wesnes K, Warburton DM. The effects of cigarette smoking and nicotine tablets upon human attention. In: Thornton RE, ed. Smoking Behaviour: Physiological and Psychological Influences. London: Churchill-Livingstone; 1978: 131&#x2013; 147</Citation></Reference><Reference><Citation>Wesnes K, Warburton DM. The effects of cigarettes of varying yield on rapid information processing performance. Psychopharmacology 1984; 82: 338&#x2013; 342</Citation><ArticleIdList><ArticleId IdType="pubmed">6427826</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesnes K, Simpson PM, Christmas L. Puff by puff profiles of performance, mood and acceptability in low and non-low tar smokers. In: Rand MJ, Thurau K, eds. The Pharmacology of Nicotine. Oxford: IRL Press; 1988: 406&#x2013; 408</Citation></Reference><Reference><Citation>Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study&#x2013;Clinical Global Impression of Change: The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 2 (11 suppl): S22&#x2013; S32</Citation><ArticleIdList><ArticleId IdType="pubmed">9236949</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 2 (11 suppl): S33&#x2013; S39</Citation><ArticleIdList><ArticleId IdType="pubmed">9236950</ArticleId></ArticleIdList></Reference><Reference><Citation>Guigoz Y, Vellas B, Garry PJ. Mini Nutritional Assessment: A Practical Assessment Tool for Grading the Nutritional State of Elderly Patients. Paris: Serdi Publishing Company; 1997: 15&#x2013; 60</Citation></Reference><Reference><Citation>Brigidi BD, Achenbach TM, Dumenci L, Newhouse PA. Broad spectrum assessment of psychopathology and adaptive functioning with the Older Adult Behavior Checklist: a validation and diagnostic discrimination study. Int J Geriatr Psychiatry 2010; 25: 1177&#x2013; 1185</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2957545</ArticleId><ArticleId IdType="pubmed">20054835</ArticleId></ArticleIdList></Reference><Reference><Citation>White HK, Levin ED. Chronic transdermal nicotine patch treatment effects on cognitive performance in age-associated memory impairment. Psychopharmacology 2004; 171: 465&#x2013; 471</Citation><ArticleIdList><ArticleId IdType="pubmed">14534771</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter A, Corwin J, Lang J, Piasecki M, Lenox R, Newhouse P. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacology 1999; 142: 334&#x2013; 342</Citation><ArticleIdList><ArticleId IdType="pubmed">10229057</ArticleId></ArticleIdList></Reference><Reference><Citation>Newhouse PA, Potter A, Singh A. Effects of nicotinic stimulation on cognitive performance. Curr Opin Pharmacol 2004; 4: 36&#x2013; 46</Citation><ArticleIdList><ArticleId IdType="pubmed">15018837</ArticleId></ArticleIdList></Reference><Reference><Citation>Kihara T, Shimohama S, Sawada H, et al. &#x3b1;7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block a &#x3b2;-amyloid-induced neurotoxicity. J Biol Chem 2001; 276: 13541&#x2013; 13546</Citation><ArticleIdList><ArticleId IdType="pubmed">11278378</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng J, Shen C, Wang YJ, et al. Nicotine exacerbates tau phosphorylation and cognitive impairment induced by amyloid-beta 25&#x2013;35 in rats. Eur J Pharmacol 2010; 637: 83&#x2013; 88</Citation><ArticleIdList><ArticleId IdType="pubmed">20363218</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchant NL, King SL, Tabet N, Rusted JM. Positive effects of cholinergic stimulation favor young APOE [epsiv]4 carriers. Neuropsychopharmacology 2010; 35: 1090&#x2013; 1096</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3055410</ArticleId><ArticleId IdType="pubmed">20072115</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Ikonomovic MD, Styren SD, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002; 51: 145&#x2013; 155</Citation><ArticleIdList><ArticleId IdType="pubmed">11835370</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22196329</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2011</Year><Month>12</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Dec</Month><Day>22</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>A hippocampal marker of recollection memory ability among healthy young adults: contributions of posterior and anterior segments.</ArticleTitle><Pagination><StartPage>931</StartPage><EndPage>937</EndPage><MedlinePgn>931-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2011.10.014</ELocationID><Abstract><AbstractText>The hippocampus is known to support recollection memory, but the relation between its structure and recollection in healthy adults has not been established. Here we show that the hippocampus (including subiculum, DG, and CA1-CA4), when separated into posterior and anterior segments, can reliably predict recollection in healthy young adults. Better memory was associated with larger posterior and smaller anterior segments, as evaluated relative to the uncal apex. Overall hippocampal volume, however, did not predict memory. This pattern was confirmed in four separate data sets from different studies and laboratories. The relationship between the posterior hippocampus and memory was mediated by the structure's functional connectivity with a neocortical network identified during a postencoding resting-state scan. The relationship was also weakest in an experiment involving no appreciable study-test interval. These findings suggest that enhanced posterior-hippocampal postencoding processes may account for the memory benefit associated with larger posterior hippocampi.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Poppenk</LastName><ForeName>Jordan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Toronto, 100 St. George Street, Toronto, ON M5S 3G3, Canada. jpoppenk@princeton.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moscovitch</LastName><ForeName>Morris</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MOP49566</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="Y">Brain Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011939" MajorTopicYN="N">Mental Recall</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22196329</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2011.10.014</ArticleId><ArticleId IdType="pii">S0896-6273(11)00924-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20655099</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>142</Volume><Issue>3</Issue><PubDate><Year>2010</Year><Month>Aug</Month><Day>06</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models.</ArticleTitle><Pagination><StartPage>387</StartPage><EndPage>397</EndPage><MedlinePgn>387-97</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2010.06.036</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is characterized by amyloid-beta (Abeta) and tau deposition in brain. It has emerged that Abeta toxicity is tau dependent, although mechanistically this link remains unclear. Here, we show that tau, known as axonal protein, has a dendritic function in postsynaptic targeting of the Src kinase Fyn, a substrate of which is the NMDA receptor (NR). Missorting of tau in transgenic mice expressing truncated tau (Deltatau) and absence of tau in tau(-/-) mice both disrupt postsynaptic targeting of Fyn. This uncouples NR-mediated excitotoxicity and hence mitigates Abeta toxicity. Deltatau expression and tau deficiency prevent memory deficits and improve survival in Abeta-forming APP23 mice, a model of AD. These deficits are also fully rescued with a peptide that uncouples the Fyn-mediated interaction of NR and PSD-95 in vivo. Our findings suggest that this dendritic role of tau confers Abeta toxicity at the postsynapse with direct implications for pathogenesis and treatment of AD.</AbstractText><CopyrightInformation>Copyright 2010 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ittner</LastName><ForeName>Lars M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Alzheimer's and Parkinson's Disease Laboratory, Brain and Mind Research Institute, University of Sydney, Sydney NSW 2050, Australia. littner@med.usyd.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ke</LastName><ForeName>Yazi D</ForeName><Initials>YD</Initials></Author><Author ValidYN="Y"><LastName>Delerue</LastName><ForeName>Fabien</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Bi</LastName><ForeName>Mian</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gladbach</LastName><ForeName>Amadeus</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>van Eersel</LastName><ForeName>Janet</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>W&#xf6;lfing</LastName><ForeName>Heidrun</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Chieng</LastName><ForeName>Billy C</ForeName><Initials>BC</Initials></Author><Author ValidYN="Y"><LastName>Christie</LastName><ForeName>MacDonald J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Napier</LastName><ForeName>Ian A</ForeName><Initials>IA</Initials></Author><Author ValidYN="Y"><LastName>Eckert</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hardeman</LastName><ForeName>Edna</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>G&#xf6;tz</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>07</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000076122">Disks Large Homolog 4 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C501447">Dlg4 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber><NameOfSubstance UI="C494960">Fyn protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber><NameOfSubstance UI="D051076">Proto-Oncogene Proteins c-fyn</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.4.8</RegistryNumber><NameOfSubstance UI="D051528">Guanylate Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell. 2010 Aug 6;142(3):356-8. doi: 10.1016/j.cell.2010.07.032.</RefSource><PMID Version="1">20691893</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2010 Sep;11(9):608. doi: 10.1038/nrn2904.</RefSource><PMID Version="1">20803786</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003712" MajorTopicYN="N">Dendrites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000076122" MajorTopicYN="N">Disks Large Homolog 4 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051528" MajorTopicYN="N">Guanylate Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051076" MajorTopicYN="N">Proto-Oncogene Proteins c-fyn</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2010.06.036</ArticleId><ArticleId IdType="pii">S0092-8674(10)00726-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22009379</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1619-7089</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Feb</Month></PubDate></JournalIssue><Title>European journal of nuclear medicine and molecular imaging</Title><ISOAbbreviation>Eur J Nucl Med Mol Imaging</ISOAbbreviation></Journal><ArticleTitle>Amyloid-&#x3b2; imaging with PET in Alzheimer's disease: is it feasible with current radiotracers and technologies?</ArticleTitle><Pagination><StartPage>202</StartPage><EndPage>208</EndPage><MedlinePgn>202-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00259-011-1960-4</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moghbel</LastName><ForeName>Mateen C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Saboury</LastName><ForeName>Babak</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Basu</LastName><ForeName>Sandip</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Metzler</LastName><ForeName>Scott D</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Torigian</LastName><ForeName>Drew A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>L&#xe5;ngstr&#xf6;m</LastName><ForeName>Bengt</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Alavi</LastName><ForeName>Abass</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Nucl Med Mol Imaging</MedlineTA><NlmUniqueID>101140988</NlmUniqueID><ISSNLinking>1619-7070</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011868">Radioisotopes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Eur J Nucl Med Mol Imaging. 2012 Feb;39(2):209-19. doi: 10.1007/s00259-011-2045-0.</RefSource><PMID Version="1">22218879</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003952" MajorTopicYN="N">Diagnostic Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011868" MajorTopicYN="N">Radioisotopes</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22009379</ArticleId><ArticleId IdType="doi">10.1007/s00259-011-1960-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4703-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11930016</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2002 Jul 19;297(5580):353-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1702-14</Citation><ArticleIdList><ArticleId IdType="pubmed">21547601</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1996 Jun;46(6):1592-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8649554</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med. 2009 Feb 19;7:7</Citation><ArticleIdList><ArticleId IdType="pubmed">19228370</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):1104-19</Citation><ArticleIdList><ArticleId IdType="pubmed">21336694</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2006 Nov 14;67(9):1575-80</Citation><ArticleIdList><ArticleId IdType="pubmed">16971697</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2009 Dec;66(12):1557-62</Citation><ArticleIdList><ArticleId IdType="pubmed">20008664</ArticleId></ArticleIdList></Reference><Reference><Citation>Open Neuroimag J. 2008 Nov 13;2:114-25</Citation><ArticleIdList><ArticleId IdType="pubmed">19526073</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2004 May-Jun;25(5):609-15</Citation><ArticleIdList><ArticleId IdType="pubmed">15172738</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1985 Nov;42(11):1097-105</Citation><ArticleIdList><ArticleId IdType="pubmed">2864910</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2008 Nov;65(11):1509-17</Citation><ArticleIdList><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1998 Feb 19;338(8):506-11</Citation><ArticleIdList><ArticleId IdType="pubmed">9468467</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1986 Nov;49(11):1221-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3794727</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2002;112(1):75-91</Citation><ArticleIdList><ArticleId IdType="pubmed">12044473</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunotherapy. 2010 Nov;2(6):767-82</Citation><ArticleIdList><ArticleId IdType="pubmed">21091109</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Radiol. 2006 Jan;16(1):193-206</Citation><ArticleIdList><ArticleId IdType="pubmed">16402259</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2011;26 Suppl 3:105-16</Citation><ArticleIdList><ArticleId IdType="pubmed">21971455</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Med Sci. 2011 Feb;7(1):102-11</Citation><ArticleIdList><ArticleId IdType="pubmed">22291741</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2008 Mar;49(3):390-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18287270</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2009 Dec 16;302(23):2557-64</Citation><ArticleIdList><ArticleId IdType="pubmed">20009055</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Psychiatr Nervenkr (1970). 1976 Dec 31;223(1):15-33</Citation><ArticleIdList><ArticleId IdType="pubmed">828039</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nucl Med Mol Imaging. 2002 Dec;29(12):1639-47</Citation><ArticleIdList><ArticleId IdType="pubmed">12458399</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nucl Med Mol Imaging. 2004 Jan;31(1):44-51</Citation><ArticleIdList><ArticleId IdType="pubmed">14551751</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2011 Nov;68(11):1404-11</Citation><ArticleIdList><ArticleId IdType="pubmed">21747008</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2011 Jan 19;305(3):275-83</Citation><ArticleIdList><ArticleId IdType="pubmed">21245183</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2010 Jun;51(6):913-20</Citation><ArticleIdList><ArticleId IdType="pubmed">20501908</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1993 Nov-Dec;14(6):589-96</Citation><ArticleIdList><ArticleId IdType="pubmed">8295661</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2002 Sep;17(1):302-16</Citation><ArticleIdList><ArticleId IdType="pubmed">12482085</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2007 Aug;6(8):734-46</Citation><ArticleIdList><ArticleId IdType="pubmed">17616482</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1975 Feb;25(2):120-6</Citation><ArticleIdList><ArticleId IdType="pubmed">46597</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2011 Aug;52(8):1210-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21764791</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2007 Jul;3(3):186-91</Citation><ArticleIdList><ArticleId IdType="pubmed">19595937</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2010 Sep;68(3):319-29</Citation><ArticleIdList><ArticleId IdType="pubmed">20687209</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2009 Jul 15;46(4):908-14</Citation><ArticleIdList><ArticleId IdType="pubmed">19303447</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucl Med Biol. 2010 May;37(4):497-508</Citation><ArticleIdList><ArticleId IdType="pubmed">20447562</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2009 Dec 15;73(24):2061-70</Citation><ArticleIdList><ArticleId IdType="pubmed">19923550</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Sci. 2007 Jun 15;257(1-2):49-55</Citation><ArticleIdList><ArticleId IdType="pubmed">17306303</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Investig Drugs. 2011 Mar;20(3):325-41</Citation><ArticleIdList><ArticleId IdType="pubmed">21222550</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Pharmacother. 2009 Jun;7(3):167-85</Citation><ArticleIdList><ArticleId IdType="pubmed">19616185</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Nucl Med. 2011 Jul;41(4):300-4</Citation><ArticleIdList><ArticleId IdType="pubmed">21624563</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Alzheimers Dis. 2011;2011:687945</Citation><ArticleIdList><ArticleId IdType="pubmed">21629709</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2007 May 8;68(19):1603-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17485647</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2011 May;10(5):424-35</Citation><ArticleIdList><ArticleId IdType="pubmed">21481640</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1997 Jul-Aug;18(4):351-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2003 Feb 1;23(3):994-1005</Citation><ArticleIdList><ArticleId IdType="pubmed">12574429</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1984 Jul;34(7):939-44</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Pharmacol. 2003 Sep;59(5-6):357-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12937873</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm (Vienna). 2002 Apr;109(4):537-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11956972</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2003 Jul;106(1):89-91</Citation><ArticleIdList><ArticleId IdType="pubmed">12698265</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2009 Feb;50(2):198-204</Citation><ArticleIdList><ArticleId IdType="pubmed">19164220</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comput Assist Tomogr. 1984 Jun;8(3):514-22</Citation><ArticleIdList><ArticleId IdType="pubmed">6609942</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2008 May;16(5):384-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18448850</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2004 Mar;55(3):306-19</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 1991 Jan-Feb;1(1):103-16</Citation><ArticleIdList><ArticleId IdType="pubmed">1822725</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">22218879</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1619-7089</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Feb</Month></PubDate></JournalIssue><Title>European journal of nuclear medicine and molecular imaging</Title><ISOAbbreviation>Eur J Nucl Med Mol Imaging</ISOAbbreviation></Journal><ArticleTitle>A&#x3b2; Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>209</StartPage><EndPage>219</EndPage><MedlinePgn>209-19</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00259-011-2045-0</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Villemagne</LastName><ForeName>Victor L</ForeName><Initials>VL</Initials></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chester A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Christopher C</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Ikonomovic</LastName><ForeName>Milos D</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Ishii</LastName><ForeName>Kenji</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Lowe</LastName><ForeName>Val J</ForeName><Initials>VJ</Initials></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Nordberg</LastName><ForeName>Agneta</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Van Laere</LastName><ForeName>Koen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Drzezga</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G1100810</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U120036861</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Nucl Med Mol Imaging</MedlineTA><NlmUniqueID>101140988</NlmUniqueID><ISSNLinking>1619-7070</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011868">Radioisotopes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Eur J Nucl Med Mol Imaging. 2012 Feb;39(2):202-8. doi: 10.1007/s00259-011-1960-4.</RefSource><PMID Version="1">22009379</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011868" MajorTopicYN="N">Radioisotopes</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>1</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22218879</ArticleId><ArticleId IdType="pmc">PMC3261395</ArticleId><ArticleId IdType="doi">10.1007/s00259-011-2045-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Moghbel MC, Saboury B, Basu S, Metzler SD, Torigian DA, L&#xe5;ngstr&#xf6;m B, Alavi A. Amyloid-beta imaging with PET in Alzheimer&#x2019;s disease: is it feasible with current radiotracers and technologies? Eur J Nucl Med Mol Imaging 2011. doi:10.1007/s00259-011-1960-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">22009379</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Shao L, Hamilton RL, Ikonomovic MD, DeKosky ST, Mathis CA. The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci. 2003;23(6):2086&#x2013;2092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741999</ArticleId><ArticleId IdType="pubmed">12657667</ArticleId></ArticleIdList></Reference><Reference><Citation>Fodero-Tavoletti MT, Rowe CC, McLean CA, Leone L, Li QX, Masters CL, Cappai R, Villemagne VL. Characterization of PiB binding to white matter in Alzheimer disease and other dementias. J Nucl Med. 2009;50(2):198&#x2013;204. doi: 10.2967/jnumed.108.057984.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.108.057984</ArticleId><ArticleId IdType="pubmed">19164220</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstr&#xf6;m M, Savitcheva I, Huang GF, Estrada S, Aus&#xe9;n B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, L&#xe5;ngstr&#xf6;m B. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306&#x2013;319. doi: 10.1002/ana.20009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20009</ArticleId><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46(13):2740&#x2013;2754. doi: 10.1021/jm030026b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm030026b</ArticleId><ArticleId IdType="pubmed">12801237</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, Dekosky ST, Halligan EM, Klunk WE. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65(11):1509&#x2013;1517. doi: 10.1001/archneur.65.11.1509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.65.11.1509</ArticleId><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, Hasselbalch S, Law I, Andersen A, Korner A, Minthon L, Garraux G, Nelissen N, Bormans G, Buckley C, Owenius R, Thurfjell L, Farrar G, Brooks DJ. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68(3):319&#x2013;329. doi: 10.1002/ana.22068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22068</ArticleId><ArticleId IdType="pubmed">20687209</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O&#x2019;Keefe G, Tochon-Danguy H, Chan G, Berlangieri SU, Jones G, Dickinson-Rowe KL, Kung HP, Zhang W, Kung MP, Skovronsky D, Dyrks T, Holl G, Krause S, Friebe M, Lehman L, Lindemann S, Dinkelborg LM, Masters CL, Villemagne VL. Imaging of amyloid beta in Alzheimer&#x2019;s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7(2):129&#x2013;135. doi: 10.1016/S1474-4422(08)70001-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(08)70001-2</ArticleId><ArticleId IdType="pubmed">18191617</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, Dannals RF, Nandi A, Brasi&#x107; JR, Ye W, Hilton J, Lyketsos C, Kung HF, Joshi AD, Skovronsky DM, Pontecorvo MJ. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18) J Nucl Med. 2010;51(6):913&#x2013;920. doi: 10.2967/jnumed.109.069088.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.109.069088</ArticleId><ArticleId IdType="pmc">PMC3101877</ArticleId><ArticleId IdType="pubmed">20501908</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou YC, Teng MM, Guo WY, Hsieh JC, Wu YT. Classification of hemodynamics from dynamic-susceptibility-contrast magnetic resonance (DSC-MR) brain images using noiseless independent factor analysis. Med Image Anal. 2007;11(3):242&#x2013;253. doi: 10.1016/j.media.2007.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.media.2007.02.002</ArticleId><ArticleId IdType="pubmed">17433760</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu P, Uh J, Devous MD, Adinoff B, Lu H. Comparison of relative cerebral blood flow maps using pseudo-continuous arterial spin labeling and single photon emission computed tomography. NMR Biomed 2011 [Epub ahead of print]. doi: 10.1002/nbm.1792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3298573</ArticleId><ArticleId IdType="pubmed">22139764</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichise M, Golan H, Ballinger JR, Vines D, Blackman A, Moldofsky H. Regional differences in technetium-99m-ECD clearance on brain SPECT in healthy subjects. J Nucl Med. 1997;38(8):1253&#x2013;1260.</Citation><ArticleIdList><ArticleId IdType="pubmed">9255160</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O&#x2019;Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68(20):1718&#x2013;1725. doi: 10.1212/01.wnl.0000261919.22630.ea.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000261919.22630.ea</ArticleId><ArticleId IdType="pubmed">17502554</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickeson M, Yun M, Matthies A, Zhuang H, Adam LE, Lacorte L, Alavi A. Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging. 2002;29(12):1639&#x2013;1647. doi: 10.1007/s00259-002-0924-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-002-0924-0</ArticleId><ArticleId IdType="pubmed">12458399</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, O&#x2019;Keefe G, Ackerman U, Tochon-Danguy H, Chan JG, Reininger CB, Fels L, Putz B, Rohde B, Masters CL, Rowe CC. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52(8):1210&#x2013;1217. doi: 10.2967/jnumed.111.089730.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.111.089730</ArticleId><ArticleId IdType="pubmed">21764791</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, Hiemeyer F, Wittemer-Rump SM, Seibyl J, Reininger C, Sabri O. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer&#x2019;s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10(5):424&#x2013;435. doi: 10.1016/S1474-4422(11)70077-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70077-1</ArticleId><ArticleId IdType="pubmed">21481640</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, Joshi AD, Clark CM, Mintun MA, Pontecorvo MJ, Doraiswamy PM, Johnson KA, Skovronsky DM, Reiman EM. Using positron emission tomography and florbetapir F 18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 2011;68:1404&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">21747008</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, DeKosky ST, Mathis CA. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25(11):1528&#x2013;1547. doi: 10.1038/sj.jcbfm.9600146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.jcbfm.9600146</ArticleId><ArticleId IdType="pubmed">15944649</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas BA, Erlandsson K, Modat M, Thurfjell L, Vandenberghe R, Ourselin S, Hutton BF. The importance of appropriate partial volume correction for PET quantification in Alzheimer&#x2019;s disease. Eur J Nucl Med Mol Imaging. 2011;38(6):1104&#x2013;1119. doi: 10.1007/s00259-011-1745-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-011-1745-9</ArticleId><ArticleId IdType="pubmed">21336694</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthel H, Luthardt J, Becker G, Patt M, Hammerstein E, Hartwig K, Eggers B, Sattler B, Schildan A, Hesse S, Meyer PM, Wolf H, Zimmermann T, Reischl J, Rohde B, Gertz HJ, Reininger C, Sabri O. Individualized quantification of brain beta-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer&#x2019;s disease and healthy controls. Eur J Nucl Med Mol Imaging 2011;38:1702&#x2013;14. doi:10.1007/s00259-011-1821-1.</Citation><ArticleIdList><ArticleId IdType="pubmed">21547601</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Orantes M, Braak H. Phases of A&#x3b2;-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351&#x2013;357. doi: 10.1016/S0197-4580(97)00056-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(97)00056-0</ArticleId><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer&#x2019;s disease. Cereb Cortex. 1991;1(1):103&#x2013;116. doi: 10.1093/cercor/1.1.103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/1.1.103</ArticleId><ArticleId IdType="pubmed">1822725</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold SE, Han LY, Clark CM, Grossman M, Trojanowski JQ. Quantitative neurohistological features of frontotemporal degeneration. Neurobiol Aging. 2000;21(6):913&#x2013;919. doi: 10.1016/S0197-4580(00)00173-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(00)00173-1</ArticleId><ArticleId IdType="pubmed">11124442</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolk DA, Grachev ID, Buckley C, Kazi H, Grady MS, Trojanowski JQ, Hamilton RH, Sherwin P, McLain R, Arnold SE. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol. 2011;68(11):1398&#x2013;1403. doi: 10.1001/archneurol.2011.153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.153</ArticleId><ArticleId IdType="pmc">PMC4532383</ArticleId><ArticleId IdType="pubmed">21747004</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe4;slund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000;283(12):1571&#x2013;1577. doi: 10.1001/jama.283.12.1571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.283.12.1571</ArticleId><ArticleId IdType="pubmed">10735393</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman SH, Raju S, Hyman BT, Frosch MP, Irizarry MC. Plasma Abeta levels do not reflect brain Abeta levels. J Neuropathol Exp Neurol. 2007;66(4):264&#x2013;271. doi: 10.1097/NEN.0b013e31803d3ae4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31803d3ae4</ArticleId><ArticleId IdType="pubmed">17413317</ArticleId></ArticleIdList></Reference><Reference><Citation>Attems J, Quass M, Jellinger KA, Lintner F. Topographical distribution of cerebral amyloid angiopathy and its effect on cognitive decline are influenced by Alzheimer disease pathology. J Neurol Sci. 2007;257(1&#x2013;2):49&#x2013;55. doi: 10.1016/j.jns.2007.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2007.01.013</ArticleId><ArticleId IdType="pubmed">17306303</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe VJ, Kemp BJ, Jack CR, Jr, Senjem M, Weigand S, Shiung M, Smith G, Knopman D, Boeve B, Mullan B, Petersen RC. Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med. 2009;50:878&#x2013;886. doi: 10.2967/jnumed.108.058529.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.108.058529</ArticleId><ArticleId IdType="pmc">PMC2886669</ArticleId><ArticleId IdType="pubmed">19443597</ArticleId></ArticleIdList></Reference><Reference><Citation>Drzezga A, Becker JA, Van Dijk KR, Sreenivasan A, Talukdar T, Sullivan C, Schultz AP, Sepulcre J, Putcha D, Greve D, Johnson KA, Sperling RA. Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain. 2011;134(Pt 6):1635&#x2013;1646. doi: 10.1093/brain/awr066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr066</ArticleId><ArticleId IdType="pmc">PMC3102239</ArticleId><ArticleId IdType="pubmed">21490054</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xf6;rster S, Grimmer T, Miederer I, Henriksen G, Yousefi BH, Graner P, Wester HJ, F&#xf6;rstl H, Kurz A, Dickerson BC, Bartenstein P, Drzezga A. Regional expansion of hypometabolism in Alzheimer&#x2019;s disease follows amyloid deposition with temporal delay. Biol Psychiatry 2011. doi:10.1016/j.biopsych.2011.04.023.</Citation><ArticleIdList><ArticleId IdType="pubmed">21679929</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, Ellis KA, Szoeke C, Martins RN, O&#x2019;Keefe GJ, Salvado O, Masters CL, Rowe CC. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol. 2010;67(3):317&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">20373343</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JA, Hedden T, Carmasin J, Maye J, Rentz DM, Putcha D, Fischl B, Greve DN, Marshall GA, Salloway S, Marks D, Buckner RL, Sperling RA, Johnson KA. Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69(6):1032&#x2013;1042. doi: 10.1002/ana.22333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22333</ArticleId><ArticleId IdType="pmc">PMC3117980</ArticleId><ArticleId IdType="pubmed">21437929</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, Knopman DS, Boeve BF, Klunk WE, Mathis CA, Petersen RC. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer&#x2019;s disease and amnestic mild cognitive impairment. Brain. 2008;131(Pt 3):665&#x2013;680. doi: 10.1093/brain/awm336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awm336</ArticleId><ArticleId IdType="pmc">PMC2730157</ArticleId><ArticleId IdType="pubmed">18263627</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, Irizarry MC, Klunk WE, Mathis CA, Dekosky ST, Greenberg SM, Hyman BT, Growdon JH. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007;64(3):431&#x2013;434. doi: 10.1001/archneur.64.3.431.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.64.3.431</ArticleId><ArticleId IdType="pubmed">17353389</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer&#x2019;s disease. Brain. 2008;131(Pt 6):1630&#x2013;1645. doi: 10.1093/brain/awn016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn016</ArticleId><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah A, Schmidt RE, Perry A, Reinwald LT, Carter D, Felton A, Holtzman DM, Mintun MA, Klunk WE, Morris JC. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol. 2009;66(12):1557&#x2013;1562. doi: 10.1001/archneurol.2009.279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2009.279</ArticleId><ArticleId IdType="pmc">PMC2796200</ArticleId><ArticleId IdType="pubmed">20008664</ArticleId></ArticleIdList></Reference><Reference><Citation>Burack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, Cairns NJ. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology. 2010;74(1):77&#x2013;84. doi: 10.1212/WNL.0b013e3181c7da8e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181c7da8e</ArticleId><ArticleId IdType="pmc">PMC2809026</ArticleId><ArticleId IdType="pubmed">20038776</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, McLean CA, Reardon K, Boyd A, Lewis V, Klug G, Jones G, Baxendale D, Masters CL, Rowe CC, Collins SJ. 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry. 2009;80:998&#x2013;1001. doi: 10.1136/jnnp.2008.171496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2008.171496</ArticleId><ArticleId IdType="pubmed">19332421</ArticleId></ArticleIdList></Reference><Reference><Citation>Sojkova J, Driscoll I, Iacono D, Zhou Y, Codispoti KE, Kraut MA, Ferrucci L, Pletnikova O, Mathis CA, Klunk WE, O&#x2019;Brien RJ, Wong DF, Troncoso JC, Resnick SM. In vivo fibrillar &#x3b2;-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol. 2011;68(2):232&#x2013;240. doi: 10.1001/archneurol.2010.357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.357</ArticleId><ArticleId IdType="pmc">PMC3082956</ArticleId><ArticleId IdType="pubmed">21320990</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman PE, Zehntner SP, Skovronsky DM. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305(3):275&#x2013;283. doi: 10.1001/jama.2010.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2010.2008</ArticleId><ArticleId IdType="pmc">PMC7041965</ArticleId><ArticleId IdType="pubmed">21245183</ArticleId></ArticleIdList></Reference><Reference><Citation>Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, N&#xe5;gren K, Tapiola T, Pirttil&#xe4; T, Rinne J, J&#xe4;&#xe4;skel&#xe4;inen JE, Soininen H, Rinne JO. Assessment of &#x3b2;-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol. 2008;65(10):1304&#x2013;1309. doi: 10.1001/archneur.65.10.noc80013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.65.10.noc80013</ArticleId><ArticleId IdType="pubmed">18695050</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadir A, Marutle A, Gonzalez D, Sch&#xf6;ll M, Almkvist O, Mousavi M, Mustafiz T, Darreh-Shori T, Nennesmo I, Nordberg A. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer&#x2019;s disease. Brain. 2011;134(Pt 1):301&#x2013;317. doi: 10.1093/brain/awq349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awq349</ArticleId><ArticleId IdType="pmc">PMC3009843</ArticleId><ArticleId IdType="pubmed">21149866</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, Alexander GE, Klunk WE, Mathis CA, Price JC, Aizenstein HJ, Dekosky ST, Caselli RJ. Fibrillar amyloid-&#x3b2; burden in cognitively normal people at 3 levels of genetic risk for Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2009;106:6820&#x2013;6825. doi: 10.1073/pnas.0900345106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0900345106</ArticleId><ArticleId IdType="pmc">PMC2665196</ArticleId><ArticleId IdType="pubmed">19346482</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122&#x2013;131. doi: 10.1002/ana.21843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21843</ArticleId><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O&#x2019;Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275&#x2013;1283. doi: 10.1016/j.neurobiolaging.2010.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.04.007</ArticleId><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Holtzman DM. Cerebrospinal fluid biomarkers of Alzheimer&#x2019;s disease. Biomark Med. 2010;4(1):51&#x2013;63. doi: 10.2217/bmm.09.83.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/bmm.09.83</ArticleId><ArticleId IdType="pmc">PMC2846664</ArticleId><ArticleId IdType="pubmed">20361010</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, Bi W, Hoge JA, Cohen AD, Ikonomovic MD, Saxton JA, Snitz BE, Pollen DA, Moonis M, Lippa CF, Swearer JM, Johnson KA, Rentz DM, Fischman AJ, Aizenstein HJ, DeKosky ST. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27(23):6174&#x2013;6184. doi: 10.1523/JNEUROSCI.0730-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0730-07.2007</ArticleId><ArticleId IdType="pmc">PMC3265970</ArticleId><ArticleId IdType="pubmed">17553989</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Ataka S, Mizuno T, Brooks WS, Wada Y, Kondo M, Jones G, Watanabe Y, Mulligan R, Nakagawa M, Miki T, Shimada H, O&#x2019;Keefe GJ, Masters CL, Mori H, Rowe CC. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol. 2009;66(12):1537&#x2013;1544. doi: 10.1001/archneurol.2009.285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2009.285</ArticleId><ArticleId IdType="pubmed">20008660</ArticleId></ArticleIdList></Reference><Reference><Citation>Koivunen J, Verkkoniemi A, Aalto S, Paetau A, Ahonen JP, Viitanen M, N&#xe5;gren K, Rokka J, Haaparanta M, Kalimo H, Rinne JO. PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer&#x2019;s disease. Brain. 2008;131(Pt 7):1845&#x2013;1853. doi: 10.1093/brain/awn107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn107</ArticleId><ArticleId IdType="pubmed">18583368</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Pike K, Pejoska S, Boyd A, Power M, Jones G, Masters CL, Rowe CC. 11C-PiB PET ABri imaging in Worster-Drought syndrome (familial British dementia): a case report. J Alzheimers Dis. 2010;19(2):423&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">20110591</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng SY, Villemagne VL, Masters CL, Rowe CC. Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B. Arch Neurol. 2007;64(8):1140&#x2013;1144. doi: 10.1001/archneur.64.8.1140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.64.8.1140</ArticleId><ArticleId IdType="pubmed">17698704</ArticleId></ArticleIdList></Reference><Reference><Citation>Formaglio M, Costes N, Seguin J, Tholance Y, Le Bars D, Roullet-Solignac I, Mercier B, Krolak-Salmon P, Vighetto A. In vivo demonstration of amyloid burden in posterior cortical atrophy: a case series with PET and CSF findings. J Neurol. 2011;258(10):1841&#x2013;1851. doi: 10.1007/s00415-011-6030-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-011-6030-0</ArticleId><ArticleId IdType="pubmed">21479849</ArticleId></ArticleIdList></Reference><Reference><Citation>Kambe T, Motoi Y, Ishii K, Hattori N. Posterior cortical atrophy with [11C] Pittsburgh compound B accumulation in the primary visual cortex. J Neurol. 2010;257(3):469&#x2013;471. doi: 10.1007/s00415-009-5377-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-009-5377-y</ArticleId><ArticleId IdType="pubmed">19915884</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenovuo O, Kemppainen N, Aalto S, N&#xe5;gren K, Rinne JO. Posterior cortical atrophy: a rare form of dementia with in vivo evidence of amyloid-beta accumulation. J Alzheimers Dis. 2008;15(3):351&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">18997288</ArticleId></ArticleIdList></Reference><Reference><Citation>Dierksen GA, Skehan ME, Khan MA, Jeng J, Nandigam RN, Becker JA, Kumar A, Neal KL, Betensky RA, Frosch MP, Rosand J, Johnson KA, Viswanathan A, Salat DH, Greenberg SM. Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy. Ann Neurol. 2010;68(4):545&#x2013;548. doi: 10.1002/ana.22099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22099</ArticleId><ArticleId IdType="pmc">PMC2964411</ArticleId><ArticleId IdType="pubmed">20865701</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, Smith EE, Rosand J, Rentz DM, Klunk WE, Mathis CA, Price JC, Dekosky ST, Fischman AJ, Greenberg SM. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62(3):229&#x2013;234. doi: 10.1002/ana.21164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21164</ArticleId><ArticleId IdType="pubmed">17683091</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, Wuu J, Mathis CA, Scheff SW, Mufson EJ, DeKosky ST. Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease. Neurology. 2011;77(1):39&#x2013;47. doi: 10.1212/WNL.0b013e3182231419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182231419</ArticleId><ArticleId IdType="pmc">PMC3127332</ArticleId><ArticleId IdType="pubmed">21700583</ArticleId></ArticleIdList></Reference><Reference><Citation>Mufson EJ, Binder L, Counts SE, Dekosky ST, Detoledo-Morrell L, Ginsberg SD, Ikonomovic MD, Perez SE, Scheff SW. Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol 2011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3282485</ArticleId><ArticleId IdType="pubmed">22101321</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, Holt DP, Huang GF, Shao L, DeKosky ST, Price JC, Mathis CA. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer&#x2019;s disease brain but not in transgenic mouse brain. J Neurosci. 2005;25(46):10598&#x2013;10606. doi: 10.1523/JNEUROSCI.2990-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2990-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725842</ArticleId><ArticleId IdType="pubmed">16291932</ArticleId></ArticleIdList></Reference><Reference><Citation>Svedberg MM, Hall H, Hellstr&#xf6;m-Lindahl E, Estrada S, Guan Z, Nordberg A, L&#xe5;ngstr&#xf6;m B. [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. Neurochem Int. 2009;54(5&#x2013;6):347&#x2013;357. doi: 10.1016/j.neuint.2008.12.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2008.12.016</ArticleId><ArticleId IdType="pubmed">19162107</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutchens TW, Li CM. Ligand-binding properties of estrogen receptor proteins after interaction with surface-immobilized Zn(II) ions: evidence for localized surface interactions and minimal conformational changes. J Mol Recognit. 1990;3(4):174&#x2013;179. doi: 10.1002/jmr.300030407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmr.300030407</ArticleId><ArticleId IdType="pubmed">2278734</ArticleId></ArticleIdList></Reference><Reference><Citation>Takami M, Kasuya I, Tsunoo H. A ligand-receptor binding assay by receptor immobilization. Anal Biochem. 1988;170(1):238&#x2013;242. doi: 10.1016/0003-2697(88)90113-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0003-2697(88)90113-3</ArticleId><ArticleId IdType="pubmed">3389514</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuck P. Kinetics of ligand binding to receptor immobilized in a polymer matrix, as detected with an evanescent wave biosensor. I. A computer simulation of the influence of mass transport. Biophys J. 1996;70(3):1230&#x2013;1249. doi: 10.1016/S0006-3495(96)79681-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-3495(96)79681-9</ArticleId><ArticleId IdType="pmc">PMC1225050</ArticleId><ArticleId IdType="pubmed">8785280</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyama H, Ye D, Ichise M, Liow JS, Cai L, Jacobowitz D, Musachio JL, Hong J, Crescenzo M, Tipre D, Lu JQ, Zoghbi S, Vines DC, Seidel J, Katada K, Green MV, Pike VW, Cohen RM, Innis RB. PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer&#x2019;s disease. Eur J Nucl Med Mol Imaging. 2005;32(5):593&#x2013;600. doi: 10.1007/s00259-005-1780-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-005-1780-5</ArticleId><ArticleId IdType="pubmed">15791432</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda J, Ji B, Irie T, Tomiyama T, Maruyama M, Okauchi T, Staufenbiel M, Iwata N, Ono M, Saido TC, Suzuki K, Mori H, Higuchi M, Suhara T. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer&#x2019;s disease enabled by positron emission tomography. J Neurosci. 2007;27(41):10957&#x2013;10968. doi: 10.1523/JNEUROSCI.0673-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0673-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672864</ArticleId><ArticleId IdType="pubmed">17928437</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, Takuma H, Kuwano R, Imagawa M, Ataka S, Wada Y, Yoshioka E, Nishizaki T, Watanabe Y, Mori H. A new amyloid beta variant favoring oligomerization in Alzheimer&#x2019;s-type dementia. Ann Neurol. 2008;63(3):377&#x2013;387. doi: 10.1002/ana.21321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21321</ArticleId><ArticleId IdType="pubmed">18300294</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, Libri V, Leppert D, Beach TG. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain. 2007;130(Pt 10):2607&#x2013;2615. doi: 10.1093/brain/awm191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awm191</ArticleId><ArticleId IdType="pubmed">17698496</ArticleId></ArticleIdList></Reference><Reference><Citation>Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, Leone L, Perez K, Cort&#xe9;s M, Culvenor JG, Li QX, Laughton KM, Rowe CC, Masters CL, Cappai R, Villemagne VL. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci. 2007;27(39):10365&#x2013;10371. doi: 10.1523/JNEUROSCI.0630-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0630-07.2007</ArticleId><ArticleId IdType="pmc">PMC6673163</ArticleId><ArticleId IdType="pubmed">17898208</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye L, Velasco A, Fraser G, Beach TG, Sue L, Osredkar T, Libri V, Spillantini MG, Goedert M, Lockhart A. In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem. 2008;105(4):1428&#x2013;1437. doi: 10.1111/j.1471-4159.2008.05245.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2008.05245.x</ArticleId><ArticleId IdType="pmc">PMC2408655</ArticleId><ArticleId IdType="pubmed">18221373</ArticleId></ArticleIdList></Reference><Reference><Citation>Anonymous. Consensus recommendations for the postmortem diagnosis of Alzheimer&#x2019;s disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer&#x2019;s Disease. Neurobiol Aging 1997;18(4 Suppl):S1&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330978</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41(4):479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Khachaturian ZS. Diagnosis of Alzheimer&#x2019;s disease. Arch Neurol. 1985;42(11):1097&#x2013;1105. doi: 10.1001/archneur.1985.04060100083029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1985.04060100083029</ArticleId><ArticleId IdType="pubmed">2864910</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine H, 3rd, Walker LC. Molecular polymorphism of Abeta in Alzheimer&#x2019;s disease. Neurobiol Aging. 2010;31(4):542&#x2013;548. doi: 10.1016/j.neurobiolaging.2008.05.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2008.05.026</ArticleId><ArticleId IdType="pmc">PMC2842206</ArticleId><ArticleId IdType="pubmed">18619711</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Resolving controversies on the path to Alzheimer&#x2019;s therapeutics. Nat Med. 2011;17(9):1060&#x2013;1065. doi: 10.1038/nm.2460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2460</ArticleId><ArticleId IdType="pubmed">21900936</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, Aizenstein HJ, Cohen AD, Weissfeld LA, Mathis CA, Klunk WE, DeKosky ST. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009;65(5):557&#x2013;568. doi: 10.1002/ana.21598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21598</ArticleId><ArticleId IdType="pmc">PMC2828870</ArticleId><ArticleId IdType="pubmed">19475670</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, L&#xe5;ngstr&#xf6;m B, Nordberg A. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29(10):1456&#x2013;1465. doi: 10.1016/j.neurobiolaging.2007.03.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.03.029</ArticleId><ArticleId IdType="pubmed">17499392</ArticleId></ArticleIdList></Reference><Reference><Citation>Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, N&#xe5;gren K, Bullock R, Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ. Conversion of amyloid positive and negative MCI to AD over 3years: an 11C-PIB PET study. Neurology. 2009;73(10):754&#x2013;760. doi: 10.1212/WNL.0b013e3181b23564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181b23564</ArticleId><ArticleId IdType="pmc">PMC2830881</ArticleId><ArticleId IdType="pubmed">19587325</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Pike KE, Ch&#xe9;telat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, O&#x2019;Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69(1):181&#x2013;192. doi: 10.1002/ana.22248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22248</ArticleId><ArticleId IdType="pmc">PMC3045039</ArticleId><ArticleId IdType="pubmed">21280088</ArticleId></ArticleIdList></Reference><Reference><Citation>Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968;114(512):797&#x2013;811. doi: 10.1192/bjp.114.512.797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.114.512.797</ArticleId><ArticleId IdType="pubmed">5662937</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 2010;9(1):119&#x2013;128. doi: 10.1016/S1474-4422(09)70299-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(09)70299-6</ArticleId><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A. 2011;108(14):5819&#x2013;5824. doi: 10.1073/pnas.1017033108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1017033108</ArticleId><ArticleId IdType="pmc">PMC3078381</ArticleId><ArticleId IdType="pubmed">21421841</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat Med. 2008;14(8):837&#x2013;842. doi: 10.1038/nm1782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1782</ArticleId><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20(3 Suppl 2):S69&#x2013;S74. doi: 10.1097/00002093-200607001-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002093-200607001-00010</ArticleId><ArticleId IdType="pubmed">16917199</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Mintun MA, D&#x2019;Angelo G, Xiong C, Grant EA, Morris JC. Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Arch Neurol. 2008;65(11):1467&#x2013;1471. doi: 10.1001/archneur.65.11.1467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.65.11.1467</ArticleId><ArticleId IdType="pmc">PMC2752218</ArticleId><ArticleId IdType="pubmed">19001165</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner GG. Alzheimer&#x2019;s disease. The commonest form of amyloidosis. Arch Pathol Lab Med. 1983;107:281&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">6687789</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE. Amyloid imaging as a biomarker for cerebral beta-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging. 2011;32(Suppl 1):S20&#x2013;S36. doi: 10.1016/j.neurobiolaging.2011.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.09.006</ArticleId><ArticleId IdType="pmc">PMC3233688</ArticleId><ArticleId IdType="pubmed">22078170</ArticleId></ArticleIdList></Reference><Reference><Citation>Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, L&#xe5;ngstr&#xf6;m B, Nordberg A. Two-year follow-up of amyloid deposition in patients with Alzheimer&#x2019;s disease. Brain 2006;129(Pt 11):2856&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">16854944</ArticleId></ArticleIdList></Reference><Reference><Citation>Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, Villemagne VL, O&#x2019;Keefe G, N&#xe5;gren K, Chaudhury KR, Masters CL, Brooks DJ. Amyloid load in Parkinson&#x2019;s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry. 2008;79(12):1331&#x2013;1338. doi: 10.1136/jnnp.2007.127878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2007.127878</ArticleId><ArticleId IdType="pubmed">18653550</ArticleId></ArticleIdList></Reference><Reference><Citation>Drzezga A, Grimmer T, Henriksen G, Stangier I, Perneczky R, Diehl-Schmid J, Mathis CA, Klunk WE, Price J, DeKosky S, Wester HJ, Schwaiger M, Kurz A. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer&#x2019;s disease. Neuroimage. 2008;39(2):619&#x2013;633. doi: 10.1016/j.neuroimage.2007.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2007.09.020</ArticleId><ArticleId IdType="pubmed">17962045</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22332189</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals.</ArticleTitle><Pagination><StartPage>223</StartPage><EndPage>229</EndPage><MedlinePgn>223-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneurol.2011.666</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To study the relationship between subjective cognition and the neuropathological hallmark of Alzheimer disease (AD), amyloid-&#x3b2; (A&#x3b2;) deposition, using carbon 11-labeled Pittsburgh Compound B (PiB) positron emission tomography in normal elderly individuals.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cross-sectional analysis.</AbstractText><AbstractText Label="SUBJECTS" NlmCategory="METHODS">Forty-eight cognitively normal elderly subjects (11 with high PiB uptake and 28 with low PiB uptake) were included. All underwent clinical and neuropsychological evaluations, magnetic resonance imaging, and positron emission tomography.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Berkeley Aging Cohort Study.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Relationship between PiB uptake and subjective cognition measures.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Subjects with high PiB uptake showed significantly lower performance than those with low PiB uptake on an episodic memory measure and were less confident about their general memory abilities when required to evaluate themselves relative to other people of the same age. High and low PiB uptake groups did not differ on the accuracy of their cognitive self-reports compared with objective cognitive performance. General memory self-reports from the whole group were significantly correlated with regional PiB uptake in the right medial prefrontal cortex and anterior cingulate cortex and in the right precuneus and posterior cingulate cortex. Reduced confidence about memory abilities was associated with greater PiB uptake in these brain regions. All results were independent of demographic variables and depressive affects.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A decrease of self-confidence about memory abilities in cognitively normal elderly subjects may be related to the neuropathological hallmark of AD measured with PiB-positron emission tomography. Subjective cognitive impairment may represent a very early clinical manifestation of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perrotin</LastName><ForeName>Audrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley, CA, USA audrey.perrotin@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mormino</LastName><ForeName>Elizabeth C</ForeName><Initials>EC</Initials></Author><Author ValidYN="Y"><LastName>Madison</LastName><ForeName>Cindee M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Hayenga</LastName><ForeName>Amynta O</ForeName><Initials>AO</Initials></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG027859</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027859</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">HALMS728999</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22332189</ArticleId><ArticleId IdType="mid">HALMS728999</ArticleId><ArticleId IdType="pmc">PMC4004919</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2011.666</ArticleId><ArticleId IdType="pii">69/2/223</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. Lancet. 2006;367(9518):1262&#x2013;1270.</Citation><ArticleIdList><ArticleId IdType="pubmed">16631882</ArticleId></ArticleIdList></Reference><Reference><Citation>Jessen F, Wiese B, Bachmann C, et al. Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry. 2010;67(4):414&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pubmed">20368517</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B, Prichep L, Mosconi L, et al. The pre-mild cognitive impairment, subjective cognitive impairment stage of Alzheimer&#x2019;s disease. Alzheimers Dement. 2008;4(1 Suppl 1):S98&#x2013;S108.</Citation><ArticleIdList><ArticleId IdType="pubmed">18632010</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B, Shulman MB, Torossian C, Leng L, Zhu W. Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimers Dement. 2010;6(1):11&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3873197</ArticleId><ArticleId IdType="pubmed">20129317</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonker C, Geerlings MI, Schmand B. Are memory complaints predictive for dementia? A review of clinical and population-based studies. Int J Geriatr Psychiatry. 2000;15(11):983&#x2013;991.</Citation><ArticleIdList><ArticleId IdType="pubmed">11113976</ArticleId></ArticleIdList></Reference><Reference><Citation>van Oijen M, de Jong FJ, Hofman A, Koudstaal PJ, Breteler MMB. Subjective memory complaints, education, and risk of Alzheimer&#x2019;s disease. Alzheimers Dement. 2007;3(2):92&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">19595922</ArticleId></ArticleIdList></Reference><Reference><Citation>Comijs HC, Deeg DJH, Dik MG, Twisk JWR, Jonker C. Memory complaints; the association with psycho-affective and health problems and the role of personality characteristics. A 6-year follow-up study. J Affect Disord. 2002;72(2):157&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">12200206</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorm AF, Butterworth P, Anstey KJ, et al. Memory complaints in a community sample aged 60&#x2013;64 years: associations with cognitive functioning, psychiatric symptoms, medical conditions, APOE genotype, hippocampus and amygdala volumes, and white-matter hyperintensities. Psychol Med. 2004;34(8):1495&#x2013;1506.</Citation><ArticleIdList><ArticleId IdType="pubmed">15724880</ArticleId></ArticleIdList></Reference><Reference><Citation>Mott RT, Hulette CM. Neuropathology of Alzheimer&#x2019;s disease. Neuroimaging Clin N Am. 2005;15(4):755&#x2013;765. ix.</Citation><ArticleIdList><ArticleId IdType="pubmed">16443488</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 2010;9(1):119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68(20):1718&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">17502554</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer&#x2019;s disease. Brain. 2007;130(Pt 11):2837&#x2013;2844.</Citation><ArticleIdList><ArticleId IdType="pubmed">17928318</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart R, Dufouil C, Godin O, et al. Neuroimaging correlates of subjective memory deficits in a community population. Neurology. 2008;70(18):1601&#x2013;1607.</Citation><ArticleIdList><ArticleId IdType="pubmed">18443310</ArticleId></ArticleIdList></Reference><Reference><Citation>Striepens N, Scheef L, Wind A, et al. Volume loss of the medial temporal lobe structures in subjective memory impairment. Dement Geriatr Cogn Disord. 2010;29(1):75&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">20110703</ArticleId></ArticleIdList></Reference><Reference><Citation>van Norden AGW, Fick WF, de Laat KF, et al. Subjective cognitive failures and hippocampal volume in elderly with white matter lesions. Neurology. 2008;71(15):1152&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">18838662</ArticleId></ArticleIdList></Reference><Reference><Citation>Jessen F, Feyen L, Freymann K, et al. Volume reduction of the entorhinal cortex in subjective memory impairment. Neurobiol Aging. 2006;27(12):1751&#x2013;1756.</Citation><ArticleIdList><ArticleId IdType="pubmed">16309795</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang PJ, Saykin AJ, Flashman LA, et al. Regionally specific atrophy of the corpus callosum in AD, MCI and cognitive complaints. Neurobiol Aging. 2006;27(11):1613&#x2013;1617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3482483</ArticleId><ArticleId IdType="pubmed">16271806</ArticleId></ArticleIdList></Reference><Reference><Citation>Saykin AJ, Wishart HA, Rabin LA, et al. Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology. 2006;67(5):834&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3488276</ArticleId><ArticleId IdType="pubmed">16966547</ArticleId></ArticleIdList></Reference><Reference><Citation>Ercoli L, Siddarth P, Huang S-C, et al. Perceived loss of memory ability and cerebral metabolic decline in persons with the apolipoprotein E-IV genetic risk for Alzheimer disease. Arch Gen Psychiatry. 2006;63(4):442&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pubmed">16585474</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, De Santi S, Brys M, et al. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry. 2008;63(6):609&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386268</ArticleId><ArticleId IdType="pubmed">17720148</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW, Chen ST, Komo S, et al. Memory self-appraisal in middle-aged and older adults with the apolipoprotein E-4 allele. Am J Psychiatry. 1999;156(7):1035&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pubmed">10401448</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart R, Russ C, Richards M, et al. Depression, APOE genotype and subjective memory impairment: a cross-sectional study in an African-Caribbean population. Psychol Med. 2001;31(3):431&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">11305851</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LL, Schneider JA, Boyle PA, Bienias JL, Bennett DA. Memory complaints are related to Alzheimer disease pathology in older persons. Neurology. 2006;67(9):1581&#x2013;1585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740723</ArticleId><ArticleId IdType="pubmed">17101887</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorm AF, Masaki KH, Davis DG, et al. Memory complaints in nondemented men predict future pathologic diagnosis of Alzheimer disease. Neurology. 2004;63(10):1960&#x2013;1961.</Citation><ArticleIdList><ArticleId IdType="pubmed">15557525</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodda J, Okello A, Edison P, et al. (11)C-PIB PET in subjective cognitive impairment. Eur Psychiatry. 2010;25(2):123&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">19926266</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G, Villemagne VL, Bourgeat P, et al. Relationship between atrophy and beta- amyloid deposition in Alzheimer disease. Ann Neurol. 2010;67(3):317&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">20373343</ArticleId></ArticleIdList></Reference><Reference><Citation>Flavell JH. Metacognition and cognitive monitoring: A new area of cognitive-developmental inquiry. Am Psychol. 1979;34:906&#x2013;911.</Citation></Reference><Reference><Citation>Nelson TO, Narens L. Metamemory: A theoretical framework and new findings. In: Bower GH, editor. The psychology of learning and motivation: Advances in research and theory. New York: Academic Press; 1990. pp. 125&#x2013;173.</Citation></Reference><Reference><Citation>Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test. 2. San Antonio, TX: Psychological Corporation; 2000.</Citation></Reference><Reference><Citation>Wechsler D. Wechsler Memory Scale -Revised. San Antonio, TX: Psychological Corporation; 1987.</Citation></Reference><Reference><Citation>Stroop JP. Studies of inference in serial verbal reactions. J Exp Psychol. 1935;18:643&#x2013;662.</Citation></Reference><Reference><Citation>Wechsler D. Wechsler Adult Intelligence Scale -Revised. San Antonio, TX: Psychological Corporation; 1987.</Citation></Reference><Reference><Citation>Salthouse TA, Babcock RL. Decomposing adult age differences in working memory. Dev Psychol. 1991;27(5):763&#x2013;776.</Citation></Reference><Reference><Citation>Benton AL. Differential behavioral effects in frontal lobe disease. Neuropsychologia. 1968;6(1):53&#x2013;60.</Citation></Reference><Reference><Citation>Mathis CA, Wang Y, Holt DP, et al. Synthesis and evaluation of 11C-labeled 6-substituted 2- arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46(13):2740&#x2013;2754.</Citation><ArticleIdList><ArticleId IdType="pubmed">12801237</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan J, Fowler JS, Volkow ND, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16(5):834&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">8784228</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25(11):1528&#x2013;1547.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944649</ArticleId></ArticleIdList></Reference><Reference><Citation>Joachim CL, Mori H, Selkoe DJ. Amyloid beta-protein deposition in tissues other than brain in Alzheimer&#x2019;s disease. Nature. 1989;341(6239):226&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">2528696</ArticleId></ArticleIdList></Reference><Reference><Citation>Meltzer CC, Kinahan PE, Greer PJ, et al. Comparative evaluation of MR-based partial- volume correction schemes for PET. J Nucl Med. 1999;40(12):2053&#x2013;2065.</Citation><ArticleIdList><ArticleId IdType="pubmed">10616886</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal- mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132(Pt 5):1310&#x2013;1323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677792</ArticleId><ArticleId IdType="pubmed">19042931</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33(3):341&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, S&#xe9;gonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31(3):968&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65(11):1509&#x2013;1517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>Correa DD, Graves RE, Costa L. Awareness of memory deficit in Alzheimer&#x2019;s disease patients and memory-impaired older adults. Aging Neuropsychol Cogn. 1996;3(3):215&#x2013;228.</Citation></Reference><Reference><Citation>Duke LM, Seltzer B, Seltzer JE, Vasterling JJ. Cognitive components of deficit awareness in Alzheimer&#x2019;s disease. Neuropsychology. 2002;16(3):359&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">12146683</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Keeffe FM, Dockree PM, Moloney P, Carton S, Robertson IH. Characterising error-awareness of attentional lapses and inhibitory control failures in patients with traumatic brain injury. Exp Brain Res. 2007;180(1):59&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">17216412</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Baxter LC, Wilder LS, et al. Neural correlates of self-reflection. Brain. 2002;125(Pt 8):1808&#x2013;1814.</Citation><ArticleIdList><ArticleId IdType="pubmed">12135971</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuss DT, Picton TW, Alexander MP. Consciousness, self-awareness, and the frontal lobes. In: Salloway S, Malloy P, Duff JD, editors. The frontal lobes and neuropsychiatric illness. Washington, DC: American Psychiatric Pub; 2001. pp. 101&#x2013;112.</Citation></Reference><Reference><Citation>Schmitz TW, Kawahara-Baccus TN, Johnson SC. Metacognitive evaluation, self-relevance, and the right prefrontal cortex. Neuroimage. 2004;22(2):941&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pubmed">15193625</ArticleId></ArticleIdList></Reference><Reference><Citation>Prichep LS, John ER, Ferris SH, et al. Prediction of longitudinal cognitive decline in normal elderly with subjective complaints using electrophysiological imaging. Neurobiol Aging. 2006;27(3):471&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">16213630</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolla KI, Lindgren KN, Bonaccorsy C, Bleecker ML. Memory complaints in older adults. Fact or fiction? Arch Neurol. 1991;48(1):61&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">1986728</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22332151</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3679</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><Issue>3</Issue><PubDate><Year>2012</Year><Month>Feb</Month><Day>13</Day></PubDate></JournalIssue><Title>Archives of internal medicine</Title><ISOAbbreviation>Arch Intern Med</ISOAbbreviation></Journal><ArticleTitle>Exposure to particulate air pollution and cognitive decline in older women.</ArticleTitle><Pagination><StartPage>219</StartPage><EndPage>227</EndPage><MedlinePgn>219-27</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archinternmed.2011.683</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Chronic exposure to particulate air pollution may accelerate cognitive decline in older adults, although data on this association are limited. Our objective was to examine long-term exposure to particulate matter (PM) air pollution, both coarse ([PM 2.5-10 &#x3bc;m in diameter [PM(2.5-10)]) and fine (PM &lt;2.5 &#x3bc;m in diameter [PM(2.5)]), in relation to cognitive decline.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The study population comprised the Nurses' Health Study Cognitive Cohort, which included 19,409 US women aged 70 to 81 years. We used geographic information system-based spatiotemporal smoothing models to estimate recent (1 month) and long-term (7-14 years) exposures to PM(2.5-10), and PM(2.5) preceding baseline cognitive testing (1995-2001) of participants residing in the contiguous United States. We used generalized estimating equation regression to estimate differences in the rate of cognitive decline across levels of PM(2.5-10) and PM(2.5) exposures. The main outcome measure was cognition, via validated telephone assessments, administered 3 times at approximately 2-year intervals, including tests of general cognition, verbal memory, category fluency, working memory, and attention.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Higher levels of long-term exposure to both PM(2.5-10) and PM(2.5) were associated with significantly faster cognitive decline. Two-year decline on a global score was 0.020 (95% CI, -0.032 to -0.008) standard units worse per 10 &#x3bc;g/m(3) increment in PM(2.5-10) exposure and 0.018 (95% CI, -0.035 to -0.002) units worse per 10 &#x3bc;g/m(3) increment in PM(2.5) exposure. These differences in cognitive trajectory were similar to those between women in our cohort who were approximately 2 years apart in age, indicating that the effect of a 10-&#x3bc;g/m(3) increment in long-term PM exposure is cognitively equivalent to aging by approximately 2 years.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Long-term exposure to PM(2.5-10) and PM(2.5) at levels typically experienced by many individuals in the United States is associated with significantly worse cognitive decline in older women.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weuve</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Rush Institute for Healthy Aging, Rush University Medical Center, Chicago, IL 60625, USA. Jennifer_Weuve@rush.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puett</LastName><ForeName>Robin C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Joel</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Yanosky</LastName><ForeName>Jeff D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Laden</LastName><ForeName>Francine</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Grodstein</LastName><ForeName>Francine</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 CA087969</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 ES000002</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R24 HD041041</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 ES016829</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES017017</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Intern Med</MedlineTA><NlmUniqueID>0372440</NlmUniqueID><ISSNLinking>0003-9926</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052638">Particulate Matter</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Intern Med. 2012 Feb 13;172(3):227-8. doi: 10.1001/archinternmed.2011.799.</RefSource><PMID Version="1">22332152</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Arch Intern Med. 2012 Feb 13;172(3):271-3. doi: 10.1001/archinternmed.2011.762.</RefSource><PMID Version="1">22332161</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Arch Intern Med. 2012 Jul 9;172(13):1045; author reply 1045-6. doi: 10.1001/archinternmed.2012.1698.</RefSource><PMID Version="1">22777636</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004781" MajorTopicYN="N">Environmental Exposure</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010316" MajorTopicYN="N">Particle Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052638" MajorTopicYN="N">Particulate Matter</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>4</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22332151</ArticleId><ArticleId IdType="mid">NIHMS451584</ArticleId><ArticleId IdType="pmc">PMC3622279</ArticleId><ArticleId IdType="doi">10.1001/archinternmed.2011.683</ArticleId><ArticleId IdType="pii">172/3/219</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tomaszewski Farias S, Cahn-Weiner DA, Harvey DJ, et al. Longitudinal changes in memory and executive functioning are associated with longitudinal change in instrumental activities of daily living in older adults. Clin Neuropsychol. 2009;23(3):446&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2881703</ArticleId><ArticleId IdType="pubmed">18821181</ArticleId></ArticleIdList></Reference><Reference><Citation>Chodosh J, Seeman TE, Keeler E, et al. Cognitive decline in high-functioning older persons is associated with an increased risk of hospitalization. J Am Geriatr Soc. 2004;52(9):1456&#x2013;1462.</Citation><ArticleIdList><ArticleId IdType="pubmed">15341546</ArticleId></ArticleIdList></Reference><Reference><Citation>Linn RT, Wolf PA, Bachman DL, et al. The &#x201c;preclinical phase&#x201d; of probable Alzheimer&#x2019;s disease: a 13-year prospective study of the Framingham cohort. Arch Neurol. 1995;52(5):485&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pubmed">7733843</ArticleId></ArticleIdList></Reference><Reference><Citation>Small BJ, Fratiglioni L, Viitanen M, Winblad B, B&#xe4;ckman L. The course of cognitive impairment in preclinical Alzheimer disease: three- and 6-year follow-up of a population-based sample. Arch Neurol. 2000;57(6):839&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867781</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology. 2002;59(2):198&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">12136057</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60(8):1119&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925369</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer&#x2019;s disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88(9):1337&#x2013;1342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1509089</ArticleId><ArticleId IdType="pubmed">9736873</ArticleId></ArticleIdList></Reference><Reference><Citation>Wimo A, Winblad B, J&#xf6;nsson L. The worldwide societal costs of dementia: estimates for 2009. Alzheimers Dement. 2010;6(2):98&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">20298969</ArticleId></ArticleIdList></Reference><Reference><Citation>Daviglus ML, Bell CC, Berrettini W, et al. National Institutes of Health State-of-the-Science Conference Statement: preventing Alzheimer&#x2019;s disease and cognitive decline. NIH Consens State Sci Statements. 2010 Apr 26&#x2013;28;27(4):1&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">20445638</ArticleId></ArticleIdList></Reference><Reference><Citation>Samet J, Krewski D. Health effects associated with exposure to ambient air pollution. J Toxicol Environ Health A. 2007;70(3&#x2013;4):227&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">17365585</ArticleId></ArticleIdList></Reference><Reference><Citation>Pope CA, III, Dockery DW. Health effects of fine particulate air pollution: lines that connect. J Air Waste Manag Assoc. 2006;56(6):709&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">16805397</ArticleId></ArticleIdList></Reference><Reference><Citation>Laden F, Schwartz J, Speizer FE, Dockery DW. Reduction in fine particulate air pollution and mortality: extended follow-up of the Harvard Six Cities study. Am J Respir Crit Care Med. 2006;173(6):667&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2662950</ArticleId><ArticleId IdType="pubmed">16424447</ArticleId></ArticleIdList></Reference><Reference><Citation>Clancy L, Goodman P, Sinclair H, Dockery DW. Effect of air-pollution control on death rates in Dublin, Ireland: an intervention study. Lancet. 2002;360(9341):1210&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pubmed">12401247</ArticleId></ArticleIdList></Reference><Reference><Citation>US Environmental Protection Agency. The Particle Pollution Report: Current Understanding of Air Quality and Emissions Through 2003: Office of Air Quality Planning and Standards. Research Triangle Park, NC: Emissions, Monitoring, and Analysis Division; 2004.</Citation></Reference><Reference><Citation>Adar SD, Gold DR, Coull BA, Schwartz J, Stone PH, Suh H. Focused exposures to airborne traffic particles and heart rate variability in the elderly. Epidemiology. 2007;18(1):95&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">17149139</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominici F, Peng RD, Bell ML, et al. Fine particulate air pollution and hospital admission for cardiovascular and respiratory diseases. JAMA. 2006;295(10):1127&#x2013;1134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3543154</ArticleId><ArticleId IdType="pubmed">16522832</ArticleId></ArticleIdList></Reference><Reference><Citation>Sr&#xe1;m RJ, Benes I, Binkov&#xe1; B, et al. Teplice program&#x2014;the impact of air pollution on human health. Environ Health Perspect. 1996;104(suppl 4):699&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1469669</ArticleId><ArticleId IdType="pubmed">8879999</ArticleId></ArticleIdList></Reference><Reference><Citation>Suglia SF, Gryparis A, Wright RO, Schwartz J, Wright RJ. Association of black carbon with cognition among children in a prospective birth cohort study. Am J Epidemiol. 2008;167(3):280&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">18006900</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JC, Schwartz J. Neurobehavioral effects of ambient air pollution on cognitive performance in US adults. Neurotoxicology. 2009;30(2):231&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">19150462</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranft U, Schikowski T, Sugiri D, Krutmann J, Kr&#xe4;mer U. Long-term exposure to traffic-related particulate matter impairs cognitive function in the elderly. Environ Res. 2009;109(8):1004&#x2013;1011.</Citation><ArticleIdList><ArticleId IdType="pubmed">19733348</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng Y, Gu D, Purser J, Hoenig H, Christakis N. Associations of environmental factors with elderly health and mortality in China. Am J Public Health. 2010;100(2):298&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2804639</ArticleId><ArticleId IdType="pubmed">20019314</ArticleId></ArticleIdList></Reference><Reference><Citation>Power MC, Weisskopf MG, Alexeeff SE, Coull BA, Spiro A, III, Schwartz J. Traffic-related air pollution and cognitive function in a cohort of older men. Environ Health Perspect. 2011;119(5):682&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094421</ArticleId><ArticleId IdType="pubmed">21172758</ArticleId></ArticleIdList></Reference><Reference><Citation>Colditz GA, Manson JE, Hankinson SE. The Nurses&#x2019; Health Study: 20-year contribution to the understanding of health among women. J Womens Health. 1997;6(1):49&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">9065374</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanosky JD, Paciorek CJ, Schwartz J, Laden F, Puett RC, Suh HH. Spatiotemporal modeling of chronic PM10 exposure for the Nurses&#x2019; Health Study. Atmos Environ. 2008;42(18):4047&#x2013;4062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2705904</ArticleId><ArticleId IdType="pubmed">19584946</ArticleId></ArticleIdList></Reference><Reference><Citation>Paciorek CJ, Yanosky JD, Puett RC, Laden F, Suh H. Practical large-scale spatiotemporal modeling of particulate matter concentrations. Ann of Appl Stat. 2009;3(1):370&#x2013;397.</Citation></Reference><Reference><Citation>Yanosky JD, Paciorek CJ, Suh HH. Predicting chronic fine and coarse particulate exposures using spatiotemporal models for the Northeastern and Midwestern United States. Environ Health Perspect. 2009;117(4):522&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2679594</ArticleId><ArticleId IdType="pubmed">19440489</ArticleId></ArticleIdList></Reference><Reference><Citation>Spengler JD, Koutrakis P, Dockery DW, Raizenne M, Speizer FE. Health effects of acid aerosols on North American children: air pollution exposures. Environ Health Perspect. 1996;104(5):492&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1469351</ArticleId><ArticleId IdType="pubmed">8743436</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh HH, Nishioka Y, Allen GA, Koutrakis P, Burton RM. The metropolitan acid aerosol characterization study: results from the summer 1994 Washington, DC field study. Environ Health Perspect. 1997;105(8):826&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1470204</ArticleId><ArticleId IdType="pubmed">9347898</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt J, Spencer M, Folstein M. The telephone interview for cognitive status. Neuropsychiatry Neuropsychol Behav Neurol. 1988;1:111&#x2013;117.</Citation></Reference><Reference><Citation>Scherr PA, Albert MS, Funkenstein HH, et al. Correlates of cognitive function in an elderly community population. Am J Epidemiol. 1988;128(5):1084&#x2013;1101.</Citation><ArticleIdList><ArticleId IdType="pubmed">3189282</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert M, Smith LA, Scherr PA, Taylor JO, Evans DA, Funkenstein HH. Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer&#x2019;s disease. Int J Neurosci. 1991;57(3&#x2013;4):167&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">1938160</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodglass H, Kaplan E. The Assessment of Aphasia. Philadelphia, PA: Lea &amp; Febiger; 1983.</Citation></Reference><Reference><Citation>Lezak MD. Neuropsychological Assessment. 3. New York, NY: Oxford; 1995. pp. 335&#x2013;384.</Citation></Reference><Reference><Citation>Bretsky P, Guralnik JM, Launer L, Albert M, Seeman TE MacArthur Studies of Successful Aging. The role of APOE-epsilon4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging. Neurology. 2003;60(7):1077&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pubmed">12682309</ArticleId></ArticleIdList></Reference><Reference><Citation>Small BJ, Mobly JL, Laukka EJ, Jones S, B&#xe4;ckman L. Cognitive deficits in preclinical Alzheimer&#x2019;s disease. Acta Neurol Scand Suppl. 2003;179:29&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">12603248</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzmaurice GM, Laird NM, Ware JH. Marginal Models: Generalized Estimating Equations (GEE): Applied Longitudinal Analysis. Hoboken, NJ: John Wiley &amp; Sons, Inc; 2004. pp. 291&#x2013;323.</Citation></Reference><Reference><Citation>Weuve J, Kang JH, Manson JE, Breteler MM, Ware JH, Grodstein F. Physical activity, including walking, and cognitive function in older women. JAMA. 2004;292(12):1454&#x2013;1461.</Citation><ArticleIdList><ArticleId IdType="pubmed">15383516</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberd&#xf6;rster G, Utell MJ. Ultrafine particles in the urban air: to the respiratory tract&#x2014;and beyond? Environ Health Perspect. 2002;110(8):A440&#x2013;A441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1240959</ArticleId><ArticleId IdType="pubmed">12153769</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters A, Veronesi B, Calder&#xf3;n-Garcidue&#xf1;as L, et al. Translocation and potential neurological effects of fine and ultrafine particles a critical update. Part Fibre Toxicol. 2006 Sep 8;3:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1570474</ArticleId><ArticleId IdType="pubmed">16961926</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberd&#xf6;rster G, Sharp Z, Atudorei V, et al. Translocation of inhaled ultrafine particles to the brain. Inhal Toxicol. 2004;16(6&#x2013;7):437&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">15204759</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell A, Oldham M, Becaria A, et al. Particulate matter in polluted air may increase biomarkers of inflammation in mouse brain. Neurotoxicology. 2005;26(1):133&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">15527881</ArticleId></ArticleIdList></Reference><Reference><Citation>Levesque S, Taetzsch T, Lull ME, et al. Diesel exhaust activates and primes microglia: air pollution, neuroinflammation, &amp; regulation of dopaminergic neurotoxicity. Environ Health Perspect. 2011;119(8):1149&#x2013;1155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3237351</ArticleId><ArticleId IdType="pubmed">21561831</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan TE, Davis DA, Iwata N, et al. Glutamatergic neurons in rodent models respond to nanoscale particulate urban air pollutants in vivo and in vitro. Environ Health Perspect. 2011;119(7):1003&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3222976</ArticleId><ArticleId IdType="pubmed">21724521</ArticleId></ArticleIdList></Reference><Reference><Citation>Calder&#xf3;n-Garcidue&#xf1;as L, Azzarelli B, Acuna H, et al. Air pollution and brain damage. Toxicol Pathol. 2002;30(3):373&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">12051555</ArticleId></ArticleIdList></Reference><Reference><Citation>Calder&#xf3;n-Garcidue&#xf1;as L, Reed W, Maronpot RR, et al. Brain inflammation and Alzheimer&#x2019;s-like pathology in individuals exposed to severe air pollution. Toxicol Pathol. 2004;32(6):650&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pubmed">15513908</ArticleId></ArticleIdList></Reference><Reference><Citation>Brook RD, Franklin B, Cascio W, et al. Expert Panel on Population and Prevention Science of the American Heart Association. Air pollution and cardiovascular disease: a statement for healthcare professionals from the Expert Panel on Population and Prevention Science of the American Heart Association. Circulation. 2004;109(21):2655&#x2013;2671.</Citation><ArticleIdList><ArticleId IdType="pubmed">15173049</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller KA, Siscovick DS, Sheppard L, et al. Long-term exposure to air pollution and incidence of cardiovascular events in women. N Engl J Med. 2007;356 (5):447&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">17267905</ArticleId></ArticleIdList></Reference><Reference><Citation>Stampfer MJ. Cardiovascular disease and Alzheimer&#x2019;s disease: common links. J Intern Med. 2006;260(3):211&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">16918818</ArticleId></ArticleIdList></Reference><Reference><Citation>Breteler MM. Vascular involvement in cognitive decline and dementia: epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann N Y Acad Sci. 2000;903:457&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pubmed">10818538</ArticleId></ArticleIdList></Reference><Reference><Citation>Puett RC, Hart JE, Yanosky JD, et al. Chronic fine and coarse particulate exposure, mortality, and coronary heart disease in the Nurses&#x2019; Health Study. Environ Health Perspect. 2009;117(11):1697&#x2013;1701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2801178</ArticleId><ArticleId IdType="pubmed">20049120</ArticleId></ArticleIdList></Reference><Reference><Citation>Puett RC, Schwartz J, Hart JE, et al. Chronic particulate exposure, mortality, and coronary heart disease in the nurses&#x2019; health study. Am J Epidemiol. 2008;168 (10):1161&#x2013;1168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732957</ArticleId><ArticleId IdType="pubmed">18835862</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">22332161</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3679</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><Issue>3</Issue><PubDate><Year>2012</Year><Month>Feb</Month><Day>13</Day></PubDate></JournalIssue><Title>Archives of internal medicine</Title><ISOAbbreviation>Arch Intern Med</ISOAbbreviation></Journal><ArticleTitle>Passive smoking and risk of cognitive impairment in women who never smoke.</ArticleTitle><Pagination><StartPage>271</StartPage><EndPage>273</EndPage><MedlinePgn>271-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archinternmed.2011.762</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ruoling</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Dongmei</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yang</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Zhi</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Ken</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Intern Med</MedlineTA><NlmUniqueID>0372440</NlmUniqueID><ISSNLinking>0003-9926</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052638">Particulate Matter</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Arch Intern Med. 2012 Feb 13;172(3):219-27. doi: 10.1001/archinternmed.2011.683.</RefSource><PMID Version="1">22332151</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004781" MajorTopicYN="N">Environmental Exposure</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052638" MajorTopicYN="N">Particulate Matter</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22332161</ArticleId><ArticleId IdType="doi">10.1001/archinternmed.2011.762</ArticleId><ArticleId IdType="pii">172/3/271</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22312439</PMID><DateCompleted><Year>2012</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>2</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families.</ArticleTitle><Pagination><StartPage>e31039</StartPage><MedlinePgn>e31039</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e31039</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0031039</ELocationID><Abstract><AbstractText>Pathogenic mutations in APP, PSEN1, PSEN2, MAPT and GRN have previously been linked to familial early onset forms of dementia. Mutation screening in these genes has been performed in either very small series or in single families with late onset AD (LOAD). Similarly, studies in single families have reported mutations in MAPT and GRN associated with clinical AD but no systematic screen of a large dataset has been performed to determine how frequently this occurs. We report sequence data for 439 probands from late-onset AD families with a history of four or more affected individuals. Sixty sequenced individuals (13.7%) carried a novel or pathogenic mutation. Eight pathogenic variants, (one each in APP and MAPT, two in PSEN1 and four in GRN) three of which are novel, were found in 14 samples. Thirteen additional variants, present in 23 families, did not segregate with disease, but the frequency of these variants is higher in AD cases than controls, indicating that these variants may also modify risk for disease. The frequency of rare variants in these genes in this series is significantly higher than in the 1,000 genome project (p&#x200a;=&#x200a;5.09 &#xd7; 10&#x207b;&#x2075;; OR&#x200a;=&#x200a;2.21; 95%CI&#x200a;=&#x200a;1.49-3.28) or an unselected population of 12,481 samples (p&#x200a;=&#x200a;6.82 &#xd7; 10&#x207b;&#x2075;; OR&#x200a;=&#x200a;2.19; 95%CI&#x200a;=&#x200a;1.347-3.26). Rare coding variants in APP, PSEN1 and PSEN2, increase risk for or cause late onset AD. The presence of variants in these genes in LOAD and early-onset AD demonstrates that factors other than the mutation can impact the age at onset and penetrance of at least some variants associated with AD. MAPT and GRN mutations can be found in clinical series of AD most likely due to misdiagnosis. This study clearly demonstrates that rare variants in these genes could explain an important proportion of genetic heritability of AD, which is not detected by GWAS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Hope Center Program on Protein Aggregation and Neurodegeneration, Washington University, St. Louis, Missouri, United States of America. cruchagc@psychiatry.wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haller</LastName><ForeName>Gabe</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Chakraverty</LastName><ForeName>Sumitra</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mayo</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Vallania</LastName><ForeName>Francesco L M</ForeName><Initials>FL</Initials></Author><Author ValidYN="Y"><LastName>Mitra</LastName><ForeName>Robi D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Faber</LastName><ForeName>Kelley</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Bird</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Diaz-Arrastia</LastName><ForeName>Ramon</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials></Author><Author ValidYN="Y"><LastName>St Jean</LastName><ForeName>Pamela</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lawson</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ehm</LastName><ForeName>Margaret G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><CollectiveName>NIA-LOAD/NCRAD Family Study Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH060009</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1P30NS069329-01</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041797</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG21886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37AG15473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG016208</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG035083</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG056270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG035083</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG16208</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG026395</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS069329</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492314">GRN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508861">PSEN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>PLoS One. 2012;7(5): doi/10.1371/annotation/c92e16da-7733-421d-b063-1db19488daa6</RefSource><Note>Haller, Gabe [added].</Note></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have read the journal's policy and have the following conflicts: PSJ, ML and ME are employed by GlaxoSmithKline. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santana</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schmechel</LastName><ForeName>Donald</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gaskell</LastName><ForeName>Perry</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Welsh-Bohmer</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>Margaret</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horner</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Growdon</LastName><ForeName>John H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blacker</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuntz</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norgaard</LastName><ForeName>Lindsay</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Larson</LastName><ForeName>Nathan</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kistler</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parfitt</LastName><ForeName>Fracine</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haddwow</LastName><ForeName>Jenny</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silverman</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beeri</LastName><ForeName>Michal Schnaider</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sano</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Joy</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lally</LastName><ForeName>Rachel</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulum</LastName><ForeName>Marcel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bigio</LastName><ForeName>Eileen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffery</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kramer</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Payne-Murphy</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bennett</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Holli</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chang</LastName><ForeName>Jeen-Soo</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arends</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harrell</LastName><ForeName>Lindy</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartzokis</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffery</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>Po H</ForeName><Initials>PH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toland</LastName><ForeName>Usha</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Markesbery</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brickhouse</LastName><ForeName>Alise</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deerlin</LastName><ForeName>Vivianna Van</ForeName><Initials>VV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wood</LastName><ForeName>Elisabeth McCarty</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weamer</LastName><ForeName>Elise</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chui</LastName><ForeName>I Helena</ForeName><Initials>IH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varpetian</LastName><ForeName>Arousiak</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diaz-Arrastia</LastName><ForeName>Ramon</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bird</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rumbaugh</LastName><ForeName>Malia</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raskind</LastName><ForeName>Murray</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norton</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levitch</LastName><ForeName>Denise</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grant</LastName><ForeName>Betsy</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coats</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22312439</ArticleId><ArticleId IdType="pmc">PMC3270040</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0031039</ArticleId><ArticleId IdType="pii">PONE-D-11-25311</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cruts M, van Duijn CM, Backhovens H, Van den Broeck M, Wehnert A, et al. Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Hum Mol Genet. 1998;7:43&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">9384602</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva EA, Fafel KC, Song YQ, Medeiros H, Sato C, et al. Screening for PS1 mutations in a referral-based series of AD cases: 21 novel mutations. Neurology. 2001;57:621&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pubmed">11524469</ArticleId></ArticleIdList></Reference><Reference><Citation>Brickell KL, Leverenz JB, Steinbart EJ, Rumbaugh M, Schellenberg GD, et al. Clinicopathological concordance and discordance in three monozygotic twin pairs with familial Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2007;78:1050&#x2013;1055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117553</ArticleId><ArticleId IdType="pubmed">17615170</ArticleId></ArticleIdList></Reference><Reference><Citation>Athan ES, Williamson J, Ciappa A, Santana V, Romas SN, et al. A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families. Jama. 2001;286:2257&#x2013;2263.</Citation><ArticleIdList><ArticleId IdType="pubmed">11710891</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991;349:704&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe JS, Jacquart S, Chakraverty S, Wang J, Mayo K, et al. Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Ann Neurol. 2007;61:446&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">17366635</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi G, Fotiou A, Jyrinji D, Tycko B, DeArmand S, et al. Novel presenilin 1 mutations associated with early onset of dementia in a family with both early-onset and late-onset Alzheimer disease. Archives of Neurology. 2000;57:1454&#x2013;1457.</Citation><ArticleIdList><ArticleId IdType="pubmed">11030797</ArticleId></ArticleIdList></Reference><Reference><Citation>Larner AJ, Ray PS, Doran M. The R269H mutation in presenilin-1 presenting as late-onset autosomal dominant Alzheimer's disease. J Neurol Sci. 2007;252:173&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">17188713</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayadev S, Leverenz JB, Steinbart E, Stahl J, Klunk W, et al. Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. Brain: a journal of neurology. 2010;133:1143&#x2013;1154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850581</ArticleId><ArticleId IdType="pubmed">20375137</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomaino C, Bernardi L, Anfossi M, Costanzo A, Ferrise F, et al. Presenilin 2 Ser130Leu mutation in a case of late-onset &#x201c;sporadic&#x201d; Alzheimer's disease. Journal of Neurology. 2007;254:391&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pubmed">17345043</ArticleId></ArticleIdList></Reference><Reference><Citation>Arango D, Cruts M, Torres O, Backhovens H, Serrano ML, et al. Systematic genetic study of Alzheimer disease in Latin America: mutation frequencies of the amyloid beta precursor protein and presenilin genes in Colombia. American journal of medical genetics. 2001;103:138&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">11568920</ArticleId></ArticleIdList></Reference><Reference><Citation>Scacchi R, Gambina G, Moretto G, Corbo RM. A mutation screening by DHPLC of PSEN1 and APP genes reveals no significant variation associated with the sporadic late-onset form of Alzheimer's disease. Neuroscience letters. 2007;418:282&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">17412506</ArticleId></ArticleIdList></Reference><Reference><Citation>Taddei K, Fisher C, Laws SM, Martins G, Paton A, et al. Association between presenilin-1 Glu318Gly mutation and familial Alzheimer's disease in the Australian population. Molecular Psychiatry. 2002;7:776&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">12192622</ArticleId></ArticleIdList></Reference><Reference><Citation>de Silva R, Weiler M, Morris HR, Martin ER, Wood NW, et al. Strong association of a novel Tau promoter haplotype in progressive supranuclear palsy. Neurosci Lett. 2001;311:145&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">11578815</ArticleId></ArticleIdList></Reference><Reference><Citation>Houlden H, Crawford F, Rossor M, Mullan M. Screening for the APP codon 670/671 mutations in Alzheimer's disease. Neuroscience letters. 1993;154:161&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">8395665</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Vaula G, Romano DM, Mortilla M, Huang TL, et al. Assessment of amyloid beta-protein precursor gene mutations in a large set of familial and sporadic Alzheimer disease cases. American journal of human genetics. 1992;51:273&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1682666</ArticleId><ArticleId IdType="pubmed">1642228</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamino K, Orr HT, Payami H, Wijsman EM, Alonso ME, et al. Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region. American journal of human genetics. 1992;51:998&#x2013;1014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1682859</ArticleId><ArticleId IdType="pubmed">1415269</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, Wood EM, Moore P, Yuan W, Forman MS, et al. Clinical, genetic, and pathologic characteristics of patients with frontotemporal dementia and progranulin mutations. Arch Neurol. 2007;64:1148&#x2013;1153.</Citation><ArticleIdList><ArticleId IdType="pubmed">17698705</ArticleId></ArticleIdList></Reference><Reference><Citation>Huey ED, Grafman J, Wassermann EM, Pietrini P, Tierney MC, et al. Characteristics of frontotemporal dementia patients with a Progranulin mutation. Ann Neurol. 2006;60:374&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2987739</ArticleId><ArticleId IdType="pubmed">16983677</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortini F, Fenoglio C, Guidi I, Venturelli E, Pomati S, et al. Novel exon 1 progranulin gene variant in Alzheimer's disease. Eur J Neurol. 2008;15:1111&#x2013;1117.</Citation><ArticleIdList><ArticleId IdType="pubmed">18752597</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley BJ, Haidar W, Boeve BF, Baker M, Shiung M, et al. Alzheimer disease-like phenotype associated with the c.154delA mutation in progranulin. Arch Neurol. 2010;67:171&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902004</ArticleId><ArticleId IdType="pubmed">20142525</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Baker M, Gass J, Adamson J, Huey ED, et al. Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C&#x2212;&gt;T (Arg493X) mutation: an international initiative. Lancet Neurol. 2007;6:857&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pubmed">17826340</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwers N, Nuytemans K, van der Zee J, Gijselinck I, Engelborghs S, et al. Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch Neurol. 2007;64:1436&#x2013;1446.</Citation><ArticleIdList><ArticleId IdType="pubmed">17923627</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindquist SG, Holm IE, Schwartz M, Law I, Stokholm J, et al. Alzheimer disease-like clinical phenotype in a family with FTDP-17 caused by a MAPT R406W mutation. European journal of neurology: the official journal of the European Federation of Neurological Societies. 2008;15:377&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">18284428</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Dermaut B, Peeters K, Cruts M, Heutink P, et al. Tau (MAPT) mutation Arg406Trp presenting clinically with Alzheimer disease does not share a common founder in Western Europe. Human mutation. 2003;22:409&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">14517953</ArticleId></ArticleIdList></Reference><Reference><Citation>Momeni P, Pittman A, Lashley T, Vandrovcova J, Malzer E, et al. Clinical and pathological features of an Alzheimer's disease patient with the MAPT Delta K280 mutation. Neurobiology of aging. 2009;30:388&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2666148</ArticleId><ArticleId IdType="pubmed">17723255</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, Kassubek J, Landwehrmeyer BG, Mandelkow E, Mandelkow EM, et al. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol. 2009;16:297&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2847416</ArticleId><ArticleId IdType="pubmed">19364361</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LA, Grabowski TJ, Schmidt ML, Morris JC, Goate A, et al. Autosomal dominant dementia with widespread neurofibrillary tangles. Ann Neurol. 1997;42:564&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">9382467</ArticleId></ArticleIdList></Reference><Reference><Citation>The AlzGene Database. Alzheimer Research Forum.  Available at:  http://www.alzgene.org. (Accessed 09/27/2011)</Citation></Reference><Reference><Citation>Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, et al. Role of genes and environments for explaining Alzheimer disease. Archives of general psychiatry. 2006;63:168&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41:1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, Campion D, Sleegers K, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. Jama. 2010;303:1832&#x2013;1840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics. 2011;43:429&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genetics. 2011;43:436&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertekin-Taner N. Genetics of Alzheimer disease in the pre- and post-GWAS era. Alzheimers Res Ther. 2010;2:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2874262</ArticleId><ArticleId IdType="pubmed">20236449</ArticleId></ArticleIdList></Reference><Reference><Citation>So HC, Gui AH, Cherny SS, Sham PC. Evaluating the heritability explained by known susceptibility variants: a survey of ten complex diseases. Genetic epidemiology. 2011;35:310&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">21374718</ArticleId></ArticleIdList></Reference><Reference><Citation>Nejentsev S, Walker N, Riches D, Egholm M, Todd JA. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science. 2009;324:387&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707798</ArticleId><ArticleId IdType="pubmed">19264985</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzopardi D, Dallosso AR, Eliason K, Hendrickson BC, Jones N, et al. Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas. Cancer Res. 2008;68:358&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pubmed">18199528</ArticleId></ArticleIdList></Reference><Reference><Citation>Masson E, Chen JM, Scotet V, Le Marechal C, Ferec C. Association of rare chymotrypsinogen C (CTRC) gene variations in patients with idiopathic chronic pancreatitis. Hum Genet. 2008;123:83&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">18172691</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X, Liu Y, Gowen BB, Graviss EA, Clark AG, et al. Full-exon resequencing reveals toll-like receptor variants contribute to human susceptibility to tuberculosis disease. PLoS One. 2007;2:e1318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117342</ArticleId><ArticleId IdType="pubmed">18091991</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamboh MI, Aston CE, Perez-Tur J, Kokmen E, Ferrell RE, et al. A novel mutation in the apolipoprotein E gene (APOE*4 Pittsburgh) is associated with the risk of late-onset Alzheimer's disease. Neurosci Lett. 1999;263:129&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">10213152</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M, Suh J, Romano D, Truong MH, Mullin K, et al. Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity. Hum Mol Genet. 2009;18:3987&#x2013;3996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748890</ArticleId><ArticleId IdType="pubmed">19608551</ArticleId></ArticleIdList></Reference><Reference><Citation>Druley TE, Vallania FL, Wegner DJ, Varley KE, Knowles OL, et al. Quantification of rare allelic variants from pooled genomic DNA. Nat Methods. 2009;6:263&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2776647</ArticleId><ArticleId IdType="pubmed">19252504</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallania FL, Druley TE, Ramos E, Wang J, Borecki I, et al. High-throughput discovery of rare insertions and deletions in large cohorts. Genome Res. 2010;20:1711&#x2013;1718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989997</ArticleId><ArticleId IdType="pubmed">21041413</ArticleId></ArticleIdList></Reference><Reference><Citation>Exome Variant Server.  Available:  http://evsgswashingtonedu/EVS/). Accessed 2011 Nov 1.</Citation></Reference><Reference><Citation>Yu CE, Bird TD, Bekris LM, Montine TJ, Leverenz JB, et al. The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch Neurol. 2010;67:161&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2901991</ArticleId><ArticleId IdType="pubmed">20142524</ArticleId></ArticleIdList></Reference><Reference><Citation>Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2855889</ArticleId><ArticleId IdType="pubmed">20354512</ArticleId></ArticleIdList></Reference><Reference><Citation>Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Molecular Psychiatry 2011</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3162068</ArticleId><ArticleId IdType="pubmed">21556001</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerrish A, Russo G, Richards A, Moskvina V, Ivanov D, et al. The Role of Variation at AbetaPP, PSEN1, PSEN2, and MAPT in Late Onset Alzheimer's Disease. J Alzheimers Dis 2011</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4118466</ArticleId><ArticleId IdType="pubmed">22027014</ArticleId></ArticleIdList></Reference><Reference><Citation>Gass J, Cannon A, Mackenzie IR, Boeve B, Baker M, et al. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet. 2006;15:2988&#x2013;3001.</Citation><ArticleIdList><ArticleId IdType="pubmed">16950801</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickering-Brown SM, Baker M, Gass J, Boeve BF, Loy CT, et al. Mutations in progranulin explain atypical phenotypes with variants in MAPT. Brain. 2006;129:3124&#x2013;3126.</Citation><ArticleIdList><ArticleId IdType="pubmed">17071927</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam M, Johnson N, Krefft TA, Gass JM, Cannon AD, et al. Progranulin mutations in primary progressive aphasia: the PPA1 and PPA3 families. Arch Neurol. 2007;64:43&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210807</ArticleId></ArticleIdList></Reference><Reference><Citation>Spina S, Murrell JR, Huey ED, Wassermann EM, Pietrini P, et al. Clinicopathologic features of frontotemporal dementia with Progranulin sequence variation. Neurology 2007</Citation><ArticleIdList><ArticleId IdType="pubmed">17202431</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossor MN, Fox NC, Beck J, Campbell TC, Collinge J. Incomplete penetrance of familial Alzheimer's disease in a pedigree with a novel presenilin-1 gene mutation. Lancet. 1996;347:1560.</Citation><ArticleIdList><ArticleId IdType="pubmed">8684135</ArticleId></ArticleIdList></Reference><Reference><Citation>Llado A, Fortea J, Ojea T, Bosch B, Sanz P, et al. A novel PSEN1 mutation (K239N) associated with Alzheimer's disease with wide range age of onset and slow progression. Eur J Neurol. 2010;17:994&#x2013;996.</Citation><ArticleIdList><ArticleId IdType="pubmed">20158511</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Ber I, van der Zee J, Hannequin D, Gijselinck I, Campion D, et al. Progranulin null mutations in both sporadic and familial frontotemporal dementia. Hum Mutat. 2007;28:846&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pubmed">17436289</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain. 2007;130:2616&#x2013;2635.</Citation><ArticleIdList><ArticleId IdType="pubmed">17704526</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman JM, Smith CJ, Marin DB, Mohs RC, Propper CB. Familial patterns of risk in very late-onset Alzheimer disease. Arch Gen Psychiatry. 2003;60:190&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">12578437</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman JM, Ciresi G, Smith CJ, Marin DB, Schnaider-Beeri M. Variability of familial risk of Alzheimer disease across the late life span. Arch Gen Psychiatry. 2005;62:565&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pubmed">15867110</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez MF, McMurtray A. Frontotemporal dementia-like phenotypes associated with presenilin-1 mutations. Am J Alzheimers Dis Other Demen. 2006;21:281&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10833339</ArticleId><ArticleId IdType="pubmed">16948293</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardi L, Tomaino C, Anfossi M, Gallo M, Geracitano S, et al. Novel PSEN1 and PGRN mutations in early-onset familial frontotemporal dementia. Neurobiol Aging. 2009;30:1825&#x2013;1833.</Citation><ArticleIdList><ArticleId IdType="pubmed">18314228</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcon G, Di Fede G, Giaccone G, Rossi G, Giovagnoli AR, et al. A novel Italian presenilin 2 gene mutation with prevalent behavioral phenotype. J Alzheimers Dis. 2009;16:509&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">19276543</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijsman EM, Pankratz ND, Choi Y, Rothstein JH, Faber KM, et al. Genome-wide association of familial late-onset Alzheimer's disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. PLoS genetics. 2011;7:e1001308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3040659</ArticleId><ArticleId IdType="pubmed">21379329</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunak S, Engelbrecht J, Knudsen S. Prediction of human mRNA donor and acceptor sites from the DNA sequence. J Mol Biol. 1991;220:49&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">2067018</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22323707</PMID><DateCompleted><Year>2012</Year><Month>03</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>6</Issue><PubDate><Year>2012</Year><Month>Feb</Month><Day>08</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Temporal order memory assessed during spatiotemporal navigation as a behavioral cognitive marker for differential Alzheimer's disease diagnosis.</ArticleTitle><Pagination><StartPage>1942</StartPage><EndPage>1952</EndPage><MedlinePgn>1942-52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4556-11.2012</ELocationID><Abstract><AbstractText>Episodic memory impairment is a hallmark for early diagnosis of Alzheimer's disease. Most actual tests used to diagnose Alzheimer's disease do not assess the spatiotemporal properties of episodic memory and lead to false-positive or -negative diagnosis. We used a newly developed, nonverbal navigation test for Human, based on the objective experimental testing of a spatiotemporal experience, to differentially Alzheimer's disease at the mild stage (N = 16 patients) from frontotemporal lobar degeneration (N = 11 patients) and normal aging (N = 24 subjects). Comparing navigation parameters and standard neuropsychological tests, temporal order memory appeared to have the highest predictive power for mild Alzheimer's disease diagnosis versus frontotemporal lobar degeneration and normal aging. This test was also nonredundant with classical neuropsychological tests. As a conclusion, our results suggest that temporal order memory tested in a spatial navigation task may provide a selective behavioral marker of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bellassen</LastName><ForeName>Virginie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Pierre et Marie Curie Paris 6 University, Navigation, Memory and Aging Team, Equipe Navigation Memoire et Vieillissement team, UMR7102, CNRS, F75005 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Igl&#xf3;i</LastName><ForeName>Kinga</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>de Souza</LastName><ForeName>Leonardo Cruz</ForeName><Initials>LC</Initials></Author><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Rondi-Reig</LastName><ForeName>Laure</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010775" MajorTopicYN="N">Photic Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013037" MajorTopicYN="N">Spatial Behavior</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>8</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22323707</ArticleId><ArticleId IdType="pmc">PMC6621707</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4556-11.2012</ArticleId><ArticleId IdType="pii">32/6/1942</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Antonova E, Parslow D, Brammer M, Dawson GR, Jackson SH, Morris RG. Age-related neural activity during allocentric spatial memory. Memory. 2009;17:125&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">18608980</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L. Clinical Dementia Rating (CDR) Psychopharmacol Bull. 1988;24:637&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">3249765</ArticleId></ArticleIdList></Reference><Reference><Citation>Bird CM, Burgess N. The hippocampus and memory: insights from spatial processing. Nat Rev Neurosci. 2008;9:182&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">18270514</ArticleId></ArticleIdList></Reference><Reference><Citation>Bird CM, Chan D, Hartley T, Pijnenburg YA, Rossor MN, Burgess N. Topographical short-term memory differentiates Alzheimer's disease from frontotemporal lobar degeneration. Hippocampus. 2010;20:1154&#x2013;1169.</Citation><ArticleIdList><ArticleId IdType="pubmed">19852032</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess N, Maguire EA, O'Keefe J. The human hippocampus and spatial and episodic memory. Neuron. 2002;35:625&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">12194864</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgui&#xe8;re E, Arleo A, Hojjati M, Elgersma Y, De Zeeuw CI, Berthoz A, Rondi-Reig L. Spatial navigation impairment in mice lacking cerebellar LTD: a motor adaptation deficit? Nat Neurosci. 2005;8:1292&#x2013;1294.</Citation><ArticleIdList><ArticleId IdType="pubmed">16136042</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Ratcliff G, Belle SH, Cauley JA, DeKosky ST, Ganguli M. Cognitive tests that best discriminate between presymptomatic AD and those who remain nondemented. Neurology. 2000;55:1847&#x2013;1853.</Citation><ArticleIdList><ArticleId IdType="pubmed">11134384</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherrier MM, Mendez M, Perryman K. Route learning performance in Alzheimer disease patients. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14:159&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">11513099</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiba AA, Kesner RP, Reynolds AM. Memory for spatial location as a function of temporal lag in rats: role of hippocampus and medial prefrontal cortex. Behav Neural Biol. 1994;61:123&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">8204078</ArticleId></ArticleIdList></Reference><Reference><Citation>Chupin M, G&#xe9;rardin E, Cuingnet R, Boutet C, Lemieux L, Leh&#xe9;ricy S, Benali H, Garnero L, Colliot O. Fully automatic hippocampus segmentation and classification in Alzheimer's disease and mild cognitive impairment applied on data from ADNI. Hippocampus. 2009;19:579&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2837195</ArticleId><ArticleId IdType="pubmed">19437497</ArticleId></ArticleIdList></Reference><Reference><Citation>Corsi P. Human memory and the medial temporal region of the brain. Abstracts Int. 1972;34:891B.</Citation></Reference><Reference><Citation>Cushman LA, Stein K, Duffy CJ. Detecting navigational deficits in cognitive aging and Alzheimer disease using virtual reality. Neurology. 2008;71:888&#x2013;895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676944</ArticleId><ArticleId IdType="pubmed">18794491</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCoteau WE, Kesner RP. A double dissociation between the rat hippocampus and medial caudoputamen in processing two forms of knowledge. Behav Neurosci. 2000;114:1096&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pubmed">11142642</ArticleId></ArticleIdList></Reference><Reference><Citation>deIpolyi AR, Rankin KP, Mucke L, Miller BL, Gorno-Tempini ML. Spatial cognition and the human navigation network in AD and MCI. Neurology. 2007;69:986&#x2013;997.</Citation><ArticleIdList><ArticleId IdType="pubmed">17785667</ArticleId></ArticleIdList></Reference><Reference><Citation>Dere E, Huston JP, De Souza Silva MA. Episodic-like memory in mice: simultaneous assessment of object, place and temporal order memory. Brain Res Brain Res Protoc. 2005;16:10&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">16185914</ArticleId></ArticleIdList></Reference><Reference><Citation>Driscoll I, Sutherland RJ. The aging hippocampus: navigating between rat and human experiments. Rev Neurosci. 2005;16:87&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">15957576</ArticleId></ArticleIdList></Reference><Reference><Citation>Drzezga A, Grimmer T, Henriksen G, Stangier I, Perneczky R, Diehl-Schmid J, Mathis CA, Klunk WE, Price J, DeKosky S, Wester HJ, Schwaiger M, Kurz A. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage. 2008;39:619&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pubmed">17962045</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Albert ML. Amnestic MCI or prodromal Alzheimer's disease? Lancet Neurol. 2004;3:246&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">15039037</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000;55:1621&#x2013;1626.</Citation><ArticleIdList><ArticleId IdType="pubmed">11113214</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">17616482</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010;9:1118&#x2013;1127.</Citation><ArticleIdList><ArticleId IdType="pubmed">20934914</ArticleId></ArticleIdList></Reference><Reference><Citation>Eichenbaum H. Hippocampus: cognitive processes and neural representations that underlie declarative memory. Neuron. 2004;44:109&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450164</ArticleId></ArticleIdList></Reference><Reference><Citation>Elfgren C, Brun A, Gustason L, Johanson A, Minthon L, Passnt U, Risberg J. Neuropsychological tests as discriminators between dementia of Alzheimer type and frontotemporal dementia. Int J Geriatric Psychiatry. 1994;9:635&#x2013;642.</Citation></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Fouquet C, Tobin C, Rondi-Reig L. A new approach for modeling episodic memory from rodents to humans: the temporal order memory. Behav Brain Res. 2010;215:172&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">20570697</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuster JM. The prefrontal cortex&#x2014;an update: time is of the essence. Neuron. 2001;30:319&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pubmed">11394996</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert PE, Kesner RP, Lee I. Dissociating hippocampal subregions: double dissociation between dentate gyrus and CA1. Hippocampus. 2001;11:626&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">11811656</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, Buschke H. Genuine memory deficits in dementia. Dev Neuropsychol. 1987;3:13&#x2013;36.</Citation></Reference><Reference><Citation>Hannesson DK, Vacca G, Howland JG, Phillips AG. Medial prefrontal cortex is involved in spatial temporal order memory but not spatial recognition memory in tests relying on spontaneous exploration in rats. Behav Brain Res. 2004;153:273&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">15219729</ArticleId></ArticleIdList></Reference><Reference><Citation>Hort J, Lacz&#xf3; J, Vyhn&#xe1;lek M, Bojar M, Bures J, Vlcek K. Spatial navigation deficit in amnestic mild cognitive impairment. Proc Natl Acad Sci U S A. 2007;104:4042&#x2013;4047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820705</ArticleId><ArticleId IdType="pubmed">17360474</ArticleId></ArticleIdList></Reference><Reference><Citation>Howland JG, Harrison RA, Hannesson DK, Phillips AG. Ventral hippocampal involvement in temporal order, but not recognition, memory for spatial information. Hippocampus. 2008;18:251&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">18064705</ArticleId></ArticleIdList></Reference><Reference><Citation>Igl&#xf3;i K, Zaoui M, Berthoz A, Rondi-Reig L. Sequential egocentric strategy is acquired as early as allocentric strategy: Parallel acquisition of these two navigation strategies. Hippocampus. 2009;19:1199&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pubmed">19360853</ArticleId></ArticleIdList></Reference><Reference><Citation>Igl&#xf3;i K, Doeller CF, Berthoz A, Rondi-Reig L, Burgess N. Lateralized human hippocampal activity predicts navigation based on sequence or place memory. Proc Natl Acad Sci U S A. 2010;107:14466&#x2013;14471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922562</ArticleId><ArticleId IdType="pubmed">20660746</ArticleId></ArticleIdList></Reference><Reference><Citation>Jobst KA, Smith AD, Szatmari M, Molyneux A, Esiri ME, King E, Smith A, Jaskowski A, McDonald B, Wald N. Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet. 1992;340:1179&#x2013;1183.</Citation><ArticleIdList><ArticleId IdType="pubmed">1359259</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalov&#xe1; E, Vlcek K, Jarol&#xed;mov&#xe1; E, Bures J. Allothetic orientation and sequential ordering of places is impaired in early stages of Alzheimer's disease: corresponding results in real space tests and computer tests. Behav Brain Res. 2005;159:175&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">15817181</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesner RP, Gilbert PE, Barua LA. The role of the hippocampus in memory for the temporal order of a sequence of odors. Behav Neurosci. 2002;116:286&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">11996313</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessels RP, Feijen J, Postma A. Implicit and explicit memory for spatial information in Alzheimer's disease. Dement Geriatr Cogn Disord. 2005;20:184&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">16088143</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessels RP, van den Berg E, Ruis C, Brands AM. The backward span of the Corsi Block-Tapping Task and its association with the WAIS-III Digit Span. Assessment. 2008;15:426&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">18483192</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremin H, Perrier D, De Wilde M. DENO-100&#x2014;Paradigme exp&#xe9;rimental et test clinique de d&#xe9;nomination contr&#xf4;l&#xe9;e: effet relatif de 7 variables exp&#xe9;rimentales sur les performances de 16 sujets atteints de maladies d&#xe9;g&#xe9;n&#xe9;ratives. Rev Neuropsychol. 1999:439&#x2013;440.</Citation></Reference><Reference><Citation>Kumaran D, Maguire EA. The dynamics of hippocampal activation during encoding of overlapping sequences. Neuron. 2006;49:617&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">16476669</ArticleId></ArticleIdList></Reference><Reference><Citation>Lezak MD. Neuropsychological assessment. Ed 2. New York: Oxford UP; 1983.</Citation></Reference><Reference><Citation>Longoni AM, Richardson JT, Aiello A. Articulatory rehearsal and phonological storage in working memory. Mem Cognit. 1993;21:11&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">8433641</ArticleId></ArticleIdList></Reference><Reference><Citation>Maguire EA, Burgess N, Donnett JG, Frackowiak RS, Frith CD, O'Keefe J. Knowing where and getting there: a human navigation network. Science. 1998;280:921&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">9572740</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol. 2001;58:1803&#x2013;1809.</Citation><ArticleIdList><ArticleId IdType="pubmed">11708987</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Moffat SD, Resnick SM. Effects of age on virtual environment place navigation and allocentric cognitive mapping. Behav Neurosci. 2002;116:851&#x2013;859.</Citation><ArticleIdList><ArticleId IdType="pubmed">12369805</ArticleId></ArticleIdList></Reference><Reference><Citation>Moffat SD, Zonderman AB, Resnick SM. Age differences in spatial memory in a virtual environment navigation task. Neurobiol Aging. 2001;22:787&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pubmed">11705638</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546&#x2013;1554.</Citation><ArticleIdList><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M, Chang L, Tseng W, Oakley H, Citron M, Klein WL, Vassar R, Disterhoft JF. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. Eur J Neurosci. 2006;23:251&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">16420434</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen AM, Downes JJ, Sahakian BJ, Polkey CE, Robbins TW. Planning and spatial working memory following frontal lobe lesions in man. Neuropsychologia. 1990;28:1021&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pubmed">2267054</ArticleId></ArticleIdList></Reference><Reference><Citation>Pai MC, Jacobs WJ. Topographical disorientation in community-residing patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2004;19:250&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">15027040</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Furst AJ, O'Neil JP, Racine CA, Mormino EC, Baker SL, Chetty S, Patel P, Pagliaro TA, Klunk WE, Mathis CA, Rosen HJ, Miller BL, Jagust WJ. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007;68:1205&#x2013;1212.</Citation><ArticleIdList><ArticleId IdType="pubmed">17420404</ArticleId></ArticleIdList></Reference><Reference><Citation>Rey A. Psychological examination of traumatic encephalopathy. Clin Neuropsychologist. 1993;7:3&#x2013;21.</Citation></Reference><Reference><Citation>Rondi-Reig L, Petit GH, Tobin C, Tonegawa S, Mariani J, Berthoz A. Impaired sequential egocentric and allocentric memories in forebrain-specific-NMDA receptor knock-out mice during a new task dissociating strategies of navigation. J Neurosci. 2006;26:4071&#x2013;4081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673881</ArticleId><ArticleId IdType="pubmed">16611824</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarazin M, Berr C, De Rotrou J, Fabrigoule C, Pasquier F, Legrain S, Michel B, Puel M, Volteau M, Touchon J, Verny M, Dubois B. Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology. 2007;69:1859&#x2013;1867.</Citation><ArticleIdList><ArticleId IdType="pubmed">17984454</ArticleId></ArticleIdList></Reference><Reference><Citation>Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC. Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci U S A. 2002;99:4703&#x2013;4707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123711</ArticleId><ArticleId IdType="pubmed">11930016</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweickert R, Boruff B. Short-term memory capacity: magic number or magic spell? J Exp Psychol Learn Mem Cogn. 1986;12:419&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">2942626</ArticleId></ArticleIdList></Reference><Reference><Citation>Seab JP, Jagust WJ, Wong ST, Roos MS, Reed BR, Budinger TF. Quantitative NMR measurements of hippocampal atrophy in Alzheimer's disease. Magn Reson Med. 1988;8:200&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">3210957</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons JS, Verfaellie M, Galton CJ, Miller BL, Hodges JR, Graham KS. Recollection-based memory in frontotemporal dementia: implications for theories of long-term memory. Brain. 2002;125:2523&#x2013;2536.</Citation><ArticleIdList><ArticleId IdType="pubmed">12390977</ArticleId></ArticleIdList></Reference><Reference><Citation>Slachevsky A, Villalpando JM, Sarazin M, Hahn-Barma V, Pillon B, Dubois B. Frontal assessment battery and differential diagnosis of frontotemporal dementia and Alzheimer disease. Arch Neurol. 2004;61:1104&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pubmed">15262742</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson JC, Stopford CL, Snowden JS, Neary D. Qualitative neuropsychological performance characteristics in frontotemporal dementia and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2005;76:920&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739700</ArticleId><ArticleId IdType="pubmed">15965196</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PM, Hayashi KM, de Zubicaray G, Janke AL, Rose SE, Semple J, Herman D, Hong MS, Dittmer SS, Doddrell DM, Toga AW. Dynamics of gray matter loss in Alzheimer's disease. J Neurosci. 2003;23:994&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741905</ArticleId><ArticleId IdType="pubmed">12574429</ArticleId></ArticleIdList></Reference><Reference><Citation>Tierney MC, Yao C, Kiss A, McDowell I. Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years. Neurology. 2005;64:1853&#x2013;1859.</Citation><ArticleIdList><ArticleId IdType="pubmed">15955933</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivedi MA, Wichmann AK, Torgerson BM, Ward MA, Schmitz TW, Ries ML, Koscik RL, Asthana S, Johnson SC. Structural MRI discriminates individuals with Mild Cognitive Impairment from age-matched controls: a combined neuropsychological and voxel based morphometry study. Alzheimers Dement. 2006;2:296&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2584359</ArticleId><ArticleId IdType="pubmed">19020671</ArticleId></ArticleIdList></Reference><Reference><Citation>Tulving E. Episodic memory: from mind to brain. Annu Rev Psychol. 2002;53:1&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">11752477</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hoesen GW, Hyman BT, Damasio AR. Entorhinal cortex pathology in Alzheimer's disease. Hippocampus. 1991;1:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1669339</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Opstal F, Verguts T, Orban GA, Fias W. A hippocampal-parietal network for learning an ordered sequence. Neuroimage. 2008;40:333&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">18155926</ArticleId></ArticleIdList></Reference><Reference><Citation>Weniger G, Ruhleder M, Lange C, Wolf S, Irle E. Egocentric and allocentric memory as assessed by virtual reality in individuals with amnestic mild cognitive impairment. Neuropsychologia. 2011;49:518&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">21185847</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22316444</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>366</Volume><Issue>6</Issue><PubDate><Year>2012</Year><Month>Feb</Month><Day>09</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Memory enhancement and deep-brain stimulation of the entorhinal area.</ArticleTitle><Pagination><StartPage>502</StartPage><EndPage>510</EndPage><MedlinePgn>502-10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1107212</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The medial temporal structures, including the hippocampus and the entorhinal cortex, are critical for the ability to transform daily experience into lasting memories. We tested the hypothesis that deep-brain stimulation of the hippocampus or entorhinal cortex alters memory performance.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We implanted intracranial depth electrodes in seven subjects to identify seizure-onset zones for subsequent epilepsy surgery. The subjects completed a spatial learning task during which they learned destinations within virtual environments. During half the learning trials, focal electrical stimulation was given below the threshold that elicits an afterdischarge (i.e., a neuronal discharge that occurs after termination of the stimulus).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Entorhinal stimulation applied while the subjects learned locations of landmarks enhanced their subsequent memory of these locations: the subjects reached these landmarks more quickly and by shorter routes, as compared with locations learned without stimulation. Entorhinal stimulation also resulted in a resetting of the phase of the theta rhythm, as shown on the hippocampal electroencephalogram. Direct hippocampal stimulation was not effective. In this small series, no adverse events associated with the procedure were observed.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Stimulation of the entorhinal region enhanced memory of spatial information when applied during learning. (Funded by the National Institutes of Health and the Dana Foundation.).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Suthana</LastName><ForeName>Nanthia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, David Geffen School of Medicine and Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA 90095-7039, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haneef</LastName><ForeName>Zulfi</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mukamel</LastName><ForeName>Roy</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Behnke</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Knowlton</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Fried</LastName><ForeName>Itzhak</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 NS007449</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5T32NS07449</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS033221</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS033221</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 NS033221</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2012 Feb 9;366(6):563-5. doi: 10.1056/NEJMe1114531.</RefSource><PMID Version="1">22316451</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2012 May 17;366(20):1945; author reply 1946. doi: 10.1056/NEJMc1203204.</RefSource><PMID Version="1">22591306</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2012 May 17;366(20):1945; author reply 1946. doi: 10.1056/NEJMc1203204.</RefSource><PMID Version="1">22591307</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2012 May 17;366(20):1945-6; author reply 1946. doi: 10.1056/NEJMc1203204.</RefSource><PMID Version="1">22591308</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D046690" MajorTopicYN="Y">Deep Brain Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004567" MajorTopicYN="N">Electrodes, Implanted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018728" MajorTopicYN="Y">Entorhinal Cortex</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="N">Epilepsy</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="Y">Hippocampus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007360" MajorTopicYN="N">Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="Y">Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="Y">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013037" MajorTopicYN="Y">Spatial Behavior</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>9</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22316444</ArticleId><ArticleId IdType="mid">NIHMS356891</ArticleId><ArticleId IdType="pmc">PMC3447081</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1107212</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Squire LR, Stark CE, Clark RE. The medial temporal lobe. Annu Rev Neurosci. 2004;27:279&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">15217334</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang AE, Lozano AM. Parkinson&#x2019;s disease: second of two parts. N Engl J Med. 1998;339:1130&#x2013;1143.</Citation><ArticleIdList><ArticleId IdType="pubmed">9770561</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis KD, Taub E, Houle S, et al. Globus pallidus stimulation activates the cortical motor system during alleviation of parkinsonian symptoms. Nat Med. 1997;3:671&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">9176495</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45:651&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748841</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidailhet M, Vercueil L, Houeto JL, et al. Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med. 2005;352:459&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">15689584</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehret A, Haaf A, Jeltsch H, Heimrich B, Feuerstein TJ, Jackisch R. Modulation of electrically evoked acetylcholine release in cultured rat septal neurones. J Neurochem. 2001;76:555&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">11208918</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliss TV, Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol. 1973;232:331&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1350458</ArticleId><ArticleId IdType="pubmed">4727084</ArticleId></ArticleIdList></Reference><Reference><Citation>Vertes RP. Hippocampal theta rhythm: a tag for short-term memory. Hippocampus. 2005;15:923&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pubmed">16149083</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams JM, Givens B. Stimulation-induced reset of hippocampal theta in the freely performing rat. Hippocampus. 2003;13:109&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">12625462</ArticleId></ArticleIdList></Reference><Reference><Citation>Toda H, Hamani C, Fawcett AP, Hutchison WD, Lozano AM. The regulation of adult rodent hippocampal neurogenesis by deep brain stimulation. J Neurosurg. 2008;108:132&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">18173322</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano-Mas C, Redolar-Ripoll D, Aldavert-Vera L, Morgado-Bernal I, Segura-Torres P. Post-training intracranial self-stimulation facilitates a hippocampus-dependent task. Behav Brain Res. 2005;160:141&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">15836909</ArticleId></ArticleIdList></Reference><Reference><Citation>Halgren E, Wilson CL. Recall deficits produced by afterdischarges in the human hippocampal formation and amygdala. Electroencephalogr Clin Neurophysiol. 1985;61:375&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">2412789</ArticleId></ArticleIdList></Reference><Reference><Citation>Halgren E, Wilson CL, Stapleton JM. Human medial temporal-lobe stimulation disrupts both formation and retrieval of recent memories. Brain Cogn. 1985;4:287&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">4027062</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleshill SG, Binnie CD, Morris RG, et al. Material-specific recognition memory deficits elicited by unilateral hippocampal electrical stimulation. J Neurosci. 2004;24:1612&#x2013;1616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730466</ArticleId><ArticleId IdType="pubmed">14973245</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacruz ME, Valent&#xed;n A, Seoane JJ, Morris RG, Selway RP, Alarc&#xf3;n G. Single pulse electrical stimulation of the hippocampus is sufficient to impair human episodic memory. Neuroscience. 2010;170:623&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">20643192</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Wechsler Adult Intelligence Scale, third edition (WAIS-III) San Antonio, TX: Psychological Corporation; 1997.</Citation></Reference><Reference><Citation>Idem. Wechsler Memory Scale, revised. New York: Psychological Corporation/Harcourt Brace Jovanovich; 2005.</Citation></Reference><Reference><Citation>Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test. 2nd ed. San Antonio, TX: Psychological Corporation; 2000.</Citation></Reference><Reference><Citation>Meyers JE, Meyers KR. Rey Complex Figure Test and recognition trial. Odessa, FL: Psychological Assessment Resources; 1995.</Citation></Reference><Reference><Citation>Lezak MD, Howieson DB, Loring DW. Neuropsychological assessment. New York: Oxford University Press; 2004.</Citation></Reference><Reference><Citation>Engel J., Jr . Appendix 2: presurgical evaluation protocols (University of California, Los Angeles) In: Engel J Jr, editor. Surgical treatment of the epilepsies. 2nd ed. New York: Raven Press; 1993. pp. 743&#x2013;745.</Citation></Reference><Reference><Citation>Fried I, Wilson CW, Zhang JX, et al. Implantation of depth electrodes for EEG recording. In: De Salles AAF, Goetsch SJ, editors. Stereotactic surgery and radiosurgery. Madison, WI: Medical Physics Publishing; 1993. pp. 149&#x2013;158.</Citation></Reference><Reference><Citation>Fried I, Wilson CL, Maidment NT, et al. Cerebral microdialysis combined with single-neuron and electroencephalographic recording in neurosurgical patients: technical note. J Neurosurg. 1999:91697&#x2013;91705.</Citation><ArticleIdList><ArticleId IdType="pubmed">10507396</ArticleId></ArticleIdList></Reference><Reference><Citation>Agnew WF, McCreery DB. Considerations for safety with chronically implanted nerve electrodes. Epilepsia. 1991;31(Suppl 2):S27&#x2013;S32.</Citation><ArticleIdList><ArticleId IdType="pubmed">2226363</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon B, Lesser RP, Rance NE, et al. Parameters for direct cortical electrical stimulation in the human: histopathologic confirmation. Electroencephalogr Clin Neurophysiol. 1990;75:371&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">1692272</ArticleId></ArticleIdList></Reference><Reference><Citation>Boon P, Vonck K, De Herdt V, et al. Deep brain stimulation in patients with refractory temporal lobe epilepsy. Epilepsia. 2007;48:1551&#x2013;1560.</Citation><ArticleIdList><ArticleId IdType="pubmed">17726798</ArticleId></ArticleIdList></Reference><Reference><Citation>Jobst B. Brain stimulation for surgical epilepsy. Epilepsy Res. 2010;89:154&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">19766458</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekstrom AD, Kahana MJ, Caplan JB, et al. Cellular networks underlying human spatial navigation. Nature. 2003;425:184&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">12968182</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekstrom AD, Caplan JB, Ho E, Shattuck K, Fried I, Kahana MJ. Human hippocampal theta activity during virtual navigation. Hippocampus. 2005;15:881&#x2013;889. [Erratum, Hippocampus 2006;16:101.]</Citation><ArticleIdList><ArticleId IdType="pubmed">16114040</ArticleId></ArticleIdList></Reference><Reference><Citation>Suthana NA, Ekstrom AD, Moshirvaziri S, Knowlton B, Bookheimer SY. Human hippocampal CA1 involvement during allocentric encoding of spatial information. J Neurosci. 2009;29:10512&#x2013;10519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873654</ArticleId><ArticleId IdType="pubmed">19710304</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartley T, Maguire EA, Spiers HJ, Burgess N. The well-worn route and the path less traveled: distinct neural bases of route following and wayfinding in humans. Neuron. 2003;37:877&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pubmed">12628177</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisk V, Milner B. The relationship of working memory to the immediate recall of stories following unilateral temporal or frontal lobectomy. Neuropsychologia. 1990;28:121&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">2107457</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith ML, Milner B. Right hippocampal impairment in the recall of spatial location: encoding deficit or rapid forgetting? Neuropsychologia. 1989;27:71&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">2496329</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamani C, McAndrews MP, Cohn M, et al. Memory enhancement induced by hypothalamic/fornix deep brain stimulation. Ann Neurol. 2008;63:119&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">18232017</ArticleId></ArticleIdList></Reference><Reference><Citation>Laxton AW, Tang-Wai DF, McAndrews MP, et al. A phase I trial of deep brain stimulation of memory circuits in Alzheimer&#x2019;s disease. Ann Neurol. 2010;68:521&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">20687206</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone SSD, Teixeira CM, DeVito L, et al. Stimulation of entorhinal cortex promotes adult neurogenesis and facilitates spatial memory. J Neurosci. 2011;31:13469&#x2013;13484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6623309</ArticleId><ArticleId IdType="pubmed">21940440</ArticleId></ArticleIdList></Reference><Reference><Citation>Buzs&#xe1;ki G. Theta oscillations in the hippocampus. Neuron. 2002;33:325&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832222</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinogradova OS, Brazhnik ES, Kitchigina VF, Stafekhina VS. Modulation of the reaction of hippocampal neurons to sensory stimuli by cholinergic substances. Neurosci Behav Physiol. 1996;26:113&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">8782214</ArticleId></ArticleIdList></Reference><Reference><Citation>McCartney H, Johnson AD, Weil ZM, Givens B. Theta reset produces optimal conditions for long-term potentiation. Hippocampus. 2004;14:684&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pubmed">15318327</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez G, Brewer JB, Zhao Z, Glover GH, Gabrieli JD. Level of sustained entorhinal activity at study correlates with subsequent cued-recall performance: a functional magnetic resonance imaging study with high acquisition rate. Hippocampus. 1999;9:35&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">10088898</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22193532</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1535-7228</ISSN><JournalIssue CitedMedium="Internet"><Volume>169</Volume><Issue>3</Issue><PubDate><Year>2012</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Association of cerebral emboli with accelerated cognitive deterioration in Alzheimer's disease and vascular dementia.</ArticleTitle><Pagination><StartPage>300</StartPage><EndPage>308</EndPage><MedlinePgn>300-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.ajp.2011.11010009</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Spontaneous cerebral emboli occur frequently in patients with Alzheimer's disease and vascular dementia. The authors investigated the effect of cerebral emboli on cognitive and functional decline in both Alzheimer's disease and vascular dementia patients over a 2-year period.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Cerebral emboli entering the middle cerebral arteries were counted at baseline and every 6 months over the following 18 months using transcranial Doppler ultrasonography in 144 patients with dementia (Alzheimer's disease, N=84; vascular dementia, N=60). Deterioration in cognition was measured every 6 months over 2 years using the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog), the Mini-Mental State Examination (to assess cognition), the Interview for Deterioration in Daily Living Activities in Dementia (to assess function), and the Neuropsychiatric Inventory (to assess behavioral and psychological symptoms). The relationship between cerebral emboli and progression of dementia was analyzed using longitudinal regression modeling, adjusted for age, sex, diagnostic subtype, age at onset of dementia, and significant vascular risk factors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Spontaneous cerebral emboli were detected in 63 (44%) dementia patients, 36 (43%) Alzheimer's disease patients, and 27 (45%) vascular dementia patients. ADAS-Cog scores revealed faster deterioration in cognitive functioning in patients with cerebral emboli over 2 years, with a mean increase in score of 15.4 in these patients, compared with only 6.0 for those without cerebral emboli. Similarly, Interview for Deterioration in Daily Living Activities in Dementia scores revealed more rapid deterioration in those with cerebral emboli, with a mean increase in score of 59.0 in these patients, compared with 17.9 for those without cerebral emboli. Neuropsychiatric Inventory scores also indicated faster decline in patients with cerebral emboli, with a mean increase in score of 12.0 in these patients, compared with a mean decrease in score of -3.8 for patients in whom no emboli were detected.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Spontaneous cerebral emboli predict more rapid progression of dementia over 2 years in both Alzheimer's disease and vascular dementia. Clinical trials on the inhibition of cerebral emboli in the prevention and treatment of dementia are needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Purandare</LastName><ForeName>Nitin</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Manchester Academic Health Science Center, University of Manchester, UK. nitin.purandare@manchester.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Alistair</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>Ewan P</ForeName><Initials>EP</Initials></Author><Author ValidYN="Y"><LastName>Wren</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>McCollum</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Am J Psychiatry. 2012 Mar 1;169(3):338</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Am J Psychiatry. 2012 Mar;169(3):251-4. doi: 10.1176/appi.ajp.2011.11121830.</RefSource><PMID Version="1">22407112</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020766" MajorTopicYN="N">Intracranial Embolism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017585" MajorTopicYN="N">Ultrasonography, Doppler, Transcranial</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22193532</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.2011.11010009</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22302812</PMID><DateCompleted><Year>2012</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>5</Issue><PubDate><Year>2012</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Novel G&#x3b1;S-protein signaling associated with membrane-tethered amyloid precursor protein intracellular domain.</ArticleTitle><Pagination><StartPage>1714</StartPage><EndPage>1729</EndPage><MedlinePgn>1714-29</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5433-11.2012</ELocationID><Abstract><AbstractText>Numerous physiological functions, including a role as a cell surface receptor, have been ascribed to Alzheimer's disease-associated amyloid precursor protein (APP). However, detailed analysis of intracellular signaling mediated by APP in neurons has been lacking. Here, we characterized intrinsic signaling associated with membrane-bound APP C-terminal fragments, which are generated following APP ectodomain release by &#x3b1;- or &#x3b2;-secretase cleavage. We found that accumulation of APP C-terminal fragments or expression of membrane-tethered APP intracellular domain results in adenylate cyclase-dependent activation of PKA (protein kinase A) and inhibition of GSK3&#x3b2; signaling cascades, and enhancement of axodendritic arborization in rat immortalized hippocampal neurons, mouse primary cortical neurons, and mouse neuroblastoma. We discovered an interaction between BBXXB motif of APP intracellular domain and the heterotrimeric G-protein subunit G&#x3b1;(S), and demonstrate that G&#x3b1;(S) coupling to adenylate cyclase mediates membrane-tethered APP intracellular domain-induced neurite outgrowth. Our study provides clear evidence that APP intracellular domain can have a nontranscriptional role in regulating neurite outgrowth through its membrane association. The novel functional coupling of membrane-bound APP C-terminal fragments with G&#x3b1;(S) signaling identified in this study could impact several brain functions such as synaptic plasticity and memory formation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deyts</LastName><ForeName>Carole</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Neurology, and Pathology, The University of Chicago, Chicago, Illinois 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vetrivel</LastName><ForeName>Kulandaivelu S</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Shibandri</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Shepherd</LastName><ForeName>Yumiko M</ForeName><Initials>YM</Initials></Author><Author ValidYN="Y"><LastName>Dupr&#xe9;</LastName><ForeName>Denis J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Thinakaran</LastName><ForeName>Gopal</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Parent</LastName><ForeName>Ang&#xe8;le T</ForeName><Initials>AT</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG019070</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS055223</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS055223</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG019070</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.1</RegistryNumber><NameOfSubstance UI="D019205">GTP-Binding Protein alpha Subunits, Gs</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 4.6.1.1</RegistryNumber><NameOfSubstance UI="D000262">Adenylyl Cyclases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000262" MajorTopicYN="N">Adenylyl Cyclases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019556" MajorTopicYN="N">COS Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002461" MajorTopicYN="N">Cell Line, Transformed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019205" MajorTopicYN="N">GTP-Binding Protein alpha Subunits, Gs</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007425" MajorTopicYN="N">Intracellular Membranes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22302812</ArticleId><ArticleId IdType="mid">NIHMS357476</ArticleId><ArticleId IdType="pmc">PMC3567462</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5433-11.2012</ArticleId><ArticleId IdType="pii">32/5/1714</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abel T, Nguyen PV. Regulation of hippocampus-dependent memory by cyclic AMP-dependent protein kinase. Prog Brain Res. 2008;169:97&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2914307</ArticleId><ArticleId IdType="pubmed">18394470</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with ImageJ. Biophotonics Int. 2004;11:36&#x2013;42.</Citation></Reference><Reference><Citation>Allen JA, Halverson-Tamboli RA, Rasenick MM. Lipid raft microdomains and neurotransmitter signalling. Nat Rev Neurosci. 2007;8:128&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">17195035</ArticleId></ArticleIdList></Reference><Reference><Citation>Allinquant B, Hantraye P, Mailleux P, Moya K, Bouillot C, Prochiantz A. Downregulation of amyloid precursor protein inhibits neurite outgrowth in vitro. J Cell Biol. 1995;128:919&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2120404</ArticleId><ArticleId IdType="pubmed">7876315</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando K, Oishi M, Takeda S, Iijima K, Isohara T, Nairn AC, Kirino Y, Greengard P, Suzuki T. Role of phosphorylation of Alzheimer's amyloid precursor protein during neuronal differentiation. J Neurosci. 1999;19:4421&#x2013;4427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782598</ArticleId><ArticleId IdType="pubmed">10341243</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnsten AF, Ramos BP, Birnbaum SG, Taylor JR. Protein kinase A as a therapeutic target for memory disorders: rationale and challenges. Trends Mol Med. 2005;11:121&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">15760770</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydin D, Weyer SW, Muller UC. Functions of the APP gene family in the nervous system: insights from mouse models. Exp Brain Res. 2012 doi: 10.1007/s00221-011-2861-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00221-011-2861-2</ArticleId><ArticleId IdType="pubmed">21931985</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes NY, Shi J, Yajima H, Thinakaran G, Parent AT. Steady-state increase of cAMP-response element binding protein, Rac, and PAK signaling in presenilin-deficient neurons. J Neurochem. 2008;104:1637&#x2013;1648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2598774</ArticleId><ArticleId IdType="pubmed">17996025</ArticleId></ArticleIdList></Reference><Reference><Citation>Biederer T, Cao X, S&#xfc;dhof TC, Liu X. Regulation of APP-dependent transcription complexes by Mint/X11s: differential functions of Mint isoforms. J Neurosci. 2002;22:7340&#x2013;7351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757996</ArticleId><ArticleId IdType="pubmed">12196555</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouillet E, Trembleau A, Galanaud D, Volovitch M, Bouillot C, Valenza C, Prochiantz A, Allinquant B. The amyloid precursor protein interacts with Go heterotrimeric protein within a cell compartment specialized in signal transduction. J Neurosci. 1999;19:1717&#x2013;1727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782156</ArticleId><ArticleId IdType="pubmed">10024358</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng H, Vetrivel KS, Gong P, Meckler X, Parent A, Thinakaran G. Mechanisms of disease: new therapeutic strategies for Alzheimer's disease&#x2014;targeting APP processing in lipid rafts. Nat Clin Pract Neurol. 2007;3:374&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2880530</ArticleId><ArticleId IdType="pubmed">17611486</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Teplow DB, Selkoe DJ. Generation of amyloid beta protein from its precursor is sequence specific. Neuron. 1995;14:661&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">7695913</ArticleId></ArticleIdList></Reference><Reference><Citation>Deyts C, Galan-Rodriguez B, Martin E, Bouveyron N, Roze E, Charvin D, Caboche J, B&#xe9;tuing S. Dopamine D2 receptor stimulation potentiates PolyQ-Huntingtin-induced mouse striatal neuron dysfunctions via Rho/ROCK-II activation. PLoS One. 2009;4:e8287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2790370</ArticleId><ArticleId IdType="pubmed">20016831</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupr&#xe9; DJ, Robitaille M, Richer M, Ethier N, Mamarbachi AM, H&#xe9;bert TE. Dopamine receptor-interacting protein 78 acts as a molecular chaperone for Ggamma subunits before assembly with Gbeta. J Biol Chem. 2007;282:13703&#x2013;13715.</Citation><ArticleIdList><ArticleId IdType="pubmed">17363375</ArticleId></ArticleIdList></Reference><Reference><Citation>Eason MG, Kurose H, Holt BD, Raymond JR, Liggett SB. Simultaneous coupling of alpha 2-adrenergic receptors to two G-proteins with opposing effects. Subtype-selective coupling of alpha 2C10, alpha 2C4, and alpha 2C2 adrenergic receptors to Gi and Gs. J Biol Chem. 1992;267:15795&#x2013;15801.</Citation><ArticleIdList><ArticleId IdType="pubmed">1322406</ArticleId></ArticleIdList></Reference><Reference><Citation>Eves EM, Tucker MS, Roback JD, Downen M, Rosner MR, Wainer BH. Immortal rat hippocampal cell lines exhibit neuronal and glial lineages and neurotrophin gene expression. Proc Natl Acad Sci U S A. 1992;89:4373&#x2013;4377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC49084</ArticleId><ArticleId IdType="pubmed">1316607</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang X, Yu SX, Lu Y, Bast RC, Jr, Woodgett JR, Mills GB. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A. 2000;97:11960&#x2013;11965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC17277</ArticleId><ArticleId IdType="pubmed">11035810</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginty DD, Kornhauser JM, Thompson MA, Bading H, Mayo KE, Takahashi JS, Greenberg ME. Regulation of CREB phosphorylation in the suprachiasmatic nucleus by light and a circadian clock. Science. 1993;260:238&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">8097062</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong P, Vetrivel KS, Nguyen PD, Meckler X, Cheng H, Kounnas MZ, Wagner SL, Parent AT, Thinakaran G. Mutation analysis of the presenilin 1 N-terminal domain reveals a broad spectrum of gamma-secretase activity toward amyloid precursor protein and other substrates. J Biol Chem. 2010;285:38042&#x2013;38052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2992238</ArticleId><ArticleId IdType="pubmed">20921220</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xf8;nborg M, Kristiansen TZ, Stensballe A, Andersen JS, Ohara O, Mann M, Jensen ON, Pandey A. A mass spectrometry-based proteomic approach for identification of serine/threonine-phosphorylated proteins by enrichment with phospho-specific antibodies: identification of a novel protein, Frigg, as a protein kinase A substrate. Mol Cell Proteomics. 2002;1:517&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">12239280</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Wang Z, Li H, Wiese M, Zheng H. APP physiological and pathophysiological functions: insights from animal models. Cell Res. 2012;22:78&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3351924</ArticleId><ArticleId IdType="pubmed">21769132</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez F, G&#xf3;mez de Barreda E, Fuster-Matanzo A, Lucas JJ, Avila J. GSK3: a possible link between beta amyloid peptide and tau protein. Exp Neurol. 2010;223:322&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">19782073</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoe HS, Lee KJ, Carney RS, Lee J, Markova A, Lee JY, Howell BW, Hyman BT, Pak DT, Bu G, Rebeck GW. Interaction of reelin with amyloid precursor protein promotes neurite outgrowth. J Neurosci. 2009;29:7459&#x2013;7473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2759694</ArticleId><ArticleId IdType="pubmed">19515914</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoe HS, Lee HK, Pak DT. The upside of APP at synapses. CNS Neurosci Ther. 2012 doi: 10.1111/j.1755-5949.2010.00221.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1755-5949.2010.00221.x</ArticleId><ArticleId IdType="pmc">PMC3116065</ArticleId><ArticleId IdType="pubmed">21199446</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J Neurochem. 2008;104:1433&#x2013;1439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073119</ArticleId><ArticleId IdType="pubmed">18088381</ArticleId></ArticleIdList></Reference><Reference><Citation>Hur EM, Zhou FQ. GSK3 signalling in neural development. Nat Rev Neurosci. 2010;11:539&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3533361</ArticleId><ArticleId IdType="pubmed">20648061</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutchins BI. Competitive outgrowth of neural processes arising from long-distance cAMP signaling. Sci Signal. 2010;3:jc1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329774</ArticleId><ArticleId IdType="pubmed">20407121</ArticleId></ArticleIdList></Reference><Reference><Citation>Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci. 2004;29:95&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">15102436</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KJ, Moussa CE, Lee Y, Sung Y, Howell BW, Turner RS, Pak DT, Hoe HS. Beta amyloid-independent role of amyloid precursor protein in generation and maintenance of dendritic spines. Neuroscience. 2010;169:344&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2900520</ArticleId><ArticleId IdType="pubmed">20451588</ArticleId></ArticleIdList></Reference><Reference><Citation>Leem JY, Saura CA, Pietrzik C, Christianson J, Wanamaker C, King LT, Veselits ML, Tomita T, Gasparini L, Iwatsubo T, Xu H, Green WN, Koo EH, Thinakaran G. A role for presenilin 1 in regulating the delivery of amyloid precursor protein to the cell surface. Neurobiol Dis. 2002;11:64&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">12460547</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefkowitz RJ. G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization. J Biol Chem. 1998;273:18677&#x2013;18680.</Citation><ArticleIdList><ArticleId IdType="pubmed">9668034</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyssen M, Ayaz D, H&#xe9;bert SS, Reeve S, De Strooper B, Hassan BA. Amyloid precursor protein promotes post-developmental neurite arborization in the Drosophila brain. EMBO J. 2005;24:2944&#x2013;2955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1187942</ArticleId><ArticleId IdType="pubmed">16052209</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenthaler SF, Haass C, Steiner H. Regulated intramembrane proteolysis&#x2014;lessons from amyloid precursor protein processing. J Neurochem. 2011;117:779&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pubmed">21413990</ArticleId></ArticleIdList></Reference><Reference><Citation>Lonze BE, Ginty DD. Function and regulation of CREB family transcription factors in the nervous system. Neuron. 2002;35:605&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="pubmed">12194863</ArticleId></ArticleIdList></Reference><Reference><Citation>Malenka RC, Nicoll RA. Long-term potentiation&#x2014;a decade of progress? Science. 1999;285:1870&#x2013;1874.</Citation><ArticleIdList><ArticleId IdType="pubmed">10489359</ArticleId></ArticleIdList></Reference><Reference><Citation>Malinow R, Malenka RC. AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci. 2002;25:103&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">12052905</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller T, Meyer HE, Egensperger R, Marcus K. The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics-relevance for Alzheimer's disease. Prog Neurobiol. 2008;85:393&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">18603345</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimoto I, Okamoto T, Matsuura Y, Takahashi S, Okamoto T, Murayama Y, Ogata E. Alzheimer amyloid protein precursor complexes with brain GTP-binding protein Go. Nature. 1993;362:75&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446172</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto T, Nishimoto I. Detection of G protein-activator regions in M4 subtype muscarinic, cholinergic, and alpha 2-adrenergic receptors based upon characteristics in primary structure. J Biol Chem. 1992;267:8342&#x2013;8346.</Citation><ArticleIdList><ArticleId IdType="pubmed">1314825</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto T, Katada T, Murayama Y, Ui M, Ogata E, Nishimoto I. A simple structure encodes G protein-activating function of the IGF-II/mannose 6-phosphate receptor. Cell. 1990;62:709&#x2013;717.</Citation><ArticleIdList><ArticleId IdType="pubmed">2167177</ArticleId></ArticleIdList></Reference><Reference><Citation>Onishi M, Kinoshita S, Morikawa Y, Shibuya A, Phillips J, Lanier LL, Gorman DM, Nolan GP, Miyajima A, Kitamura T. Applications of retrovirus-mediated expression cloning. Exp Hematol. 1996;24:324&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">8641361</ArticleId></ArticleIdList></Reference><Reference><Citation>Parent AT, Barnes NY, Taniguchi Y, Thinakaran G, Sisodia SS. Presenilin attenuates receptor-mediated signaling and synaptic function. J Neurosci. 2005;25:1540&#x2013;1549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725985</ArticleId><ArticleId IdType="pubmed">15703408</ArticleId></ArticleIdList></Reference><Reference><Citation>Pauwels PJ, Gouble A, Wurch T. Activation of constitutive 5-hydroxytryptamine(1B) receptor by a series of mutations in the BBXXB motif: positioning of the third intracellular loop distal junction and its Goalpha protein interactions. Biochem J. 1999;343:435&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1220572</ArticleId><ArticleId IdType="pubmed">10510311</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez RG, Zheng H, Van der Ploeg LH, Koo EH. The beta-amyloid precursor protein of Alzheimer's disease enhances neuron viability and modulates neuronal polarity. J Neurosci. 1997;17:9407&#x2013;9414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573428</ArticleId><ArticleId IdType="pubmed">9390996</ArticleId></ArticleIdList></Reference><Reference><Citation>Peverelli E, Lania AG, Mantovani G, Beck-Peccoz P, Spada A. Characterization of intracellular signaling mediated by human somatostatin receptor 5: role of the DRY motif and the third intracellular loop. Endocrinology. 2009;150:3169&#x2013;3176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2703549</ArticleId><ArticleId IdType="pubmed">19342453</ArticleId></ArticleIdList></Reference><Reference><Citation>Pindon A, van Hecke G, van Gompel P, Lesage AS, Leysen JE, Jurzak M. Differences in signal transduction of two 5-HT4 receptor splice variants: compound specificity and dual coupling with Galphas- and Galphai/o-proteins. Mol Pharmacol. 2002;61:85&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">11752209</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez S, Sayas CL, Lim F, Diaz-Nido J, Avila J, Wandosell F. The inhibition of phosphatidylinositol-3-kinase induces neurite retraction and activates GSK3. J Neurochem. 2001;78:468&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">11483649</ArticleId></ArticleIdList></Reference><Reference><Citation>Schettini G, Govoni S, Racchi M, Rodriguez G. Phosphorylation of APP-CTF-AICD domains and interaction with adaptor proteins: signal transduction and/or transcriptional role&#x2014;relevance for Alzheimer pathology. J Neurochem. 2010;115:1299&#x2013;1308.</Citation><ArticleIdList><ArticleId IdType="pubmed">21039524</ArticleId></ArticleIdList></Reference><Reference><Citation>Seiffert D, Bradley JD, Rominger CM, Rominger DH, Yang F, Meredith JE, Jr, Wang Q, Roach AH, Thompson LA, Spitz SM, Higaki JN, Prakash SR, Combs AP, Copeland RA, Arneric SP, Hartig PR, Robertson DW, Cordell B, Stern AM, Olson RE, et al. Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitors. J Biol Chem. 2000;275:34086&#x2013;34091.</Citation><ArticleIdList><ArticleId IdType="pubmed">10915801</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaked GM, Chauv S, Ubhi K, Hansen LA, Masliah E. Interactions between the amyloid precursor protein C-terminal domain and G proteins mediate calcium dysregulation and amyloid beta toxicity in Alzheimer's disease. FEBS J. 2009;276:2736&#x2013;2751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838422</ArticleId><ArticleId IdType="pubmed">19368557</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelly M, Lim BK, Cancedda L, Heilshorn SC, Gao H, Poo MM. Local and long-range reciprocal regulation of cAMP and cGMP in axon/dendrite formation. Science. 2010;327:547&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">20110498</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia SS. Beta-amyloid precursor protein cleavage by a membrane-bound protease. Proc Natl Acad Sci U S A. 1992;89:6075&#x2013;6079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC49440</ArticleId><ArticleId IdType="pubmed">1631093</ArticleId></ArticleIdList></Reference><Reference><Citation>Small DH, Clarris HL, Williamson TG, Reed G, Key B, Mok SS, Beyreuther K, Masters CL, Nurcombe V. Neurite-outgrowth regulating functions of the amyloid protein precursor of Alzheimer's disease. J Alzheimers Dis. 1999;1:275&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">12214125</ArticleId></ArticleIdList></Reference><Reference><Citation>Soba P, Eggert S, Wagner K, Zentgraf H, Siehl K, Kreger S, L&#xf6;wer A, Langer A, Merdes G, Paro R, Masters CL, M&#xfc;ller U, Kins S, Beyreuther K. Homo- and heterodimerization of APP family members promotes intercellular adhesion. EMBO J. 2005;24:3624&#x2013;3634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1276707</ArticleId><ArticleId IdType="pubmed">16193067</ArticleId></ArticleIdList></Reference><Reference><Citation>Sola Vigo F, Kedikian G, Heredia L, Heredia F, A&#xf1;el AD, Rosa AL, Lorenzo A. Amyloid-beta precursor protein mediates neuronal toxicity of amyloid beta through Go protein activation. Neurobiol Aging. 2009;30:1379&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">18187234</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki T, Nakaya T. Regulation of amyloid beta-protein precursor by phosphorylation and protein interactions. J Biol Chem. 2008;283:29633&#x2013;29637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2662050</ArticleId><ArticleId IdType="pubmed">18650433</ArticleId></ArticleIdList></Reference><Reference><Citation>Thathiah A, De Strooper B. The role of G protein-coupled receptors in the pathology of Alzheimer's disease. Nat Rev Neurosci. 2011;12:73&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">21248787</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem. 2008;283:29615&#x2013;29619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2573065</ArticleId><ArticleId IdType="pubmed">18650430</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Regard JB, Bouton CM, Harris CL, Price DL, Borchelt DR, Sisodia SS. Stable association of presenilin derivatives and absence of presenilin interactions with APP. Neurobiol Dis. 1998;4:438&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">9666482</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner PR, O'Connor K, Tate WP, Abraham WC. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol. 2003;70:1&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">12927332</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulloa-Aguirre A, Uribe A, Zarinan T, Bustos-Jaimes I, Perez-Solis MA, Dias JA. Role of the intracellular domains of the human FSH receptor in G(alphaS) protein coupling and receptor expression. Mol Cell Endocrinol. 2007;260&#x2013;262:153&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1782136</ArticleId><ArticleId IdType="pubmed">17045734</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrivel KS, Cheng H, Lin W, Sakurai T, Li T, Nukina N, Wong PC, Xu H, Thinakaran G. Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes. J Biol Chem. 2004;279:44945&#x2013;44954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201506</ArticleId><ArticleId IdType="pubmed">15322084</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrivel KS, Cheng H, Kim SH, Chen Y, Barnes NY, Parent AT, Sisodia SS, Thinakaran G. Spatial segregation of gamma-secretase and substrates in distinct membrane domains. J Biol Chem. 2005;280:25892&#x2013;25900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201532</ArticleId><ArticleId IdType="pubmed">15886206</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrivel KS, Zhang X, Meckler X, Cheng H, Lee S, Gong P, Lopes KO, Chen Y, Iwata N, Yin KJ, Lee JM, Parent AT, Saido TC, Li YM, Sisodia SS, Thinakaran G. Evidence that CD147 modulation of beta-amyloid (Abeta) levels is mediated by extracellular degradation of secreted Abeta. J Biol Chem. 2008;283:19489&#x2013;19498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2443668</ArticleId><ArticleId IdType="pubmed">18456655</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrivel KS, Meckler X, Chen Y, Nguyen PD, Seidah NG, Vassar R, Wong PC, Fukata M, Kounnas MZ, Thinakaran G. Alzheimer disease Abeta production in the absence of S-palmitoylation-dependent targeting of BACE1 to lipid rafts. J Biol Chem. 2009;284:3793&#x2013;3803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2635050</ArticleId><ArticleId IdType="pubmed">19074428</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrivel KS, Barman A, Chen Y, Nguyen PD, Wagner SL, Prabhakar R, Thinakaran G. Loss of cleavage at &#x3b2;&#x2032;-site contributes to apparent increase in &#x3b2;-amyloid peptide (A&#x3b2;) secretion by &#x3b2;-secretase (BACE1)-glycosylphosphatidylinositol (GPI) processing of amyloid precursor protein. J Biol Chem. 2011;286:26166&#x2013;26177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3138254</ArticleId><ArticleId IdType="pubmed">21642424</ArticleId></ArticleIdList></Reference><Reference><Citation>von Koch CS, Zheng H, Chen H, Trumbauer M, Thinakaran G, van der Ploeg LH, Price DL, Sisodia SS. Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO mice. Neurobiol Aging. 1997;18:661&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pubmed">9461064</ArticleId></ArticleIdList></Reference><Reference><Citation>Wedegaertner PB, Chu DH, Wilson PT, Levis MJ, Bourne HR. Palmitoylation is required for signaling functions and membrane attachment of Gq alpha and Gs alpha. J Biol Chem. 1993;268:25001&#x2013;25008.</Citation><ArticleIdList><ArticleId IdType="pubmed">8227063</ArticleId></ArticleIdList></Reference><Reference><Citation>Woehler A, Ponimaskin EG. G protein-mediated signaling: same receptor, multiple effectors. Curr Mol Pharmacol. 2009;2:237&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">20021461</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 1999;398:513&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D, Jiang H, Simon MI. Different alpha 1-adrenergic receptor sequences required for activating different G alpha subunits of Gq class of G proteins. J Biol Chem. 1995;270:9828&#x2013;9832.</Citation><ArticleIdList><ArticleId IdType="pubmed">7730363</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Petralia RS, Kurushima H, Patel H, Jung MY, Volk L, Chowdhury S, Shepherd JD, Dehoff M, Li Y, Kuhl D, Huganir RL, Price DL, Scannevin R, Troncoso JC, Wong PC, Worley PF. Arc/Arg3.1 regulates an endosomal pathway essential for activity-dependent beta-amyloid generation. Cell. 2011;147:615&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3207263</ArticleId><ArticleId IdType="pubmed">22036569</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Zagranichnaya TK, Gurda GT, Eves EM, Villereal ML. A TRPC1/TRPC3-mediated increase in store-operated calcium entry is required for differentiation of H19-7 hippocampal neuronal cells. J Biol Chem. 2004;279:43392&#x2013;43402.</Citation><ArticleIdList><ArticleId IdType="pubmed">15297455</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao RP. Beta-adrenergic signaling in the heart: dual coupling of the beta2-adrenergic receptor to Gs and Gi proteins. Sci STKE. 2001;2001:re15.</Citation><ArticleIdList><ArticleId IdType="pubmed">11604549</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimura T, Arimura N, Kaibuchi K. Signaling networks in neuronal polarization. J Neurosci. 2006;26:10626&#x2013;10630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674748</ArticleId><ArticleId IdType="pubmed">17050700</ArticleId></ArticleIdList></Reference><Reference><Citation>Young-Pearse TL, Chen AC, Chang R, Marquez C, Selkoe DJ. Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin beta1. Neural Dev. 2008;3:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442059</ArticleId><ArticleId IdType="pubmed">18573216</ArticleId></ArticleIdList></Reference><Reference><Citation>Zacharias DA, Violin JD, Newton AC, Tsien RY. Partitioning of lipid-modified monomeric GFPs into membrane microdomains of live cells. Science. 2002;296:913&#x2013;916.</Citation><ArticleIdList><ArticleId IdType="pubmed">11988576</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, Koo EH. The amyloid precursor protein: beyond amyloid. Mol Neurodegener. 2006;1:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1538601</ArticleId><ArticleId IdType="pubmed">16930452</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H, Murthy KS. Identification of the G protein-activating sequence of the single-transmembrane natriuretic peptide receptor C (NPR-C) Am J Physiol Cell Physiol. 2003;284:C1255&#x2013;C1261.</Citation><ArticleIdList><ArticleId IdType="pubmed">12676657</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22170863</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1757-4684</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>3</Issue><PubDate><Year>2012</Year><Month>Mar</Month></PubDate></JournalIssue><Title>EMBO molecular medicine</Title><ISOAbbreviation>EMBO Mol Med</ISOAbbreviation></Journal><ArticleTitle>&#x3b2;- but not &#x3b3;-secretase proteolysis of APP causes synaptic and memory deficits in a mouse model of dementia.</ArticleTitle><Pagination><StartPage>171</StartPage><EndPage>179</EndPage><MedlinePgn>171-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/emmm.201100195</ELocationID><Abstract><AbstractText>A mutation in the BRI2/ITM2b gene causes loss of BRI2 protein leading to familial Danish dementia (FDD). BRI2 deficiency of FDD provokes an increase in amyloid-&#x3b2; precursor protein (APP) processing since BRI2 is an inhibitor of APP proteolysis, and APP mediates the synaptic/memory deficits in FDD. APP processing is linked to Alzheimer disease (AD) pathogenesis, which is consistent with a common mechanism involving toxic APP metabolites in both dementias. We show that inhibition of APP cleavage by &#x3b2;-secretase rescues synaptic/memory deficits in a mouse model of FDD. &#x3b2;-cleavage of APP yields amino-terminal-soluble APP&#x3b2; (sAPP&#x3b2;) and &#x3b2;-carboxyl-terminal fragments (&#x3b2;-CTF). Processing of &#x3b2;-CTF by &#x3b3;-secretase releases amyloid-&#x3b2; (A&#x3b2;), which is assumed to cause AD. However, inhibition of &#x3b3;-secretase did not ameliorate synaptic/memory deficits of FDD mice. These results suggest that sAPP&#x3b2; and/or &#x3b2;-CTF, rather than A&#x3b2;, are the toxic species causing dementia, and indicate that reducing &#x3b2;-cleavage of APP is an appropriate therapeutic approach to treating human dementias. Our data and the failures of anti-A&#x3b2; therapies in humans advise against targeting &#x3b3;-secretase cleavage of APP and/or A&#x3b2;.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 EMBO Molecular Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tamayev</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuda</LastName><ForeName>Shuji</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Arancio</LastName><ForeName>Ottavio</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>D'Adamio</LastName><ForeName>Luciano</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01AG033007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041531</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG041577</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007288</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG027139</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>01</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>EMBO Mol Med</MedlineTA><NlmUniqueID>101487380</NlmUniqueID><ISSNLinking>1757-4676</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492300">Itm2b protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C538209">Dementia, familial Danish</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002386" MajorTopicYN="N">Cataract</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002524" MajorTopicYN="N">Cerebellar Ataxia</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003638" MajorTopicYN="N">Deafness</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="Y">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="Y">Neuronal Plasticity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="N">Proteolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22170863</ArticleId><ArticleId IdType="pmc">PMC3376850</ArticleId><ArticleId IdType="doi">10.1002/emmm.201100195</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron. 2010;68:270&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">20955934</ArticleId></ArticleIdList></Reference><Reference><Citation>Bevins RA, Besheer J. Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study &#x2018;recognition memory&#x2019;. Nat Protoc. 2006;1:1306&#x2013;1311.</Citation><ArticleIdList><ArticleId IdType="pubmed">17406415</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SI, Vidal R, Frangione B, Levy E. Axonal transport of British and Danish amyloid peptides via secretory vesicles. FASEB J. 2004;18:373&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">14656991</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole SL, Vassar R. The Alzheimer's disease beta-secretase enzyme, BACE1. Mol Neurodegener. 2007;2:22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2211305</ArticleId><ArticleId IdType="pubmed">18005427</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 2007;8:141&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1796779</ArticleId><ArticleId IdType="pubmed">17268505</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol. 2010;6:99&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2879045</ArticleId><ArticleId IdType="pubmed">20139999</ArticleId></ArticleIdList></Reference><Reference><Citation>Fotinopoulou A, Tsachaki M, Vlavaki M, Poulopoulos A, Rostagno A, Frangione B, Ghiso J, Efthimiopoulos S. BRI2 interacts with amyloid precursor protein (APP) and regulates amyloid beta (Abeta) production. J Biol Chem. 2005;280:30768&#x2013;30772.</Citation><ArticleIdList><ArticleId IdType="pubmed">16027166</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganjei JK. Targeting amyloid precursor protein secretases: Alzheimer's disease and beyond. Drug News Perspect. 2010;23:573&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pubmed">21152452</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianni D, Zambrano N, Bimonte M, Minopoli G, Mercken L, Talamo F, Scaloni A, Russo T. Platelet-derived growth factor induces the beta-gamma-secretase-mediated cleavage of Alzheimer's amyloid precursor protein through a Src-Rac-dependent pathway. J Biol Chem. 2003;278:9290&#x2013;9297.</Citation><ArticleIdList><ArticleId IdType="pubmed">12645527</ArticleId></ArticleIdList></Reference><Reference><Citation>Giliberto L, Matsuda S, Vidal R, D'Adamio L. Generation and initial characterization of FDD knock in mice. PLoS One. 2009;4:e7900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774945</ArticleId><ArticleId IdType="pubmed">19924302</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, Yan R. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci. 2006;9:1520&#x2013;1525.</Citation><ArticleIdList><ArticleId IdType="pubmed">17099708</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Zhou X, He W, Yang J, Xiong W, Wong P, Wilson CG, Yan R. BACE1 deficiency causes altered neuronal activity and neurodegeneration. J Neurosci. 2010;30:8819&#x2013;8829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902368</ArticleId><ArticleId IdType="pubmed">20592204</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M. The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med. 2010;16:1210&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pubmed">21052075</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DY, Carey BW, Wang H, Ingano LA, Binshtok AM, Wertz MH, Pettingell WH, He P, Lee VM, Woolf CJ, et al. BACE1 regulates voltage-gated sodium channels and neuronal activity. Nat Cell Biol. 2007;9:755&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2747787</ArticleId><ArticleId IdType="pubmed">17576410</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda S, Giliberto L, Matsuda Y, Davies P, McGowan E, Pickford F, Ghiso J, Frangione B, D'Adamio L. The familial dementia BRI2 gene binds the Alzheimer gene amyloid-beta precursor protein and inhibits amyloid-beta production. J Biol Chem. 2005;280:28912&#x2013;28916.</Citation><ArticleIdList><ArticleId IdType="pubmed">15983050</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda S, Giliberto L, Matsuda Y, McGowan EM, D'Adamio L. BRI2 inhibits amyloid beta-peptide precursor protein processing by interfering with the docking of secretases to the substrate. J Neurosci. 2008;28:8668&#x2013;8676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3844774</ArticleId><ArticleId IdType="pubmed">18753367</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda S, Matsuda Y, Snapp EL, D'Adamio L. Maturation of BRI2 generates a specific inhibitor that reduces APP processing at the plasma membrane and in endocytic vesicles. Neurobiol Aging. 2011a;32:1400&#x2013;1408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2932834</ArticleId><ArticleId IdType="pubmed">19748705</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda S, Tamayev R, D'Adamio L. Increased AbetaPP processing in familial Danish dementia patients. J Alzheimers Dis. 2011b;27:385&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3690758</ArticleId><ArticleId IdType="pubmed">21841249</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature. 2009;457:981&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677572</ArticleId><ArticleId IdType="pubmed">19225519</ArticleId></ArticleIdList></Reference><Reference><Citation>Puzzo D, Privitera L, Leznik E, Fa M, Staniszewski A, Palmeri A, Arancio O. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci. 2008;28:14537&#x2013;14545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2673049</ArticleId><ArticleId IdType="pubmed">19118188</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, Chattarji S, Kelleher RJ, III, Kandel ER, Duff K, et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004;42:23&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066262</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheinfeld MH, Roncarati R, Vito P, Lopez PA, Abdallah M, D'Adamio L. Jun NH2-terminal kinase (JNK) interacting protein 1 (JIP1) binds the cytoplasmic domain of the Alzheimer's beta-amyloid precursor protein (APP) J Biol Chem. 2002;277:3767&#x2013;3775.</Citation><ArticleIdList><ArticleId IdType="pubmed">11724784</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Kelleher RJ., III The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci USA. 2007;104:403&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1766397</ArticleId><ArticleId IdType="pubmed">17197420</ArticleId></ArticleIdList></Reference><Reference><Citation>St George-Hyslop PH, Petit A. Molecular biology and genetics of Alzheimer's disease. C R Biol. 2005;328:119&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">15770998</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamayev R, Giliberto L, Li W, d'Abramo C, Arancio O, Vidal R, D'Adamio L. Memory deficits due to familial British dementia BRI2 mutation are caused by loss of BRI2 function rather than amyloidosis. J Neurosci. 2010a;30:14915&#x2013;14924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056548</ArticleId><ArticleId IdType="pubmed">21048150</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamayev R, Matsuda S, Fa M, Arancio O, D'Adamio L. Danish dementia mice suggest that loss of function and not the amyloid cascade causes synaptic plasticity and memory deficits. Proc Natl Acad Sci USA. 2010b;107:20822&#x2013;20827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2996452</ArticleId><ArticleId IdType="pubmed">21098268</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamayev R, Matsuda S, Giliberto L, Arancio O, D'Adamio L. APP heterozygosity averts memory deficit in knockin mice expressing the Danish dementia BRI2 mutant. EMBO J. 2011;30:2501&#x2013;2509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3116289</ArticleId><ArticleId IdType="pubmed">21587206</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal R, Revesz T, Rostagno A, Kim E, Holton JL, Bek T, Bojsen-Moller M, Braendgaard H, Plant G, Ghiso J, et al. A decamer duplication in the 3&#x2032; region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred. Proc Natl Acad Sci USA. 2000;97:4920&#x2013;4925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18333</ArticleId><ArticleId IdType="pubmed">10781099</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C. Control of peripheral nerve myelination by the beta-secretase BACE1. Science. 2006;314:664&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990514</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Wu B, Beglopoulos V, Wines-Samuelson M, Zhang D, Dragatsis I, Sudhof TC, Shen J. Presenilins are essential for regulating neurotransmitter release. Nature. 2009;460:632&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744588</ArticleId><ArticleId IdType="pubmed">19641596</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22328928</PMID><DateCompleted><Year>2012</Year><Month>06</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>2</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>BACE1 inhibition induces a specific cerebrospinal fluid &#x3b2;-amyloid pattern that identifies drug effects in the central nervous system.</ArticleTitle><Pagination><StartPage>e31084</StartPage><MedlinePgn>e31084</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e31084</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0031084</ELocationID><Abstract><AbstractText>BACE1 is a key enzyme for amyloid-&#x3b2; (A&#x3b2;) production, and an attractive therapeutic target in Alzheimer's disease (AD). Here we report that BACE1 inhibitors have distinct effects on neuronal A&#x3b2; metabolism, inducing a unique pattern of secreted A&#x3b2; peptides, analyzed in cell media from amyloid precursor protein (APP) transfected cells and in cerebrospinal fluid (CSF) from dogs by immunoprecipitation-mass spectrometry, using several different BACE1 inhibitors. Besides the expected reductions in A&#x3b2;1-40 and A&#x3b2;1-42, treatment also changed the relative levels of several other A&#x3b2; isoforms. In particular A&#x3b2;1-34 decreased, while A&#x3b2;5-40 increased, and these changes were more sensitive to BACE1 inhibition than the changes in A&#x3b2;1-40 and A&#x3b2;1-42. The effects on A&#x3b2;5-40 indicate the presence of a BACE1 independent pathway of APP degradation. The described CSF A&#x3b2; pattern may be used as a pharmacodynamic fingerprint to detect biochemical effects of BACE1-therapies in clinical trials, which might accelerate development of novel therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mattsson</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, M&#xf6;lndal, Sweden. niklas.mattsson@neuro.gu.se</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajendran</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Gustavsson</LastName><ForeName>Mikael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Andreasson</LastName><ForeName>Ulf</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Olsson</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Brinkmalm</LastName><ForeName>Gunnar</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Lundkvist</LastName><ForeName>Johan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Laura H</ForeName><Initials>LH</Initials></Author><Author ValidYN="Y"><LastName>Perrot</LastName><ForeName>Ludovic</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>Ulf</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Borghys</LastName><ForeName>Herman</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Mercken</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Dhuyvetter</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Jeppsson</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Portelius</LastName><ForeName>Erik</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>YOW8V9698H</RegistryNumber><NameOfSubstance UI="D004121">Dimethyl Sulfoxide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002555" MajorTopicYN="N">Cerebrospinal Fluid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002853" MajorTopicYN="N">Chromatography, Liquid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004121" MajorTopicYN="N">Dimethyl Sulfoxide</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007118" MajorTopicYN="N">Immunoassay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have read the journal's policy and have the following conflicts: JL and FP are employed by Astra Zeneca. LHJ, LP and UN are employed by Novartis. HB, MM and DD are employed by Janssen. Astra Zeneca patent: * AZ-20 International application WO2010/056196. Novartis patents: * NB-B4 WO2010/003976 A1, 14. Jan 2010 * NB-C8 WO2011/009943 A1, 27. Jan 2011 Janssen patents: * (Applied for) Beauchamp, Jeremy; Benardeau, Agnes; Hilpert, Hans; Migliorini, Cristiano; Riboulet, William; Wang, Haiyan. 2-Aminodihydro[1,3]thiazines as BACE 2 inhibitors and their preparation and use in the treatment of diabetes. PCT Int. Appl. (2011), 64pp. CODEN: PIXXD2 WO 2011029803 A1 20110317 CAN 154:361040 AN 2011:326345 CAPLUS * (Applied for) Kobayashi, Naotake; Ueda, Kazuo; Itoh, Naohiro; Suzuki, Shinji; Sakaguchi, Gaku; Kato, Akira; Yukimasa, Akira; Hori, Akihiro; Kooriyama, Yuji; Haraguchi, Hidekazu; Yasui, Ken; Kanda, Yasuhiko. Preparation of 2-amino-4-phenyl-4,5-dihydro-5H-1,3-thiazine derivatives and related compounds for treatment of Alzheimer's disease. PCT Int. Appl. (2008), 354pp. CODEN: PIXXD2 WO 2008133273 A1 20081106 CAN 149:534229 AN 2008:1339943 CAPLUS * (Granted in South Korea) Kobayashi, Naotake; Ueda, Kazuo; Itoh, Naohiro; Suzuki, Shinji; Sakaguchi, Gaku; Kato, Akira; Yukimasa, Akira; Hori, Akihiro; Koriyama, Yuji; Haraguchi, Hidekazu; Yasui, Ken; Kanda, Yasuhiko. Preparation of 2-aminodihydrothiazine derivatives as beta-secretase inhibitors. PCT Int. Appl. (2007), 330pp. CODEN: PIXXD2 WO 2007049532 A1 20070503 CAN 146:482079 AN 2007:485607 CAPLUS This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>2</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22328928</ArticleId><ArticleId IdType="pmc">PMC3273469</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0031084</ArticleId><ArticleId IdType="pii">PONE-D-11-24101</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006;368:387&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron. 1991;6:487&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">1673054</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci. 1991;12:383&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">1763432</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov. 2010;9:387&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">20431570</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature. 1999;402:537&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591214</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature. 1999;402:533&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591213</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Kovacs DM, Yan R, Wong PC. The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J Neurosci. 2009;29:12787&#x2013;12794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2879048</ArticleId><ArticleId IdType="pubmed">19828790</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Mattsson N, Andreasson U, Blennow K, Zetterberg H. Novel Abeta Isoforms in Alzheimer s Disease - Their Role in Diagnosis and Treatment. Curr Pharm Des 2011</Citation><ArticleIdList><ArticleId IdType="pubmed">21728980</ArticleId></ArticleIdList></Reference><Reference><Citation>Miravalle L, Calero M, Takao M, Roher AE, Ghetti B, et al. Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques. Biochemistry. 2005;44:10810&#x2013;10821.</Citation><ArticleIdList><ArticleId IdType="pubmed">16086583</ArticleId></ArticleIdList></Reference><Reference><Citation>Naslund J, Schierhorn A, Hellman U, Lannfelt L, Roses AD, et al. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A. 1994;91:8378&#x2013;8382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44609</ArticleId><ArticleId IdType="pubmed">8078890</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Bogdanovic N, Gustavsson MK, Volkmann I, Brinkmalm G, et al. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol. 2010;120:185&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3568930</ArticleId><ArticleId IdType="pubmed">20419305</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Tran AJ, Andreasson U, Persson R, Brinkmalm G, et al. Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res. 2007;6:4433&#x2013;4439.</Citation><ArticleIdList><ArticleId IdType="pubmed">17927230</ArticleId></ArticleIdList></Reference><Reference><Citation>Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, Schenk DB. Characterization of beta-amyloid peptide from human cerebrospinal fluid. J Neurochem. 1993;61:1965&#x2013;1968.</Citation><ArticleIdList><ArticleId IdType="pubmed">8229004</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, et al. A novel pathway for amyloid precursor protein processing. Neurobiol Aging. 2011;32:1090&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">19604603</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook JJ, Wildsmith KR, Gilberto DB, Holahan MA, Kinney GG, et al. Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound. J Neurosci. 2010;30:6743&#x2013;6750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2913973</ArticleId><ArticleId IdType="pubmed">20463236</ArticleId></ArticleIdList></Reference><Reference><Citation>Esch FS, Keim PS, Beattie EC, Blacher RW, Culwell AR, et al. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science. 1990;248:1122&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">2111583</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn PH, Wang H, Dislich B, Colombo A, Zeitschel U, et al. ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J. 2010;29:3020&#x2013;3032.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2944055</ArticleId><ArticleId IdType="pubmed">20676056</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xe4;lting J, Neelissen J, Jeppsson F, Rades&#xe4;ter A, Eketj&#xe4;ll S, et al. Bace Inhibitors for the Treatment of Alzheimer's Disease. Alzheimer's &amp; Dementia. 2009;5:e5&#x2013;e6.</Citation></Reference><Reference><Citation>Rueeger H, Desrayaud S, Jacobson L, Lueoend R, Machauer R, et al. Structure based design of cyclic sulfoxide hydroxyethylamine BACE1 inhibitors. 2011. 241st ACS National Meeting &amp; Exposition.</Citation><ArticleIdList><ArticleId IdType="pubmed">23981898</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasugi N, Sasaki T, Suzuki K, Osawa S, Isshiki H, et al. BACE1 activity is modulated by cell-associated sphingosine-1-phosphate. J Neurosci. 2011;31:6850&#x2013;6857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4534000</ArticleId><ArticleId IdType="pubmed">21543615</ArticleId></ArticleIdList></Reference><Reference><Citation>Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, et al. A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo. Sci Transl Med. 2011;3:84ra43.</Citation><ArticleIdList><ArticleId IdType="pubmed">21613622</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med. 2011;3:84ra44.</Citation><ArticleIdList><ArticleId IdType="pubmed">21613623</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, Chavez-Gutierrez L, Bockstael K, Sannerud R, Annaert W, et al. Inhibition of beta-secretase in vivo via antibody binding to unique loops (D and F) of BACE1. J Biol Chem. 2011;286:8677&#x2013;8687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048749</ArticleId><ArticleId IdType="pubmed">21209097</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol. 2008;65:1102&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pubmed">18695061</ArticleId></ArticleIdList></Reference><Reference><Citation>Farah MH, Pan BH, Hoffman PN, Ferraris D, Tsukamoto T, et al. Reduced BACE1 Activity Enhances Clearance of Myelin Debris and Regeneration of Axons in the Injured Peripheral Nervous System. J Neurosci. 31:5744&#x2013;5754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3302726</ArticleId><ArticleId IdType="pubmed">21490216</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Van Broeck B, Andreasson U, Gustavsson MK, Mercken M, et al. Acute effect on the Abeta isoform pattern in CSF in response to gamma-secretase modulator and inhibitor treatment in dogs. J Alzheimers Dis. 2010;21:1005&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pubmed">20634579</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Dean RA, Gustavsson MK, Andreasson U, Zetterberg H, et al. A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer's disease. Alzheimers Res Ther. 2010;2:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2876785</ArticleId><ArticleId IdType="pubmed">20350302</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankaranarayanan S, Holahan MA, Colussi D, Crouthamel MC, Devanarayan V, et al. First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J Pharmacol Exp Ther. 2009;328:131&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">18854490</ArticleId></ArticleIdList></Reference><Reference><Citation>May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, et al. Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor. J Neurosci. 2011;31:16507&#x2013;16516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633289</ArticleId><ArticleId IdType="pubmed">22090477</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008;65:1031&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2682361</ArticleId><ArticleId IdType="pubmed">18695053</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Zhang B, Gustavsson MK, Brinkmalm G, Westman-Brinkmalm A, et al. Effects of gamma-Secretase Inhibition on the Amyloid beta Isoform Pattern in a Mouse Model of Alzheimer's Disease. Neurodegener Dis. 2009;6:258&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2837891</ArticleId><ArticleId IdType="pubmed">19955704</ArticleId></ArticleIdList></Reference><Reference><Citation>Fluhrer R, Multhaup G, Schlicksupp A, Okochi M, Takeda M, et al. Identification of a beta-secretase activity, which truncates amyloid beta-peptide after its presenilin-dependent generation. J Biol Chem. 2003;278:5531&#x2013;5538.</Citation><ArticleIdList><ArticleId IdType="pubmed">12471021</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi XP, Tugusheva K, Bruce JE, Lucka A, Wu GX, et al. Beta-secretase cleavage at amino acid residue 34 in the amyloid beta peptide is dependent upon gamma-secretase activity. J Biol Chem. 2003;278:21286&#x2013;21294.</Citation><ArticleIdList><ArticleId IdType="pubmed">12665519</ArticleId></ArticleIdList></Reference><Reference><Citation>John V. BACE : lead target for orchestrated therapy of Alzheimer's disease. Hoboken: John Wiley &amp; Sons; 2010. 266</Citation></Reference><Reference><Citation>Laird FM, Cai H, Savonenko AV, Farah MH, He K, et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci. 2005;25:11693&#x2013;11709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2564291</ArticleId><ArticleId IdType="pubmed">16354928</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Bolon B, Damore MA, Fitzpatrick D, Liu H, et al. BACE1 (beta-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time. Neurobiol Dis. 2003;14:81&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">13678669</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci. 2001;4:231&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224535</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda K, Araki W, Akiyama H, Tabira T. Amino-truncated amyloid beta-peptide (Abeta5-40/42) produced from caspase-cleaved amyloid precursor protein is deposited in Alzheimer's disease brain. FASEB J. 2004;18:1755&#x2013;1757.</Citation><ArticleIdList><ArticleId IdType="pubmed">15364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol. 2002;59:1381&#x2013;1389.</Citation><ArticleIdList><ArticleId IdType="pubmed">12223024</ArticleId></ArticleIdList></Reference><Reference><Citation>Holsinger RM, McLean CA, Collins SJ, Masters CL, Evin G. Increased beta-Secretase activity in cerebrospinal fluid of Alzheimer's disease subjects. Ann Neurol. 2004;55:898&#x2013;899.</Citation><ArticleIdList><ArticleId IdType="pubmed">15174031</ArticleId></ArticleIdList></Reference><Reference><Citation>Holsinger RM, Lee JS, Boyd A, Masters CL, Collins SJ. CSF BACE1 activity is increased in CJD and Alzheimer disease versus [corrected] other dementias. Neurology. 2006;67:710&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pubmed">16924032</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang LB, Lindholm K, Yan R, Citron M, Xia W, et al. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med. 2003;9:3&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">12514700</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston JA, Liu WW, Todd SA, Coulson DT, Murphy S, et al. Expression and activity of beta-site amyloid precursor protein cleaving enzyme in Alzheimer's disease. Biochem Soc Trans. 2005;33:1096&#x2013;1100.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246054</ArticleId></ArticleIdList></Reference><Reference><Citation>Verheijen JH, Huisman LG, van Lent N, Neumann U, Paganetti P, et al. Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. Clin Chem. 2006;52:1168&#x2013;1174.</Citation><ArticleIdList><ArticleId IdType="pubmed">16614000</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller DL, Papayannopoulos IA, Styles J, Bobin SA, Lin YY, et al. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys. 1993;301:41&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">8442665</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Bogdanovic N, Gustavsson MK, Volkmann I, Brinkmalm G, et al. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol 2010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3568930</ArticleId><ArticleId IdType="pubmed">20419305</ArticleId></ArticleIdList></Reference><Reference><Citation>Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS. Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res. 1978;38:3751&#x2013;3757.</Citation><ArticleIdList><ArticleId IdType="pubmed">29704</ArticleId></ArticleIdList></Reference><Reference><Citation>Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, et al. Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem. 1995;270:9564&#x2013;9570.</Citation><ArticleIdList><ArticleId IdType="pubmed">7721886</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SF, Shah S, Li H, Yu C, Han W, et al. Mammalian APH-1 interacts with presenilin and nicastrin and is required for intramembrane proteolysis of amyloid-beta precursor protein and Notch. J Biol Chem. 2002;277:45013&#x2013;45019.</Citation><ArticleIdList><ArticleId IdType="pubmed">12297508</ArticleId></ArticleIdList></Reference><Reference><Citation>Stachel SJ, Coburn CA, Steele TG, Jones KG, Loutzenhiser EF, et al. Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1). J Med Chem. 2004;47:6447&#x2013;6450.</Citation><ArticleIdList><ArticleId IdType="pubmed">15588077</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, et al. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging. 2010;31:357&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">18486992</ArticleId></ArticleIdList></Reference><Reference><Citation>Bylesj&#xf6; M, Rantalainen M, Cloarec O, Nicholson J, Holmes E, et al. OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification. J Chemometrics. 2007;20:341&#x2013;351.</Citation></Reference><Reference><Citation>Portelius E, Andreasson U, Ringman JM, Buerger K, Daborg J, et al. Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease. Mol Neurodegener. 2010;5:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2818651</ArticleId><ArticleId IdType="pubmed">20145736</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22204380</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><PubDate><Year>2011</Year><Month>Dec</Month><Day>28</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>The Alzheimer's &#x3b2;-secretase enzyme BACE1 is required for accurate axon guidance of olfactory sensory neurons and normal glomerulus formation in the olfactory bulb.</ArticleTitle><Pagination><StartPage>88</StartPage><MedlinePgn>88</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1750-1326-6-88</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The &#x3b2;-secretase, &#x3b2;-site amyloid precursor protein cleaving enzyme 1 (BACE1), is a prime therapeutic target for lowering cerebral &#x3b2;-amyloid (A&#x3b2;) levels in Alzheimer's disease (AD). Clinical development of BACE1 inhibitors is being intensely pursued. However, little is known about the physiological functions of BACE1, and the possibility exists that BACE1 inhibition may cause mechanism-based side effects. Indeed, BACE1-/- mice exhibit a complex neurological phenotype. Interestingly, BACE1 co-localizes with presynaptic neuronal markers, indicating a role in axons and/or terminals. Moreover, recent studies suggest axon guidance molecules are potential BACE1 substrates. Here, we used a genetic approach to investigate the function of BACE1 in axon guidance of olfactory sensory neurons (OSNs), a well-studied model of axon targeting in vivo.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We bred BACE1-/- mice with gene-targeted mice in which GFP is expressed from the loci of two odorant-receptors (ORs), MOR23 and M72, and olfactory marker protein (OMP) to produce offspring that were heterozygous for MOR23-GFP, M72-GFP, or OMP-GFP and were either BACE1+/+ or BACE1-/-. BACE1-/- mice had olfactory bulbs (OBs) that were smaller and weighed less than OBs of BACE1+/+ mice. In wild-type mice, BACE1 was present in OSN axon terminals in OB glomeruli. In whole-mount preparations and tissue sections, many OB glomeruli from OMP-GFP; BACE1-/- mice were malformed compared to wild-type glomeruli. MOR23-GFP; BACE1-/- mice had an irregular MOR23 glomerulus that was innervated by randomly oriented, poorly fasciculated OSN axons compared to BACE1+/+ mice. Most importantly, M72-GFP; BACE1-/- mice exhibited M72 OSN axons that were mis-targeted to ectopic glomeruli, indicating impaired axon guidance in BACE1-/- mice.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results demonstrate that BACE1 is required for the accurate targeting of OSN axons and the proper formation of glomeruli in the OB, suggesting a role for BACE1 in axon guidance. OSNs continually undergo regeneration and hence require ongoing axon guidance. Neurogenesis and the regeneration of neurons and axons occur in other adult populations of peripheral and central neurons that also require axon guidance throughout life. Therefore, BACE1 inhibitors under development for the treatment of AD may potentially cause axon targeting defects in these neuronal populations as well.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rajapaksha</LastName><ForeName>Tharinda W</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eimer</LastName><ForeName>William A</ForeName><Initials>WA</Initials></Author><Author ValidYN="Y"><LastName>Bozza</LastName><ForeName>Thomas C</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Vassar</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2 R01 AG022560</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>12</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C561468">M72 odorant receptor, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C118713">Olfr16 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018035">Receptors, Odorant</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009830" MajorTopicYN="N">Olfactory Bulb</DescriptorName><QualifierName UI="Q000002" MajorTopicYN="N">abnormalities</QualifierName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName><QualifierName UI="Q000254" MajorTopicYN="Y">growth &amp; development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018034" MajorTopicYN="N">Olfactory Receptor Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000254" MajorTopicYN="Y">growth &amp; development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018035" MajorTopicYN="N">Receptors, Odorant</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>12</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22204380</ArticleId><ArticleId IdType="pmc">PMC3269394</ArticleId><ArticleId IdType="doi">10.1186/1750-1326-6-88</ArticleId><ArticleId IdType="pii">#N/A</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R. et al.Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741. doi: 10.1126/science.286.5440.735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.286.5440.735</ArticleId><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashler JR, Stratman NC, Mathews WR, Buhl AE. et al.Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature. 1999;402:533&#x2013;537. doi: 10.1038/990107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/990107</ArticleId><ArticleId IdType="pubmed">10591213</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J. et al.Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature. 1999;402:537&#x2013;540. doi: 10.1038/990114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/990114</ArticleId><ArticleId IdType="pubmed">10591214</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, Gloger IS, Murphy KE, Southan CD, Ryan DM. et al.Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci. 1999;14:419&#x2013;427. doi: 10.1006/mcne.1999.0811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/mcne.1999.0811</ArticleId><ArticleId IdType="pubmed">10656250</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci USA. 2000;97:1456&#x2013;1460. doi: 10.1073/pnas.97.4.1456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.97.4.1456</ArticleId><ArticleId IdType="pmc">PMC26455</ArticleId><ArticleId IdType="pubmed">10677483</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y. et al.Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci. 2001;4:231&#x2013;232. doi: 10.1038/85059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/85059</ArticleId><ArticleId IdType="pubmed">11224535</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, Freedman SB, Frigon NL, Games D, Hu K. et al.BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet. 2001;10:1317&#x2013;1324. doi: 10.1093/hmg/10.12.1317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/10.12.1317</ArticleId><ArticleId IdType="pubmed">11406613</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, Vassar R, Disterhoft JF. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron. 2004;41:27&#x2013;33. doi: 10.1016/S0896-6273(03)00810-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00810-9</ArticleId><ArticleId IdType="pubmed">14715132</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M, Chang L, Tseng W, Oakley H, Citron M, Klein WL, Vassar R, Disterhoft JF. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. Eur J Neurosci. 2006;23:251&#x2013;260. doi: 10.1111/j.1460-9568.2005.04551.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2005.04551.x</ArticleId><ArticleId IdType="pubmed">16420434</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, Chiang HC, Xu G, Koliatsos VE. et al.BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci. 2005;25:11693&#x2013;11709. doi: 10.1523/JNEUROSCI.2766-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2766-05.2005</ArticleId><ArticleId IdType="pmc">PMC2564291</ArticleId><ArticleId IdType="pubmed">16354928</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitt BD, Jaramillo TC, Chetkovich DM, Vassar R. BACE1-/- mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization. Mol Neurodegener. 2010;5:31. doi: 10.1186/1750-1326-5-31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-5-31</ArticleId><ArticleId IdType="pmc">PMC2933677</ArticleId><ArticleId IdType="pubmed">20731874</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Zhou X, He W, Yang J, Xiong W, Wong P, Wilson CG, Yan R. BACE1 deficiency causes altered neuronal activity and neurodegeneration. J Neurosci. 2010;30:8819&#x2013;8829. doi: 10.1523/JNEUROSCI.1334-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1334-10.2010</ArticleId><ArticleId IdType="pmc">PMC2902368</ArticleId><ArticleId IdType="pubmed">20592204</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C. Control of peripheral nerve myelination by the beta-secretase BACE1. Science. 2006;314:664&#x2013;666. doi: 10.1126/science.1132341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1132341</ArticleId><ArticleId IdType="pubmed">16990514</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, Yan R. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci. 2006;9:1520&#x2013;1525. doi: 10.1038/nn1797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1797</ArticleId><ArticleId IdType="pubmed">17099708</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DY, Carey BW, Wang H, Ingano LA, Binshtok AM, Wertz MH, Pettingell WH, He P, Lee VM, Woolf CJ, Kovacs DM. BACE1 regulates voltage-gated sodium channels and neuronal activity. Nat Cell Biol. 2007;9:755&#x2013;764. doi: 10.1038/ncb1602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1602</ArticleId><ArticleId IdType="pmc">PMC2747787</ArticleId><ArticleId IdType="pubmed">17576410</ArticleId></ArticleIdList></Reference><Reference><Citation>Gersbacher MT, Kim DY, Bhattacharyya R, Kovacs DM. Identification of BACE1 cleavage sites in human voltage-gated sodium channel beta 2 subunit. Mol Neurodegener. 2010;5:61. doi: 10.1186/1750-1326-5-61.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-5-61</ArticleId><ArticleId IdType="pmc">PMC3022600</ArticleId><ArticleId IdType="pubmed">21182789</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Kovacs DM, Yan R, Wong PC. The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J Neurosci. 2009;29:12787&#x2013;12794. doi: 10.1523/JNEUROSCI.3657-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3657-09.2009</ArticleId><ArticleId IdType="pmc">PMC2879048</ArticleId><ArticleId IdType="pubmed">19828790</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemming ML, Elias JE, Gygi SP, Selkoe DJ. Identification of beta-secretase (BACE1) substrates using quantitative proteomics. PLoS One. 2009;4:e8477. doi: 10.1371/journal.pone.0008477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0008477</ArticleId><ArticleId IdType="pmc">PMC2793532</ArticleId><ArticleId IdType="pubmed">20041192</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Fu Y, Yasvoina M, Shao P, Hitt B, O'Connor T, Logan S, Maus E, Citron M, Berry R. et al.Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. J Neurosci. 2007;27:3639&#x2013;3649. doi: 10.1523/JNEUROSCI.4396-06.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4396-06.2007</ArticleId><ArticleId IdType="pmc">PMC6672403</ArticleId><ArticleId IdType="pubmed">17409228</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan XX, Xiong K, Luo XG, Struble RG, Clough RW. beta-Secretase expression in normal and functionally deprived rat olfactory bulbs: inverse correlation with oxidative metabolic activity. J Comp Neurol. 2007;501:52&#x2013;69. doi: 10.1002/cne.21239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.21239</ArticleId><ArticleId IdType="pubmed">17206602</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakano H. Neural map formation in the mouse olfactory system. Neuron. 2010;67:530&#x2013;542. doi: 10.1016/j.neuron.2010.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.07.003</ArticleId><ArticleId IdType="pubmed">20797531</ArticleId></ArticleIdList></Reference><Reference><Citation>Buck L, Axel R. A novel multigene family may encode odorant receptors: a molecular basis for odor recognition. Cell. 1991;65:175&#x2013;187. doi: 10.1016/0092-8674(91)90418-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(91)90418-X</ArticleId><ArticleId IdType="pubmed">1840504</ArticleId></ArticleIdList></Reference><Reference><Citation>Ressler KJ, Sullivan SL, Buck LB. A zonal organization of odorant receptor gene expression in the olfactory epithelium. Cell. 1993;73:597&#x2013;609. doi: 10.1016/0092-8674(93)90145-G.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(93)90145-G</ArticleId><ArticleId IdType="pubmed">7683976</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Ngai J, Axel R. Spatial segregation of odorant receptor expression in the mammalian olfactory epithelium. Cell. 1993;74:309&#x2013;318. doi: 10.1016/0092-8674(93)90422-M.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(93)90422-M</ArticleId><ArticleId IdType="pubmed">8343958</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Chao SK, Sitcheran R, Nu&#xf1;ez JM, Vosshall LB, Axel R. Topographic organization of sensory projections to the olfactory bulb. Cell. 1994;79:981&#x2013;991. doi: 10.1016/0092-8674(94)90029-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(94)90029-9</ArticleId><ArticleId IdType="pubmed">8001145</ArticleId></ArticleIdList></Reference><Reference><Citation>Ressler KJ, Sullivan SL, Buck LB. Information coding in the olfactory system: evidence for a stereotyped and highly organized epitope map in the olfactory bulb. Cell. 1994;79:1245&#x2013;1255. doi: 10.1016/0092-8674(94)90015-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(94)90015-9</ArticleId><ArticleId IdType="pubmed">7528109</ArticleId></ArticleIdList></Reference><Reference><Citation>Mombaerts P, Wang F, Dulac C, Chao SK, Nemes A, Mendelsohn M, Edmondson J, Axel R. Visualizing an olfactory sensory map. Cell. 1996;87:675&#x2013;686. doi: 10.1016/S0092-8674(00)81387-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)81387-2</ArticleId><ArticleId IdType="pubmed">8929536</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, Serneels L, Camacho IE, Marjaux E, Craessaerts K. et al.Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem. 2005;280:30797&#x2013;30806. doi: 10.1074/jbc.M505249200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M505249200</ArticleId><ArticleId IdType="pubmed">15987683</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin DM, Wang F, Lowe G, Gold GH, Axel R, Ngai J, Brunet L. Formation of precise connections in the olfactory bulb occurs in the absence of odorant-evoked neuronal activity. Neuron. 2000;26:69&#x2013;80. doi: 10.1016/S0896-6273(00)81139-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)81139-3</ArticleId><ArticleId IdType="pubmed">10798393</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng C, Feinstein P, Bozza T, Rodriguez I, Mombaerts P. Peripheral olfactory projections are differentially affected in mice deficient in a cyclic nucleotide-gated channel subunit. Neuron. 2000;26:81&#x2013;91. doi: 10.1016/S0896-6273(00)81140-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)81140-X</ArticleId><ArticleId IdType="pubmed">10798394</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong ST, Trinh K, Hacker B, Chan GC, Lowe G, Gaggar A, Xia Z, Gold GH, Storm DR. Disruption of the type III adenylyl cyclase gene leads to peripheral and behavioral anosmia in transgenic mice. Neuron. 2000;27:487&#x2013;497. doi: 10.1016/S0896-6273(00)00060-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)00060-X</ArticleId><ArticleId IdType="pubmed">11055432</ArticleId></ArticleIdList></Reference><Reference><Citation>Belluscio L, Gold GH, Nemes A, Axel R. Mice deficient in G(olf) are anosmic. Neuron. 1998;20:69&#x2013;81. doi: 10.1016/S0896-6273(00)80435-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80435-3</ArticleId><ArticleId IdType="pubmed">9459443</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunjes PC, Borror MJ. Unilateral odor deprivation: differential effects due to time of treatment. Brain Res Bull. 1983;11:501&#x2013;503. doi: 10.1016/0361-9230(83)90121-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0361-9230(83)90121-1</ArticleId><ArticleId IdType="pubmed">6667380</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter SM, Zheng C, Koos DS, Feinstein P, Fraser SE, Mombaerts P. Structure and emergence of specific olfactory glomeruli in the mouse. J Neurosci. 2001;21:9713&#x2013;9723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2570017</ArticleId><ArticleId IdType="pubmed">11739580</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassalli A, Rothman A, Feinstein P, Zapotocky M, Mombaerts P. Minigenes impart odorant receptor-specific axon guidance in the olfactory bulb. Neuron. 2002;35:681&#x2013;696. doi: 10.1016/S0896-6273(02)00793-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(02)00793-6</ArticleId><ArticleId IdType="pubmed">12194868</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci. 2001;4:233&#x2013;234. doi: 10.1038/85064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/85064</ArticleId><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22312444</PMID><DateCompleted><Year>2012</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>2</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Trans-synaptic spread of tau pathology in vivo.</ArticleTitle><Pagination><StartPage>e31302</StartPage><MedlinePgn>e31302</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e31302</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0031302</ELocationID><Abstract><AbstractText>Tauopathy in the brain of patients with Alzheimer's disease starts in the entorhinal cortex (EC) and spreads anatomically in a defined pattern. To test whether pathology initiating in the EC spreads through the brain along synaptically connected circuits, we have generated a transgenic mouse model that differentially expresses pathological human tau in the EC and we have examined the distribution of tau pathology at different timepoints. In relatively young mice (10-11 months old), human tau was present in some cell bodies, but it was mostly observed in axons within the superficial layers of the medial and lateral EC, and at the terminal zones of the perforant pathway. In old mice (&gt;22 months old), intense human tau immunoreactivity was readily detected not only in neurons in the superficial layers of the EC, but also in the subiculum, a substantial number of hippocampal pyramidal neurons especially in CA1, and in dentate gyrus granule cells. Scattered immunoreactive neurons were also seen in the deeper layers of the EC and in perirhinal and secondary somatosensory cortex. Immunoreactivity with the conformation-specific tau antibody MC1 correlated with the accumulation of argyrophilic material seen in old, but not young mice. In old mice, axonal human tau immunoreactivity, especially at the endzones of the perforant pathway, was greatly reduced. Relocalization of tau from axons to somatodendritic compartments and propagation of tauopathy to regions outside of the EC correlated with mature tangle formation in neurons in the EC as revealed by thioflavin-S staining. Our data demonstrate propagation of pathology from the EC and support a trans-synaptic mechanism of spread along anatomically connected networks, between connected and vulnerable neurons. In general, the mouse recapitulates the tauopathy that defines the early stages of AD and provides a model for testing mechanisms and functional outcomes associated with disease progression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Taub Institute for Alzheimer's Disease Research, Columbia University, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drouet</LastName><ForeName>Valerie</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jessica W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Witter</LastName><ForeName>Menno P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Small</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Clelland</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Duff</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS74874</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG025161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG033790</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG033790</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034618</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS074874</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG034618</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018728" MajorTopicYN="N">Entorhinal Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22312444</ArticleId><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0031302</ArticleId><ArticleId IdType="pii">PONE-D-11-23353</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>van Groen T, Miettinen P, Kadish I. The entorhinal cortex of the mouse: organization of the projection to the hippocampal formation. Hippocampus. 2003;13:133&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">12625464</ArticleId></ArticleIdList></Reference><Reference><Citation>Witter MP, Wouterlood FG, Naber PA, Van Haeften T. Anatomical organization of the parahippocampal-hippocampal network. Ann N Y Acad Sci. 2000;911:1&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">10911864</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. Alzheimer's pathogenesis: is there neuron-to-neuron propagation? Acta Neuropathol. 2011;121:589&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">21516512</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaizot X, Meguro K, Millien I, Baron JC, Chavoix C. Correlations between visual recognition memory and neocortical and hippocampal glucose metabolism after bilateral rhinal cortex lesions in the baboon: implications for Alzheimer's disease. J Neurosci. 2002;22:9166&#x2013;9170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758045</ArticleId><ArticleId IdType="pubmed">12417640</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Bowser R, Kazam IG, Davies P. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res. 1997;48:128&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">9130141</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver CL, Espinoza M, Kress Y, Davies P. Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol Aging. 2000;21:719&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">11016541</ArticleId></ArticleIdList></Reference><Reference><Citation>Witter MP. The perforant path: projections from the entorhinal cortex to the dentate gyrus. Prog Brain Res. 2007;163:43&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">17765711</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernat J, Mandelkow EM, Schroter C, Lichtenberg-Kraag B, Steiner B, et al. The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J. 1992;11:1593&#x2013;1597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556608</ArticleId><ArticleId IdType="pubmed">1563356</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Bancroft JD, Stevens A. Theory and Practice of Histological Techniques 1982</Citation></Reference><Reference><Citation>Mayford M, Baranes D, Podsypanina K, Kandel ER. The 3&#x2032;-untranslated region of CaMKII alpha is a cis-acting signal for the localization and translation of mRNA in dendrites. Proc Natl Acad Sci U S A. 1996;93:13250&#x2013;13255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24079</ArticleId><ArticleId IdType="pubmed">8917577</ArticleId></ArticleIdList></Reference><Reference><Citation>Saman S, Kim W, Raya M, Visnick Y, Miro S, et al. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid (CSF) in early Alzheimer's Disease. J Biol Chem 2011</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281682</ArticleId><ArticleId IdType="pubmed">22057275</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda M, Mayford MR. CaMKII activation in the entorhinal cortex disrupts previously encoded spatial memory. Neuron. 2006;50:309&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">16630840</ArticleId></ArticleIdList></Reference><Reference><Citation>Juntti SA, Tollkuhn J, Wu MV, Fraser EJ, Soderborg T, et al. The androgen receptor governs the execution, but not programming, of male sexual and territorial behaviors. Neuron. 2010;66:260&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2923659</ArticleId><ArticleId IdType="pubmed">20435002</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun A, Nguyen XV, Bing G. Comparative analysis of an improved thioflavin-s stain, Gallyas silver stain, and immunohistochemistry for neurofibrillary tangle demonstration on the same sections. J Histochem Cytochem. 2002;50:463&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">11897799</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22279212</PMID><DateCompleted><Year>2012</Year><Month>03</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>Jan</Month><Day>25</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Transgenic expression of intraneuronal A&#x3b2;42 but not A&#x3b2;40 leads to cellular A&#x3b2; lesions, degeneration, and functional impairment without typical Alzheimer's disease pathology.</ArticleTitle><Pagination><StartPage>1273</StartPage><EndPage>1283</EndPage><MedlinePgn>1273-83</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4586-11.2012</ELocationID><Abstract><AbstractText>An early role of amyloid-&#x3b2; peptide (A&#x3b2;) aggregation in Alzheimer's disease pathogenesis is well established. However, the contribution of intracellular or extracellular forms of A&#x3b2; to the neurodegenerative process is a subject of considerable debate. We here describe transgenic mice expressing A&#x3b2;1-40 (APP47) and A&#x3b2;1-42 (APP48) with a cleaved signal sequence to insert both peptides during synthesis into the endoplasmic reticulum. Although lower in transgene mRNA, APP48 mice reach a higher brain A&#x3b2; concentration. The reduced solubility and increased aggregation of A&#x3b2;1-42 may impair its degradation. APP48 mice develop intracellular A&#x3b2; lesions in dendrites and lysosomes. The hippocampal neuron number is reduced already at young age. The brain weight decreases during aging in conjunction with severe white matter atrophy. The mice show a motor impairment. Only very few A&#x3b2;1-40 lesions are found in APP47 mice. Neither APP47 nor APP48 nor the bigenic mice develop extracellular amyloid plaques. While intracellular membrane expression of A&#x3b2;1-42 in APP48 mice does not lead to the AD-typical lesions, A&#x3b2; aggregates develop within cells accompanied by considerable neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abramowski</LastName><ForeName>Dorothee</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Novartis Institutes for Biomedical Research, CH-4056 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabe</LastName><ForeName>Sabine</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Upadhaya</LastName><ForeName>Ajeet Rijal</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Reichwald</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Danner</LastName><ForeName>Simone</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Staab</LastName><ForeName>Dieter</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Capetillo-Zarate</LastName><ForeName>Estibaliz</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Yamaguchi</LastName><ForeName>Haruyasu</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Saido</LastName><ForeName>Takaomi C</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Wiederhold</LastName><ForeName>Karl-Heinz</ForeName><Initials>KH</Initials></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>Dietmar Rudolf</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007425" MajorTopicYN="N">Intracellular Membranes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>7</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22279212</ArticleId><ArticleId IdType="pmc">PMC6796269</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4586-11.2012</ArticleId><ArticleId IdType="pii">32/4/1273</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abramowski D, Wiederhold KH, Furrer U, Jaton AL, Neuenschwander A, Runser MJ, Danner S, Reichwald J, Ammaturo D, Staab D, Stoeckli M, Rueeger H, Neumann U, Staufenbiel M. Dynamics of A beta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J Pharmacol Exp Ther. 2008;327:411&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">18687920</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H. On the structure of the human archicortex. I. The cornu ammonis. A Golgi and pigmentarchitectonic study. Cell Tissue Res. 1974;152:349&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">4140757</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1991;1:213&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">1669710</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C, Staufenbiel M, Sommer B, Jucker M. Neuron loss in APP transgenic mice. Nature. 1998;395:755&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">9796810</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun ME, Burgermeister P, Phinney AL, Stalder M, Tolnay M, Wiederhold KH, Abramowski D, Sturchler-Pierrat C, Sommer B, Staufenbiel M, Jucker M. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci U S A. 1999;96:14088&#x2013;14093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24195</ArticleId><ArticleId IdType="pubmed">10570203</ArticleId></ArticleIdList></Reference><Reference><Citation>Capetillo-Zarate E, Staufenbiel M, Abramowski D, Haass C, Escher A, Stadelmann C, Yamaguchi H, Wiestler OD, Thal DR. Selective vulnerability of different types of commissural neurons for amyloid &#x3b2;-protein-induced neurodegeneration in APP23 mice correlates with dendritic tree morphology. Brain. 2006;129:2992&#x2013;3005.</Citation><ArticleIdList><ArticleId IdType="pubmed">16844716</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov. 2010;9:387&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">20431570</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Tampellini D, Takahashi RH, Capetillo-Zarate E. Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathol. 2010;119:523&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3183823</ArticleId><ArticleId IdType="pubmed">20354705</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;29:577&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">6166661</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihara M, Polvikoski TM, Hall R, Slade JY, Perry RH, Oakley AE, Englund E, O'Brien JT, Ince PG, Kalaria RN. Quantification of myelin loss in frontal lobe white matter in vascular dementia, Alzheimer's disease, and dementia with Lewy bodies. Acta Neuropathol. 2010;119:579&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2849937</ArticleId><ArticleId IdType="pubmed">20091409</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9:119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji Y, Permanne B, Sigurdsson EM, Holtzman DM, Wisniewski T. Amyloid beta40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. J Alzheimers Dis. 2001;3:23&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">12214069</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, M&#xfc;ller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987;325:733&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pubmed">2881207</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C, Dickson DW, Golde T, McGowan E. A&#x3b2;40 inhibits amyloid deposition in vivo. J Neurosci. 2007;27:627&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672801</ArticleId><ArticleId IdType="pubmed">17234594</ArticleId></ArticleIdList></Reference><Reference><Citation>Klafki HW, Wiltfang J, Staufenbiel M. Electrophoretic separation of betaA4 peptides (1&#x2013;40) and (1&#x2013;42) Anal Biochem. 1996;237:24&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">8660532</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, Vandersteen A, Segers-Nolten I, Van Der Werf K, Subramaniam V, Braeken D, Callewaert G, Bartic C, D'Hooge R, Martins IC, Rousseau F, Schymkowitz J, De Strooper B. Neurotoxicity of Alzheimer's disease Abeta peptides is induced by small changes in the Abeta42 to Abeta40 ratio. EMBO J. 2010;29:3408&#x2013;3420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2957213</ArticleId><ArticleId IdType="pubmed">20818335</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;thi A, Van der Putten H, Botteri FM, Mansuy IM, Meins M, Frey U, Sansig G, Portet C, Schmutz M, Schr&#xf6;der M, Nitsch C, Laurent JP, Monard D. Endogenous serine protease inhibitor modulates epileptic activity and hippocampal long-term potentiation. J Neurosci. 1997;17:4688&#x2013;4699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573330</ArticleId><ArticleId IdType="pubmed">9169529</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama K, Tagawa K, Kawamura Y, Asada H, Ishiura S, Obata K. Secretion of Alzheimer beta/A4 protein (1&#x2013;40) and intracellular retention of beta/A4 protein (1&#x2013;42) in transfected COS cells. Biochem Biophys Res Commun. 1995;207:971&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pubmed">7864903</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005;47:191&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1373682</ArticleId><ArticleId IdType="pubmed">16039562</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmrich V, Ebert U. Is Alzheimer's disease a result of presynaptic failure? Synaptic dysfunctions induced by oligomeric beta-amyloid. Rev Neurosci. 2009;20:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">19526730</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci. 2010;13:812&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072750</ArticleId><ArticleId IdType="pubmed">20581818</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichwald J, Danner S, Wiederhold KH, Staufenbiel M. Expression of complement system components during aging and amyloid deposition in APP transgenic mice. J Neuroinflammation. 2009;6:35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2784442</ArticleId><ArticleId IdType="pubmed">19917141</ArticleId></ArticleIdList></Reference><Reference><Citation>Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron. 1995;14:457&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pubmed">7857653</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlenzig D, Manhart S, Cinar Y, Kleinschmidt M, Hause G, Willbold D, Funke SA, Schilling S, Demuth HU. Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides. Biochemistry. 2009;48:7072&#x2013;7078.</Citation><ArticleIdList><ArticleId IdType="pubmed">19518051</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz C, Hof PR. Recommendations for straightforward and rigorous methods of counting neurons based on a computer simulation approach. J Chem Neuroanat. 2000;20:93&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">11074347</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Yamazaki T, Citron M, Podlisny MB, Koo EH, Teplow DB, Haass C. The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Ann N Y Acad Sci. 1996;777:57&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">8624127</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Staufenbiel M, Paganetti PA. Electrophoretic separation and immunoblotting of A&#x3b2;1&#x2013;40 and A&#x3b2;1&#x2013;42. Methods Mol Med. 2000;32:91&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">21318513</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, B&#xfc;rki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A. 1997;94:13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, Beal MF, Xu H, Greengard P, Gouras GK. Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol. 2002;161:1869&#x2013;1879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850783</ArticleId><ArticleId IdType="pubmed">12414533</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Sassin I, Schultz C, Haass C, Braak E, Braak H. Fleecy amyloid deposits in the internal layers of the human entorhinal cortex are comprised of N-terminal truncated fragments of Abeta. J Neuropathol Exp Neurol. 1999;58:210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">10029103</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Larionov S, Abramowski D, Wiederhold KH, Van Dooren T, Yamaguchi H, Haass C, Van Leuven F, Staufenbiel M, Capetillo-Zarate E. Occurrence and co-localization of amyloid beta-protein and apolipoprotein E in perivascular drainage channels of wild-type and APP-transgenic mice. Neurobiol Aging. 2007;28:1221&#x2013;1230.</Citation><ArticleIdList><ArticleId IdType="pubmed">16815595</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K, Ishibashi K, Teraoka R, Sakama N, Yamashita T, Nishitsuji K, Ito K, Shimada H, Lambert MP, Klein WL, Mori H. A mouse model of amyloid &#x3b2; oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci. 2010;30:4845&#x2013;4856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632783</ArticleId><ArticleId IdType="pubmed">20371804</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirths O, Breyhan H, Cynis H, Schilling S, Demuth HU, Bayer TA. Intraneuronal pyroglutamate-Abeta 3&#x2013;42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol. 2009;118:487&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737116</ArticleId><ArticleId IdType="pubmed">19547991</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi H, Sugihara S, Ogawa A, Saido TC, Ihara Y. Diffuse plaques associated with astroglial amyloid beta protein, possibly showing a disappearing stage of senile plaques. Acta Neuropathol. 1998;95:217&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">9542585</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22445347</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>6</Issue><PubDate><Year>2012</Year><Month>Mar</Month><Day>22</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>A network diffusion model of disease progression in dementia.</ArticleTitle><Pagination><StartPage>1204</StartPage><EndPage>1215</EndPage><MedlinePgn>1204-15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2011.12.040</ELocationID><Abstract><AbstractText>Patterns of dementia are known to fall into dissociated but dispersed brain networks, suggesting that the disease is transmitted along neuronal pathways rather than by proximity. This view is supported by neuropathological evidence for "prion-like" transsynaptic transmission of disease agents like misfolded tau and beta amyloid. We mathematically model this transmission by a diffusive mechanism mediated by&#xa0;the brain's connectivity network obtained from tractography of 14 healthy-brain MRIs. Subsequent graph theoretic analysis provides a fully quantitative, testable, predictive model of dementia. Specifically, we predict spatially distinct "persistent modes," which, we found, recapitulate known patterns of dementia and match recent reports of selectively vulnerable dissociated brain networks. Model predictions also closely match T1-weighted MRI volumetrics of 18 Alzheimer's and 18 frontotemporal dementia subjects. Prevalence rates predicted by the model strongly agree with published data. This work has many important implications, including dimensionality reduction, differential diagnosis, and especially prediction of future atrophy using baseline MRI morphometrics.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raj</LastName><ForeName>Ashish</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiology, Weill Medical College of Cornell University, 515 E. 71 Street, Suite S123, New York, NY 10044, USA. ashish@med.cornell.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuceyeski</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P41 RR023953-02S1</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 EB008138</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 RR023953</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS075425</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 EB012404</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2012 Mar 22;73(6):1060-2. doi: 10.1016/j.neuron.2012.03.006.</RefSource><PMID Version="1">22445334</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2012 Apr 17;8(5):237. doi: 10.1038/nrneurol.2012.64.</RefSource><PMID Version="1">22508230</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2012 Apr 18;13(5):288. doi: 10.1038/nrn3248.</RefSource><PMID Version="1">22510888</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001703" MajorTopicYN="N">Biophysics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="Y">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="Y">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>4</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22445347</ArticleId><ArticleId IdType="mid">NIHMS357429</ArticleId><ArticleId IdType="pmc">PMC3623298</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2011.12.040</ArticleId><ArticleId IdType="pii">S0896-6273(12)00135-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Acosta-Cabronero Julio, Williams Guy B, Pengas George, Nestor Peter J. Absolute diffusivities define the landscape of white matter degeneration in Alzheimer&#x2019;s disease. Brain. 2010;133:529&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">19914928</ArticleId></ArticleIdList></Reference><Reference><Citation>Alem&#xe1;n-G&#xf3;mez Y, Melie-Garc&#xed;a L, Vald&#xe9;s-Hernandez P. IBASPM: toolbox for automatic parcellation of brain structures. Presented at the 12th Annual Meeting of the Organization for Human Brain Mapping; Florence, Italy. 2005.</Citation></Reference><Reference><Citation>Almond DP, Budd CJ, McCullen NJ. Emergent behaviour in large electrical networks. In: Georgoulis E, Iske A, Levesley J, editors. Approximation Algorithms for Complex Systems. New York: Springer; 2011. pp. 3&#x2013;26.</Citation></Reference><Reference><Citation>Apostolova LG, Steiner CA, Akopyan GG, Dutton RA, Hayashi KM, Toga AW, Cummings JL, Thompson PM. Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease. Arch Neurol. 2007;64:1489&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197839</ArticleId><ArticleId IdType="pubmed">17923632</ArticleId></ArticleIdList></Reference><Reference><Citation>Barreda JL, Zhou HX. A solvable model for the diffusion and reaction of neurotransmitters in a synaptic junction. BMC Biophys. 2011;4:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3093673</ArticleId><ArticleId IdType="pubmed">21596000</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer&#x2019;s disease. Neurobiol Aging. 2004;25:5&#x2013;18. author reply 49&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">14675724</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrens TEJ, Berg HJ, Jbabdi S, Rushworth MFS, Woolrich MW. Probabilistic diffusion tractography with multiple fibre orientations: What can we gain? Neuroimage. 2007;34:144&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116582</ArticleId><ArticleId IdType="pubmed">17070705</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhalla US. Understanding complex signaling networks through models and metaphors. Prog Biophys Mol Biol. 2002;81:45&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">12475569</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxer AL, Miller BL. Clinical features of frontotemporal dementia. Alzheimer Dis Assoc Disord. 2005;19(Suppl 1):S3&#x2013;S6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16317256</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxer AL, Geschwind MD, Belfor N, Gorno-Tempini ML, Schauer GF, Miller BL, Weiner MW, Rosen HJ. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol. 2006;63:81&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401739</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K, Schultz C, Braak E. Vulnerability of select neuronal types to Alzheimer&#x2019;s disease. Ann N Y Acad Sci. 2000;924:53&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193802</ArticleId></ArticleIdList></Reference><Reference><Citation>Broe M, Hodges JR, Schofield E, Shepherd CE, Kril JJ, Halliday GM. Staging disease severity in pathologically confirmed cases of frontotemporal dementia. Neurology. 2003;60:1005&#x2013;1011.</Citation><ArticleIdList><ArticleId IdType="pubmed">12654969</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, et al. Molecular, structural, and functional characterization of Alzheimer&#x2019;s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlo AD, et al. Incidence of dementia, Alzheimer&#x2019;s disease, and vascular dementia in Italy. The ILSA Study. J Am Geriatr Soc. 2002;50:41&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">12028245</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis CE, D&#x2019;Esposito M. Persistent activity in the prefrontal cortex during working memory. Trends Cogn Sci. 2003;7:415&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">12963473</ArticleId></ArticleIdList></Reference><Reference><Citation>Du AT, Schuff N, Kramer JH, Rosen HJ, Gorno-Tempini ML, Rankin K, Miller BL, Weiner MW. Different regional patterns of cortical thinning in Alzheimer&#x2019;s disease and frontotemporal dementia. Brain. 2007;130:1159&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853284</ArticleId><ArticleId IdType="pubmed">17353226</ArticleId></ArticleIdList></Reference><Reference><Citation>Englund E, Brun A, Alling C. White matter changes in dementia of Alzheimer&#x2019;s type. Biochemical and neuropathological correlates. Brain. 1988;111:1425&#x2013;1439.</Citation><ArticleIdList><ArticleId IdType="pubmed">3208064</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33:341&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman MS, et al. Frontotemporal dementia: clinicopathological correlations. Ann Neurol. 2006;59:952&#x2013;962.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2629792</ArticleId><ArticleId IdType="pubmed">16718704</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci. 2010;11:155&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3648341</ArticleId><ArticleId IdType="pubmed">20029438</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem. 2009a;284:12845&#x2013;12852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Ollesch J, Wille H, Diamond MI. Conformational diversity of wild-type Tau fibrils specified by templated conformation change. J Biol Chem. 2009b;284:3546&#x2013;3551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2635036</ArticleId><ArticleId IdType="pubmed">19010781</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg II, Harel M, Malach R. When the brain loses its self: prefrontal inactivation during sensorimotor processing. Neuron. 2006;50:329&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">16630842</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Dronkers NF, Rankin KP, Ogar JM, Phengrasamy L, Rosen HJ, Johnson JK, Weiner MW, Miller BL. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol. 2004;55:335&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2362399</ArticleId><ArticleId IdType="pubmed">14991811</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J. Expression of normal sequence pathogenic proteins for neurodegenerative disease contributes to disease risk: &#x201c;permissive templating&#x201d; as a general mechanism underlying neurodegeneration. Biochem Soc Trans. 2005;33:578&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pubmed">16042548</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey RJ. The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry. 2003;74:1206&#x2013;1209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738690</ArticleId><ArticleId IdType="pubmed">12933919</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Chen Z, Evans A. Structural insights into aberrant topological patterns of large-scale cortical networks in Alzheimer&#x2019;s disease. J Neurosci. 2008;28:4756&#x2013;4766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670444</ArticleId><ArticleId IdType="pubmed">18448652</ArticleId></ArticleIdList></Reference><Reference><Citation>Hess CP, Mukherjee P, Han ET, Xu D, Vigneron DB. Q-ball reconstruction of multimodal fiber orientations using the spherical harmonic basis. Magn Res Med. 2006;56:104&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">16755539</ArticleId></ArticleIdList></Reference><Reference><Citation>Iturria-Medina Y, Canales-Rodriguez EJ, Aleman-Gomez Y, Sotero RC, Melie-Garcia L. Studying the human brain anatomical network via diffusion-weighted MRI and graph theory. Neuroimage. 2008;40:1064&#x2013;1076.</Citation><ArticleIdList><ArticleId IdType="pubmed">18272400</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA, Attems J. Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathol. 2010;119:421&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">20204386</ArticleId></ArticleIdList></Reference><Reference><Citation>Klauschen F, Goldman A, Barra V, Meyer-Lindenberg A, Lundervold A. Evaluation of automated brain MR image segmentation and volume-try methods. Hum Brain Mapp. 2009;30:1310&#x2013;1327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6870639</ArticleId><ArticleId IdType="pubmed">18537111</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi M, Sato T, Sato A, Imamura T. Oldest-old dementia in a Japanese memory clinic. Brain and Nerve. 2009;61:972&#x2013;978.</Citation><ArticleIdList><ArticleId IdType="pubmed">19697887</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondor RI, Lafferty J. Diffusion kernels on graphs and other discrete structures. Proc. 19th Intl. Conf. on Machine Learning; 2002. pp. 315&#x2013;322.</Citation></Reference><Reference><Citation>Kuczynski B, Targan E, Madison C, Weiner M, Zhang Yu, Reed B, Chui HC, Jagust W. White matter integrity and cortical metabolic associations in aging and dementia. Alzheimers Dement. 2010;6:54&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2817977</ArticleId><ArticleId IdType="pubmed">20129319</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukull WA, Higdon R, Bowen JD, McCormick WC, Teri L, Schellenberg GD, van Belle G, Jolley L, Larson EB. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol. 2002;59:1737&#x2013;1746.</Citation><ArticleIdList><ArticleId IdType="pubmed">12433261</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo CY, Wang PN, Chou KH, Wang J, He Y, Lin CP. Diffusion tensor tractography reveals abnormal topological organization in structural cortical networks in Alzheimer&#x2019;s disease. J Neurosci. 2010;30:16876&#x2013;16885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6634928</ArticleId><ArticleId IdType="pubmed">21159959</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomasko T, Lumsden CJ. One-hit stochastic decline in a mechanochemical model of cytoskeleton-induced neuron death III: diffusion pulse death zones. J Theor Biol. 2009;256:104&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">18824176</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez S, Cortes J, Bullo F. Motion coordination with distributed information. IEEE Contr Syst. 2007;27:75&#x2013;88.</Citation></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison PJ. Accurate prevalence and uptake of testing for Huntington&#x2019;s disease. Lancet Neurol. 2010;9:1147.</Citation><ArticleIdList><ArticleId IdType="pubmed">21087736</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D, Snowden J. Frontotemporal dementia: nosology, neuropsychology, and neuropathology. Brain Cogn. 1996;31:176&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">8811995</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546&#x2013;1554.</Citation><ArticleIdList><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. Amyloid-&#x3b2;-induced neuronal dysfunction in Alzheimer&#x2019;s disease: from synapses toward neural networks. Nat Neurosci. 2010;13:812&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072750</ArticleId><ArticleId IdType="pubmed">20581818</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature. 2006;443:768&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051202</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira JMS, Williams GB, Acosta-Cabronero J, Pengas G, Spillantini MG, Xuereb JH, Hodges JR, Nestor PJ. Atrophy patterns in histologic vs clinical groupings of frontotemporal lobar degeneration. Neurology. 2009;72:1653&#x2013;1660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827263</ArticleId><ArticleId IdType="pubmed">19433738</ArticleId></ArticleIdList></Reference><Reference><Citation>Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, Burke JR, Hurd MD, Potter GG, Rodgers WL, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29:125&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2705925</ArticleId><ArticleId IdType="pubmed">17975326</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol. 2009;21:117&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2804478</ArticleId><ArticleId IdType="pubmed">19847050</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Furst AJ, Alkalay A, Racine CA, O&#x2019;Neil PJ, Janabi M, Baker SL, Agarwal N, Bonasera SJ, Mormino EC, et al. Increased metabolic vulnerability in early-onset Alzheimer&#x2019;s disease is not related to amyloid burden. Brain. 2010;133:512&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2858015</ArticleId><ArticleId IdType="pubmed">20080878</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj A, Chen Y. The wiring economy principle: connectivity determines anatomy in the human brain. PLoS ONE. 2011;6:e14832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3168442</ArticleId><ArticleId IdType="pubmed">21915250</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology. 2002;58:1615&#x2013;1621.</Citation><ArticleIdList><ArticleId IdType="pubmed">12058088</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosas HD, Salat DH, Lee SY, Zaleta AK, Pappu V, Fischl B, Greve D, Hevelone N, Hersch SM. Cerebral cortex and the clinical expression of Huntington&#x2019;s disease: complexity and heterogeneity. Brain. 2008;131:1057&#x2013;1068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657201</ArticleId><ArticleId IdType="pubmed">18337273</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos SF, Pierrot N, Octave JN. Network excitability dysfunction in Alzheimer&#x2019;s disease: insights from in vitro and in vivo models. Rev Neurosci. 2010;21:153&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">20879690</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena S, Caroni P. Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration. Neuron. 2011;71:35&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">21745636</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Crawford R, Rascovsky K, Kramer JH, Weiner M, Miller BL, Gorno-Tempini ML. Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia. Arch Neurol. 2008;65:249&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544627</ArticleId><ArticleId IdType="pubmed">18268196</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62:42&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2691647</ArticleId><ArticleId IdType="pubmed">19376066</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalizi C.  PhD thesis. University of Wisconsin; Madison, WI: 2001. Causal architecture, complexity and self-organization in time series and cellular automata. ( http://www.cscs.umich.edu/crshalizi/thesis/)</Citation></Reference><Reference><Citation>Smith SM, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage. 2004;23(Suppl 1):S208&#x2013;S219.</Citation><ArticleIdList><ArticleId IdType="pubmed">15501092</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PM, et al. Dynamics of gray matter loss in Alzheimer&#x2019;s disease. J Neurosci. 2003;23:994&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741905</ArticleId><ArticleId IdType="pubmed">12574429</ArticleId></ArticleIdList></Reference><Reference><Citation>Villain N, Desgranges B, Viader F, Sayette V, de la M&#xe9;zenge F, Landeau B, Baron J-C, Eustache F, Ch&#xe9;telat G. Relationships between hippocampal atrophy, white matter disruption, and gray matter hypometabolism in Alzheimer&#x2019;s disease. J Neurosci. 2008;28:6174&#x2013;6181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902815</ArticleId><ArticleId IdType="pubmed">18550759</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Josephs KA, Rossor MN, Stevens JM, Revesz T, Holton JL, Al-Sarraj S, Godbolt AK, Fox NC, Warren JD. Magnetic resonance imaging signatures of tissue pathology in frontotemporal dementia. Arch Neurol. 2005;62:1402&#x2013;1408.</Citation><ArticleIdList><ArticleId IdType="pubmed">16157747</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Jack CR, Senjem ML, Parisi JE, Boeve BF, Knopman DS, Dickson DW, Petersen RC, Josephs KA. MRI correlates of protein deposition and disease severity in postmortem frontotemporal lobar degeneration. Neurodegener Dis. 2009;6:106&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745704</ArticleId><ArticleId IdType="pubmed">19299900</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu M, Rosano C, Lopez-Garcia P, Carter CS, Aizenstein HJ. Optimum template selection for atlas-based segmentation. Neuroimage. 2007;34:1612&#x2013;1618.</Citation><ArticleIdList><ArticleId IdType="pubmed">17188896</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, et al. Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer&#x2019;s disease. Brain. 2010;133:1352&#x2013;1367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912696</ArticleId><ArticleId IdType="pubmed">20410145</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22445348</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>6</Issue><PubDate><Year>2012</Year><Month>Mar</Month><Day>22</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Predicting regional neurodegeneration from the healthy brain functional connectome.</ArticleTitle><Pagination><StartPage>1216</StartPage><EndPage>1227</EndPage><MedlinePgn>1216-27</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2012.03.004</ELocationID><Abstract><AbstractText>Neurodegenerative diseases target large-scale neural networks. Four competing mechanistic hypotheses have been proposed to explain network-based disease patterning: nodal stress, transneuronal spread, trophic failure, and shared vulnerability. Here, we used task-free fMRI to derive the healthy intrinsic connectivity patterns seeded by brain regions vulnerable to any of five distinct neurodegenerative diseases. These data enabled us to investigate how intrinsic connectivity in health predicts region-by-region vulnerability to disease. For each illness, specific regions emerged as critical network "epicenters" whose normal connectivity profiles most resembled the disease-associated atrophy pattern. Graph theoretical analyses in healthy subjects revealed that regions with higher total connectional flow and, more consistently, shorter functional paths to the epicenters, showed greater disease-related vulnerability. These findings best fit a transneuronal spread model of network-based vulnerability. Molecular pathological approaches may help clarify what makes each epicenter vulnerable to its targeting disease and how toxic protein species travel between networked brain structures.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gennatas</LastName><ForeName>Efstathios D</ForeName><Initials>ED</Initials></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Joel H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG19724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG1657303</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2012 Mar 22;73(6):1060-2. doi: 10.1016/j.neuron.2012.03.006.</RefSource><PMID Version="1">22445334</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2012 Apr 18;13(5):288. doi: 10.1038/nrn3248.</RefSource><PMID Version="1">22510888</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="Y">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>3</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22445348</ArticleId><ArticleId IdType="mid">NIHMS365069</ArticleId><ArticleId IdType="pmc">PMC3361461</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2012.03.004</ArticleId><ArticleId IdType="pii">S0896-6273(12)00227-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annual Review of Neuroscience. 1986;9:357&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pubmed">3085570</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH. A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer disease. Ann Neurol. 1981;10:499&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">6173010</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker HF, Ridley RM, Duchen LW, Crow TJ, Bruton CJ. Evidence for the experimental transmission of cerebral beta-amyloidosis to primates. Int J Exp Pathol. 1993;74:441&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2002177</ArticleId><ArticleId IdType="pubmed">8217779</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker HF, Ridley RM, Duchen LW, Crow TJ, Bruton CJ. Induction of beta (A4)-amyloid in primates by injection of Alzheimer&#x2019;s disease brain homogenate. Comparison with transmission of spongiform encephalopathy. Mol Neurobiol. 1994;8:25&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">8086126</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70:960&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Brundin P, Melki R, Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol. 2010;11:301&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2892479</ArticleId><ArticleId IdType="pubmed">20308987</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Sepulcre J, Talukdar T, Krienen FM, Liu H, Hedden T, Andrews-Hanna JR, Sperling RA, Johnson KA. Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer&#x2019;s Disease. J Neurosci. 2009;29:1860&#x2013;1873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750039</ArticleId><ArticleId IdType="pubmed">19211893</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, et al. Molecular, structural, and functional characterization of Alzheimer&#x2019;s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C, Staufenbiel M, Sommer B, Jucker M. Neuron loss in APP transgenic mice. Nature. 1998;395:755&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">9796810</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11:909&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Devlin JT, Russell RP, Davis MH, Price CJ, Wilson J, Moss HE, Matthews PM, Tyler LK. Susceptibility-induced loss of signal: comparing PET and fMRI on a semantic task. Neuroimage. 2000;11:589&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">10860788</ArticleId></ArticleIdList></Reference><Reference><Citation>Forstl H, Kurz A. Clinical features of Alzheimer&#x2019;s disease. Eur Arch Psychiatry Clin Neurosci. 1999;249:288&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">10653284</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci. 2010;11:155&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3648341</ArticleId><ArticleId IdType="pubmed">20029438</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Ollesch J, Wille H, Diamond MI. Conformational diversity of wild-type Tau fibrils specified by templated conformation change. J Biol Chem. 2009;284:3546&#x2013;3551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2635036</ArticleId><ArticleId IdType="pubmed">19010781</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci U S A. 2003;100:253&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140943</ArticleId><ArticleId IdType="pubmed">12506194</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer&#x2019;s disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A. 2004;101:4637&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen C, Angot E, Bergstrom AL, Steiner JA, Pieri L, Paul G, Outeiro TF, Melki R, Kallunki P, Fog K, et al. alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest. 2011;121:715&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026723</ArticleId><ArticleId IdType="pubmed">21245577</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkes CH, Del Tredici K, Braak H. Parkinson&#x2019;s disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol. 2007;33:599&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194308</ArticleId><ArticleId IdType="pubmed">17961138</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, Knopman DS, Boeve BF, Klunk WE, Mathis CA, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer&#x2019;s disease and amnestic mild cognitive impairment. Brain : a journal of neurology. 2008;131:665&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730157</ArticleId><ArticleId IdType="pubmed">18263627</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol. 2011;70:532&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203752</ArticleId><ArticleId IdType="pubmed">22028219</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim EJ, Cho SS, Jeong Y, Park KC, Kang SJ, Kang E, Kim SE, Lee KH, Na DL. Glucose metabolism in early onset versus late onset Alzheimer&#x2019;s disease: an SPM analysis of 120 patients. Brain. 2005;128:1790&#x2013;1801.</Citation><ArticleIdList><ArticleId IdType="pubmed">15888536</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim EJ, Sidhu M, Gaus SE, Huang EJ, Hof PR, Miller BL, Dearmond SJ, Seeley WW. Selective Frontoinsular von Economo Neuron and Fork Cell Loss in Early Behavioral Variant Frontotemporal Dementia. Cereb Cortex. 2011</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3256403</ArticleId><ArticleId IdType="pubmed">21653702</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JK, Jin HK, Endo S, Schuchman EH, Carter JE, Bae JS. Intracerebral transplantation of bone marrow-derived mesenchymal stem cells reduces amyloid-beta deposition and rescues memory deficits in Alzheimer&#x2019;s disease mice by modulation of immune responses. Stem Cells. 2010a;28:329&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">20014009</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SE, Rabinovici GD, Mayo MC, Wilson SM, Seeley WW, DeArmond SJ, Huang EJ, Trojanowski JQ, Growdon ME, Jang JY, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol. 2011;70:327&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3154081</ArticleId><ArticleId IdType="pubmed">21823158</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SJ, Desplats P, Sigurdson C, Tsigelny I, Masliah E. Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol. 2010b;6:702&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4996353</ArticleId><ArticleId IdType="pubmed">21045796</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Bjorklund A, et al. Lewy bodies in grafted neurons in subjects with Parkinson&#x2019;s disease suggest host-to-graft disease propagation. Nat Med. 2008;14:501&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">18391963</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam M. The evolving landscape of human cortical connectivity: Facts and inferences. Neuroimage. 2011</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3321392</ArticleId><ArticleId IdType="pubmed">22209814</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller BL, Boeve BF, editors. The Behavioral Neurology of Dementia. Cambridge University Press; Cambridge, England: 2009.</Citation></Reference><Reference><Citation>Patterson K, Nestor PJ, Rogers TT. Where do you know what you know? The representation of semantic knowledge in the human brain. Nat Rev Neurosci. 2007;8:976&#x2013;987.</Citation><ArticleIdList><ArticleId IdType="pubmed">18026167</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearson RC, Esiri MM, Hiorns RW, Wilcock GK, Powell TP. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. Proc Natl Acad Sci U S A. 1985;82:4531&#x2013;4534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC391136</ArticleId><ArticleId IdType="pubmed">3859874</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB. Some speculations about prions, amyloid, and Alzheimer&#x2019;s disease. N Engl J Med. 1984;310:661&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">6363926</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridley RM, Baker HF, Windle CP, Cummings RM. Very long term studies of the seeding of beta-amyloidosis in primates. J Neural Transm. 2006;113:1243&#x2013;1251.</Citation><ArticleIdList><ArticleId IdType="pubmed">16362635</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinov M, Sporns O. Complex network measures of brain connectivity: uses and interpretations. Neuroimage. 2010;52:1059&#x2013;1069.</Citation><ArticleIdList><ArticleId IdType="pubmed">19819337</ArticleId></ArticleIdList></Reference><Reference><Citation>Salehi A, Delcroix JD, Belichenko PV, Zhan K, Wu C, Valletta JS, Takimoto-Kimura R, Kleschevnikov AM, Sambamurti K, Chung PP, et al. Increased App expression in a mouse model of Down&#x2019;s syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron. 2006;51:29&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">16815330</ArticleId></ArticleIdList></Reference><Reference><Citation>Saper CB, Wainer BH, German DC. Axonal and transneuronal transport in the transmission of neurological disease: potential role in system degenerations, including Alzheimer&#x2019;s disease. Neuroscience. 1987;23:389&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">2449630</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena S, Caroni P. Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration. Neuron. 2011;71:35&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">21745636</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheinin NM, Aalto S, Koikkalainen J, Lotjonen J, Karrasch M, Kemppainen N, Viitanen M, Nagren K, Helin S, Scheinin M, et al. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology. 2009;73:1186&#x2013;1192.</Citation><ArticleIdList><ArticleId IdType="pubmed">19726751</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Carlin DA, Allman JM, Macedo MN, Bush C, Miller BL, Dearmond SJ. Early frontotemporal dementia targets neurons unique to apes and humans. Ann Neurol. 2006;60:660&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pubmed">17187353</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Crawford R, Rascovsky K, Kramer JH, Weiner M, Miller BL, Gorno-Tempini ML. Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia. Arch Neurol. 2008;65:249&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544627</ArticleId><ArticleId IdType="pubmed">18268196</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62:42&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2691647</ArticleId><ArticleId IdType="pubmed">19376066</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Menon V, Schatzberg AF, Keller J, Glover GH, Kenna H, Reiss AL, Greicius MD. Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci. 2007;27:2349&#x2013;2356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680293</ArticleId><ArticleId IdType="pubmed">17329432</ArticleId></ArticleIdList></Reference><Reference><Citation>Sporns O, Honey CJ, Kotter R. Identification and classification of hubs in brain networks. PLoS One. 2007;2:e1049.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2013941</ArticleId><ArticleId IdType="pubmed">17940613</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker LC, Levine H, 3rd, Mattson MP, Jucker M. Inducible proteopathies. Trends Neurosci. 2006;29:438&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10725716</ArticleId><ArticleId IdType="pubmed">16806508</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts DJ, Strogatz SH. Collective dynamics of &#x2019;small-world&#x2019; networks. Nature. 1998;393:440&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">9623998</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub S, Mesulam M-M. From neuronal networks to dementia: four clinical profiles. In: F F, Y C, F B, editors. La demence: Pourquoi? Foundation Nationale de Gerontologie; Paris: 1996. pp. 75&#x2013;97.</Citation></Reference><Reference><Citation>Whitwell JL, Josephs KA, Murray ME, Kantarci K, Przybelski SA, Weigand SD, Vemuri P, Senjem ML, Parisi JE, Knopman DS, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology. 2008;71:743&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676950</ArticleId><ArticleId IdType="pubmed">18765650</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Greicius MD, Gennatas ED, Growdon ME, Jang JY, Rabinovici GD, Kramer JH, Weiner M, Miller BL, Seeley WW. Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer&#x2019;s disease. Brain. 2010;133:1352&#x2013;1367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912696</ArticleId><ArticleId IdType="pubmed">20410145</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo XN, Kelly C, Di Martino A, Mennes M, Margulies DS, Bangaru S, Grzadzinski R, Evans AC, Zang YF, Castellanos FX, et al. Growing together and growing apart: regional and sex differences in the lifespan developmental trajectories of functional homotopy. J Neurosci. 2010;30:15034&#x2013;15043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2997358</ArticleId><ArticleId IdType="pubmed">21068309</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22457485</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>13</Issue><PubDate><Year>2012</Year><Month>Mar</Month><Day>28</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Bidirectional relationship between functional connectivity and amyloid-&#x3b2; deposition in mouse brain.</ArticleTitle><Pagination><StartPage>4334</StartPage><EndPage>4340</EndPage><MedlinePgn>4334-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5845-11.2012</ELocationID><Abstract><AbstractText>Brain region-specific deposition of extracellular amyloid plaques principally composed of aggregated amyloid-&#x3b2; (A&#x3b2;) peptide is a pathological signature of Alzheimer's disease (AD). Recent human neuroimaging data suggest that resting-state functional connectivity strength is reduced in patients with AD, cognitively normal elderly harboring elevated amyloid burden, and in advanced aging. Interestingly, there exists a striking spatial correlation between functional connectivity strength in cognitively normal adults and the location of A&#x3b2; plaque deposition in AD. However, technical limitations have heretofore precluded examination of the relationship between functional connectivity, A&#x3b2; deposition, and normal aging in mouse models. Using a novel functional connectivity optical intrinsic signal (fcOIS) imaging technique, we demonstrate that A&#x3b2; deposition is associated with significantly reduced bilateral functional connectivity in multiple brain regions of older APP/PS1 transgenic mice. The amount of A&#x3b2; deposition in each brain region was associated with the degree of local, age-related bilateral functional connectivity decline. Normal aging was associated with reduced bilateral functional connectivity specifically in retrosplenial cortex. Furthermore, we found that the magnitude of regional bilateral functional correlation in young APP/PS1 mice before A&#x3b2; plaque formation was proportional to the amount of region-specific plaque deposition seen later in older APP/PS1 mice. Together, these findings suggest that A&#x3b2; deposition and normal aging are associated with region-specific disruption of functional connectivity and that the magnitude of local bilateral functional connectivity predicts regional vulnerability to subsequent A&#x3b2; deposition in mouse brain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bero</LastName><ForeName>Adam W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>Adam Q</ForeName><Initials>AQ</Initials></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Floy R</ForeName><Initials>FR</Initials></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Brian R</ForeName><Initials>BR</Initials></Author><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Raichle</LastName><ForeName>Marcus E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Culver</LastName><ForeName>Joseph P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS074969</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-EB008085</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T90-DA022871</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-EB009233</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB009233</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 AG033452</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG033452</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T90 DA022871</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB008085</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059907" MajorTopicYN="N">Functional Neuroimaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008815" MajorTopicYN="N">Mice, Inbred Strains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>9</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22457485</ArticleId><ArticleId IdType="mid">NIHMS368764</ArticleId><ArticleId IdType="pmc">PMC3326343</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5845-11.2012</ArticleId><ArticleId IdType="pii">32/13/4334</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andrews-Hanna JR, Snyder AZ, Vincent JL, Lustig C, Head D, Raichle ME, Buckner RL. Disruption of large-scale brain systems in advanced aging. Neuron. 2007;56:924&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2709284</ArticleId><ArticleId IdType="pubmed">18054866</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, Holtzman DM. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci. 2011;14:750&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Sepulcre J, Talukdar T, Krienen FM, Liu H, Hedden T, Andrews-Hanna JR, Sperling RA, Johnson KA. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci. 2009;29:1860&#x2013;1873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750039</ArticleId><ArticleId IdType="pubmed">19211893</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcoran KA, Donnan MD, Tronson NC, Guzm&#xe1;n YF, Gao C, Jovasevic V, Guedea AL, Radulovic J. NMDA receptors in retrosplenial cortex are necessary for retrieval of recent and remote context fear memory. J Neurosci. 2011;31:11655&#x2013;11659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3159389</ArticleId><ArticleId IdType="pubmed">21832195</ArticleId></ArticleIdList></Reference><Reference><Citation>Drzezga A, Becker JA, Van Dijk KR, Sreenivasan A, Talukdar T, Sullivan C, Schultz AP, Sepulcre J, Putcha D, Greve D, Johnson KA, Sperling RA. Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain. 2011;134:1635&#x2013;1646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102239</ArticleId><ArticleId IdType="pubmed">21490054</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, Snyder AZ, Vincent JL, Corbetta M, Van Essen DC, Raichle ME. The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc Natl Acad Sci U S A. 2005;102:9673&#x2013;9678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1157105</ArticleId><ArticleId IdType="pubmed">15976020</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin KB, Paxinos G. The mouse brain in stereotaxic coordinates. Ed 1. San Diego: Academic; 1996.</Citation></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A. 2004;101:4637&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagmann P, Cammoun L, Gigandet X, Meuli R, Honey CJ, Wedeen VJ, Sporns O. Mapping the structural core of human cerebral cortex. PLoS Biol. 2008;6:e159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2443193</ArticleId><ArticleId IdType="pubmed">18597554</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn TT, Sakmann B, Mehta MR. Phase-locking of hippocampal interneurons' membrane potential to neocortical up-down states. Nat Neurosci. 2006;9:1359&#x2013;1361.</Citation><ArticleIdList><ArticleId IdType="pubmed">17041594</ArticleId></ArticleIdList></Reference><Reference><Citation>He BJ, Snyder AZ, Zempel JM, Smyth MD, Raichle ME. Electrophysiological correlates of the brain's intrinsic large-scale functional architecture. Proc Natl Acad Sci U S A. 2008;105:16039&#x2013;16044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2564983</ArticleId><ArticleId IdType="pubmed">18843113</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, Van Dijk KR, Becker JA, Mehta A, Sperling RA, Johnson KA, Buckner RL. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci. 2009;29:12686&#x2013;12694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2808119</ArticleId><ArticleId IdType="pubmed">19812343</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 2004;13:159&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones DT, Machulda MM, Vemuri P, McDade EM, Zeng G, Senjem ML, Gunter JL, Przybelski SA, Avula RT, Knopman DS, Boeve BF, Petersen RC, Jack CR., Jr Age-related changes in the default mode network are more advanced in Alzheimer disease. Neurology. 2011;77:1524&#x2013;1531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3198977</ArticleId><ArticleId IdType="pubmed">21975202</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchibhotla KV, Goldman ST, Lattarulo CR, Wu HY, Hyman BT, Bacskai BJ. Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron. 2008;59:214&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2578820</ArticleId><ArticleId IdType="pubmed">18667150</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu H, Zuo Y, Gu H, Waltz JA, Zhan W, Scholl CA, Rea W, Yang Y, Stein EA. Synchronized delta oscillations correlate with the resting-state function MRI signal. Proc Natl Acad Sci U S A. 2007;104:18265&#x2013;18269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2084331</ArticleId><ArticleId IdType="pubmed">17991778</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature. 2008;451:720&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Smiljic A, Hayenga AO, Onami SH, Greicius MD, Rabinovici GD, Janabi M, Baker SL, Yen IV, Madison CM, Miller BL, Jagust WJ. Relationships between beta-amyloid and functional connectivity in different components of the default mode network in aging. Cereb Cortex. 2011;21:2399&#x2013;2407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169663</ArticleId><ArticleId IdType="pubmed">21383234</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizoli CE, Shah MN, Snyder AZ, Shimony JS, Limbrick DD, Raichle ME, Schlaggar BL, Smyth MD. Resting-state activity in development and maintenance of normal brain function. Proc Natl Acad Sci U S A. 2011;108:11638&#x2013;11643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136307</ArticleId><ArticleId IdType="pubmed">21709227</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheline YI, Raichle ME, Snyder AZ, Morris JC, Head D, Wang S, Mintun MA. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry. 2010;67:584&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829379</ArticleId><ArticleId IdType="pubmed">19833321</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern EA, Bacskai BJ, Hickey GA, Attenello FJ, Lombardo JA, Hyman BT. Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. J Neurosci. 2004;24:4535&#x2013;4540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729398</ArticleId><ArticleId IdType="pubmed">15140924</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko AG, Vaishnavi SN, Couture L, Sacco D, Shannon BJ, Mach RH, Morris JC, Raichle ME, Mintun MA. Spatial correlation between brain aerobic glycolysis and amyloid-beta (Abeta) deposition. Proc Natl Acad Sci U S A. 2010;107:17763&#x2013;17767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2955133</ArticleId><ArticleId IdType="pubmed">20837517</ArticleId></ArticleIdList></Reference><Reference><Citation>White BR, Snyder AZ, Cohen AL, Petersen SE, Raichle ME, Schlaggar BL, Culver JP. Resting-state functional connectivity in the human brain revealed with diffuse optical tomography. Neuroimage. 2009;47:148&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2699418</ArticleId><ArticleId IdType="pubmed">19344773</ArticleId></ArticleIdList></Reference><Reference><Citation>White BR, Bauer AQ, Snyder AZ, Schlaggar BL, Lee JM, Culver JP. Imaging of functional connectivity in the mouse brain. PLoS One. 2011;6:e16322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3024435</ArticleId><ArticleId IdType="pubmed">21283729</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan P, Bero AW, Cirrito JR, Xiao Q, Hu X, Wang Y, Gonzales E, Holtzman DM, Lee JM. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci. 2009;29:10706&#x2013;10714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756291</ArticleId><ArticleId IdType="pubmed">19710322</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Raichle ME. Disease and the brain's dark energy. Nat Rev Neurol. 2010;6:15&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">20057496</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22431837</PMID><DateCompleted><Year>2012</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>7</Issue><PubDate><Year>2012</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures.</ArticleTitle><Pagination><StartPage>836</StartPage><EndPage>841</EndPage><MedlinePgn>836-41</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate whether antioxidant supplements presumed to target specific cellular compartments affected cerebrospinal fluid (CSF) biomarkers.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Double-blind, placebo-controlled clinical trial.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Academic medical centers.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Subjects with mild to moderate Alzheimer disease.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Random assignment to treatment for 16 weeks with 800 IU/d of vitamin E (&#x3b1;-tocopherol) plus 500 mg/d of vitamin C plus 900 mg/d of &#x3b1;-lipoic acid (E/C/ALA); 400 mg of coenzyme Q 3 times/d; or placebo.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Changes from baseline to 16 weeks in CSF biomarkers related to Alzheimer disease and oxidative stress, cognition (Mini-Mental State Examination), and function (Alzheimer's Disease Cooperative Study Activities of Daily Living Scale).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Seventy-eight subjects were randomized; 66 provided serial CSF specimens adequate for biochemical analyses. Study drugs were well tolerated, but accelerated decline in Mini-Mental State Examination scores occurred in the E/C/ALA group, a potential safety concern. Changes in CSF A&#x3b2;42, tau, and P-tau(181) levels did not differ between the 3 groups. Cerebrospinal fluid F2-isoprostane levels, an oxidative stress biomarker, decreased on average by 19% from baseline to week 16 in the E/C/ALA group but were unchanged in the other groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Antioxidants did not influence CSF biomarkers related to amyloid or tau pathology. Lowering of CSF F2-isoprostane levels in the E/C/ALA group suggests reduction of oxidative stress in the brain. However, this treatment raised the caution of faster cognitive decline, which would need careful assessment if longer-term clinical trials are conducted.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">clinicaltrials.gov Identifier: NCT00117403.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, 92093, USA. dgalasko@ucsd.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peskind</LastName><ForeName>Elaine</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Ringman</LastName><ForeName>John M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Jicha</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Cotman</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Cottrell</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Cooperative Study</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00117403</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG10483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AR47752</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AR047752</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG00538</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AGO5136</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG000096</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG31892</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01AG10483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG019241</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UO1 AG10483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AGO5131</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD064993-0110</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG016381</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031892</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG000538</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES16754</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 ES07032</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AGO33133</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG32984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES016754</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 ES007032</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AGO0817</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30AG032934</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000096</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS062684</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG16381</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG019241</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS62684</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AG032934</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030048</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D028441">F2-Isoprostanes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>1339-63-5</RegistryNumber><NameOfSubstance UI="D014451">Ubiquinone</NameOfSubstance></Chemical><Chemical><RegistryNumber>73Y7P0K73Y</RegistryNumber><NameOfSubstance UI="D008063">Thioctic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EJ27X76M46</RegistryNumber><NameOfSubstance UI="C024989">coenzyme Q10</NameOfSubstance></Chemical><Chemical><RegistryNumber>H4N855PNZ1</RegistryNumber><NameOfSubstance UI="D024502">alpha-Tocopherol</NameOfSubstance></Chemical><Chemical><RegistryNumber>PQ6CK8PD0R</RegistryNumber><NameOfSubstance UI="D001205">Ascorbic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001205" MajorTopicYN="N">Ascorbic Acid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019587" MajorTopicYN="Y">Dietary Supplements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D028441" MajorTopicYN="N">F2-Isoprostanes</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008063" MajorTopicYN="N">Thioctic Acid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014451" MajorTopicYN="N">Ubiquinone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024502" MajorTopicYN="N">alpha-Tocopherol</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Weisman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pay</LastName><ForeName>Mary Margaret</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lerner</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ziol</LastName><ForeName>Elaine</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulnard</LastName><ForeName>Ruth</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>McAdams-Ortiz</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ringman</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bardens</LastName><ForeName>Jenny</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jicha</LastName><ForeName>Gregory</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pham</LastName><ForeName>Cassie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peskind</LastName><ForeName>Elaine</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mandelco</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walker</LastName><ForeName>Aljoeson</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kirbach</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mishler-Rickard</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kittur</LastName><ForeName>Smita</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mirje</LastName><ForeName>Seema</ForeName><Initials>S</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>5</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22431837</ArticleId><ArticleId IdType="mid">NIHMS446574</ArticleId><ArticleId IdType="pmc">PMC3661272</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2012.85</ArticleId><ArticleId IdType="pii">archneurol.2012.85</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lovell MA, Markesbery WR. Oxidative damage in mild cognitive impairment and early Alzheimer&#x2019;s disease. J Neurosci Res. 2007;85(14):3036&#x2013;3040.</Citation><ArticleIdList><ArticleId IdType="pubmed">17510979</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Neely MD, Quinn JF, et al. Lipid peroxidation in aging brain and Alzheimer&#x2019;s disease. Free Radic Biol Med. 2002;33(5):620&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pubmed">12208348</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris MC. The role of nutrition in Alzheimer&#x2019;s disease: epidemiological evidence. Eur J Neurol. 2009;16(suppl 1):1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3393525</ArticleId><ArticleId IdType="pubmed">19703213</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Clemons TE, McBee WL, Lindblad AS Age-Related Eye Disease Study Research Group. Impact of antioxidants, zinc, and copper on cognition in the elderly: a randomized, controlled trial. Neurology. 2004;63(9):1705&#x2013;1707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1473037</ArticleId><ArticleId IdType="pubmed">15534261</ArticleId></ArticleIdList></Reference><Reference><Citation>Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):23&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">12114037</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer&#x2019;s disease: the Alzheimer&#x2019;s Disease Cooperative Study. N Engl J Med. 1997;336(17):1216&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pubmed">9110909</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Thomas RG, Grundman M, et al. Alzheimer&#x2019;s Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379&#x2013;2388.</Citation><ArticleIdList><ArticleId IdType="pubmed">15829527</ArticleId></ArticleIdList></Reference><Reference><Citation>Floyd RA, Hensley K. Oxidative stress in brain aging: implications for therapeutics of neurodegenerative diseases. Neurobiol Aging. 2002;23(5):795&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pubmed">12392783</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith AR, Shenvi SV, Widlansky M, Suh JH, Hagen TM. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr Med Chem. 2004;11(9):1135&#x2013;1146.</Citation><ArticleIdList><ArticleId IdType="pubmed">15134511</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung S, Yao Y, Uryu K, et al. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer&#x2019;s disease. FASEB J. 2004;18(2):323&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">14656990</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison FE, Allard J, Bixler R, et al. Antioxidants and cognitive training interact to affect oxidative stress and memory in APP/PSEN1 mice. Nutr Neurosci. 2009;12(5):203&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3730134</ArticleId><ArticleId IdType="pubmed">19761651</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Alloza M, Dodwell SA, Meyer-Luehmann M, Hyman BT, Bacskai BJ. Plaque-derived oxidative stress mediates distorted neurite trajectories in the Alzheimer mouse model. J Neuropathol Exp Neurol. 2006;65(11):1082&#x2013;1089.</Citation><ArticleIdList><ArticleId IdType="pubmed">17086105</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotman CW, Head E. The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. J Alzheimers Dis. 2008;15(4):685&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">19096165</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn JF, Bussiere JR, Hammond RS, et al. Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiol Aging. 2007;28(2):213&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pubmed">16448723</ArticleId></ArticleIdList></Reference><Reference><Citation>Siedlak SL, Casadesus G, Webber KM, et al. Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer&#x2019;s disease. Free Radic Res. 2009;43(2):156&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2675191</ArticleId><ArticleId IdType="pubmed">19160110</ArticleId></ArticleIdList></Reference><Reference><Citation>Hager K, Kenklies M, McAfoose J, Engel J, M&#xfc;nch G. Alpha-lipoic acid as a new treatment option for Alzheimer&#x2019;s disease: a 48 months follow-up analysis. J Neural Transm Suppl. 2007;72(72):189&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">17982894</ArticleId></ArticleIdList></Reference><Reference><Citation>Beal MF. Mitochondrial dysfunction and oxidative damage in Alzheimer&#x2019;s and Parkinson&#x2019;s diseases and coenzyme Q10 as a potential treatment. J Bioenerg Biomembr. 2004;36(4):381&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">15377876</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Yang Y, Li G, Wang J, Yang ES. Coenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation. J Mol Neurosci. 2008;34(2):165&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">18181031</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadsworth TL, Bishop JA, Pappu AS, Woltjer RL, Quinn JF. Evaluation of co-enzyme Q as an antioxidant strategy for Alzheimer&#x2019;s disease. J Alzheimers Dis. 2008;14(2):225&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2931577</ArticleId><ArticleId IdType="pubmed">18560133</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Kershaw PR, Schneider L, Zhu Y, Tariot PN. Galantamine maintains ability to perform activities of daily living in patients with Alzheimer&#x2019;s disease. J Am Geriatr Soc. 2004;52(7):1070&#x2013;1076.</Citation><ArticleIdList><ArticleId IdType="pubmed">15209643</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal LJ, Kantarci K, Reiman EM, et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20(1):6&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820855</ArticleId><ArticleId IdType="pubmed">16493230</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Montine TJ. Biomarkers of oxidative damage and inflammation in Alzheimer&#x2019;s disease. Biomark Med. 2010;4(1):27&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850111</ArticleId><ArticleId IdType="pubmed">20383271</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Beal MF, Cudkowicz ME, et al. Increased CSF F2-isoprostane concentration in probable AD. Neurology. 1999;52(3):562&#x2013;565.</Citation><ArticleIdList><ArticleId IdType="pubmed">10025788</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringman JM, Younkin SG, Pratico D, et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology. 2008;71(2):85&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">18509095</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson A, Vanderstichele H, Andreasen N, et al. Simultaneous measurement of beta-amyloid(1&#x2013;42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem. 2005;51(2):336&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">15563479</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75(4):800&#x2013;802. doi: 10.2307/2336325.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2336325</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Zetterberg H, Minthon L, et al. Longitudinal stability of CSF biomarkers in Alzheimer&#x2019;s disease. Neurosci Lett. 2007;419(1):18&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">17482358</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews RT, Yang L, Browne S, Baik M, Beal MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A. 1998;95(15):8892&#x2013;8897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21173</ArticleId><ArticleId IdType="pubmed">9671775</ArticleId></ArticleIdList></Reference><Reference><Citation>Shults CW, Oakes D, Kieburtz K, et al. Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59(10):1541&#x2013;1550.</Citation><ArticleIdList><ArticleId IdType="pubmed">12374491</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann P, Thompson JL, Levy G, et al. QALS Study Group. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009;66(2):235&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2854625</ArticleId><ArticleId IdType="pubmed">19743457</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal LJ, Grundman M, Berg J, et al. Idebenone treatment fails to slow cognitive decline in Alzheimer&#x2019;s disease. Neurology. 2003;61(11):1498&#x2013;1502.</Citation><ArticleIdList><ArticleId IdType="pubmed">14663031</ArticleId></ArticleIdList></Reference><Reference><Citation>Wray DW, Nishiyama SK, Monnet A, et al. Antioxidants and aging: NMR-based evidence of improved skeletal muscle perfusion and energetics. Am J Physiol Heart Circ Physiol. 2009;297(5):H1870&#x2013;H1875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2781367</ArticleId><ArticleId IdType="pubmed">19767527</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller ER, III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142(1):37&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">15537682</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006;12(7):856&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2983090</ArticleId><ArticleId IdType="pubmed">16799555</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesse C, Rosengren L, Andreasen N, et al. Transient increase in total tau but not phosphotau in human cerebrospinal fluid after acute stroke. Neurosci Lett. 2001;297(3):187&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">11137759</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22357717</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>10</Issue><PubDate><Year>2012</Year><Month>Mar</Month><Day>06</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease.</ArticleTitle><Pagination><StartPage>709</StartPage><EndPage>719</EndPage><MedlinePgn>709-19</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0b013e318248e568</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Measures of neuronal damage/dysfunction are likely good surrogates for disease progression in Alzheimer disease (AD). CSF markers of neuronal injury may offer utility in predicting disease progression and guiding prognostic and outcome assessments in therapeutic trials. Visinin-like protein-1 (VILIP-1) has demonstrated potential utility as a marker of neuronal injury. We here investigate the utility of VILIP-1 and VILIP-1/A&#x3b2;42 in predicting rates of cognitive decline in early AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Individuals with a clinical diagnosis of very mild or mild AD (n = 60) and baseline CSF measures of VILIP-1, tau, p-tau181, and A&#x3b2;42 were followed longitudinally for an average of 2.6 years. Annual assessments included the Clinical Dementia Rating (CDR), CDR-sum of boxes (CDR-SB), and global composite scores. Mixed linear models assessed the ability of CSF biomarker measures to predict rates of cognitive decline over time.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Baseline CSF VILIP-1 and VILIP-1/A&#x3b2;42 levels predicted rates of future decline in CDR-SB and global composite scores over the follow-up period. Individuals with CSF VILIP-1 &#x2265;560 pg/mL (corresponding to the upper tercile) progressed much more rapidly in CDR-SB (1.61 boxes/year; p = 0.0077) and global scores (-0.53 points/year; p = 0.0002) than individuals with lower values (0.85 boxes/year and -0.15 points/year, respectively) over the follow-up period. CSF tau, p-tau181, tau/A&#x3b2;42, and p-tau181/A&#x3b2;42 also predicted more rapid cognitive decline in CDR-SB and global scores over time.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings suggest that CSF VILIP-1 and VILIP-1/A&#x3b2;42 predict rates of global cognitive decline similarly to tau and tau/A&#x3b2;42, and may be useful CSF surrogates for neurodegeneration in early AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tarawneh</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>J-M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Ladenson</LastName><ForeName>J H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>D M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS055977</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-NS55977</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30-NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-26276</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-NS67905</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS067905</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>02</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051596">Neurocalcin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C496688">VSNL1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051596" MajorTopicYN="N">Neurocalcin</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>3</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22357717</ArticleId><ArticleId IdType="pmc">PMC3306162</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e318248e568</ArticleId><ArticleId IdType="pii">WNL.0b013e318248e568</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer's disease. Ann Neurol 1999;45:358&#x2013;368</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119&#x2013;128</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Ko AI, Wade MJ, et al. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol 2001;58:1395&#x2013;1402</Citation><ArticleIdList><ArticleId IdType="pubmed">11559310</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Shiung MM, Weigand SD, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 2005;65:1227&#x2013;1231</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2753547</ArticleId><ArticleId IdType="pubmed">16247049</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunewell K, Riederer P, Spilker C, et al. Abnormal localization of two neuronal calcium sensor proteins, visinin-like proteins (vilips)-1 and -3, in neocortical brain areas of Alzheimer disease patients. Dement Geriatr Cogn Disord 2001;12:110&#x2013;116</Citation><ArticleIdList><ArticleId IdType="pubmed">11173883</ArticleId></ArticleIdList></Reference><Reference><Citation>Laterza OF, Modur VR, Crimmins DL, et al. Identification of novel brain biomarkers. Clin Chem 2006;52:1713&#x2013;1721</Citation><ArticleIdList><ArticleId IdType="pubmed">16858073</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JM, Blennow K, Andreasen N, et al. The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer's disease patients. Clin Chem 2008;54:1617&#x2013;1623</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2672199</ArticleId><ArticleId IdType="pubmed">18703769</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarawneh R, D'Angelo G, Macy E, et al. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol 2011;70:274&#x2013;285</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3154071</ArticleId><ArticleId IdType="pubmed">21823155</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot C, Lendon C, Craddock N, et al. Protection against Alzheimer's disease with apoE epsilon 2. Lancet 1994;343:1432&#x2013;1433</Citation><ArticleIdList><ArticleId IdType="pubmed">7910910</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412&#x2013;2414</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Grant EA, Miller JP, Morris JC. Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology 2006;67:467&#x2013;473</Citation><ArticleIdList><ArticleId IdType="pubmed">16894109</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, Miller JP, Baty J, et al. Mild senile dementia of the Alzheimer type: 4: evaluation of intervention. Ann Neurol 1992;31:242&#x2013;249</Citation><ArticleIdList><ArticleId IdType="pubmed">1637132</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, McKeel DW, Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 1998;55:326&#x2013;335</Citation><ArticleIdList><ArticleId IdType="pubmed">9520006</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 2006;20:210&#x2013;216</Citation><ArticleIdList><ArticleId IdType="pubmed">17132964</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, Buschke H, Crystal H, et al. Screening for dementia by memory testing. Neurology 1988;38:900&#x2013;903</Citation><ArticleIdList><ArticleId IdType="pubmed">3368071</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D, Stone CP. Manual: Wechsler Memory Scale. New York: Psychological Corporation; 1973</Citation></Reference><Reference><Citation>Wechsler D. Manual: Wechsler Adult Intelligence Scale. New York: Psychological Corporation; 1955</Citation></Reference><Reference><Citation>Goodglass H, Kaplan E. The Assessment of Aphasia and Related Disorders, 2nd ed. Philadelphia: Lea &amp; Febiger; 1983</Citation></Reference><Reference><Citation>Thurstone LL, Thurstone LG. Examiner Manual for the SRA Primary Mental Abilities Test. Chicago: Chicago Science Research Associates; 1949</Citation></Reference><Reference><Citation>Armitage SG. An analysis of certain psychological tests used in the evaluation of brain injury. Psychol Monographs 1946;60:1&#x2013;48</Citation></Reference><Reference><Citation>Johnson DK, Storandt M, Morris JC, Galvin JE. Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol 2009;66:1254&#x2013;1259</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2795328</ArticleId><ArticleId IdType="pubmed">19822781</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59:512&#x2013;519</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, May PC, O'Dell MA, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci 2003;23:8844&#x2013;8853</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnurra I, Bernstein HG, Riederer P, Braunewell KH. The neuronal calcium sensor protein VILIP-1 is associated with amyloid plaques and extracellular tangles in Alzheimer's disease and promotes cell death and tau phosphorylation in vitro: a link between calcium sensors and Alzheimer's disease? Neurobiol Dis 2001;8:900&#x2013;909</Citation><ArticleIdList><ArticleId IdType="pubmed">11592857</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito K, Corrigan B, Zhao Q, et al. Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database. Alzheimers Dement 2011;7:151&#x2013;160</Citation><ArticleIdList><ArticleId IdType="pubmed">20810324</ArticleId></ArticleIdList></Reference><Reference><Citation>Snider BJ, Fagan AM, Roe C, et al. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 2009;66:638&#x2013;645</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2759394</ArticleId><ArticleId IdType="pubmed">19433664</ArticleId></ArticleIdList></Reference><Reference><Citation>Kester MI, van der Vlies AE, Blankenstein MA, et al. CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology 2009;73:1353&#x2013;1358</Citation><ArticleIdList><ArticleId IdType="pubmed">19858456</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingelsson M, Fukumoto H, Newell KL, et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 2004;62:925&#x2013;931</Citation><ArticleIdList><ArticleId IdType="pubmed">15037694</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarawneh R, Holtzman DM. Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention. CNS Neurol Disord Drug Targets 2009;8:144&#x2013;159</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812706</ArticleId><ArticleId IdType="pubmed">19355934</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Zetterberg H, Minthon L, et al. Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett 2007;419:18&#x2013;22</Citation><ArticleIdList><ArticleId IdType="pubmed">17482358</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid beta-amyloid(1&#x2013;42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 1999;56:673&#x2013;680</Citation><ArticleIdList><ArticleId IdType="pubmed">10369305</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 2009;73:294&#x2013;301</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715214</ArticleId><ArticleId IdType="pubmed">19636049</ArticleId></ArticleIdList></Reference><Reference><Citation>Herukka SK, Hallikainen M, Soininen H, Pirttila T. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 2005;64:1294&#x2013;1297</Citation><ArticleIdList><ArticleId IdType="pubmed">15824371</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Zetterberg H, Buchhave P, et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228&#x2013;234</Citation><ArticleIdList><ArticleId IdType="pubmed">16488378</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudas RB, Clague F, Thompson SA, et al. Episodic and semantic memory in mild cognitive impairment. Neuropsychologia 2005;43:1266&#x2013;1276</Citation><ArticleIdList><ArticleId IdType="pubmed">15949511</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jager CA, Hogervorst E, Combrinck M, Budge MM. Sensitivity and specificity of neuropsychological tests for mild cognitive impairment, vascular cognitive impairment and Alzheimer's disease. Psychol Med 2003;33:1039&#x2013;1050</Citation><ArticleIdList><ArticleId IdType="pubmed">12946088</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggleton JP, Brown MW. Episodic memory, amnesia, and the hippocampal-anterior thalamic axis. Behav Brain Sci 1999;22:425&#x2013;444 discussion 444&#x2013;489</Citation><ArticleIdList><ArticleId IdType="pubmed">11301518</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin A, Chao LL. Semantic memory and the brain: structure and processes. Curr Opin Neurobiol 2001;11:194&#x2013;201</Citation><ArticleIdList><ArticleId IdType="pubmed">11301239</ArticleId></ArticleIdList></Reference><Reference><Citation>Convit A, de Asis J, de Leon MJ, et al. Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimer's disease. Neurobiol Aging 2000;21:19&#x2013;26</Citation><ArticleIdList><ArticleId IdType="pubmed">10794844</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22403062</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><Issue>12</Issue><PubDate><Year>2012</Year><Month>Mar</Month><Day>20</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Antiparallel &#x3b2;-sheet architecture in Iowa-mutant &#x3b2;-amyloid fibrils.</ArticleTitle><Pagination><StartPage>4443</StartPage><EndPage>4448</EndPage><MedlinePgn>4443-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1111305109</ELocationID><Abstract><AbstractText>Wild-type, full-length (40- and 42-residue) amyloid &#x3b2;-peptide (A&#x3b2;) fibrils have been shown by a variety of magnetic resonance techniques to contain cross-&#x3b2; structures in which the &#x3b2;-sheets have an in-register parallel supramolecular organization. In contrast, recent studies of fibrils formed in vitro by the Asp23-to-Asn mutant of 40-residue A&#x3b2; (D23N-A&#x3b2;(1-40)), which is associated with early onset neurodegeneration, indicate that D23N-A&#x3b2;(1-40) fibrils can contain either parallel or antiparallel &#x3b2;-sheets. We report a protocol for producing structurally pure antiparallel D23N-A&#x3b2;(1-40) fibril samples and a series of solid state nuclear magnetic resonance and electron microscopy measurements that lead to a specific model for the antiparallel D23N-A&#x3b2;(1-40) fibril structure. This model reveals how both parallel and antiparallel cross-&#x3b2; structures can be constructed from similar peptide monomer conformations and stabilized by similar sets of interactions, primarily hydrophobic in nature. We find that antiparallel D23N-A&#x3b2;(1-40) fibrils are thermodynamically metastable with respect to conversion to parallel structures, propagate less efficiently than parallel fibrils in seeded fibril growth, and therefore must nucleate more efficiently than parallel fibrils in order to be observable. Experiments in neuronal cell cultures indicate that both antiparallel and parallel D23N-A&#x3b2;(1-40) fibrils are cytotoxic. Thus, our antiparallel D23N-A&#x3b2;(1-40) fibril model represents a specific "toxic intermediate" in the aggregation process of a disease-associated A&#x3b2; mutant.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qiang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yau</LastName><ForeName>Wai-Ming</ForeName><Initials>WM</Initials></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Yongquan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Mattson</LastName><ForeName>Mark P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Tycko</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>PDB</DataBankName><AccessionNumberList><AccessionNumber>2LNQ</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>03</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001667" MajorTopicYN="N">Binding, Competitive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046529" MajorTopicYN="N">Microscopy, Electron, Transmission</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008968" MajorTopicYN="N">Molecular Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013816" MajorTopicYN="N">Thermodynamics</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>9</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22403062</ArticleId><ArticleId IdType="pmc">PMC3311365</ArticleId><ArticleId IdType="doi">10.1073/pnas.1111305109</ArticleId><ArticleId IdType="pii">1111305109</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Benzinger TLS, et al. Propagating structure of Alzheimer&#x2019;s &#x3b2;-amyloid((10&#x2013;35)) is parallel &#x3b2;-sheet with residues in exact register. Proc Natl Acad Sci USA. 1998;95:13407&#x2013;13412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24832</ArticleId><ArticleId IdType="pubmed">9811813</ArticleId></ArticleIdList></Reference><Reference><Citation>Kheterpal I, Williams A, Murphy C, Bledsoe B, Wetzel R. Structural features of the A&#x3b2; amyloid fibril elucidated by limited proteolysis. Biochemistry. 2001;40:11757&#x2013;11767.</Citation><ArticleIdList><ArticleId IdType="pubmed">11570876</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed M, et al. Structural conversion of neurotoxic amyloid-&#x3b2;1&#x2013;42 oligomers to fibrils. Nat Struct Mol Biol. 2010;17:561&#x2013;U56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922021</ArticleId><ArticleId IdType="pubmed">20383142</ArticleId></ArticleIdList></Reference><Reference><Citation>Chimon S, et al. Evidence of fibril-like &#x3b2;-sheet structures in a neurotoxic amyloid intermediate of Alzheimer&#x2019;s &#x3b2;-amyloid. Nat Struct Mol Biol. 2007;14:1157&#x2013;1164.</Citation><ArticleIdList><ArticleId IdType="pubmed">18059284</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;hrs T, et al. 3D structure of Alzheimer&#x2019;s amyloid-&#x3b2;1&#x2013;42 fibrils. Proc Natl Acad Sci USA. 2005;102:17342&#x2013;17347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1297669</ArticleId><ArticleId IdType="pubmed">16293696</ArticleId></ArticleIdList></Reference><Reference><Citation>Torok M, et al. Structural and dynamic features of Alzheimer&#x2019;s A&#x3b2; peptide in amyloid fibrils studied by site-directed spin labeling. J Biol Chem. 2002;277:40810&#x2013;40815.</Citation><ArticleIdList><ArticleId IdType="pubmed">12181315</ArticleId></ArticleIdList></Reference><Reference><Citation>Olofsson A, Lindhagen-Persson M, Sauer-Eriksson AE, Ohman A. Amide solvent protection analysis demonstrates that amyloid-&#x3b2;1&#x2013;40 and amyloid-&#x3b2;1&#x2013;42 form different fibrillar structures under identical conditions. Biochem J. 2007;404:63&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868839</ArticleId><ArticleId IdType="pubmed">17280549</ArticleId></ArticleIdList></Reference><Reference><Citation>Antzutkin ON, et al. Multiple quantum solid state NMR indicates a parallel, not antiparallel, organization of &#x3b2;-sheets in Alzheimer&#x2019;s &#x3b2;-amyloid fibrils. Proc Natl Acad Sci USA. 2000;97:13045&#x2013;13050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27175</ArticleId><ArticleId IdType="pubmed">11069287</ArticleId></ArticleIdList></Reference><Reference><Citation>Antzutkin ON, Leapman RD, Balbach JJ, Tycko R. Supramolecular structural constraints on Alzheimer&#x2019;s &#x3b2;-amyloid fibrils from electron microscopy and solid state nuclear magnetic resonance. Biochemistry. 2002;41:15436&#x2013;15450.</Citation><ArticleIdList><ArticleId IdType="pubmed">12484785</ArticleId></ArticleIdList></Reference><Reference><Citation>Balbach JJ, et al. Supramolecular structure in full-length Alzheimer&#x2019;s &#x3b2;-amyloid fibrils: Evidence for a parallel &#x3b2;-sheet organization from solid state nuclear magnetic resonance. Biophys J. 2002;83:1205&#x2013;1216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1302222</ArticleId><ArticleId IdType="pubmed">12124300</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, et al. Self-propagating, molecular-level polymorphism in Alzheimer&#x2019;s &#x3b2;-amyloid fibrils. Science. 2005;307:262&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653506</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, Yau WM, Tycko R. Experimental constraints on quaternary structure in Alzheimer&#x2019;s &#x3b2;-amyloid fibrils. Biochemistry. 2006;45:498&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1435828</ArticleId><ArticleId IdType="pubmed">16401079</ArticleId></ArticleIdList></Reference><Reference><Citation>Paravastu AK, Leapman RD, Yau WM, Tycko R. Molecular structural basis for polymorphism in Alzheimer&#x2019;s &#x3b2;-amyloid fibrils. Proc Natl Acad Sci USA. 2008;105:18349&#x2013;18354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587602</ArticleId><ArticleId IdType="pubmed">19015532</ArticleId></ArticleIdList></Reference><Reference><Citation>Paravastu AK, Qahwash I, Leapman RD, Meredith SC, Tycko R. Seeded growth of &#x3b2;-amyloid fibrils from Alzheimer&#x2019;s brain-derived fibrils produces a distinct fibril structure. Proc Natl Acad Sci USA. 2009;106:7443&#x2013;7448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678625</ArticleId><ArticleId IdType="pubmed">19376973</ArticleId></ArticleIdList></Reference><Reference><Citation>Tycko R, Sciarretta KL, Orgel J, Meredith SC. Evidence for novel &#x3b2;-sheet structures in Iowa mutant &#x3b2;-amyloid fibrils. Biochemistry. 2009;48:6072&#x2013;6084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2910621</ArticleId><ArticleId IdType="pubmed">19358576</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiang W, Yau WM, Tycko R. Structural evolution of Iowa mutant &#x3b2;-amyloid fibrils from polymorphic to homogeneous states under repeated seeded growth. J Am Chem Soc. 2011;133:4018&#x2013;4029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3060308</ArticleId><ArticleId IdType="pubmed">21355554</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertini I, Gonnelli L, Luchinat C, Mao J, Nesi A. A new structural model of A&#x3b2;40 fibrils. J Am Chem Soc. 2011;133:16013&#x2013;16022.</Citation><ArticleIdList><ArticleId IdType="pubmed">21882806</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldsbury CS, et al. Studies on the in vitro assembly of A&#x3b2;1&#x2013;40: Implications for the search for A&#x3b2; fibril formation inhibitors. J Struct Biol. 2000;130:217&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">10940227</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodali R, Williams AD, Chemuru S, Wetzel R. A&#x3b2;1&#x2013;40 forms five distinct amyloid structures whose &#x3b2;-sheet contents and fibril stabilities are correlated. J Mol Biol. 2010;401:503&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919579</ArticleId><ArticleId IdType="pubmed">20600131</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayasinghe SA, Langen R. Identifying structural features of fibrillar islet amyloid polypeptide using site-directed spin labeling. J Biol Chem. 2004;279:48420&#x2013;48425.</Citation><ArticleIdList><ArticleId IdType="pubmed">15358791</ArticleId></ArticleIdList></Reference><Reference><Citation>Luca S, Yau WM, Leapman R, Tycko R. Peptide conformation and supramolecular organization in amylin fibrils: Constraints from solid state NMR. Biochemistry. 2007;46:13505&#x2013;13522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2562526</ArticleId><ArticleId IdType="pubmed">17979302</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Margittai M, Chen J, Langen R. Investigation of &#x3b1;-synuclein fibril structure by site-directed spin labeling. J Biol Chem. 2007;282:24970&#x2013;24979.</Citation><ArticleIdList><ArticleId IdType="pubmed">17573347</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladner CL, et al. Stacked sets of parallel, in-register &#x3b2;-strands of &#x3b2;2-microglobulin in amyloid fibrils revealed by site-directed spin labeling and chemical labeling. J Biol Chem. 2010;285:17137&#x2013;17147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2878032</ArticleId><ArticleId IdType="pubmed">20335170</ArticleId></ArticleIdList></Reference><Reference><Citation>Debelouchina GT, Platt GW, Bayro MJ, Radford SE, Griffin RG. Intermolecular alignment in &#x3b2;2-microglobulin amyloid fibrils. J Am Chem Soc. 2010;132:17077&#x2013;17079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2996106</ArticleId><ArticleId IdType="pubmed">21077676</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan JCC, Oyler NA, Yau WM, Tycko R. Parallel &#x3b2;-sheets and polar zippers in amyloid fibrils formed by residues 10&#x2013;39 of the yeast prion protein Ure2p. Biochemistry. 2005;44:10669&#x2013;10680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1380259</ArticleId><ArticleId IdType="pubmed">16060675</ArticleId></ArticleIdList></Reference><Reference><Citation>Shewmaker F, Wickner RB, Tycko R. Amyloid of the prion domain of Sup35p has an in-register parallel &#x3b2;-sheet structure. Proc Natl Acad Sci USA. 2006;103:19754&#x2013;19759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1750918</ArticleId><ArticleId IdType="pubmed">17170131</ArticleId></ArticleIdList></Reference><Reference><Citation>Kryndushkin DS, Wickner RB, Tycko R. The core of Ure2p prion fibrils is formed by the N-terminal segment in a parallel cross-&#x3b2; structure: Evidence from solid state NMR. J Mol Biol. 2011;409:263&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3095661</ArticleId><ArticleId IdType="pubmed">21497604</ArticleId></ArticleIdList></Reference><Reference><Citation>Cobb NJ, Sonnichsen FD, McHaourab H, Surewicz WK. Molecular architecture of human prion protein amyloid: A parallel, in-register &#x3b2;-structure. Proc Natl Acad Sci USA. 2007;104:18946&#x2013;18951.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2141888</ArticleId><ArticleId IdType="pubmed">18025469</ArticleId></ArticleIdList></Reference><Reference><Citation>Tycko R, Savtchenko R, Ostapchenko VG, Makarava N, Baskakov IV. The &#x3b1;-helical C-terminal domain of full-length recombinant PrP converts to an in-register parallel &#x3b2;-sheet structure in PrP fibrils: Evidence from solid state nuclear magnetic resonance. Biochemistry. 2010;49:9488&#x2013;9497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025268</ArticleId><ArticleId IdType="pubmed">20925423</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansbury PT, et al. Structural model for the &#x3b2;-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide. Nat Struct Biol. 1995;2:990&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pubmed">7583673</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, et al. Solid state NMR reveals a pH-dependent antiparallel &#x3b2;-sheet registry in fibrils formed by a &#x3b2;-amyloid peptide. J Mol Biol. 2004;335:247&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">14659754</ArticleId></ArticleIdList></Reference><Reference><Citation>Balbach JJ, et al. Amyloid fibril formation by A&#x3b2;16&#x2013;22, a seven-residue fragment of the Alzheimer&#x2019;s &#x3b2;-amyloid peptide, and structural characterization by solid state NMR. Biochemistry. 2000;39:13748&#x2013;13759.</Citation><ArticleIdList><ArticleId IdType="pubmed">11076514</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawaya MR, et al. Atomic structures of amyloid cross-&#x3b2; spines reveal varied steric zippers. Nature. 2007;447:453&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468747</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabowski TJ, Cho HS, Vonsattel JPG, Rebeck GW, Greenberg SM. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann Neurol. 2001;49:697&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">11409420</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii Y. 13C-13C dipolar recoupling under very fast magic angle spinning in solid state nuclear magnetic resonance: Applications to distance measurements, spectral assignments, and high-throughput secondary-structure determination. J Chem Phys. 2001;114:8473&#x2013;8483.</Citation></Reference><Reference><Citation>Bennett AE, et al. Homonuclear radio frequency-driven recoupling in rotating solids. J Chem Phys. 1998;108:9463&#x2013;9479.</Citation></Reference><Reference><Citation>Wishart DS, Bigam CG, Holm A, Hodges RS, Sykes BD. 1H, 13C, and 15N random coil NMR chemical shifts of the common amino-acids. 1. Investigations of nearest-neighbor effects. J Biomol NMR. 1995;5:67&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">7881273</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y, Delaglio F, Cornilescu G, Bax A. TALOS+: A hybrid method for predicting protein backbone torsion angles from NMR chemical shifts. J Biomol NMR. 2009;44:213&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726990</ArticleId><ArticleId IdType="pubmed">19548092</ArticleId></ArticleIdList></Reference><Reference><Citation>Tycko R, Ishii Y. Constraints on supramolecular structure in amyloid fibrils from two-dimensional solid state NMR spectroscopy with uniform isotopic labeling. J Am Chem Soc. 2003;125:6606&#x2013;6607.</Citation><ArticleIdList><ArticleId IdType="pubmed">12769550</ArticleId></ArticleIdList></Reference><Reference><Citation>Takegoshi K, Nakamura S, Terao T. 13C-1H dipolar-assisted rotational resonance in magic-angle spinning NMR. Chem Phys Lett. 2001;344:631&#x2013;637.</Citation></Reference><Reference><Citation>Morcombe CR, Gaponenko V, Byrd RA, Zilm KW. Diluting abundant spins by isotope edited radio frequency field assisted diffusion. J Am Chem Soc. 2004;126:7196&#x2013;7197.</Citation><ArticleIdList><ArticleId IdType="pubmed">15186155</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaroniec CP, Tounge BA, Herzfeld J, Griffin RG. Frequency selective heteronuclear dipolar recoupling in rotating solids: Accurate 13C-15N distance measurements in uniformly 13C,15N-labeled peptides. J Am Chem Soc. 2001;123:3507&#x2013;3519.</Citation><ArticleIdList><ArticleId IdType="pubmed">11472123</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B, Thurber KR, Shewmaker F, Wickner RB, Tycko R. Measurement of amyloid fibril mass-per-length by tilted-beam transmission electron microscopy. Proc Natl Acad Sci USA. 2009;106:14339&#x2013;14344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732815</ArticleId><ArticleId IdType="pubmed">19706519</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwieters CD, Kuszewski JJ, Clore GM. Using XPLOR-NIH for NMR molecular structure determination. Prog Nucl Magn Reson Spectrosc. 2006;48:47&#x2013;62.</Citation></Reference><Reference><Citation>Mattson MP, et al. &#x3b2;-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci. 1992;12:376&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575616</ArticleId><ArticleId IdType="pubmed">1346802</ArticleId></ArticleIdList></Reference><Reference><Citation>Perutz MF, Johnson T, Suzuki M, Finch JT. Glutamine repeats as polar zippers: Their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci USA. 1994;91:5355&#x2013;5358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC43993</ArticleId><ArticleId IdType="pubmed">8202492</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson R, et al. Structure of the cross-&#x3b2; spine of amyloid-like fibrils. Nature. 2005;435:773&#x2013;778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1479801</ArticleId><ArticleId IdType="pubmed">15944695</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Melckebeke H, et al. Atomic-resolution three-dimensional structure of HET-s(218&#x2013;289) amyloid fibrils by solid state NMR spectroscopy. J Am Chem Soc. 2010;132:13765&#x2013;13775.</Citation><ArticleIdList><ArticleId IdType="pubmed">20828131</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu K, Jacob J, Thiyagarajan P, Conticello VP, Lynn DG. Exploiting amyloid fibril lamination for nanotube self-assembly. J Am Chem Soc. 2003;125:6391&#x2013;6393.</Citation><ArticleIdList><ArticleId IdType="pubmed">12785778</ArticleId></ArticleIdList></Reference><Reference><Citation>Tycko R. Symmetry-based constant-time homonuclear dipolar recoupling in solid state NMR. J Chem Phys. 2007;126</Citation><ArticleIdList><ArticleId IdType="pubmed">17313228</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett AE, Rienstra CM, Auger M, Lakshmi KV, Griffin RG. Heteronuclear decoupling in rotating solids. J Chem Phys. 1995;103:6951&#x2013;6958.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22399772</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>10</Issue><PubDate><Year>2012</Year><Month>Mar</Month><Day>07</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>The secreted Wnt antagonist Dickkopf-1 is required for amyloid &#x3b2;-mediated synaptic loss.</ArticleTitle><Pagination><StartPage>3492</StartPage><EndPage>3498</EndPage><MedlinePgn>3492-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4562-11.2012</ELocationID><Abstract><AbstractText>Extensive evidence supports a central role for amyloid-&#x3b2; (A&#x3b2;) in the pathogenesis of Alzheimer's disease (AD). Synaptic loss mediated by A&#x3b2; in early stages of the disease might contribute to cognitive impairments. However, little is known about the mechanism by which A&#x3b2; induces the loss of synapses. The expression of the Wnt antagonist Dickkopf-1 (Dkk1) is increased in brains of AD patients and in AD transgenic mouse models, suggesting that dysfunction of Wnt signaling could contribute to AD pathology. Here we report that acute exposure to A&#x3b2; oligomers induces Dkk1 expression together with the loss of synaptic sites. Importantly, Dkk1-neutralizing antibodies suppress A&#x3b2;-induced synapse loss in mouse brain slices. In mature rat hippocampal neurons, Dkk1 decreases the number of synapses without affecting cell viability. Ultrastructural analyses revealed that Wnt blockade decreases the size of presynaptic and postsynaptic terminals. Time-lapse recordings of RFP-labeled stable synaptic sites demonstrate that Dkk1 induces the dispersal of synaptic components. These findings identify Dkk1 as a potential therapeutic target for the treatment of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Purro</LastName><ForeName>Silvia A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Cell and Developmental Biology, University College London, London WC1E 6BT, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickins</LastName><ForeName>Ellen M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Salinas</LastName><ForeName>Patricia C</ForeName><Initials>PC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C531384">Dkk1 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060449" MajorTopicYN="N">Wnt Signaling Pathway</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>9</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22399772</ArticleId><ArticleId IdType="pmc">PMC6621056</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4562-11.2012</ArticleId><ArticleId IdType="pii">32/10/3492</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahmad-Annuar A, Ciani L, Simeonidis I, Herreros J, Fredj NB, Rosso SB, Hall A, Brickley S, Salinas PC. Signaling across the synapse: a role for Wnt and Dishevelled in presynaptic assembly and neurotransmitter release. J Cell Biol. 2006;174:127&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064170</ArticleId><ArticleId IdType="pubmed">16818724</ArticleId></ArticleIdList></Reference><Reference><Citation>Budnik V, Salinas PC. Wnt signaling during synaptic development and plasticity. Curr Opin Neurobiol. 2011;21:151&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3499977</ArticleId><ArticleId IdType="pubmed">21239163</ArticleId></ArticleIdList></Reference><Reference><Citation>Busceti CL, Biagioni F, Aronica E, Riozzi B, Storto M, Battaglia G, Giorgi FS, Gradini R, Fornai F, Caricasole A, Nicoletti F, Bruno V. Induction of the Wnt inhibitor, Dickkopf-1, is associated with neurodegeneration related to temporal lobe epilepsy. Epilepsia. 2007;48:694&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">17437412</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappuccio I, Calderone A, Busceti CL, Biagioni F, Pontarelli F, Bruno V, Storto M, Terstappen GT, Gaviraghi G, Fornai F, Battaglia G, Melchiorri D, Zukin S, Nicoletti F, Caricasole A. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is required for the development of ischemic neuronal death. J Neurosci. 2005;25:2647&#x2013;2657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725177</ArticleId><ArticleId IdType="pubmed">15758175</ArticleId></ArticleIdList></Reference><Reference><Citation>Caricasole A, Copani A, Caraci F, Aronica E, Rozemuller AJ, Caruso A, Storto M, Gaviraghi G, Terstappen GC, Nicoletti F. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J Neurosci. 2004;24:6021&#x2013;6027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729239</ArticleId><ArticleId IdType="pubmed">15229249</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerpa W, Dinamarca MC, Inestrosa NC. Structure-function implications in Alzheimer's disease: effect of Abeta oligomers at central synapses. Curr Alzheimer Res. 2008a;5:233&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">18537540</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerpa W, Godoy JA, Alfaro I, Far&#xed;as GG, Metcalfe MJ, Fuentealba R, Bonansco C, Inestrosa NC. Wnt-7a modulates the synaptic vesicle cycle and synaptic transmission in hippocampal neurons. J Biol Chem. 2008b;283:5918&#x2013;5927.</Citation><ArticleIdList><ArticleId IdType="pubmed">18096705</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerpa W, Far&#xed;as GG, Godoy JA, Fuenzalida M, Bonansco C, Inestrosa NC. Wnt-5a occludes Abeta oligomer-induced depression of glutamatergic transmission in hippocampal neurons. Mol Neurodegener. 2010;5:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823745</ArticleId><ArticleId IdType="pubmed">20205789</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciani L, Boyle KA, Dickins E, Sahores M, Anane D, Lopes DM, Gibb AJ, Salinas PC. Wnt7a signaling promotes dendritic spine growth and synaptic strength through Ca2+/Calmodulin-dependent protein kinase II. Proc Natl Acad Sci U S A. 2011;108:10732&#x2013;10737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3127879</ArticleId><ArticleId IdType="pubmed">21670302</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuitino L, Godoy JA, Far&#xed;as GG, Couve A, Bonansco C, Fuenzalida M, Inestrosa NC. Wnt-5a modulates recycling of functional GABAA receptors on hippocampal neurons. J Neurosci. 2010;30:8411&#x2013;8420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6634644</ArticleId><ArticleId IdType="pubmed">20573888</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis EK, Zou Y, Ghosh A. Wnts acting through canonical and noncanonical signaling pathways exert opposite effects on hippocampal synapse formation. Neural Dev. 2008;3:32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2596118</ArticleId><ArticleId IdType="pubmed">18986540</ArticleId></ArticleIdList></Reference><Reference><Citation>De Ferrari GV, Moon RT. The ups and downs of Wnt signaling in prevalent neurological disorders. Oncogene. 2006;25:7545&#x2013;7553.</Citation><ArticleIdList><ArticleId IdType="pubmed">17143299</ArticleId></ArticleIdList></Reference><Reference><Citation>De Ferrari GV, Chac&#xf3;n MA, Barr&#xed;a MI, Garrido JL, Godoy JA, Olivares G, Reyes AE, Alvarez A, Bronfman M, Inestrosa NC. Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol Psychiatry. 2003;8:195&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">12610652</ArticleId></ArticleIdList></Reference><Reference><Citation>De Ferrari GV, Papassotiropoulos A, Biechele T, Wavrant De-Vrieze F, Avila ME, Major MB, Myers A, S&#xe1;ez K, Henr&#xed;quez JP, Zhao A, Wollmer MA, Nitsch RM, Hock C, Morris CM, Hardy J, Moon RT. Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease. Proc Natl Acad Sci U S A. 2007;104:9434&#x2013;9439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1890512</ArticleId><ArticleId IdType="pubmed">17517621</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol. 1990;27:457&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotti CG, Sullivan CA, Banker GA. The establishment of polarity by hippocampal neurons in culture. J Neurosci. 1988;8:1454&#x2013;1468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569279</ArticleId><ArticleId IdType="pubmed">3282038</ArticleId></ArticleIdList></Reference><Reference><Citation>Far&#xed;as GG, Alfaro IE, Cerpa W, Grabowski CP, Godoy JA, Bonansco C, Inestrosa NC. Wnt-5a/JNK signaling promotes the clustering of PSD-95 in hippocampal neurons. J Biol Chem. 2009;284:15857&#x2013;15866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2708882</ArticleId><ArticleId IdType="pubmed">19332546</ArticleId></ArticleIdList></Reference><Reference><Citation>Gogolla N, Galimberti I, Deguchi Y, Caroni P. Wnt signaling mediates experience-related regulation of synapse numbers and mossy fiber connectivities in the adult hippocampus. Neuron. 2009;62:510&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">19477153</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris KM, Rosenberg PA. Localization of synapses in rat cortical cultures. Neuroscience. 1993;53:495&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">8098515</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J Neurochem. 2008;104:1433&#x2013;1439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073119</ArticleId><ArticleId IdType="pubmed">18088381</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopf FW, Waters J, Mehta S, Smith SJ. Stability and plasticity of developing synapses in hippocampal neuronal cultures. J Neurosci. 2002;22:775&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758526</ArticleId><ArticleId IdType="pubmed">11826107</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A. 1999;96:3228&#x2013;3233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Inestrosa NC, Arenas E. Emerging roles of Wnts in the adult nervous system. Nat Rev Neurosci. 2010;11:77&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">20010950</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int. 2002;41:345&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">12176077</ArticleId></ArticleIdList></Reference><Reference><Citation>Knobloch M, Mansuy IM. Dendritic spine loss and synaptic alterations in Alzheimer's disease. Mol Neurobiol. 2008;37:73&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">18438727</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007;27:796&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastroiacovo F, Busceti CL, Biagioni F, Moyanova SG, Meisler MH, Battaglia G, Caricasole A, Bruno V, Nicoletti F. Induction of the Wnt antagonist, Dickkopf-1, contributes to the development of neuronal death in models of brain focal ischemia. J Cereb Blood Flow Metab. 2009;29:264&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">18827832</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudher A, Chapman S, Richardson J, Asuni A, Gibb G, Pollard C, Killick R, Iqbal T, Raymond L, Varndell I, Sheppard P, Makoff A, Gower E, Soden PE, Lewis P, Murphy M, Golde TE, Rupniak HT, Anderton BH, Lovestone S. Dishevelled regulates the metabolism of amyloid precursor protein via protein kinase C/mitogen-activated protein kinase and c-Jun terminal kinase. J Neurosci. 2001;21:4987&#x2013;4995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762860</ArticleId><ArticleId IdType="pubmed">11438574</ArticleId></ArticleIdList></Reference><Reference><Citation>Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene. 2006;25:7469&#x2013;7481.</Citation><ArticleIdList><ArticleId IdType="pubmed">17143291</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosi MC, Luccarini I, Grossi C, Fiorentini A, Spillantini MG, Prisco A, Scali C, Gianfriddo M, Caricasole A, Terstappen GC, Casamenti F. Increased Dickkopf-1 expression in transgenic mouse models of neurodegenerative disease. J Neurochem. 2010;112:1539&#x2013;1551.</Citation><ArticleIdList><ArticleId IdType="pubmed">20050968</ArticleId></ArticleIdList></Reference><Reference><Citation>Scali C, Caraci F, Gianfriddo M, Diodato E, Roncarati R, Pollio G, Gaviraghi G, Copani A, Nicoletti F, Terstappen GC, Caricasole A. Inhibition of Wnt signaling, modulation of Tau phosphorylation and induction of neuronal cell death by DKK1. Neurobiol Dis. 2006;24:254&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">16919965</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Svitkina TM, Verkhovsky AB, Borisy GG. Improved procedures for electron microscopic visualization of the cytoskeleton of cultured cells. J Struct Biol. 1995;115:290&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">8573471</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron. 2004;44:181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450169</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD., Jr Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2007;109:2106&#x2013;2111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1801040</ArticleId><ArticleId IdType="pubmed">17068150</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22399757</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>10</Issue><PubDate><Year>2012</Year><Month>Mar</Month><Day>07</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>FBL2 regulates amyloid precursor protein (APP) metabolism by promoting ubiquitination-dependent APP degradation and inhibition of APP endocytosis.</ArticleTitle><Pagination><StartPage>3352</StartPage><EndPage>3365</EndPage><MedlinePgn>3352-65</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5659-11.2012</ELocationID><Abstract><AbstractText>The ubiquitin-proteasome pathway is a major protein degradation pathway whose dysfunction is now widely accepted as a cause of neurodegenerative diseases, including Alzheimer's disease. Here we demonstrate that the F-box and leucine rich repeat protein2 (FBL2), a component of the E3 ubiquitin ligase complex, regulates amyloid precursor protein (APP) metabolism through APP ubiquitination. FBL2 overexpression decreased the amount of secreted amyloid &#x3b2; (A&#x3b2;) peptides and sAPP&#x3b2;, whereas FBL2 mRNA knockdown by siRNA increased these levels. FBL2 overexpression also decreased the amount of intracellular A&#x3b2; in Neuro2a cells stably expressing APP with Swedish mutation. FBL2 bound with APP specifically at its C-terminal fragment (CTF), which promoted APP/CTF ubiquitination. FBL2 overexpression also accelerated APP proteasome-dependent degradation and decreased APP protein localization in lipid rafts by inhibiting endocytosis. These effects were not observed in an F-box-deleted FBL2 mutant that does not participate in the E3 ubiquitin ligase complex. Furthermore, a reduced insoluble A&#x3b2; and A&#x3b2; plaque burden was observed in the hippocampus of 7-month-old FBL2 transgenic mice crossed with double-transgenic mice harboring APPswe and PS1(M146V) transgenes. These findings indicate that FBL2 is a novel and dual regulator of APP metabolism through FBL2-dependent ubiquitination of APP.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Tomomichi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>CNS Drug Discovery Unit, Oncology Drug Discovery Unit, Evotec Neurosciences, 8008 Zurich, Switzerland. Watanabe_Tomomichi@takeda.co.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hikichi</LastName><ForeName>Yukiko</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Willuweit</LastName><ForeName>Antje</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Shintani</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Horiguchi</LastName><ForeName>Takashi</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044783">F-Box Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C122028">FBXL2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="Y">Endocytosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044783" MajorTopicYN="N">F-Box Proteins</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009433" MajorTopicYN="Y">Neural Inhibition</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054875" MajorTopicYN="Y">Ubiquitination</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>9</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22399757</ArticleId><ArticleId IdType="pmc">PMC6621050</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5659-11.2012</ArticleId><ArticleId IdType="pii">32/10/3352</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alves-Rodrigues A, Gregori L, Figueiredo-Pereira ME. Ubiquitin, cellular inclusions and their role in neurodegeneration. Trends Neurosci. 1998;21:516&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">9881849</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedford L, Lowe J, Dick LR, Mayer RJ, Brownell JE. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov. 2011;10:29&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097807</ArticleId><ArticleId IdType="pubmed">21151032</ArticleId></ArticleIdList></Reference><Reference><Citation>Biffi A, Anderson CD, Desikan RS, Sabuncu M, Cortellini L, Schmansky N, Salat D, Rosand J, Alzheimer's Disease Neuroimageing Initiative (ADNI) Genetic variation and neuroimaging measures in Alzheimer disease. Arch Neurol. 2010;67:677&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2956757</ArticleId><ArticleId IdType="pubmed">20558387</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mouse. Neuron. 2005;45:675&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748844</ArticleId></ArticleIdList></Reference><Reference><Citation>Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A. 2004;101:2173&#x2013;2178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC357071</ArticleId><ArticleId IdType="pubmed">14769913</ArticleId></ArticleIdList></Reference><Reference><Citation>Busciglio J, Pelsman A, Wong C, Pigino G, Yuan M, Mori H, Yankner BA. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction of Down's syndrome. Neuron. 2002;33:677&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">11879646</ArticleId></ArticleIdList></Reference><Reference><Citation>Carey RM, Balcz BA, Lopez-Coviella I, Slack BE. Inhibition of dynamin-dependent endocytosis increases shedding of the amyloid precursor protein ectodomain and reduces generation of amyloid beta protein. BMC Cell Biol. 2005;6:30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1208872</ArticleId><ArticleId IdType="pubmed">16095541</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Thiruchelvam MJ, Madura K, Richfield EK. Proteasome dysfunction in aged human alpha-synuclein transgenic mice. Neurobiol Dis. 2006;23:120&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">16713278</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciechanover A, Brundin P. The ubiquitin proteasome system in neurodegenerative diseases. Neuron. 2003;40:427&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">14556719</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, Bu G, Mennerick S, Holtzman DM. Endocytosis is required for synaptic activity-dependent release of amyloid-&#x3b2; in vivo. Neuron. 2008;58:42&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2390913</ArticleId><ArticleId IdType="pubmed">18400162</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Andrea MR, Nagele RG, Wang HY, Peterson PA, Lee DH. Evidence that neurons accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology. 2001;38:120&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">11207825</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of Alzheimer &#x3b2;-amyloid precursor protein depends on lipid rafts. J Cell Biol. 2003;160:113&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172747</ArticleId><ArticleId IdType="pubmed">12515826</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford MG, Pearse BM, Higgins MK, Vallis Y, Owen DJ, Gibson A, Hopkins CR, Evans PR, McMahon HT. Simultaneous binding of PtdIns(4,5)P2 and clathrin by AP180 in the nucleation of clathrin lattices on membranes. Science. 2001;291:1051&#x2013;1055.</Citation><ArticleIdList><ArticleId IdType="pubmed">11161218</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol. 2000;156:15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868613</ArticleId><ArticleId IdType="pubmed">10623648</ArticleId></ArticleIdList></Reference><Reference><Citation>Graeve L, Drickamer K, Rodriguez-Boulan E. Polarized endocytosis by Madin-Darby canine kidney cells transfected with functional chicken liver glycoprotein receptor. J Cell Biol. 1989;109:2809&#x2013;2816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2115943</ArticleId><ArticleId IdType="pubmed">2687287</ArticleId></ArticleIdList></Reference><Reference><Citation>Haglund K, Sigismund S, Polo S, Szymkiewicz I, Di Fiore PP, Dikic I. Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat Cell Biol. 2003;5:461&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pubmed">12717448</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid &#x3b2;-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L, Selkoe DJ. The Swedish mutation causes early-onset Alzheimer's disease by &#x3b2;-secretase cleavage within the secretory pathway. Nat Med. 1995;1:1291&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">7489411</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;42:1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Hershko A, Ciechanover A, Varshavsky A. Basic Medical Research Award: the ubiquitin system. Nat Med. 2000;6:73&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pubmed">11017125</ArticleId></ArticleIdList></Reference><Reference><Citation>Hicke L. Protein regulation by monoubiquitination. Nat Rev Mol Cell Biol. 2001;2:195&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">11265249</ArticleId></ArticleIdList></Reference><Reference><Citation>Hicke L, Dunn R. Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu Rev Cell Dev Biol. 2003;19:141&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">14570567</ArticleId></ArticleIdList></Reference><Reference><Citation>Hislop JN, von Zastrow M. Role of ubiquitination in endocytic trafficking of G-protein-coupled receptors. Traffic. 2011;12:137&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3625703</ArticleId><ArticleId IdType="pubmed">20854416</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofmann RM, Pickart CM. Noncanonical MMS2-encoded ubiquitin-conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair. Cell. 1999;96:645&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pubmed">10089880</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilyin GP, Rialland M, Glaise D, Guguen-Guillouzo C. Identification of a novel Skp2-like mammalian protein containing F-box and leucine-rich repeats. FEBS Lett. 1999;459:75&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">10508920</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko M, Koike H, Saito R, Kitamura Y, Okuma Y, Nomura Y. Loss of HRD1-mediated protein degradation causes amyloid precursor protein accumulation and amyloid-&#x3b2; generation. J Neurosci. 2010;30:3924&#x2013;3932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632277</ArticleId><ArticleId IdType="pubmed">20237263</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392:605&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">9560156</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Squazzo SL. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem. 1994;269:17386&#x2013;17389.</Citation><ArticleIdList><ArticleId IdType="pubmed">8021238</ArticleId></ArticleIdList></Reference><Reference><Citation>Lah JJ, Levey AI. Endogenous presenilin-1 targets to endocytic rather than biosynthetic compartments. Mol Cell Neurosci. 2000;16:111&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">10924255</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakshmana MK, Yoon IS, Chen E, Bianchi E, Koo EH, Kang DE. Novel role of RanBP9 in BACE1 processing of amyloid precursor protein and amyloid peptide generation. J Biol Chem. 2009;284:11863&#x2013;11872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2673255</ArticleId><ArticleId IdType="pubmed">19251705</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam YA, Pickart CM, Alban A, Landon M, Jamieson C, Ramage R, Mayer RJ, Layfield R. Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc Natl Acad Sci U S A. 2000;97:9902&#x2013;9906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27620</ArticleId><ArticleId IdType="pubmed">10944193</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Pauley AM, Myers RL, Shuang R, Brashler JR, Yan R, Buhl AE, Ruble C, Gurney ME. SEL-10 interacts with presenilin1, facilitates its ubiquitination, and alters A-beta peptide production. J Neurochem. 2002;82:1540&#x2013;1548.</Citation><ArticleIdList><ArticleId IdType="pubmed">12354302</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez Salon L, Morelli L, Casta&#xf1;o EM, Soto EF, Pasquini JM. Defective ubiquitination of cerebral proteins in Alzheimer's disease. J Neurosci Res. 2000;62:302&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">11020223</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordstedt C, Caporaso GL, Thyberg J, Gandy SE, Greengard P. Identification of the Alzheimer beta/A4 amyloid precursor protein in clathrin-coated vesicles purified from PC12 cells. J Biol Chem. 1993;268:608&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pubmed">8416966</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunan J, Shearman MS, Checler F, Cappai R, Evin G, Beyreuther K, Masters CL, Small DH. The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from gamma-secretase. Eur J Biochem. 2001;268:5329&#x2013;5336.</Citation><ArticleIdList><ArticleId IdType="pubmed">11606195</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunan J, Williamson NA, Hill AF, Sernee MF, Masters CL, Small DH. Proteasome-mediated degradation of the C-terminus of the Alzheimer's disease beta-amyloid protein precursor: effect of C-terminal truncation on production of beta-amyloid protein. J Neurosci Res. 2003;74:378&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">14598314</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortega Z, D&#xed;az-Hern&#xe1;ndez M, Maynard CJ, Hern&#xe1;ndez F, Dantuma NP, Lucas JJ. Acute polyglutamine expression in inducible mouse model unravels ubiquitin/proteasome system impairment and permanent recovery attributable to aggregate formation. J Neurosci. 2010;30:3675&#x2013;3688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632247</ArticleId><ArticleId IdType="pubmed">20220001</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry G, Friedman R, Shaw G, Chau V. Ubiquitin is detected in neurofibrillary tangles and senile plaque neuritis of Alzheimer disease brain. Proc Natl Acad Sci U S A. 1987;84:3033&#x2013;3036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC304795</ArticleId><ArticleId IdType="pubmed">3033674</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickart CM. Ubiquitin enters new millennium. Mol Cell. 2001;8:499&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">11583613</ArticleId></ArticleIdList></Reference><Reference><Citation>Schjeide BM, Schnack C, Lambert JC, Lill CM, Kirchheiner J, Tumani H, Otto M, Tanzi RE, Lehrach H, Amouyel P, von Arnim CA, Bertram L. The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels. Arch Gen Psychiatry. 2011;68:207&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">21300948</ArticleId></ArticleIdList></Reference><Reference><Citation>Seibler J, Zevnik B, K&#xfc;ter-Luks B, Andreas S, Kern H, Hennek T, Rode A, Heimann C, Faust N, Kauselmann G, Schoor M, Jaenisch R, Rajewsky K, K&#xfc;hn R, Schwenk F. Rapid generation of inducible mouse mutants. Nucleic Acids Res. 2003;31:e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC150244</ArticleId><ArticleId IdType="pubmed">12582257</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 1998;8:447&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">9854312</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, Suzuki T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet. 2000;25:302&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">10888878</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigismund S, Woelk T, Puri C, Maspero E, Tacchetti C, Transidico P, Di Fiore PP, Polo S. Clathrin-independent endocytosis of ubiquitinated cargos. Proc Natl Acad Sci U S A. 2005;102:2760&#x2013;2765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC549482</ArticleId><ArticleId IdType="pubmed">15701692</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, Iwatsubo T, Odaka A, Ishibashi Y, Kitada C, Ihara Y. High tissue content of soluble beta 1&#x2013;40 is linked to cerebral amyloid angiopathy. Am J Pathol. 1994;145:452&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887395</ArticleId><ArticleId IdType="pubmed">8053502</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabira T, Chui DH, Kuroda S. Significance of intracellular Abeta42 accumulation in Alzheimer's disease. Front Biosci. 2002;7:a44&#x2013;a49.</Citation><ArticleIdList><ArticleId IdType="pubmed">11897569</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Z, Sun X, Hou FS, Oh HW, Hilgenberg LG, Hol EM, van Leeuwen FW, Smith MA, O'Dowd DK, Schreiber SS. Mutant ubiquitin found in Alzheimer's disease causes neuritic beading of mitochondria in association with neuronal degeneration. Cell Death Differ. 2007;10:1721&#x2013;1732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3258508</ArticleId><ArticleId IdType="pubmed">17571083</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell. 2005;120:545&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Peck A, DeTeresa R, Schechter R, Horoupian DS. Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol. 1981;10:184&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">7283403</ArticleId></ArticleIdList></Reference><Reference><Citation>Tun H, Marlow L, Pinnix I, Kinsey R, Sambamurti K. Lipid rafts play an important role in A&#x3b2; biogenesis by regulating the &#x3b2;-secretase pathway. J Mol Neurosci. 2002;19:31&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">12212790</ArticleId></ArticleIdList></Reference><Reference><Citation>van Leeuwen FW, de Kleijn DP, van den Hurk HH, Neubauer A, Sonnemans MA, Sluijs JA, K&#xf6;yc&#xfc; S, Ramdjielal RD, Salehi A, Martens GJ, Grosveld FG, Peter J, Burbach H, Hol EM. Frameshift mutants of &#x3b2; amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science. 1998;279:242&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">9422699</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Gale M, Jr, Keller BC, Huang H, Brown MS, Goldstein JL, Ye J. Identification of FBL2 as a geranylgeranylated cellular protein required for Hepatitis C virus RNA replication. Mol Cell. 2005;18:425&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">15893726</ArticleId></ArticleIdList></Reference><Reference><Citation>Willuweit A, Velden J, Godemann R, Manook A, Jetzek F, Tintrup H, Kauselmann G, Zevnik B, Henriksen G, Drzezga A, Pohlner J, Schoor M, Kemp JA, von der Kammer H. Early-onset and robust amyloid pathology in a new homozygous mouse models of Alzheimer's diseases. PLoS One. 2009;4:e7931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2775952</ArticleId><ArticleId IdType="pubmed">19936202</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe BL, Marchese A, Trejo J. Ubiquitination differentially regulates clathrin-dependent internalization of protease-activated receptor-1. J Cell Biol. 2007;177:905&#x2013;916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064289</ArticleId><ArticleId IdType="pubmed">17535965</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22397651</PMID><DateCompleted><Year>2012</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>366</Volume><Issue>10</Issue><PubDate><Year>2012</Year><Month>Mar</Month><Day>08</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Donepezil and memantine for moderate-to-severe Alzheimer's disease.</ArticleTitle><Pagination><StartPage>893</StartPage><EndPage>903</EndPage><MedlinePgn>893-903</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1106668</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer's disease (a score of 5 to 13 on the Standardized Mini-Mental State Examination [SMMSE, on which scores range from 0 to 30, with higher scores indicating better cognitive function]) to continue donepezil, discontinue donepezil, discontinue donepezil and start memantine, or continue donepezil and start memantine. Patients received the study treatment for 52 weeks. The coprimary outcomes were scores on the SMMSE and on the Bristol Activities of Daily Living Scale (BADLS, on which scores range from 0 to 60, with higher scores indicating greater impairment). The minimum clinically important differences were 1.4 points on the SMMSE and 3.5 points on the BADLS.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients assigned to continue donepezil, as compared with those assigned to discontinue donepezil, had a score on the SMMSE that was higher by an average of 1.9 points (95% confidence interval [CI], 1.3 to 2.5) and a score on the BADLS that was lower (indicating less impairment) by 3.0 points (95% CI, 1.8 to 4.3) (P&lt;0.001 for both comparisons). Patients assigned to receive memantine, as compared with those assigned to receive memantine placebo, had a score on the SMMSE that was an average of 1.2 points higher (95% CI, 0.6 to 1.8; P&lt;0.001) and a score on the BADLS that was 1.5 points lower (95% CI, 0.3 to 2.8; P=0.02). The efficacy of donepezil and of memantine did not differ significantly in the presence or absence of the other. There were no significant benefits of the combination of donepezil and memantine over donepezil alone.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In patients with moderate or severe Alzheimer's disease, continued treatment with donepezil was associated with cognitive benefits that exceeded the minimum clinically important difference and with significant functional benefits over the course of 12 months. (Funded by the U.K. Medical Research Council and the U.K. Alzheimer's Society; Current Controlled Trials number, ISRCTN49545035.).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Howard</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, King's College London, London SE5 8AF, United Kingdom. robert.j.howard@kcl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McShane</LastName><ForeName>Rupert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Lindesay</LastName><ForeName>James</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Ritchie</LastName><ForeName>Craig</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Baldwin</LastName><ForeName>Ashley</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Barber</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Alistair</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Dening</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Findlay</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Clive</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Jacoby</LastName><ForeName>Robin</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Rob</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Roy</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>McKeith</LastName><ForeName>Ian</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Macharouthu</LastName><ForeName>Ajay</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Passmore</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Sheehan</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Juszczak</LastName><ForeName>Edmund</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Katona</LastName><ForeName>Cornelius</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hills</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Knapp</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Clive</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Banerjee</LastName><ForeName>Sube</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Onions</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Griffin</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Adams</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Gray</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Tony</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Bentham</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Phillips</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ISRCTN</DataBankName><AccessionNumberList><AccessionNumber>ISRCTN49545035</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>G0600989</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U122888466</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U137686861</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance></Chemical><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2012 Mar 8;366(10):957-9. doi: 10.1056/NEJMe1200429.</RefSource><PMID Version="1">22397659</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2012 Jun 7;366(23):2227-8; author reply 2228. doi: 10.1056/NEJMc1204656.</RefSource><PMID Version="1">22670911</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2012 Jun 7;366(23):2227-8; author reply 2228. doi: 10.1056/NEJMc1204656.</RefSource><PMID Version="1">22670912</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Ann Intern Med. 2012 Jun 19;156(12):JC6-10. doi: 10.7326/0003-4819-156-12-201206190-02010.</RefSource><PMID Version="1">22711111</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Evid Based Med. 2013 Apr;18(2):62-3. doi: 10.1136/eb-2012-100722.</RefSource><PMID Version="1">22736656</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077265" MajorTopicYN="N">Donepezil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010352" MajorTopicYN="N">Patient Dropouts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011581" MajorTopicYN="N">Psychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22397651</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1106668</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22388814</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>483</Volume><Issue>7388</Issue><PubDate><Year>2012</Year><Month>Feb</Month><Day>29</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>An epigenetic blockade of cognitive functions in the neurodegenerating brain.</ArticleTitle><Pagination><StartPage>222</StartPage><EndPage>226</EndPage><MedlinePgn>222-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature10849</ELocationID><Abstract><AbstractText>Cognitive decline is a debilitating feature of most neurodegenerative diseases of the central nervous system, including Alzheimer's disease. The causes leading to such impairment are only poorly understood and effective treatments are slow to emerge. Here we show that cognitive capacities in the neurodegenerating brain are constrained by an epigenetic blockade of gene transcription that is potentially reversible. This blockade is mediated by histone deacetylase 2, which is increased by Alzheimer's-disease-related neurotoxic insults in vitro, in two mouse models of neurodegeneration and in patients with Alzheimer's disease. Histone deacetylase 2 associates with and reduces the histone acetylation of genes important for learning and memory, which show a concomitant decrease in expression. Importantly, reversing the build-up of histone deacetylase 2 by short-hairpin-RNA-mediated knockdown unlocks the repression of these genes, reinstates structural and synaptic plasticity, and abolishes neurodegeneration-associated memory impairments. These findings advocate for the development of selective inhibitors of histone deacetylase 2 and suggest that cognitive capacities following neurodegeneration are not entirely lost, but merely impaired by this epigenetic blockade.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gr&#xe4;ff</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rei</LastName><ForeName>Damien</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Guan</LastName><ForeName>Ji-Song</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wen-Yuan</ForeName><Initials>WY</Initials></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Jinsoo</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hennig</LastName><ForeName>Krista M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Nieland</LastName><ForeName>Thomas J F</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Fass</LastName><ForeName>Daniel M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Kao</LastName><ForeName>Patricia F</ForeName><Initials>PF</Initials></Author><Author ValidYN="Y"><LastName>Kahn</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Susan C</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Samiei</LastName><ForeName>Alireza</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Joseph</LastName><ForeName>Nadine</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Haggarty</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Delalle</LastName><ForeName>Ivana</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Li-Huei</ForeName><Initials>LH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01DA028301</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS078839</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS078839</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA028301</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH095088</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>02</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006657">Histones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011965">Receptors, Glucocorticoid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>BBX060AN9V</RegistryNumber><NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.-</RegistryNumber><NameOfSubstance UI="D012319">RNA Polymerase II</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.98</RegistryNumber><NameOfSubstance UI="C533423">HDAC2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.98</RegistryNumber><NameOfSubstance UI="C533424">Hdac2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.98</RegistryNumber><NameOfSubstance UI="D056464">Histone Deacetylase 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000107" MajorTopicYN="N">Acetylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044127" MajorTopicYN="Y">Epigenesis, Genetic</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056464" MajorTopicYN="N">Histone Deacetylase 2</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006657" MajorTopicYN="N">Histones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012319" MajorTopicYN="N">RNA Polymerase II</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011965" MajorTopicYN="N">Receptors, Glucocorticoid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>11</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22388814</ArticleId><ArticleId IdType="mid">NIHMS409621</ArticleId><ArticleId IdType="pmc">PMC3498952</ArticleId><ArticleId IdType="doi">10.1038/nature10849</ArticleId><ArticleId IdType="pii">nature10849</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer&#x2019;s disease. Neuron. 2004;44:181&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450169</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Morris JC, Goate AM. Alzheimer&#x2019;s disease: the challenge of the second century. Sci Transl Med. 2011;3:77sr1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandel ER. The molecular biology of memory storage: a dialogue between genes and synapses. Science. 2001;294:1030&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11691980</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xe4;ff J, Kim D, Dobbin MM, Tsai LH. Epigenetic regulation of gene expression in physiological and pathological brain processes. Physiol Rev. 2011;91:603&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">21527733</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownell JE, Allis CD. Special HATs for special occasions: linking histone acetylation to chromatin assembly and gene activation. Curr Opin Genet Dev. 1996;6:176&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">8722174</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazantsev AG, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov. 2008;7:854&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">18827828</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan JS, et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature. 2009;459:55&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498958</ArticleId><ArticleId IdType="pubmed">19424149</ArticleId></ArticleIdList></Reference><Reference><Citation>Akhtar MW, et al. Histone deacetylases 1 and 2 form a developmental switch that controls excitatory synapse maturation and function. J Neurosci. 2009;29:8288&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2895817</ArticleId><ArticleId IdType="pubmed">19553468</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron. 2003;40:471&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">14642273</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz JC, et al. p25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid beta in vivo. J Neurosci. 2006;26:10536&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674706</ArticleId><ArticleId IdType="pubmed">17035538</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz JC, Tsai LH. A Jekyll and Hyde kinase: roles for Cdk5 in brain development and disease. Curr Opin Neurobiol. 2004;14:390&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">15194121</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick GN, et al. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 1999;402:615&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">10604467</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer A, Sananbenesi F, Pang PT, Lu B, Tsai LH. Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. Neuron. 2005;48:825&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">16337919</ArticleId></ArticleIdList></Reference><Reference><Citation>Frankland PW, Bontempi B. The organization of recent and remote memories. Nature Reviews Neuroscience. 2005;6:119&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">15685217</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuown SC, et al. HDAC3 is a critical negative regulator of long-term memory formation. J Neurosci. 2011;31:764&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3160172</ArticleId><ArticleId IdType="pubmed">21228185</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura R, Devi L, Ohno M. Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer&#x2019;s disease transgenic mice. J Neurochem. 2010;113:248&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2921968</ArticleId><ArticleId IdType="pubmed">20089133</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauterborn JC, et al. Differential effects of protein synthesis inhibition on the activity-dependent expression of BDNF transcripts: evidence for immediate-early gene responses from specific promoters. J Neurosci. 1996;16:7428&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579105</ArticleId><ArticleId IdType="pubmed">8922398</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun JM, Chen HY, Davie JR. Differential distribution of unmodified and phosphorylated histone deacetylase 2 in chromatin. J Biol Chem. 2007;282:33227&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">17827154</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer A, Sananbenesi F, Wang XY, Dobbin M, Tsai LH. Recovery of learning and memory is associated with chromatin remodelling. Nature. 2007;447:178&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468743</ArticleId></ArticleIdList></Reference><Reference><Citation>Markesbery WR, Carney JM. Oxidative alterations in Alzheimer&#x2019;s disease. Brain Pathol. 1999;9:133&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098393</ArticleId><ArticleId IdType="pubmed">9989456</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankner BA. Mechanisms of neuronal degeneration in Alzheimer&#x2019;s disease. Neuron. 1996;16:921&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">8630250</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandelin A, Alkema W, Engstrom P, Wasserman WW, Lenhard B. JASPAR: an open-access database for eukaryotic transcription factor binding profiles. Nucleic Acids Res. 2004;32:D91&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC308747</ArticleId><ArticleId IdType="pubmed">14681366</ArticleId></ArticleIdList></Reference><Reference><Citation>Chrousos GP, Kino T. Glucocorticoid signaling in the cell. Expanding clinical implications to complex human behavioral and somatic disorders. Ann N Y Acad Sci. 2009;1179:153&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2791367</ArticleId><ArticleId IdType="pubmed">19906238</ArticleId></ArticleIdList></Reference><Reference><Citation>Kino T, et al. Cyclin-dependent kinase 5 differentially regulates the transcriptional activity of the glucocorticoid receptor through phosphorylation: clinical implications for the nervous system response to glucocorticoids and stress. Mol Endocrinol. 2007;21:1552&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">17440046</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan JS, et al. Cdk5 Is Required for Memory Function and Hippocampal Plasticity via the cAMP Signaling Pathway. PLoS One. 2011;6:e25735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3184170</ArticleId><ArticleId IdType="pubmed">21984943</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M. Alzheimer&#x2019;s disease: strategies for disease modification. Nat Rev Drug Discov. 2010;9:387&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">20431570</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer&#x2019;s disease. Neurobiol Aging. 1997;18:S85&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330992</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, et al. Memory and mental status correlates of modified Braak staging. Neurobiol Aging. 1999;20:573&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10674422</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer&#x2019;s disease: from synapses toward neural networks. Nat Neurosci. 2009;13:812&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072750</ArticleId><ArticleId IdType="pubmed">20581818</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi Y, Wang JK, McMillian M, Chikaraishi DM. Characterization of a CNS cell line, CAD, in which morphological differentiation is initiated by serum deprivation. J Neurosci. 1997;17:1217&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793738</ArticleId><ArticleId IdType="pubmed">9006967</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Lindquist S. Creating a protein-based element of inheritance. Science. 2000;287:661&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">10650001</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Z, Sanada K, Samuels BA, Shih H, Tsai LH. Serine 732 phosphorylation of FAK by Cdk5 is important for microtubule organization, nuclear movement, and neuronal migration. Cell. 2003;114:469&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">12941275</ArticleId></ArticleIdList></Reference><Reference><Citation>Koshibu K, et al. Protein phosphatase 1 regulates the histone code for long-term memory. J Neurosci. 2009;29:13079&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665317</ArticleId><ArticleId IdType="pubmed">19828821</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Moffat J, et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell. 2006;124:1283&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">16564017</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">15718470</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22366723</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1552-4469</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>Feb</Month><Day>26</Day></PubDate></JournalIssue><Title>Nature chemical biology</Title><ISOAbbreviation>Nat Chem Biol</ISOAbbreviation></Journal><ArticleTitle>Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation.</ArticleTitle><Pagination><StartPage>393</StartPage><EndPage>399</EndPage><MedlinePgn>393-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nchembio.797</ELocationID><Abstract><AbstractText>Oligomerization of tau is a key process contributing to the progressive death of neurons in Alzheimer's disease. Tau is modified by O-linked N-acetylglucosamine (O-GlcNAc), and O-GlcNAc can influence tau phosphorylation in certain cases. We therefore speculated that increasing tau O-GlcNAc could be a strategy to hinder pathological tau-induced neurodegeneration. Here we found that treatment of hemizygous JNPL3 tau transgenic mice with an O-GlcNAcase inhibitor increased tau O-GlcNAc, hindered formation of tau aggregates and decreased neuronal cell loss. Notably, increases in tau O-GlcNAc did not alter tau phosphorylation in vivo. Using in vitro biochemical aggregation studies, we found that O-GlcNAc modification, on its own, hinders tau oligomerization. O-GlcNAc also inhibits thermally induced aggregation of an unrelated protein, TAK-1 binding protein, suggesting that a basic biochemical function of O-GlcNAc may be to prevent protein aggregation. These results also suggest O-GlcNAcase as a potential therapeutic target that could hinder progression of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yuzwa</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shan</LastName><ForeName>Xiaoyang</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Macauley</LastName><ForeName>Matthew S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Skorobogatko</LastName><ForeName>Yuliya</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Vosseller</LastName><ForeName>Keith</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Vocadlo</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>02</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Chem Biol</MedlineTA><NlmUniqueID>101231976</NlmUniqueID><ISSNLinking>1552-4450</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011714">Pyrans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C531463">Tab1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C572247">thiamet G</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.1.-</RegistryNumber><NameOfSubstance UI="D017351">N-Acetylglucosaminyltransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>V956696549</RegistryNumber><NameOfSubstance UI="D000117">Acetylglucosamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Chem Biol. 2012 Mar 16;8(4):325-6. doi: 10.1038/nchembio.920.</RefSource><PMID Version="1">22426191</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000117" MajorTopicYN="N">Acetylglucosamine</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002236" MajorTopicYN="N">Carbohydrate Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017351" MajorTopicYN="N">N-Acetylglucosaminyltransferases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011714" MajorTopicYN="N">Pyrans</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22366723</ArticleId><ArticleId IdType="doi">10.1038/nchembio.797</ArticleId><ArticleId IdType="pii">nchembio.797</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10804-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15249677</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2009 Jul;132(Pt 7):1820-32</Citation><ArticleIdList><ArticleId IdType="pubmed">19451179</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2005 Feb;7(1):63-80</Citation><ArticleIdList><ArticleId IdType="pubmed">15750215</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2002 Dec;83(6):1498-508</Citation><ArticleIdList><ArticleId IdType="pubmed">12472903</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1991 Mar 15;266(8):4706-12</Citation><ArticleIdList><ArticleId IdType="pubmed">2002019</ArticleId></ArticleIdList></Reference><Reference><Citation>FEBS Lett. 2005 Feb 28;579(6):1399-404</Citation><ArticleIdList><ArticleId IdType="pubmed">15733848</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurosci. 2006 Apr;23(8):2078-86</Citation><ArticleIdList><ArticleId IdType="pubmed">16630055</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 1998 Jul 14;37(28):10223-30</Citation><ArticleIdList><ArticleId IdType="pubmed">9665729</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Biosyst. 2011 May;7(5):1420-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21327254</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1997 Apr 4;272(14):9308-15</Citation><ArticleIdList><ArticleId IdType="pubmed">9083067</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1996 Nov 15;271(46):28741-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8910513</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2003 Jan 20;1619(2):167-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12527113</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Jul 15;309(5733):476-81</Citation><ArticleIdList><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 2005 Apr 19;44(15):5862-72</Citation><ArticleIdList><ArticleId IdType="pubmed">15823045</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Chem Biol. 2008 Aug;4(8):483-90</Citation><ArticleIdList><ArticleId IdType="pubmed">18587388</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2001 Mar 30;276(13):9838-45</Citation><ArticleIdList><ArticleId IdType="pubmed">11148210</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6923-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11381127</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3131-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19204290</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2000 Sep-Oct;21(5):719-27</Citation><ArticleIdList><ArticleId IdType="pubmed">11016541</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 2008 Oct 22;27(20):2780-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18818698</ArticleId></ArticleIdList></Reference><Reference><Citation>Amino Acids. 2011 Mar;40(3):857-68</Citation><ArticleIdList><ArticleId IdType="pubmed">20706749</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1994 Jul 29;269(30):19321-30</Citation><ArticleIdList><ArticleId IdType="pubmed">8034696</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 1991;640:65-71</Citation><ArticleIdList><ArticleId IdType="pubmed">1776760</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1995 Jan;52(1):81-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7826280</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2009 Oct;111(1):242-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19659459</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 1997 Jun;150(6):2181-95</Citation><ArticleIdList><ArticleId IdType="pubmed">9176408</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 1996 Mar 19;35(11):3578-86</Citation><ArticleIdList><ArticleId IdType="pubmed">8639509</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2010 Feb;1800(2):67-79</Citation><ArticleIdList><ArticleId IdType="pubmed">19732809</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurogenet. 2011 Dec;25(4):127-33</Citation><ArticleIdList><ArticleId IdType="pubmed">22091726</ArticleId></ArticleIdList></Reference><Reference><Citation>Dementia. 1994 Jan-Feb;5(1):36-41</Citation><ArticleIdList><ArticleId IdType="pubmed">8156085</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9673-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16769887</ArticleId></ArticleIdList></Reference><Reference><Citation>FEBS Lett. 1999 May 7;450(3):306-11</Citation><ArticleIdList><ArticleId IdType="pubmed">10359094</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nucl Med Mol Imaging. 2003 Aug;30(8):1104-13</Citation><ArticleIdList><ArticleId IdType="pubmed">12764551</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1997 Apr 4;272(14):9316-24</Citation><ArticleIdList><ArticleId IdType="pubmed">9083068</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2004 Oct;6(5):489-95</Citation><ArticleIdList><ArticleId IdType="pubmed">15505370</ArticleId></ArticleIdList></Reference><Reference><Citation>Ageing Res Rev. 2005 May;4(2):240-57</Citation><ArticleIdList><ArticleId IdType="pubmed">15950548</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1998 Jun 18;393(6686):702-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm (Vienna). 2005 Jun;112(6):813-38</Citation><ArticleIdList><ArticleId IdType="pubmed">15517432</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2011 Feb 11;88(2):232-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21295279</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 2006 Nov 1;399(3):427-34</Citation><ArticleIdList><ArticleId IdType="pubmed">16879102</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Proteomics. 2010 Jan;9(1):153-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19692427</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2011 Feb 4;331(6017):571-5</Citation><ArticleIdList><ArticleId IdType="pubmed">21292975</ArticleId></ArticleIdList></Reference><Reference><Citation>Chem Biol. 2010 Sep 24;17(9):949-58</Citation><ArticleIdList><ArticleId IdType="pubmed">20851344</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2006 Oct 18;26(42):10636-45</Citation><ArticleIdList><ArticleId IdType="pubmed">17050703</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Biol Cell. 2000 Dec;11(12):4093-104</Citation><ArticleIdList><ArticleId IdType="pubmed">11102510</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2009 Nov 3;1296:148-63</Citation><ArticleIdList><ArticleId IdType="pubmed">19698704</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2000 Aug;25(4):402-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1996 Oct 10;383(6600):550-3</Citation><ArticleIdList><ArticleId IdType="pubmed">8849730</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2005 Feb 4;280(5):3628-35</Citation><ArticleIdList><ArticleId IdType="pubmed">15525637</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2010 Apr 22;464(7292):1201-4</Citation><ArticleIdList><ArticleId IdType="pubmed">20357768</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22366796</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>135</Volume><Issue>Pt 3</Issue><PubDate><Year>2012</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies.</ArticleTitle><Pagination><StartPage>807</StartPage><EndPage>818</EndPage><MedlinePgn>807-18</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/aws013</ELocationID><Abstract><AbstractText>The microtubule-binding protein, tau, is the major component of neurofibrillary inclusions characteristic of Alzheimer's disease and related neurodegenerative tauopathies. When tau fibrillizes, it undergoes abnormal post-translational modifications resulting in decreased solubility and altered microtubule-stabilizing properties. Recently, we reported that the abnormal acetylation of tau at lysine residue 280 is a novel, pathological post-translational modification. Here, we performed detailed immunohistochemistry to further examine acetylated-tau expression in Alzheimer's disease and other major tauopathies. Immunohistochemistry using a polyclonal antibody specific for acetylated-tau at lysine 280 was conducted on 30 post-mortem central nervous system regions from patients with Alzheimer's disease (10 patients), corticobasal degeneration (5 patients), and progressive supranuclear palsy (5 patients). Acetylated-tau pathology was compared with the sequential emergence of other tau modifications in the Alzheimer's disease hippocampus using monoclonal antibodies to multiple well-characterized tau epitopes. All cases studied showed significant acetylated-tau pathology in a distribution pattern similar to hyperphosphorylated-tau. Acetylated-tau pathology was largely in intracellular, thioflavin-S-positive tau inclusions in Alzheimer's disease, and also thioflavin-S-negative pathology in corticobasal degeneration and progressive supranuclear palsy. Acetylated-tau was present throughout all stages of Alzheimer's disease pathology, but was more prominently associated with pathological tau epitopes in moderate to severe-stage cases. These temporal and morphological immunohistochemical features suggest acetylation of tau at this epitope is preceded by early modifications, including phosphorylation, and followed by later truncation events and cell death in Alzheimer's disease. Acetylation of tau at lysine 280 is a pathological modification that may contribute to tau-mediated neurodegeneration by both augmenting losses of normal tau properties (reduced solubility and microtubule assembly) as well as toxic gains of function (increased tau fibrillization). Thus, inhibiting tau acetylation could be a disease-modifying target for drug discovery target in tauopathies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Irwin</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Centre for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Alzheimer's Disease Core Centre, Institute on Ageing, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Todd J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Grossman</LastName><ForeName>Murray</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Sharon X</ForeName><Initials>SX</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M-Y</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010124-20</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32-AG000255</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000107" MajorTopicYN="N">Acetylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001479" MajorTopicYN="N">Basal Ganglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057165" MajorTopicYN="N">Proteostasis Deficiencies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013494" MajorTopicYN="N">Supranuclear Palsy, Progressive</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014015" MajorTopicYN="N">Tissue Banks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22366796</ArticleId><ArticleId IdType="pmc">PMC3286338</ArticleId><ArticleId IdType="doi">10.1093/brain/aws013</ArticleId><ArticleId IdType="pii">aws013</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arai T, Ikeda K, Akiyama H, Tsuchiya K, Iritani S, Ishiguro K, et al. Different immunoreactivities of the microtubule-binding region of tau and its molecular basis in brains from patients with Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol. 2003;105:489&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">12677450</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 2002;103:26&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">11837744</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry RW, Sweet AP, Clark FA, Lagalwar S, Lapin BR, Wang T, et al. Tau epitope display in progressive supranuclear palsy and corticobasal degeneration. J Neurocytol. 2004;33:287&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">15475684</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernat J, Gustke N, Drewes G, Mandelkow EM, Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron. 1993;11:153&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">8393323</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VM. Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron. 1993;10:1089&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">8318230</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev. 2000;33:95&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">10967355</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmel G, Mager EM, Binder LI, Kuret J. The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology. J Biol Chem. 1996;271:32789&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">8955115</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen TJ, Guo JL, Hurtado DE, Kwong LK, Mills IP, Trojanowski JQ, et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun. 2011;2:252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3120096</ArticleId><ArticleId IdType="pubmed">21427723</ArticleId></ArticleIdList></Reference><Reference><Citation>de Silva R, Lashley T, Gibb G, Hanger D, Hope A, Reid A, et al. Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol Appl Neurobiol. 2003;29:288&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">12787326</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson D. Sporadic Tauopaties: Pick's disease, corticobasal degeneration, progressive supranuclear palsy and argyrophilic grain disease. In: Esiri M, Lee VM-Y, Trojanowski JQ, editors. The neuropathology of dementia. 2 edn. New York, NY: Cambridge University Press; 2004. pp. 227&#x2013;55.</Citation></Reference><Reference><Citation>Espinoza M, de Silva R, Dickson DW, Davies P. Differential incorporation of tau isoforms in Alzheimer's disease. J Alzheimers Dis. 2008;14:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2882247</ArticleId><ArticleId IdType="pubmed">18525123</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman MS, Farmer J, Johnson JK, Clark CM, Arnold SE, Coslett HB, et al. Frontotemporal dementia: clinicopathological correlations. Ann Neurol. 2006;59:952&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2629792</ArticleId><ArticleId IdType="pubmed">16718704</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Sierra F, Ghoshal N, Quinn B, Berry RW, Binder LI. Conformational changes and truncation of tau protein during tangle evolution in Alzheimer's disease. J Alzheimers Dis. 2003;5:65&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">12719624</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Sierra F, Wischik CM, Harrington CR, Luna-Munoz J, Mena R. Accumulation of C-terminally truncated tau protein associated with vulnerability of the perforant pathway in early stages of neurofibrillary pathology in Alzheimer's disease. J Chem Neuroanat. 2001;22:65&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">11470555</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal N, Garcia-Sierra F, Wuu J, Leurgans S, Bennett DA, Berry RW, et al. Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer's disease. Exp Neurol. 2002;177:475&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">12429193</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillozet-Bongaarts AL, Garcia-Sierra F, Reynolds MR, Horowitz PM, Fu Y, Wang T, et al. Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease. Neurobiol Aging. 2005;26:1015&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748781</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann R, Lee VM, Leight S, Varga I, Otvos L., Jr Unique Alzheimer's disease paired helical filament specific epitopes involve double phosphorylation at specific sites. Biochemistry. 1997;36:8114&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">9201960</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Akiyama H, Haga C, Haga S. Evidence that neurofibrillary tangles undergo glial modification. Acta Neuropathol. 1992;85:101&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">1285492</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9:119&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Bowser R, Kazam IG, Davies P. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res. 1997a;48:128&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">9130141</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Lane E, Vincent I, Otvos L, Jr, Hoffmann R, Davies P. A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease. J Neurochem. 1997b;69:2087&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">9349554</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik KS, Orecchio LD, Binder L, Trojanowski JQ, Lee VM, Lee G. Epitopes that span the tau molecule are shared with paired helical filaments. Neuron. 1988;1:817&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">2483104</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauckner J, Frey P, Geula C. Comparative distribution of tau phosphorylated at Ser262 in pre-tangles and tangles. Neurobiol Aging. 2003;24:767&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">12927759</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Balin BJ, Otvos L, Jr, Trojanowski JQ. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science. 1991;251:675&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1899488</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Li B, Tung EJ, Grundke-Iqbal I, Iqbal K, Gong CX. Site-specific effects of tau phosphorylation on its microtubule assembly activity and self-aggregation. Eur J Neurosci. 2007;26:3429&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2262108</ArticleId><ArticleId IdType="pubmed">18052981</ArticleId></ArticleIdList></Reference><Reference><Citation>Luna-Munoz J, Garcia-Sierra F, Falcon V, Menendez I, Chavez-Macias L, Mena R. Regional conformational change involving phosphorylation of tau protein at the Thr231, precedes the structural change detected by Alz-50 antibody in Alzheimer's disease. J Alzheimers Dis. 2005;8:29&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">16155347</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuo ES, Shin RW, Billingsley ML, Van deVoorde A, O'Connor M, Trojanowski JQ, et al. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron. 1994;13:989&#x2013;1002.</Citation><ArticleIdList><ArticleId IdType="pubmed">7946342</ArticleId></ArticleIdList></Reference><Reference><Citation>Mena R, Wischik CM, Novak M, Milstein C, Cuello AC. A progressive deposition of paired helical filaments (PHF) in the brain characterizes the evolution of dementia in Alzheimer's disease. An immunocytochemical study with a monoclonal antibody against the PHF core. J Neuropathol Exp Neurol. 1991;50:474&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">2061714</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercken M, Vandermeeren M, Lubke U, Six J, Boons J, Van de Voorde A, et al. Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes. Acta Neuropathol. 1992;84:265&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">1384266</ArticleId></ArticleIdList></Reference><Reference><Citation>Miki Y, Mori F, Tanji K, Kakita A, Takahashi H, Wakabayashi K. Accumulation of histone deacetylase 6, an aggresome-related protein, is specific to Lewy bodies and glial inclusions. Neuropathology. 2011 Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pubmed">21284752</ArticleId></ArticleIdList></Reference><Reference><Citation>Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron. 2010;67:953&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3035103</ArticleId><ArticleId IdType="pubmed">20869593</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondragon-Rodriguez S, Basurto-Islas G, Santa-Maria I, Mena R, Binder LI, Avila J, et al. Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease. Int J Exp Pathol. 2008;89:81&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2525766</ArticleId><ArticleId IdType="pubmed">18336525</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukaetova-Ladinska EB, Harrington CR, Roth M, Wischik CM. Biochemical and anatomical redistribution of tau protein in Alzheimer's disease. Am J Pathol. 1993;143:565&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887045</ArticleId><ArticleId IdType="pubmed">8342603</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak M, Wischik CM, Edwards P, Pannell R, Milstein C. Characterisation of the first monoclonal antibody against the pronase resistant core of the Alzheimer PHF. Prog Clin Biol Res. 1989;317:755&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">2602435</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak M, Jakes R, Edwards PC, Milstein C, Wischik CM. Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of monoclonal antibodies 423 and 7.51. Proc Natl Acad Sci U S A. 1991;88:5837&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC51973</ArticleId><ArticleId IdType="pubmed">1712107</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak M, Kabat J, Wischik CM. Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament. EMBO J. 1993;12:365&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC413214</ArticleId><ArticleId IdType="pubmed">7679073</ArticleId></ArticleIdList></Reference><Reference><Citation>Otvos L, Jr, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res. 1994;39:669&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">7534834</ArticleId></ArticleIdList></Reference><Reference><Citation>Rankin CA, Sun Q, Gamblin TC. Tau phosphorylation by GSK-3beta promotes tangle-like filament morphology. Mol Neurodegener. 2007;2:12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1936422</ArticleId><ArticleId IdType="pubmed">17598919</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt ML, Gur RE, Gur RC, Trojanowski JQ. Intraneuronal and extracellular neurofibrillary tangles exhibit mutually exclusive cytoskeletal antigens. Ann Neurol. 1988;23:184&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">3377439</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider A, Biernat J, von Bergen M, Mandelkow E, Mandelkow EM. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry. 1999;38:3549&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">10090741</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweers O, Schonbrunn-Hanebeck E, Marx A, Mandelkow E. Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure. J Biol Chem. 1994;269:24290&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">7929085</ArticleId></ArticleIdList></Reference><Reference><Citation>Seubert P, Mawal-Dewan M, Barbour R, Jakes R, Goedert M, Johnson GV, et al. Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau. J Biol Chem. 1995;270:18917&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">7642549</ArticleId></ArticleIdList></Reference><Reference><Citation>Wischik CM, Novak M, Edwards PC, Klug A, Tichelaar W, Crowther RA. Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A. 1988;85:4884&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC280541</ArticleId><ArticleId IdType="pubmed">2455299</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin BL, Pruchnicki A, Dickson DW, Davies P. A neuronal antigen in the brains of Alzheimer patients. Science. 1986;232:648&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">3083509</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie SX, Baek Y, Grossman M, Arnold SE, Karlawish J, Siderowf A, et al. Building an integrated neurodegenerative disease database at an academic health center. Alzheimers Dement. 2011;7:e84&#x2013;e93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3145967</ArticleId><ArticleId IdType="pubmed">21784346</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M. Cellular tau pathology and immunohistochemical study of tau isoforms in sporadic tauopathies. Neuropathology. 2006;26:457&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">17080726</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22378880</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>9</Issue><PubDate><Year>2012</Year><Month>Feb</Month><Day>29</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Astrocyte-originated ATP protects A&#x3b2;(1-42)-induced impairment of synaptic plasticity.</ArticleTitle><Pagination><StartPage>3081</StartPage><EndPage>3087</EndPage><MedlinePgn>3081-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.6357-11.2012</ELocationID><Abstract><AbstractText>Activated microglia and reactive astrocytes are commonly found in and around the senile plaque, which is the central pathological hallmark of Alzheimer's disease. Astrocytes respond to neuronal activity through the release of gliotransmitters such as glutamate, D-serine, and ATP. However, it is largely unknown whether and how gliotransmitters affect neuronal functions. In this study, we explored the effect of a gliotransmitter, ATP, on neurons damaged by &#x3b2;-amyloid peptide (A&#x3b2;). We found that A&#x3b2;(1-42) (A&#x3b2;42) increased the release of ATP in cultures of primary astrocytes and U373 astrocyte cell line. We also found that exogenous ATP protected A&#x3b2;42-mediated reduction in synaptic molecules, such as NMDA receptor 2A and PSD-95, through P2 purinergic receptors and prevented A&#x3b2;42-induced spine reduction in cultured primary hippocampal neurons. Moreover, ATP prevented A&#x3b2;42-induced impairment of long-term potentiation in acute hippocampal slices. Our findings suggest that A&#x3b2;-induced release of gliotransmitter ATP plays a protective role against A&#x3b2;42-mediated disruption of synaptic plasticity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Eun Sun</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biomedical Science, Seoul National University College of Medicine, Seoul, 110-799, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Kyongman</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Hyun Seok</ForeName><Initials>HS</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Joung-Hun</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Mook-Jung</LastName><ForeName>Inhee</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>8L70Q75FXE</RegistryNumber><NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019706" MajorTopicYN="N">Excitatory Postsynaptic Potentials</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008813" MajorTopicYN="N">Mice, Inbred ICR</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>8</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22378880</ArticleId><ArticleId IdType="pmc">PMC6622014</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.6357-11.2012</ArticleId><ArticleId IdType="pii">32/9/3081</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abramov AY, Canevari L, Duchen MR. Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity. J Neurosci. 2003;23:5088&#x2013;5095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741151</ArticleId><ArticleId IdType="pubmed">12832532</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Angulo MC, Kozlov AS, Charpak S, Audinat E. Glutamate released from glial cells synchronizes neuronal activity in the hippocampus. J Neurosci. 2004;24:6920&#x2013;6927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729611</ArticleId><ArticleId IdType="pubmed">15295027</ArticleId></ArticleIdList></Reference><Reference><Citation>Araque A. Astrocytes process synaptic information. Neuron Glia Biol. 2008;4:3&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">19250562</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;&#xef;que JC, Andrade R. PSD-95 regulates synaptic transmission and plasticity in rat cerebral cortex. J Physiol. 2003;546:859&#x2013;867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2342599</ArticleId><ArticleId IdType="pubmed">12563010</ArticleId></ArticleIdList></Reference><Reference><Citation>Benavides A, Pastor D, Santos P, Tranque P, Calvo S. CHOP plays a pivotal role in the astrocyte death induced by oxygen and glucose deprivation. Glia. 2005;52:261&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">16001425</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogdanov Y, Rubino A, Burnstock G. Characterisation of subtypes of the P2X and P2Y families of ATP receptors in the foetal human heart. Life Sci. 1998;62:697&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">9489506</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowser DN, Khakh BS. ATP excites interneurons and astrocytes to increase synaptic inhibition in neuronal networks. J Neurosci. 2004;24:8606&#x2013;8620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729897</ArticleId><ArticleId IdType="pubmed">15456834</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer GJ, Torricelli JR, Evege EK, Price PJ. Optimized survival of hippocampal neurons in B27-supplemented neurobasal, a new serum-free medium combination. J Neurosci Res. 1993;35:567&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pubmed">8377226</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnstock G. The past, present and future of purine nucleotides as signalling molecules. Neuropharmacology. 1997;36:1127&#x2013;1139.</Citation><ArticleIdList><ArticleId IdType="pubmed">9364468</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnstock G, Knight GE. Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol. 2004;240:31&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">15548415</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen QS, Kagan BL, Hirakura Y, Xie CW. Impairment of hippocampal long-term potentiation by Alzheimer amyloid beta-peptides. J Neurosci Res. 2000;60:65&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">10723069</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow SK, Yu D, Macdonald CL, Buibas M, Silva GA. Amyloid beta-peptide directly induces spontaneous calcium transients, delayed intercellular calcium waves and gliosis in rat cortical astrocytes. ASN Neuro. 2010;2:e00026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810812</ArticleId><ArticleId IdType="pubmed">20001968</ArticleId></ArticleIdList></Reference><Reference><Citation>Coco S, Calegari F, Pravettoni E, Pozzi D, Taverna E, Rosa P, Matteoli M, Verderio C. Storage and release of ATP from astrocytes in culture. J Biol Chem. 2003;278:1354&#x2013;1362.</Citation><ArticleIdList><ArticleId IdType="pubmed">12414798</ArticleId></ArticleIdList></Reference><Reference><Citation>Collin C, Miyaguchi K, Segal M. Dendritic spine density and LTP induction in cultured hippocampal slices. J Neurophysiol. 1997;77:1614&#x2013;1623.</Citation><ArticleIdList><ArticleId IdType="pubmed">9084624</ArticleId></ArticleIdList></Reference><Reference><Citation>Collingridge GL, Kehl SJ, McLennan H. Excitatory amino acids in synaptic transmission in the Schaffer collateral-commissural pathway of the rat hippocampus. J Physiol. 1983;334:33&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1197298</ArticleId><ArticleId IdType="pubmed">6306230</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen WK, Suh YH, Anwyl R, Rowan MJ. Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. Neuroreport. 1997;8:3213&#x2013;3217.</Citation><ArticleIdList><ArticleId IdType="pubmed">9351645</ArticleId></ArticleIdList></Reference><Reference><Citation>Dar&#xe9; E, Schulte G, Karovic O, Hammarberg C, Fredholm BB. Modulation of glial cell functions by adenosine receptors. Physiol Behav. 2007;92:15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">17574632</ArticleId></ArticleIdList></Reference><Reference><Citation>Elgersma Y, Silva AJ. Molecular mechanisms of synaptic plasticity and memory. Curr Opin Neurobiol. 1999;9:209&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">10322188</ArticleId></ArticleIdList></Reference><Reference><Citation>Fellin T, Pascual O, Gobbo S, Pozzan T, Haydon PG, Carmignoto G. Neuronal synchrony mediated by astrocytic glutamate through activation of extrasynaptic NMDA receptors. Neuron. 2004;43:729&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pubmed">15339653</ArticleId></ArticleIdList></Reference><Reference><Citation>Geinisman Y. Structural synaptic modifications associated with hippocampal LTP and behavioral learning. Cereb Cortex. 2000;10:952&#x2013;962.</Citation><ArticleIdList><ArticleId IdType="pubmed">11007546</ArticleId></ArticleIdList></Reference><Reference><Citation>Geinisman Y, deToledo-Morrell L, Morrell F. Induction of long-term potentiation is associated with an increase in the number of axospinous synapses with segmented postsynaptic densities. Brain Res. 1991;566:77&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">1814558</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon GR, Baimoukhametova DV, Hewitt SA, Rajapaksha WR, Fisher TE, Bains JS. Norepinephrine triggers release of glial ATP to increase postsynaptic efficacy. Nat Neurosci. 2005;8:1078&#x2013;1086.</Citation><ArticleIdList><ArticleId IdType="pubmed">15995701</ArticleId></ArticleIdList></Reference><Reference><Citation>Halassa MM, Fellin T, Haydon PG. The tripartite synapse: roles for gliotransmission in health and disease. Trends Mol Med. 2007;13:54&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">17207662</ArticleId></ArticleIdList></Reference><Reference><Citation>Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int. 2004;45:583&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">15234100</ArticleId></ArticleIdList></Reference><Reference><Citation>Illes P, Alexandre Ribeiro J. Molecular physiology of P2 receptors in the central nervous system. Eur J Pharmacol. 2004;483:5&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">14709321</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii T, Moriyoshi K, Sugihara H, Sakurada K, Kadotani H, Yokoi M, Akazawa C, Shigemoto R, Mizuno N, Masu M. Molecular characterization of the family of the N-methyl-D-aspartate receptor subunits. J Biol Chem. 1993;268:2836&#x2013;2843.</Citation><ArticleIdList><ArticleId IdType="pubmed">8428958</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanjhan R, Housley GD, Thorne PR, Christie DL, Palmer DJ, Luo L, Ryan AF. Localization of ATP-gated ion channels in cerebellum using P2x2R subunit-specific antisera. Neuroreport. 1996;7:2665&#x2013;2669.</Citation><ArticleIdList><ArticleId IdType="pubmed">8981443</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaster MP, Rosa AO, Rosso MM, Goulart EC, Santos AR, Rodrigues AL. Adenosine administration produces an antidepressant-like effect in mice: evidence for the involvement of A1 and A2A receptors. Neurosci Lett. 2004;355:21&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">14729225</ArticleId></ArticleIdList></Reference><Reference><Citation>Khakh BS. Molecular physiology of P2X receptors and ATP signalling at synapses. Nat Rev Neurosci. 2001;2:165&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">11256077</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimelberg HK, Cai Z, Rastogi P, Charniga CJ, Goderie S, Dave V, Jalonen TO. Transmitter-induced calcium responses differ in astrocytes acutely isolated from rat brain and in culture. J Neurochem. 1997;68:1088&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">9048754</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornau HC, Schenker LT, Kennedy MB, Seeburg PH. Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science. 1995;269:1737&#x2013;1740.</Citation><ArticleIdList><ArticleId IdType="pubmed">7569905</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozlov AS, Angulo MC, Audinat E, Charpak S. Target cell-specific modulation of neuronal activity by astrocytes. Proc Natl Acad Sci U S A. 2006;103:10058&#x2013;10063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1502505</ArticleId><ArticleId IdType="pubmed">16782808</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchibhotla KV, Lattarulo CR, Hyman BT, Bacskai BJ. Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science. 2009;323:1211&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2884172</ArticleId><ArticleId IdType="pubmed">19251629</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Abeta1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambrecht G. Agonists and antagonists acting at P2X receptors: selectivity profiles and functional implications. Naunyn Schmiedebergs Arch Pharmacol. 2000;362:340&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">11111828</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambrecht G, Braun K, Damer M, Ganso M, Hildebrandt C, Ullmann H, Kassack MU, Nickel P. Structure-activity relationships of suramin and pyridoxal-5&#x2032;-phosphate derivatives as P2 receptor antagonists. Curr Pharm Des. 2002;8:2371&#x2013;2399.</Citation><ArticleIdList><ArticleId IdType="pubmed">12369951</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarowski ER, Boucher RC, Harden TK. Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. Mol Pharmacol. 2003;64:785&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pubmed">14500734</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy KD, de Vellis J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol. 1980;85:890&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2111442</ArticleId><ArticleId IdType="pubmed">6248568</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Monyer H, Sprengel R, Schoepfer R, Herb A, Higuchi M, Lomeli H, Burnashev N, Sakmann B, Seeburg PH. Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science. 1992;256:1217&#x2013;1221.</Citation><ArticleIdList><ArticleId IdType="pubmed">1350383</ArticleId></ArticleIdList></Reference><Reference><Citation>Moser MB, Trommald M, Andersen P. An increase in dendritic spine density on hippocampal CA1 pyramidal cells following spatial learning in adult rats suggests the formation of new synapses. Proc Natl Acad Sci U S A. 1994;91:12673&#x2013;12675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45501</ArticleId><ArticleId IdType="pubmed">7809099</ArticleId></ArticleIdList></Reference><Reference><Citation>Mothet JP, Pollegioni L, Ouanounou G, Martineau M, Fossier P, Baux G. Glutamate receptor activation triggers a calcium-dependent and SNARE protein-dependent release of the gliotransmitter D-serine. Proc Natl Acad Sci U S A. 2005;102:5606&#x2013;5611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556243</ArticleId><ArticleId IdType="pubmed">15800046</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science. 1992;258:597&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">1329206</ArticleId></ArticleIdList></Reference><Reference><Citation>Niethammer M, Kim E, Sheng M. Interaction between the C terminus of NMDA receptor subunits and multiple members of the PSD-95 family of membrane-associated guanylate kinases. J Neurosci. 1996;16:2157&#x2013;2163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578538</ArticleId><ArticleId IdType="pubmed">8601796</ArticleId></ArticleIdList></Reference><Reference><Citation>North RA. Molecular physiology of P2X receptors. Physiol Rev. 2002;82:1013&#x2013;1067.</Citation><ArticleIdList><ArticleId IdType="pubmed">12270951</ArticleId></ArticleIdList></Reference><Reference><Citation>Orellana JA, Shoji KF, Abudara V, Ezan P, Amigou E, S&#xe1;ez PJ, Jiang JX, Naus CC, S&#xe1;ez JC, Giaume C. Amyloid beta-induced death in neurons involves glial and neuronal hemichannels. J Neurosci. 2011;31:4962&#x2013;4977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6622997</ArticleId><ArticleId IdType="pubmed">21451035</ArticleId></ArticleIdList></Reference><Reference><Citation>Panatier A, Theodosis DT, Mothet JP, Touquet B, Pollegioni L, Poulain DA, Oliet SH. Glia-derived D-serine controls NMDA receptor activity and synaptic memory. Cell. 2006;125:775&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pubmed">16713567</ArticleId></ArticleIdList></Reference><Reference><Citation>Parpura V, Basarsky TA, Liu F, Jeftinija K, Jeftinija S, Haydon PG. Glutamate-mediated astrocyte-neuron signalling. Nature. 1994;369:744&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">7911978</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascual O, Casper KB, Kubera C, Zhang J, Revilla-Sanchez R, Sul JY, Takano H, Moss SJ, McCarthy K, Haydon PG. Astrocytic purinergic signaling coordinates synaptic networks. Science. 2005;310:113&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">16210541</ArticleId></ArticleIdList></Reference><Reference><Citation>Raff MC, Abney ER, Cohen J, Lindsay R, Noble M. Two types of astrocytes in cultures of developing rat white matter: differences in morphology, surface gangliosides, and growth characteristics. J Neurosci. 1983;3:1289&#x2013;1300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6564607</ArticleId><ArticleId IdType="pubmed">6343560</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 1998;50:413&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">9755289</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson SJ, Ennion SJ, Evans RJ, Edwards FA. Synaptic P2X receptors. Curr Opin Neurobiol. 2001;11:378&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">11399438</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubio ME, Soto F. Distinct localization of P2X receptors at excitatory postsynaptic specializations. J Neurosci. 2001;21:641&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763822</ArticleId><ArticleId IdType="pubmed">11160443</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. The origins of Alzheimer disease: a is for amyloid. JAMA. 2000;283:1615&#x2013;1617.</Citation><ArticleIdList><ArticleId IdType="pubmed">10735401</ArticleId></ArticleIdList></Reference><Reference><Citation>Stix B, Reiser G. Beta-amyloid peptide 25&#x2013;35 regulates basal and hormone-stimulated Ca2+ levels in cultured rat astrocytes. Neurosci Lett. 1998;243:121&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">9535128</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci. 2004;24:3370&#x2013;3378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730034</ArticleId><ArticleId IdType="pubmed">15056716</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegiel J, Wang KC, Tarnawski M, Lach B. Microglia cells are the driving force in fibrillar plaque formation, whereas astrocytes are a leading factor in plague degradation. Acta Neuropathol. 2000;100:356&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">10985692</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xed;sniewski HM, Robe A, Zigman W, Silverman W. Neuropathological diagnosis of Alzheimer disease. J Neuropathol Exp Neurol. 1989;48:606&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">2477504</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Ge W, Chen Y, Zhang Z, Shen W, Wu C, Poo M, Duan S. Contribution of astrocytes to hippocampal long-term potentiation through release of D-serine. Proc Natl Acad Sci U S A. 2003;100:15194&#x2013;15199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC299953</ArticleId><ArticleId IdType="pubmed">14638938</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankner BA. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron. 1996;16:921&#x2013;932.</Citation><ArticleIdList><ArticleId IdType="pubmed">8630250</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang JM, Wang HK, Ye CQ, Ge W, Chen Y, Jiang ZL, Wu CP, Poo MM, Duan S. ATP released by astrocytes mediates glutamatergic activity-dependent heterosynaptic suppression. Neuron. 2003;40:971&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pubmed">14659095</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao D, Watson JB, Xie CW. Amyloid beta prevents activation of calcium/calmodulin-dependent protein kinase II and AMPA receptor phosphorylation during hippocampal long-term potentiation. J Neurophysiol. 2004;92:2853&#x2013;2858.</Citation><ArticleIdList><ArticleId IdType="pubmed">15212428</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann H. Signalling via ATP in the nervous system. Trends Neurosci. 1994;17:420&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">7530880</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22351850</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2012</Year><Month>08</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>6</Issue><PubDate><Year>2012</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>CD4(+) T cells predominate in cerebrospinal fluid and leptomeningeal and parenchymal infiltrates in cerebral amyloid &#x3b2;-related angiitis.</ArticleTitle><Pagination><StartPage>773</StartPage><EndPage>777</EndPage><MedlinePgn>773-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneurol.2011.2441</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In amyloid (A&#x3b2;)-related angiitis (ABRA)of the central nervous system (CNS), cerebral amyloid angiopathy occurs in association with primary vasculitis of small- and medium-sized leptomeningeal and cortical arteries. It has been suggested that ABRA is triggered by vascular deposition of A followed by an A&#x3b2;-directed (auto)immune response.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To provide a detailed description of the cellular composition of the inflammatory infiltrates in the cerebrospinal fluid (CSF) and CNS and their response to immunotherapy in a typical case of ABRA.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Report of a single case.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Neurologic referral center.</AbstractText><AbstractText Label="PATIENT" NlmCategory="METHODS">67-year-old white woman.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Neurologic examination,magnetic resonance imaging, lumbar puncture, flow cytometry,leptomeningeal biopsy, and histopathologic analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In a typical case of ABRA, we demonstrate for the first time the presence of a vast majority of partially activated CD4(+) T cells in CSF and leptomeningeal and parenchymal (peri)vascular infiltrates, which were frequently found in close proximity to major histocompatibility complex (MHC) class II-expressing microglia, epithelioid macrophages, and multinucleated giant cells containing intracellular deposits of A&#x3b2;.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings support the notion of adaptive A&#xdf;-directed autoimmunity as the underlying pathogenic mechanism in ABRA.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Melzer</LastName><ForeName>Nico</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Departments of Neurology, Inflammatory Disorders of the Nervous System, and Neurooncology, University of M&#xfc;nster, Albert-Schweitzer-Campus 1, M&#xfc;nster, 48149 Germany. nico.melzer@ukmuenster.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harder</LastName><ForeName>Anja</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>Catharina C</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>W&#xf6;lfer</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Stummer</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Niederstadt</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Meuth</LastName><ForeName>Sven G</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>Marziniak</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Grauer</LastName><ForeName>Oliver Martin</ForeName><Initials>OM</Initials></Author><Author ValidYN="Y"><LastName>Wiendl</LastName><ForeName>Heinz</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="Y">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020293" MajorTopicYN="Y">Vasculitis, Central Nervous System</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22351850</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2011.2441</ArticleId><ArticleId IdType="pii">archneurol.2011.2441</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22406537</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-8238</ISSN><JournalIssue CitedMedium="Internet"><Volume>122</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Journal of clinical investigation</Title><ISOAbbreviation>J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>A multimodal RAGE-specific inhibitor reduces amyloid &#x3b2;-mediated brain disorder in a mouse model of Alzheimer disease.</ArticleTitle><Pagination><StartPage>1377</StartPage><EndPage>1392</EndPage><MedlinePgn>1377-92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI58642</ELocationID><ELocationID EIdType="pii" ValidYN="Y">58642</ELocationID><Abstract><AbstractText>In Alzheimer disease (AD), amyloid &#x3b2; peptide (A&#x3b2;) accumulates in plaques in the brain. Receptor for advanced glycation end products (RAGE) mediates A&#x3b2;-induced perturbations in cerebral vessels, neurons, and microglia in AD. Here, we identified a high-affinity RAGE-specific inhibitor (FPS-ZM1) that blocked A&#x3b2; binding to the V domain of RAGE and inhibited A&#x3b2;40- and A&#x3b2;42-induced cellular stress in RAGE-expressing cells in vitro and in the mouse brain in vivo. FPS-ZM1 was nontoxic to mice and readily crossed the blood-brain barrier (BBB). In aged APPsw/0 mice overexpressing human A&#x3b2;-precursor protein, a transgenic mouse model of AD with established A&#x3b2; pathology, FPS-ZM1 inhibited RAGE-mediated influx of circulating A&#x3b2;40 and A&#x3b2;42 into the brain. In brain, FPS-ZM1 bound exclusively to RAGE, which inhibited &#x3b2;-secretase activity and A&#x3b2; production and suppressed microglia activation and the neuroinflammatory response. Blockade of RAGE actions at the BBB and in the brain reduced A&#x3b2;40 and A&#x3b2;42 levels in brain markedly and normalized cognitive performance and cerebral blood flow responses in aged APPsw/0 mice. Our data suggest that FPS-ZM1 is a potent multimodal RAGE blocker that effectively controls progression of A&#x3b2;-mediated brain disorder and that it may have the potential to be a disease-modifying agent for AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deane</LastName><ForeName>Rashid</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center of Neurodegenerative and Vascular Brain Disorders, University of Rochester, Rochester, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Itender</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Sagare</LastName><ForeName>Abhay P</ForeName><Initials>AP</Initials></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Nathan T</ForeName><Initials>NT</Initials></Author><Author ValidYN="Y"><LastName>LaRue</LastName><ForeName>Barbra</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Love</LastName><ForeName>Rachal</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>Sheldon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Paquette</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Deane</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Thiyagarajan</LastName><ForeName>Meenakshisundaram</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Zarcone</LastName><ForeName>Troy</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Fritz</LastName><ForeName>Gunter</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>Alan E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Benjamin L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Zlokovic</LastName><ForeName>Berislav V</ForeName><Initials>BV</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG029481</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG023084</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG029481</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Invest</MedlineTA><NlmUniqueID>7802877</NlmUniqueID><ISSNLinking>0021-9738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001549">Benzamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C572629">FPS-ZM1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067759">Receptor for Advanced Glycation End Products</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054852">Small Molecule Libraries</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Drug Discov. 2012 May;11(5):351. doi: 10.1038/nrd3727.</RefSource><PMID Version="1">22685712</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>CNS Neurol Disord Drug Targets. 2012 Aug;11(5):494. doi: 10.2174/187152712801661275.</RefSource><PMID Version="1">22691133</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067759" MajorTopicYN="N">Receptor for Advanced Glycation End Products</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054852" MajorTopicYN="N">Small Molecule Libraries</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>3</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22406537</ArticleId><ArticleId IdType="pmc">PMC3314449</ArticleId><ArticleId IdType="doi">10.1172/JCI58642</ArticleId><ArticleId IdType="pii">58642</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Querfurth HW, LaFerla FM. Alzheimer&#x2019;s disease. . N Engl J Med. 2010;362(4):329&#x2013;344. doi: 10.1056/NEJMra0909142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra0909142</ArticleId><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL. Alzheimer&#x2019;s disease. N Engl J Med. 2004;351(1):56&#x2013;67. doi: 10.1056/NEJMra040223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra040223</ArticleId><ArticleId IdType="pubmed">15229308</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. Neurovascular mechanisms of Alzheimer&#x2019;s neurodegeneration. Trends Neurosci. 2005;28(4):202&#x2013;208. doi: 10.1016/j.tins.2005.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2005.02.001</ArticleId><ArticleId IdType="pubmed">15808355</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Torre JC. Vascular risk factor detection and control may prevent Alzheimer&#x2019;s disease. Ageing Res Rev. 2010;9(3):218&#x2013;225. doi: 10.1016/j.arr.2010.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2010.04.002</ArticleId><ArticleId IdType="pubmed">20385255</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchesi VT. Alzheimer&#x2019;s dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. FASEB J. 2011;25(1):5&#x2013;13. doi: 10.1096/fj.11-0102ufm.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.11-0102ufm</ArticleId><ArticleId IdType="pubmed">21205781</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer&#x2019;s disease and other disorders. Nat Rev Neurosci. 2011;12(12):723&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4036520</ArticleId><ArticleId IdType="pubmed">22048062</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron. 2010;68(3):409&#x2013;427. doi: 10.1016/j.neuron.2010.09.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.09.043</ArticleId><ArticleId IdType="pmc">PMC3056408</ArticleId><ArticleId IdType="pubmed">21040844</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 2004;43(3):333&#x2013;344. doi: 10.1016/j.neuron.2004.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2004.07.017</ArticleId><ArticleId IdType="pubmed">15294142</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. 2003;9(7):907&#x2013;913. doi: 10.1038/nm890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm890</ArticleId><ArticleId IdType="pubmed">12808450</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS, et al. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science. 2010;330(6006):980&#x2013;982. doi: 10.1126/science.1194516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1194516</ArticleId><ArticleId IdType="pmc">PMC3233904</ArticleId><ArticleId IdType="pubmed">20966215</ArticleId></ArticleIdList></Reference><Reference><Citation>Atwood CS, Bishop GM, Perry G, Smith MA. Amyloid&#x2013;beta: a vascular sealant that protects against hemorrhage? J Neurosci Res. 2002;70(3):356. doi: 10.1002/jnr.10388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.10388</ArticleId><ArticleId IdType="pubmed">12391596</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar-Singh S, et al. Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer&#x2019;s disease are centered on vessel walls. Am J Pathol. 2005;167(2):527&#x2013;543. doi: 10.1016/S0002-9440(10)62995-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)62995-1</ArticleId><ArticleId IdType="pmc">PMC1603563</ArticleId><ArticleId IdType="pubmed">16049337</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen KM, Kocsi Z, Stone J. Microvascular pathology in the aging human brain: evidence that senile plaques are sites of microhaemorrhages. Neurobiol Aging. 2006;27(12):1786&#x2013;1796. doi: 10.1016/j.neurobiolaging.2005.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2005.10.016</ArticleId><ArticleId IdType="pubmed">17063559</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer&#x2019;s disease. Brain Pathol. 2008;18(2):253&#x2013;266. doi: 10.1111/j.1750-3639.2008.00133.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2008.00133.x</ArticleId><ArticleId IdType="pmc">PMC8095597</ArticleId><ArticleId IdType="pubmed">18363936</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, et al. SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat Cell Biol. 2009;11(2):143&#x2013;153. doi: 10.1038/ncb1819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1819</ArticleId><ArticleId IdType="pmc">PMC2654279</ArticleId><ArticleId IdType="pubmed">19098903</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan SD, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer&#x2019;s disease. Nature. 1996;382(6593):685&#x2013;691. doi: 10.1038/382685a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/382685a0</ArticleId><ArticleId IdType="pubmed">8751438</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416(6880):535&#x2013;539. doi: 10.1038/416535a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/416535a</ArticleId><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Takuma K, et al. RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction. Proc Natl Acad Sci U S A. 2009;106(47):20021&#x2013;20026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785285</ArticleId><ArticleId IdType="pubmed">19901339</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science. 2006;313(5794):1781&#x2013;1784. doi: 10.1126/science.1131864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1131864</ArticleId><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer&#x2019;s disease. Nature. 2008;451(7179):720&#x2013;724. doi: 10.1038/nature06616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06616</ArticleId><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB.Prion Biology and Diseases . Vol. 41. Woodbury, New York, USA: Cold Spring Harbor Laboratory Press; 2004.</Citation></Reference><Reference><Citation>Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57(2):178&#x2013;201. doi: 10.1016/j.neuron.2008.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2008.01.003</ArticleId><ArticleId IdType="pubmed">18215617</ArticleId></ArticleIdList></Reference><Reference><Citation>Neeper M, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267(21):14998&#x2013;15004.</Citation><ArticleIdList><ArticleId IdType="pubmed">1378843</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res. 2010;106(5):842&#x2013;853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2862596</ArticleId><ArticleId IdType="pubmed">20299674</ArticleId></ArticleIdList></Reference><Reference><Citation>Park H, Boyington JC. The 1.5 A crystal structure of human receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique features determining ligand binding. J Biol Chem. 2010;285(52):40762&#x2013;40770. doi: 10.1074/jbc.M110.169276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.169276</ArticleId><ArticleId IdType="pmc">PMC3003376</ArticleId><ArticleId IdType="pubmed">20943659</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch M, et al. Structural basis for ligand recognition and activation of RAGE. Structure. 2010;18(10):1342&#x2013;1352. doi: 10.1016/j.str.2010.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2010.05.017</ArticleId><ArticleId IdType="pmc">PMC4250094</ArticleId><ArticleId IdType="pubmed">20947022</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucciarelli LG, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation. 2002;106(22):2827&#x2013;2835. doi: 10.1161/01.CIR.0000039325.03698.36.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000039325.03698.36</ArticleId><ArticleId IdType="pubmed">12451010</ArticleId></ArticleIdList></Reference><Reference><Citation>Bierhaus A, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med. 2005;83(11):876&#x2013;886. doi: 10.1007/s00109-005-0688-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-005-0688-7</ArticleId><ArticleId IdType="pubmed">16133426</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt AM, Sahagan B, Nelson RB, Selmer J, Rothlein R, Bell JM. The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer&#x2019;s disease. Curr Opin Investig Drugs. 2009;10(7):672&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">19579173</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler E, Galichet A, Weibel M, Leclerc E, Heizmann CW. Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity. . J Neurosci. 2008;28(20):5149&#x2013;5158. doi: 10.1523/JNEUROSCI.4878-07.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4878-07.2008</ArticleId><ArticleId IdType="pmc">PMC6670634</ArticleId><ArticleId IdType="pubmed">18480271</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackic JB, et al. Human blood-brain barrier receptors for Alzheimer&#x2019;s amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J Clin Invest. 1998;102(4):734&#x2013;743. doi: 10.1172/JCI2029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI2029</ArticleId><ArticleId IdType="pmc">PMC508936</ArticleId><ArticleId IdType="pubmed">9710442</ArticleId></ArticleIdList></Reference><Reference><Citation>Giri R, et al. beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. Am J Physiol Cell Physiol. 2000;279(6):C1772&#x2013;C1781.</Citation><ArticleIdList><ArticleId IdType="pubmed">11078691</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan SD, et al. Non-enzymatically glycated tau in Alzheimer&#x2019;s disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat Med. 1995;1(7):693&#x2013;699. doi: 10.1038/nm0795-693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0795-693</ArticleId><ArticleId IdType="pubmed">7585153</ArticleId></ArticleIdList></Reference><Reference><Citation> 
RI: RAGE inhibitor study. Alzheimer&#x2019;s Disease Education and Referral Center. NIH National Institute on Aging Web site. 
http://www.alzheimers.org/clinicaltrials/fullrec.asp?PrimaryKey=287
. Accessed February 14, 2012.
</Citation></Reference><Reference><Citation>Hsiao K, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274(5284):99&#x2013;102. doi: 10.1126/science.274.5284.99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.274.5284.99</ArticleId><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Waterbeemd H, Camenisch G, Folkers G, Chretien JR, Raevsky OA. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target. 1998;6(2):151&#x2013;165. doi: 10.3109/10611869808997889.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10611869808997889</ArticleId><ArticleId IdType="pubmed">9886238</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews PR, Craik DJ, Martin JL. Functional group contributions to drug-receptor interactions. J Med Chem. 1984;27(12):1648&#x2013;1657. doi: 10.1021/jm00378a021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm00378a021</ArticleId><ArticleId IdType="pubmed">6094812</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris D, et al. Inhibition of Abeta production by NF-kappaB inhibitors. Neurosci Lett. 2007;415(1):11&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">17223266</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourne KZ, Ferrari DC, Lange-Dohna C, Rossner S, Wood TG, Perez-Polo JR. Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides. J Neurosci Res. 2007;85(6):1194&#x2013;1204. doi: 10.1002/jnr.21252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.21252</ArticleId><ArticleId IdType="pubmed">17385716</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglielmotto M, et al. AGEs/RAGE complex upregulates BACE1 via NF-kappaB pathway activation. Neurobiol Aging. 2012;33(1):196.e13&#x2013;e27. doi: 10.1016/j.neurobiolaging.2010.05.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.05.026</ArticleId><ArticleId IdType="pubmed">20638753</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer&#x2019;s disease. Nat Rev Neurosci. 2007;8(7):499&#x2013;509. doi: 10.1038/nrn2168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2168</ArticleId><ArticleId IdType="pubmed">17551515</ArticleId></ArticleIdList></Reference><Reference><Citation>LaRue B, et al. Method for measurement of the blood&#x2013;brain barrier permeability in the perfused mouse brain: application to amyloid&#x2013;beta peptide in wild type and Alzheimer&#x2019;s Tg2576 mice. J Neurosci Methods. 2004;138(1&#x2013;2):233&#x2013;242. doi: 10.1016/j.jneumeth.2004.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2004.04.026</ArticleId><ArticleId IdType="pubmed">15325132</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer M, et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science. 2002;298(5597):1379. doi: 10.1126/science.1078259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1078259</ArticleId><ArticleId IdType="pubmed">12434053</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung S, et al. Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer&#x2019;s disease. Am J Pathol. 2004;165(6):2197&#x2013;2206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618710</ArticleId><ArticleId IdType="pubmed">15579461</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, et al. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer&#x2019;s disease: identification of a cellular activation mechanism. Exp Neurol. 2001;171(1):29&#x2013;45. doi: 10.1006/exnr.2001.7732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.2001.7732</ArticleId><ArticleId IdType="pubmed">11520119</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann GE, Zlokovic BV, Yudilevich DL. Evidence for a lactate transport system in the sarcolemmal membrane of the perfused rabbit heart: kinetics of unidirectional influx, carrier specificity and effects of glucagon. Biochim Biophys Acta. 1985;819(2):241&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">4041458</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV, Apuzzo ML. Cellular and molecular neurosurgery: pathways from concept to reality--part I: target disorders and concept approaches to gene therapy of the central nervous system. Neurosurgery. 1997;40(4):789&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">9092853</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV, Begley DJ, Chain-Eliash DG. Blood-brain barrier permeability to leucine-enkephalin, D-alanine2-D-leucine5-enkephalin and their N-terminal amino acid (tyrosine). Brain Res. 1985;336(1):125&#x2013;132. doi: 10.1016/0006-8993(85)90423-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(85)90423-8</ArticleId><ArticleId IdType="pubmed">3891014</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV, Segal MB, Begley DJ, Davson H, Rakic L. Permeability of the blood&#x2013;cerebrospinal fluid and blood&#x2013;brain barriers to thyrotropin&#x2013;releasing hormone. Brain Res. 1985;358(1&#x2013;2):191&#x2013;199. doi: 10.1016/0006-8993(85)90963-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(85)90963-1</ArticleId><ArticleId IdType="pubmed">3935272</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV, Mackic JB, Djuricic B, Davson H. Kinetic analysis of leucine-enkephalin cellular uptake at the luminal side of the blood-brain barrier of an in situ perfused guinea-pig brain. J Neurochem. 1989;53(5):1333&#x2013;1340. doi: 10.1111/j.1471-4159.1989.tb08522.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.1989.tb08522.x</ArticleId><ArticleId IdType="pubmed">2795003</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV, Hyman S, McComb JG, Lipovac MN, Tang G, Davson H. Kinetics of arginine-vasopressin uptake at the blood-brain barrier. Biochim Biophys Acta. 1990;1025(2):191&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">2364078</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutcliffe JG, Hedlund PB, Thomas EA, Bloom FE, Hilbush BS. Peripheral reduction of beta-amyloid is sufficient to reduce brain beta-amyloid: Implications for Alzheimer&#x2019;s disease. J Neurosci Res. 2011;89(6):808&#x2013;814. doi: 10.1002/jnr.22603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22603</ArticleId><ArticleId IdType="pubmed">21374699</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackic JB, et al. Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer&#x2019;s disease lesions. Vascul Pharmacol. 2002;38(6):303&#x2013;313. doi: 10.1016/S1537-1891(02)00198-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1537-1891(02)00198-2</ArticleId><ArticleId IdType="pubmed">12529925</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalea AZ, Reiniger N, Yang H, Arriero M, Schmidt AM, Hudson BI. Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene. FASEB J. 2009;23(6):1766&#x2013;1774. doi: 10.1096/fj.08-117739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.08-117739</ArticleId><ArticleId IdType="pmc">PMC2698653</ArticleId><ArticleId IdType="pubmed">19164451</ArticleId></ArticleIdList></Reference><Reference><Citation>Arancio O, et al. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J. 2004;23(20):4096&#x2013;4105. doi: 10.1038/sj.emboj.7600415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7600415</ArticleId><ArticleId IdType="pmc">PMC524347</ArticleId><ArticleId IdType="pubmed">15457210</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med. 2007;13(4):432&#x2013;438. doi: 10.1038/nm1555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1555</ArticleId><ArticleId IdType="pubmed">17351623</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer&#x2019;s disease mice. J Neurosci. 2008;28(33):8354&#x2013;8360. doi: 10.1523/JNEUROSCI.0616-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0616-08.2008</ArticleId><ArticleId IdType="pmc">PMC2597474</ArticleId><ArticleId IdType="pubmed">18701698</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelsins MC, et al. Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am J Pathol. 2008;173(6):1768&#x2013;1782. doi: 10.2353/ajpath.2008.080528.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2008.080528</ArticleId><ArticleId IdType="pmc">PMC2626388</ArticleId><ArticleId IdType="pubmed">18974297</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata M, et al. Clearance of Alzheimer&#x2019;s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest. 2000;106(12):1489&#x2013;1499. doi: 10.1172/JCI10498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI10498</ArticleId><ArticleId IdType="pmc">PMC387254</ArticleId><ArticleId IdType="pubmed">11120756</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300(5618):486&#x2013;489. doi: 10.1126/science.1079469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1079469</ArticleId><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno K, Pettigrew KD, Rapoport SI. Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am J Physiol. 1978;235(3):H299&#x2013;H307.</Citation><ArticleIdList><ArticleId IdType="pubmed">696840</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagare A, et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med. 2007;13(9):1029&#x2013;1031. doi: 10.1038/nm1635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1635</ArticleId><ArticleId IdType="pmc">PMC2936449</ArticleId><ArticleId IdType="pubmed">17694066</ArticleId></ArticleIdList></Reference><Reference><Citation>Mumby DG, Gaskin S, Glenn MJ, Schramek TE, Lehmann H. Hippocampal damage and exploratory preferences in rats: memory for objects, places, and contexts. Learn Mem. 2002;9(2):49&#x2013;57. doi: 10.1101/lm.41302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/lm.41302</ArticleId><ArticleId IdType="pmc">PMC155935</ArticleId><ArticleId IdType="pubmed">11992015</ArticleId></ArticleIdList></Reference><Reference><Citation>Winters BD, Bussey TJ. Transient inactivation of perirhinal cortex disrupts encoding, retrieval, and consolidation of object recognition memory. J Neurosci. 2005;25(1):52&#x2013;61. doi: 10.1523/JNEUROSCI.3827-04.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3827-04.2005</ArticleId><ArticleId IdType="pmc">PMC6725205</ArticleId><ArticleId IdType="pubmed">15634766</ArticleId></ArticleIdList></Reference><Reference><Citation>Shichinohe H, et al. Neuroprotective effects of the free radical scavenger Edaravone (MCI-186) in mice permanent focal brain ischemia. Brain Res. 2004;1029(2):200&#x2013;206. doi: 10.1016/j.brainres.2004.09.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2004.09.055</ArticleId><ArticleId IdType="pubmed">15542075</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanz TA, Hosley JD, Adams WJ, Merchant KM. Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo -6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575). J Pharmacol Exp Ther. 2004;309(1):49&#x2013;55. doi: 10.1124/jpet.103.060715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.103.060715</ArticleId><ArticleId IdType="pubmed">14718585</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22491322</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><PubDate><Year>2012</Year><Month>Apr</Month><Day>10</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Staged decline of neuronal function in vivo in an animal model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>774</StartPage><MedlinePgn>774</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms1783</ELocationID><Abstract><AbstractText>The accumulation of amyloid-&#x3b2; in the brain is an essential feature of Alzheimer's disease. However, the impact of amyloid-&#x3b2;-accumulation on neuronal dysfunction on the single cell level in vivo is poorly understood. Here we investigate the progression of amyloid-&#x3b2; load in relation to neuronal dysfunction in the visual system of the APP23&#xd7;PS45 mouse model of Alzheimer's disease. Using in vivo two-photon calcium imaging in the visual cortex, we demonstrate that a progressive deterioration of neuronal tuning for the orientation of visual stimuli occurs in parallel with the age-dependent increase of the amyloid-&#x3b2; load. Importantly, we find this deterioration only in neurons that are hyperactive during spontaneous activity. This impairment of visual cortical circuit function also correlates with pronounced deficits in visual-pattern discrimination. Together, our results identify distinct stages of decline in sensory cortical performance in vivo as a function of the increased amyloid-&#x3b2;-load.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grienberger</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Center for Integrated Protein Science, Technical University Munich, Biedersteinerstr. 29, 80802 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rochefort</LastName><ForeName>Nathalie L</ForeName><Initials>NL</Initials></Author><Author ValidYN="Y"><LastName>Adelsberger</LastName><ForeName>Helmuth</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Henning</LastName><ForeName>Horst A</ForeName><Initials>HA</Initials></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Daniel N</ForeName><Initials>DN</Initials></Author><Author ValidYN="Y"><LastName>Reichwald</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Konnerth</LastName><ForeName>Arthur</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>04</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22491322</ArticleId><ArticleId IdType="pmc">PMC3337977</ArticleId><ArticleId IdType="doi">10.1038/ncomms1783</ArticleId><ArticleId IdType="pii">ncomms1783</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blennow K., de Leon M. J. &amp; Zetterberg H. Alzheimer's disease. Lancet 368, 387&#x2013;403 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>Nestor P. J., Scheltens P. &amp; Hodges J. R. Advances in the early detection of Alzheimer's disease. Nat. Med. 10(Suppl), S34&#x2013;S41 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15298007</ArticleId></ArticleIdList></Reference><Reference><Citation>Djordjevic J., Jones-Gotman M., De Sousa K. &amp; Chertkow H. Olfaction in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging 29, 693&#x2013;706 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">17207898</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesholam R. I., Moberg P. J., Mahr R. N. &amp; Doty R. L. Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer's and Parkinson's diseases. Arch. Neurol. 55, 84&#x2013;90 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9443714</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand D. P. et al.. Olfactory deficits in patients with mild cognitive impairment predict Alzheimer's disease at follow-up. Am. J. Psychiatry 157, 1399&#x2013;1405 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10964854</ArticleId></ArticleIdList></Reference><Reference><Citation>Bublak P. et al.. Staged decline of visual processing capacity in mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging 32, 1219&#x2013;1230 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">19713001</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin-Golomb A. et al.. Visual dysfunction in Alzheimer's disease: relation to normal aging. Ann. Neurol 29, 41&#x2013;52 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1996878</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez R., Kavcic V. &amp; Duffy C. J. Neurophysiologic analyses of low- and high-level visual processing in Alzheimer disease. Neurology 68, 2066&#x2013;2076 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17562827</ArticleId></ArticleIdList></Reference><Reference><Citation>Trick G. L. &amp; Silverman S. E. Visual sensitivity to motion: age-related changes and deficits in senile dementia of the Alzheimer type. Neurology 41, 1437&#x2013;1440 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1891094</ArticleId></ArticleIdList></Reference><Reference><Citation>Glabe C. G. Structural classification of toxic amyloid oligomers. J. Biol. Chem. 283, 29639&#x2013;29643 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2573087</ArticleId><ArticleId IdType="pubmed">18723507</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartley D. M. et al.. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19, 8876&#x2013;8884 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782787</ArticleId><ArticleId IdType="pubmed">10516307</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H. et al.. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52, 831&#x2013;843 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar G. M. et al.. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27, 2866&#x2013;2875 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F. et al.. APP processing and synaptic function. Neuron 37, 925&#x2013;937 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman P. F. et al.. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 2, 271&#x2013;276 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10195221</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W. et al.. Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat. Neurosci. 13, 190&#x2013;196 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3310198</ArticleId><ArticleId IdType="pubmed">20037574</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S. et al.. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62, 788&#x2013;801 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702854</ArticleId><ArticleId IdType="pubmed">19555648</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar G. M. et al.. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837&#x2013;842 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles R. B. et al.. Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer's disease. Proc. Natl Acad. Sci. USA 96, 5274&#x2013;5279 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21854</ArticleId><ArticleId IdType="pubmed">10220456</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M. et al.. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 451, 720&#x2013;724 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchibhotla K. V. et al.. Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron 59, 214&#x2013;225 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2578820</ArticleId><ArticleId IdType="pubmed">18667150</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern E. A. et al.. Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. J. Neurosci. 24, 4535&#x2013;4540 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729398</ArticleId><ArticleId IdType="pubmed">15140924</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop J. J. &amp; Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 13, 812&#x2013;818 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072750</ArticleId><ArticleId IdType="pubmed">20581818</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop J. J. et al.. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55, 697&#x2013;711 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesson D. W. et al.. Sensory network dysfunction, behavioral impairments, and their reversibility in an Alzheimer's beta-amyloidosis mouse model. J. Neurosci. 31, 15962&#x2013;15971 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3417321</ArticleId><ArticleId IdType="pubmed">22049439</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche M. A. et al.. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science 321, 1686&#x2013;1689 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18802001</ArticleId></ArticleIdList></Reference><Reference><Citation>Rochefort N. L. et al.. Sparsification of neuronal activity in the visual cortex at eye-opening. Proc. Natl Acad. Sci. USA 106, 15049&#x2013;15054 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2736444</ArticleId><ArticleId IdType="pubmed">19706480</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohki K., Chung S., Ch'ng Y. H., Kara P. &amp; Reid R. C. Functional imaging with cellular resolution reveals precise micro-architecture in visual cortex. Nature 433, 597&#x2013;603 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15660108</ArticleId></ArticleIdList></Reference><Reference><Citation>Stosiek C., Garaschuk O., Holthoff K. &amp; Konnerth A. In vivo two-photon calcium imaging of neuronal networks. Proc. Natl Acad. Sci. USA 100, 7319&#x2013;7324 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165873</ArticleId><ArticleId IdType="pubmed">12777621</ArticleId></ArticleIdList></Reference><Reference><Citation>Rochefort N. L. et al.. Development of direction selectivity in mouse cortical neurons. Neuron 71, 425&#x2013;432 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21835340</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffie R. M. et al.. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl Acad. Sci. USA 106, 4012&#x2013;4017 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656196</ArticleId><ArticleId IdType="pubmed">19228947</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C. et al.. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl Acad. Sci. USA 94, 13287&#x2013;13292 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzig M. C. et al.. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat. Neurosci. 7, 954&#x2013;960 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15311281</ArticleId></ArticleIdList></Reference><Reference><Citation>Rochefort N. L., Jia H. &amp; Konnerth A. Calcium imaging in the living brain: prospects for molecular medicine. Trends Mol. Med. 14, 389&#x2013;399 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18701348</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr J. N., Greenberg D. &amp; Helmchen F. Imaging input and output of neocortical networks in vivo. Proc. Natl Acad. Sci. USA 102, 14063&#x2013;14068 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201343</ArticleId><ArticleId IdType="pubmed">16157876</ArticleId></ArticleIdList></Reference><Reference><Citation>Niell C. M. &amp; Stryker M. P. Highly selective receptive fields in mouse visual cortex. J. Neurosci. 28, 7520&#x2013;7536 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3040721</ArticleId><ArticleId IdType="pubmed">18650330</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong A. A. &amp; Brown R. E. Age-related changes in visual acuity, learning and memory in C57BL/6J and DBA/2J mice. Neurobiol. Aging 28, 1577&#x2013;1593 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17010477</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusky G. T., West P. W. &amp; Douglas R. M. Behavioral assessment of visual acuity in mice and rats. Vision Res. 40, 2201&#x2013;2209 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10878281</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusky G. T., Alam N. M., Beekman S. &amp; Douglas R. M. Rapid quantification of adult and developing mouse spatial vision using a virtual optomotor system. Invest. Ophthalmol. Vis. Sci. 45, 4611&#x2013;4616 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15557474</ArticleId></ArticleIdList></Reference><Reference><Citation>Douglas R. M. et al.. Independent visual threshold measurements in the two eyes of freely moving rats and mice using a virtual-reality optokinetic system. Vis. Neurosci. 22, 677&#x2013;684 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16332278</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaung C., Arnold K., Jackson I. J. &amp; Coffey P. J. Presence of visual head tracking differentiates normal sighted from retinal degenerate mice. Neurosci. Lett. 325, 21&#x2013;24 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12023058</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchibhotla K. V., Lattarulo C. R., Hyman B. T. &amp; Bacskai B. J. Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science 323, 1211&#x2013;1215 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2884172</ArticleId><ArticleId IdType="pubmed">19251629</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires T. L. et al.. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J. Neurosci. 25, 7278&#x2013;7287 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820616</ArticleId><ArticleId IdType="pubmed">16079410</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop J. J., Chin J. &amp; Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature 443, 768&#x2013;773 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17051202</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashe K. H. &amp; Zahs K. R. Probing the biology of Alzheimer's disease in mice. Neuron 66, 631&#x2013;645 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2956420</ArticleId><ArticleId IdType="pubmed">20547123</ArticleId></ArticleIdList></Reference><Reference><Citation>Price J. L. &amp; Morris J. C. Tangles and plaques in nondemented aging and 'preclinical' Alzheimer's disease. Ann. Neurol. 45, 358&#x2013;368 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Marin V. et al.. Diminished perisomatic GABAergic terminals on cortical neurons adjacent to amyloid plaques. Front. Neuroanat. 3, 28 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2784678</ArticleId><ArticleId IdType="pubmed">19949482</ArticleId></ArticleIdList></Reference><Reference><Citation>Kharatishvili I. &amp; Pitkanen A. Posttraumatic epilepsy. Curr. Opin. Neurol. 23, 183&#x2013;188 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20125011</ArticleId></ArticleIdList></Reference><Reference><Citation>Eysel U. T. &amp; Schmidt-Kastner R. Neuronal dysfunction at the border of focal lesions in cat visual cortex. Neurosci. Lett. 131, 45&#x2013;48 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1791978</ArticleId></ArticleIdList></Reference><Reference><Citation>Eysel U. T. &amp; Schweigart G. Increased receptive field size in the surround of chronic lesions in the adult cat visual cortex. Cereb. Cortex 9, 101&#x2013;109 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10220223</ArticleId></ArticleIdList></Reference><Reference><Citation>Eysel U. T. et al.. Reorganization in the visual cortex after retinal and cortical damage. Restor. Neurol. Neurosci. 15, 153&#x2013;164 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">12671230</ArticleId></ArticleIdList></Reference><Reference><Citation>Winship I. R. &amp; Murphy T. H. In vivo calcium imaging reveals functional rewiring of single somatosensory neurons after stroke. J. Neurosci. 28, 6592&#x2013;6606 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670410</ArticleId><ArticleId IdType="pubmed">18579732</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy T. H. &amp; Corbett D. Plasticity during stroke recovery: from synapse to behaviour. Nat. Rev. Neurosci. 10, 861&#x2013;872 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19888284</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince D. A. et al.. Epilepsy following cortical injury: cellular and molecular mechanisms as targets for potential prophylaxis. Epilepsia 50(Suppl 2), 30&#x2013;40 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2710960</ArticleId><ArticleId IdType="pubmed">19187292</ArticleId></ArticleIdList></Reference><Reference><Citation>Garaschuk O., Milos R. I. &amp; Konnerth A. Targeted bulk-loading of fluorescent indicators for two-photon brain imaging in vivo. Nat. Protoc. 1, 380&#x2013;386 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17406260</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G. &amp; Franklin K. B. J. The Mouse Brain in Stereotaxic Coordinates 157: (Academic Press, San Diego, California, 2001).</Citation></Reference><Reference><Citation>Sanderson M. J. &amp; Parker I. Video-rate confocal microscopy. Methods Enzymol. 360, 447&#x2013;481 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12622163</ArticleId></ArticleIdList></Reference><Reference><Citation>Garaschuk O. et al.. Optical monitoring of brain function in vivo: from neurons to networks. Pfl&#xfc;gers Arch. 453, 385&#x2013;396 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17047983</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A., Kirchhoff F., Kerr J. N. &amp; Helmchen F. Sulforhodamine 101 as a specific marker of astroglia in the neocortex in vivo. Nat. Methods 1, 31&#x2013;37 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15782150</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun A., Nguyen X. V. &amp; Bing G. Comparative analysis of an improved thioflavin-s stain, Gallyas silver stain, and immunohistochemistry for neurofibrillary tangle demonstration on the same sections. J. Histochem. Cytochem. 50, 463&#x2013;472 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11897799</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22517108</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>17</Issue><PubDate><Year>2012</Year><Month>Apr</Month><Day>24</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Total daily physical activity and the risk of AD and cognitive decline in older adults.</ArticleTitle><Pagination><StartPage>1323</StartPage><EndPage>1329</EndPage><MedlinePgn>1323-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0b013e3182535d35</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Studies examining the link between objective measures of total daily physical activity and incident Alzheimer disease (AD) are lacking. We tested the hypothesis that an objective measure of total daily physical activity predicts incident AD and cognitive decline.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Total daily exercise and nonexercise physical activity was measured continuously for up to 10 days with actigraphy (Actical&#xae;; Philips Healthcare, Bend, OR) from 716 older individuals without dementia participating in the Rush Memory and Aging Project, a prospective, observational cohort study. All participants underwent structured annual clinical examination including a battery of 19 cognitive tests.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During an average follow-up of about 4 years, 71 subjects developed clinical AD. In a Cox proportional hazards model adjusting for age, sex, and education, total daily physical activity was associated with incident AD (hazard ratio = 0.477; 95% confidence interval 0.273-0.832). The association remained after adjusting for self-report physical, social, and cognitive activities, as well as current level of motor function, depressive symptoms, chronic health conditions, and APOE allele status. In a linear mixed-effect model, the level of total daily physical activity was associated with the rate of global cognitive decline (estimate 0.033, SE 0.012, p = 0.007).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A higher level of total daily physical activity is associated with a reduced risk of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Buchman</LastName><ForeName>A S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Rush Alzheimer&#x2019;s Disease Center, Rush University Medical Center, Chicago, IL, USA. Aron_S_Buchman@rush.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyle</LastName><ForeName>P A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>R C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>R S</ForeName><Initials>RS</Initials></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>D A</ForeName><Initials>DA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG024480</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG17917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG34374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG24480</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>04</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2012 Apr 24;78(17):1290-1. doi: 10.1212/WNL.0b013e3182535f0e.</RefSource><PMID Version="1">22517099</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2012 Apr 24;78(17):e110-2. doi: 10.1212/WNL.0b013e318255e0c9.</RefSource><PMID Version="1">22529211</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2012 Sep 4;79(10):1071; author reply 1071. doi: 10.1212/WNL.0b013e31826bd5cf.</RefSource><PMID Version="1">22946116</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015984" MajorTopicYN="N">Causality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="N">Exercise</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008019" MajorTopicYN="N">Life Style</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="Y">Motor Activity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017678" MajorTopicYN="N">Sex Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>4</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22517108</ArticleId><ArticleId IdType="pmc">PMC3335448</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e3182535d35</ArticleId><ArticleId IdType="pii">WNL.0b013e3182535d35</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Warburton DE, Nicol CW, Bredin SS. Health benefits of physical activity: the evidence. Can Med Assoc J 2006; 174: 801&#x2013; 809</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1402378</ArticleId><ArticleId IdType="pubmed">16534088</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese J, Lipton RB, Katz MJ, et al. Leisure activities and the risk of dementia in the elderly. N Engl J Med 2003; 348: 2508&#x2013; 2516</Citation><ArticleIdList><ArticleId IdType="pubmed">12815136</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson EB, Wang L, Bowen JD, et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med 2006; 144: 73&#x2013; 81</Citation><ArticleIdList><ArticleId IdType="pubmed">16418406</ArticleId></ArticleIdList></Reference><Reference><Citation>Daviglus ML, Plassman BL, Pirzada A, et al. Risk factors and preventive interventions for Alzheimer disease: state of the science. Arch Neurol Epub 2011</Citation><ArticleIdList><ArticleId IdType="pubmed">21555601</ArticleId></ArticleIdList></Reference><Reference><Citation>Plassman BL, Williams JW, Burke JR, Holsinger T, Benjamin S. Systematic review: factors associated with risk for and possible prevention of cognitive decline in later life. Ann Intern Med 2010; 153: 182&#x2013; 193</Citation><ArticleIdList><ArticleId IdType="pubmed">20547887</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris AM, Lanningham-Foster LM, McCrady SK, Levine JA. Nonexercise movement in elderly compared with young people. AJP Endocrinol Metab 2007; 292: E1207&#x2013; E1212</Citation><ArticleIdList><ArticleId IdType="pubmed">17401138</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine JA. Nonexercise activity thermogenesis: liberating the life-force. J Intern Med 2007; 262: 273&#x2013; 287</Citation><ArticleIdList><ArticleId IdType="pubmed">17697152</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews CE, Jurj AL, Shu X-O, et al. Influence of exercise, walking, cycling, and overall nonexercise physical activity on mortality in chinese women. Am J Epidemiol 2007; 165: 1343&#x2013; 1350</Citation><ArticleIdList><ArticleId IdType="pubmed">17478434</ArticleId></ArticleIdList></Reference><Reference><Citation>Sesso HD. Invited commentary: a challenge for physical activity epidemiology. Am J Epidemiol 2007; 165: 1351&#x2013; 1353</Citation><ArticleIdList><ArticleId IdType="pubmed">17470453</ArticleId></ArticleIdList></Reference><Reference><Citation>Middleton LE, Manini TM, Simonsick EM, et al. Activity energy expenditure and incident cognitive impairment in older adults. Arch Intern Med 2011; 171: 1251&#x2013; 1257</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3923462</ArticleId><ArticleId IdType="pubmed">21771893</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes DE, Blackwell T, Stone KL, Goldman SE, Hillier T, Yaffe K. Cognition in older women: the importance of daytime movement. J Am Geriatr Soc 2008; 56: 1658&#x2013; 1664</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680379</ArticleId><ArticleId IdType="pubmed">18662201</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Buchman AS, Mendes de Leon C, Bienias JL, Wilson RS. The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort. Neuroepidemiology 2005; 25: 163&#x2013; 175</Citation><ArticleIdList><ArticleId IdType="pubmed">16103727</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman AS, Wilson RS, Bennett DA. Total daily activity is associated with cognition in older persons. Am J Geriatr Psychiatry 2008; 16: 697&#x2013; 701</Citation><ArticleIdList><ArticleId IdType="pubmed">18669949</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman AS, Boyle PA, Wilson RS, Fleischman DA, Leurgans S, Bennett DA. Association between late-life social activity and motor decline in older adults. Arch Intern Med 2009; 169: 1139&#x2013; 1146</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2775502</ArticleId><ArticleId IdType="pubmed">19546415</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman AS, Wilson RS, Boyle PA, Bienias JL, Bennett DA. Change in motor function and risk of mortality in older persons. J Am Geriatr Soc 2007; 55: 11&#x2013; 19</Citation><ArticleIdList><ArticleId IdType="pubmed">17233680</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Schneider JA, Boyle PA, Arnold SE, Tang Y, Bennett DA. Chronic distress and incidence of mild cognitive impairment. Neurology 2007; 68: 2085&#x2013; 2092</Citation><ArticleIdList><ArticleId IdType="pubmed">17562829</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman AS, Boyle PA, Wilson RS, Beck T, Kelly JF, Bennett DA. Apolipoprotein E epsilon 4 allele is associated with more rapid motor decline in older persons. Alzheimer Dis Assoc Disord 2009; 23: 63&#x2013; 69</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2662708</ArticleId><ArticleId IdType="pubmed">19266700</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox DR. Regression models and life-tables. J R Stat Soc Ser B 1972; 34: 187&#x2013; 220</Citation></Reference><Reference><Citation>SAS/STAT&#xae; software for Unix, version 9.18. Cary, NC: SAS Institute Inc.; 2002&#x2013;2003</Citation></Reference><Reference><Citation>Boyle PA, Buchman AS, Wilson RS, Leurgans SE, Bennett DA. Association of muscle strength with the risk of Alzheimer disease and the rate of cognitive decline in community-dwelling older persons. Arch Neurol 2009; 66: 1339&#x2013; 1344</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838435</ArticleId><ArticleId IdType="pubmed">19901164</ArticleId></ArticleIdList></Reference><Reference><Citation>
US Census Bureau News Report.
Dramatic Changes in US Aging:
2006. 
Available at: www.census.gov/newsroom/releases/archives/aging_population/cv06-36.html
Accessed on September 13, 2011</Citation></Reference><Reference><Citation>Brach JS, FitzGerald S, Newman AB, et al. Physical activity and functional status in community-dwelling older women: a 14-year prospective study. Arch Intern Med 2003; 163: 2565&#x2013; 2571</Citation><ArticleIdList><ArticleId IdType="pubmed">14638556</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis MG, Fox KR. Physical activity patterns assessed by accelerometry in older people. Eur J Appl Physiol 2007; 100: 581&#x2013; 589</Citation><ArticleIdList><ArticleId IdType="pubmed">17063361</ArticleId></ArticleIdList></Reference><Reference><Citation>Pruitt LA, Glynn NW, King AC, et al. Use of accelerometry to measure physical activity in older adults at risk for mobility disability. J Aging Phys Act 2008; 16: 416&#x2013; 434</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2895565</ArticleId><ArticleId IdType="pubmed">19033603</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris TJ, Owen CG, Victor CR, Adams R, Cook DG. What factors are associated with physical activity in older people, assessed objectively by accelerometry? Br J Sports Med 2009; 43: 442&#x2013; 450</Citation><ArticleIdList><ArticleId IdType="pubmed">18487253</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaye JA, Maxwell SA, Mattek N, et al. Intelligent systems for assessing aging changes: home-based, unobtrusive, and continuous assessment of aging. J Gerontol B Psychol Sci Soc Sci 2011; 66 (suppl 1): i180&#x2013; i190</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3132763</ArticleId><ArticleId IdType="pubmed">21743050</ArticleId></ArticleIdList></Reference><Reference><Citation>Garland T, Schutz H, Chappell MA, et al. The biological control of voluntary exercise, spontaneous physical activity and daily energy expenditure in relation to obesity: human and rodent perspectives. J Exp Biol 2011; 214: 206&#x2013; 229</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3008631</ArticleId><ArticleId IdType="pubmed">21177942</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim AGP, Yu L, Costa MD, et al. Quantification of the fragmentation of rest-activity patterns in elderly individuals using a state transition analysis. Sleep 2011; 34: 1569&#x2013; 1581</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3198212</ArticleId><ArticleId IdType="pubmed">22043128</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim ASP, Yu L, Costa MD, et al. Increased fragmentation of rest-activity patterns is associated with a characteristic pattern of cognitive impairment in older individuals. Sleep (in press 2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3321422</ArticleId><ArticleId IdType="pubmed">22547889</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22529236</PMID><DateCompleted><Year>2012</Year><Month>06</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3679</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><Issue>8</Issue><PubDate><Year>2012</Year><Month>Apr</Month><Day>23</Day></PubDate></JournalIssue><Title>Archives of internal medicine</Title><ISOAbbreviation>Arch Intern Med</ISOAbbreviation></Journal><ArticleTitle>Resistance training promotes cognitive and functional brain plasticity in seniors with probable mild cognitive impairment.</ArticleTitle><Pagination><StartPage>666</StartPage><EndPage>668</EndPage><MedlinePgn>666-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archinternmed.2012.379</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nagamatsu</LastName><ForeName>Lindsay S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Handy</LastName><ForeName>Todd C</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>C Liang</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Voss</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Liu-Ambrose</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>113561</GrantID><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Intern Med</MedlineTA><NlmUniqueID>0372440</NlmUniqueID><ISSNLinking>0003-9926</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Arch Intern Med. 2013 Aug 12;173(15):1477</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="Y">Neuronal Plasticity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011340" MajorTopicYN="N">Problem Solving</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055070" MajorTopicYN="Y">Resistance Training</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">CAMS2324</OtherID><CoiStatement><b>Conflict of Interest:</b> All authors have nothing to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>4</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22529236</ArticleId><ArticleId IdType="mid">CAMS2324</ArticleId><ArticleId IdType="pmc">PMC3514552</ArticleId><ArticleId IdType="doi">10.1001/archinternmed.2012.379</ArticleId><ArticleId IdType="pii">172/8/666</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005 Dec 17;366(9503):2112&#x2013;2117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850264</ArticleId><ArticleId IdType="pubmed">16360788</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol Mar. 1999;56(3):303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Ambrose T, Nagamatsu LS, Graf P, Beattie BL, Ashe MC, Handy TC. Resistance training and executive functions: a 12-month randomized controlled trial. Arch Intern Med. 2010 Jan 25;170(2):170&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3448565</ArticleId><ArticleId IdType="pubmed">20101012</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Ambrose T, Nagamatsu LS, Voss MW, Khan KM, Handy TC. Resistance training and functional plasticity of the aging brain: a 12-month randomized controlled trial. Neurobiol Aging. Jul 6;</Citation><ArticleIdList><ArticleId IdType="pubmed">21741129</ArticleId></ArticleIdList></Reference><Reference><Citation>Colcombe SJ, Kramer AF, Erickson KI, et al. Cardiovascular fitness, cortical plasticity, and aging. Proc Natl Acad Sci U S A. 2004;101(9):3316&#x2013;3321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC373255</ArticleId><ArticleId IdType="pubmed">14978288</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker LD, Frank LL, Foster-Schubert K, et al. Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol Jan. 2010;67(1):71&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056436</ArticleId><ArticleId IdType="pubmed">20065132</ArticleId></ArticleIdList></Reference><Reference><Citation>Royall DR, Palmer R, Chiodo LK, Polk MJ. Declining Executive Control in Normal Aging Predicts Change in Functional Status: The Freedom House Study. Journal of the American Geriatrics Society. 2004;52(3):346&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">14962147</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc Apr. 2005;53(4):695&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pubmed">15817019</ArticleId></ArticleIdList></Reference><Reference><Citation>Spreen O, Strauss E. A compendium of neurological tests. 2. New York: Oxford University Press, Inc; 1998.</Citation></Reference><Reference><Citation>Herholz K, Ehlen P, Kessler J, Strotmann T, Kalbe E, Markowitsch H-J. Learning face-name associations and the effect of age and performance: A PET activation study. Neuropsychologia. 2001;39:643&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">11257289</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22541439</PMID><DateCompleted><Year>2012</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>149</Volume><Issue>3</Issue><PubDate><Year>2012</Year><Month>Apr</Month><Day>27</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model.</ArticleTitle><Pagination><StartPage>708</StartPage><EndPage>721</EndPage><MedlinePgn>708-21</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2012.02.046</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) results in cognitive decline and altered network activity, but the mechanisms are&#xa0;unknown. We studied human amyloid precursor protein (hAPP) transgenic mice, which simulate key aspects of AD. Electroencephalographic recordings in hAPP mice revealed spontaneous epileptiform discharges, indicating network hypersynchrony, primarily during reduced gamma oscillatory activity. Because this oscillatory rhythm is generated by inhibitory parvalbumin (PV) cells, network dysfunction in hAPP mice might arise from impaired PV cells. Supporting this hypothesis, hAPP mice and AD patients had decreased levels of the interneuron-specific and PV cell-predominant voltage-gated sodium channel subunit Nav1.1. Restoring Nav1.1 levels in hAPP mice by Nav1.1-BAC expression increased inhibitory synaptic activity and gamma oscillations and reduced hypersynchrony, memory deficits, and premature mortality. We conclude that reduced Nav1.1 levels and PV cell dysfunction critically contribute to abnormalities in oscillatory rhythms, network synchrony, and memory in hAPP mice and possibly in AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Verret</LastName><ForeName>Laure</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mann</LastName><ForeName>Edward O</ForeName><Initials>EO</Initials></Author><Author ValidYN="Y"><LastName>Hang</LastName><ForeName>Giao B</ForeName><Initials>GB</Initials></Author><Author ValidYN="Y"><LastName>Barth</LastName><ForeName>Albert M I</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Cobos</LastName><ForeName>Inma</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Kaitlyn</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Devidze</LastName><ForeName>Nino</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Kreitzer</LastName><ForeName>Anatol C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Mody</LastName><ForeName>Istvan</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Mucke</LastName><ForeName>Lennart</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Palop</LastName><ForeName>Jorge J</ForeName><Initials>JJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG011385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS065780</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG018440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS065780</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG011385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG5131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS002808</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS030549</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS030549</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS030549</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG011385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS002808</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG18440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062550">NAV1.1 Voltage-Gated Sodium Channel</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568242">SCN1A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568249">Scn1a protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015222">Sodium Channels</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007395" MajorTopicYN="N">Interneurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="N">Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062550" MajorTopicYN="N">NAV1.1 Voltage-Gated Sodium Channel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015222" MajorTopicYN="N">Sodium Channels</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>4</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22541439</ArticleId><ArticleId IdType="mid">NIHMS362541</ArticleId><ArticleId IdType="pmc">PMC3375906</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2012.02.046</ArticleId><ArticleId IdType="pii">S0092-8674(12)00284-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amatniek JC, Hauser WA, DelCastillo-Castaneda C, Jacobs DM, Marder K, Bell K, Albert M, Brandt J, Stern Y. Incidence and predictors of seizures in patients with Alzheimer&#x2019;s disease. Epilepsia. 2006;47:867&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">16686651</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth AM, Mody I. Changes in hippocampal neuronal activity during and after unilateral selective hippocampal ischemia in vivo. J Neurosci. 2011;31:851&#x2013;860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632935</ArticleId><ArticleId IdType="pubmed">21248108</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, Holtzman DM. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci. 2011;14:750&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, et al. Molecular, structural, and functional characterization of Alzheimer&#x2019;s disease: Evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold KH, Haass C, Staufenbiel M, Konnerth A, Garaschuk O. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer&#x2019;s disease. Science. 2008;321:1686&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pubmed">18802001</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrejo L, Guyant-Mar&#xe9;chal L, Laquerri&#xe9;re A, Vercelletto M, De La Fourni&#xe9;re F, Thomas-Ant&#xe9;rion C, Verny C, Letournel F, Pasquier F, Vital A, et al. Phenotype associated with APP duplication in five families. Brain. 2006;129:2966&#x2013;2976.</Citation><ArticleIdList><ArticleId IdType="pubmed">16959815</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardin JA, Carlen M, Meletis K, Knoblich U, Zhang F, Deisseroth K, Tsai LH, Moore CI. Driving fast-spiking cells induces gamma rhythm and controls sensory responses. Nature. 2009;459:663&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3655711</ArticleId><ArticleId IdType="pubmed">19396156</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter MD, Weaver DF, Joudrey HR, Carter AO, Rockwood K. Epilepsy and antiepileptic drug use in elderly people as risk factors for dementia. J Neurol Sci. 2007;252:169&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">17182059</ArticleId></ArticleIdList></Reference><Reference><Citation>Catterall WA, Kalume F, Oakley JC. NaV1.1 channels and epilepsy. J Physiol. 2010;588:1849&#x2013;1859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2901973</ArticleId><ArticleId IdType="pubmed">20194124</ArticleId></ArticleIdList></Reference><Reference><Citation>Chattopadhyaya B, Di Cristo G, Higashiyama H, Knott GW, Kuhlman SJ, Welker E, Huang ZJ. Experience and activity-dependent maturation of perisomatic GABAergic innervation in primary visual cortex during a postnatal critical period. J Neurosci. 2004;24:9598&#x2013;9611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730138</ArticleId><ArticleId IdType="pubmed">15509747</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng I, Scearce-Levie K, Legleiter J, Palop J, Gerstein H, Bien-Ly N, Puoliv&#xe4;li J, Lesn&#xe9; S, Ashe K, Muchowski P, et al. Accelerating amyloid-&#x3b2; fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem. 2007;282:23818&#x2013;23828.</Citation><ArticleIdList><ArticleId IdType="pubmed">17548355</ArticleId></ArticleIdList></Reference><Reference><Citation>Cisse M, Halabisky B, Harris JA, Devidze N, Dubal D, Lotz G, Kim DH, Hamto T, Ho K, Yu G-Q, et al. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature. 2011;469:47&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3030448</ArticleId><ArticleId IdType="pubmed">21113149</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazzari P, Paternain AV, Valiente M, Pla R, Lujan R, Lloyd K, Lerma J, Marin O, Rico B. Control of cortical GABA circuitry development by Nrg1 and ErbB4 signalling. Nature. 2010;464:1376&#x2013;1380.</Citation><ArticleIdList><ArticleId IdType="pubmed">20393464</ArticleId></ArticleIdList></Reference><Reference><Citation>Freund TF, Katona I. Perisomatic inhibition. Neuron. 2007;56:33&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">17920013</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: Progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, Devidze N, Verret L, Ho K, Hamto T, Lo I, Yu G-Q, Palop JJ, Masliah E, Mucke L. Transsynaptic progression of amyloid-&#x3b2;-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron. 2010;68:428&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3050043</ArticleId><ArticleId IdType="pubmed">21040845</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser WA, Morris ML, Heston LL, Anderson VE. Seizures and myoclonus in patients with Alzheimer&#x2019;s disease. Neurology. 1986;36:1226&#x2013;1230.</Citation><ArticleIdList><ArticleId IdType="pubmed">3092131</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann CS, Demiralp T. Human EEG gamma oscillations in neuropsychiatric disorders. Clin Neurophysiol. 2005;116:2719&#x2013;2733.</Citation><ArticleIdList><ArticleId IdType="pubmed">16253555</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao KK, Borchelt DR, Olson K, Johannsdottir R, Kitt C, Yunis W, Xu S, Eckman C, Younkin S, Price D, et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron. 1995;15:1203&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pubmed">7576662</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R. AMPAR removal underlies A&#x3b2;-induced synaptic depression and dendritic spine loss. Neuron. 2006;52:831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer&#x2019;s disease mouse models. Cell. 2010;142:387&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayadev S, Leverenz JB, Steinbart E, Stahl J, Klunk W, Yu CE, Bird TD. Alzheimer&#x2019;s disease phenotypes and genotypes associated with mutations in presenilin 2. Brain. 2010;133:1143&#x2013;1154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850581</ArticleId><ArticleId IdType="pubmed">20375137</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Korotkova T, Fuchs EC, Ponomarenko A, von Engelhardt J, Monyer H. NMDA receptor ablation on parvalbumin-positive interneurons impairs hippocampal synchrony, spatial representations, and working memory. Neuron. 2010;68:557&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">21040854</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalonde R, Dumont M, Staufenbiel M, Strazielle C. Neurobehavioral characterization of APP23 transgenic mice with the SHIRPA primary screen. Behav Brain Res. 2005;157:91&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">15617775</ArticleId></ArticleIdList></Reference><Reference><Citation>Larner AJ, Doran M. Clinical phenotypic heterogeneity of Alzheimer&#x2019;s disease associated with mutations of the presenilin-1 gene. J Neurol. 2006;253:139&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">16267640</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao WP, Shi YW, Long YS, Zeng Y, Li T, Yu MJ, Su T, Deng P, Lei ZG, Xu SJ, et al. Partial epilepsy with antecedent febrile seizures and seizure aggravation by antiepileptic drugs: Associated with loss of function of Na(v) 1.1. Epilepsia. 2010;51:1669&#x2013;1678.</Citation><ArticleIdList><ArticleId IdType="pubmed">20550552</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorincz A, Nusser Z. Cell-type-dependent molecular composition of the axon initial segment. J Neurosci. 2008;28:14329&#x2013;14340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2628579</ArticleId><ArticleId IdType="pubmed">19118165</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann EO, Paulsen O. Role of GABAergic inhibition in hippocampal network oscillations. Trends Neurosci. 2007;30:343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17532059</ArticleId></ArticleIdList></Reference><Reference><Citation>Medvedev AV. Epileptiform spikes desynchronize and diminish fast (gamma) activity of the brain. An "anti-binding" mechanism? Brain Res Bull. 2002;58:115&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">12121821</ArticleId></ArticleIdList></Reference><Reference><Citation>Meisler MH, Kearney JA. Sodium channel mutations in epilepsy and other neurological disorders. J Clin Invest. 2005;115:2010&#x2013;2017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1180547</ArticleId><ArticleId IdType="pubmed">16075041</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez M, Lim G. Seizures in elderly patients with dementia: Epidemiology and management. Drugs Aging. 2003;20:791&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pubmed">12964886</ArticleId></ArticleIdList></Reference><Reference><Citation>Minkeviciene R, Rheims S, Dobszay MB, Zilberter M, Hartikainen J, Fulop L, Penke B, Zilberter Y, Harkany T, Pitkanen A, et al. Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci. 2009;29:3453&#x2013;3462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665248</ArticleId><ArticleId IdType="pubmed">19295151</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu G-Q, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of A&#x3b2;1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogiwara I, Miyamoto H, Morita N, Atapour N, Mazaki E, Inoue I, Takeuchi T, Itohara S, Yanagawa Y, Obata K, et al. Na(v)1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: A circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J Neurosci. 2007;27:5903&#x2013;5914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672241</ArticleId><ArticleId IdType="pubmed">17537961</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Bien-Ly N, Massaro C, Yeung BZ, Yu G-Q, Mucke L. Vulnerability of dentate granule cells to disruption of Arc expression in human amyloid precursor protein transgenic mice. J Neurosci. 2005;25:9686&#x2013;9693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725729</ArticleId><ArticleId IdType="pubmed">16237173</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu G-Q, Kreitzer A, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer&#x2019;s disease. Neuron. 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Jones B, Kekonius L, Chin J, Yu G-Q, Raber J, Masliah E, Mucke L. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer&#x2019;s disease-related cognitive deficits. Proc Natl Acad Sci USA. 2003;100:9572&#x2013;9577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC170959</ArticleId><ArticleId IdType="pubmed">12881482</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol. 2009;66:435&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812914</ArticleId><ArticleId IdType="pubmed">19204149</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer&#x2019;s disease: From synapses toward neural networks. Nat Neurosci. 2010;13:812&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072750</ArticleId><ArticleId IdType="pubmed">20581818</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu G-Q, et al. Amyloid-&#x3b2;/Fyn-induced synaptic, network, and cognitive impairments depend on Tau levels in multiple mouse models of Alzheimer&#x2019;s disease. J Neurosci. 2011;31:700&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3325794</ArticleId><ArticleId IdType="pubmed">21228179</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu G-Q, Mucke L. Reducing endogenous tau ameliorates amyloid &#x3b2;-induced deficits in an Alzheimer&#x2019;s disease mouse model. Science. 2007;316:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Sederberg PB, Schulze-Bonhage A, Madsen JR, Bromfield EB, McCarthy DC, Brandt A, Tully MS, Kahana MJ. Hippocampal and neocortical gamma oscillations predict memory formation in humans. Cereb Cortex. 2007;17:1190&#x2013;1196.</Citation><ArticleIdList><ArticleId IdType="pubmed">16831858</ArticleId></ArticleIdList></Reference><Reference><Citation>Snider BJ, Norton J, Coats MA, Chakraverty S, Hou CE, Jervis R, Lendon CL, Goate AM, McKeel DW, Jr, Morris JC. Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. Arch Neurol. 2005;62:1821&#x2013;1830.</Citation><ArticleIdList><ArticleId IdType="pubmed">16344340</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohal VS, Zhang F, Yizhar O, Deisseroth K. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature. 2009;459:698&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969859</ArticleId><ArticleId IdType="pubmed">19396159</ArticleId></ArticleIdList></Reference><Reference><Citation>Spadoni F, Hainsworth AH, Mercuri NB, Caputi L, Martella G, Lavaroni F, Bernardi G, Stefani A. Lamotrigine derivatives and riluzole inhibit INa,P in cortical neurons. Neuroreport. 2002;13:1167&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pubmed">12151762</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Laviolette PS, O'Keefe K, O'Brien J, Rentz DM, Pihlajamaki M, Marshall G, Hyman BT, Selkoe DJ, Hedden T, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63:178&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2738994</ArticleId><ArticleId IdType="pubmed">19640477</ArticleId></ArticleIdList></Reference><Reference><Citation>Striano P, Striano S, Minetti C, Zara F. Refractory, life-threatening status epilepticus in a 3-year-old girl. Lancet Neurol. 2008;7:278&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">18275929</ArticleId></ArticleIdList></Reference><Reference><Citation>Suls A, Claeys KG, Goossens D, Harding B, Van Luijk R, Scheers S, Deprez L, Audenaert D, Van Dyck T, Beeckmans S, et al. Microdeletions involving the SCN1A gene may be common in SCN1A-mutation-negative SMEI patients. Hum Mutat. 2006;27:914&#x2013;920.</Citation><ArticleIdList><ArticleId IdType="pubmed">16865694</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang B, Dutt K, Papale L, Rusconi R, Shankar A, Hunter J, Tufik S, Yu FH, Catterall WA, Mantegazza M, et al. A BAC transgenic mouse model reveals neuron subtype-specific effects of a Generalized Epilepsy with Febrile Seizures Plus (GEFS+) mutation. Neurobiol Dis. 2009;35:91&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735447</ArticleId><ArticleId IdType="pubmed">19409490</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsiouris JA, Patti PJ, Tipu O, Raguthu S. Adverse effects of phenytoin given for late-onset seizures in adults with Down syndrome. Neurology. 2002;59:779&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pubmed">12221182</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid &#x3b2; protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang WZ, Takashima S, Segawa Y, Itoh M, Shi XY, Hwang SK, Nabeshima K, Takeshita M, Hirose S. The developmental changes of Na(v)1.1 and Na(v)1.2 expression in the human hippocampus and temporal lobe. Brain Res. 2011;1389:61&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">21377452</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Dye CA, Sohal V, Long JE, Estrada RC, Roztocil T, Lufkin T, Deisseroth K, Baraban SC, Rubenstein JL. Dlx5 and Dlx6 regulate the development of parvalbumin-expressing cortical interneurons. J Neurosci. 2010;30:5334&#x2013;5345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919857</ArticleId><ArticleId IdType="pubmed">20392955</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu FH, Mantegazza M, Westenbroek RE, Robbins CA, Kalume F, Burton KA, Spain WJ, McKnight GS, Scheuer T, Catterall WA. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci. 2006;9:1142&#x2013;1149.</Citation><ArticleIdList><ArticleId IdType="pubmed">16921370</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22552903</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1550-7416</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2012</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The AAPS journal</Title><ISOAbbreviation>AAPS J</ISOAbbreviation></Journal><ArticleTitle>Development and advanced validation of an optimized method for the quantitation of A&#x3b2;42 in human cerebrospinal fluid.</ArticleTitle><Pagination><StartPage>510</StartPage><EndPage>518</EndPage><MedlinePgn>510-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1208/s12248-012-9360-7</ELocationID><Abstract><AbstractText>Cerebrospinal fluid (CSF) biomarkers have been extensively utilized in the diagnosis of Alzheimer's disease (AD) and characterization of progression. One important CSF biomarker is the amyloid beta 42 (A&#x3b2;(42)) peptide, a key player in AD pathogenesis. The INNOTEST&#xae; A&#x3b2;(42) ELISA kit has been widely used but an advanced level of method development and validation has not been reported. To support a clinical trial in AD, we successfully completed a Good Laboratory Practices (GLP)-level validation of the method to establish the parameters of precision, accuracy, parallelism, selectivity, specificity, and linearity of dilution of the assay in CSF matrix, as well as CSF storage stability. Several modifications were required to optimize the assay and ensure consistent results in a clinical-trial setting. These included the use of additional calibrators, an adjusted standard curve range, a minimum required dilution (MRD) of CSF by 6-fold to avoid matrix interference and mitigation of analyte adsorption to labware by the addition of Tween-20. The optimized method displayed a quantitative range of 375-4,500 pg/mL. The inter-assay precision was &#x2264;12.1 % CV and the inter-assay relative accuracy was &#x2264;10.9 % absolute bias, bringing the total error of the assay to &#x2264;23 %. The intra-assay precision of the assay at the high validation standard and below was &#x2264;5.5 % CV; this enables sensitive detection of biomarker changes across a therapeutic regime. The INNOTEST&#xae; A&#x3b2;(42) ELISA kit, modified as reported here, may be appropriate for many applications, including regulatory agency acceptable clinical diagnosis and pharmacodynamic assessment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cullen</LastName><ForeName>Valerie C</ForeName><Initials>VC</Initials><AffiliationInfo><Affiliation>Link Medicine Corporation, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fredenburg</LastName><ForeName>Ross A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Cindy</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Conliffe</LastName><ForeName>Phyllis R</ForeName><Initials>PR</Initials></Author><Author ValidYN="Y"><LastName>Solomon</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>05</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AAPS J</MedlineTA><NlmUniqueID>101223209</NlmUniqueID><ISSNLinking>1550-7416</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000327" MajorTopicYN="N">Adsorption</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002138" MajorTopicYN="N">Calibration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057230" MajorTopicYN="N">Limit of Detection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>5</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22552903</ArticleId><ArticleId IdType="pmc">PMC3385823</ArticleId><ArticleId IdType="doi">10.1208/s12248-012-9360-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Apostolova LG, Hwang KS, Andrawis JP, Green AE, Babakchanian S, Morra JH, et al. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging. 2010;31:1284&#x2013;1303. doi: 10.1016/j.neurobiolaging.2010.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.05.003</ArticleId><ArticleId IdType="pmc">PMC3051831</ArticleId><ArticleId IdType="pubmed">20538372</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouwman FH, Schoonenboom NS, Verwey NA, van Elk EJ, Kok A, Blankenstein MA, et al. CSF biomarker levels in early and late onset Alzheimer&#x2019;s disease. Neurobiol Aging. 2009;30:1895&#x2013;1901. doi: 10.1016/j.neurobiolaging.2008.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2008.02.007</ArticleId><ArticleId IdType="pubmed">18403055</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelborghs S, Maertens K, Vloeberghs E, Aerts T, Somers N, Marien P, et al. Neuropsychological and behavioural correlates of CSF biomarkers in dementia. Neurochem Int. 2006;48:286&#x2013;295. doi: 10.1016/j.neuint.2005.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2005.11.002</ArticleId><ArticleId IdType="pubmed">16434124</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama M, Arai H, Sugita M, Tanji H, Higuchi M, Okamura N, et al. Cerebrospinal fluid amyloid beta(1&#x2013;42) levels in the mild cognitive impairment stage of Alzheimer&#x2019;s disease. Exp Neurol. 2001;172:433&#x2013;436. doi: 10.1006/exnr.2001.7814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.2001.7814</ArticleId><ArticleId IdType="pubmed">11716567</ArticleId></ArticleIdList></Reference><Reference><Citation>Parnetti L, Lanari A, Silvestrelli G, Saggese E, Reboldi P. Diagnosing prodromal Alzheimer&#x2019;s disease: role of CSF biochemical markers. Mech Ageing Dev. 2006;127:129&#x2013;132. doi: 10.1016/j.mad.2005.09.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mad.2005.09.022</ArticleId><ArticleId IdType="pubmed">16274728</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403&#x2013;413. doi: 10.1002/ana.21610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21610</ArticleId><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Diniz BS, Pinto Junior JA, Forlenza OV. Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer&#x2019;s disease? A systematic review and meta-analysis of the literature. World J Biol Psychiatry. 2008;9:172&#x2013;182. doi: 10.1080/15622970701535502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15622970701535502</ArticleId><ArticleId IdType="pubmed">17886169</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, et al. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer&#x2019;s disease. J Neurosci. 2010;30:2088&#x2013;2101. doi: 10.1523/JNEUROSCI.3785-09.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3785-09.2010</ArticleId><ArticleId IdType="pmc">PMC2828879</ArticleId><ArticleId IdType="pubmed">20147537</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, et al. Value of CSF beta-amyloid1&#x2013;42 and tau as predictors of Alzheimer&#x2019;s disease in patients with mild cognitive impairment. Mol Psychiatry. 2004;9:705&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pubmed">14699432</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanoiu A, Sindic CJ. Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimer&#x2019;s disease and correlation with the neuropsychological examination. Neurocase. 2005;11:32&#x2013;39. doi: 10.1080/13554790490896901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13554790490896901</ArticleId><ArticleId IdType="pubmed">15804922</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302:385&#x2013;393. doi: 10.1001/jama.2009.1064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2009.1064</ArticleId><ArticleId IdType="pubmed">19622817</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, et al. Prevalence and prognostic value of CSF markers of Alzheimer&#x2019;s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009;8:619&#x2013;627. doi: 10.1016/S1474-4422(09)70139-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(09)70139-5</ArticleId><ArticleId IdType="pubmed">19523877</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry. 2004;61:95&#x2013;102. doi: 10.1001/archpsyc.61.1.95.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.61.1.95</ArticleId><ArticleId IdType="pubmed">14706948</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Ewers M, Burger K, Annas P, Mortberg A, Bogstedt A, et al. Lithium trial in Alzheimer&#x2019;s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry. 2009;70:922&#x2013;931. doi: 10.4088/JCP.08m04606.</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.08m04606</ArticleId><ArticleId IdType="pubmed">19573486</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouwman FH, van der Flier WM, Schoonenboom NS, van Elk EJ, Kok A, Rijmen F, et al. Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology. 2007;69:1006&#x2013;1011. doi: 10.1212/01.wnl.0000271375.37131.04.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000271375.37131.04</ArticleId><ArticleId IdType="pubmed">17785669</ArticleId></ArticleIdList></Reference><Reference><Citation>Maddalena A, Papassotiropoulos A, Muller-Tillmanns B, Jung HH, Hegi T, Nitsch RM, et al. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. Arch Neurol. 2003;60:1202&#x2013;1206. doi: 10.1001/archneur.60.9.1202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.60.9.1202</ArticleId><ArticleId IdType="pubmed">12975284</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsater H, Anckarsater R, et al. Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Int J Alzheimers Dis. 2010;2010:986310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2925386</ArticleId><ArticleId IdType="pubmed">20798852</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewczuk P, Beck G, Esselmann H, Bruckmoser R, Zimmermann R, Fiszer M, et al. Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid &#x3b2; peptides. Clin Chem. 2006;52:332&#x2013;334. doi: 10.1373/clinchem.2005.058776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2005.058776</ArticleId><ArticleId IdType="pubmed">16449222</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, et al. Cerebrospinal fluid &#x3b2;-amyloid(1&#x2013;42) in Alzheimer disease. Arch Neurol. 1999;56:673&#x2013;680. doi: 10.1001/archneur.56.6.673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.56.6.673</ArticleId><ArticleId IdType="pubmed">10369305</ArticleId></ArticleIdList></Reference><Reference><Citation>Pica-Mendez AM, Tanen M, Dallob A, Tanaka W, Laterza OF. Nonspecific binding of A&#x3b2;42 to polypropylene tubes and the effect of Tween-20. Clin Chim Acta. 2010;411:1833. doi: 10.1016/j.cca.2010.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2010.07.019</ArticleId><ArticleId IdType="pubmed">20655889</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res. 2006;23:312&#x2013;328. doi: 10.1007/s11095-005-9045-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-005-9045-3</ArticleId><ArticleId IdType="pubmed">16397743</ArticleId></ArticleIdList></Reference><Reference><Citation>McCush F, Raha N, Durham R, Chappell J, Sharma V, Tew Z, Lane D. Validation of Alzheimer biomarker assays using various analytical techniques in CSF and plasma. In 9th Annual Marian S Ware Neurodegeneration Research Retreat (Current Research in Alzheimer Biomarkers; 2009 October 16, 2009).</Citation></Reference><Reference><Citation>Siemers E, DeMattos RB, May PC, Dean RA. Role of biochemical Alzheimer&#x2019;s disease biomarkers as end points in clinical trials. Biomark Med. 2010;4:81&#x2013;89. doi: 10.2217/bmm.09.85.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/bmm.09.85</ArticleId><ArticleId IdType="pubmed">20387304</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Mattsson N, Shaw LM, Blennow K. Biochemical markers in Alzheimer&#x2019;s disease clinical trials. Biomark Med. 2010;4:91&#x2013;98. doi: 10.2217/bmm.09.80.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/bmm.09.80</ArticleId><ArticleId IdType="pubmed">20387305</ArticleId></ArticleIdList></Reference><Reference><Citation>Parnetti L, Lanari A, Saggese E, Spaccatini C, Gallai V. Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice. Neurol Sci. 2003;24:199&#x2013;200. doi: 10.1007/s10072-003-0129-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-003-0129-8</ArticleId><ArticleId IdType="pubmed">14598086</ArticleId></ArticleIdList></Reference><Reference><Citation>Viswanathan CT, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm Res. 2007;24:1962&#x2013;1973. doi: 10.1007/s11095-007-9291-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-007-9291-7</ArticleId><ArticleId IdType="pubmed">17458684</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA, Trojanowski JQ, et al. Comparison of analytical platforms for cerebrospinal fluid measures of {beta}-Amyloid 1&#x2013;42, total tau, and P-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol. 2011;68:1137&#x2013;1144. doi: 10.1001/archneurol.2011.105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.105</ArticleId><ArticleId IdType="pmc">PMC3154969</ArticleId><ArticleId IdType="pubmed">21555603</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, et al. The Alzheimer&#x2019;s association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 2011;7:386.e6&#x2013;395.e6. doi: 10.1016/j.jalz.2011.05.2243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.05.2243</ArticleId><ArticleId IdType="pmc">PMC3710290</ArticleId><ArticleId IdType="pubmed">21784349</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22305861</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-2191</ISSN><JournalIssue CitedMedium="Internet"><Volume>180</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The American journal of pathology</Title><ISOAbbreviation>Am J Pathol</ISOAbbreviation></Journal><ArticleTitle>Amyloid precursor protein is a biomarker for transformed human pluripotent stem cells.</ArticleTitle><Pagination><StartPage>1636</StartPage><EndPage>1652</EndPage><MedlinePgn>1636-52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajpath.2011.12.015</ELocationID><Abstract><AbstractText>Increasing evidence suggests an important function of the &#x3b2;-amyloid precursor protein (APP) in malignant disease in humans; however, the biological basis for this evidence is not well understood at present. To understand the role of APP in transformed pluripotent stem cells, we studied its expression levels in human testicular germ cell tumors using patient tissues, model cell lines, and an established xenograft mouse model. In the present study, we demonstrate the cooperative expression of APP with prominent pluripotency-related genes such as Sox2, NANOG, and POU5F1 (Oct3/4). The closest homologue family member, APLP2, showed no correlation to these stem cell factors. In addition, treatment with histone deacetylase (HDAC) inhibitors suppressed the levels of APP and stem cell markers. Loss of pluripotency, either spontaneously or as a consequence of treatment with an HDAC inhibitor, was accompanied by decreased APP protein levels both in vitro and in vivo. These observations suggest that APP represents a novel and specific biomarker in human transformed pluripotent stem cells that can be selectively modulated by HDAC inhibitors.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Venkataramani</LastName><ForeName>Vivek</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Molecular Psychiatry, Department of Psychiatry, University Medicine Goettingen, Goettingen, Germany. ramani@med.unigoettingen.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thiele</LastName><ForeName>Knut</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Behnes</LastName><ForeName>Carl Ludwig</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Wulf</LastName><ForeName>Gerald G</ForeName><Initials>GG</Initials></Author><Author ValidYN="Y"><LastName>Thelen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Opitz</LastName><ForeName>Lennart</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Salinas-Riester</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Wirths</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Bayer</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>Schweyer</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Pathol</MedlineTA><NlmUniqueID>0370502</NlmUniqueID><ISSNLinking>0002-9440</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000091342">Endoplasmic Reticulum Chaperone BiP</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006360">Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D056572">Histone Deacetylase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Am J Pathol. 2012 Jul;181(1):374</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002471" MajorTopicYN="N">Cell Transformation, Neoplastic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000091342" MajorTopicYN="N">Endoplasmic Reticulum Chaperone BiP</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006360" MajorTopicYN="N">Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056572" MajorTopicYN="N">Histone Deacetylase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009373" MajorTopicYN="N">Neoplasms, Germ Cell and Embryonal</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039904" MajorTopicYN="N">Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="N">Protein Processing, Post-Translational</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013736" MajorTopicYN="N">Testicular Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22305861</ArticleId><ArticleId IdType="doi">10.1016/j.ajpath.2011.12.015</ArticleId><ArticleId IdType="pii">S0002-9440(12)00018-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22566582</PMID><DateCompleted><Year>2012</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3636</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>5</Issue><PubDate><Year>2012</Year><Month>May</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Effect of purpose in life on the relation between Alzheimer disease pathologic changes on cognitive function in advanced age.</ArticleTitle><Pagination><StartPage>499</StartPage><EndPage>505</EndPage><MedlinePgn>499-505</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archgenpsychiatry.2011.1487</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Purpose in life is associated with a substantially reduced risk of Alzheimer disease (AD), but the neurobiologic basis of this protective effect remains unknown.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To test the hypothesis that purpose in life reduces the deleterious effects of AD pathologic changes on cognition in advanced age.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">A longitudinal, epidemiologic, clinicopathologic study of aging was conducted that included detailed annual clinical evaluations and brain autopsy.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Two hundred forty-six community-based older persons from the Rush Memory and Aging Project participated.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Purpose in life was assessed via structured interview, and cognitive function was evaluated annually and proximate to death. On postmortem examination, 3 indexes of AD pathologic features were quantified: global AD pathologic changes, amyloid, and tangles. The associations of disease pathologic changes and purpose in life with cognition were examined using linear regression and mixed models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Purpose in life modified the association between the global measure of AD pathologic changes and cognition (mean [SE] parameter estimate, 0.532 [0.211]; P = .01), such that participants who reported higher levels of purpose in life exhibited better cognitive function despite the burden of the disease. Purpose in life also reduced the association of tangles with cognition (parameter estimate, 0.042 [0.019]; P = .03), and the protective effect of purpose in life persisted even after controlling for several potentially confounding variables. Furthermore, in analyses examining whether purpose in life modified the association between AD pathologic effects and the rate of cognitive decline, we found that higher levels of purpose in life reduced the effect of AD pathologic changes on cognitive decline (parameter estimate, 0.085 [0.039]; P = .03).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Higher levels of purpose in life reduce the deleterious effects of AD pathologic changes on cognition in advanced age.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boyle</LastName><ForeName>Patricia A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, 600 S Paulina Ave, Ste 1020B, Chicago, IL 60612, USA. Patricia_Boyle@rush.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buchman</LastName><ForeName>Aron S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Robert S</ForeName><Initials>RS</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Lei</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01AG33678</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033678</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG34374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG17917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000223" MajorTopicYN="N">Adaptation, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011581" MajorTopicYN="N">Psychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>7</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22566582</ArticleId><ArticleId IdType="mid">NIHMS378562</ArticleId><ArticleId IdType="pmc">PMC3389510</ArticleId><ArticleId IdType="doi">10.1001/archgenpsychiatry.2011.1487</ArticleId><ArticleId IdType="pii">69/5/499</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stern Y. Cognitive reserve. Neuropsychologia. 2009;47(10):2015&#x2013;2028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739591</ArticleId><ArticleId IdType="pubmed">19467352</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratiglioni L, Wang HX, Ericsson K, Maytan M, Winblad B. Influence of social network on occurrence of dementia: a community-based longitudinal study. Lancet. 2000;355(9212):1315&#x2013;1319.</Citation><ArticleIdList><ArticleId IdType="pubmed">10776744</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Stern Y. Cognitive reserve and lifestyle. J Clin Exp Neuropsychol. 2003;25(5):625&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3024591</ArticleId><ArticleId IdType="pubmed">12815500</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Zarahn E, Anderson KE, Habeck CG, Hilton J, Flynn J, Marder KS, Bell KL, Sackeim HA, Van Heertum RL, Moeller JR, Stern Y. Association of life activities with cerebral blood flow in Alzheimer disease: implications for the cognitive reserve hypothesis. Arch Neurol. 2003;60(3):359&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3028534</ArticleId><ArticleId IdType="pubmed">12633147</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Schneider JA, Arnold SE, Bienias JL, Bennett DA. Conscientiousness and the incidence of Alzheimer disease and mild cognitive impairment. Arch Gen Psychiatry. 2007;64(10):1204&#x2013;1212.</Citation><ArticleIdList><ArticleId IdType="pubmed">17909133</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Education modifies the association of amyloid but not tangles with cognitive function. Neurology. 2005;65(6):953&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">16186546</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Wilson RS, Schneider JA, Evans DA, Mendes de Leon CF, Arnold SE, Barnes LL, Bienias JL. Education modifies the relation of AD pathology to level of cognitive function in older persons. Neurology. 2003;60(12):1909&#x2013;1915.</Citation><ArticleIdList><ArticleId IdType="pubmed">12821732</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentz DM, Locascio JJ, Becker JA, Moran EK, Eng E, Buckner RL, Sperling RA, Johnson KA. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol. 2010;67(3):353&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3074985</ArticleId><ArticleId IdType="pubmed">20373347</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Mintun MA, D&#x2019;Angelo G, Xiong C, Grant EA, Morris JC. Alzheimer disease and cognitive reserve: variation of education effect with carbon 11&#x2013;labeled Pittsburgh Compound B uptake. Arch Neurol. 2008;65(11):1467&#x2013;1471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2752218</ArticleId><ArticleId IdType="pubmed">19001165</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Tang Y, Arnold SE, Wilson RS. The effect of social networks on the relation between Alzheimer&#x2019;s disease pathology and level of cognitive function in old people: a longitudinal cohort study. Lancet Neurol. 2006;5(5):406&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">16632311</ArticleId></ArticleIdList></Reference><Reference><Citation>Frankl VE. Man&#x2019;s Search for Meaning. New York, NY: Washington Square Press, Simon &amp; Schuster; 1963.</Citation></Reference><Reference><Citation>Friedman EM, Hayney MS, Love GD, Urry HL, Rosenkranz MA, Davidson RJ, Singer BH, Ryff CD. Social relationships, sleep quality, and interleukin-6 in aging women. Proc Natl Acad Sci U S A. 2005;102(51):18757&#x2013;18762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1317967</ArticleId><ArticleId IdType="pubmed">16339311</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott RA, Ploubidis GB, Huppert FA, Kuh D, Wadsworth ME, Croudace TJ. Psychometric evaluation and predictive validity of Ryff&#x2019;s Psychological Well-Being items in a UK birth cohort sample of women. Health Qual Life Outcomes. 2006;4:76. doi: 10.1186/1477-7525-4-76.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7525-4-76</ArticleId><ArticleId IdType="pmc">PMC1634744</ArticleId><ArticleId IdType="pubmed">17020614</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryff CD, Singer B. Psychological well-being: meaning, measurement, and implications for psychotherapy research. Psychother Psychosom. 1996;65(1):14&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">8838692</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryff CD, Singer BH, Dienberg Love G. Positive health: connecting well-being with biology. Philos Trans R Soc Lond B Biol Sci. 2004;359(1449):1383&#x2013;1394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1693417</ArticleId><ArticleId IdType="pubmed">15347530</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedberg P, Gustafson Y, Brulin C. Purpose in life among men and women aged 85 years and older. Int J Aging Hum Dev. 2010;70(3):213&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">20503806</ArticleId></ArticleIdList></Reference><Reference><Citation>Phelan CH, Love GD, Ryff CD, Brown RL, Heidrich SM. Psychosocial predictors of changing sleep patterns in aging women: a multiple pathway approach. Psychol Aging. 2010;25(4):858&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3780608</ArticleId><ArticleId IdType="pubmed">20731498</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood AM, Joseph S. The absence of positive psychological (eudemonic) well-being as a risk factor for depression: a ten year cohort study. J Affect Disord. 2010;122(3):213&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pubmed">19706357</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerstorf D, L&#xf6;vd&#xe9;n M, R&#xf6;cke C, Smith J, Lindenberger U. Well-being affects changes in perceptual speed in advanced old age: longitudinal evidence for a dynamic link. Dev Psychol. 2007;43(3):705&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pubmed">17484582</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryff CD, Dienberg Love G, Urry HL, Muller D, Rosenkranz MA, Friedman EM, Davidson RJ, Singer B. Psychological well-being and ill-being: do they have distinct or mirrored biological correlates? Psychother Psychosom. 2006;75(2):85&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">16508343</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Buchman AS, Barnes LL, Bennett DA. Effect of a purpose in life on risk of incident Alzheimer disease and mild cognitive impairment in community-dwelling older persons. Arch Gen Psychiatry. 2010;67(3):304&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2897172</ArticleId><ArticleId IdType="pubmed">20194831</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Barnes LL, Buchman AS, Bennett DA. Purpose in life is associated with mortality among community-dwelling older persons. Psychosom Med. 2009;71(5):574&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740716</ArticleId><ArticleId IdType="pubmed">19414613</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Buchman AS, Bennett DA. Purpose in life is associated with a reduced risk of incident disability among community-dwelling older persons. Am J Geriatr Psychiatry. 2010;18(12):1093&#x2013;1102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2992099</ArticleId><ArticleId IdType="pubmed">20808115</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Buchman AS, Mendes de Leon C, Bienias JL, Wilson RS. The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort. Neuroepidemiology. 2005;25(4):163&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">16103727</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s disease. Neurology. 1984;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Aggarwal NT, Arvanitakis Z, Shah RC, Kelly JF, Fox JH, Cochran EJ, Arends D, Treinkman AD, Wilson RS. Decision rules guiding the clinical diagnosis of Alzheimer&#x2019;s disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study. Neuroepidemiology. 2006;27(3):169&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035694</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Wilson RS, Aggarwal NT, Tang Y, Bennett DA. Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline. Neurology. 2006;67(3):441&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894105</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Barnes LL, Krueger KR, Hoganson G, Bienias JL, Bennett DA. Early and late life cognitive activity and cognitive systems in old age. J Int Neuropsychol Soc. 2005;11(4):400&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">16209420</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryff CD, Keyes CL. The structure of psychological well-being revisited. J Pers Soc Psychol. 1995;69(4):719&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">7473027</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LL, Wilson RS, Bienias JL, de Leon CF, Kim HJ, Buchman AS, Bennett DA. Correlates of life space in a volunteer cohort of older adults. Exp Aging Res. 2007;33(1):77&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">17132565</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Schneider JA, Bienias JL, Arnold SE, Evans DA, Bennett DA. Depressive symptoms, clinical AD, and cortical plaques and tangles in older persons. Neurology. 2003;61(8):1102&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pubmed">14581672</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Arnold SE, Schneider JA, Li Y, Bennett DA. Chronic distress, age-related neuropathology, and late-life dementia. Psychosom Med. 2007;69(1):47&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">17244848</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Schneider JA, Boyle PA, Arnold SE, Tang Y, Bennett DA. Chronic distress and incidence of mild cognitive impairment. Neurology. 2007;68(24):2085&#x2013;2092.</Citation><ArticleIdList><ArticleId IdType="pubmed">17562829</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Aggarwal NT, Barnes L, Boyle P, Bennett DA. The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis. 2009;18(3):691&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853869</ArticleId><ArticleId IdType="pubmed">19749406</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, Wilson RS. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66(12):1837&#x2013;1844.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA. Postmortem indices linking risk factors to cognition: results from the Religious Order Study and the Memory and Aging Project. Alzheimer Dis Assoc Disord. 2006;20(3 suppl 2):S63&#x2013;S68.</Citation><ArticleIdList><ArticleId IdType="pubmed">16917198</ArticleId></ArticleIdList></Reference><Reference><Citation>SAS 9.2 Help and Documentation. Cary, NC: SAS Institute Inc; 2009.</Citation></Reference><Reference><Citation>Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65(11):1509&#x2013;1517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemppainen NM, Aalto S, Karrasch M, N&#xe5;gren K, Savisto N, Oikonen V, Viitanen M, Parkkola R, Rinne JO. Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer&#x2019;s disease. Ann Neurol. 2008;63(1):112&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">18023012</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, Smith GE, Dickson DW, Johnson KA, Petersen LE, McDonald WC, Braak H, Petersen RC. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003;62(11):1087&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pubmed">14656067</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortimer JA, Borenstein AR, Gosche KM, Snowdon DA. Very early detection of Alzheimer neuropathology and the role of brain reserve in modifying its clinical expression. J Geriatr Psychiatry Neurol. 2005;18(4):218&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1405917</ArticleId><ArticleId IdType="pubmed">16306243</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley KP, Snowdon DA, Markesbery WR. Alzheimer&#x2019;s neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study. Ann Neurol. 2002;51(5):567&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">12112102</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigue KM, Kennedy KM, Park DC. Beta-amyloid deposition and the aging brain. Neuropsychol Rev. 2009;19(4):436&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2844114</ArticleId><ArticleId IdType="pubmed">19908146</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Xiong C, Grant E, Miller JP, Morris JC. Education and reported onset of symptoms among individuals with Alzheimer disease. Arch Neurol. 2008;65 (1):108&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830808</ArticleId><ArticleId IdType="pubmed">18195147</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Abner EL, Schmitt FA, Kryscio RJ, Riley KP, Cooper GE, Stiles N, Mendiondo MS, Smith CD, Van Eldik LJ, Nelson PT. Preclinical AD Workgroup staging: pathological correlates and potential challenges. Neurobiol Aging. 2012;33(3):622.e1&#x2013;622.e16. doi: 10.1016/j.neurobiolaging.2011.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.02.018</ArticleId><ArticleId IdType="pmc">PMC3245887</ArticleId><ArticleId IdType="pubmed">21507528</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerhof GJ, Bohlmeijer ET, van Beljouw IM, Pot AM. Improvement in personal meaning mediates the effects of a life review intervention on depressive symptoms in a randomized controlled trial. Gerontologist. 2010;50(4):541&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pubmed">20045873</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinquart M. Creating and maintaining purpose in life in old age: a meta-analysis. Ageing Int. 2002;27(2):90&#x2013;114. doi: 10.1007/s12126-002-1004-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12126-002-1004-2</ArticleId></ArticleIdList></Reference><Reference><Citation>McKnight PE, Kashdan TB. Purpose in life as a system that creates and sustains health and well-being: an integrative, testable theory. Rev Gen Psychol. 2009;13(3):242&#x2013;251. doi: 10.1037/a0017152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/a0017152</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmutte PS, Ryff CD. Personality and well-being: reexamining methods and meanings. J Pers Soc Psychol. 1997;73(3):549&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pubmed">9294901</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin RA, MacKinnon S, Johnson J, Rohsenow DJ. Purpose in life predicts treatment outcome among adult cocaine abusers in treatment. J Subst Abuse Treat. 2011;40(2):183&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3031725</ArticleId><ArticleId IdType="pubmed">21129893</ArticleId></ArticleIdList></Reference><Reference><Citation>Adolphs R. The neurobiology of social cognition. Curr Opin Neurobiol. 2001;11 (2):231&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">11301245</ArticleId></ArticleIdList></Reference><Reference><Citation>Adolphs R. The social brain: neural basis of social knowledge. Annu Rev Psychol. 2009;60:693&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2588649</ArticleId><ArticleId IdType="pubmed">18771388</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakopoulos PHF, Herrmann FR, Bussi&#xe8;re T, Bouras C, K&#xf6;vari E, Perl DP, Morrison JH, Gold G, Hof PR. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer&#x2019;s disease. Neurology. 2003;60(9):1495&#x2013;1500.</Citation><ArticleIdList><ArticleId IdType="pubmed">12743238</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Wilson RS, Schneider JA, Bienias JL, Bennett DA. Processing resources reduce the effect of Alzheimer pathology on other cognitive systems. Neurology. 2008;70(17):1534&#x2013;1542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10382255</ArticleId><ArticleId IdType="pubmed">18354077</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22566581</PMID><DateCompleted><Year>2012</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3636</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>5</Issue><PubDate><Year>2012</Year><Month>May</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Midlife vs late-life depressive symptoms and risk of dementia: differential effects for Alzheimer disease and vascular dementia.</ArticleTitle><Pagination><StartPage>493</StartPage><EndPage>498</EndPage><MedlinePgn>493-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archgenpsychiatry.2011.1481</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Depression and dementia are common in older adults and often co-occur, but it is unclear whether depression is an etiologic risk factor for dementia.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To clarify the timing and nature of the association between depression and dementia.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">We examined depressive symptoms assessed in midlife (1964-1973) and late life (1994-2000) and the risks of dementia, Alzheimer disease (AD), and vascular dementia (VaD) (2003-2009) in a retrospective cohort study. Depressive symptoms were categorized as none, midlife only, late life only, or both. Cox proportional hazards models (age as timescale) adjusted for demographics and medical comorbidities were used to examine depressive symptom category and risk of dementia, AD, or VaD.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Kaiser Permanente Medical Care Program of Northern California.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Thirteen thousand five hundred thirty-five long-term Kaiser Permanente members.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Any medical record diagnosis of dementia or neurology clinic diagnosis of AD or VaD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Subjects had a mean (SD) age of 81.1 (4.5) years in 2003, 57.9% were women, and 24.2% were nonwhite. Depressive symptoms were present in 14.1% of subjects in midlife only, 9.2% in late life only, and 4.2% in both. During 6 years of follow-up, 22.5% were diagnosed with dementia (5.5% with AD and 2.3% with VaD). The adjusted hazard of dementia was increased by approximately 20% for midlife depressive symptoms only (hazard ratio, 1.19 [95% CI, 1.07-1.32]), 70% for late-life symptoms only (1.72 [1.54-1.92]), and 80% for both (1.77 [1.52-2.06]). When we examined AD and VaD separately, subjects with late-life depressive symptoms only had a 2-fold increase in AD risk (hazard ratio, 2.06 [95% CI, 1.67-2.55]), whereas subjects with midlife and late-life symptoms had more than a 3-fold increase in VaD risk (3.51 [2.44-5.05]).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Depressive symptoms in midlife or in late life are associated with an increased risk of developing dementia. Depression that begins in late life may be part of the AD prodrome, while recurrent depression may be etiologically associated with increased risk of VaD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Deborah E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Francisco, 4150 Clement St., San Francisco, CA 94121, USA. deborah.barnes@ucsf.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaffe</LastName><ForeName>Kristine</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Byers</LastName><ForeName>Amy L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>McCormick</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Schaefer</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Whitmer</LastName><ForeName>Rachel A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 AG031155</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH086498</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015438" MajorTopicYN="N">Health Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><u>Conflicts of interest and financial disclosures</u>. We have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>7</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22566581</ArticleId><ArticleId IdType="mid">NIHMS477394</ArticleId><ArticleId IdType="pmc">PMC3704214</ArticleId><ArticleId IdType="doi">10.1001/archgenpsychiatry.2011.1481</ArticleId><ArticleId IdType="pii">69/5/493</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer&#x2019;s Association.  [Accessed November 5, 2010];Alzheimer&#x2019;s Disease Facts &amp; Figures.   http://www.alz.org/documents_custom/report_alzfactsfigures2010.pdf.</Citation></Reference><Reference><Citation>Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer&#x2019;s disease. Alzheimers Dement. 2007 Jul;3(3):186&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">19595937</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffens DC, Fisher GG, Langa KM, Potter GG, Plassman BL. Prevalence of depression among older Americans: the Aging, Demographics and Memory Study. Int Psychogeriatr. 2009 Oct;21(5):879&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2747379</ArticleId><ArticleId IdType="pubmed">19519984</ArticleId></ArticleIdList></Reference><Reference><Citation>Heun R, Kockler M, Ptok U. Depression in Alzheimer&#x2019;s disease: is there a temporal relationship between the onset of depression and the onset of dementia? Eur Psychiatry. 2002 Sep;17(5):254&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">12381494</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganguli M, Du Y, Dodge HH, Ratcliff GG, Chang CC. Depressive symptoms and cognitive decline in late life: a prospective epidemiological study. Arch Gen Psychiatry. 2006 Feb;63(2):153&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461857</ArticleId></ArticleIdList></Reference><Reference><Citation>Dufouil C, Fuhrer R, Dartigues JF, Alperovitch A. Longitudinal analysis of the association between depressive symptomatology and cognitive deterioration. Am J Epidemiol. 1996 Oct 1;144(7):634&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">8823058</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinkers DJ, Gussekloo J, Stek ML, Westendorp RG, van der Mast RC. Temporal relation between depression and cognitive impairment in old age: prospective population based study. Bmj. 2004 Oct 16;329(7471):881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC523108</ArticleId><ArticleId IdType="pubmed">15345599</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Ganguli M, Mulsant BH, DeKosky ST. The temporal relationship between depressive symptoms and dementia: a community-based prospective study. Arch Gen Psychiatry. 1999 Mar;56(3):261&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">10078504</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorm AF. History of depression as a risk factor for dementia: an updated review. Aust N Z J Psychiatry. 2001 Dec;35(6):776&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">11990888</ArticleId></ArticleIdList></Reference><Reference><Citation>Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry. 2006 May;63(5):530&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530614</ArticleId><ArticleId IdType="pubmed">16651510</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Blackwell T, Gore R, Sands L, Reus V, Browner WS. Depressive symptoms and cognitive decline in nondemented elderly women: a prospective study. Arch Gen Psychiatry. 1999 May;56(5):425&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">10232297</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes DE, Alexopoulos GS, Lopez OL, Williamson JD, Yaffe K. Depressive symptoms, vascular disease, and mild cognitive impairment: findings from the Cardiovascular Health Study. Arch Gen Psychiatry. 2006 Mar;63(3):273&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">16520432</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Arnold SE, Beck TL, Bienias JL, Bennett DA. Change in depressive symptoms during the prodromal phase of Alzheimer disease. Arch Gen Psychiatry. 2008 Apr;65(4):439&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">18391132</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Hoganson GM, Rajan KB, Barnes LL, Mendes de Leon CF, Evans DA. Temporal course of depressive symptoms during the development of Alzheimer disease. Neurology. Jul 6;75(1):21&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906401</ArticleId><ArticleId IdType="pubmed">20603481</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotson VM, Beydoun MA, Zonderman AB. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology. Jul 6;75(1):27&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906403</ArticleId><ArticleId IdType="pubmed">20603482</ArticleId></ArticleIdList></Reference><Reference><Citation>Saczynski JS, Beiser A, Seshadri S, Auerbach S, Wolf PA, Au R. Depressive symptoms and risk of dementia: the Framingham Heart Study. Neurology. Jul 6;75(1):35&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906404</ArticleId><ArticleId IdType="pubmed">20603483</ArticleId></ArticleIdList></Reference><Reference><Citation>Daviglus ML, Bell CC, Berrettini W, Bowen PE, Connolly ES, Cox NJ, Dunbar-Jacob JM, Granieri EC, Hunt G, McGarry K, Patel D, Potosky AL, Sanders-Bush E, Silberberg D, Trevisan M. NIH State-of-the-Science Conference Statement: Preventing Alzheimer&#x2019;s Disease and Cognitive Decline. NIH Consens State Sci Statements. 2010 Apr 28;27(4)</Citation><ArticleIdList><ArticleId IdType="pubmed">20445638</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos GS. Vascular disease, depression, and dementia. J Am Geriatr Soc. 2003 Aug;51(8):1178&#x2013;1180.</Citation><ArticleIdList><ArticleId IdType="pubmed">12890087</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. &#x2018;Vascular depression&#x2019; hypothesis. Arch Gen Psychiatry. 1997 Oct;54(10):915&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">9337771</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos GS. The vascular depression hypothesis: 10 years later. Biol Psychiatry. 2006 Dec 15;60(12):1304&#x2013;1305.</Citation><ArticleIdList><ArticleId IdType="pubmed">17157096</ArticleId></ArticleIdList></Reference><Reference><Citation>Newberg AR, Davydow DS, Lee HB. Cerebrovascular disease basis of depression: post-stroke depression and vascular depression. Int Rev Psychiatry. 2006 Oct;18(5):433&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">17085362</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer LJ. Demonstrating the case that AD is a vascular disease: epidemiologic evidence. Ageing Res Rev. 2002 Feb;1(1):61&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">12039449</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005 Jan 25;64(2):277&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">15668425</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology. 2005 Aug 23;65(4):545&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1619350</ArticleId><ArticleId IdType="pubmed">16116114</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Neill D, O&#x2019;Brien J, McKeith IG, Ince P, Perry R. Anxiety, depression and psychosis in vascular dementia: prevalence and associations. J Affect Disord. 2000 Aug;59(2):97&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">10837878</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowirrat A, Oscar-Berman M, Logroscino G. Association of depression with Alzheimer&#x2019;s disease and vascular dementia in an elderly Arab population of Wadi-Ara, Israel. Int J Geriatr Psychiatry. 2006 Mar;21(3):246&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">16477584</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman SC. The prevalence of depression in Alzheimer&#x2019;s disease and vascular dementia in a population sample. J Affect Disord. 1999 Jan-Mar;52(1&#x2013;3):169&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">10357030</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JH, Lee SB, Lee TJ, Lee DY, Jhoo JH, Youn JC, Choo IH, Choi EA, Jeong JW, Choe JY, Woo JI, Kim KW. Depression in vascular dementia is quantitatively and qualitatively different from depression in Alzheimer&#x2019;s disease. Dement Geriatr Cogn Disord. 2007;23(2):67&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">17114882</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusanen M, Kivipelto M, Quesenberry CP, Jr, Zhou J, Whitmer RA. Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia. Arch Intern Med. Oct 25;</Citation><ArticleIdList><ArticleId IdType="pubmed">20975015</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA. Midlife serum cholesterol and increased risk of Alzheimer&#x2019;s and vascular dementia three decades later. Dement Geriatr Cogn Disord. 2009;28(1):75&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2814023</ArticleId><ArticleId IdType="pubmed">19648749</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmer RA, Gunderson EP, Quesenberry CP, Jr, Zhou J, Yaffe K. Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr Alzheimer Res. 2007 Apr;4(2):103&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">17430231</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP, Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009 Apr 15;301(15):1565&#x2013;1572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782622</ArticleId><ArticleId IdType="pubmed">19366776</ArticleId></ArticleIdList></Reference><Reference><Citation>Green RC, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick D, Duara R, Kukull WA, Chui H, Edeki T, Griffith PA, Friedland RP, Bachman D, Farrer L. Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol. 2003 May;60(5):753&#x2013;759.</Citation><ArticleIdList><ArticleId IdType="pubmed">12756140</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickie I, Scott E, Wilhelm K, Brodaty H. Subcortical hyperintensities on magnetic resonance imaging in patients with severe depression--a longitudinal evaluation. Biol Psychiatry. 1997 Sep 1;42(5):367&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">9276077</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann LL, Masurier M Le, Ebmeier KP. White matter hyperintensities in late life depression: a systematic review. J Neurol Neurosurg Psychiatry. 2008;79(6):619&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pubmed">17717021</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffens DC, MacFall JR, Payne ME, Welsh-Bohmer KA, Krishnan KR. Grey-matter lesions and dementia. Lancet. 2000 Nov 11;356(9242):1686&#x2013;1687.</Citation><ArticleIdList><ArticleId IdType="pubmed">11089848</ArticleId></ArticleIdList></Reference><Reference><Citation>Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010 Jul 26;341:c3666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2910261</ArticleId><ArticleId IdType="pubmed">20660506</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer&#x2019;s disease prevalence. Lancet Neurol. 2011 Sep;10(9):819&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3647614</ArticleId><ArticleId IdType="pubmed">21775213</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22566505</PMID><DateCompleted><Year>2012</Year><Month>12</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>9</Issue><PubDate><Year>2012</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Increased cerebral metabolism after 1 year of deep brain stimulation in Alzheimer disease.</ArticleTitle><Pagination><StartPage>1141</StartPage><EndPage>1148</EndPage><MedlinePgn>1141-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneurol.2012.590</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The importance of developing unique, neural circuitry-based treatments for the cognitive and neuropsychiatric symptoms of Alzheimer disease (AD) was the impetus for a phase I study of deep brain stimulation (DBS) in patients with AD that targeted the fornix.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To test the hypotheses that DBS would increase cerebral glucose metabolism in cortical and hippocampal circuits and that increased metabolism would be correlated with better clinical outcomes.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Open-label trial.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Academic medical center.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">A total of 5 patients with mild, probable AD (1 woman and 4 men, with a mean [SD] age of 62.6 [4.2] years).</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Deep brain stimulation of the fornix.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">All patients underwent clinical follow-up and high-resolution positron emission tomography studies of cerebral glucose metabolism after 1 year of DBS.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Functional connectivity analyses revealed that 1 year of DBS increased cerebral glucose metabolism in 2 orthogonal networks: a frontal-temporal-parietal-striatal-thalamic network and a frontal-temporal-parietal-occipital-hippocampal network. In similar cortical regions, higher baseline metabolism prior to DBS and increased metabolism after 1 year of DBS were correlated with better outcomes in global cognition, memory, and quality of life.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Increased connectivity after 1 year of DBS is observed, which is in contrast to the decreased connectivity observed over the course of AD. The persistent cortical metabolic increases after 1 year of DBS were associated with better clinical outcomes in this patient sample and are greater in magnitude and more extensive in the effects on cortical circuitry compared with the effects reported for pharmacotherapy over 1 year in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Gwenn S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Division of Geriatric Psychiatry and Neuropsychiatry, The Johns Hopkins University School of Medicine, The Johns Hopkins Bayview Medical Center, 5300 Alpha Commons Dr, 4th Floor, Baltimore, MD 21224, USA. gsmith95@jhmi.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laxton</LastName><ForeName>Adrian W</ForeName><Initials>AW</Initials></Author><Author ValidYN="Y"><LastName>Tang-Wai</LastName><ForeName>David F</ForeName><Initials>DF</Initials></Author><Author ValidYN="Y"><LastName>McAndrews</LastName><ForeName>Mary Pat</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Diaconescu</LastName><ForeName>Andreea Oliviana</ForeName><Initials>AO</Initials></Author><Author ValidYN="Y"><LastName>Workman</LastName><ForeName>Clifford I</ForeName><Initials>CI</Initials></Author><Author ValidYN="Y"><LastName>Lozano</LastName><ForeName>Andres M</ForeName><Initials>AM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K02 MH001621</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1 K02 MH01621</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2012 Jun 12;8(7):356. doi: 10.1038/nrneurol.2012.105.</RefSource><PMID Version="1">22688784</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046690" MajorTopicYN="Y">Deep Brain Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020712" MajorTopicYN="N">Fornix, Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011877" MajorTopicYN="N">Radionuclide Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>12</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22566505</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2012.590</ArticleId><ArticleId IdType="pii">archneurol.2012.590</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22573671</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>19</Issue><PubDate><Year>2012</Year><Month>May</Month><Day>09</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>&#x3b2;-amyloid inhibits protein prenylation and induces cholesterol sequestration by impairing SREBP-2 cleavage.</ArticleTitle><Pagination><StartPage>6490</StartPage><EndPage>6500</EndPage><MedlinePgn>6490-500</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0630-12.2012</ELocationID><Abstract><AbstractText>Accumulation of &#x3b2;-amyloid (A&#x3b2;) inside brain neurons is an early and crucial event in Alzheimer's disease (AD). Studies in brains of AD patients and mice models of AD suggested that cholesterol homeostasis is altered in neurons that accumulate A&#x3b2;. Here we directly investigated the role of intracellular oligomeric A&#x3b2;(42) (oA&#x3b2;(42)) in neuronal cholesterol homeostasis. We report that oA&#x3b2;(42) induces cholesterol sequestration without increasing cellular cholesterol mass. Several features of AD, such as endosomal abnormalities, brain accumulation of A&#x3b2; and neurofibrillary tangles, and influence of apolipoprotein E genotype, are also present in Niemann-Pick type C, a disease characterized by impairment of intracellular cholesterol trafficking. These common features and data presented here suggest that a pathological mechanism involving abnormal cholesterol trafficking could take place in AD. Cholesterol sequestration in A&#x3b2;-treated neurons results from impairment of intracellular cholesterol trafficking secondary to inhibition of protein prenylation. oA&#x3b2;(42) reduces sterol regulatory element-binding protein-2 (SREBP-2) cleavage, causing decrease of protein prenylation. Inhibition of protein prenylation represents a mechanism of oA&#x3b2;(42)-induced neuronal death. Supply of the isoprenoid geranylgeranyl pyrophosphate to oA&#x3b2;(42)-treated neurons recovers normal protein prenylation, reduces cholesterol sequestration, and prevents A&#x3b2;-induced neurotoxicity. Significant to AD, reduced levels of protein prenylation are present in the cerebral cortex of the TgCRND8 mouse model. In conclusion, we demonstrate a significant inhibitory effect of A&#x3b2; on protein prenylation and identify SREBP-2 as a target of oA&#x3b2;(42), directly linking A&#x3b2; to cholesterol homeostasis impairment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mohamed</LastName><ForeName>Amany</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada T6G 2H7.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saavedra</LastName><ForeName>Lucila</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Di Pardo</LastName><ForeName>Alba</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sipione</LastName><ForeName>Simonetta</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Posse de Chaves</LastName><ForeName>Elena</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000924">Anticholesteremic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051782">Sterol Regulatory Element Binding Protein 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000924" MajorTopicYN="N">Anticholesteremic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001692" MajorTopicYN="N">Biological Transport</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042541" MajorTopicYN="N">Intracellular Space</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017368" MajorTopicYN="N">Protein Prenylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051782" MajorTopicYN="N">Sterol Regulatory Element Binding Protein 2</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>11</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22573671</ArticleId><ArticleId IdType="pmc">PMC6621131</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0630-12.2012</ArticleId><ArticleId IdType="pii">32/19/6490</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Appelqvist H, Nilsson C, Garner B, Brown AJ, K&#xe5;gedal K, Ollinger K. Attenuation of the lysosomal death pathway by lysosomal cholesterol accumulation. Am J Pathol. 2011;178:629&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069902</ArticleId><ArticleId IdType="pubmed">21281795</ArticleId></ArticleIdList></Reference><Reference><Citation>Aqul A, Liu B, Ramirez CM, Pieper AA, Estill SJ, Burns DK, Liu B, Repa JJ, Turley SD, Dietschy JM. Unesterified cholesterol accumulation in late endosomes/lysosomes causes neurodegeneration and is prevented by driving cholesterol export from this compartment. J Neurosci. 2011;31:9404&#x2013;9413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3134878</ArticleId><ArticleId IdType="pubmed">21697390</ArticleId></ArticleIdList></Reference><Reference><Citation>Berridge MV, Tan AS. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys. 1993;303:474&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pubmed">8390225</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 2005;45:675&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748844</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanchard V, Moussaoui S, Czech C, Touchet N, Bonici B, Planche M, Canton T, Jedidi I, Gohin M, Wirths O, Bayer TA, Langui D, Duyckaerts C, Tremp G, Pradier L. Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP/PS1 transgenic mice. Exp Neurol. 2003;184:247&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">14637096</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer GJ, Torricelli JR. Isolation and culture of adult neurons and neurospheres. Nat Protoc. 2007;2:1490&#x2013;1498.</Citation><ArticleIdList><ArticleId IdType="pubmed">17545985</ArticleId></ArticleIdList></Reference><Reference><Citation>Camargo N, Smit AB, Verheijen MH. SREBPs: SREBP function in glia-neuron interactions. FEBS J. 2009;276:628&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">19143832</ArticleId></ArticleIdList></Reference><Reference><Citation>Canepa E, Borghi R, Vi&#xf1;a J, Traverso N, Gambini J, Domenicotti C, Marinari UM, Poli G, Pronzato MA, Ricciarelli R. Cholesterol and amyloid-beta: evidence for a cross-talk between astrocytes and neuronal cells. J Alzheimers Dis. 2011;25:645&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pubmed">21483097</ArticleId></ArticleIdList></Reference><Reference><Citation>Casas C, Sergeant N, Itier JM, Blanchard V, Wirths O, van der Kolk N, Vingtdeux V, van de Steeg E, Ret G, Canton T, Drobecq H, Clark A, Bonici B, Delacourte A, Benavides J, Schmitz C, Tremp G, Bayer TA, Benoit P, Pradier L. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol. 2004;165:1289&#x2013;1300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618627</ArticleId><ArticleId IdType="pubmed">15466394</ArticleId></ArticleIdList></Reference><Reference><Citation>Cenedella RJ. Cholesterol synthesis inhibitor U18666A and the role of sterol metabolism and trafficking in numerous pathophysiological processes. Lipids. 2009;44:477&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">19440746</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhury A, Sharma DK, Marks DL, Pagano RE. Elevated endosomal cholesterol levels in Niemann-Pick cells inhibit rab4 and perturb membrane recycling. Mol Biol Cell. 2004;15:4500&#x2013;4511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC519144</ArticleId><ArticleId IdType="pubmed">15292453</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen DZ, Kraus SL, Flohr A, Cotel MC, Wirths O, Bayer TA. Transient intraneuronal A beta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. Acta Neuropathol. 2008;116:647&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pubmed">18974993</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen DZ, Bayer TA, Wirths O. Intracellular Abeta triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer's disease. Neurobiol Aging. 2010;31:1153&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pubmed">18771817</ArticleId></ArticleIdList></Reference><Reference><Citation>Chui DH, Dobo E, Makifuchi T, Akiyama H, Kawakatsu S, Petit A, Checler F, Araki W, Takahashi K, Tabira T. Apoptotic neurons in Alzheimer's disease frequently show intracellular Abeta42 labeling. J Alzheimers Dis. 2001;3:231&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">12214064</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole SL, Grudzien A, Manhart IO, Kelly BL, Oakley H, Vassar R. Statins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism. J Biol Chem. 2005;280:18755&#x2013;18770.</Citation><ArticleIdList><ArticleId IdType="pubmed">15718241</ArticleId></ArticleIdList></Reference><Reference><Citation>Coxon FP, Ebetino FH, Mules EH, Seabra MC, McKenna CE, Rogers MJ. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone. 2005;37:349&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">16006204</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahlgren KN, Manelli AM, Stine WB, Jr, Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem. 2002;277:32046&#x2013;32053.</Citation><ArticleIdList><ArticleId IdType="pubmed">12058030</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Andrea MR, Nagele RG, Wang HY, Peterson PA, Lee DH. Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology. 2001;38:120&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">11207825</ArticleId></ArticleIdList></Reference><Reference><Citation>de Chaves EI, Rusi&#xf1;ol AE, Vance DE, Campenot RB, Vance JE. Role of lipoproteins in the delivery of lipids to axons during axonal regeneration. J Biol Chem. 1997;272:30766&#x2013;30773.</Citation><ArticleIdList><ArticleId IdType="pubmed">9388216</ArticleId></ArticleIdList></Reference><Reference><Citation>Ditaranto K, Tekirian TL, Yang AJ. Lysosomal membrane damage in soluble Abeta-mediated cell death in Alzheimer's disease. Neurobiol Dis. 2001;8:19&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">11162237</ArticleId></ArticleIdList></Reference><Reference><Citation>Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">12509763</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckert GP, Hooff GP, Strandjord DM, Igbavboa U, Volmer DA, M&#xfc;ller WE, Wood WG. Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients. Neurobiol Dis. 2009;35:251&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3778879</ArticleId><ArticleId IdType="pubmed">19464372</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Y, Press B, Wandinger-Ness A. Rab 7: an important regulator of late endocytic membrane traffic. J Cell Biol. 1995;131:1435&#x2013;1452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2120682</ArticleId><ArticleId IdType="pubmed">8522602</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez A, Llacuna L, Fern&#xe1;ndez-Checa JC, Colell A. Mitochondrial cholesterol loading exacerbates amyloid &#x3b2; peptide-induced inflammation and neurotoxicity. J Neurosci. 2009;29:6394&#x2013;6405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740839</ArticleId><ArticleId IdType="pubmed">19458211</ArticleId></ArticleIdList></Reference><Reference><Citation>Folch J, Lees M, Sloane-Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 1959;226:495&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">13428781</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xfc;nfschilling U, Saher G, Xiao L, M&#xf6;bius W, Nave KA. Survival of adult neurons lacking cholesterol synthesis in vivo. BMC Neurosci. 2007;8:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1769390</ArticleId><ArticleId IdType="pubmed">17199885</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganley IG, Pfeffer SR. Cholesterol accumulation sequesters Rab9 and disrupts late endosome function in NPC1-deficient cells. J Biol Chem. 2006;281:17890&#x2013;17899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3650718</ArticleId><ArticleId IdType="pubmed">16644737</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell. 2006;124:35&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">16413480</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Ramos P, Asunci&#xf3;n Mor&#xe1;n M. Ultrastructural localization of intraneuronal Abeta-peptide in Alzheimer disease brains. J Alzheimers Dis. 2007;11:53&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">17361035</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong JS, Sawamura N, Zou K, Sakai J, Yanagisawa K, Michikawa M. Amyloid beta-protein affects cholesterol metabolism in cultured neurons: implications for pivotal role of cholesterol in the amyloid cascade. J Neurosci Res. 2002;70:438&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">12391604</ArticleId></ArticleIdList></Reference><Reference><Citation>Greeve I, Hermans-Borgmeyer I, Brellinger C, Kasper D, Gomez-Isla T, Behl C, Levkau B, Nitsch RM. The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegeneration and oxidative stress. J Neurosci. 2000;20:7345&#x2013;7352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772756</ArticleId><ArticleId IdType="pubmed">11007892</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimm MO, Grimm HS, P&#xe4;tzold AJ, Zinser EG, Halonen R, Duering M, Tsch&#xe4;pe JA, De Strooper B, M&#xfc;ller U, Shen J, Hartmann T. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol. 2005;7:1118&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pubmed">16227967</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch-Reinshagen V, Burgess BL, Wellington CL. Why lipids are important for Alzheimer disease? Mol Cell Biochem. 2009;326:121&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">19116777</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooff GP, Wood WG, M&#xfc;ller WE, Eckert GP. Isoprenoids, small GTPases and Alzheimer's disease. Biochim Biophys Acta. 2010;1801:896&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886181</ArticleId><ArticleId IdType="pubmed">20382260</ArticleId></ArticleIdList></Reference><Reference><Citation>Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109:1125&#x2013;1131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC150968</ArticleId><ArticleId IdType="pubmed">11994399</ArticleId></ArticleIdList></Reference><Reference><Citation>Igbavboa U, Pidcock JM, Johnson LN, Malo TM, Studniski AE, Yu S, Sun GY, Wood WG. Cholesterol distribution in the Golgi complex of DITNC1 astrocytes is differentially altered by fresh and aged amyloid beta-peptide-(1-42) J Biol Chem. 2003;278:17150&#x2013;17157.</Citation><ArticleIdList><ArticleId IdType="pubmed">12584199</ArticleId></ArticleIdList></Reference><Reference><Citation>Igbavboa U, Sun GY, Weisman GA, He Y, Wood WG. Amyloid beta-protein stimulates trafficking of cholesterol and caveolin-1 from the plasma membrane to the Golgi complex in mouse primary astrocytes. Neuroscience. 2009;162:328&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083247</ArticleId><ArticleId IdType="pubmed">19401218</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin LW, Shie FS, Maezawa I, Vincent I, Bird T. Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. Am J Pathol. 2004;164:975&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1614713</ArticleId><ArticleId IdType="pubmed">14982851</ArticleId></ArticleIdList></Reference><Reference><Citation>Karten B, Vance DE, Campenot RB, Vance JE. Cholesterol accumulates in cell bodies, but is decreased in distal axons, of Niemann-Pick C1-deficient neurons. J Neurochem. 2002;83:1154&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pubmed">12437586</ArticleId></ArticleIdList></Reference><Reference><Citation>Karten B, Vance DE, Campenot RB, Vance JE. Trafficking of cholesterol from cell bodies to distal axons in Niemann Pick C1-deficient neurons. J Biol Chem. 2003;278:4168&#x2013;4175.</Citation><ArticleIdList><ArticleId IdType="pubmed">12458210</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura N, Yanagisawa K. Endosomal accumulation of GM1 ganglioside-bound amyloid beta-protein in neurons of aged monkey brains. Neuroreport. 2007;18:1669&#x2013;1673.</Citation><ArticleIdList><ArticleId IdType="pubmed">17921865</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh CH, Cheung NS. Cellular mechanism of U18666A-mediated apoptosis in cultured murine cortical neurons: bridging Niemann-Pick disease type C and Alzheimer's disease. Cell Signal. 2006;18:1844&#x2013;1853.</Citation><ArticleIdList><ArticleId IdType="pubmed">16797161</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotti TJ, Ramirez DM, Pfeiffer BE, Huber KM, Russell DW. Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc Natl Acad Sci U S A. 2006;103:3869&#x2013;3874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1450160</ArticleId><ArticleId IdType="pubmed">16505352</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotti T, Head DD, McKenna CE, Russell DW. Biphasic requirement for geranylgeraniol in hippocampal long-term potentiation. Proc Natl Acad Sci U S A. 2008;105:11394&#x2013;11399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2516227</ArticleId><ArticleId IdType="pubmed">18685105</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, Ladd T, Khan MA, Kache R, Beard J, Dodson M, Merit S, Ozols VV, Anastasiadis PZ, Das P, Fauq A, Koo EH, Golde TE. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med. 2005;11:545&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834426</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Tinkle BT, Bieberich CJ, Haudenschild CC, Jay G. The Alzheimer's A beta peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat Genet. 1995;9:21&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">7704018</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange Y, Ye J, Rigney M, Steck TL. Regulation of endoplasmic reticulum cholesterol by plasma membrane cholesterol. J Lipid Res. 1999;40:2264&#x2013;2270.</Citation><ArticleIdList><ArticleId IdType="pubmed">10588952</ArticleId></ArticleIdList></Reference><Reference><Citation>Langui D, Girardot N, El Hachimi KH, Allinquant B, Blanchard V, Pradier L, Duyckaerts C. Subcellular topography of neuronal Abeta peptide in APPxPS1 transgenic mice. Am J Pathol. 2004;165:1465&#x2013;1477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618656</ArticleId><ArticleId IdType="pubmed">15509518</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebrand C, Corti M, Goodson H, Cosson P, Cavalli V, Mayran N, Faur &#xe9; J, Gruenberg J. Late endosome motility depends on lipids via the small GTPase Rab7. EMBO J. 2002;21:1289&#x2013;1300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125356</ArticleId><ArticleId IdType="pubmed">11889035</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JP, Tang Y, Zhou S, Toh BH, McLean C, Li H. Cholesterol involvement in the pathogenesis of neurodegenerative diseases. Mol Cell Neurosci. 2010;43:33&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">19660552</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Peterson DA, Schubert D. Amyloid beta peptide alters intracellular vesicle trafficking and cholesterol homeostasis. Proc Natl Acad Sci U S A. 1998;95:13266&#x2013;13271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23777</ArticleId><ArticleId IdType="pubmed">9789077</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardi D, Soldati T, Riederer MA, Goda Y, Zerial M, Pfeffer SR. Rab9 functions in transport between late endosomes and the trans Golgi network. EMBO J. 1993;12:677&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC413253</ArticleId><ArticleId IdType="pubmed">8440258</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthies H, Jr, Schulz S, Hollt V, Krug M. Inhibition by compactin demonstrates a requirement of isoprenoid metabolism for long-term potentiation in rat hippocampal slices. Neuroscience. 1997;79:341&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pubmed">9200719</ArticleId></ArticleIdList></Reference><Reference><Citation>Meske V, Albert F, Richter D, Schwarze J, Ohm TG. Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease. Eur J Neurosci. 2003;17:93&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">12534972</ArticleId></ArticleIdList></Reference><Reference><Citation>Narita K, Choudhury A, Dobrenis K, Sharma DK, Holicky EL, Marks DL, Walkley SU, Pagano RE. Protein transduction of Rab9 in Niemann-Pick C cells reduces cholesterol storage. FASEB J. 2005;19:1558&#x2013;1560.</Citation><ArticleIdList><ArticleId IdType="pubmed">15972801</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieweg K, Schaller H, Pfrieger FW. Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats. J Neurochem. 2009;109:125&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">19166509</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. Endosome function and dysfunction in Alzheimer's disease and other neurodegenerative diseases. Neurobiol Aging. 2005;26:373&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">15639316</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohm TG, Treiber-Held S, Distl R, Glockner F, Schonheit B, Tamanai M, Meske V. Cholesterol and tau protein&#x2013;findings in Alzheimer's and Niemann Pick C's disease. Pharmacopsychiatry. 2003;36(Suppl 2):S120&#x2013;S126.</Citation><ArticleIdList><ArticleId IdType="pubmed">14574625</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowski SM, Wilkinson BL, Golde TE, Landreth G. Statins reduce amyloid-beta production through inhibition of protein isoprenylation. J Biol Chem. 2007;282:26832&#x2013;26844.</Citation><ArticleIdList><ArticleId IdType="pubmed">17646164</ArticleId></ArticleIdList></Reference><Reference><Citation>Peri A, Benvenuti S, Luciani P, Deledda C, Cellai I. Membrane cholesterol as a mediator of the neuroprotective effects of estrogens. Neuroscience. 2011;191:107&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">21396986</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeffer SR, Dirac-Svejstrup AB, Soldati T. Rab GDP dissociation inhibitor: putting rab GTPases in the right place. J Biol Chem. 1995;270:17057&#x2013;17059.</Citation><ArticleIdList><ArticleId IdType="pubmed">7615494</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiners JJ, Jr, Kleinman M, Kessel D, Mathieu PA, Caruso JA. Nonesterified cholesterol content of lysosomes modulates susceptibility to oxidant-induced permeabilization. Free Radic Biol Med. 2011;50:281&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3018561</ArticleId><ArticleId IdType="pubmed">21074609</ArticleId></ArticleIdList></Reference><Reference><Citation>Runz H, Rietdorf J, Tomic I, de Bernard M, Beyreuther K, Pepperkok R, Hartmann T. Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J Neurosci. 2002;22:1679&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758870</ArticleId><ArticleId IdType="pubmed">11880497</ArticleId></ArticleIdList></Reference><Reference><Citation>Saavedra L, Mohamed A, Ma V, Kar S, de Chaves EP. Internalization of beta-amyloid peptide by primary neurons in the absence of apolipoprotein E. J Biol Chem. 2007;282:35722&#x2013;35732.</Citation><ArticleIdList><ArticleId IdType="pubmed">17911110</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito Y, Suzuki K, Nanba E, Yamamoto T, Ohno K, Murayama S. Niemann-Pick type C disease: accelerated neurofibrillary tangle formation and amyloid beta deposition associated with apolipoprotein E epsilon 4 homozygosity. Ann Neurol. 2002;52:351&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">12205649</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz JG, B&#xf6;sel J, Stoeckel M, Megow D, Dirnagl U, Endres M. HMG-CoA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis. J Neurochem. 2004;89:24&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">15030386</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer disease: mechanistic understanding predicts novel therapies. Ann Intern Med. 2004;140:627&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">15096334</ArticleId></ArticleIdList></Reference><Reference><Citation>Song MS, Saavedra L, de Chaves EI. Apoptosis is secondary to non-apoptotic axonal degeneration in neurons exposed to Abeta in distal axons. Neurobiol Aging. 2006;27:1224&#x2013;1238.</Citation><ArticleIdList><ArticleId IdType="pubmed">16122841</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenmark H. Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol. 2009;10:513&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">19603039</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, Beal MF, Xu H, Greengard P, Gouras GK. Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol. 2002;161:1869&#x2013;1879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850783</ArticleId><ArticleId IdType="pubmed">12414533</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka T, Tatsuno I, Uchida D, Moroo I, Morio H, Nakamura S, Noguchi Y, Yasuda T, Kitagawa M, Saito Y, Hirai A. Geranylgeranyl-pyrophosphate, an isoprenoid of mevalonate cascade, is a critical compound for rat primary cultured cortical neurons to protect the cell death induced by 3-hydroxy-3-methylglutaryl-CoA reductase inhibition. J Neurosci. 2000;20:2852&#x2013;2859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772198</ArticleId><ArticleId IdType="pubmed">10751437</ArticleId></ArticleIdList></Reference><Reference><Citation>Tashiro Y, Yamazaki T, Shimada Y, Ohno-Iwashita Y, Okamoto K. Axon-dominant localization of cell-surface cholesterol in cultured hippocampal neurons and its disappearance in Niemann-Pick type C model cells. Eur J Neurosci. 2004;20:2015&#x2013;2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450080</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K, Ishibashi K, Teraoka R, Sakama N, Yamashita T, Nishitsuji K, Ito K, Shimada H, Lambert MP, Klein WL, Mori H. A mouse model of amyloid &#x3b2; oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci. 2010;30:4845&#x2013;4856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632783</ArticleId><ArticleId IdType="pubmed">20371804</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdez CM, Smith MA, Perry G, Phelix CF, Santamaria F. Cholesterol homeostasis markers are localized to mouse hippocampal pyramidal and granule layers. Hippocampus. 2010;20:902&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2889181</ArticleId><ArticleId IdType="pubmed">20054815</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Rogers PM, Stayrook KR, Su C, Varga G, Shen Q, Nagpal S, Burris TP. The selective Alzheimer's disease indicator-1 gene (Seladin-1/DHCR24) is a liver X receptor target gene. Mol Pharmacol. 2008;74:1716&#x2013;1721.</Citation><ArticleIdList><ArticleId IdType="pubmed">18815215</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirths O, Multhaup G, Czech C, Feldmann N, Blanchard V, Tremp G, Beyreuther K, Pradier L, Bayer TA. Intraneuronal APP/A beta trafficking and plaque formation in beta-amyloid precursor protein and presenilin-1 transgenic mice. Brain Pathol. 2002;12:275&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095864</ArticleId><ArticleId IdType="pubmed">12146796</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong J, Quinn CM, Brown AJ. SREBP-2 positively regulates transcription of the cholesterol efflux gene, ABCA1, by generating oxysterol ligands for LXR. Biochem J. 2006;400:485&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698594</ArticleId><ArticleId IdType="pubmed">16901265</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong H, Callaghan D, Jones A, Walker DG, Lue LF, Beach TG, Sue LI, Woulfe J, Xu H, Stanimirovic DB, Zhang W. Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and Abeta production. Neurobiol Dis. 2008;29:422&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2720683</ArticleId><ArticleId IdType="pubmed">18086530</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki T, Chang TY, Haass C, Ihara Y. Accumulation and aggregation of amyloid beta-protein in late endosomes of Niemann-pick type C cells. J Biol Chem. 2001;276:4454&#x2013;4460.</Citation><ArticleIdList><ArticleId IdType="pubmed">11085995</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, McLaughlin R, Goodyer C, LeBlanc A. Selective cytotoxicity of intracellular amyloid beta peptide1&#x2013;42 through p53 and Bax in cultured primary human neurons. J Cell Biol. 2002;156:519&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173346</ArticleId><ArticleId IdType="pubmed">11815632</ArticleId></ArticleIdList></Reference><Reference><Citation>Zipp F, Waiczies S, Aktas O, Neuhaus O, Hemmer B, Schraven B, Nitsch R, Hartung HP. Impact of HMG-CoA reductase inhibition on brain pathology. Trends Pharmacol Sci. 2007;28:342&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17573124</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22578498</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>3</Issue><PubDate><Year>2012</Year><Month>May</Month><Day>10</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.</ArticleTitle><Pagination><StartPage>467</StartPage><EndPage>474</EndPage><MedlinePgn>467-74</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2012.03.023</ELocationID><Abstract><AbstractText>Elevated hippocampal activation is observed in conditions that confer risk for Alzheimer's disease, including amnestic mild cognitive impairment (aMCI). Studies in relevant animal models have indicated that overactivity in selective hippocampal circuits contributes to cognitive impairment. Here, we tested the effect of reducing hippocampal activation in aMCI. Under placebo treatment, hippocampal activation in the dentate gyrus/CA3 was elevated in aMCI patients compared to a healthy control group. By using a low dose of the antiepileptic levetiracetam hippocampal activation in aMCI was reduced to&#xa0;a level that did not differ from the control group. Compared to aMCI memory performance under placebo, performance in the scanning task was significantly improved under drug treatment. Contrary to the view that greater hippocampal activation might serve a beneficial function, these results support the view that increased hippocampal activation in aMCI is a dysfunctional condition and that targeting excess hippocampal activity has therapeutic potential.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bakker</LastName><ForeName>Arnold</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD 21218, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krauss</LastName><ForeName>Gregory L</ForeName><Initials>GL</Initials></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Speck</LastName><ForeName>Caroline L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Lauren R</ForeName><Initials>LR</Initials></Author><Author ValidYN="Y"><LastName>Stark</LastName><ForeName>Craig E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Yassa</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Bassett</LastName><ForeName>Susan S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Shelton</LastName><ForeName>Amy L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Gallagher</LastName><ForeName>Michela</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG034613</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 AG036419</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG027668</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2AG036419</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>44YRR34555</RegistryNumber><NameOfSubstance UI="D000077287">Levetiracetam</NameOfSubstance></Chemical><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical><Chemical><RegistryNumber>ZH516LNZ10</RegistryNumber><NameOfSubstance UI="D010889">Piracetam</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000647" MajorTopicYN="N">Amnesia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002755" MajorTopicYN="N">Choice Behavior</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077287" MajorTopicYN="N">Levetiracetam</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010775" MajorTopicYN="N">Photic Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010889" MajorTopicYN="N">Piracetam</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>5</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22578498</ArticleId><ArticleId IdType="mid">NIHMS369300</ArticleId><ArticleId IdType="pmc">PMC3351697</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2012.03.023</ArticleId><ArticleId IdType="pii">S0896-6273(12)00325-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andrews-Zwilling Y, Bien-Ly N, Xu Q, Li G, Bernardo A, Yoon SY, Zwilling D, Yan TX, Chen L, Huang Y. Apolipoprotein E4 cause age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. J. Neurosci. 2010;41:13707&#x2013;13717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2988475</ArticleId><ArticleId IdType="pubmed">20943911</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker A, Kirwan CB, Miller M, Stark CE. Pattern separation in the human hippocampal CA3 and dentate gyrus. Science. 2008;319:1640&#x2013;1642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829853</ArticleId><ArticleId IdType="pubmed">18356518</ArticleId></ArticleIdList></Reference><Reference><Citation>Benton AL. Revised Visual Retention Test 4th. New York: Psychological Corporation; 1974.</Citation></Reference><Reference><Citation>Bero AW, Yan P, Roth JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, Holtzman DM. Neuronal activity regulates the regional vulnerability to amyloid-&#x3b2; deposition. Nat. Neurosci. 2011;14:750&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, Small GW. Patterns of brain activation in people at risk for Alzheimer&#x2019;s disease. N. Engl. J. Med. 2000;343:450&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831477</ArticleId><ArticleId IdType="pubmed">10944562</ArticleId></ArticleIdList></Reference><Reference><Citation>Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology. 1974;24:1019&#x2013;1025.</Citation><ArticleIdList><ArticleId IdType="pubmed">4473151</ArticleId></ArticleIdList></Reference><Reference><Citation>Celone KA, Calhoun VD, Dickerson BC, Atri A, Chua EF, Miller SL, DePeau K, Rentz DM, Selkoe DJ, Blacker D, et al. Alterations in memory networks in mild cognitive impairment and Alzheimer&#x2019;s disease: and independent component analysis. J Neurosci. 2006;26:10222&#x2013;10231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674636</ArticleId><ArticleId IdType="pubmed">17021177</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox RW. AFNI software for analysis and visualization of functional magnetic resonance neuroimages. Comput. Biomed. Res. 1996;29:162&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">8812068</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis NA, Browndyke JN, Stokes J, Need A, Burke JR, Welsh-Bohmer KA, Cabeza R. Temporal lobe functional activity and connectivity in young adult APOE &#x3b5;4 carriers. Alzheimers Dement. 2010;6:303&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891943</ArticleId><ArticleId IdType="pubmed">19744893</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Salat DH, Bates JF, Atiya M, Killiany RJ, Greve DN, Dale AM, Stern CE, Blacker D, Albert MS, et al. Medial temporal lobe function and structure in mild cognitive impairment. Ann. Neurol. 2004;56:27&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335689</ArticleId><ArticleId IdType="pubmed">15236399</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Salat DH, Greve DN, Chua EF, Rand-Giovannetti E, Rentz DM, Bertram L, Mullin K, Tanzi RE, Blacker D, et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology. 2005;65:404&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335677</ArticleId><ArticleId IdType="pubmed">16087905</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, Sperling RA, Klunk WE, Weiner MW, Hampel H. Neuroimaging markers for the prediction and early diagnosis of Alzheimer&#x2019;s disease dementia. Trends Neurosci. 2011;34:430&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3275347</ArticleId><ArticleId IdType="pubmed">21696834</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippini N, MacIntosh BJ, Hough MG, Goodwin GM, Frisoni GB, Smith SM, Matthews PM, Beckmann CF, Mackay CE. Distinct patterns of brain activity in young carriers of the APOE-&#x3b5;4 allele. Proc. Natl. Acad. Sci. USA. 2009;106:7209&#x2013;7214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678478</ArticleId><ArticleId IdType="pubmed">19357304</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;m&#xe4;l&#xe4;inen A, Pihlajamaki M, Tanila H, Hanninen T, Niskanen E, Tervo S, Karjalainen PA, Vanninen RL, Soininen H. Increased fMRI responses during encoding in mild cognitive impairment. Neurobiol. Aging. 2007;28:1889&#x2013;1903.</Citation><ArticleIdList><ArticleId IdType="pubmed">16997428</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirwan CB, Stark CE. Overcoming interference: an fMRI investigation of pattern separation in the medial temporal lobe. Learn. Mem. 2007;14:625&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1994079</ArticleId><ArticleId IdType="pubmed">17848502</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirwan CB, Jones CK, Miller MI, Stark CEL. High-resolution fMRI investigation of the medial temporal lobe. Hum Brain Mapp. 2007;28:959&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853185</ArticleId><ArticleId IdType="pubmed">17133381</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh MT, Haberman RP, Foti S, McCown TJ, Gallagher M. Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment. Neuropsychopharmacology. 2010;35:1016&#x2013;1025.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2820138</ArticleId><ArticleId IdType="pubmed">20032967</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy JW, Yassa MA, Stark SM, Muftuler LT, Stark CE. Distinct pattern separation related transfer functions in human CA3/dentate and CA1 revealed using high-resolution fMRI and variable mnemonic similarity. Learn. Mem. 2011;18:15&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3023966</ArticleId><ArticleId IdType="pubmed">21164173</ArticleId></ArticleIdList></Reference><Reference><Citation>Leutgeb S, Leutgeb JK. Pattern separation, pattern completion, and new neuronal codes within a continuous CA3 map. Learn. Mem. 2007;14:745&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pubmed">18007018</ArticleId></ArticleIdList></Reference><Reference><Citation>Leutgeb S, Leutgeb JK, Treves A, Moser MB, Moser EI. Distinct ensemble codes in hippocampal areas CA3 and CA1. Science. 2004;305:1295&#x2013;1298.</Citation><ArticleIdList><ArticleId IdType="pubmed">15272123</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyseng-Williamson KA. Levetiracetam: A review of its use in epilepsy. Drug. 2011;71:489&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pubmed">21395360</ArticleId></ArticleIdList></Reference><Reference><Citation>McHugh TJ, Jones MW, Quinn JJ, Balthasar N, Coppari R, Elmquist JK, Lowell BB, Fanselow MS, Wilson MA, Tonegawa S. Dentate gyrus NMDA receptors mediate rapid pattern separation in the hippocampal network. Science. 2007;317:94&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">17556551</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller SL, Fenstermacher E, Bates J, Blacker D, Sperling RA, Dickerson BC. Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline. J. Neurol. Neurosurg. Psychiatry. 2008;79:630&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683145</ArticleId><ArticleId IdType="pubmed">17846109</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien JL, O&#x2019;Keefe KM, LaViolette PS, DeLuca AN, Blacker D, Dickerson BC, Sperling RA. Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline. Neurology. 2010;74:1969&#x2013;1976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2905893</ArticleId><ArticleId IdType="pubmed">20463288</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Robertson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer&#x2019;s disease. Neuron. 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 1999;56:303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Putcha D, Brickhouse M, O&#x2019;Keefe K, Sullivan C, Rentz D, Marshall G, Dickerson B, Sperling R. Hippocampal hyperactivation associated with cortical thinning in Alzheimer&#x2019;s disease signature regions in non-demented elderly adults. J. Neurosci. 2011;31:17680&#x2013;17688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3289551</ArticleId><ArticleId IdType="pubmed">22131428</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroz YT, Budson AE, Celone K, Ruiz A, Newmark R, Castrillon G, Lopera F, Stern CE. Hippocampal hyperactivation in presymptomatic familial Alzheimer&#x2019;s disease. Ann. Neurol. 2010;68:865&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175143</ArticleId><ArticleId IdType="pubmed">21194156</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark SM, Yassa MA, Stark CEL. Individual differences in spatial pattern separation performance associated with healthy aging in humans. Learn. Mem. 2010;17:284&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2884287</ArticleId><ArticleId IdType="pubmed">20495062</ArticleId></ArticleIdList></Reference><Reference><Citation>Toner CK, Pirogovsky E, Kirwan CB, Gilbert PE. Visual object pattern separation deficits in nondemented older adults. Learn. Mem. 2009;16:338&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">19403797</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivedi MA, Schmitz TW, Ries ML, Hess TM, Fitzgerald ME, Atwood CS, Rowley HA, Asthana S, Sager MA, Johnson SC. fMRI activation during episodic encoding and metacognitive appraisal across the lifespan: risk factors for Alzheimer&#x2019;s disease. Neuropsychologia. 2008;46:1667&#x2013;1678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2443867</ArticleId><ArticleId IdType="pubmed">18241895</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Wechsler Adult Intelligence Scale &#x2013; Third Edition (WAIS-III) San Antonio, TX: The Psychological Corporation; 1997.</Citation></Reference><Reference><Citation>Wilson IA, Gallagher M, Eichenbaum H, Tanila H. Neurocognitive aging: prior memories hinder new hippocampal encoding. Trends Neurosci. 2006;29:662&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2614702</ArticleId><ArticleId IdType="pubmed">17046075</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson IA, Ikonen S, Gallagher M, Eichenbaum H, Tanila H. Age-associated alterations of hippocampal place cells are subregion specific. J. Neurosci. 2005;25:6877&#x2013;6886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725350</ArticleId><ArticleId IdType="pubmed">16033897</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson IA, Ikonen S, McMahan RW, Gallagher M, Eichenbaum H, Tanila H. Place cell rigidity correlates with impaired spatial learning in aged rats. Neurobiol. Aging. 2003;24:297&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">12498963</ArticleId></ArticleIdList></Reference><Reference><Citation>Yassa MA, Stark CE. A quantitative evaluation of cross-participant registration techniques for MRI studies of the medial temporal lobe. Neuroimage. 2009;44:319&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">18929669</ArticleId></ArticleIdList></Reference><Reference><Citation>Yassa MA, Stark SM, Bakker A, Albert MS, Gallagher M, Stark CE. High-resolution structural and functional MRI of hippocampal CA3 and dentate gyrus in patients with amnestic Mild Cognitive Impairment. Neuroimage. 2010;51:1242&#x2013;1252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2909476</ArticleId><ArticleId IdType="pubmed">20338246</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19295151</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>11</Issue><PubDate><Year>2009</Year><Month>Mar</Month><Day>18</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy.</ArticleTitle><Pagination><StartPage>3453</StartPage><EndPage>3462</EndPage><MedlinePgn>3453-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5215-08.2009</ELocationID><Abstract><AbstractText>Alzheimer's disease is associated with an increased risk of unprovoked seizures. However, the underlying mechanisms of seizure induction remain elusive. Here, we performed video-EEG recordings in mice carrying mutant human APPswe and PS1dE9 genes (APdE9 mice) and their wild-type littermates to determine the prevalence of unprovoked seizures. In two recording episodes at the onset of amyloid beta (Abeta) pathogenesis (3 and 4.5 months of age), at least one unprovoked seizure was detected in 65% of APdE9 mice, of which 46% had multiple seizures and 38% had a generalized seizure. None of the wild-type mice had seizures. In a subset of APdE9 mice, seizure phenotype was associated with a loss of calbindin-D28k immunoreactivity in dentate granular cells and ectopic expression of neuropeptide Y in mossy fibers. In APdE9 mice, persistently decreased resting membrane potential in neocortical layer 2/3 pyramidal cells and dentate granule cells underpinned increased network excitability as identified by patch-clamp electrophysiology. At stimulus strengths evoking single-component EPSPs in wild-type littermates, APdE9 mice exhibited decreased action potential threshold and burst firing of pyramidal cells. Bath application (1 h) of Abeta1-42 or Abeta25-35 (proto-)fibrils but not oligomers induced significant membrane depolarization of pyramidal cells and increased the activity of excitatory cell populations as measured by extracellular field recordings in the juvenile rodent brain, confirming the pathogenic significance of bath-applied Abeta (proto-)fibrils. Overall, these data identify fibrillar Abeta as a pathogenic entity powerfully altering neuronal membrane properties such that hyperexcitability of pyramidal cells culminates in epileptiform activity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Minkeviciene</LastName><ForeName>Rimante</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>A. I. Virtanen Institute, University of Kuopio, FIN-70211 Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rheims</LastName><ForeName>Sylvain</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Dobszay</LastName><ForeName>Marton B</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Zilberter</LastName><ForeName>Misha</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hartikainen</LastName><ForeName>Jarmo</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>F&#xfc;l&#xf6;p</LastName><ForeName>L&#xed;via</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Penke</LastName><ForeName>Botond</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Zilberter</LastName><ForeName>Yuri</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Harkany</LastName><ForeName>Tibor</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Pitk&#xe4;nen</LastName><ForeName>Asla</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tanila</LastName><ForeName>Heikki</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C074636">amyloid beta-protein (25-35)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000200" MajorTopicYN="N">Action Potentials</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="N">Epilepsy</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008809" MajorTopicYN="N">Mice, Inbred C3H</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017966" MajorTopicYN="N">Pyramidal Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>3</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>9</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19295151</ArticleId><ArticleId IdType="pmc">PMC6665248</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5215-08.2009</ArticleId><ArticleId IdType="pii">29/11/3453</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amatniek JC, Hauser WA, DelCastillo-Castaneda C, Jacobs DM, Marder K, Bell K, Albert M, Brandt J, Stern Y. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia. 2006;47:867&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">16686651</ArticleId></ArticleIdList></Reference><Reference><Citation>Babic T, Zurak N. Convulsions induced by donepezil. J Neurol Neurosurg Psychiatry. 1999;66:410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1736251</ArticleId><ArticleId IdType="pubmed">10084551</ArticleId></ArticleIdList></Reference><Reference><Citation>Breteler MM, Claus JJ, van Duijn CM, Launer LJ, Hofman A. Epidemiology of Alzheimer's disease. Epidemiol Rev. 1992;14:59&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">1289117</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold KH, Haass C, Staufenbiel M, Konnerth A, Garaschuk O. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science. 2008;321:1686&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pubmed">18802001</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson GA, Borchelt DR, Dake A, Turner S, Danielson V, Coffin JD, Eckman C, Meiners J, Nilsen SP, Younkin SG, Hsiao KK. Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice. Hum Mol Genet. 1997;611:1951&#x2013;1959.</Citation><ArticleIdList><ArticleId IdType="pubmed">9302276</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavazos JE, Golarai G, Sutula TP. Mossy fiber synaptic reorganization induced by kindling: time course of development, progression, and permanence. J Neurosci. 1991;11:2795&#x2013;2803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575263</ArticleId><ArticleId IdType="pubmed">1880549</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J, Palop JJ, Yu GQ, Kojima N, Masliah E, Mucke L. Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neurosci. 2004;24:4692&#x2013;4697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729387</ArticleId><ArticleId IdType="pubmed">15140940</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Vecchio RA, Gold LH, Novick SJ, Wong G, Hyde LA. Increased seizure threshold and severity in young transgenic CRND8 mice. Neurosci Lett. 2004;367:164&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">15331144</ArticleId></ArticleIdList></Reference><Reference><Citation>Diez M, Danner S, Frey P, Sommer B, Staufenbiel M, Wiederhold KH, H&#xf6;kfelt T. Neuropeptide alterations in the hippocampal formation and cortex of transgenic mice overexpressing b-amyloid precursor protein (APP) with the Swedish double mutation (APP23) Neurobiol Dis. 2003;14:579&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">14678773</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P, Engel J., Jr Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE) Epilepsia. 2005;46:470&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">15816939</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, Montoya-Zavala M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin B, Zhao J. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995;373:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, Greenberg SM, Bacskai BJ, Frosch MP. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis. 2006;24:516&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">17029828</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Streffer JR, David D, Schild A, Hoerndli F, Pennanen L, Kurosinski P, Chen F. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol Psychiatry. 2004;9:664&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">15052274</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SM, Tennis MK, Brown LB, Gomez-Isla T, Hayden DL, Schoenfeld DA, Walsh KL, Corwin C, Daffner KR, Friedman P, Meadows ME, Sperling RA, Growdon JH. Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol. 2000;57:94&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">10634454</ArticleId></ArticleIdList></Reference><Reference><Citation>Harkany T, O'Mahony S, Kelly JP, Soos K, Toro I, Penke B, Luiten PG, Nyakas C, Gulya K, Leonard BE. Beta-amyloid(Phe (SO3H)24)25&#x2013;35 in rat nucleus basalis induces behavioral dysfunctions, impairs learning and memory and disrupts cortical cholinergic innervation. Behav Brain Res. 1998;90:133&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">9580273</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser WA, Morris ML, Heston LL, Anderson VE. Seizures and myoclonus in patients with Alzheimer's disease. Neurology. 1986;36:1226&#x2013;1230.</Citation><ArticleIdList><ArticleId IdType="pubmed">3092131</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesdorffer DC, Hauser WA, Annegers JF, Kokmen E, Rocca WA. Dementia and adult-onset unprovoked seizures. Neurology. 1996;46:727&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">8618673</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof PR, Young WG, Bloom FE, Belichenko PV, Celio MR. Comparative cytoarchitechtonic atlas of the C57BL/6 and 129/Sv mouse brains. Amsterdam: Elsevier; 2000.</Citation></Reference><Reference><Citation>Hsiao KK, Borchelt DR, Olson K, Johannsdottir R, Kitt C, Yunis W, Xu S, Eckman C, Younkin S, Price D, ladecola C, Clark HB, Carlson G. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron. 1995;15:1203&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pubmed">7576662</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 2004;13:159&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Knobloch M, Farinelli M, Konietzko U, Nitsch RM, Mansuy IM. A&#x3b2; oligomermediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms. J Neurosci. 2007;27:7648&#x2013;7653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672892</ArticleId><ArticleId IdType="pubmed">17634359</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi DT, Chen KS. Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease. Genes Brain Behav. 2005;4:173&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">15810905</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003;40:1087&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pubmed">14687544</ArticleId></ArticleIdList></Reference><Reference><Citation>Lima PA, Vicente MI, Alves FM, Dionisio JC, Costa PF. Insulin increases excitability via a dose-dependent dual inhibition of voltage-activated K+ currents in differentiated N1E-115 neuroblastoma cells. Eur J Neurosci. 2008;27:2019&#x2013;2032.</Citation><ArticleIdList><ArticleId IdType="pubmed">18412623</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozsadi DA, Larner AJ. Prevalence and causes of seizures at the time of diagnosis of probable Alzheimer's disease. Dement Geriatr Cogn Disord. 2006;22:121&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">16733353</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez MF, Catanzaro P, Doss RC, Arguello R, Frey WH., 2nd Seizures in Alzheimer's disease: clinicopathologic study. J Geriatr Psychiatry Neurol. 1994;7:230&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">7826492</ArticleId></ArticleIdList></Reference><Reference><Citation>Minkeviciene R, Ihalainen J, Malm T, Matilainen O, Keksa-Goldsteine V, Goldsteins G, Iivonen H, Leguit N, Glennon J, Koistinaho J, Banerjee P, Tanila H. Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice. J Neurochem. 2008;105:584&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">18042177</ArticleId></ArticleIdList></Reference><Reference><Citation>Misonou H, Mohapatra DP, Trimmer JS. Kv2.1: a voltage-gated K+ channel critical to dynamic control of neuronal excitability. NeuroToxicology. 2005;26:743&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pubmed">15950285</ArticleId></ArticleIdList></Reference><Reference><Citation>Nissinen J, Lukasiuk K, Pitk&#xe4;nen A. Is mossy fiber sprouting present at the time of the first spontaneous seizures in rat experimental temporal lobe epilepsy? Hippocampus. 2001;11:299&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">11769311</ArticleId></ArticleIdList></Reference><Reference><Citation>Oksman M, Iivonen H, Hogyes E, Amtul Z, Penke B, Leenders I, Broersen L, L&#xfc;tjohann D, Hartmann T, Tanila H. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis. 2006;23:563&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">16765602</ArticleId></ArticleIdList></Reference><Reference><Citation>Olafsson E, Ludvigsson P, Gudmundsson G, Hesdorffer D, Kjartansson O, Hauser WA. Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study. Lancet Neurol. 2005;4:627&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">16168931</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Plant LD, Webster NJ, Boyle JP, Ramsden M, Freir DB, Peers C, Pearson HA. Amyloid beta peptide as a physiological modulator of neuronal &#x201c;A&#x201d;-type K+ current. Neurobiol Aging. 2006;27:1673&#x2013;1683.</Citation><ArticleIdList><ArticleId IdType="pubmed">16271805</ArticleId></ArticleIdList></Reference><Reference><Citation>Price DL, Sisodia SS, Borchelt DR. Genetic neurodegenerative diseases: the human illness and transgenic models. Science. 1998;282:1079&#x2013;1083.</Citation><ArticleIdList><ArticleId IdType="pubmed">9804539</ArticleId></ArticleIdList></Reference><Reference><Citation>Racine RJ. Modification of seizure activity by electrical stimulation II. Motor seizures. Electroencephalogr Clinl Neurophysiol. 1972;32:281&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">4110397</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheims S, Minlebaev M, Ivanov A, Represa A, Khazipov R, Holmes GL, Ben-Ari Y, Zilberter Y. Excitatory GABA in rodent developing neocortex in vitro. J Neurophysiol. 2008;100:609&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">18497364</ArticleId></ArticleIdList></Reference><Reference><Citation>Shemer I, Holmgren C, Min R, F&#xfc;l&#xf6;p L, Zilberter M, Sousa KM, Farkas T, H&#xe4;rtig W, Penke B, Burnashev N, Tanila H, Zilberter Y, Harkany T. Non-fibrillar betaamyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors. Eur J Neurosci. 2006;23:2035&#x2013;2047.</Citation><ArticleIdList><ArticleId IdType="pubmed">16630051</ArticleId></ArticleIdList></Reference><Reference><Citation>Sloviter RS. A simplified Timm stain procedure compatible with formaldehyde fixation and routine paraffin embedding of rat brain. Brain Res Bull. 1982;8:771&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">6182964</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorvari H, Soininen H, Pitk&#xe4;nen A. Calbindin-D28K-immunoreactive cells and fibres in the human amygdaloid complex. Neuroscience. 1996;75:421&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pubmed">8931007</ArticleId></ArticleIdList></Reference><Reference><Citation>Szegedi V, Juh&#xe1;sz G, R&#xf3;zsa E, Juh&#xe1;sz-Vedres G, Datki Z, F&#xfc;l&#xf6;p L, Bozs&#xf3; Z, Lakatos A, Laczk&#xf3; I, Farkas T, Kis Z, T&#xf3;th G, So&#xf3;s K, Zar&#xe1;ndi M, Budai D, Toldi J, Penke B. Endomorphin-2, an endogenous tetrapeptide, protects against Abeta1&#x2013;42 in vitro and in vivo. FASEB J. 2006;20:1191&#x2013;1193.</Citation><ArticleIdList><ArticleId IdType="pubmed">16636106</ArticleId></ArticleIdList></Reference><Reference><Citation>Talley EM, Sirois JE, Lei Q, Bayliss DA. Two-pore-domain (KCNK) potassium channels: dynamic roles in neuronal function. Neuroscientist. 2003;9:46&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">12580339</ArticleId></ArticleIdList></Reference><Reference><Citation>Tauck DL, Nadler JV. Evidence of functional mossy fiber sprouting in hippocampal formation of kainic acid-treated rats. J Neurosci. 1985;5:1016&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6565006</ArticleId><ArticleId IdType="pubmed">3981241</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonder N, Kragh J, Bolwig T, Zimmer J. Transient decrease in calbindin immunoreactivity of the rat fascia dentata granule cells after repeated electroconvulsive shocks. Hippocampus. 1994;4:79&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">8061754</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyzio R, Ivanov A, Bernard C, Holmes GL, Ben-Ari Y, Khazipov R. Membrane potential of CA3 hippocampal pyramidal cells during postnatal development. J Neurophysiol. 2003;90:2964&#x2013;2972.</Citation><ArticleIdList><ArticleId IdType="pubmed">12867526</ArticleId></ArticleIdList></Reference><Reference><Citation>Vezzani A, Sperk G, Colmers WF. Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends Neurosci. 1999;22:25&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">10088996</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Rowan MJ, Anwyl R. &#x3b2;-Amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J Neurosci. 2007;24:6049&#x2013;6056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729673</ArticleId><ArticleId IdType="pubmed">15240796</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye CP, Selkoe DJ, Hartley DM. Protofibrils of amyloid beta-protein inhibit specific K+ currents in neocortical cultures. Neurobiol Dis. 2003;13:177&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">12901832</ArticleId></ArticleIdList></Reference><Reference><Citation>Zar&#xe1;ndi M, So&#xf3;s K, F&#xfc;l&#xf6;p L, Bozs&#xf3; Z, Datki Z, T&#xf3;th GK, Penke B. Synthesis of Abeta[1&#x2013;42] and its derivatives with improved efficiency. J Pept Sci. 2007;13:94&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">17103463</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22586122</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><Issue>22</Issue><PubDate><Year>2012</Year><Month>May</Month><Day>29</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Identification of a tetratricopeptide repeat-like domain in the nicastrin subunit of &#x3b3;-secretase using synthetic antibodies.</ArticleTitle><Pagination><StartPage>8534</StartPage><EndPage>8539</EndPage><MedlinePgn>8534-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1202691109</ELocationID><Abstract><AbstractText>The &#x3b3;-secretase complex, composed of presenilin, anterior-pharynx-defective 1, nicastrin, and presenilin enhancer 2, catalyzes the intramembranous processing of a wide variety of type I membrane proteins, including amyloid precursor protein (APP) and Notch. Earlier studies have revealed that nicastrin, a type I membrane-anchored glycoprotein, plays a role in &#x3b3;-secretase assembly and trafficking and has been proposed to bind substrates. To gain more insights regarding nicastrin structure and function, we generated a conformation-specific synthetic antibody and used it as a molecular probe to map functional domains within nicastrin ectodomain. The antibody bound to a conformational epitope within a nicastrin segment encompassing residues 245-630 and inhibited the processing of APP and Notch substrates in in vitro &#x3b3;-secretase activity assays, suggesting that a functional domain pertinent to &#x3b3;-secretase activity resides within this region. Epitope mapping and database searches revealed the presence of a structured segment, located downstream of the previously identified DAP domain (DYIGS and peptidase; residues 261-502), that is homologous to a tetratricopeptide repeat (TPR) domain commonly involved in peptide recognition. Mutagenesis analyses within the predicted TPR-like domain showed that disruption of the signature helical structure resulted in the loss of &#x3b3;-secretase activity but not the assembly of the &#x3b3;-secretase and that Leu571 within the TPR-like domain plays an important role in mediating substrate binding. Taken together, these studies offer provocative insights pertaining to the structural basis for nicastrin function as a "substrate receptor" within the &#x3b3;-secretase complex.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xulun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, University of Chicago, Chicago, IL 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoey</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Guoqing</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Koide</LastName><ForeName>Akiko</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Leung</LastName><ForeName>Brenda</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Kwangwook</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Dolios</LastName><ForeName>Georgia</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Paduch</LastName><ForeName>Marcin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ikeuchi</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Rong</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yue-Ming</ForeName><Initials>YM</Initials></Author><Author ValidYN="Y"><LastName>Koide</LastName><ForeName>Shohei</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Sisodia</LastName><ForeName>Sangram S</ForeName><Initials>SS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 CA062948</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS061777</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM072688</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM087519</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR022415</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54-GM087519</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-GM072688</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>05</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009842">Oligopeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C413604">nicastrin protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055162" MajorTopicYN="N">Biocatalysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002942" MajorTopicYN="N">Circular Dichroism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009842" MajorTopicYN="N">Oligopeptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020449" MajorTopicYN="N">Repetitive Sequences, Amino Acid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020349" MajorTopicYN="N">Surface Plasmon Resonance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest. S.S.S. is a paid consultant of Nociris Inc. and Eisai Research Labs Inc. but is not a shareholder in any company that is a maker or owner of a US Food and Drug Administration-regulated drug or device.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>11</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22586122</ArticleId><ArticleId IdType="pmc">PMC3365189</ArticleId><ArticleId IdType="doi">10.1073/pnas.1202691109</ArticleId><ArticleId IdType="pii">1202691109</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Price DL, Sisodia SS. Mutant genes in familial Alzheimer&#x2019;s disease and transgenic models. Annu Rev Neurosci. 1998;21:479&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">9530504</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole SL, Vassar R. The role of amyloid precursor protein processing by BACE1, the beta-secretase, in Alzheimer disease pathophysiology. J Biol Chem. 2008;283:29621&#x2013;29625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2662048</ArticleId><ArticleId IdType="pubmed">18650431</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolia A, De Strooper B. Structure and function of gamma-secretase. Semin Cell Dev Biol. 2009;20:211&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">19007897</ArticleId></ArticleIdList></Reference><Reference><Citation>Edbauer D, et al. Reconstitution of gamma-secretase activity. Nat Cell Biol. 2003;5:486&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">12679784</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn K, et al. Activation and intrinsic gamma-secretase activity of presenilin 1. Proc Natl Acad Sci USA. 2010;107:21435&#x2013;21440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3003001</ArticleId><ArticleId IdType="pubmed">21115843</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutte C, Tsunozaki M, Hale VA, Priess JR. APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc Natl Acad Sci USA. 2002;99:775&#x2013;779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC117381</ArticleId><ArticleId IdType="pubmed">11792846</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah S, et al. Nicastrin functions as a gamma-secretase-substrate receptor. Cell. 2005;122:435&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">16096062</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasugi N, et al. The role of presenilin cofactors in the gamma-secretase complex. Nature. 2003;422:438&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">12660785</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature. 2000;407:48&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">10993067</ArticleId></ArticleIdList></Reference><Reference><Citation>Dries DR, et al. Glu-333 of nicastrin directly participates in gamma-secretase activity. J Biol Chem. 2009;284:29714&#x2013;29724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785603</ArticleId><ArticleId IdType="pubmed">19729449</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe1;vez-Guti&#xe9;rrez L, et al. Glu(332) in the Nicastrin ectodomain is essential for gamma-secretase complex maturation but not for its activity. J Biol Chem. 2008;283:20096&#x2013;20105.</Citation><ArticleIdList><ArticleId IdType="pubmed">18502756</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao G, Liu Z, Ilagan MX, Kopan R. Gamma-secretase composed of PS1/Pen2/Aph1a can cleave notch and amyloid precursor protein in the absence of nicastrin. J Neurosci. 2010;30:1648&#x2013;1656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853942</ArticleId><ArticleId IdType="pubmed">20130175</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi I, et al. Neutralization of the &#x3b3;-secretase activity by monoclonal antibody against extracellular domain of nicastrin. Oncogene. 2012;31:787&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4058788</ArticleId><ArticleId IdType="pubmed">21725355</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi I, et al. Single chain variable fragment against nicastrin inhibits the gamma-secretase activity. J Biol Chem. 2009;284:27838&#x2013;27847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2788834</ArticleId><ArticleId IdType="pubmed">19684016</ArticleId></ArticleIdList></Reference><Reference><Citation>Fellouse FA, et al. High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries. J Mol Biol. 2007;373:924&#x2013;940.</Citation><ArticleIdList><ArticleId IdType="pubmed">17825836</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Andrea LD, Regan L. TPR proteins: The versatile helix. Trends Biochem Sci. 2003;28:655&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pubmed">14659697</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirotani K, et al. Gamma-secretase activity is associated with a conformational change of nicastrin. J Biol Chem. 2003;278:16474&#x2013;16477.</Citation><ArticleIdList><ArticleId IdType="pubmed">12644462</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreman A, et al. gamma-Secretase activity requires the presenilin-dependent trafficking of nicastrin through the Golgi apparatus but not its complex glycosylation. J Cell Sci. 2003;116:1127&#x2013;1136.</Citation><ArticleIdList><ArticleId IdType="pubmed">12584255</ArticleId></ArticleIdList></Reference><Reference><Citation>Reeves PJ, Callewaert N, Contreras R, Khorana HG. Structure and function in rhodopsin: High-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. Proc Natl Acad Sci USA. 2002;99:13419&#x2013;13424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC129688</ArticleId><ArticleId IdType="pubmed">12370423</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeter EH, Kisslinger JA, Kopan R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature. 1998;393:382&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">9620803</ArticleId></ArticleIdList></Reference><Reference><Citation>Kounnas MZ, et al. Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer&#x2019;s disease. Neuron. 2010;67:769&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947312</ArticleId><ArticleId IdType="pubmed">20826309</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Ikeuchi T, Yu C, Sisodia SS. Regulated hyperaccumulation of presenilin-1 and the &#x201c;gamma-secretase&#x201d; complex. Evidence for differential intramembranous processing of transmembrane subatrates. J Biol Chem. 2003;278:33992&#x2013;34002.</Citation><ArticleIdList><ArticleId IdType="pubmed">12821663</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xfc;llekrug J, et al. Human Rer1 is localized to the Golgi apparatus and complements the deletion of the homologous Rer1 protein of Saccharomyces cerevisiae. Eur J Cell Biol. 1997;74:31&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">9309388</ArticleId></ArticleIdList></Reference><Reference><Citation>Spasic D, et al. Rer1p competes with APH-1 for binding to nicastrin and regulates gamma-secretase complex assembly in the early secretory pathway. J Cell Biol. 2007;176:629&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064021</ArticleId><ArticleId IdType="pubmed">17325205</ArticleId></ArticleIdList></Reference><Reference><Citation>Placanica L, Chien JW, Li YM. Characterization of an atypical gamma-secretase complex from hematopoietic origin. Biochemistry. 2010;49:2796&#x2013;2804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2880330</ArticleId><ArticleId IdType="pubmed">20178366</ArticleId></ArticleIdList></Reference><Reference><Citation>Niesen FH, Berglund H, Vedadi M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc. 2007;2:2212&#x2013;2221.</Citation><ArticleIdList><ArticleId IdType="pubmed">17853878</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheufler C, et al. Structure of TPR domain-peptide complexes: Critical elements in the assembly of the Hsp70-Hsp90 multichaperone machine. Cell. 2000;101:199&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">10786835</ArticleId></ArticleIdList></Reference><Reference><Citation>Edbauer D, Winkler E, Haass C, Steiner H. Presenilin and nicastrin regulate each other and determine amyloid beta-peptide production via complex formation. Proc Natl Acad Sci USA. 2002;99:8666&#x2013;8671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124353</ArticleId><ArticleId IdType="pubmed">12048259</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YW, et al. Nicastrin is critical for stability and trafficking but not association of other presenilin/gamma-secretase components. J Biol Chem. 2005;280:17020&#x2013;17026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201533</ArticleId><ArticleId IdType="pubmed">15711015</ArticleId></ArticleIdList></Reference><Reference><Citation>Koide S. Engineering of recombinant crystallization chaperones. Curr Opin Struct Biol. 2009;19:449&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2736338</ArticleId><ArticleId IdType="pubmed">19477632</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizk SS, et al. Allosteric control of ligand-binding affinity using engineered conformation-specific effector proteins. Nat Struct Mol Biol. 2011;18:437&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077571</ArticleId><ArticleId IdType="pubmed">21378967</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly SM, Jess TJ, Price NC. How to study proteins by circular dichroism. Biochim Biophys Acta. 2005;1751:119&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">16027053</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22476197</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1558-8238</ISSN><JournalIssue CitedMedium="Internet"><Volume>122</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Journal of clinical investigation</Title><ISOAbbreviation>J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.</ArticleTitle><Pagination><StartPage>1316</StartPage><EndPage>1338</EndPage><MedlinePgn>1316-38</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI59903</ELocationID><Abstract><AbstractText>While a potential causal factor in Alzheimer's disease (AD), brain insulin resistance has not been demonstrated directly in that disorder. We provide such a demonstration here by showing that the hippocampal formation (HF) and, to a lesser degree, the cerebellar cortex in AD cases without diabetes exhibit markedly reduced responses to insulin signaling in the IR&#x2192;IRS-1&#x2192;PI3K signaling pathway with greatly reduced responses to IGF-1 in the IGF-1R&#x2192;IRS-2&#x2192;PI3K signaling pathway. Reduced insulin responses were maximal at the level of IRS-1 and were consistently associated with basal elevations in IRS-1 phosphorylated at serine 616 (IRS-1 pS&#x2076;&#xb9;&#x2076;) and IRS-1 pS&#x2076;&#xb3;&#x2076;/&#x2076;&#xb3;&#x2079;. In the HF, these candidate biomarkers of brain insulin resistance increased commonly and progressively from normal cases to mild cognitively impaired cases to AD cases regardless of diabetes or APOE &#x3b5;4 status. Levels of IRS-1 pS&#x2076;&#xb9;&#x2076; and IRS-1 pS&#x2076;&#xb3;&#x2076;/&#x2076;&#xb3;&#x2079; and their activated kinases correlated positively with those of oligomeric A&#x3b2; plaques and were negatively associated with episodic and working memory, even after adjusting for A&#x3b2; plaques, neurofibrillary tangles, and APOE &#x3b5;4. Brain insulin resistance thus appears to be an early and common feature of AD, a phenomenon accompanied by IGF-1 resistance and closely associated with IRS-1 dysfunction potentially triggered by A&#x3b2; oligomers and yet promoting cognitive decline independent of classic AD pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Talbot</LastName><ForeName>Konrad</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania 19104-3403, USA. talbotk2@mail.med.upenn.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hoau-Yan</ForeName><Initials>HY</Initials></Author><Author ValidYN="Y"><LastName>Kazi</LastName><ForeName>Hala</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Li-Ying</ForeName><Initials>LY</Initials></Author><Author ValidYN="Y"><LastName>Bakshi</LastName><ForeName>Kalindi P</ForeName><Initials>KP</Initials></Author><Author ValidYN="Y"><LastName>Stucky</LastName><ForeName>Andres</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Fuino</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Kawaguchi</LastName><ForeName>Krista R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Samoyedny</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Robert S</ForeName><Initials>RS</Initials></Author><Author ValidYN="Y"><LastName>Arvanitakis</LastName><ForeName>Zoe</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Bryan A</ForeName><Initials>BA</Initials></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R25 GM056833</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG10161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG15819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG10124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Invest</MedlineTA><NlmUniqueID>7802877</NlmUniqueID><ISSNLinking>0021-9738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C526292">IRS1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055504">Insulin Receptor Substrate Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>17885-08-4</RegistryNumber><NameOfSubstance UI="D010768">Phosphoserine</NameOfSubstance></Chemical><Chemical><RegistryNumber>67763-96-6</RegistryNumber><NameOfSubstance UI="D007334">Insulin-Like Growth Factor I</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Clin Invest. 2012 Apr;122(4):1191. doi: 10.1172/jci62745.</RefSource><PMID Version="1">22754953</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002525" MajorTopicYN="N">Cerebellar Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048909" MajorTopicYN="N">Diabetes Complications</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055504" MajorTopicYN="N">Insulin Receptor Substrate Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007333" MajorTopicYN="Y">Insulin Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007334" MajorTopicYN="N">Insulin-Like Growth Factor I</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010768" MajorTopicYN="N">Phosphoserine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="N">Protein Processing, Post-Translational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>3</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22476197</ArticleId><ArticleId IdType="pmc">PMC3314463</ArticleId><ArticleId IdType="doi">10.1172/JCI59903</ArticleId><ArticleId IdType="pii">59903</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goldstein BJ. Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol. 2002;90(5A):3G&#x2013;10G.</Citation><ArticleIdList><ArticleId IdType="pubmed">12231073</ArticleId></ArticleIdList></Reference><Reference><Citation>DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004;88(4):787&#x2013;835. doi: 10.1016/j.mcna.2004.04.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcna.2004.04.013</ArticleId><ArticleId IdType="pubmed">15308380</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Holscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev. 2007;56(2):384&#x2013;402. doi: 10.1016/j.brainresrev.2007.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresrev.2007.09.001</ArticleId><ArticleId IdType="pubmed">17920690</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W-Q, Townsend M. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer&#x2019;s disease. Biochim Biophys Acta. 2009;1792(5):482&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">19026743</ArticleId></ArticleIdList></Reference><Reference><Citation>Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5(1):64&#x2013;74. doi: 10.1016/S1474-4422(05)70284-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(05)70284-2</ArticleId><ArticleId IdType="pubmed">16361024</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahtiluoto S, et al. Diabetes, Alzheimer disease, and vascular dementia, a population-based neuropathologic study. Neurology. 2010;75(13):1195&#x2013;1202. doi: 10.1212/WNL.0b013e3181f4d7f8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181f4d7f8</ArticleId><ArticleId IdType="pubmed">20739645</ArticleId></ArticleIdList></Reference><Reference><Citation>Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer&#x2019;s disease risk with obesity, diabetes, and related disorders. Biol Psychiatry. 2010;67(6):505&#x2013;512. doi: 10.1016/j.biopsych.2009.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2009.02.013</ArticleId><ArticleId IdType="pubmed">19358976</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohara T, et al. Glucose tolerance status and risk of dementia in the community, the Hisayama study. Neurology. 2011;77(12):1126&#x2013;1134. doi: 10.1212/WNL.0b013e31822f0435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31822f0435</ArticleId><ArticleId IdType="pubmed">21931106</ArticleId></ArticleIdList></Reference><Reference><Citation>Haan MN. Therapy insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer&#x2019;s disease. Nat Clin Pract Neurol. 2006;2(3):159&#x2013;166. doi: 10.1038/ncpneuro0124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncpneuro0124</ArticleId><ArticleId IdType="pubmed">16932542</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw JE, Sicree R. Epidemiology of type 2 diabetes. In: Feinglos MN, Bethel MA, eds.Contemporary Endocrinology: Type 2 Diabetes Mellitus: An Evidence Based Approach to Practical Management . Totowa, New Jersey, USA: Humana Press; 2008:1&#x2013;16.</Citation></Reference><Reference><Citation>Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol. 2011;68(1):51&#x2013;57. doi: 10.1001/archneurol.2010.225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.225</ArticleId><ArticleId IdType="pmc">PMC3023149</ArticleId><ArticleId IdType="pubmed">20837822</ArticleId></ArticleIdList></Reference><Reference><Citation>Correia SC, Santos RX, Perry G, Zhu X, Moreira PI, Smith MA. Insulin-resistant brain state: the culprit in sporadic Alzheimer&#x2019;s disease? Ageing Res Rev. 2011;10(2):264&#x2013;273. doi: 10.1016/j.arr.2011.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2011.01.001</ArticleId><ArticleId IdType="pmc">PMC3056939</ArticleId><ArticleId IdType="pubmed">21262392</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan ZS, et al. Association of metabolic dysregulation with volumetric brain magnetic resonance imaging and cognitive markers of subclinical brain aging in middle-aged adults, the Framingham Offspring Study. Diabetes Care. 2011;34(8):1766&#x2013;1770. doi: 10.2337/dc11-0308.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc11-0308</ArticleId><ArticleId IdType="pmc">PMC3142014</ArticleId><ArticleId IdType="pubmed">21680719</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrijvers EM, Witteman JC, Sijbrands EJ, Hofman A, Koudstaal PJ, Breteler MM. Insulin metabolism and the risk of Alzheimer disease: the Rotterdam Study. Neurology. 2010;75(22):1982&#x2013;1987. doi: 10.1212/WNL.0b013e3181ffe4f6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181ffe4f6</ArticleId><ArticleId IdType="pmc">PMC3014236</ArticleId><ArticleId IdType="pubmed">21115952</ArticleId></ArticleIdList></Reference><Reference><Citation>Janson J, Laedtke T, Parisi JE, O&#x2019;Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes. 2004;53(2):474&#x2013;481. doi: 10.2337/diabetes.53.2.474.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diabetes.53.2.474</ArticleId><ArticleId IdType="pubmed">14747300</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho L, et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer&#x2019;s disease. FASEB J. 2004;18(7):902&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">15033922</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke JG, et al. A biochemical and functional characterization of diet-induced brain insulin resistance. J Neurochem. 2005;93(6):1568&#x2013;1578. doi: 10.1111/j.1471-4159.2005.03155.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03155.x</ArticleId><ArticleId IdType="pubmed">15935073</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratchayasakul W, Kerdphoo S, Petsophonsakul P, Pongchaidecha A, Chattipakorn N, Chattipakorn SC. Effects of high&#x2013;fat diet on insulin receptor function in rat hippocampus and the level of neuronal corticosterone. Life Sci. 2011;88(13&#x2013;14):619&#x2013;627. doi: 10.1016/j.lfs.2011.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2011.02.003</ArticleId><ArticleId IdType="pubmed">21315737</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuzaki T, et al. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology. 2010;75(9):764&#x2013;770. doi: 10.1212/WNL.0b013e3181eee25f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181eee25f</ArticleId><ArticleId IdType="pubmed">20739649</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasgon NL, et al. Insulin resistance and hippocampal volume in women at risk for Alzheimer disease. Neurobiol Aging. 2011;32(11):1942&#x2013;1948. doi: 10.1016/j.neurobiolaging.2009.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.12.005</ArticleId><ArticleId IdType="pmc">PMC2891925</ArticleId><ArticleId IdType="pubmed">20031276</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft S. Insulin resistance syndrome and Alzheimer&#x2019;s disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging. 2005;26(suppl 1):65&#x2013;69. doi: 10.1016/j.neurobiolaging.2005.08.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2005.08.021</ArticleId><ArticleId IdType="pubmed">16266773</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole AR, Astell A, Green C, Sutherland C. Molecular connexions between dementia and diabetes. Neurosci Biobehav Rev. 2007;31(7):1046&#x2013;1063. doi: 10.1016/j.neubiorev.2007.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2007.04.004</ArticleId><ArticleId IdType="pubmed">17544131</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann KF, Rojo L, Navarrete LP, Far&#xed;as G, Reyes P, Maccioni RB. Insulin resistance and Alzheimer&#x2019;s disease: molecular links &amp; clinical implications. Curr Alzheimer Res. 2008;5(5):438&#x2013;447. doi: 10.2174/156720508785908919.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720508785908919</ArticleId><ArticleId IdType="pubmed">18855585</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims-Robinson C, Kim B, Rosko A, Feldman EL. How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol. 2010;6(10):551&#x2013;559. doi: 10.1038/nrneurol.2010.130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2010.130</ArticleId><ArticleId IdType="pmc">PMC3199576</ArticleId><ArticleId IdType="pubmed">20842183</ArticleId></ArticleIdList></Reference><Reference><Citation>Cholerton B, Baker LD, Craft S. Insulin resistance and pathological brain ageing. Diabet Med. 2011;28(12):1463&#x2013;1475. doi: 10.1111/j.1464-5491.2011.03464.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-5491.2011.03464.x</ArticleId><ArticleId IdType="pubmed">21974744</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyer S. Is sporadic Alzheimer disease the brain type of non&#x2013;insulin dependent diabetes mellitus? A challenging hypothesis. J Neural Transm. 1998;105(4&#x2013;5):415&#x2013;422. doi: 10.1007/s007020050067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s007020050067</ArticleId><ArticleId IdType="pubmed">9720971</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer&#x2019;s disease: link to brain reductions in acetylcholine. J Alzheimers Dis. 2005;8(3):247&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">16340083</ArticleId></ArticleIdList></Reference><Reference><Citation>Steen E, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer&#x2019;s disease--is this type 3 diabetes? J Alzheimers Dis. 2005;7(1):63&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">15750215</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot K, et al. O3-02-02: Expression of pIRS-1 (S312 and S616) is elevated in MCI and AD and correlates with cognitive impairment and neurofibrillary pathology. Alzheimers Dement. 2006;2(3):S54.</Citation></Reference><Reference><Citation>Salkovic-Petrisic M, Hoyer S. Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. J Neural Transm Suppl. 2007;(72):217&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">17982898</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W-Q, et al. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J. 2008;22(1):246&#x2013;260. doi: 10.1096/fj.06-7703com.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.06-7703com</ArticleId><ArticleId IdType="pubmed">17720802</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Monte SM. Insulin resistance and Alzheimer&#x2019;s disease. BMB Reports. 2009;42(8):475&#x2013;481. doi: 10.5483/BMBRep.2009.42.8.475.</Citation><ArticleIdList><ArticleId IdType="doi">10.5483/BMBRep.2009.42.8.475</ArticleId><ArticleId IdType="pmc">PMC4600067</ArticleId><ArticleId IdType="pubmed">19712582</ArticleId></ArticleIdList></Reference><Reference><Citation>Moloney AM, Griffin RJ, Timmons S, O&#x2019;Connor R, Ravid R, O&#x2019;Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer&#x2019;s disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging. 2010;31(2):224&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">18479783</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuljia RO, Salkovic-Petriaic M. Dementia, diabetes, Alzheimer&#x2019;s disease, and insulin resistance in the brain: progress, dilemmas, new opportunities, and a hypothesis to tackle intersecting epidemics. . J Alzheimers Dis. 2011;25(1):29&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">21335659</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Liu F, Grundke-Iqbal K, Gong C-X. Deficient brain insulin signalling pathway in Alzheimer&#x2019;s disease and diabetes. J Pathol. 2011;225(1):54&#x2013;62. doi: 10.1002/path.2912.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.2912</ArticleId><ArticleId IdType="pmc">PMC4484598</ArticleId><ArticleId IdType="pubmed">21598254</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin RJ, et al. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer&#x2019;s disease pathology. J Neurochem. 2005;93(1):105&#x2013;117. doi: 10.1111/j.1471-4159.2004.02949.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2004.02949.x</ArticleId><ArticleId IdType="pubmed">15773910</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma QL, et al. &#x3b2;-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci. 2009;29(28):9078&#x2013;9089. doi: 10.1523/JNEUROSCI.1071-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1071-09.2009</ArticleId><ArticleId IdType="pmc">PMC3849615</ArticleId><ArticleId IdType="pubmed">19605645</ArticleId></ArticleIdList></Reference><Reference><Citation>Reger MA, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-&#x3b2; in memory-impaired older adults. J Alzheimers Dis. 2008;13(3):323&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2804944</ArticleId><ArticleId IdType="pubmed">18430999</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft S, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment, a pilot clinical trial. Arch Neurol. 2012;69(1):29&#x2013;38. doi: 10.1001/archneurol.2011.233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.233</ArticleId><ArticleId IdType="pmc">PMC3260944</ArticleId><ArticleId IdType="pubmed">21911655</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7(2):85&#x2013;96. doi: 10.1038/nrm1837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm1837</ArticleId><ArticleId IdType="pubmed">16493415</ArticleId></ArticleIdList></Reference><Reference><Citation>Sesti G. Pathophysiology of insulin resistance. Best Pract Res Clin Endocrinol Metab. 2006;20(4):665&#x2013;679. doi: 10.1016/j.beem.2006.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beem.2006.09.007</ArticleId><ArticleId IdType="pubmed">17161338</ArticleId></ArticleIdList></Reference><Reference><Citation>Boura-Halfon S, Zick Y. Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab. 2009;296(4):E581&#x2013;E591. doi: 10.1152/ajpendo.90437.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.90437.2008</ArticleId><ArticleId IdType="pubmed">18728222</ArticleId></ArticleIdList></Reference><Reference><Citation>Fr&#xf6;jd&#xf6; S, Vidal H, Pirola L. Alterations of insulin signaling in type 2 diabetes: a review of the current evidence from humans. Biochim Biophys Acta. 2009;1792(2):83&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">19041393</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdul-Ghani MA, DeFronzo RA. Pathogenesis of insulin resistance in skeletal muscle. J Biomed Biotechnol. 2010;2010:476279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2860140</ArticleId><ArticleId IdType="pubmed">20445742</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoehn KL, et al. IRS1-independent defects define major nodes of insulin resistance. Cell Metab. 2008;7(5):421&#x2013;433. doi: 10.1016/j.cmet.2008.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2008.04.005</ArticleId><ArticleId IdType="pmc">PMC2443409</ArticleId><ArticleId IdType="pubmed">18460333</ArticleId></ArticleIdList></Reference><Reference><Citation>Morino K, et al. Muscle-specific IRS-1 Ser &#x2192; Ala transgenic mice are protected from fat-induced insulin resistance in skeletal muscle. Diabetes. 2008;57(10):2644&#x2013;2651. doi: 10.2337/db06-0454.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db06-0454</ArticleId><ArticleId IdType="pmc">PMC2551673</ArticleId><ArticleId IdType="pubmed">18633112</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun XJ, Liu F. Phosphorylation of IRS proteins: yin-yang regulation of insulin signaling. Vitam Horm. 2009;80:351&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">19251044</ArticleId></ArticleIdList></Reference><Reference><Citation>Copps KD, Hancer NJ, Opare-Ado L, Qiu W, Walsh C, White MF. Irs1 serine 307 promotes insulin sensitivity in mice. Cell Metab. 2010;11(1):84&#x2013;92. doi: 10.1016/j.cmet.2009.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2009.11.003</ArticleId><ArticleId IdType="pmc">PMC3314336</ArticleId><ArticleId IdType="pubmed">20074531</ArticleId></ArticleIdList></Reference><Reference><Citation>Boura-Halfon S, Zick Y. Serine kinases of insulin receptor substrate proteins. Vitam Horm. 2009;80:313&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">19251043</ArticleId></ArticleIdList></Reference><Reference><Citation>Gual P, Le Marchand-Brustel Y, Tanti JF. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie. 2005;87(1):99&#x2013;109. doi: 10.1016/j.biochi.2004.10.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biochi.2004.10.019</ArticleId><ArticleId IdType="pubmed">15733744</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanti J-F, Jager J. Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr Opin Pharmacol. 2009;9(6):753&#x2013;762. doi: 10.1016/j.coph.2009.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2009.07.004</ArticleId><ArticleId IdType="pubmed">19683471</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei JJ, et al. Role of protein kinase B in Alzheimer&#x2019;s neurofibrillary pathology. Acta Neuropathol. 2003;105(4):381&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">12624792</ArticleId></ArticleIdList></Reference><Reference><Citation>Rickle A, Bogdanovic N, Volkman I, Winblad B, Ravid R, Cowburn RF. Akt activity in Alzheimer&#x2019;s disease and other neurodegenerative disorders. Neuroreport. 2004;15(6):955&#x2013;959. doi: 10.1097/00001756-200404290-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-200404290-00005</ArticleId><ArticleId IdType="pubmed">15076714</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Alafuzoff I, Soininen H, Winblad B, Pei JJ. Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer&#x2019;s disease brain. FEBS J. 2005;272(16):4211&#x2013;4220. doi: 10.1111/j.1742-4658.2005.04833.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2005.04833.x</ArticleId><ArticleId IdType="pubmed">16098202</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer&#x2019;s disease. J Neurochem. 2008;104(6):1433&#x2013;1439. doi: 10.1111/j.1471-4159.2007.05194.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.05194.x</ArticleId><ArticleId IdType="pmc">PMC3073119</ArticleId><ArticleId IdType="pubmed">18088381</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Roith D. The insulin-like growth factor system. Exp Diabesity Res. 2003;4(4):205&#x2013;212. doi: 10.1155/EDR.2003.205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/EDR.2003.205</ArticleId><ArticleId IdType="pmc">PMC2478611</ArticleId><ArticleId IdType="pubmed">14668044</ArticleId></ArticleIdList></Reference><Reference><Citation>Entingh-Pearsall A, Kahn CR. Differential roles of the insulin and insulin-like growth factor-I (IGF-I) receptors in response to insulin and IGF-I. J Biol Chem. 2004;279(36):38016&#x2013;38024. doi: 10.1074/jbc.M313201200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M313201200</ArticleId><ArticleId IdType="pubmed">15247278</ArticleId></ArticleIdList></Reference><Reference><Citation>Denley A, et al. Differential activation of insulin receptor isoforms by insulin-like growth factors is determined by the C domain. Endocrinology. 2006;147(2):1029&#x2013;1036. doi: 10.1210/en.2005-0736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2005-0736</ArticleId><ArticleId IdType="pubmed">16239300</ArticleId></ArticleIdList></Reference><Reference><Citation>Denley A, et al. Differential activation of insulin receptor substrates 1 and 2 by insulin-like growth factor-activated insulin receptors. Mol Cell Biol. 2007;27(10):3569&#x2013;3577. doi: 10.1128/MCB.01447-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.01447-06</ArticleId><ArticleId IdType="pmc">PMC1899985</ArticleId><ArticleId IdType="pubmed">17325037</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann M, et al. ELISA-quantification of phosphorylated tau protein in the Alzheimer&#x2019;s disease brain. Eur Neurol. 1999;42(4):205&#x2013;210. doi: 10.1159/000008108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000008108</ArticleId><ArticleId IdType="pubmed">10567816</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Orantes M, Braak H. Phases of A&#x3b2;-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto M, Bogdanovic N, Volkmann I, Aoki M, Winblad B, Tjernberg LO. Analysis of microdissected human neurons by a sensitive ELISA reveals a correlation between elevated intracellular concentrations of A&#x3b2;42 and Alzheimer&#x2019;s disease neuropathology. Acta Neuropathol. 2010;119(5):543&#x2013;554. doi: 10.1007/s00401-010-0661-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0661-6</ArticleId><ArticleId IdType="pubmed">20198479</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239&#x2013;259. doi: 10.1007/BF00308809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Unger JW, Livingston JN, Moss AM. Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects. Prog Neurobiol. 1991;36(5):343&#x2013;362. doi: 10.1016/0301-0082(91)90015-S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0301-0082(91)90015-S</ArticleId><ArticleId IdType="pubmed">1887067</ArticleId></ArticleIdList></Reference><Reference><Citation>Kar S, Chabot J-G, Quirion R. Quantitative autoradiographic localization of [125I]insulin-like growth factor I, [125I]insulin-like growth factor II, and [125I]insulin receptor binding sites in developing and adult rat brain. . J Comp Neurol. 1993;333(3):375&#x2013;397. doi: 10.1002/cne.903330306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.903330306</ArticleId><ArticleId IdType="pubmed">8349849</ArticleId></ArticleIdList></Reference><Reference><Citation>El Messari S, Leloup C, Quignon M, Brisorgueil MJ, Penicaud L, Arluison M. Immunocytochemical localization of the insulin-responsive glucose transporter 4 (Glut4) in the rat central nervous system. . J Comp Neurol. 1998;399(4):492&#x2013;512. doi: 10.1002/(SICI)1096-9861(19981005)399:4&lt;492::AID-CNE4&gt;3.0.CO;2-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-9861(19981005)399:4&lt;492::AID-CNE4&gt;3.0.CO;2-X</ArticleId><ArticleId IdType="pubmed">9741479</ArticleId></ArticleIdList></Reference><Reference><Citation>El Messari S, Ait-Ikhlef A, Ambroise DH, Penicaud L, Arluison M. Expression of insulin-responsive glucose transporter GLUT4 mRNA in the rat brain and spinal cord: an in situ hybridization study. . J Chem Neuroanat. 2002;24(4):225&#x2013;242. doi: 10.1016/S0891-0618(02)00058-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0891-0618(02)00058-3</ArticleId><ArticleId IdType="pubmed">12406499</ArticleId></ArticleIdList></Reference><Reference><Citation>Apelt J, Melhorn G, Schliebs R. Insulin-sensitive GLUT4 glucose transporters are colocalized with GLUT3-expressing cells and demonstrate a chemically distinct neuron-specific localization in rat brain. J Neurosci Res. 1999;57(5):693&#x2013;705. doi: 10.1002/(SICI)1097-4547(19990901)57:5&lt;693::AID-JNR11&gt;3.0.CO;2-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4547(19990901)57:5&lt;693::AID-JNR11&gt;3.0.CO;2-X</ArticleId><ArticleId IdType="pubmed">10462693</ArticleId></ArticleIdList></Reference><Reference><Citation>Choeiri C, Staines W, Messier C. Immuno&#xad;histo&#xad;chemical localization and quantification of glucose transporters in the mouse brain. NeuroScience. 2002;111(1):19&#x2013;34. doi: 10.1016/S0306-4522(01)00619-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4522(01)00619-4</ArticleId><ArticleId IdType="pubmed">11955709</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwen BS, Reagan LP. Glucose transporter expression in the central nervous system: relationship to synaptic function. Eur J Pharmacol. 2004;490(1&#x2013;3):13&#x2013;24. doi: 10.1016/j.ejphar.2004.02.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2004.02.041</ArticleId><ArticleId IdType="pubmed">15094070</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Sperling RA. Functional abnormalities of the medial temporal lobe memory system in mild cognitive impairment and Alzheimer&#x2019;s disease: insights from functional MRI studies. Neuropsychologia. 2008;46(6):1624&#x2013;1635. doi: 10.1016/j.neuropsychologia.2007.11.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropsychologia.2007.11.030</ArticleId><ArticleId IdType="pmc">PMC2760288</ArticleId><ArticleId IdType="pubmed">18206188</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarazin M, et al. The amnestic syndrome of hippocampal type in Alzheimer&#x2019;s disease: an MRI study. J Alzheimers Dis. 2010;22(1):285&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">20847406</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn C-G, et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med. 2006;12(7):824&#x2013;828. doi: 10.1038/nm1418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1418</ArticleId><ArticleId IdType="pubmed">16767099</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HY, Stucky A, Liu J, Shen C, Trocme-Thibierge C, Morain P. Dissociating beta-amyloid from alpha 7 nicotinic acetylcholine receptor by a novel therapeutic agent, S 24795, normalizes alpha 7 nicotinic acetylcholine and NMDA receptor function in Alzheimer&#x2019;s disease brain. J Neurosci. 2009;29(35):10961&#x2013;10973. doi: 10.1523/JNEUROSCI.6088-08.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6088-08.2009</ArticleId><ArticleId IdType="pmc">PMC6665534</ArticleId><ArticleId IdType="pubmed">19726654</ArticleId></ArticleIdList></Reference><Reference><Citation>Verwer RWH, et al. Cells in human postmortem brain tissue slices remain alive for several weeks in culture. FASEB J. 2002;16(1):54&#x2013;60. doi: 10.1096/fj.01-0504com.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.01-0504com</ArticleId><ArticleId IdType="pubmed">11772936</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Roith D, et al. Insulin in brain and other extrapancreatic tissues of vertebrates and nonvertebrates. Adv Metab Disord. 1983;10:303&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">6364717</ArticleId></ArticleIdList></Reference><Reference><Citation>Baskin DG, Figlewicz DP, Woods SC, Porte D, Jr, Dorsa DM. Insulin in the brain. Ann Rev Physiol. 1987;49:335&#x2013;347. doi: 10.1146/annurev.ph.49.030187.002003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.ph.49.030187.002003</ArticleId><ArticleId IdType="pubmed">3551804</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi F, et al. Insulin-like growth factor 1 (IGF-1) distribution in the tissue and extracellular compartment in different regions of rat brain. Brain Res. 1990;533(2):344&#x2013;347. doi: 10.1016/0006-8993(90)91361-J.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(90)91361-J</ArticleId><ArticleId IdType="pubmed">2289149</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheatham B, Kahn CR. Insulin action and the insulin signaling network. Endocr Rev. 1995;16(2):117&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">7781591</ArticleId></ArticleIdList></Reference><Reference><Citation>Combettes-Souverain M, Isaad T. Molecular basis of insulin action. Diabetes Metab. 1998;24(6):477&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">9932214</ArticleId></ArticleIdList></Reference><Reference><Citation>LeRoith D, Werner H, Beitner-Johnson D, Roberts CT., Jr Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev. 1995;16(2):143&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">7540132</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, Field SJ, Lee JY, Engelman JA, Cantley LC. The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. J Cell Biol. 2005;170(3):455&#x2013;464. doi: 10.1083/jcb.200503088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200503088</ArticleId><ArticleId IdType="pmc">PMC2171479</ArticleId><ArticleId IdType="pubmed">16043515</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikegami Y, Inukai K, Awata T, Asano T, Katayama S. SH3 domain of the phosphatidylinositol 3-kinase regulatory subunit is responsible for the formation of a sequestration complex with insulin receptor substrate-1. Biochem Biophys Res Commun. 2008;365(3):433&#x2013;438. doi: 10.1016/j.bbrc.2007.10.187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2007.10.187</ArticleId><ArticleId IdType="pubmed">17991427</ArticleId></ArticleIdList></Reference><Reference><Citation>Folli F, Bonfanti L, Renard E, Kahn CR, Merighi A. Insulin receptor substrate-1 (IRS-1) distribution in the rat central nervous system. J Neurosci. 1994;14(11 pt 1):6412&#x2013;6422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577292</ArticleId><ArticleId IdType="pubmed">7965046</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hoesen GW, Hyman BT. Hippocampal formation: anatomy and the patterns of pathology in Alzheimer&#x2019;s disease. Prog Brain Res. 1990;83:445&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">2392569</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer&#x2019;s disease. Cereb Cortex. 1991;1(1):103&#x2013;116. doi: 10.1093/cercor/1.1.103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/1.1.103</ArticleId><ArticleId IdType="pubmed">1822725</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim&#xf3;n D, et al. Pharmacological inhibition of GSK-3 is not strictly correlated with a decrease in tyrosine phosphorylation of residues 216/279. . J Neurosci Res. 2008;86(3):668&#x2013;674. doi: 10.1002/jnr.21523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.21523</ArticleId><ArticleId IdType="pubmed">17893926</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres SH, De Sanctis JB, de L Brice&#xf1;o M, Hern&#xe1;ndez N, Finol HJ. Inflammation and nitric oxide production in skeletal muscle of type 2 diabetic patients. J Endocrinol. 2004;181(3):419&#x2013;427. doi: 10.1677/joe.0.1810419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1677/joe.0.1810419</ArticleId><ArticleId IdType="pubmed">15171690</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartley D, Cooper GM. Role of mTOR in the degradation of IRS-1: regulation of PP2A activity. J Cell Biochem. 2002;85(2):304&#x2013;314. doi: 10.1002/jcb.10135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.10135</ArticleId><ArticleId IdType="pubmed">11948686</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallak H, Ramadan B, Rubin R. Tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) by oxidant stress in cerebellar granule neurons: modulation by N-methyl-D-aspartate through calcineurin activity. J Neurochem. 2001;77(1):63&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">11279262</ArticleId></ArticleIdList></Reference><Reference><Citation>Park CH, et al. Calcineurin mediates AKT dephosphorylation in the ischemic rat retina. Brain Res. 2008;1234:148&#x2013;157. doi: 10.1016/j.brainres.2008.07.082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2008.07.082</ArticleId><ArticleId IdType="pubmed">18703031</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmeen A, Andersen JN, Myers MP, Tonks NK, Barford D. Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B. Mol Cell. 2000;6(6):1401&#x2013;1412. doi: 10.1016/S1097-2765(00)00137-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1097-2765(00)00137-4</ArticleId><ArticleId IdType="pubmed">11163213</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia--meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009;119(4):252&#x2013;265. doi: 10.1111/j.1600-0447.2008.01326.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0447.2008.01326.x</ArticleId><ArticleId IdType="pubmed">19236314</ArticleId></ArticleIdList></Reference><Reference><Citation>Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129(7):1261&#x2013;1274. doi: 10.1016/j.cell.2007.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.06.009</ArticleId><ArticleId IdType="pmc">PMC2756685</ArticleId><ArticleId IdType="pubmed">17604717</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaid H, Antonescu CN, Randhawa VK, Klip A. Insulin action on glucose transporters through molecular switches, tracks and tethers. Biochem J. 2008;413(2):201&#x2013;215. doi: 10.1042/BJ20080723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20080723</ArticleId><ArticleId IdType="pubmed">18570632</ArticleId></ArticleIdList></Reference><Reference><Citation>Garippa RJ, Johnson A, Park J, Petrush RL, McGraw TE. The carboxyl terminus of GLUT4 contains a serine-leucine-leucine sequence that functions as a potent internalization motif in Chinese hamster ovary cells. J Biol Chem. 1996;271(34):20660&#x2013;20668. doi: 10.1074/jbc.271.34.20660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.271.34.20660</ArticleId><ArticleId IdType="pubmed">8702815</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuong MDT, Brion F, Schwartz J-C. Stimulation of deoxy[3H]glucose uptake into slices from cerebral cortex elicited by excitatory amino acids. . NeuroScience. 1984;12(2):385&#x2013;393. doi: 10.1016/0306-4522(84)90060-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0306-4522(84)90060-5</ArticleId><ArticleId IdType="pubmed">6146948</ArticleId></ArticleIdList></Reference><Reference><Citation>Bak LK, Walls AB, Schousboe A, Ring A, Sonnewald U, Waagepetersen HS. Neuronal glucose but not lactate utilization is positively correlated with NMDA-induced neurotransmission and fluctuations in cytosolic Ca2+ levels. . J Neurochem. 2009;109(suppl 1):87&#x2013;93. doi: 10.1111/j.1471-4159.2009.05943.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.05943.x</ArticleId><ArticleId IdType="pubmed">19393013</ArticleId></ArticleIdList></Reference><Reference><Citation>Uemura E, Greenlee HW. Insulin regulates neuronal glucose uptake by promoting translocation of glucose transporter GLUT3. Exp Neurol. 2006;198(1):48&#x2013;53. doi: 10.1016/j.expneurol.2005.10.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2005.10.035</ArticleId><ArticleId IdType="pubmed">16337941</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernando RN, Albiston AL, Chai SY. The insulin-regulated aminopeptidase IRAP is colocalized with GLUT4 in the mouse hippocampus &#x2013; potential role in modulation of glucose uptake in neurons? Eur J Neurosci. 2008;28(3):588&#x2013;598. doi: 10.1111/j.1460-9568.2008.06347.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2008.06347.x</ArticleId><ArticleId IdType="pubmed">18702730</ArticleId></ArticleIdList></Reference><Reference><Citation>Rother KI, Imai Y, Caruso M, Beguinot F, Formisano P, Accili D. Evidence that IRS-2 phosphorylation is required for insulin action action in hepatocytes. J Biol Chem. 1998;273(28):17491&#x2013;17497. doi: 10.1074/jbc.273.28.17491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.273.28.17491</ArticleId><ArticleId IdType="pubmed">9651339</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidenreich KA, Zahniser NR, Berhanu P, Brandenburg D, Olefsky JM. Structural differences between insulin receptors in the brain and peripheral target tissues. J Biol Chem. 1983;258(14):8527&#x2013;8530.</Citation><ArticleIdList><ArticleId IdType="pubmed">6345543</ArticleId></ArticleIdList></Reference><Reference><Citation>Gammeltoft S, Fehlmann M, Van Obberghen E. Insulin receptors in the mammalian central nervous system: binding characteristics and subunit structure. Biochimie. 1985;67(10&#x2013;11):1147&#x2013;1153. doi: 10.1016/S0300-9084(85)80113-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0300-9084(85)80113-9</ArticleId><ArticleId IdType="pubmed">3907719</ArticleId></ArticleIdList></Reference><Reference><Citation>Seino S, Bell GI. Alternative splicing of human insulin receptor messenger RNA. Biochem Biophys Res Commun. 1989;159(1):312&#x2013;316. doi: 10.1016/0006-291X(89)92439-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-291X(89)92439-X</ArticleId><ArticleId IdType="pubmed">2538124</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonntag WE, Ramsey M, Carter CS. Growth hormone and insulin-like growth factor-1 (IGF-1) and their influence on cognitive aging. Ageing Res Rev. 2005;4(2):195&#x2013;212. doi: 10.1016/j.arr.2005.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2005.02.001</ArticleId><ArticleId IdType="pubmed">16024298</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng CM, Reinhardt RR, Lee WH, Joncas G, Patel SC, Bondy CA. Insulin-like growth factor 1 regulates developing brain glucose metabolism. Proc Natl Acad Sci U S A. 2000;97(18):10236&#x2013;10241. doi: 10.1073/pnas.170008497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.170008497</ArticleId><ArticleId IdType="pmc">PMC27834</ArticleId><ArticleId IdType="pubmed">10954733</ArticleId></ArticleIdList></Reference><Reference><Citation>Freude S, et al. Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer&#x2019;s disease. FASEB J. 2009;23(10):3315&#x2013;3324. doi: 10.1096/fj.09-132043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.09-132043</ArticleId><ArticleId IdType="pubmed">19487308</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen E, et al. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell. 2009;139(6):1157&#x2013;1169. doi: 10.1016/j.cell.2009.11.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2009.11.014</ArticleId><ArticleId IdType="pmc">PMC3017511</ArticleId><ArticleId IdType="pubmed">20005808</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, et al. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem. 1996;271(8):4077&#x2013;4081. doi: 10.1074/jbc.271.8.4077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.271.8.4077</ArticleId><ArticleId IdType="pubmed">8626743</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y, et al. Alzheimer&#x2019;s disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A. 2003;100(18):10417&#x2013;10422. doi: 10.1073/pnas.1834302100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1834302100</ArticleId><ArticleId IdType="pmc">PMC193576</ArticleId><ArticleId IdType="pubmed">12925731</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham E, et al. Progressive accumulation of amyloid-&#x3b2; oligomers in Alzheimer&#x2019;s disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. FEBS J. 2010;277(14):3051&#x2013;3067. doi: 10.1111/j.1742-4658.2010.07719.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2010.07719.x</ArticleId><ArticleId IdType="pmc">PMC2933033</ArticleId><ArticleId IdType="pubmed">20573181</ArticleId></ArticleIdList></Reference><Reference><Citation>Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem. 2005;280(17):17294&#x2013;17300. doi: 10.1074/jbc.M500997200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M500997200</ArticleId><ArticleId IdType="pubmed">15722360</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W-Q, et al. Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. J Biol Chem. 1999;274(49):34893&#x2013;34902. doi: 10.1074/jbc.274.49.34893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.49.34893</ArticleId><ArticleId IdType="pubmed">10574963</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberdi E, et al. Amyloid b oligomers induce Ca2+ dysregulation and neuronal cell death through activation of iontotropic glutamate receptors. Cell Calcium. 2010;47(3):264&#x2013;272. doi: 10.1016/j.ceca.2009.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceca.2009.12.010</ArticleId><ArticleId IdType="pubmed">20061018</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkinton MS, Ip JK, Wood GL, Crossthwaite AJ, Williams RJ. Phosphatidylinositol 3-kinase is a central mediator of NMDA receptor signalling to MAP kinase (Erk1/2), Akt/PKB and CREB in striatal neurones. J Neurochem. 2002;80(2):239&#x2013;254. doi: 10.1046/j.0022-3042.2001.00699.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0022-3042.2001.00699.x</ArticleId><ArticleId IdType="pubmed">11902114</ArticleId></ArticleIdList></Reference><Reference><Citation>Morisco C, et al. Akt mediates the cross-talk between beta-adrenergic and insulin receptors in neonatal cardiomyocytes. Circ Res. 2005;96(2):180&#x2013;188. doi: 10.1161/01.RES.0000152968.71868.c3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.RES.0000152968.71868.c3</ArticleId><ArticleId IdType="pubmed">15591229</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W-Q, et al. Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric A&#x3b2;. J Biol Chem. 2009;284(28):18742&#x2013;18753. doi: 10.1074/jbc.M109.011015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.011015</ArticleId><ArticleId IdType="pmc">PMC2707198</ArticleId><ArticleId IdType="pubmed">19406747</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Amyloid-beta protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat Med. 2008;14(8):837&#x2013;842. doi: 10.1038/nm1782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1782</ArticleId><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Beeri MS, et al. Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology. 2008;71(10):750&#x2013;757. doi: 10.1212/01.wnl.0000324925.95210.6d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000324925.95210.6d</ArticleId><ArticleId IdType="pmc">PMC2676951</ArticleId><ArticleId IdType="pubmed">18765651</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Bisht B, Dey CS. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer&#x2019;s-like changes. Neuropharmacology. 2011;60(6):910&#x2013;920. doi: 10.1016/j.neuropharm.2011.01.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2011.01.033</ArticleId><ArticleId IdType="pubmed">21277873</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao H, et al. GLP-1 amplifies insulin signaling by up-regulation of IRbeta, IRS-1 and Glut4 in 3T3-L1 adipocytes. Endocrine. 2007;32(1):90&#x2013;95. doi: 10.1007/s12020-007-9011-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-007-9011-4</ArticleId><ArticleId IdType="pubmed">17992607</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, et al. GLP-1 receptor stimulation reduces amyloid-&#x3b2; peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer&#x2019;s disease. J Alzheimers Dis. 2010;19(4):1205&#x2013;1219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2948479</ArticleId><ArticleId IdType="pubmed">20308787</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;lscher C. Diabetes as a risk factor for Alzheimer&#x2019;s disease: insulin signaling impairment in the brain as an alternative model of Alzheimer&#x2019;s disease. Biochem Soc Trans. 2011;39(4):891&#x2013;897. doi: 10.1042/BST0390891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST0390891</ArticleId><ArticleId IdType="pubmed">21787319</ArticleId></ArticleIdList></Reference><Reference><Citation>McClean PL, Parthsarathy V, Faivre E, H&#xf6;lscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer&#x2019;s disease. J Neurosci. 2011;31(17):6587&#x2013;6594. doi: 10.1523/JNEUROSCI.0529-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0529-11.2011</ArticleId><ArticleId IdType="pmc">PMC6622662</ArticleId><ArticleId IdType="pubmed">21525299</ArticleId></ArticleIdList></Reference><Reference><Citation>Bomfim TR, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer&#x2019;s disease&#x2013;associated A&#x3b2; oligomers. J Clin Invest. 2012;122(4):1339&#x2013;1353. doi: 10.1172/JCI57256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI57256</ArticleId><ArticleId IdType="pmc">PMC3314445</ArticleId><ArticleId IdType="pubmed">22476196</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami K, et al. Insulin receptor mutation results in insulin resistance and hyperinsulinemia but does not exacerbate Alzheimer&#x2019;s-like phenotypes in mice. Biochem Biophys Res Comm. 2011;409(1):34&#x2013;39. doi: 10.1016/j.bbrc.2011.04.101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2011.04.101</ArticleId><ArticleId IdType="pubmed">21549686</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriksen EJ, Teachey MK. Short-term in vitro inhibition of glycogen synthase kinase 3 potentiates insulin signaling in type I skeletal muscle of Zucker diabetic fatty rats. Metabolism. 2007;56(7):931&#x2013;938. doi: 10.1016/j.metabol.2007.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2007.03.002</ArticleId><ArticleId IdType="pmc">PMC1986761</ArticleId><ArticleId IdType="pubmed">17570255</ArticleId></ArticleIdList></Reference><Reference><Citation>Mothe I, Van Obberghen E. Phosphorylation of insulin receptor substrate-1 on multiple serine residues, 612, 632, 662, and 731, modulates insulin action. J Biol Chem. 1996;271(19):11222&#x2013;11227. doi: 10.1074/jbc.271.19.11222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.271.19.11222</ArticleId><ArticleId IdType="pubmed">8626671</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong YH, Shin YJ, Lee EO, Kayed R, Glabe CG, Tenner AJ. ERK1/2 activation mediates A&#x3b2; oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J Biol Chem. 2006;281(29):20315&#x2013;20325. doi: 10.1074/jbc.M601016200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M601016200</ArticleId><ArticleId IdType="pubmed">16714296</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaskar K, Miller M, Chludzinski A, Herrup K, Zagorski M, Lamb BT. The PI3K-Akt-mTOR pathway regulates A&#x3b2; oligomer induced neuronal cell cycle events. Mol Neurodegener. 2009;4:14. doi: 10.1186/1750-1326-4-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-4-14</ArticleId><ArticleId IdType="pmc">PMC2663563</ArticleId><ArticleId IdType="pubmed">19291319</ArticleId></ArticleIdList></Reference><Reference><Citation>Miscia S, et al. A&#x3b2;1-42 stimulated T cells express P-PKC-&#x3b4; and P-PKC-&#x3b6; in Alzheimer disease. Neurobiol Aging. 2009;30(3):394&#x2013;406. doi: 10.1016/j.neurobiolaging.2007.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.07.011</ArticleId><ArticleId IdType="pubmed">17850925</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R, et al. A&#x3b2;42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7(9):940&#x2013;946. doi: 10.1038/sj.embor.7400784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.embor.7400784</ArticleId><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H-Y, et al. The diabetes drug liraglutide ameliorates insulin resistance in the hippocampal formation of Alzheimer&#x2019;s disease (AD) cases. 2011 Neuroscience Meeting Planner. Washington, DC, USA: Society for Neuroscience, 2011.</Citation></Reference><Reference><Citation>Zhande R, et al. Dephosphorylation by default, a potential mechanism for regulation of insulin receptor substrate-1/2, Akt, and ERK1/2. J Biol Chem. 2006;281(51):39071&#x2013;39080. doi: 10.1074/jbc.M605251200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M605251200</ArticleId><ArticleId IdType="pubmed">17068339</ArticleId></ArticleIdList></Reference><Reference><Citation>Hers I, et al. Reciprocal feedback regulation of insulin receptor and insulin receptor substrate tyrosine phosphorylation by phosphoinositide 3-kinase in primary adipocytes. Biochem J. 2002;368(pt 3):875&#x2013;884. doi: 10.1042/BJ20020903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20020903</ArticleId><ArticleId IdType="pmc">PMC1223033</ArticleId><ArticleId IdType="pubmed">12220227</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi Z, Luo M, Carroll CA, Weintraub ST, Mandarino LJ. Identification of phosphorylation sites in insulin receptor substrate-1 by hypothesis-driven high-performance liquid chromatography-electrospray ionization tandem mass spectrometry. Anal Chem. 2005;77(17):5693&#x2013;5699. doi: 10.1021/ac050760y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ac050760y</ArticleId><ArticleId IdType="pubmed">16131083</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu BR, Ko HW, Jou I, Noh JS, Gwap BJ. Phosphatidylinositol 3-kinase-mediated regulation of neuronal apoptosis and necrosis by insulin and IGF-1. J Neurobiol. 1999;39(4):536&#x2013;546. doi: 10.1002/(SICI)1097-4695(19990615)39:4&lt;536::AID-NEU7&gt;3.0.CO;2-J.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4695(19990615)39:4&lt;536::AID-NEU7&gt;3.0.CO;2-J</ArticleId><ArticleId IdType="pubmed">10380075</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng Y-H, Ueki K, Kriauciunas KM, Kahn CR. Differential roles of insulin receptor substrates in the anti-apoptotic function of insulin-like growth factor-1 and insulin. J Biol Chem. 2002;277(35):31601&#x2013;31611. doi: 10.1074/jbc.M202932200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M202932200</ArticleId><ArticleId IdType="pubmed">12082100</ArticleId></ArticleIdList></Reference><Reference><Citation>Picone P, et al. Insulin activated Akt rescues A&#x3b2; oxidative stress-induced cell death by orchestrating molecular trafficking. Aging Cell. 2011;10(5):832&#x2013;843. doi: 10.1111/j.1474-9726.2011.00724.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1474-9726.2011.00724.x</ArticleId><ArticleId IdType="pubmed">21624038</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikoulina SE, Ciaraldi TP, Mudaliar S, Mohideen P, Carter L, Henry RR. Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes. 2000;49(2):263&#x2013;271. doi: 10.2337/diabetes.49.2.263.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diabetes.49.2.263</ArticleId><ArticleId IdType="pubmed">10868943</ArticleId></ArticleIdList></Reference><Reference><Citation>Larner AJ. The cerebellum in Alzheimer&#x2019;s disease. Dement Geriatr Cogn Disord. 1997;8(4):203&#x2013;209. doi: 10.1159/000106632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000106632</ArticleId><ArticleId IdType="pubmed">9213064</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibberson M, Riederer BM, Uldry M, Guhl B, Roth J, Thorens B. Immunolocalization of GLUTX1 in the testis and to specific brain areas and vasopressin-containing neurons. Endocrinology. 2002;143(1):276&#x2013;284. doi: 10.1210/en.143.1.276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.143.1.276</ArticleId><ArticleId IdType="pubmed">11751619</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin B-C, McKnight RA, Devaskar SU. Glucose transporter GLUT8 translocation in neurons is not insulin responsive. J Neurosci Res. 2004;75(6):835&#x2013;844. doi: 10.1002/jnr.20054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.20054</ArticleId><ArticleId IdType="pubmed">14994344</ArticleId></ArticleIdList></Reference><Reference><Citation>Piroli GG. Corticosterone impairs insulin-stimulated translocation of GLUT4 in the rat hippocampus. Neuroendocrinology. 2007;85(2):71&#x2013;80. doi: 10.1159/000101694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000101694</ArticleId><ArticleId IdType="pubmed">17426391</ArticleId></ArticleIdList></Reference><Reference><Citation>Grillo CA, Piroli GG, Hendry RM, Reagan LP. Insulin-stimulated translocation of GLUT4 to the plasma membrane in rat hippocampus is PI3-kinase dependent. Brain Res. 2009;1296:35&#x2013;45. doi: 10.1016/j.brainres.2009.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2009.08.005</ArticleId><ArticleId IdType="pmc">PMC2997526</ArticleId><ArticleId IdType="pubmed">19679110</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakirtzi K, et al. Cerebellar neurons possess a vesicular compartment structurally and functionally similar to Glut4-storage vesicles from peripheral insulin-sensitive tissues. J Neurosci. 2009;29(16):5193&#x2013;5201. doi: 10.1523/JNEUROSCI.0858-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0858-09.2009</ArticleId><ArticleId IdType="pmc">PMC2692175</ArticleId><ArticleId IdType="pubmed">19386915</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond I, Fishman RA. High affinity transport and phosphorylation of 2-deoxy-D-glucose in synaptosomes. J Neurochem. 1973;20(6):1533&#x2013;1542. doi: 10.1111/j.1471-4159.1973.tb00271.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.1973.tb00271.x</ArticleId><ArticleId IdType="pubmed">4719311</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharyya MV, Brodsky JL. Characterization of the glucose transporter from rat brain synaptosomes. Biochem Biophys Res Commun. 1988;155(2):685&#x2013;691. doi: 10.1016/S0006-291X(88)80549-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-291X(88)80549-7</ArticleId><ArticleId IdType="pubmed">3048260</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidenreich KA, Gilmore PR, Garvey WT. Glucose transport in primary cultured neurons. J Neurosci Res. 1989;22(4):397&#x2013;407. doi: 10.1002/jnr.490220405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.490220405</ArticleId><ArticleId IdType="pubmed">2760941</ArticleId></ArticleIdList></Reference><Reference><Citation>Miichi Y, Sakurai T, Akisaki T, Yokono K. Effects of insulin and amyloid &#x3b2;1&#x2013;42 oligomers on glucose incorporation and mitochondrial function in cultured rat hippocampal neurons. . Geriatr Gerontol Int. 2011;11(4):517&#x2013;524. doi: 10.1111/j.1447-0594.2011.00712.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1447-0594.2011.00712.x</ArticleId><ArticleId IdType="pubmed">21592272</ArticleId></ArticleIdList></Reference><Reference><Citation>Klip A. The many ways to regulate glucose transporter 4. Appl Physiol Nutr Metab. 2009;34(3):481&#x2013;487. doi: 10.1139/H09-047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/H09-047</ArticleId><ArticleId IdType="pubmed">19448718</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijesekara N, Tung A, Thong F, Klip A. Muscle dell depolarization induces a gain in surface GLUT4 via reduced endocytosis independently of AMPK. Am J Physiol Endocrinol Metab. 2006;290(6):E1276&#x2013;E1286. doi: 10.1152/ajpendo.00573.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.00573.2005</ArticleId><ArticleId IdType="pubmed">16418206</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacks DB, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2011;57(6): e1&#x2013;e47. doi: 10.1373/clinchem.2010.161596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2010.161596</ArticleId><ArticleId IdType="pubmed">21617152</ArticleId></ArticleIdList></Reference><Reference><Citation>Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am. 2004;33(2):283&#x2013;303. doi: 10.1016/j.ecl.2004.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ecl.2004.03.002</ArticleId><ArticleId IdType="pubmed">15158520</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009;2(5&#x2013;6):231&#x2013;237. doi: 10.1242/dmm.001180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.001180</ArticleId><ArticleId IdType="pmc">PMC2675814</ArticleId><ArticleId IdType="pubmed">19407331</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuusisto J, et al. Association between features of the insulin resistance syndrome and Alzheimer&#x2019;s disease independently of apolipoprotein E4 phenotype: cros sectional population based study. BMJ. 1997;315(7115):1045&#x2013;1049. doi: 10.1136/bmj.315.7115.1045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.315.7115.1045</ArticleId><ArticleId IdType="pmc">PMC2127678</ArticleId><ArticleId IdType="pubmed">9366728</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdul-Ghani MA, DeFronzo RA. Pathophysiology of prediabetes. Curr Diab Rep. 2009;9(3):193&#x2013;199. doi: 10.1007/s11892-009-0032-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11892-009-0032-7</ArticleId><ArticleId IdType="pubmed">19490820</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowie CC, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care. 2009;32(2):287&#x2013;294. doi: 10.2337/dc08-1296.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc08-1296</ArticleId><ArticleId IdType="pmc">PMC2628695</ArticleId><ArticleId IdType="pubmed">19017771</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer&#x2019;s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009;11(2):111&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3181909</ArticleId><ArticleId IdType="pubmed">19585947</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Lara JM, Aguilar-Navarro S, Guti&#xe9;rrez-Robledo LM, Avila-Funes JA. The metabolic syndrome, diabetes, and Alzheimer&#x2019;s disease. Rev Invest Clin. 2010;62(4):343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">21218671</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao WQ, Chen H, Quon M, Alkon DL. Insulin and the insulin receptor in experimental models of learning and memory. Eur J Pharmacol. 2004;490(1&#x2013;3):71&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">15094074</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Heide LP, Ramakers GMJ, Smidt MP. Insulin signaling in the central nervous system: learning to survive. Prog Neurobiol. 2006;79(4):205&#x2013;221. doi: 10.1016/j.pneurobio.2006.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2006.06.003</ArticleId><ArticleId IdType="pubmed">16916571</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu S-L, Cline HT. Insulin receptor signaling in the development of neuronal structure and function. Neural Dev. 2010;5:7. doi: 10.1186/1749-8104-5-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1749-8104-5-7</ArticleId><ArticleId IdType="pmc">PMC2843688</ArticleId><ArticleId IdType="pubmed">20230616</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging and the Alzheimer&#x2019;s Association workgroup. Alzheimers Dement. 2011;7(3):280&#x2013;292. doi: 10.1016/j.jalz.2011.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.003</ArticleId><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Aabuzek K, Suchy D, Gabryel B, Bielecka A, Liber S, Okopien B. Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol Rep. 2010;62(5):956&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pubmed">21098880</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, et al. Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels. Diabetes Obes Metab. 2008;10(10):921&#x2013;930. doi: 10.1111/j.1463-1326.2007.00832.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1463-1326.2007.00832.x</ArticleId><ArticleId IdType="pubmed">18093209</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;lscher C. The role of GLP-1 in neuronal activity and neurodegeneration. Vitam Horm. 2010;84:331&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">21094907</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;lscher C. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer&#x2019;s disease. Recent Pat CNS Drug Discov. 2010;5(2):109&#x2013;117. doi: 10.2174/157488910791213130.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/157488910791213130</ArticleId><ArticleId IdType="pubmed">20337586</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton A, Patterson S, Porter D, Gault VA, Holscher C. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J Neurosci Res. 2011;89(4):481&#x2013;489. doi: 10.1002/jnr.22565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22565</ArticleId><ArticleId IdType="pubmed">21312223</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot K, et al. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest. 2004;113(9):1353&#x2013;1363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC398430</ArticleId><ArticleId IdType="pubmed">15124027</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorente de N&#xf2; R. Studies on the structure of the cerebral cortex. II. Continuation of the study of the ammonic system. J Psychol Neurol. 1934;46:113&#x2013;177.</Citation></Reference><Reference><Citation>Amaral DG, Insausti R. Hippocampal formation. In: Paxinos G, ed.The Human Nervous System . 1st ed. San Diego, California, USA: Academic Press;1990:711&#x2013;755.</Citation></Reference><Reference><Citation>Ramsey PH, Ramsey PP. Power of pairwise comparisons in the equal variance and unequal sample size case. Br J Math Stat Psychol. 2008;61(pt 1):115&#x2013;131. doi: 10.1348/000711006X153051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1348/000711006X153051</ArticleId><ArticleId IdType="pubmed">18482478</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22592800</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><Issue>22</Issue><PubDate><Year>2012</Year><Month>May</Month><Day>29</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Critical role of soluble amyloid-&#x3b2; for early hippocampal hyperactivity in a mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>8740</StartPage><EndPage>8745</EndPage><MedlinePgn>8740-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1206171109</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is characterized by a progressive dysfunction of central neurons. Recent experimental evidence indicates that in the cortex, in addition to the silencing of a fraction of neurons, other neurons are hyperactive in amyloid-&#x3b2; (A&#x3b2;) plaque-enriched regions. However, it has remained unknown what comes first, neuronal silencing or hyperactivity, and what mechanisms might underlie the primary neuronal dysfunction. Here we examine the activity patterns of hippocampal CA1 neurons in a mouse model of AD in vivo using two-photon Ca(2+) imaging. We found that neuronal activity in the plaque-bearing CA1 region of older mice is profoundly altered. There was a marked increase in the fractions of both silent and hyperactive neurons, as previously also found in the cortex. Remarkably, in the hippocampus of young mice, we observed a selective increase in hyperactive neurons already before the formation of plaques, suggesting that soluble species of A&#x3b2; may underlie this impairment. Indeed, we found that acute treatment with the &#x3b3;-secretase inhibitor LY-411575 reduces soluble A&#x3b2; levels and rescues the neuronal dysfunction. Furthermore, we demonstrate that direct application of soluble A&#x3b2; can induce neuronal hyperactivity in wild-type mice. Thus, our study identifies hippocampal hyperactivity as a very early functional impairment in AD transgenic mice and provides direct evidence that soluble A&#x3b2; is crucial for hippocampal hyperactivity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Busche</LastName><ForeName>Marc Aurel</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Institut f&#xfc;r Neurowissenschaften,  Technische Universit&#xe4;t M&#xfc;nchen, 80802 Munich,  Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiaowei</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Henning</LastName><ForeName>Horst A</ForeName><Initials>HA</Initials></Author><Author ValidYN="Y"><LastName>Reichwald</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sakmann</LastName><ForeName>Bert</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Konnerth</LastName><ForeName>Arthur</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001381">Azepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C484278">N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001381" MajorTopicYN="N">Azepines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056547" MajorTopicYN="N">CA1 Region, Hippocampal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036641" MajorTopicYN="N">Microscopy, Fluorescence, Multiphoton</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>11</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22592800</ArticleId><ArticleId IdType="pmc">PMC3365221</ArticleId><ArticleId IdType="doi">10.1073/pnas.1206171109</ArticleId><ArticleId IdType="pii">1206171109</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mattson MP. Pathways towards and away from Alzheimer&#x2019;s disease. Nature. 2004;430:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman DH, et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA. 2001;286:2120&#x2013;2127.</Citation><ArticleIdList><ArticleId IdType="pubmed">11694153</ArticleId></ArticleIdList></Reference><Reference><Citation>Prvulovic D, Van de Ven V, Sack AT, Maurer K, Linden DE. Functional activation imaging in aging and dementia. Psychiatry Res. 2005;140(2):97&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">16257186</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer&#x2019;s disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, et al. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer&#x2019;s disease. Science. 2008;321:1686&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pubmed">18802001</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchibhotla KV, et al. A&#x3b2; plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron. 2008;59:214&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2578820</ArticleId><ArticleId IdType="pubmed">18667150</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer&#x2019;s disease. Neuron. 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Squire LR, Zola-Morgan S. The medial temporal lobe memory system. Science. 1991;253:1380&#x2013;1386.</Citation><ArticleIdList><ArticleId IdType="pubmed">1896849</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer&#x2019;s disease: Cell-specific pathology isolates the hippocampal formation. Science. 1984;225:1168&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pubmed">6474172</ArticleId></ArticleIdList></Reference><Reference><Citation>Moran PM, Higgins LS, Cordell B, Moser PC. Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human &#x3b2;-amyloid precursor protein. Proc Natl Acad Sci USA. 1995;92:5341&#x2013;5345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC41690</ArticleId><ArticleId IdType="pubmed">7777509</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, et al. High-level neuronal expression of A&#x3b2;1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia AY, et al. Plaque-independent disruption of neural circuits in Alzheimer&#x2019;s disease mouse models. Proc Natl Acad Sci USA. 1999;96:3228&#x2013;3233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Moechars D, et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem. 1999;274:6483&#x2013;6492.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037741</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandel ER, Spencer WA, Brinley FJ., Jr Electrophysiology of hippocampal neurons. I. Sequential invasion and synaptic organization. J Neurophysiol. 1961;24:225&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">13751136</ArticleId></ArticleIdList></Reference><Reference><Citation>Dombeck DA, Harvey CD, Tian L, Looger LL, Tank DW. Functional imaging of hippocampal place cells at cellular resolution during virtual navigation. Nat Neurosci. 2010;13:1433&#x2013;1440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2967725</ArticleId><ArticleId IdType="pubmed">20890294</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi A, Crowley JC, Shtoyerman E, Katz LC. High-resolution in vivo imaging of hippocampal dendrites and spines. J Neurosci. 2004;24:3147&#x2013;3151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730023</ArticleId><ArticleId IdType="pubmed">15056694</ArticleId></ArticleIdList></Reference><Reference><Citation>Stosiek C, Garaschuk O, Holthoff K, Konnerth A. In vivo two-photon calcium imaging of neuronal networks. Proc Natl Acad Sci USA. 2003;100:7319&#x2013;7324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165873</ArticleId><ArticleId IdType="pubmed">12777621</ArticleId></ArticleIdList></Reference><Reference><Citation>Garaschuk O, Milos RI, Konnerth A. Targeted bulk-loading of fluorescent indicators for two-photon brain imaging in vivo. Nat Protoc. 2006;1:380&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">17406260</ArticleId></ArticleIdList></Reference><Reference><Citation>Rochefort NL, et al. Sparsification of neuronal activity in the visual cortex at eye-opening. Proc Natl Acad Sci USA. 2009;106:15049&#x2013;15054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2736444</ArticleId><ArticleId IdType="pubmed">19706480</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr JN, Greenberg D, Helmchen F. Imaging input and output of neocortical networks in vivo. Proc Natl Acad Sci USA. 2005;102:14063&#x2013;14068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201343</ArticleId><ArticleId IdType="pubmed">16157876</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezprozvanny I, Mattson MP. Neuronal calcium mishandling and the pathogenesis of Alzheimer&#x2019;s disease. Trends Neurosci. 2008;31:454&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2566585</ArticleId><ArticleId IdType="pubmed">18675468</ArticleId></ArticleIdList></Reference><Reference><Citation>Goussakov I, Miller MB, Stutzmann GE. NMDA-mediated Ca2+ influx drives aberrant ryanodine receptor activation in dendrites of young Alzheimer&#x2019;s disease mice. J Neurosci. 2010;30:12128&#x2013;12137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2944253</ArticleId><ArticleId IdType="pubmed">20826675</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramowski D, et al. Dynamics of A&#x3b2; turnover and deposition in different &#x3b2;-amyloid precursor protein transgenic mouse models following &#x3b3;-secretase inhibition. J Pharmacol Exp Ther. 2008;327:411&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">18687920</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanz TA, Hosley JD, Adams WJ, Merchant KM. Studies of A&#x3b2; pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the &#x3b3;-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575) J Pharmacol Exp Ther. 2004;309(1):49&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">14718585</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C. Initiation and propagation of neurodegeneration. Nat Med. 2010;16:1201&#x2013;1204.</Citation><ArticleIdList><ArticleId IdType="pubmed">21052073</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Amyloid-&#x3b2; protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu NW, Smith IM, Walsh DM, Rowan MJ. Soluble amyloid-&#x3b2; peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfunction in vivo. Brain. 2008;131:2414&#x2013;2424.</Citation><ArticleIdList><ArticleId IdType="pubmed">18678563</ArticleId></ArticleIdList></Reference><Reference><Citation>Mc Donald JM, et al. Medical Research Council Cognitive Function and Ageing Study The presence of sodium dodecyl sulphate-stable A&#x3b2; dimers is strongly associated with Alzheimer-type dementia. Brain. 2010;133:1328&#x2013;1341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2859152</ArticleId><ArticleId IdType="pubmed">20403962</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Shankar GM, Selkoe DJ. How do soluble oligomers of amyloid &#x3b2;-protein impair hippocampal synaptic plasticity? Front Cell Neurosci. 2010;4:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2859875</ArticleId><ArticleId IdType="pubmed">20428510</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, et al. Soluble oligomers of amyloid &#x3b2; protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron. 2009;62:788&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702854</ArticleId><ArticleId IdType="pubmed">19555648</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Nuallain B, et al. Amyloid &#x3b2;-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci. 2010;30:14411&#x2013;14419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2987723</ArticleId><ArticleId IdType="pubmed">20980598</ArticleId></ArticleIdList></Reference><Reference><Citation>Brorson JR, et al. The Ca2+ influx induced by &#x3b2;-amyloid peptide 25&#x2013;35 in cultured hippocampal neurons results from network excitation. J Neurobiol. 1995;26:325&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">7775966</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Mejia RO, et al. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer&#x2019;s disease. Nat Neurosci. 2008;11:1311&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2597064</ArticleId><ArticleId IdType="pubmed">18931664</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, et al. Regulation of NMDA receptor trafficking by amyloid-&#x3b2;. Nat Neurosci. 2005;8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberdi E, et al. Amyloid &#x3b2; oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium. 2010;47:264&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">20061018</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien JL, et al. Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline. Neurology. 2010;74:1969&#x2013;1976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2905893</ArticleId><ArticleId IdType="pubmed">20463288</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology. 2005;65:404&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335677</ArticleId><ArticleId IdType="pubmed">16087905</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid &#x3b2; protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng IH, et al. Accelerating amyloid-&#x3b2; fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem. 2007;282:23818&#x2013;23828.</Citation><ArticleIdList><ArticleId IdType="pubmed">17548355</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomiyama T, et al. A mouse model of amyloid &#x3b2; oligomers: Their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci. 2010;30:4845&#x2013;4856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632783</ArticleId><ArticleId IdType="pubmed">20371804</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, et al. Natural oligomers of the amyloid-&#x3b2; protein specifically disrupt cognitive function. Nat Neurosci. 2005;8(1):79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesn&#xe9; S, et al. A specific amyloid-&#x3b2; protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Comery TA, et al. Acute &#x3b3;-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer&#x2019;s disease. J Neurosci. 2005;25:8898&#x2013;8902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725598</ArticleId><ArticleId IdType="pubmed">16192379</ArticleId></ArticleIdList></Reference><Reference><Citation>Balducci C, et al. Synthetic amyloid-&#x3b2; oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci USA. 2010;107:2295&#x2013;2300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2836680</ArticleId><ArticleId IdType="pubmed">20133875</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanderson MJ, Parker I. Video-rate confocal microscopy. Methods Enzymol. 2003;360:447&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">12622163</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A, Kirchhoff F, Kerr JN, Helmchen F. Sulforhodamine 101 as a specific marker of astroglia in the neocortex in vivo. Nat Methods. 2004;1(1):31&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">15782150</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura K, Judkewitz B, Kano M, Denk W, H&#xe4;usser M. Targeted patch-clamp recordings and single-cell electroporation of unlabeled neurons in vivo. Nat Methods. 2008;5(1):61&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">18157136</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22622580</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>485</Volume><Issue>7399</Issue><PubDate><Year>2012</Year><Month>May</Month><Day>16</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Apolipoprotein E controls cerebrovascular integrity via cyclophilin A.</ArticleTitle><Pagination><StartPage>512</StartPage><EndPage>516</EndPage><MedlinePgn>512-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature11087</ELocationID><Abstract><AbstractText>Human apolipoprotein E has three isoforms: APOE2, APOE3 and APOE4. APOE4 is a major genetic risk factor for Alzheimer's disease and is associated with Down's syndrome dementia and poor neurological outcome after traumatic brain injury and haemorrhage. Neurovascular dysfunction is present in normal APOE4 carriers and individuals with APOE4-associated disorders. In mice, lack of Apoe leads to blood-brain barrier (BBB) breakdown, whereas APOE4 increases BBB susceptibility to injury. How APOE genotype affects brain microcirculation remains elusive. Using different APOE transgenic mice, including mice with ablation and/or inhibition of cyclophilin A (CypA), here we show that expression of APOE4 and lack of murine Apoe, but not APOE2 and APOE3, leads to BBB breakdown by activating a proinflammatory CypA-nuclear factor-&#x3ba;B-matrix-metalloproteinase-9 pathway in pericytes. This, in turn, leads to neuronal uptake of multiple blood-derived neurotoxic proteins, and microvascular and cerebral blood flow reductions. We show that the vascular defects in Apoe-deficient and APOE4-expressing mice precede neuronal dysfunction and can initiate neurodegenerative changes. Astrocyte-secreted APOE3, but not APOE4, suppressed the CypA-nuclear factor-&#x3ba;B-matrix-metalloproteinase-9 pathway in pericytes through a lipoprotein receptor. Our data suggest that CypA is a key target for treating APOE4-mediated neurovascular injury and the resulting neuronal dysfunction and degeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative and Vascular Brain Disorders, University of Rochester Medical Center, Rochester, New York 14642, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winkler</LastName><ForeName>Ethan A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Itender</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Sagare</LastName><ForeName>Abhay P</ForeName><Initials>AP</Initials></Author><Author ValidYN="Y"><LastName>Deane</LastName><ForeName>Rashid</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Zhenhua</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Betsholtz</LastName><ForeName>Christer</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Armulik</LastName><ForeName>Annika</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sallstrom</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Berk</LastName><ForeName>Bradford C</ForeName><Initials>BC</Initials></Author><Author ValidYN="Y"><LastName>Zlokovic</LastName><ForeName>Berislav V</ForeName><Initials>BV</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37AG13956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS034467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37AG23084</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG039452</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37NS34467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS034467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG039452</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG039452</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG023084</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053329">Apolipoprotein E2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053318">Apolipoprotein E3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.35</RegistryNumber><NameOfSubstance UI="D020780">Matrix Metalloproteinase 9</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 5.2.1.-</RegistryNumber><NameOfSubstance UI="D021984">Cyclophilin A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2012 May 23;485(7399):451-2. doi: 10.1038/485451a.</RefSource><PMID Version="1">22622564</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Nature. 2023 May;617(7961):E12. doi: 10.1038/s41586-023-06118-0.</RefSource><PMID Version="1">37142785</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053329" MajorTopicYN="N">Apolipoprotein E2</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053318" MajorTopicYN="N">Apolipoprotein E3</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021984" MajorTopicYN="N">Cyclophilin A</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020780" MajorTopicYN="N">Matrix Metalloproteinase 9</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008833" MajorTopicYN="N">Microcirculation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020286" MajorTopicYN="N">Pericytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>6</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22622580</ArticleId><ArticleId IdType="mid">NIHMS581947</ArticleId><ArticleId IdType="pmc">PMC4047116</ArticleId><ArticleId IdType="doi">10.1038/nature11087</ArticleId><ArticleId IdType="pii">nature11087</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer&#x2019;s disease to AIDS. J Lipid Res. 2009;50 (Suppl):S183&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674716</ArticleId><ArticleId IdType="pubmed">19106071</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer&#x2019;s disease. Neuron. 2009;63:287&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer&#x2019;s disease and other neurological disorders. Lancet Neurol. 2011;10:241&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3132088</ArticleId><ArticleId IdType="pubmed">21349439</ArticleId></ArticleIdList></Reference><Reference><Citation>Thambisetty M, Beason-Held L, An Y, Kraut MA, Resnick SM. APOE epsilon4 genotype and longitudinal changes in cerebral blood flow in normal aging. Arch Neurol-Chicago. 2010;67:93&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856443</ArticleId><ArticleId IdType="pubmed">20065135</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheline YI, et al. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Abeta42. J Neurosci. 2010;30:17035&#x2013;17040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3023180</ArticleId><ArticleId IdType="pubmed">21159973</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer&#x2019;s dementia. Proc Natl Acad Sci USA. 2004;101:284&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314177</ArticleId><ArticleId IdType="pubmed">14688411</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer&#x2019;s disease and other disorders. Nature Rev Nsci. 2011;12:723&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4036520</ArticleId><ArticleId IdType="pubmed">22048062</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon DA, et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997;277:813&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052711</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermeer SE, et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pubmed">12660385</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruitenberg A, et al. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann Neurol. 2005;57:789&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">15929050</ArticleId></ArticleIdList></Reference><Reference><Citation>Methia N, et al. ApoE deficiency compromises the blood brain barrier especially after injury. Mol Med. 2001;7:810&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950012</ArticleId><ArticleId IdType="pubmed">11844869</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafezi-Moghadam A, Thomas KL, Wagner DD. ApoE deficiency leads to a progressive age-dependent blood-brain barrier leakage. Am J Physiol Cell Physiol. 2007;292:C1256&#x2013;1262.</Citation><ArticleIdList><ArticleId IdType="pubmed">16870825</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishitsuji K, Hosono T, Nakamura T, Bu G, Michikawa M. Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain barrier model. J Bio Chem. 2011;286:17536&#x2013;17542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3093828</ArticleId><ArticleId IdType="pubmed">21471207</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron. 2010;68:409&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056408</ArticleId><ArticleId IdType="pubmed">21040844</ArticleId></ArticleIdList></Reference><Reference><Citation>Armulik A, et al. Pericytes regulate the blood-brain barrier. Nature. 2010;468:557&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">20944627</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PM, et al. Reduced levels of human apoE4 protein in an animal model of cognitive impairment. Neurobio Aging. 2011;32:791&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">19577821</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh K, et al. Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med. 2009;15:649&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2704983</ArticleId><ArticleId IdType="pubmed">19430489</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin ZG, et al. Cyclophilin A is a proinflammatory cytokine that activates endothelial cells. Arterioscler Thromb Vasc Biol. 2004;24:1186&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pubmed">15130913</ArticleId></ArticleIdList></Reference><Reference><Citation>Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science. 1984;226:544&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">6238408</ArticleId></ArticleIdList></Reference><Reference><Citation>Begley DJ, et al. Permeability of the blood-brain barrier to the immunosuppressive cyclic peptide cyclosporin A. J Neurochem. 1990;55:1222&#x2013;1230.</Citation><ArticleIdList><ArticleId IdType="pubmed">2398356</ArticleId></ArticleIdList></Reference><Reference><Citation>Grammas P. Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer&#x2019;s disease. J Neuroinflammation. 2011;8:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072921</ArticleId><ArticleId IdType="pubmed">21439035</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul J, Strickland S, Melchor JP. Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer&#x2019;s disease. J Exp Med. 2007;204:1999&#x2013;2008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2118680</ArticleId><ArticleId IdType="pubmed">17664291</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z, et al. Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest. 2009;119:3437&#x2013;3449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2769191</ArticleId><ArticleId IdType="pubmed">19841542</ArticleId></ArticleIdList></Reference><Reference><Citation>Candelario-Jalil E, et al. Matrix metalloproteinases are associated with increased blood-brain barrier opening in vascular cognitive impairment. Stroke. 2011;42:1345&#x2013;1350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3119779</ArticleId><ArticleId IdType="pubmed">21454822</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Alloza M, et al. Matrix metalloproteinase inhibition reduces oxidative stress associated with cerebral amyloid angiopathy in vivo in transgenic mice. J Neurochem. 2009;109:1636&#x2013;1647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281746</ArticleId><ArticleId IdType="pubmed">19457117</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaeger LB, et al. Testing the neurovascular hypothesis of Alzheimer&#x2019;s disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition. J Alz Dis. 2009;17:553&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2802833</ArticleId><ArticleId IdType="pubmed">19433890</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Lu N, Zhou J, Chen ZN, Zhu P. Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes/macrophages via CD147 signalling pathway in rheumatoid arthritis. Rheumatology. 2008;47:1299&#x2013;1310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7107241</ArticleId><ArticleId IdType="pubmed">18567920</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008;118:4002&#x2013;4013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2582453</ArticleId><ArticleId IdType="pubmed">19033669</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, et al. Neurodegeneration and cognitive impairment in apoE-deficient mice is ameliorated by infusion of recombinant apoE. Brain Res. 1997;751:307&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">9099820</ArticleId></ArticleIdList></Reference><Reference><Citation>Zipser BD, et al. Microvascular injury and blood&#x2013;brain barrier leakage in Alzheimer&#x2019;s disease. Neurobiol Aging. 2007;28:977&#x2013;986.</Citation><ArticleIdList><ArticleId IdType="pubmed">16782234</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22626851</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>380</Volume><Issue>9836</Issue><PubDate><Year>2012</Year><Month>Jul</Month><Day>07</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Dementia incidence and mortality in middle-income countries, and associations with indicators of cognitive reserve: a 10/66 Dementia Research Group population-based cohort study.</ArticleTitle><Pagination><StartPage>50</StartPage><EndPage>58</EndPage><MedlinePgn>50-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(12)60399-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Results of the few cohort studies from countries with low incomes or middle incomes suggest a lower incidence of dementia than in high-income countries. We assessed incidence of dementia according to criteria from the 10/66 Dementia Research Group and Diagnostic and Statistical Manual of Mental Disorders (DSM) IV, the effect of dementia at baseline on mortality, and the independent effects of age, sex, socioeconomic position, and indicators of cognitive reserve.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We did a population-based cohort study of all people aged 65 years and older living in urban sites in Cuba, the Dominican Republic, and Venezuela, and rural and urban sites in Peru, Mexico, and China, with ascertainment of incident 10/66 and DSM-IV dementia 3-5 years after cohort inception. We used questionnaires to obtain information about age in years, sex, educational level, literacy, occupational attainment, and number of household assets. We obtained information about mortality from all sites. For participants who had died, we interviewed a friend or relative to ascertain the likelihood that they had dementia before death.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">12,887 participants were interviewed at baseline. 11,718 were free of dementia, of whom 8137 (69%) were reinterviewed, contributing 34,718 person-years of follow-up. Incidence for 10/66 dementia varied between 18&#xb7;2 and 30&#xb7;4 per 1000 person-years, and were 1&#xb7;4-2&#xb7;7 times higher than were those for DSM-IV dementia (9&#xb7;9-15&#xb7;7 per 1000 person-years). Mortality hazards were 1&#xb7;56-5&#xb7;69 times higher in individuals with dementia at baseline than in those who were dementia-free. Informant reports suggested a high incidence of dementia before death; overall incidence might be 4-19% higher if these data were included. 10/66 dementia incidence was independently associated with increased age (HR 1&#xb7;67; 95% CI 1&#xb7;56-1&#xb7;79), female sex (0&#xb7;72; 0&#xb7;61-0&#xb7;84), and low education (0&#xb7;89; 0&#xb7;81-0&#xb7;97), but not with occupational attainment (1&#xb7;04; 0&#xb7;95-1&#xb7;13).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Our results provide supportive evidence for the cognitive reserve hypothesis, showing that in middle-income countries as in high-income countries, education, literacy, verbal fluency, and motor sequencing confer substantial protection against the onset of dementia.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Wellcome Trust Health Consequences of Population Change Programme, WHO, US Alzheimer's Association, FONACIT/ CDCH/ UCV.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prince</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Global Mental Health, Health Service and Population Research Department, Institute of Psychiatry, King's College London, London, UK. martin.prince@kcl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acosta</LastName><ForeName>Daisy</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Ferri</LastName><ForeName>Cleusa P</ForeName><Initials>CP</Initials></Author><Author ValidYN="Y"><LastName>Guerra</LastName><ForeName>Mariella</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yueqin</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Llibre Rodriguez</LastName><ForeName>Juan J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Salas</LastName><ForeName>Aquiles</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sosa</LastName><ForeName>Ana Luisa</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Joseph D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Dewey</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Acosta</LastName><ForeName>Isaac</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Jotheeswaran</LastName><ForeName>Amuthavalli T</ForeName><Initials>AT</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhaorui</ForeName><Initials>Z</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>GR08002</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>GR066133</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>05</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2012 Jul 7;380(9836):11-2. doi: 10.1016/S0140-6736(12)60767-3.</RefSource><PMID Version="1">22626852</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2012 Oct 27;380(9852):1470-1. doi: 10.1016/S0140-6736(12)61839-X.</RefSource><PMID Version="1">23101712</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2012 Oct 27;380(9852):1470. doi: 10.1016/S0140-6736(12)61838-8.</RefSource><PMID Version="1">23101713</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002489" MajorTopicYN="N" Type="Geographic">Central America</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003462" MajorTopicYN="N" Type="Geographic">Cuba</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012423" MajorTopicYN="N">Rural Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013020" MajorTopicYN="N" Type="Geographic">South America</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014504" MajorTopicYN="N">Urban Health</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>7</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22626851</ArticleId><ArticleId IdType="pmc">PMC3525981</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(12)60399-7</ArticleId><ArticleId IdType="pii">S0140-6736(12)60399-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hendrie HC, Ogunniyi A, Hall KS. Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA. 2001;285:739&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">11176911</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra V, Pandav R, Dodge HH. Incidence of Alzheimer's disease in a rural community in India: the Indo-US study. Neurology. 2001;57:985&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pubmed">11571321</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitrini R, Caramelli P, Herrera E., Jr Incidence of dementia in a community-dwelling Brazilian population. Alzheimer Dis Assoc Disord. 2004;18:241&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">15592138</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Shen Y-C, Chen C-H. A three-year follow-up study of age-related dementia in an urban area of Beijing. Acta Psychiatr Scand. 1991;83:99&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">2017918</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 4th edn. APA; Washington DC: 1994.</Citation></Reference><Reference><Citation>Prince M, Acosta D, Chiu H, Scazufca M, Varghese M, for the 10/66 Dementia Research Group Dementia diagnosis in developing countries: a cross-cultural validation study. Lancet. 2003;361:909&#x2013;917.</Citation><ArticleIdList><ArticleId IdType="pubmed">12648969</ArticleId></ArticleIdList></Reference><Reference><Citation>Llibre Rodriguez JJ, Ferri CP, Acosta D. Prevalence of dementia in Latin America, India, and China: a population-based cross-sectional survey. Lancet. 2008;372:464&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2854470</ArticleId><ArticleId IdType="pubmed">18657855</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones RN, Manly J, Glymour MM, Rentz DM, Jefferson AL, Stern Y. Conceptual and measurement challenges in research on cognitive reserve. J Int Neuropsychol Soc. 2011:1&#x2013;9. published online Mar 17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3289742</ArticleId><ArticleId IdType="pubmed">21411036</ArticleId></ArticleIdList></Reference><Reference><Citation>Satz P, Cole MA, Hardy DJ, Rassovsky Y. Brain and cognitive reserve: mediator(s) and construct validity, a critique. J Clin Exp Neuropsychol. 2011;33:121&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">20680883</ArticleId></ArticleIdList></Reference><Reference><Citation>Siedlecki KL, Stern Y, Reuben A, Sacco RL, Elkind MS, Wright CB. Construct validity of cognitive reserve in a multiethnic cohort: The Northern Manhattan Study. J Int Neuropsychol Soc. 2009;15:558&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2803322</ArticleId><ArticleId IdType="pubmed">19573274</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenzuela MJ, Sachdev P. Brain reserve and dementia: a systematic review. Psychol Med. 2006;36:441&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207391</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M, Ferri CP, Acosta D. The protocols for the 10/66 Dementia Research Group population-based research programme. BMC Public Health. 2007;7:165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1965476</ArticleId><ArticleId IdType="pubmed">17659078</ArticleId></ArticleIdList></Reference><Reference><Citation>Jotheeswaran AT, Williams JD, Prince MJ. The predictive validity of the 10/66 dementia diagnosis in Chennai, India: a 3-year follow-up study of cases identified at baseline. Alzheimer Dis Assoc Disord. 2010;24:296&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2929463</ArticleId><ArticleId IdType="pubmed">20473137</ArticleId></ArticleIdList></Reference><Reference><Citation>Jotheeswaran AT, Williams JD, Prince MJ. Predictors of mortality among elderly people living in a south Indian urban community; a 10/66 Dementia Research Group prospective population-based cohort study. BMC Public Health. 2010;10:366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2910676</ArticleId><ArticleId IdType="pubmed">20573243</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince MJ, de Rodriguez JL, Noriega L. The 10/66 Dementia Research Group's fully operationalised DSM-IV dementia computerized diagnostic algorithm, compared with the 10/66 dementia algorithm and a clinician diagnosis: a population validation study. BMC Public Health. 2008;8:219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2474864</ArticleId><ArticleId IdType="pubmed">18577205</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall KS, Hendrie HH, Brittain HM. The development of a dementia screening interview in two distinct languages. Int J Methods Psychiatr Res. 1993;3:1&#x2013;28.</Citation></Reference><Reference><Citation>Ganguli M, Chandra V, Gilbey J. Cognitive test performance in a community-based non demented elderly sample in rural India: the Indo-US cross national dementia epidemiology study. Int Psychogeriatr. 1996;8:507&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">9147167</ArticleId></ArticleIdList></Reference><Reference><Citation>Copeland JRM, Dewey ME, Griffith-Jones HM. A computerised psychiatric diagnostic system and case nomenclature for elderly subjects: GMS and AGECAT. Psychol Med. 1986;16:89&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">3515380</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewey ME, Copeland JR. Diagnosis of dementia from the history and aetiology schedule. Int J Geriatr Psychiatry. 2001;16:912&#x2013;917.</Citation><ArticleIdList><ArticleId IdType="pubmed">11571773</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer LJ, Andersen K, Dewey ME. Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology. 1999;52:78&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">9921852</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Biometrics. 1999;94:496&#x2013;509.</Citation></Reference><Reference><Citation>Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539&#x2013;1558.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111919</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejia-Arango S, Gutierrez LM. Prevalence and incidence rates of dementia and cognitive impairment no dementia in the Mexican population: data from the Mexican Health and Aging Study. J Aging Health. 2011;23:1050&#x2013;1074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3557523</ArticleId><ArticleId IdType="pubmed">21948770</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis PB, White H, Price JL, McKeel D, Robins LN. Retrospective postmortem dementia assessment. Validation of a new clinical interview to assist neuropathologic study. Arch Neurol. 1991;48:613&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">2039384</ArticleId></ArticleIdList></Reference><Reference><Citation>Brayne C, Gao L, Dewey M, Matthews FE. Dementia before death in ageing societies&#x2014;the promise of prevention and the reality. PLoS Med. 2006;3:e397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1626550</ArticleId><ArticleId IdType="pubmed">17076551</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewey ME, Saz P. Dementia, cognitive impairment and mortality in persons aged 65 and over living in the community: a systematic review of the literature. Int J Geriatr Psychiatry. 2001;16:751&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pubmed">11536341</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkins AJ, Hui SL, Ogunniyi A. Risk of mortality for dementia in a developing country: the Yoruba in Nigeria. Int J Geriatr Psychiatry. 2002;17:566&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pubmed">12112181</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitrini R, Caramelli P, Herrera E., Jr Mortality from dementia in a community-dwelling Brazilian population. Int J Geriatr Psychiatry. 2005;20:247&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">15717343</ArticleId></ArticleIdList></Reference><Reference><Citation>Manly JJ, Jacobs DM, Touradji P, Small SA, Stern Y. Reading level attenuates differences in neuropsychological test performance between African American and White elders. J Int Neuropsychol Soc. 2002;8:341&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">11939693</ArticleId></ArticleIdList></Reference><Reference><Citation>Auriacombe S, Lechevallier N, Amieva H, Harston S, Raoux N, Dartigues JF. A longitudinal study of quantitative and qualitative features of category verbal fluency in incident Alzheimer's disease subjects: results from the PAQUID study. Dement Geriatr Cogn Disord. 2006;21:260&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">16465054</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxton J, Lopez OL, Ratcliff G. Preclinical Alzheimer disease: neuropsychological test performance 1&#xb7;5 to 8 years prior to onset. Neurology. 2004;63:2341&#x2013;2347.</Citation><ArticleIdList><ArticleId IdType="pubmed">15623697</ArticleId></ArticleIdList></Reference><Reference><Citation>Tierney MC, Yao C, Kiss A, McDowell I. Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years. Neurology. 2005;64:1853&#x2013;1859.</Citation><ArticleIdList><ArticleId IdType="pubmed">15955933</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark LJ, Gatz M, Zheng L, Chen YL, McCleary C, Mack WJ. Longitudinal verbal fluency in normal aging, preclinical, and prevalent Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2009;24:461&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824246</ArticleId><ArticleId IdType="pubmed">19759254</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan RC, Rao H, Chen EE, Ye B, Zhang C. The neural basis of motor sequencing: an fMRI study of healthy subjects. Neurosci Lett. 2006;398:189&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">16469446</ArticleId></ArticleIdList></Reference><Reference><Citation>Umetsu A, Okuda J, Fujii T. Brain activation during the fist-edge-palm test: a functional MRI study. Neuroimage. 2002;17:385&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">12482091</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermsdorfer J, Terlinden G, Muhlau M, Goldenberg G, Wohlschlager AM. Neural representations of pantomimed and actual tool use: evidence from an event-related fMRI study. Neuroimage. 2007;36:T109&#x2013;T118.</Citation><ArticleIdList><ArticleId IdType="pubmed">17499158</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitrini R, Caramelli P, Herrera E, Jr, Charchat-Fichman H, Porto CS. Performance in Luria's fist-edge-palm test according to educational level. Cogn Behav Neurol. 2005;18:211&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">16340394</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11312286</PMID><DateCompleted><Year>2001</Year><Month>06</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>9</Issue><PubDate><Year>2001</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Mitochondrial abnormalities in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>3017</StartPage><EndPage>3023</EndPage><MedlinePgn>3017-23</MedlinePgn></Pagination><Abstract><AbstractText>The finding that oxidative damage, including that to nucleic acids, in Alzheimer's disease is primarily limited to the cytoplasm of susceptible neuronal populations suggests that mitochondrial abnormalities might be part of the spectrum of chronic oxidative stress of Alzheimer's disease. In this study, we used in situ hybridization to mitochondrial DNA (mtDNA), immunocytochemistry of cytochrome oxidase, and morphometry of electron micrographs of biopsy specimens to determine whether there are mitochondrial abnormalities in Alzheimer's disease and their relationship to oxidative damage marked by 8-hydroxyguanosine and nitrotyrosine. We found that the same neurons showing increased oxidative damage in Alzheimer's disease have a striking and significant increase in mtDNA and cytochrome oxidase. Surprisingly, much of the mtDNA and cytochrome oxidase is found in the neuronal cytoplasm and in the case of mtDNA, the vacuoles associated with lipofuscin. Morphometric analysis showed that mitochondria are significantly reduced in Alzheimer's disease. The relationship shown here between the site and extent of mitochondrial abnormalities and oxidative damage suggests an intimate and early association between these features in Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hirai</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Pathology, Department of Neurology, Case Western Reserve University, Cleveland, Ohio 44106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aliev</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Nunomura</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Fujioka</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Russell</LastName><ForeName>R L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Atwood</LastName><ForeName>C S</ForeName><Initials>CS</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>A B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Kress</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Vinters</LastName><ForeName>H V</ForeName><Initials>HV</Initials></Author><Author ValidYN="Y"><LastName>Tabaton</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Shimohama</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Cash</LastName><ForeName>A D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Siedlak</LastName><ForeName>S L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>P L</ForeName><Initials>PL</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>P K</ForeName><Initials>PK</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>R B</ForeName><Initials>RB</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG014249</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG09287</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG14249</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS38648</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS038648</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004272">DNA, Mitochondrial</NameOfSubstance></Chemical><Chemical><RegistryNumber>12133JR80S</RegistryNumber><NameOfSubstance UI="D006151">Guanosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>3604-79-3</RegistryNumber><NameOfSubstance UI="C002744">3-nitrotyrosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>3868-31-3</RegistryNumber><NameOfSubstance UI="C046215">8-hydroxyguanosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>42HK56048U</RegistryNumber><NameOfSubstance UI="D014443">Tyrosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.9.3.1</RegistryNumber><NameOfSubstance UI="D003576">Electron Transport Complex IV</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002531" MajorTopicYN="N">Cerebellum</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004272" MajorTopicYN="N">DNA, Mitochondrial</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003576" MajorTopicYN="N">Electron Transport Complex IV</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006151" MajorTopicYN="N">Guanosine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017403" MajorTopicYN="N">In Situ Hybridization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="Y">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014443" MajorTopicYN="N">Tyrosine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>4</Month><Day>20</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>6</Month><Day>8</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>4</Month><Day>20</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2001</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11312286</ArticleId><ArticleId IdType="pmc">PMC6762571</ArticleId><ArticleId IdType="pii">21/9/3017</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.21-09-03017.2001</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blass JP, Gibson GE. The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease. Rev Neurol (Paris) 1991;147:513&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">1962057</ArticleId></ArticleIdList></Reference><Reference><Citation>Blass JP, Baker AC, Ko L, Black RS. Induction of Alzheimer antigens by an uncoupler of oxidative phosphorylation. Arch Neurol. 1990;47:864&#x2013;869.</Citation><ArticleIdList><ArticleId IdType="pubmed">2375692</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunk UT, Jones CB, Sohal RS. A novel hypothesis of lipofuscinogenesis and cellular aging based on interactions between oxidative stress and autophagocytosis. Mutat Res. 1992;275:395&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">1383780</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowson JH, Mountjoy CQ, Cairns MR, Wilton-Cox H, Bondareff W. Lipopigment changes in Purkinje cells in Alzheimer's disease. J Alzheimer's Dis. 1998;1:71&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">12214004</ArticleId></ArticleIdList></Reference><Reference><Citation>Friguet B, Stadtman ER, Szweda LI. Modification of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonenal. Formation of cross-linked protein that inhibits the multicatalytic protease. J Biol Chem. 1994;269:21639&#x2013;21643.</Citation><ArticleIdList><ArticleId IdType="pubmed">8063806</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabuzda D, Busciglio J, Chen L, Matsudaira P, Yankner BA. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem. 1994;269:13623&#x2013;13628.</Citation><ArticleIdList><ArticleId IdType="pubmed">8175797</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh SS, Swerdlow RH, Miller SW, Sheeman B, Parker WD, Davis RE., Jr Use of cytoplasmic hybrid cell lines for elucidating the role of mitochondrial dysfunction in Alzheimer's disease and Parkinson's disease. Ann NY Acad Sci. 1999;893:176&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">10672237</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphries KM, Szweda LI. Selective inactivation of alpha-ketoglutarate dehydrogenase and pyruvate dehydrogenase: reaction of lipoic acid with 4-hydroxy-2-nonenal. Biochemistry. 1998;37:15835&#x2013;15841.</Citation><ArticleIdList><ArticleId IdType="pubmed">9843389</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito S, Ohta S, Nishimaki K, Kagawa Y, Soma R, Kuno S-Y, Komatsuzaki Y, Mizusawa H, Hayashi J-I. Functional integrity of mitochondrial genomes in human platelets and autopsied brain tissues from elderly patients with Alzheimer's disease. Proc Natl Acad Sci USA. 1999;96:2099&#x2013;2103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26743</ArticleId><ArticleId IdType="pubmed">10051601</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzman R. Alzheimer's disease. N Engl J Med. 1986;314:964&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">2870433</ArticleId></ArticleIdList></Reference><Reference><Citation>Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol. 1985;42:1097&#x2013;1105.</Citation><ArticleIdList><ArticleId IdType="pubmed">2864910</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan SM, Cassarino DS, Abramova NN, Keeney PM, Borland MK, Trimmer PA, Krebs CT, Bennett JC, Parks JK, Swerdlow RH, Parker WD, Jr, Bennett JP., Jr Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways. Ann Neurol. 2000;48:148&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">10939564</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KS, Miller DL, Sapienza VJ, Chen CMJ, Bai C, Grundke-Iqbal I, Currie JR, Wisniewski HM. Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. Neurosci Res Commun. 1988;2:121&#x2013;130.</Citation></Reference><Reference><Citation>Luo Y, Bond JD, Ingram VM. Compromised mitochondrial function leads to increased cytosolic calcium and to activation of MAP kinases. Proc Natl Acad Sci USA. 1997;94:9705&#x2013;9710.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23254</ArticleId><ArticleId IdType="pubmed">9275188</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GD, Drachman DA, Folstein MF, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Amarnath V, Martin ME, Strittmatter WJ, Graham DG. E-4-hydroxy-2-nonenal is cytotoxic and cross-links cytoskeletal proteins in P19 neuroglial cultures. Am J Pathol. 1996;148:89&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1861611</ArticleId><ArticleId IdType="pubmed">8546230</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura N, Hattori N, Tanaka M, Mizuno Y. Specific detection of deleted mitochondrial DNA by in situ hybridization using a chimera probe. Biochim Biophys Acta. 1996;1308:215&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">8809113</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunomura A, Perry G, Pappolla MA, Wade R, Hirai K, Chiba S, Smith MA. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci. 1999;19:1959&#x2013;1964.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782583</ArticleId><ArticleId IdType="pubmed">10066249</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker WD, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol. 1989;26:719&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">2557792</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry G, Rizzuto N, Autilio-Gambetti L, Gambetti P. Paired helical filaments from Alzheimer disease patients contain cytoskeletal components. Proc Natl Acad Sci USA. 1985;82:3916&#x2013;3920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC397900</ArticleId><ArticleId IdType="pubmed">3889918</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry G, Kawai M, Tabaton M, Onorato M, Mulvihill P, Richey P, Morandi A, Connolly JA, Gambetti P. Neuropil threads of Alzheimer's disease show a marked alteration of the normal cytoskeleton. J Neurosci. 1991;11:1748&#x2013;1755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575401</ArticleId><ArticleId IdType="pubmed">1904481</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry G, Roder H, Nunomura A, Takeda A, Friedlich AL, Zhu X, Raina AK, Holbrook N, Siedlak SL, Harris PLR, Smith MA. Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. NeuroReport. 1999;10:2411&#x2013;2415.</Citation><ArticleIdList><ArticleId IdType="pubmed">10439473</ArticleId></ArticleIdList></Reference><Reference><Citation>Praprotnik D, Smith MA, Richey PL, Vinters HV, Perry G. Plasma membrane fragility in dystrophic neurites in senile plaques of Alzheimer's disease: an index of oxidative stress. Acta Neuropathol. 1996a;91:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">8773139</ArticleId></ArticleIdList></Reference><Reference><Citation>Praprotnik D, Smith MA, Richey PL, Vinters HV, Perry G. Filament heterogeneity within the dystrophic neurites of senile plaques suggests blockage of fast axonal transport in Alzheimer's disease. Acta Neuropathol. 1996b;91:226&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">8834534</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayre LM, Zelasko DA, Harris PLR, Perry G, Salomon RG, Smith MA. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem. 1997;68:2092&#x2013;2097.</Citation><ArticleIdList><ArticleId IdType="pubmed">9109537</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith MA. Alzheimer disease. In: Bradley JY, Harris RA, editors. International review of neurobiology. Academic; San Diego: 1998. pp. 1&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">9476170</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith MA, Perry G, Richey PL, Sayre LM, Anderson VM, Beal MF, Kowall N. Oxidative damage in Alzheimer's. Nature. 1996;382:120&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">8700201</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith MA, Harris PLR, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci. 1997;17:2653&#x2013;2657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573097</ArticleId><ArticleId IdType="pubmed">9092586</ArticleId></ArticleIdList></Reference><Reference><Citation>Sternberger LA. Immunocytochemistry, Ed 3. Wiley; New York: 1986.</Citation></Reference><Reference><Citation>Stewart PA, Hayakawa K, Akers M-A, Vinters HV. A morphometric study of the blood-brain barrier in Alzheimer's disease. Lab Invest. 1992;67:734&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">1460864</ArticleId></ArticleIdList></Reference><Reference><Citation>Trimmer PA, Swerdlow RH, Parks JK, Keeney P, Bennett JP, Jr, Miller SW, Davis RE, Parker WD., Jr Abnormal mitochondrial morphology in sporadic Parkinson's and Alzheimer's disease cybrid cell lines. Exp Neurol. 2000;162:37&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">10716887</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong-Riley M, Antuono P, Ho K-V, Egan R, Hevner R, Liebl W, Huang Z, Rachel R, Jones J. Cytochrome oxidase in Alzheimer's disease: biochemical, histochemical, and immunohistochemical analyses of the visual and other systems. Vision Res. 1997;37:3593&#x2013;3608.</Citation><ArticleIdList><ArticleId IdType="pubmed">9425533</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, Smith MA. Activation of p38 pathway links tau phosphorylation, oxidative stress and cell cycle related events in Alzheimer disease. J Neuropathol Exp Neurol. 2000;59:880&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pubmed">11079778</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Raina AK, Rottkamp CA, Aliev G, Perry G, Boux H, Smith MA. Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J Neurochem. 2001;76:435&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">11208906</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19342591</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>324</Volume><Issue>5923</Issue><PubDate><Year>2009</Year><Month>Apr</Month><Day>03</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury.</ArticleTitle><Pagination><StartPage>102</StartPage><EndPage>105</EndPage><MedlinePgn>102-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1171091</ELocationID><Abstract><AbstractText>Mitochondria continuously undergo two opposing processes, fission and fusion. The disruption of this dynamic equilibrium may herald cell injury or death and may contribute to developmental and neurodegenerative disorders. Nitric oxide functions as a signaling molecule, but in excess it mediates neuronal injury, in part via mitochondrial fission or fragmentation. However, the underlying mechanism for nitric oxide-induced pathological fission remains unclear. We found that nitric oxide produced in response to beta-amyloid protein, thought to be a key mediator of Alzheimer's disease, triggered mitochondrial fission, synaptic loss, and neuronal damage, in part via S-nitrosylation of dynamin-related protein 1 (forming SNO-Drp1). Preventing nitrosylation of Drp1 by cysteine mutation abrogated these neurotoxic events. SNO-Drp1 is increased in brains of human Alzheimer's disease patients and may thus contribute to the pathogenesis of neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Dong-Hyung</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Center for Neuroscience, Aging, and Stem Cell Research, Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Tomohiro</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Jianguo</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Cieplak</LastName><ForeName>Piotr</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Godzik</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Zezong</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Lipton</LastName><ForeName>Stuart A</ForeName><Initials>SA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 EY005477</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS057096</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY05477</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 HD029587</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 ES016738</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 HD29587</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026403">S-Nitrosothiols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C074636">amyloid beta-protein (25-35)</NameOfSubstance></Chemical><Chemical><RegistryNumber>31C4KY9ESH</RegistryNumber><NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>926P2322P4</RegistryNumber><NameOfSubstance UI="C021315">S-nitrosocysteine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D020558">GTP Phosphohydrolases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.5</RegistryNumber><NameOfSubstance UI="C110768">DNM1L protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.5</RegistryNumber><NameOfSubstance UI="D034281">Dynamins</NameOfSubstance></Chemical><Chemical><RegistryNumber>K848JZ4886</RegistryNumber><NameOfSubstance UI="D003545">Cysteine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020816" MajorTopicYN="N">Amino Acid Motifs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003545" MajorTopicYN="N">Cysteine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034281" MajorTopicYN="N">Dynamins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020558" MajorTopicYN="N">GTP Phosphohydrolases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="N">Protein Multimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026403" MajorTopicYN="N">S-Nitrosothiols</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>2</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19342591</ArticleId><ArticleId IdType="mid">NIHMS173661</ArticleId><ArticleId IdType="pmc">PMC2823371</ArticleId><ArticleId IdType="doi">10.1126/science.1171091</ArticleId><ArticleId IdType="pii">324/5923/102</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Youle RJ, Karbowski M. Nat Rev Mol Cell Biol. 2005;6:657.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025099</ArticleId></ArticleIdList></Reference><Reference><Citation>Barsoum MJ, et al. EMBO J. 2006;25:3900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1553198</ArticleId><ArticleId IdType="pubmed">16874299</ArticleId></ArticleIdList></Reference><Reference><Citation>Knott AB, Perkins G, Schwarzenbacher R, Bossy-Wetzel E. Nat Rev Neurosci. 2008;9:505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2711514</ArticleId><ArticleId IdType="pubmed">18568013</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, et al. Proc Natl Acad Sci USA. 2008;105:2169.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Okamoto K, Hayashi Y, Sheng M. Cell. 2004;119:873.</Citation><ArticleIdList><ArticleId IdType="pubmed">15607982</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, et al. Proc Natl Acad Sci USA. 2008;105:19318.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Baloyannis SJ. J Alzheimers Dis. 2006;9:119.</Citation><ArticleIdList><ArticleId IdType="pubmed">16873959</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang-Decker N, et al. J Cell Sci. 2007;120:492.</Citation><ArticleIdList><ArticleId IdType="pubmed">17251380</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Moniri NH, Ozawa K, Stamler JS, Daaka Y. Proc Natl Acad Sci USA. 2006;103:1295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1360548</ArticleId><ArticleId IdType="pubmed">16432212</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan H, et al. Cell Death Differ. 2007;14:462.</Citation><ArticleIdList><ArticleId IdType="pubmed">17053808</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffrey SR, Erdjument-Bromage H, Ferris CD, Tempst P, Snyder SH. Nat Cell Biol. 2001;3:193.</Citation><ArticleIdList><ArticleId IdType="pubmed">11175752</ArticleId></ArticleIdList></Reference><Reference><Citation>Uehara T, et al. Nature. 2006;441:513.</Citation><ArticleIdList><ArticleId IdType="pubmed">16724068</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu PP, et al. J Biol Chem. 2004;279:35967.</Citation><ArticleIdList><ArticleId IdType="pubmed">15208300</ArticleId></ArticleIdList></Reference><Reference><Citation>Low HH, Lowe J. Nature. 2006;444:766.</Citation><ArticleIdList><ArticleId IdType="pubmed">17122778</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamler JS, Toone EJ, Lipton SA, Sucher NJ. Neuron. 1997;18:691.</Citation><ArticleIdList><ArticleId IdType="pubmed">9182795</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran R, et al. EMBO J. 2007;26:559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1783472</ArticleId><ArticleId IdType="pubmed">17170701</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitts KR, McNiven MA, Yoon Y. J Biol Chem. 2004;279:50286.</Citation><ArticleIdList><ArticleId IdType="pubmed">15364948</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YJ, Zhang P, Egelman EH, Hinshaw JE. Nat Struct Mol Biol. 2004;11:574.</Citation><ArticleIdList><ArticleId IdType="pubmed">15133500</ArticleId></ArticleIdList></Reference><Reference><Citation>Estaquier J, Arnoult D. Cell Death Differ. 2007;14:1086.</Citation><ArticleIdList><ArticleId IdType="pubmed">17332775</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan H, et al. Cell Death Differ. 2007;14:462.</Citation><ArticleIdList><ArticleId IdType="pubmed">17053808</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. J Neurosci. 2007;27:2866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Bush AI, Masters CL, Tanzi RE. Proc Natl Acad Sci USA. 2003;100:11193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC208731</ArticleId><ArticleId IdType="pubmed">14506299</ArticleId></ArticleIdList></Reference><Reference><Citation>Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS. Nat Rev Mol Cell Biol. 2005;6:150.</Citation><ArticleIdList><ArticleId IdType="pubmed">15688001</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21459773</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2083</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>13</Issue><PubDate><Year>2011</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Human molecular genetics</Title><ISOAbbreviation>Hum Mol Genet</ISOAbbreviation></Journal><ArticleTitle>Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage.</ArticleTitle><Pagination><StartPage>2495</StartPage><EndPage>2509</EndPage><MedlinePgn>2495-509</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/hmg/ddr139</ELocationID><Abstract><AbstractText>The purpose of our study was to better understand the relationship between mitochondrial structural proteins, particularly dynamin-related protein 1 (Drp1) and amyloid beta (A&#x3b2;) in the progression of Alzheimer's disease (AD). Using qRT-PCR and immunoblotting analyses, we measured mRNA and protein levels of mitochondrial structural genes in the frontal cortex of patients with early, definite and severe AD and in control subjects. We also characterized monomeric and oligomeric forms of A&#x3b2; in these patients. Using immunoprecipitation/immunoblotting analysis, we investigated the interaction between A&#x3b2; and Drp1. Using immunofluorescence analysis, we determined the localization of Drp1 and intraneuronal and oligomeric A&#x3b2; in the AD brains and primary hippocampal neurons from A&#x3b2; precursor protein (A&#x3b2;PP) transgenic mice. We found increased expression of the mitochondrial fission genes Drp1 and Fis1 (fission 1) and decreased expression of the mitochondrial fusion genes Mfn1 (mitofusin 1), Mfn2 (mitofusin 2), Opa1 (optic atrophy 1) and Tomm40. The matrix gene CypD was up-regulated in AD patients. Results from our qRT-PCR and immunoblotting analyses suggest that abnormal mitochondrial dynamics increase as AD progresses. Immunofluorescence analysis of the Drp1 antibody and the A&#x3b2; antibodies 6E10 and A11 revealed the colocalization of Drp1 and A&#x3b2;. Drp1 immunoprecipitation/immunoblotting analysis of A&#x3b2; antibodies 6E10 and A11 revealed that Drp1 interacts with A&#x3b2; monomers and oligomers in AD patients, and these abnormal interactions are increased with disease progression. Primary neurons that were found with accumulated oligomeric A&#x3b2; had lost branches and were degenerated, indicating that oligomeric A&#x3b2; may cause neuronal degeneration. These findings suggest that in patients with AD, increased production of A&#x3b2; and the interaction of A&#x3b2; with Drp1 are crucial factors in mitochondrial fragmentation, abnormal mitochondrial dynamics and synaptic damage. Inhibiting, these abnormal interactions may be a therapeutic strategy to reduce mitochondrial fragmentation, neuronal and synaptic damage and cognitive decline in patients with AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Manczak</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurogenetics Laboratory, Division of Neuroscience, Oregon National Primate Research Center, Oregon Health &amp; Science University, 505 NW 185th Avenue, Beaverton, OR 97006, USA</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calkins</LastName><ForeName>Marcus J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Reddy</LastName><ForeName>P Hemachandra</ForeName><Initials>PH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RR00163</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG028072</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG028072</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10RR024585</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG026051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hum Mol Genet</MedlineTA><NlmUniqueID>9208958</NlmUniqueID><ISSNLinking>0964-6906</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.99.1</RegistryNumber><NameOfSubstance UI="D051545">Cyclooxygenase 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D020558">GTP Phosphohydrolases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.5</RegistryNumber><NameOfSubstance UI="C110768">DNM1L protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.5</RegistryNumber><NameOfSubstance UI="D034281">Dynamins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051545" MajorTopicYN="N">Cyclooxygenase 1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034281" MajorTopicYN="N">Dynamins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020558" MajorTopicYN="N">GTP Phosphohydrolases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050259" MajorTopicYN="N">Genes, Mitochondrial</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21459773</ArticleId><ArticleId IdType="pmc">PMC3109997</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddr139</ArticleId><ArticleId IdType="pii">ddr139</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller J.N., Pang Z., Geddes J.W., Begley J.G., Germeyer A., Waeg G., Mattson M.P. Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: role of the lipid peroxidation product 4-hydroxynonenal. J. Neurochem. 1997;69:273&#x2013;284.  doi:10.1046/j.1471-4159.1997.69010273.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1997.69010273.x</ArticleId><ArticleId IdType="pubmed">9202320</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow R.H., Parks J.K., Cassarino D.S., Maguire D.J., Maguire R.S., Bennett J.P., Jr, Davis R.E., Parker W.D., Jr Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology. 1997;49:918&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">9339668</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy P.H., Reddy P.H. Mitochondria are a therapeutic target for neurodegenerative disease. Curr. Alzheimer Res. 2010 in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3295247</ArticleId><ArticleId IdType="pubmed">21470101</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature. 2004;430:631&#x2013;639.  doi:10.1038/nature02621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02621</ArticleId><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>Barsoum M.J., Yuan H., Gerencser A.A., Liot G., Kushnareva Y., Gr&#xe4;ber S., Kovacs I., Lee W.D., Waggoner J., Cui J., et al.  Nitric oxide-induced mitochondrial fission is regulated by dynamin-related GTPases in neurons. EMBO J. 2006;25:3900&#x2013;3911.  doi:10.1038/sj.emboj.7601253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7601253</ArticleId><ArticleId IdType="pmc">PMC1553198</ArticleId><ArticleId IdType="pubmed">16874299</ArticleId></ArticleIdList></Reference><Reference><Citation>Greig N.H., Utsuki T., Ingram D.K., Wang Y., Pepeu G., Scali C., Yu Q.S., Mamczarz J., Holloway H.W., Giordano T., et al.  Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc. Natl Acad. Sci. USA. 2009;102:17213&#x2013;17218.  doi:10.1073/pnas.0508575102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0508575102</ArticleId><ArticleId IdType="pmc">PMC1288010</ArticleId><ArticleId IdType="pubmed">16275899</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy P.H., Beal M.F. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol. Med. 2008;14:45&#x2013;53.  doi:10.1016/j.molmed.2007.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2007.12.002</ArticleId><ArticleId IdType="pmc">PMC3107703</ArticleId><ArticleId IdType="pubmed">18218341</ArticleId></ArticleIdList></Reference><Reference><Citation>Querfurth H.W., LaFerla F.M. Alzheimer's disease. N. Engl. J. Med. 2010;362:329&#x2013;344.  doi:10.1056/NEJMra0909142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra0909142</ArticleId><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras G.K., Almeid C.G., Takahashi R.H. Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease. Neurobiol. Aging. 2005;26:1235&#x2013;1244.  doi:10.1016/j.neurobiolaging.2005.05.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2005.05.022</ArticleId><ArticleId IdType="pubmed">16023263</ArticleId></ArticleIdList></Reference><Reference><Citation>Zawia N.H., Lahiri D.K., Cardozo-Pelaez F. Epigenetics, oxidative stress, and Alzheimer disease. Free Radic. Biol. Med. 2009;46:1241&#x2013;1249.  doi:10.1016/j.freeradbiomed.2009.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2009.02.006</ArticleId><ArticleId IdType="pmc">PMC2673453</ArticleId><ArticleId IdType="pubmed">19245828</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy P.H., Manczak M., Mao P., Calkins M.J., Reddy A.P., Shirendeb U. Amyloid-beta and mitochondria in aging and Alzheimer's disease: implications for synaptic damage and cognitive decline. J. Alzheimers Dis. 2010;20(Suppl. 2):S499&#x2013;S512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059092</ArticleId><ArticleId IdType="pubmed">20413847</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein W.L., Krafft G.A., Finch C.E. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 2001;24:219&#x2013;224.  doi:10.1016/S0166-2236(00)01749-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0166-2236(00)01749-5</ArticleId><ArticleId IdType="pubmed">11250006</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., Krafft G.A., Klein W.L. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl Acad. Sci. USA. 2003;100:10417&#x2013;10422.  doi:10.1073/pnas.1834302100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1834302100</ArticleId><ArticleId IdType="pmc">PMC193576</ArticleId><ArticleId IdType="pubmed">12925731</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D.M., Selkoe D.J. A beta oligomers&#x2014;a decade of discovery. J. Neurochem. 2007;101:1172&#x2013;1184.  doi:10.1111/j.1471-4159.2006.04426.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.04426.x</ArticleId><ArticleId IdType="pubmed">17286590</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla F.M., Green K.N., Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci. 2007;8:499&#x2013;509.  doi:10.1038/nrn2168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2168</ArticleId><ArticleId IdType="pubmed">17551515</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham E., Crews L., Ubhi K., Hansen L., Adame A., Cartier A., Salmon D., Galasko D., Michael S., Savas J.N., et al.  Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. FEBS J. 2010;277:3051&#x2013;3067.  doi:10.1111/j.1742-4658.2010.07719.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2010.07719.x</ArticleId><ArticleId IdType="pmc">PMC2933033</ArticleId><ArticleId IdType="pubmed">20573181</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia W., Yang T., Shankar G., Smith I.M., Shen Y., Walsh D.M., Selkoe D.J. A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch. Neurol. 2009;66:190&#x2013;199.  doi:10.1001/archneurol.2008.565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2008.565</ArticleId><ArticleId IdType="pmc">PMC3618974</ArticleId><ArticleId IdType="pubmed">19204155</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H.Y., Hudry E., Hashimoto T., Kuchibhotla K., Rozkalne A., Fan Z., Spires-Jones T., Xie H., Arbel-Ornath M., Grosskreutz C.L., Bacskai B.J., Hyman B.T. Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J. Neurosci. 2010;30:2636&#x2013;2649.  doi:10.1523/JNEUROSCI.4456-09.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4456-09.2010</ArticleId><ArticleId IdType="pmc">PMC2841957</ArticleId><ArticleId IdType="pubmed">20164348</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesn&#xe9; S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.  doi:10.1038/nature04533.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04533</ArticleId><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., et al.  Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008;14:837&#x2013;842.  doi:10.1038/nm1782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1782</ArticleId><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Manczak M., Anekonda T.S., Henson E., Park B.S., Quinn J., Reddy P.H. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 2006;15:1437&#x2013;1449.  doi:10.1093/hmg/ddl066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddl066</ArticleId><ArticleId IdType="pubmed">16551656</ArticleId></ArticleIdList></Reference><Reference><Citation>Caspersen C., Wang N., Yao J., Sosunov A., Chen X., Lustbader J.W., Xu H.W., Stern D., McKhann G., Yan S.D. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J. 2005;19:2040&#x2013;2041.</Citation><ArticleIdList><ArticleId IdType="pubmed">16210396</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi L., Prabhu B.M., Galati D.F., Avadhani N.G., Anandatheerthavarada H.K. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J. Neurosci. 2006;26:9057&#x2013;9068.  doi:10.1523/JNEUROSCI.1469-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1469-06.2006</ArticleId><ArticleId IdType="pmc">PMC6675337</ArticleId><ArticleId IdType="pubmed">16943564</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao J., Irwin R.W., Zhao L., Nilsen J., Hamilton R.T., Brinton R.D. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA. 2009;106:14670&#x2013;14675.  doi:10.1073/pnas.0903563106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0903563106</ArticleId><ArticleId IdType="pmc">PMC2732886</ArticleId><ArticleId IdType="pubmed">19667196</ArticleId></ArticleIdList></Reference><Reference><Citation>Manczak M., Mao P., Calkins M.J., Cornea A., Reddy A.P., Murphy M.P., Szeto H.H., Park B., Reddy P.H. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J. Alzheimers Dis. 2010;20(Suppl. 2):S609&#x2013;S631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072711</ArticleId><ArticleId IdType="pubmed">20463406</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckert A., Hauptmann S., Scherping I., Rhein V., M&#xfc;ller-Spahn F., G&#xf6;tz J., M&#xfc;ller W.E. Soluble beta-amyloid leads to mitochondrial defects in amyloid precursor protein and tau transgenic mice. Neurodegener. Dis. 2008;5:157&#x2013;159.  doi:10.1159/000113689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000113689</ArticleId><ArticleId IdType="pubmed">18322377</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhein V., Song X., Wiesner A., Ittner L.M., Baysang G., Meier F., Ozmen L., Bluethmann H., Dr&#xf6;se S., Brandt U., et al. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc. Natl Acad. Sci. USA. 2009;106:20057&#x2013;20062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774257</ArticleId><ArticleId IdType="pubmed">19897719</ArticleId></ArticleIdList></Reference><Reference><Citation>Calkins M.J., Reddy P.H. Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer's disease neurons. Biochim. Biophys. Acta. 2011;1812:507&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3042500</ArticleId><ArticleId IdType="pubmed">21241801</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Perry G., Smith M.A., Zhu X. Amyloid-beta-derived diffusible ligands cause impaired axonal transport of mitochondria in neurons. Neurodegener. Dis. 2010;7:56&#x2013;59.  doi:10.1159/000283484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000283484</ArticleId><ArticleId IdType="pmc">PMC2859232</ArticleId><ArticleId IdType="pubmed">20160460</ArticleId></ArticleIdList></Reference><Reference><Citation>Du H., Guo L., Yan S., Sosunov A.A., McKhann G.M., Yan S.S. Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc. Natl Acad. Sci. USA. 2010;107:18670&#x2013;18675.  doi:10.1073/pnas.1006586107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1006586107</ArticleId><ArticleId IdType="pmc">PMC2972922</ArticleId><ArticleId IdType="pubmed">20937894</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Su B., Siedlak S.L., Moreira P.I., Fujioka H., Wang Y., Casadesus G., Zhu X. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc. Natl Acad. Sci .USA. 2008;105:19318&#x2013;19323.  doi:10.1073/pnas.0804871105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0804871105</ArticleId><ArticleId IdType="pmc">PMC2614759</ArticleId><ArticleId IdType="pubmed">19050078</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Su B., Lee H.G., Li X., Perry G., Smith M.A., Zhu X. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J. Neurosci. 2009;29:9090&#x2013;9103.  doi:10.1523/JNEUROSCI.1357-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1357-09.2009</ArticleId><ArticleId IdType="pmc">PMC2735241</ArticleId><ArticleId IdType="pubmed">19605646</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H., Chan D.C. Mitochondrial dynamics&#x2014;fusion, fission, movement, and mitophagy&#x2014;in neurodegenerative diseases. Hum. Mol. Genet. 2009;18:R169&#x2013;R176.  doi:10.1093/hmg/ddp326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp326</ArticleId><ArticleId IdType="pmc">PMC2758711</ArticleId><ArticleId IdType="pubmed">19808793</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy P.H., Mao P., Manczak M. Mitochondrial structural and functional dynamics in Huntington's disease. Brain Res. Rev. 2009;61:33&#x2013;48.  doi:10.1016/j.brainresrev.2009.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresrev.2009.04.001</ArticleId><ArticleId IdType="pmc">PMC2748129</ArticleId><ArticleId IdType="pubmed">19394359</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy P.H., Reddy T.P., Manczak M., Calkins M.J., Shirendeb U., Mao P. Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases. Brain Res. Rev. 2010 in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3061980</ArticleId><ArticleId IdType="pubmed">21145355</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakabayashi J., Zhang Z., Wakabayashi N., Tamura Y., Fukaya M., Kensler T.W., Iijima M., Sesaki H. The dynamin-related GTPase Drp1 is required for embryonic and brain development in mice. J. Cell Biol. 2009;186:805&#x2013;816.  doi:10.1083/jcb.200903065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200903065</ArticleId><ArticleId IdType="pmc">PMC2753156</ArticleId><ArticleId IdType="pubmed">19752021</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihara N., Nomura M., Jofuku A., Kato H., Suzuki S.O., Masuda K., Otera H., Nakanishi Y., Nonaka I., Goto Y., et al.  Mitochondrial fission factor Drp1 is essential for embryonic development and synapse formation in mice. Nat. Cell Biol. 2009;11:958&#x2013;966.  doi:10.1038/ncb1907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1907</ArticleId><ArticleId IdType="pubmed">19578372</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirendeb U., Reddy A.P., Manczak M., Calkins M.J., Mao P., Tagle D.A., Reddy P.H. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum. Mol. Genet. 2011;20:1438&#x2013;1455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3049363</ArticleId><ArticleId IdType="pubmed">21257639</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju W.K., Liu Q., Kim K.Y., Crowston J.G., Lindsey J.D., Agarwal N., Ellisman M.H., Perkins G.A., Weinreb R.N. Elevated hydrostatic pressure triggers mitochondrial fission and decreases cellular ATP in differentiated RGC-5 cells. Invest. Ophthalmol. Vis. Sci. 2007;48:2145&#x2013;2151.  doi:10.1167/iovs.06-0573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.06-0573</ArticleId><ArticleId IdType="pubmed">17460273</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi R.H., Almeida C.G., Kearney P.F., Yu F., Lin M.T., Milner T.A., Gouras G.K. Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J. Neurosci. 2004;24:3592&#x2013;3599.  doi:10.1523/JNEUROSCI.5167-03.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5167-03.2004</ArticleId><ArticleId IdType="pmc">PMC6729733</ArticleId><ArticleId IdType="pubmed">15071107</ArticleId></ArticleIdList></Reference><Reference><Citation>Du H., Guo L., Fang F., Chen D., Sosunov A.A., McKhann G.M., Yan Y., Wang C., Zhang H., Molkentin J.D., et al.  Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat. Med. 2008;14:1097&#x2013;1105.  doi:10.1038/nm.1868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1868</ArticleId><ArticleId IdType="pmc">PMC2789841</ArticleId><ArticleId IdType="pubmed">18806802</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustbader J.W., Cirilli M., Lin C., Xu H.W., Takuma K., Wang N., Caspersen C., Chen X., Pollak S., Chaney M., et al.  ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science. 2004;304:448&#x2013;452.  doi:10.1126/science.1091230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1091230</ArticleId><ArticleId IdType="pubmed">15087549</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirai K., Aliev G., Nunomura A., Fujioka H., Russell R.L., Atwood C.S., Johnson A.B., Kress Y., Vinters H.V., Tabaton M., et al. Mitochondrial abnormalities in Alzheimer's disease. J. Neurosci. 2001;21:3017&#x2013;3023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762571</ArticleId><ArticleId IdType="pubmed">11312286</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy P.H., McWeeney S., Park B.S., Manczak M., Gutala R.V., Partovi D., Jung Y., Yau V., Searles R., Mori M., Quinn J. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Hum. Mol. Genet. 2004;13:1225&#x2013;1240.  doi:10.1093/hmg/ddh140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddh140</ArticleId><ArticleId IdType="pubmed">15115763</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson Petersen C.A., Alikhani N., Behbahani H., Wiehager B., Pavlov P.F., Alafuzoff I., Leinonen V., Ito A., Winblad B., Glaser E., Ankarcrona M. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc. Natl Acad. Sci. USA. 2008;105:13145&#x2013;3150.  doi:10.1073/pnas.0806192105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0806192105</ArticleId><ArticleId IdType="pmc">PMC2527349</ArticleId><ArticleId IdType="pubmed">18757748</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1991;1:213&#x2013;216.  doi:10.1111/j.1750-3639.1991.tb00661.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.1991.tb00661.x</ArticleId><ArticleId IdType="pubmed">1669710</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutala R.V., Reddy P.H. The use of real-time PCR analysis in a gene expression study of Alzheimer's disease post-mortem brains. J. Neurosci. Methods. 2004;132:101&#x2013;107.  doi:10.1016/j.jneumeth.2003.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2003.09.005</ArticleId><ArticleId IdType="pubmed">14687679</ArticleId></ArticleIdList></Reference><Reference><Citation>Manczak M., Mao P., Nakamura K., Bebbington C., Park B., Reddy P.H. Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1&#x2013;42 and suppresses microglial activity in a transgenic mouse model of Alzheimer's disease. Hum. Mol. Genet. 2009;18:3876&#x2013;3893.  doi:10.1093/hmg/ddp331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp331</ArticleId><ArticleId IdType="pmc">PMC2748895</ArticleId><ArticleId IdType="pubmed">19617638</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy T.P., Manczak M., Calkins M.J., Mao P., Reddy A.P., Shirendeb U., Park B., Reddy P.H. Toxicity of neurons treated with herbicides and neuroprotection by mitochondria-targeted antioxidant SS31. Int. J. Environ. Res. Public Health. 2011;8:203&#x2013;221.  doi:10.3390/ijerph8010203.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph8010203</ArticleId><ArticleId IdType="pmc">PMC3037070</ArticleId><ArticleId IdType="pubmed">21318024</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakker D.R., Weatherspoon M.R., Harrison J., Keene T.E., Lane D.S., Kaemmerer W.F., Stewart G.R., Shafer L.L. Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice. Proc. Natl Acad. Sci. USA. 2009;106:4501&#x2013;4516.  doi:10.1073/pnas.0813404106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0813404106</ArticleId><ArticleId IdType="pmc">PMC2647980</ArticleId><ArticleId IdType="pubmed">19246392</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489.  doi:10.1126/science.1079469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1079469</ArticleId><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt D.R., Thinakaran G., Eckman C.B., Lee M.K., Davenport F., Ratovitsky T., Prada C.M., Kim G., Seekins S., Yager D., et al.  Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1&#x2013;42/1&#x2013;40 ratio in vitro and in vivo. Neuron. 1996;17:1005&#x2013;1013.  doi:10.1016/S0896-6273(00)80230-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80230-5</ArticleId><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.  doi:10.1126/science.274.5284.99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.274.5284.99</ArticleId><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20980585</PMID><DateCompleted><Year>2010</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>43</Issue><PubDate><Year>2010</Year><Month>Oct</Month><Day>27</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer's disease transgenic mice.</ArticleTitle><Pagination><StartPage>14299</StartPage><EndPage>14304</EndPage><MedlinePgn>14299-304</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3383-10.2010</ELocationID><Abstract><AbstractText>Accumulation of &#x3b2;-amyloid (A&#x3b2;) and loss of synapses are hallmarks of Alzheimer's disease (AD). How synaptic activity relates to A&#x3b2; accumulation and loss of synapses is a current topic of major interest. Synaptic activation promotes A&#x3b2; secretion, and chronic reduction of synaptic activity reduced A&#x3b2; plaques in an AD transgenic mouse model. This suggested beneficial effects of reducing synaptic activity in AD. We now show that reduced synaptic activity causes detrimental effects on synapses and memory despite reducing plaques using two different models of chronic synaptic inhibition: deafferentation of the barrel cortex and administration of benzodiazepine. An interval of prolonged synaptic inhibition exacerbated loss of synaptophysin compared with synaptically more active brain in AD transgenic but not wild-type mice. Furthermore, an interval of benzodiazepine treatment, followed by a washout period, exacerbated memory impairment in AD transgenic mice. Exacerbation of synaptic and behavioral abnormalities occurred in the setting of reduced A&#x3b2; plaques but elevated intraneuronal A&#x3b2; immunoreactivity. These data support beneficial effects of synaptic activation on A&#x3b2;-related synaptic and behavioral impairment in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tampellini</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, New York 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capetillo-Zarate</LastName><ForeName>Estibaliz</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Dumont</LastName><ForeName>Magali</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Zhenyong</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Fangmin</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Gouras</LastName><ForeName>Gunnar K</ForeName><Initials>GK</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG020729</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG028174</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG009464</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02 AG028174</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG09464</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027140</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020729</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027140</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006993">Hypnotics and Sedatives</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016708">Synaptophysin</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q3JTX2Q7TU</RegistryNumber><NameOfSubstance UI="D003975">Diazepam</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003975" MajorTopicYN="N">Diazepam</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006993" MajorTopicYN="N">Hypnotics and Sedatives</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009044" MajorTopicYN="N">Motor Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016708" MajorTopicYN="N">Synaptophysin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014738" MajorTopicYN="N">Vibrissae</DescriptorName><QualifierName UI="Q000294" MajorTopicYN="N">innervation</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>4</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20980585</ArticleId><ArticleId IdType="mid">NIHMS248459</ArticleId><ArticleId IdType="pmc">PMC2972675</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3383-10.2010</ArticleId><ArticleId IdType="pii">30/43/14299</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Almeida CG, Tampellini D, Takahashi RH, Greengard P, Lin MT, Snyder EM, Gouras GK. Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol Dis. 2005;20:187&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">16242627</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 2005;45:675&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748844</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings LM, Green KN, McGaugh JL, LaFerla FM. Learning decreases A beta*56 and tau pathology and ameliorates behavioral decline in 3xTg-AD mice. J Neurosci. 2007;27:751&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672918</ArticleId><ArticleId IdType="pubmed">17251414</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, Bu G, Mennerick S, Holtzman DM. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron. 2008;58:42&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2390913</ArticleId><ArticleId IdType="pubmed">18400162</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz JC, Kim D, Moy LY, Dobbin MM, Sun X, Bronson RT, Tsai LH. p25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid beta in vivo. J Neurosci. 2006;26:10536&#x2013;10541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674706</ArticleId><ArticleId IdType="pubmed">17035538</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 2002;5:452&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">11941374</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumont M, Wille E, Stack C, Calingasan NY, Beal MF, Lin MT. Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J. 2009;23:2459&#x2013;2466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2717785</ArticleId><ArticleId IdType="pubmed">19346295</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandy S, Simon AJ, Steele JW, Lublin AL, Lah JJ, Walker LC, Levey AI, Krafft GA, Levy E, Checler F, Glabe C, Bilker WB, Abel T, Schmeidler J, Ehrlich ME. Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann Neurol. 2010;68:220&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094694</ArticleId><ArticleId IdType="pubmed">20641005</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldsbury C, Mocanu MM, Thies E, Kaether C, Haass C, Keller P, Biernat J, Mandelkow E, Mandelkow EM. Inhibition of APP trafficking by tau protein does not increase the generation of amyloid-beta peptides. Traffic. 2006;7:873&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pubmed">16734669</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol. 2000;156:15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868613</ArticleId><ArticleId IdType="pubmed">10623648</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Tampellini D, Takahashi RH, Capetillo-Zarate E. Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathol. 2010;119:523&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3183823</ArticleId><ArticleId IdType="pubmed">20354705</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372:216&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">18640458</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326:1005&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Knobloch M, Konietzko U, Krebs DC, Nitsch RM. Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiol Aging. 2007;28:1297&#x2013;1306.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876915</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM, Hersh LB, Sapolsky RM, Mirnics K, Sisodia SS. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell. 2005;120:701&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">15766532</ArticleId></ArticleIdList></Reference><Reference><Citation>Leon WC, Canneva F, Partridge V, Allard S, Ferretti MT, DeWilde A, Vercauteren F, Atifeh R, Ducatenzeiler A, Klein W, Szyf M, Alhonen L, Cuello AC. A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. J Alzheimers Dis. 2010;20:113&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">20164597</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F, Calingasan NY, Yu F, Mauck WM, Toidze M, Almeida CG, Takahashi RH, Carlson GA, Flint Beal M, Lin MT, Gouras GK. Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice. J Neurochem. 2004;89:1308&#x2013;1312.</Citation><ArticleIdList><ArticleId IdType="pubmed">15147524</ArticleId></ArticleIdList></Reference><Reference><Citation>Lord A, Englund H, S&#xf6;derberg L, Tucker S, Clausen F, Hillered L, Gordon M, Morgan D, Lannfelt L, Pettersson FE, Nilsson LN. Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. FEBS J. 2009;276:995&#x2013;1006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2752010</ArticleId><ArticleId IdType="pubmed">19215301</ArticleId></ArticleIdList></Reference><Reference><Citation>Mach&#xed;n R, P&#xe9;rez-Cejuela CG, Bjugn R, Avenda&#xf1;o C. Effects of long-term sensory deprivation on asymmetric synapses in the whisker barrel field of the adult rat. Brain Res. 2006;1107:104&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">16822483</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Miller LA. Senile plaques in temporal lobe epilepsy. Acta Neuropathol. 1994;87:504&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">8059603</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature. 2006;443:768&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051202</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Runz H, Rietdorf J, Tomic I, de Bernard M, Beyreuther K, Pepperkok R, Hartmann T. Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J Neurosci. 2002;22:1679&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758870</ArticleId><ArticleId IdType="pubmed">11880497</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20:S69&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">16917199</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, Beal MF, Xu H, Greengard P, Gouras GK. Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol. 2002;161:1869&#x2013;1879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850783</ArticleId><ArticleId IdType="pubmed">12414533</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, Capetillo-Zarate E, Lin MT, Milner TA, Gouras GK. Co-occurrence of Alzheimer's disease beta-amyloid and tau pathologies at synapses. Neurobiol Aging. 2010;31:1145&#x2013;1152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2909664</ArticleId><ArticleId IdType="pubmed">18771816</ArticleId></ArticleIdList></Reference><Reference><Citation>Tampellini D, Rahman N, Gallo EF, Huang Z, Dumont M, Capetillo-Zarate E, Ma T, Zheng R, Lu B, Nanus DM, Lin MT, Gouras GK. Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations. J Neurosci. 2009;29:9704&#x2013;9713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763626</ArticleId><ArticleId IdType="pubmed">19657023</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, Takuma H, Kuwano R, Imagawa M, Ataka S, Wada Y, Yoshioka E, Nishizaki T, Watanabe Y, Mori H. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol. 2008;63:377&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">18300294</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K, Ishibashi K, Teraoka R, Sakama N, Yamashita T, Nishitsuji K, Ito K, Shimada H, Lambert MP, Klein WL, Mori H. A mouse model of amyloid {beta} oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci. 2010;30:4845&#x2013;4856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632783</ArticleId><ArticleId IdType="pubmed">20371804</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirths O, Multhaup G, Czech C, Blanchard V, Moussaoui S, Tremp G, Pradier L, Beyreuther K, Bayer TA. Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci Lett. 2001;306:116&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11403971</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong-Riley MT, Welt C. Histochemical changes in cytochrome oxidase of cortical barrels after vibrissal removal in neonatal and adult mice. Proc Natl Acad Sci U S A. 1980;77:2333&#x2013;2337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC348709</ArticleId><ArticleId IdType="pubmed">6246540</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21532579</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Neuronal activity regulates the regional vulnerability to amyloid-&#x3b2; deposition.</ArticleTitle><Pagination><StartPage>750</StartPage><EndPage>756</EndPage><MedlinePgn>750-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.2801</ELocationID><Abstract><AbstractText>Amyloid-&#x3b2; (A&#x3b2;) plaque deposition in specific brain regions is a pathological hallmark of Alzheimer's disease. However, the mechanism underlying the regional vulnerability to A&#x3b2; deposition in Alzheimer's disease is unknown. Herein, we provide evidence that endogenous neuronal activity regulates the regional concentration of interstitial fluid (ISF) A&#x3b2;, which drives local A&#x3b2; aggregation. Using in vivo microdialysis, we show that ISF A&#x3b2; concentrations in several brain regions of APP transgenic mice before plaque deposition were commensurate with the degree of subsequent plaque deposition and with the concentration of lactate, a marker of neuronal activity. Furthermore, unilateral vibrissal stimulation increased ISF A&#x3b2;, and unilateral vibrissal deprivation decreased ISF A&#x3b2; and lactate, in contralateral barrel cortex. Long-term unilateral vibrissal deprivation decreased amyloid plaque formation and growth. Our results suggest a mechanism to account for the vulnerability of specific brain regions to A&#x3b2; deposition in Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bero</LastName><ForeName>Adam W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Ping</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Roh</LastName><ForeName>Jee Hoon</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Floy R</ForeName><Initials>FR</Initials></Author><Author ValidYN="Y"><LastName>Raichle</LastName><ForeName>Marcus E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jin-Moo</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 NS006833</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS67905</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS032636</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 AG033452</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS067905</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG033452</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG029524</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS06833</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS32636</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG029524</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG568127</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>05</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>33X04XA5AT</RegistryNumber><NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2011 Jun;14(6):669-70. doi: 10.1038/nn.2853.</RefSource><PMID Version="1">21613991</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2011 Jun 02;12(7):372-3. doi: 10.1038/nrn3059.</RefSource><PMID Version="1">21633382</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045604" MajorTopicYN="N">Extracellular Fluid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019344" MajorTopicYN="N">Lactic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017551" MajorTopicYN="N">Microdialysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012683" MajorTopicYN="Y">Sensory Deprivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013003" MajorTopicYN="N">Somatosensory Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21532579</ArticleId><ArticleId IdType="mid">NIHMS279971</ArticleId><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="doi">10.1038/nn.2801</ArticleId><ArticleId IdType="pii">nn.2801</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ. Alzheimer&#x2019;s disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, et al. Extracellular amyloid formation and associated pathology in neural grafts. Nat Neurosci. 2003;6:370&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">12598899</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan P, et al. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci. 2009;29:10706&#x2013;10714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756291</ArticleId><ArticleId IdType="pubmed">19710322</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, et al. A default mode of brain function. Proc Natl Acad Sci U S A. 2001;98:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, et al. Molecular, structural, and functional characterization of Alzheimer&#x2019;s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Andrews-Hanna JR, Schacter DL. The brain&#x2019;s default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci. 2008;1124:1&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">18400922</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, et al. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer&#x2019;s disease. J Neurosci. 2009;29:1860&#x2013;1873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750039</ArticleId><ArticleId IdType="pubmed">19211893</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaishnavi SN, et al. Regional aerobic glycolysis in the human brain. Proc Natl Acad Sci U S A. 2010;107:17757&#x2013;17762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2955101</ArticleId><ArticleId IdType="pubmed">20837536</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko AG, et al. Spatial correlation between brain aerobic glycolysis and amyloid-beta (Abeta ) deposition. Proc Natl Acad Sci U S A. 2010;107:17763&#x2013;17767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2955133</ArticleId><ArticleId IdType="pubmed">20837517</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer&#x2019;s disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A. 2004;101:4637&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, et al. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci. 2009;29:12686&#x2013;12694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2808119</ArticleId><ArticleId IdType="pubmed">19812343</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63:178&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2738994</ArticleId><ArticleId IdType="pubmed">19640477</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyder F, et al. Neuronal-glial glucose oxidation and glutamatergic-GABAergic function. J Cereb Blood Flow Metab. 2006;26:865&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pubmed">16407855</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, et al. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, et al. Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat Neurosci. 2010;13:190&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3310198</ArticleId><ArticleId IdType="pubmed">20037574</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, et al. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron. 2008;58:42&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2390913</ArticleId><ArticleId IdType="pubmed">18400162</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellerin L, Magistretti PJ. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci U S A. 1994;91:10625&#x2013;10629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45074</ArticleId><ArticleId IdType="pubmed">7938003</ArticleId></ArticleIdList></Reference><Reference><Citation>Uehara T, Sumiyoshi T, Itoh H, Kurata K. Lactate production and neurotransmitters; evidence from microdialysis studies. Pharmacol Biochem Behav. 2008;90:273&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">18502489</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolsey TA, Van der Loos H. The structural organization of layer IV in the somatosensory region (SI) of mouse cerebral cortex. The description of a cortical field composed of discrete cytoarchitectonic units. Brain Res. 1970;17:205&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">4904874</ArticleId></ArticleIdList></Reference><Reference><Citation>Melzer P, et al. A magnetic device to stimulate selected whiskers of freely moving or restrained small rodents: its application in a deoxyglucose study. Brain Res. 1985;348:229&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">4075083</ArticleId></ArticleIdList></Reference><Reference><Citation>Durham D, Woolsey TA. Acute whisker removal reduces neuronal activity in barrels of mouse SmL cortex. J Comp Neurol. 1978;178:629&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pubmed">632373</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas MJ, Navas JA, Rector DM. Evoked response potential markers for anesthetic and behavioral states. Am J Physiol Regul Integr Comp Physiol. 2006;291:R189&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">16455771</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326:1005&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Riedner BA, et al. Sleep homeostasis and cortical synchronization: III. A high-density EEG study of sleep slow waves in humans. Sleep. 2007;30:1643&#x2013;1657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2276133</ArticleId><ArticleId IdType="pubmed">18246974</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyazovskiy VV, Cirelli C, Pfister-Genskow M, Faraguna U, Tononi G. Molecular and electrophysiological evidence for net synaptic potentiation in wake and depression in sleep. Nat Neurosci. 2008;11:200&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">18204445</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilestro GF, Tononi G, Cirelli C. Widespread changes in synaptic markers as a function of sleep and wakefulness in Drosophila. Science. 2009;324:109&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715914</ArticleId><ArticleId IdType="pubmed">19342593</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 2004;13:159&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahmanyar S, et al. Localization of amyloid beta protein messenger RNA in brains from patients with Alzheimer&#x2019;s disease. Science. 1987;237:77&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">3299701</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M. Neuronal localization of amyloid beta protein precursor mRNA in normal human brain and in Alzheimer&#x2019;s disease. EMBO J. 1987;6:3627&#x2013;3632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC553830</ArticleId><ArticleId IdType="pubmed">3322812</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, et al. Beta-secretase cleavage of Alzheimer&#x2019;s amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Page K, Hollister R, Tanzi RE, Hyman BT. In situ hybridization analysis of presenilin 1 mRNA in Alzheimer disease and in lesioned rat brain. Proc Natl Acad Sci U S A. 1996;93:14020&#x2013;14024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19487</ArticleId><ArticleId IdType="pubmed">8943053</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol. 1997;56:965&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">9291938</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, Locascio JJ, Hyman BT. beta-site APP cleaving enzyme mRNA expression in APP transgenic mice: anatomical overlap with transgene expression and static levels with aging. Am J Pathol. 2001;158:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850271</ArticleId><ArticleId IdType="pubmed">11141490</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigl M, et al. Expression of beta-secretase mRNA in transgenic Tg2576 mouse brain with Alzheimer plaque pathology. Neurosci Lett. 2000;292:107&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">10998560</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein ME, et al. Ex vivo occupancy of gamma-secretase inhibitors correlates with brain beta-amyloid peptide reduction in Tg2576 mice. J Pharmacol Exp Ther. 2007;323:102&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">17640949</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science. 2006;313:1781&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS, et al. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science. 2010;330:980&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233904</ArticleId><ArticleId IdType="pubmed">20966215</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, et al. Transsynaptic progression of amyloid-beta-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron. 2010;68:428&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3050043</ArticleId><ArticleId IdType="pubmed">21040845</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Lee M, Peterson DA, Sisodia SS. Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci. 2002;22:9785&#x2013;9793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757836</ArticleId><ArticleId IdType="pubmed">12427834</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippini N, et al. Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc Natl Acad Sci U S A. 2009;106:7209&#x2013;7214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678478</ArticleId><ArticleId IdType="pubmed">19357304</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer&#x2019;s disease. Neuron. 2009;63:287&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Flicker L. Modifiable lifestyle risk factors for Alzheimer&#x2019;s disease. J Alzheimers Dis. 2010;20:803&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">20182016</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney JW, Wozniak DF, Farber NB. Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies. Arch Neurol. 1997;54:1234&#x2013;1240.</Citation><ArticleIdList><ArticleId IdType="pubmed">9341569</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, et al. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron. 2009;64:632&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787195</ArticleId><ArticleId IdType="pubmed">20005821</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin KB, Paxinos G. The Mouse Brain in Stereotaxic Coordinates. Academic Press; San Diego: 1996.</Citation></Reference><Reference><Citation>Klunk WE, et al. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol. 2002;61:797&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pubmed">12230326</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20829454</PMID><DateCompleted><Year>2010</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>330</Volume><Issue>6001</Issue><PubDate><Year>2010</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Tau reduction prevents Abeta-induced defects in axonal transport.</ArticleTitle><Pagination><StartPage>198</StartPage><MedlinePgn>198</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1194653</ELocationID><Abstract><AbstractText>Amyloid-&#x3b2; (A&#x3b2;) peptides, derived from the amyloid precursor protein, and the microtubule-associated protein tau are key pathogenic factors in Alzheimer's disease (AD). How exactly they impair cognitive functions is unknown. We assessed the effects of A&#x3b2; and tau on axonal transport of mitochondria and the neurotrophin receptor TrkA, cargoes that are critical for neuronal function and survival and whose distributions are altered in AD. A&#x3b2; oligomers rapidly inhibited axonal transport of these cargoes in wild-type neurons. Lowering tau levels prevented these defects without affecting baseline axonal transport. Thus, A&#x3b2; requires tau to impair axonal transport, and tau reduction protects against A&#x3b2;-induced axonal transport defects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vossel</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA. kvossel@gladstone.ucsf.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Kai</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Brodbeck</LastName><ForeName>Jens</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Daub</LastName><ForeName>Aaron C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Punita</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Finkbeiner</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Bianxiao</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Mucke</LastName><ForeName>Lennart</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K99 NS057906</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS057906</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS041787</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041787</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 NS057906</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG011385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG011385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>C06 RR018928</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D020917">Receptor, trkA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001370" MajorTopicYN="Y">Axonal Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020917" MajorTopicYN="N">Receptor, trkA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>4</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20829454</ArticleId><ArticleId IdType="mid">NIHMS251160</ArticleId><ArticleId IdType="pmc">PMC3024010</ArticleId><ArticleId IdType="doi">10.1126/science.1194653</ArticleId><ArticleId IdType="pii">science.1194653</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Roberson ED, et al. Science. 2007;316:750.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, et al. Cell. 2010;142:387.</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Decker H, Lo KY, Unger SM, Ferreira ST, Silverman MA. J. Neurosci. 2010;30:9166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632489</ArticleId><ArticleId IdType="pubmed">20610750</ArticleId></ArticleIdList></Reference><Reference><Citation>Rui Y, Tiwari P, Xie Z, Zheng JQ. J. Neurosci. 2006;26:10480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674697</ArticleId><ArticleId IdType="pubmed">17035532</ArticleId></ArticleIdList></Reference><Reference><Citation>Pigino G, et al. Proc. Natl. Acad. Sci. U.S.A. 2009;106:5907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667037</ArticleId><ArticleId IdType="pubmed">19321417</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiruma H, Katakura T, Takahashi S, Ichikawa T, Kawakami T. J. Neurosci. 2003;23:8967.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740390</ArticleId><ArticleId IdType="pubmed">14523099</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixit R, Ross JL, Goldman YE, Holzbaur EL. Science. 2008;319:1086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866193</ArticleId><ArticleId IdType="pubmed">18202255</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebneth A, et al. J. Cell Biol. 1998;143:777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2148132</ArticleId><ArticleId IdType="pubmed">9813097</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan A, Kumar A, Peterhoff C, Duff K, Nixon R-A. J. Neurosci. 2008;28:1682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2814454</ArticleId><ArticleId IdType="pubmed">18272688</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirai K, et al. J. Neurosci. 2001;21:3017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762571</ArticleId><ArticleId IdType="pubmed">11312286</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindowski K, Belarbi K, Buee L. Genes Brain Behav. 2008;7:43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2228393</ArticleId><ArticleId IdType="pubmed">18184369</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson HN, et al. Neuroscience. 2010;169:516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2900546</ArticleId><ArticleId IdType="pubmed">20434528</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17478722</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>316</Volume><Issue>5825</Issue><PubDate><Year>2007</Year><Month>May</Month><Day>04</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model.</ArticleTitle><Pagination><StartPage>750</StartPage><EndPage>754</EndPage><MedlinePgn>750-4</MedlinePgn></Pagination><Abstract><AbstractText>Many potential treatments for Alzheimer's disease target amyloid-beta peptides (Abeta), which are widely presumed to cause the disease. The microtubule-associated protein tau is also involved in the disease, but it is unclear whether treatments aimed at tau could block Abeta-induced cognitive impairments. Here, we found that reducing endogenous tau levels prevented behavioral deficits in transgenic mice expressing human amyloid precursor protein, without altering their high Abeta levels. Tau reduction also protected both transgenic and nontransgenic mice against excitotoxicity. Thus, tau reduction can block Abeta- and excitotoxin-induced neuronal dysfunction and may represent an effective strategy for treating Alzheimer's disease and related conditions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA. eroberson@gladstone.ucsf.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scearce-Levie</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Palop</LastName><ForeName>Jorge J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Fengrong</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Irene H</ForeName><Initials>IH</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Tiffany</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Gerstein</LastName><ForeName>Hilary</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Gui-Qiu</ForeName><Initials>GQ</Initials></Author><Author ValidYN="Y"><LastName>Mucke</LastName><ForeName>Lennart</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RR18928-01</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG011385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS054811</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS054811</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH070588</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003292">Convulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018690">Excitatory Amino Acid Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>SIV03811UC</RegistryNumber><NameOfSubstance UI="D007608">Kainic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>WM5Z385K7T</RegistryNumber><NameOfSubstance UI="D010433">Pentylenetetrazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003292" MajorTopicYN="N">Convulsants</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018690" MajorTopicYN="N">Excitatory Amino Acid Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005106" MajorTopicYN="N">Exploratory Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007608" MajorTopicYN="N">Kainic Acid</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010433" MajorTopicYN="N">Pentylenetetrazole</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012640" MajorTopicYN="N">Seizures</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>5</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId><ArticleId IdType="doi">10.1126/science.1141736</ArticleId><ArticleId IdType="pii">316/5825/750</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">1566067</PMID><DateCompleted><Year>1992</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0036-8075</ISSN><JournalIssue CitedMedium="Print"><Volume>256</Volume><Issue>5054</Issue><PubDate><Year>1992</Year><Month>Apr</Month><Day>10</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Alzheimer's disease: the amyloid cascade hypothesis.</ArticleTitle><Pagination><StartPage>184</StartPage><EndPage>185</EndPage><MedlinePgn>184-5</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>J A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, St. Mary's Hospital Medical School, London, U.K.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Higgins</LastName><ForeName>G A</ForeName><Initials>GA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurobiol Aging. 2004 Jul;25(6):721-3; discussion 743-6. doi: 10.1016/j.neurobiolaging.2003.12.017.</RefSource><PMID Version="1">15165694</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>28</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>4</Month><Day>10</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>4</Month><Day>10</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId><ArticleId IdType="doi">10.1126/science.1566067</ArticleId></ArticleIdList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21414900</PMID><DateCompleted><Year>2011</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>8</Issue><PubDate><Year>2011</Year><Month>Feb</Month><Day>23</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Presenilin is necessary for efficient proteolysis through the autophagy-lysosome system in a &#x3b3;-secretase-independent manner.</ArticleTitle><Pagination><StartPage>2781</StartPage><EndPage>2791</EndPage><MedlinePgn>2781-91</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5156-10.2010</ELocationID><Abstract><AbstractText>Presenilins are ubiquitous, intramembrane proteins that function in Alzheimer's disease (AD) as the catalytic component of the &#x3b3;-secretase complex. Familial AD mutations in presenilin are known to exacerbate lysosomal pathology. Hence, we sought to elucidate the function endogenous, wild-type presenilins play in autophagy-mediated protein degradation. We report the finding that genetic deletion or knockdown of presenilins alters many autophagy-related proteins demonstrating a buildup of autophagosomes, indicative of dysfunction in the system. Presenilin-deficient cells inefficiently clear long-lived proteins and fail to build up autophagosomes when challenged with lysosomal inhibitors. Our studies further show that &#x3b3;-secretase inhibitors do not adversely impact autophagy, indicating that the role of presenilins in autophagy is independent of &#x3b3;-secretase activity. Based on our findings, we conclude that endogenous, wild-type presenilins are necessary for proper protein degradation through the autophagosome-lysosome system by functioning at the lysosomal level. The role of presenilins in autophagy has many implications for its function in neurological diseases such as AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Neely</LastName><ForeName>Kara M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior and Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, California 92697-4545, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Kim N</ForeName><Initials>KN</Initials></Author><Author ValidYN="Y"><LastName>LaFerla</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG021982</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027544</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027544</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>021928</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>8</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21414900</ArticleId><ArticleId IdType="mid">NIHMS276076</ArticleId><ArticleId IdType="pmc">PMC3064964</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5156-10.2010</ArticleId><ArticleId IdType="pii">31/8/2781</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baki L, Neve RL, Shao Z, Shioi J, Georgakopoulos A, Robakis NK. Wild-type but not FAD mutant presenilin-1 prevents neuronal degeneration by promoting phosphatidylinositol 3-kinase neuroprotective signaling. J Neurosci. 2008;28:483&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670519</ArticleId><ArticleId IdType="pubmed">18184791</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauvy C, Meijer AJ, Codogno P. Autophagy in mammalian systems, Part B. New York: Elsevier; 2009.</Citation></Reference><Reference><Citation>Berger Z, Ravikumar B, Menzies FM, Oroz LG, Underwood BR, Pangalos MN, Schmitt I, Wullner U, Evert BO, O'Kane CJ, Rubinsztein DC. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet. 2006;15:433&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">16368705</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardi L, Tomaino C, Anfossi M, Gallo M, Geracitano S, Costanzo A, Colao R, Puccio G, Frangipane F, Curcio SA, Mirabelli M, Smirne N, Iapaolo D, Maletta RG, Bruni AC. Novel PSEN1 and PGRN mutations in early-onset familial frontotemporal dementia. Neurobiol Aging. 2009;30:1825&#x2013;1833.</Citation><ArticleIdList><ArticleId IdType="pubmed">18314228</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron. 1996;17:1005&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron. 1997;19:939&#x2013;945.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354339</ArticleId></ArticleIdList></Reference><Reference><Citation>Burman C, Ktistakis NT. Regulation of autophagy by phosphatidylinositol 3-phosphate. FEBS Lett. 2010;584:1302&#x2013;1312.</Citation><ArticleIdList><ArticleId IdType="pubmed">20074568</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Peterhoff CM, Schmidt SD, Terio NB, Duff K, Beard M, Mathews PM, Nixon RA. Presenilin mutations in familial Alzheimer disease and transgenic mouse models accelerate neuronal lysosomal pathology. J Neuropathol Exp Neurol. 2004;63:821&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pubmed">15330337</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Nakajima A, Choi SH, Xiong X, Tang YP. Loss of presenilin function causes Alzheimer's disease-like neurodegeneration in the mouse. J Neurosci Res. 2008;86:1615&#x2013;1625.</Citation><ArticleIdList><ArticleId IdType="pubmed">18189321</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuervo AM, Dice JF. Unique properties of lamp2a compared to other lamp2 isoforms. J Cell Sci. 2000;113:4441&#x2013;4450.</Citation><ArticleIdList><ArticleId IdType="pubmed">11082038</ArticleId></ArticleIdList></Reference><Reference><Citation>Deretic V, Levine B. Autophagy, immunity, and microbial adaptations. Cell Host Microbe. 2009;5:527&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2720763</ArticleId><ArticleId IdType="pubmed">19527881</ArticleId></ArticleIdList></Reference><Reference><Citation>Esselens C, Oorschot V, Baert V, Raemaekers T, Spittaels K, Serneels L, Zheng H, Saftig P, De Strooper B, Klumperman J, Annaert W. Presenilin 1 mediates the turnover of telencephalin in hippocampal neurons via an autophagic degradative pathway. J Cell Biol. 2004;166:1041&#x2013;1054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172014</ArticleId><ArticleId IdType="pubmed">15452145</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng R, Wang H, Wang J, Shrom D, Zeng X, Tsien JZ. Forebrain degeneration and ventricle enlargement caused by double knockout of Alzheimer's presenilin-1 and presenilin-2. Proc Natl Acad Sci U S A. 2004;101:8162&#x2013;8167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC419574</ArticleId><ArticleId IdType="pubmed">15148382</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Isla T, Growdon WB, McNamara MJ, Nochlin D, Bird TD, Arango JC, Lopera F, Kosik KS, Lantos PL, Cairns NJ, Hyman BT. The impact of different presenilin 1 andpresenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimer's disease brain: evidence for other phenotype-modifying factors. Brain. 1999;122:1709&#x2013;1719.</Citation><ArticleIdList><ArticleId IdType="pubmed">10468510</ArticleId></ArticleIdList></Reference><Reference><Citation>Green KN, Demuro A, Akbari Y, Hitt BD, Smith IF, Parker I, LaFerla FM. SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production. J Cell Biol. 2008;181:1107&#x2013;1116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442205</ArticleId><ArticleId IdType="pubmed">18591429</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanada T, Noda NN, Satomi Y, Ichimura Y, Fujioka Y, Takao T, Inagaki F, Ohsumi Y. The Atg12-Atg5 conjugate has a novel E3-like activity for protein lipidation in autophagy. J Biol Chem. 2007;282:37298&#x2013;37302.</Citation><ArticleIdList><ArticleId IdType="pubmed">17986448</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima R, Yokoyama M, Mishima K, Saito I, Okano H, Mizushima N. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature. 2006;441:885&#x2013;889.</Citation><ArticleIdList><ArticleId IdType="pubmed">16625204</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreman A, Serneels L, Annaert W, Collen D, Schoonjans L, De Strooper B. Total inactivation of gamma-secretase activity in presenilin-deficient embryonic stem cells. Nat Cell Biol. 2000;2:461&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">10878813</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyt MA, Zhang M, Coffino P. Ubiquitin-independent mechanisms of mouse ornithine decarboxylase degradation are conserved between mammalian and fungal cells. J Biol Chem. 2003;278:12135&#x2013;12143.</Citation><ArticleIdList><ArticleId IdType="pubmed">12562772</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M. Presenilin mutations associated with fronto-temporal dementia. Ann Neurol. 2004;55:604&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">15122699</ArticleId></ArticleIdList></Reference><Reference><Citation>Itakura E, Kishi C, Inoue K, Mizushima N. Beclin 1 forms two distinct phosphatidylinositol 3-kinase complexes with mammalian Atg14 and UVRAG. Mol Biol Cell. 2008;19:5360&#x2013;5372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2592660</ArticleId><ArticleId IdType="pubmed">18843052</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung CH, Ro SH, Cao J, Otto NM, Kim DH. mTOR regulation of autophagy. FEBS Lett. 2010;584:1287&#x2013;1295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2846630</ArticleId><ArticleId IdType="pubmed">20083114</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000;19:5720&#x2013;5728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC305793</ArticleId><ArticleId IdType="pubmed">11060023</ArticleId></ArticleIdList></Reference><Reference><Citation>Kittler R, Surendranath V, Heninger AK, Slabicki M, Theis M, Putz G, Franke K, Caldarelli A, Grabner H, Kozak K, Wagner J, Rees E, Korn B, Frenzel C, Sachse C, S&#xf6;nnichsen B, Guo J, Schelter J, Burchard J, Linsley PS, et al. Genome-wide resources of endoribonuclease-prepared short interfering RNAs for specific loss-of-function studies. Nat Methods. 2007;4:337&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">17351622</ArticleId></ArticleIdList></Reference><Reference><Citation>Klionsky DJ, Cuervo AM, Seglen PO. Methods for monitoring autophagy from yeast to human. Autophagy. 2007;3:181&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">17224625</ArticleId></ArticleIdList></Reference><Reference><Citation>Klionsky DJ, Elazar Z, Seglen PO, Rubinsztein DC. Does bafilomycin A1 block the fusion of autophagosomes with lysosomes? Autophagy. 2008;4:849&#x2013;950.</Citation><ArticleIdList><ArticleId IdType="pubmed">18758232</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;chl R, Hu XW, Chan EYW, Tooze SA. Microtubules facilitate autophagosome formation and fusion of autophagosomes with endosomes. Traffic. 2006;7:129&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">16420522</ArticleId></ArticleIdList></Reference><Reference><Citation>Koike MA, Green KN, Blurton-Jones M, Laferla FM. Oligemic hypoperfusion differentially affects tau and amyloid-&#x3b2;. Am J Pathol. 2010;177:300&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2893673</ArticleId><ArticleId IdType="pubmed">20472896</ArticleId></ArticleIdList></Reference><Reference><Citation>Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, Ueno T, Koike M, Uchiyama Y, Kominami E, Tanaka K. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature. 2006;441:880&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">16625205</ArticleId></ArticleIdList></Reference><Reference><Citation>Korolchuk VI, Menzies FM, Rubinsztein DC. Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems. FEBS Lett. 2010;584:1393&#x2013;1398.</Citation><ArticleIdList><ArticleId IdType="pubmed">20040365</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs DM, Fausett HJ, Page KJ, Kim TW, Moir RD, Merriam DE, Hollister RD, Hallmark OG, Mancini R, Felsenstein KM, Hyman BT, Tanzi RE, Wasco W. Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nat Med. 1996;2:224&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">8574969</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci. 2002;3:862&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">12415294</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai MT, Chen E, Crouthamel MC, DiMuzio-Mower J, Xu M, Huang Q, Price E, Register RB, Shi XP, Donoviel DB, Bernstein A, Hazuda D, Gardell SJ, Li YM. Presenilin-1 and presenilin-2 exhibit distinct yet overlapping gamma-secretase activities. J Biol Chem. 2003;278:22475&#x2013;22481.</Citation><ArticleIdList><ArticleId IdType="pubmed">12684521</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanz TA, Himes CS, Pallante G, Adams L, Yamazaki S, Amore B, Merchant KM. The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol Exp Ther. 2003;305:864&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pubmed">12626636</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, Wolfe DM, Martinez-Vicente M, Massey AC, Sovak G, Uchiyama Y, Westaway D, Cuervo AM, Nixon RA. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell. 2010;141:1146&#x2013;1158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3647462</ArticleId><ArticleId IdType="pubmed">20541250</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang C, Feng P, Ku B, Dotan I, Canaani D, Oh BH, Jung JU. Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG. Nat Cell Biol. 2006;8:688&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pubmed">16799551</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, Levine B. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature. 1999;402:672&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">10604474</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindmo K, Brech A, Finley KD, Gaumer S, Contamine D, Rusten TE, Stenmark H. The PI 3-kinase regulator Vps15 is required for autophagic clearance of protein aggregates. Autophagy. 2008;4:500&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">18326940</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DM, Iwatsubo T, Cairns NJ, Lantos PL, Nochlin D, Sumi SM, Bird TD, Poorkaj P, Hardy J, Hutton M, Prihar G, Crook R, Rossor MN, Haltia M. Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: predominance of Abeta42(43) Ann Neurol. 1996;40:149&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">8773595</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez MF, McMurtray A. Frontotemporal dementia-like phenotypes associated with presenilin-1 mutations. Am J Alzheimer's Dis Other Demen. 2006;21:281&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10833339</ArticleId><ArticleId IdType="pubmed">16948293</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizushima N, Noda T, Yoshimori T, Tanaka Y, Ishii T, George MD, Klionsky DJ, Ohsumi M, Ohsumi Y. A protein conjugation system essential for autophagy. Nature. 1998;395:395&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">9759731</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortimore GE, P&#xf6;s&#xf6; AR. Intracellular protein catabolism and its control during nutrient deprivation and supply. Annu Rev Nutr. 1987;7:539&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">3300746</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy MP, Uljon SN, Fraser PE, Fauq A, Lookingbill HA, Findlay KA, Smith TE, Lewis PA, McLendon DC, Wang R, Golde TE. Presenilin 1 regulates pharmacologically distinct gamma-secretase activities. Implications for the role of presenilin in gamma-secretase cleavage. J Biol Chem. 2000;275:26277&#x2013;26284.</Citation><ArticleIdList><ArticleId IdType="pubmed">10816583</ArticleId></ArticleIdList></Reference><Reference><Citation>Noda T, Ohsumi Y. Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J Biol Chem. 1998;273:3963&#x2013;3966.</Citation><ArticleIdList><ArticleId IdType="pubmed">9461583</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohta K, Mizuno A, Ueda M, Li S, Suzuki Y, Hida Y, Hayakawa-Yano Y, Itoh M, Ohta E, Kobori M, Nakagawa T. Autophagy impairment stimulates PS1 expression and &#x3b3;-secretase activity. Autophagy. 2010;6:345&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">20168091</ArticleId></ArticleIdList></Reference><Reference><Citation>Onodera J, Ohsumi Y. Autophagy is required for maintenance of amino acid levels and protein synthesis under nitrogen starvation. J Biol Chem. 2005;280:31582&#x2013;31586.</Citation><ArticleIdList><ArticleId IdType="pubmed">16027116</ArticleId></ArticleIdList></Reference><Reference><Citation>Page RM, Baumann K, Tomioka M, P&#xe9;rez-Revuelta BI, Fukumori A, Jacobsen H, Flohr A, Luebbers T, Ozmen L, Steiner H, Haass C. Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation. J Biol Chem. 2008;283:677&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">17962197</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacino JJ, Berechid BE, Alexander P, Eckman C, Younkin S, Nye JS, Wolozin B. Regulation of amyloid precursor protein processing by presenilin 1 (PS1) and PS2 in PS1 knockout cells. J Biol Chem. 2000;275:215&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">10617607</ArticleId></ArticleIdList></Reference><Reference><Citation>Parks AL, Curtis D. Presenilin diversifies its portfolio. Trends Genet. 2007;23:140&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">17280736</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasternak SH, Bagshaw RD, Guiral M, Zhang S, Ackerley CA, Pak BJ, Callahan JW, Mahuran DJ. Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase activity are co-localized in the lysosomal membrane. J Biol Chem. 2003;278:26687&#x2013;26694.</Citation><ArticleIdList><ArticleId IdType="pubmed">12736250</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickford F, Masliah E, Britschgi M, Lucin K, Narasimhan R, Jaeger PA, Small S, Spencer B, Rockenstein E, Levine B, Wyss-Coray T. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid &#x3b2; accumulation in mice. J Clin Invest. 2008;118:2190&#x2013;2199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2391284</ArticleId><ArticleId IdType="pubmed">18497889</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravikumar B, Duden R, Rubinsztein DC. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet. 2002;11:1107&#x2013;1117.</Citation><ArticleIdList><ArticleId IdType="pubmed">11978769</ArticleId></ArticleIdList></Reference><Reference><Citation>Salminen A, Kaarniranta K. Regulation of the aging process by autophagy. Trends Mol Med. 2009;15:217&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">19380253</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar S, Ravikumar B, Floto RA, Rubinsztein DC. Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Cell Death Differ. 2009;16:46&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">18636076</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Wolfe MS. Presenilin: running with scissors in the membrane. Cell. 2007;131:215&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">17956719</ArticleId></ArticleIdList></Reference><Reference><Citation>Spasic D, Tolia A, Dillen K, Baert V, De Strooper B, Vrijens S, Annaert W. Presenilin-1 maintains a nine-transmembrane topology throughout the secretory pathway. J Biol Chem. 2006;281:26569&#x2013;26577.</Citation><ArticleIdList><ArticleId IdType="pubmed">16846981</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer B, Potkar R, Trejo M, Rockenstein E, Patrick C, Gindi R, Adame A, Wyss-Coray T, Masliah E. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in &#x3b1;-synuclein models of Parkinson's and Lewy body diseases. J Neurosci. 2009;29:13578&#x2013;13588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812014</ArticleId><ArticleId IdType="pubmed">19864570</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun F, Anantharam V, Zhang D, Latchoumycandane C, Kanthasamy A, Kanthasamy AG. Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models. Neurotoxicology. 2006;27:807&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">16870259</ArticleId></ArticleIdList></Reference><Reference><Citation>Tandon A, Fraser P. The presenilins. Genome Biol. 2002;3:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC244923</ArticleId><ArticleId IdType="pubmed">12429067</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakabayashi T, Craessaerts K, Bammens L, Bentahir M, Borgions F, Herdewijn P, Staes A, Timmerman E, Vandekerckhove J, Rubinstein E, Boucheix C, Gevaert K, De Strooper B. Analysis of the gamma-secretase interactome and validation of its association with tetraspanin-enriched microdomains. Nat Cell Biol. 2009;11:1340&#x2013;1346.</Citation><ArticleIdList><ArticleId IdType="pubmed">19838174</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson CA, Murphy DD, Giasson BI, Zhang B, Trojanowski JQ, Lee VM. Degradative organelles containing mislocalized alpha-and beta-synuclein proliferate in presenilin-1 null neurons. J Cell Biol. 2004;165:335&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172178</ArticleId><ArticleId IdType="pubmed">15123735</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia W, Zhang J, Ostaszewski BL, Kimberly WT, Seubert P, Koo EH, Shen J, Selkoe DJ. Presenilin 1 regulates the processing of beta-amyloid precursor protein C-terminal fragments and the generation of amyloid beta-protein in endoplasmic reticulum and Golgi. Biochemistry. 1998;37:16465&#x2013;16471.</Citation><ArticleIdList><ArticleId IdType="pubmed">9843412</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto A, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R, Tashiro Y. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct. 1998;23:33&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">9639028</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Y, Flinn RJ, Wu H, Schnur RS, Backer JM. hVps15, but not Ca2+/CaM, is required for the activity and regulation of hVps34 in mammalian cells. Biochem J. 2009;417:747&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2652830</ArticleId><ArticleId IdType="pubmed">18957027</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z, Huang J, Geng J, Nair U, Klionsky DJ. Atg22 recycles amino acids to link the degradative and recycling functions of autophagy. Mol Biol Cell. 2006;17:5094&#x2013;5104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1679675</ArticleId><ArticleId IdType="pubmed">17021250</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu WH, Kumar A, Peterhoff C, Shapiro Kulnane L, Uchiyama Y, Lamb BT, Cuervo AM, Nixon RA. Autophagic vacuoles are enriched in amyloid precursor protein-secretase activities: implications for &#x3b2;-amyloid peptide over-production and localization in Alzheimer's disease. Int J Biochem Cell Biol. 2004;36:2531&#x2013;2540.</Citation><ArticleIdList><ArticleId IdType="pubmed">15325590</ArticleId></ArticleIdList></Reference><Reference><Citation>Zekanowski C, Golan MP, Krzy&#x15b;ko KA, Lipczy&#x144;ska-&#x141;ojkowska W, Filipek S, Kowalska A, Rossa G, Pep&#x142;o&#x144;ska B, Styczy&#x144;ska M, Maruszak A, Religa D, Wender M, Kulczycki J, Barcikowska M, Ku&#x17a;nicki J. Two novel presenilin 1 gene mutations connected with frontotemporal dementia-like clinical phenotype: genetic and bioinformatic assessment. Exp Neurol. 2006;200:82&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">16546171</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng X, Overmeyer JH, Maltese WA. Functional specificity of the mammalian Beclin-Vps34 PI 3-kinase complex in macroautophagy versus endocytosis and lysosomal enzyme trafficking. J Cell Sci. 2006;119:259&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">16390869</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15751225</PMID><DateCompleted><Year>2005</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3069</ISSN><JournalIssue CitedMedium="Print"><Volume>64</Volume><Issue>2</Issue><PubDate><Year>2005</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of neuropathology and experimental neurology</Title><ISOAbbreviation>J Neuropathol Exp Neurol</ISOAbbreviation></Journal><ArticleTitle>Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study.</ArticleTitle><Pagination><StartPage>113</StartPage><EndPage>122</EndPage><MedlinePgn>113-22</MedlinePgn></Pagination><Abstract><AbstractText>The accumulation of lysosomes and their hydrolases within neurons is a well-established neuropathologic feature of Alzheimer disease (AD). Here we show that lysosomal pathology in AD brain involves extensive alterations of macroautophagy, an inducible pathway for the turnover of intracellular constituents, including organelles. Using immunogold labeling with compartmental markers and electron microscopy on neocortical biopsies from AD brain, we unequivocally identified autophagosomes and other prelysosomal autophagic vacuoles (AVs), which were morphologically and biochemically similar to AVs highly purified from mouse liver. AVs were uncommon in brains devoid of AD pathology but were abundant in AD brains particularly, within neuritic processes, including synaptic terminals. In dystrophic neurites, autophagosomes, multivesicular bodies, multilamellar bodies, and cathepsin-containing autophagolysosomes were the predominant organelles and accumulated in large numbers. These compartments were distinguishable from lysosomes and lysosomal dense bodies, previously shown also to be abundant in dystrophic neurites. Autophagy was evident in the perikarya of affected neurons, particularly in those with neurofibrillary pathology where it was associated with a relative depletion of mitochondria and other organelles. These observations provide the first evidence that macroautophagy is extensively involved in the neurodegenerative/regenerative process in AD. The striking accumulations of immature AV forms in dystrophic neurites suggest that the transport of AVs and their maturation to lysosomes may be impaired, thereby impeding the suspected neuroprotective functions of autophagy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nixon</LastName><ForeName>Ralph A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan Kline Institute for Psychiatric Research, New York University School of Medicine, Orangeburg, New York 10962, USA. nixon@nki.rfmh.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wegiel</LastName><ForeName>Jerzy</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Asok</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Wai Haung</ForeName><Initials>WH</Initials></Author><Author ValidYN="Y"><LastName>Peterhoff</LastName><ForeName>Corrinne</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Cataldo</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Cuervo</LastName><ForeName>Ana Maria</ForeName><Initials>AM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG021904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG17617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neuropathol Exp Neurol</MedlineTA><NlmUniqueID>2985192R</NlmUniqueID><ISSNLinking>0022-3069</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016253" MajorTopicYN="N">Microscopy, Immunoelectron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014617" MajorTopicYN="N">Vacuoles</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>3</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>3</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>3</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15751225</ArticleId><ArticleId IdType="doi">10.1093/jnen/64.2.113</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18596167</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>27</Issue><PubDate><Year>2008</Year><Month>Jul</Month><Day>02</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>6926</StartPage><EndPage>6937</EndPage><MedlinePgn>6926-37</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0800-08.2008</ELocationID><Abstract><AbstractText>Macroautophagy, a major pathway for organelle and protein turnover, has been implicated in the neurodegeneration of Alzheimer's disease (AD). The basis for the profuse accumulation of autophagic vacuoles (AVs) in affected neurons of the AD brain, however, is unknown. In this study, we show that constitutive macroautophagy in primary cortical neurons is highly efficient, because newly formed autophagosomes are rapidly cleared by fusion with lysosomes, accounting for their scarcity in the healthy brain. Even after macroautophagy is strongly induced by suppressing mTOR (mammalian target of rapamycin) kinase activity with rapamycin or nutrient deprivation, active cathepsin-positive autolysosomes rather than LC3-II-positive autophagosomes predominate, implying efficient autophagosome clearance in healthy neurons. In contrast, selectively impeding late steps in macroautophagy by inhibiting cathepsin-mediated proteolysis within autolysosomes with cysteine- and aspartyl-protease inhibitors caused a marked accumulation of electron-dense double-membrane-limited AVs, containing cathepsin D and incompletely degraded LC3-II in perikarya and neurites. Similar structures accumulated in large numbers when fusion of autophagosomes with lysosomes was slowed by disrupting their transport on microtubules with vinblastine. Finally, we find that the autophagic vacuoles accumulating after protease inhibition or prolonged vinblastine treatment strongly resembled AVs that collect in dystrophic neurites in the AD brain and in an AD mouse model. We conclude that macroautophagy is constitutively active and highly efficient in healthy neurons and that the autophagic pathology observed in AD most likely arises from impaired clearance of AVs rather than strong autophagy induction alone. Therapeutic modulation of autophagy in AD may, therefore, require targeting late steps in the autophagic pathway.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boland</LastName><ForeName>Barry</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan Kline Institute, Orangeburg, New York 10962, USA. barry.boland@ucd.ie</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Asok</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sooyeon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Platt</LastName><ForeName>Frances M</ForeName><Initials>FM</Initials></Author><Author ValidYN="Y"><LastName>Wegiel</LastName><ForeName>Jerzy</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>W Haung</ForeName><Initials>WH</Initials></Author><Author ValidYN="Y"><LastName>Nixon</LastName><ForeName>Ralph A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P01 AG017617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 017617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C480860">Map1lc3b protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050257">Tubulin Modulators</NameOfSubstance></Chemical><Chemical><RegistryNumber>5V9KLZ54CY</RegistryNumber><NameOfSubstance UI="D014747">Vinblastine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber><NameOfSubstance UI="C546843">mTOR protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D002403">Cathepsins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010447">Peptide Hydrolases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002403" MajorTopicYN="N">Cathepsins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010447" MajorTopicYN="N">Peptide Hydrolases</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010588" MajorTopicYN="N">Phagosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050257" MajorTopicYN="N">Tubulin Modulators</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014747" MajorTopicYN="N">Vinblastine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>1</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18596167</ArticleId><ArticleId IdType="mid">NIHMS67739</ArticleId><ArticleId IdType="pmc">PMC2676733</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0800-08.2008</ArticleId><ArticleId IdType="pii">28/27/6926</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anglade P, Vyas S, Javoy-Agid F, Herrero MT, Michel PP, Marquez J, Mouatt-Prigent A, Ruberg M, Hirsch EC, Agid Y. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol. 1997;12:25&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">9046040</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber AJ, Nakamura M, Wolpert EB, Reiter CE, Seigel GM, Antonetti DA, Gardner TW. Insulin rescues retinal neurons from apoptosis by a phosphatidylinositol 3-kinase/Akt-mediated mechanism that reduces the activation of caspase-3. J Biol Chem. 2001;276:32814&#x2013;32821.</Citation><ArticleIdList><ArticleId IdType="pubmed">11443130</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg TO, Fengsrud M, Str&#xf8;mhaug PE, Berg T, Seglen PO. Isolation and characterization of rat liver amphisomes. Evidence for fusion of autophagosomes with both early and late endosomes. J Biol Chem. 1998;273:21883&#x2013;21892.</Citation><ArticleIdList><ArticleId IdType="pubmed">9705327</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi X, Zhou J, Lynch G. Lysosomal protease inhibitors induce meganeurites and tangle-like structures in entorhinohippocampal regions vulnerable to Alzheimer's disease. Exp Neurol. 1999;158:312&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">10415139</ArticleId></ArticleIdList></Reference><Reference><Citation>Blommaart EF, Luiken JJ, Blommaart PJ, van Woerkom GM, Meijer AJ. Phosphorylation of ribosomal protein S6 is inhibitory for autophagy in isolated rat hepatocytes. J Biol Chem. 1995;270:2320&#x2013;2326.</Citation><ArticleIdList><ArticleId IdType="pubmed">7836465</ArticleId></ArticleIdList></Reference><Reference><Citation>Boellaard JW, Schlote W, Tateishi J. Neuronal autophagy in experimental Creutzfeldt-Jakob's disease. Acta Neuropathol (Berl) 1989;78:410&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">2675530</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland B, Nixon RA. Neuronal macroautophagy: from development to degeneration. Mol Aspects Med. 2006;27:503&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16999991</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu CT. Autophagic stress in neuronal injury and disease. J Neuropathol Exp Neurol. 2006;65:423&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1885377</ArticleId><ArticleId IdType="pubmed">16772866</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004;305:1292&#x2013;1295.</Citation><ArticleIdList><ArticleId IdType="pubmed">15333840</ArticleId></ArticleIdList></Reference><Reference><Citation>De Duve C, Wattiaux R. Functions of lysosomes. Annu Rev Physiol. 1966;28:435&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">5322983</ArticleId></ArticleIdList></Reference><Reference><Citation>Deinhardt K, Salinas S, Verastegui C, Watson R, Worth D, Hanrahan S, Bucci C, Schiavo G. Rab5 and Rab7 control endocytic sorting along the axonal retrograde transport pathway. Neuron. 2006;52:293&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">17046692</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:710&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">8878479</ArticleId></ArticleIdList></Reference><Reference><Citation>Eskelinen EL. Maturation of autophagic vacuoles in mammalian cells. Autophagy. 2005;1:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">16874026</ArticleId></ArticleIdList></Reference><Reference><Citation>Finn PF, Dice JF. Proteolytic and lipolytic responses to starvation. Nutrition. 2006;22:830&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">16815497</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PB, Seglen PO. Prelysosomal convergence of autophagic and endocytic pathways. Biochem Biophys Res Commun. 1988;151:40&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">3126737</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima R, Yokoyama M, Mishima K, Saito I, Okano H, Mizushima N. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature. 2006;441:885&#x2013;889.</Citation><ArticleIdList><ArticleId IdType="pubmed">16625204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollenbeck PJ. Products of endocytosis and autophagy are retrieved from axons by regulated retrograde organelle transport. J Cell Biol. 1993;121:305&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2200099</ArticleId><ArticleId IdType="pubmed">7682217</ArticleId></ArticleIdList></Reference><Reference><Citation>Kegel KB, Kim M, Sapp E, McIntyre C, Casta&#xf1;o JG, Aronin N, DiFiglia M. Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy. J Neurosci. 2000;20:7268&#x2013;7278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772788</ArticleId><ArticleId IdType="pubmed">11007884</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiselyov K, Jennigs JJ, Jr, Rbaibi Y, Chu CT. Autophagy, mitochondria and cell death in lysosomal storage diseases. Autophagy. 2007;3:259&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2777544</ArticleId><ArticleId IdType="pubmed">17329960</ArticleId></ArticleIdList></Reference><Reference><Citation>Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, Baba M, Baehrecke EH, Bahr BA, Ballabio A, Bamber BA, Bassham DC, Bergamini E, Bi X, Biard-Piechaczyk M, Blum JS, Bredesen DE, Brodsky JL, Brumell JH, Brunk UT, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy. 2008;4:151&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2654259</ArticleId><ArticleId IdType="pubmed">18188003</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko DC, Milenkovic L, Beier SM, Manuel H, Buchanan J, Scott MP. Cell-autonomous death of cerebellar purkinje neurons with autophagy in Niemann-Pick type C disease. PLoS Genet. 2005;1:81&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1183526</ArticleId><ArticleId IdType="pubmed">16103921</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;chl R, Hu XW, Chan EY, Tooze SA. Microtubules facilitate autophagosome formation and fusion of autophagosomes with endosomes. Traffic. 2006;7:129&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">16420522</ArticleId></ArticleIdList></Reference><Reference><Citation>Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, Ueno T, Koike M, Uchiyama Y, Kominami E, Tanaka K. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature. 2006;441:880&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">16625205</ArticleId></ArticleIdList></Reference><Reference><Citation>Kov&#xe1;cs AL, Reith A, Seglen PO. Accumulation of autophagosomes after inhibition of hepatocytic protein degradation by vinblastine, leupeptin or a lysosomotropic amine. Exp Cell Res. 1982;137:191&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">7056284</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence BP, Brown WJ. Autophagic vacuoles rapidly fuse with pre-existing lysosomes in cultured hepatocytes. J Cell Sci. 1992;102:515&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">1324248</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell. 2004;6:463&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">15068787</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Vicente M, Cuervo AM. Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol. 2007;6:352&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">17362839</ArticleId></ArticleIdList></Reference><Reference><Citation>Marzella L, Sandberg PO, Glaumann H. Autophagic degradation in rat liver after vinblastine treatment. Exp Cell Res. 1980;128:291&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">6997059</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizushima N. Methods for monitoring autophagy. Int J Biochem Cell Biol. 2004;36:2491&#x2013;2502.</Citation><ArticleIdList><ArticleId IdType="pubmed">15325587</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell. 2004;15:1101&#x2013;1111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC363084</ArticleId><ArticleId IdType="pubmed">14699058</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. Autophagy in neurodegenerative disease: friend, foe or turncoat? Trends Neurosci. 2006;29:528&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pubmed">16859759</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, Cuervo AM. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol. 2005;64:113&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">15751225</ArticleId></ArticleIdList></Reference><Reference><Citation>Overly CC, Lee KD, Berthiaume E, Hollenbeck PJ. Quantitative measurement of intraorganelle pH in the endosomal-lysosomal pathway in neurons by using ratiometric imaging with pyranine. Proc Natl Acad Sci USA. 1995;92:3156&#x2013;3160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC42124</ArticleId><ArticleId IdType="pubmed">7724533</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillay CS, Elliott E, Dennison C. Endolysosomal proteolysis and its regulation. Biochem J. 2002;363:417&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1222494</ArticleId><ArticleId IdType="pubmed">11964142</ArticleId></ArticleIdList></Reference><Reference><Citation>Punnonen EL, Reunanen H. Effects of vinblastine, leucine, and histidine, and 3-methyladenine on autophagy in Ehrlich ascites cells. Exp Mol Pathol. 1990;52:87&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">2307216</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, Scaravilli F, Easton DF, Duden R, O'Kane CJ, Rubinsztein DC. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet. 2004;36:585&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">15146184</ArticleId></ArticleIdList></Reference><Reference><Citation>Rideout HJ, Lang-Rollin I, Stefanis L. Involvement of macroautophagy in the dissolution of neuronal inclusions. Int J Biochem Cell Biol. 2004;36:2551&#x2013;2562.</Citation><ArticleIdList><ArticleId IdType="pubmed">15325592</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinsztein DC, DiFiglia M, Heintz N, Nixon RA, Qin ZH, Ravikumar B, Stefanis L, Tolkovsky A. Autophagy and its possible roles in nervous system diseases, damage and repair. Autophagy. 2005;1:11&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">16874045</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ. Potential therapeutic applications of autophagy. Nat Rev Drug Discov. 2007;6:304&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">17396135</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G, Abraham RT. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem. 1995;270:815&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pubmed">7822316</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar S, Perlstein EO, Imarisio S, Pineau S, Cordenier A, Maglathlin RL, Webster JA, Lewis TA, O'Kane CJ, Schreiber SL, Rubinsztein DC. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat Chem Biol. 2007;3:331&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2635561</ArticleId><ArticleId IdType="pubmed">17486044</ArticleId></ArticleIdList></Reference><Reference><Citation>Settembre C, Fraldi A, Jahreiss L, Spampanato C, Venturi C, Medina D, de Pablo R, Tacchetti C, Rubinsztein DC, Ballabio A. A block of autophagy in lysosomal storage disorders. Hum Mol Genet. 2008;17:119&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">17913701</ArticleId></ArticleIdList></Reference><Reference><Citation>Shacka JJ, Klocke BJ, Young C, Shibata M, Olney JW, Uchiyama Y, Saftig P, Roth KA. Cathepsin D deficiency induces persistent neurodegeneration in the absence of Bax-dependent apoptosis. J Neurosci. 2007;27:2081&#x2013;2090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673541</ArticleId><ArticleId IdType="pubmed">17314303</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, Raman R, Davies P, Masliah E, Williams DS, Goldstein LS. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science. 2005;307:1282&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pubmed">15731448</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun-Wada GH, Wada Y, Futai M. Lysosome and lysosome-related organelles responsible for specialized functions in higher organisms, with special emphasis on vacuolar-type proton ATPase. Cell Struct Funct. 2003;28:455&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">14745137</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeshige K, Baba M, Tsuboi S, Noda T, Ohsumi Y. Autophagy in yeast demonstrated with proteinase-deficient mutants and conditions for its induction. J Cell Biol. 1992;119:301&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2289660</ArticleId><ArticleId IdType="pubmed">1400575</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanida I, Ueno T, Kominami E. LC3 conjugation system in mammalian autophagy. Int J Biochem Cell Biol. 2004;36:2503&#x2013;2518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7129593</ArticleId><ArticleId IdType="pubmed">15325588</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanida I, Minematsu-Ikeguchi N, Ueno T, Kominami E. Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy. Autophagy. 2005;1:84&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">16874052</ArticleId></ArticleIdList></Reference><Reference><Citation>Turk B, Dolenc I, Lenarcic B, Krizaj I, Turk V, Bieth JG, Bj&#xf6;rk I. Acidic pH as a physiological regulator of human cathepsin L activity. Eur J Biochem. 1999;259:926&#x2013;932.</Citation><ArticleIdList><ArticleId IdType="pubmed">10092883</ArticleId></ArticleIdList></Reference><Reference><Citation>Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol. 2007;9:316&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">17277771</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang QJ, Ding Y, Kohtz DS, Kohtz S, Mizushima N, Cristea IM, Rout MP, Chait BT, Zhong Y, Heintz N, Yue Z. Induction of autophagy in axonal dystrophy and degeneration. J Neurosci. 2006;26:8057&#x2013;8068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673783</ArticleId><ArticleId IdType="pubmed">16885219</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, Mohan PS, Mercken M, Farmery MR, Tjernberg LO, Jiang Y, Duff K, Uchiyama Y, N&#xe4;slund J, Mathews PM, Cataldo AM, Nixon RA. Macroautophagy&#x2014;a novel beta-amyloid peptide-generating pathway activated in Alzheimer's disease. J Cell Biol. 2005;171:87&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171227</ArticleId><ArticleId IdType="pubmed">16203860</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu JH, Horbinski C, Guo F, Watkins S, Uchiyama Y, Chu CT. Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death. Am J Pathol. 2007;170:75&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1762689</ArticleId><ArticleId IdType="pubmed">17200184</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19654187</PMID><DateCompleted><Year>2010</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2083</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>21</Issue><PubDate><Year>2009</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Human molecular genetics</Title><ISOAbbreviation>Hum Mol Genet</ISOAbbreviation></Journal><ArticleTitle>Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing.</ArticleTitle><Pagination><StartPage>4153</StartPage><EndPage>4170</EndPage><MedlinePgn>4153-70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/hmg/ddp367</ELocationID><Abstract><AbstractText>Aggregation and cleavage are two hallmarks of Tau pathology in Alzheimer disease (AD), and abnormal fragmentation of Tau is thought to contribute to the nucleation of Tau paired helical filaments. Clearance of the abnormally modified protein could occur by the ubiquitin-proteasome and autophagy-lysosomal pathways, the two major routes for protein degradation in cells. There is a debate on which of these pathways contributes to clearance of Tau protein and of the abnormal Tau aggregates formed in AD. Here, we demonstrate in an inducible neuronal cell model of tauopathy that the autophagy-lysosomal system contributes to both Tau fragmentation into pro-aggregating forms and to clearance of Tau aggregates. Inhibition of macroautophagy enhances Tau aggregation and cytotoxicity. The Tau repeat domain can be cleaved near the N terminus by a cytosolic protease to generate the fragment F1. Additional cleavage near the C terminus by the lysosomal protease cathepsin L is required to generate Tau fragments F2 and F3 that are highly amyloidogenic and capable of seeding the aggregation of Tau. We identify in this work that components of a selective form of autophagy, chaperone-mediated autophagy, are involved in the delivery of cytosolic Tau to lysosomes for this limited cleavage. However, F1 does not fully enter the lysosome but remains associated with the lysosomal membrane. Inefficient translocation of the Tau fragments across the lysosomal membrane seems to promote formation of Tau oligomers at the surface of these organelles which may act as precursors of aggregation and interfere with lysosomal functioning.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yipeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Max-Planck-Unit for Structural Molecular Biology, Notkestrasse 85, 22607 Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez-Vicente</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kr&#xfc;ger</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Kaushik</LastName><ForeName>Susmita</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Esther</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eva-Maria</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Cuervo</LastName><ForeName>Ana Maria</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eckhard</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG031782</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS038370</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>08</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hum Mol Genet</MedlineTA><NlmUniqueID>9208958</NlmUniqueID><ISSNLinking>0964-6906</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050883">HSC70 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C480860">Map1lc3b protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.15</RegistryNumber><NameOfSubstance UI="D056668">Cathepsin L</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056668" MajorTopicYN="N">Cathepsin L</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050883" MajorTopicYN="N">HSC70 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010588" MajorTopicYN="N">Phagosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="N">Protein Multimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>8</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>8</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19654187</ArticleId><ArticleId IdType="pmc">PMC2758146</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddp367</ArticleId><ArticleId IdType="pii">ddp367</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 2001;24:1121&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia M.L., Cleveland D.W. Going new places using an old MAP: tau, microtubules and human neurodegenerative disease. Curr. Opin. Cell Biol. 2001;13:41&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">11163132</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow E., von Bergen M., Biernat J., Mandelkow E.M. Structural principles of tau and the paired helical filaments of Alzheimer's disease. Brain Pathol. 2007;17:83&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095506</ArticleId><ArticleId IdType="pubmed">17493042</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson G.V., Seubert P., Cox T.M., Motter R., Brown J.P., Galasko D. The tau protein in human cerebrospinal fluid in Alzheimer's disease consists of proteolytically derived fragments. J. Neurochem. 1997;68:430&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">8978756</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E., Hansson S.F., Tran A.J., Zetterberg H., Grognet P., Vanmechelen E., Hoglund K., Brinkmalm G., Westman-Brinkmalm A., Nordhoff E., et al. Characterization of tau in cerebrospinal fluid using mass spectrometry. J. Proteome Res. 2008;7:2114&#x2013;2120.</Citation><ArticleIdList><ArticleId IdType="pubmed">18351740</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao J., Diamond M.I. Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum. Mol. Genet. 2007;16(Spec no. 2):R115&#x2013;R123.</Citation><ArticleIdList><ArticleId IdType="pubmed">17911155</ArticleId></ArticleIdList></Reference><Reference><Citation>Dufty B.M., Warner L.R., Hou S.T., Jiang S.X., Gomez-Isla T., Leenhouts K.M., Oxford J.T., Feany M.B., Masliah E., Rohn T.T. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am. J. Pathol. 2007;170:1725&#x2013;1738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1854966</ArticleId><ArticleId IdType="pubmed">17456777</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamblin T.C., Chen F., Zambrano A., Abraha A., Lagalwar S., Guillozet A.L., Lu M., Fu Y., Garcia-Sierra F., LaPointe N., et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc. Natl Acad. Sci. US.A. 2003;100:10032&#x2013;10037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC187753</ArticleId><ArticleId IdType="pubmed">12888622</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y.P., Biernat J., Pickhardt M., Mandelkow E., Mandelkow E.M. Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc. Natl Acad. Sci. USA. 2007;104:10252&#x2013;10257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1891218</ArticleId><ArticleId IdType="pubmed">17535890</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissman R.A., Poon W.W., Blurton-Jones M., Oddo S., Torp R., Vitek M.P., LaFerla F.M., Rohn T.T., Cotman C.W. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J. Clin. Invest. 2004;114:121&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC437967</ArticleId><ArticleId IdType="pubmed">15232619</ArticleId></ArticleIdList></Reference><Reference><Citation>Wille H., Drewes G., Biernat J., Mandelkow E.M., Mandelkow E. Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro. J. Cell Biol. 1992;118:573&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2289542</ArticleId><ArticleId IdType="pubmed">1639844</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori H., Kondo J., Ihara Y. Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science. 1987;235:1641&#x2013;1644.</Citation><ArticleIdList><ArticleId IdType="pubmed">3029875</ArticleId></ArticleIdList></Reference><Reference><Citation>David D.C., Layfield R., Serpell L., Narain Y., Goedert M., Spillantini M.G. Proteasomal degradation of tau protein. J. Neurochem. 2002;83:176&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">12358741</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J.Y., Liu S.J., Li H.L., Wang J.Z. Microtubule-associated protein tau is a substrate of ATP/Mg(2+)-dependent proteasome protease system. J. Neural Transm. 2005;112:547&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15372326</ArticleId></ArticleIdList></Reference><Reference><Citation>Feuillette S., Blard O., Lecourtois M., Frebourg T., Campion D., Dumanchin C. Tau is not normally degraded by the proteasome. J. Neurosci. Res. 2005;80:400&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">15795929</ArticleId></ArticleIdList></Reference><Reference><Citation>Delobel P., Leroy O., Hamdane M., Sambo A.V., Delacourte A., Buee L. Proteasome inhibition and Tau proteolysis: an unexpected regulation. FEBS Lett. 2005;579:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7130380</ArticleId><ArticleId IdType="pubmed">15620682</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown M.R., Bondada V., Keller J.N., Thorpe J., Geddes J.W. Proteasome or calpain inhibition does not alter cellular tau levels in neuroblastoma cells or primary neurons. J. Alzheimers Dis. 2005;7:15&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">15750211</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimura H., Schwartz D., Gygi S.P., Kosik K.S. CHIP&#x2013;Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J. Biol. Chem. 2004;279:4869&#x2013;4876.</Citation><ArticleIdList><ArticleId IdType="pubmed">14612456</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrucelli L., Dickson D., Kehoe K., Taylor J., Snyder H., Grover A., De Lucia M., McGowan E., Lewis J., Prihar G., et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet. 2004;13:703&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">14962978</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey C.A., Kamal A., Lundgren K., Klosak N., Bailey R.M., Dunmore J., Ash P., Shoraka S., Zlatkovic J., Eckman C.B., et al. The high-affinity HSP90&#x2013;CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J. Clin. Invest. 2007;117:648&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1794119</ArticleId><ArticleId IdType="pubmed">17304350</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizushima N., Levine B., Cuervo A.M., Klionsky D.J. Autophagy fights disease through cellular self-digestion. Nature. 2008;451:1069&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2670399</ArticleId><ArticleId IdType="pubmed">18305538</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler D., Nixon R.A., Bahr B.A. Potential compensatory responses through autophagic/lysosomal pathways in neurodegenerative diseases. Autophagy. 2006;2:234&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">16874061</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon R.A., Cataldo A.M., Mathews P.M. The endosomal-lysosomal system of neurons in Alzheimer's disease pathogenesis: a review. Neurochem. Res. 2000;25:1161&#x2013;1172.</Citation><ArticleIdList><ArticleId IdType="pubmed">11059790</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon R.A., Wegiel J., Kumar A., Yu W.H., Peterhoff C., Cataldo A., Cuervo A.M. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J. Neuropathol. Exp. Neurol. 2005;64:113&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">15751225</ArticleId></ArticleIdList></Reference><Reference><Citation>Ii K., Ito H., Kominami E., Hirano A. Abnormal distribution of cathepsin proteinases and endogenous inhibitors (cystatins) in the hippocampus of patients with Alzheimer's disease, parkinsonism-dementia complex on Guam, and senile dementia and in the aged. Virchows Arch. A Pathol. Anat. Histopathol. 1993;423:185&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">8236812</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenessey A., Nacharaju P., Ko L.W., Yen S.H. Degradation of tau by lysosomal enzyme cathepsin D: implication for Alzheimer neurofibrillary degeneration. J. Neurochem. 1997;69:2026&#x2013;2038.</Citation><ArticleIdList><ArticleId IdType="pubmed">9349548</ArticleId></ArticleIdList></Reference><Reference><Citation>Bednarski E., Lynch G. Cytosolic proteolysis of tau by cathepsin D in hippocampus following suppression of cathepsins B and L. J. Neurochem. 1996;67:1846&#x2013;1855.</Citation><ArticleIdList><ArticleId IdType="pubmed">8863489</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendiske J., Bahr B.A. Lysosomal activation is a compensatory response against protein accumulation and associated synaptopathogenesis&#x2014;an approach for slowing Alzheimer disease? J. Neuropathol. Exp. Neurol. 2003;62:451&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">12769185</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyama F., Murakami N., Ihara Y. Chloroquine myopathy suggests that tau is degraded in lysosomes: implication for the formation of paired helical filaments in Alzheimer's disease. Neurosci. Res. 1998;31:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9704973</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K., Akiyama H., Arai T., Kondo H., Haga C., Iritani S., Tsuchiya K. Alz-50/Gallyas-positive lysosome-like intraneuronal granules in Alzheimer's disease and control brains. Neurosci. Lett. 1998;258:113&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">9875540</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger Z., Ravikumar B., Menzies F.M., Oroz L.G., Underwood B.R., Pangalos M.N., Schmitt I., Wullner U., Evert B.O., O'Kane C.J., et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet. 2006;15:433&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">16368705</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamano T., Gendron T.F., Causevic E., Yen S.H., Lin W.L., Isidoro C., Deture M., Ko L.W. Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild-type tau expression. Eur. J. Neurosci. 2008;27:1119&#x2013;1130.</Citation><ArticleIdList><ArticleId IdType="pubmed">18294209</ArticleId></ArticleIdList></Reference><Reference><Citation>Dice J.F. Peptide sequences that target cytosolic proteins for lysosomal proteolysis. Trends. Biochem. Sci. 1990;15:305&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">2204156</ArticleId></ArticleIdList></Reference><Reference><Citation>Dice J.F. Chaperone-mediated autophagy. Autophagy. 2007;3:295&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">17404494</ArticleId></ArticleIdList></Reference><Reference><Citation>Massey A.C., Zhang C., Cuervo A.M. Chaperone-mediated autophagy in aging and disease. Curr. Top. Dev. Biol. 2006;73:205&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">16782460</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamos J.E., Oblas B., Pulaski-Salo D., Welch W.J., Bole D.G., Drachman D.A. Expression of heat shock proteins in Alzheimer's disease. Neurology. 1991;41:345&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">2005999</ArticleId></ArticleIdList></Reference><Reference><Citation>Khlistunova I., Biernat J., Wang Y., Pickhardt M., von Bergen M., Gazova Z., Mandelkow E., Mandelkow E.M. Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J. Biol. Chem. 2006;281:1205&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246844</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon R.A. Autophagy in neurodegenerative disease: friend, foe or turncoat? Trends Neurosci. 2006;29:528&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pubmed">16859759</ArticleId></ArticleIdList></Reference><Reference><Citation>Seglen P.O., Gordon P.B. 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc. Natl Acad. Sci. USA. 1982;79:1889&#x2013;1892.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC346086</ArticleId><ArticleId IdType="pubmed">6952238</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuervo A.M., Hu W., Lim B., Dice J.F. IkappaB is a substrate for a selective pathway of lysosomal proteolysis. Mol. Biol. Cell. 1998;9:1995&#x2013;2010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25451</ArticleId><ArticleId IdType="pubmed">9693362</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuervo A.M., Dice J.F. A receptor for the selective uptake and degradation of proteins by lysosomes. Science. 1996;273:501&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">8662539</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland B., Campbell V. Abeta-mediated activation of the apoptotic cascade in cultured cortical neurones: a role for cathepsin-L. Neurobiol. Aging. 2004;25:83&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">14675734</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo A.M., Paskevich P.A., Kominami E., Nixon R.A. Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer disease. Proc. Natl Acad. Sci. USA. 1991;88:10998&#x2013;11002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC53060</ArticleId><ArticleId IdType="pubmed">1837142</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence B.P., Brown W.J. Inhibition of protein synthesis separates autophagic sequestration from the delivery of lysosomal enzymes. J. Cell Sci. 1993;105(Pt 2):473&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">8408278</ArticleId></ArticleIdList></Reference><Reference><Citation>Abeliovich H., Dunn W.A., Jr, Kim J., Klionsky D.J. Dissection of autophagosome biogenesis into distinct nucleation and expansion steps. J. Cell Biol. 2000;151:1025&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174351</ArticleId><ArticleId IdType="pubmed">11086004</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo W., Dou F., Rodina A., Chip S., Kim J., Zhao Q., Moulick K., Aguirre J., Wu N., Greengard P., et al. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc. Natl Acad. Sci. USA. 2007;104:9511&#x2013;9516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1890525</ArticleId><ArticleId IdType="pubmed">17517623</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Vicente M., Talloczy Z., Kaushik S., Massey A.C., Mazzulli J., Mosharov E.V., Hodara R., Fredenburg R., Wu D.C., Follenzi A., et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J. Clin. Invest. 2008;118:777&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2157565</ArticleId><ArticleId IdType="pubmed">18172548</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuervo A.M., Stefanis L., Fredenburg R., Lansbury P.T., Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004;305:1292&#x2013;1295.</Citation><ArticleIdList><ArticleId IdType="pubmed">15333840</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvador N., Aguado C., Horst M., Knecht E. Import of a cytosolic protein into lysosomes by chaperone-mediated autophagy depends on its folding state. J. Biol. Chem. 2000;275:27447&#x2013;27456.</Citation><ArticleIdList><ArticleId IdType="pubmed">10862611</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuervo A.M., Dice J.F., Knecht E. A population of rat liver lysosomes responsible for the selective uptake and degradation of cytosolic proteins. J. Biol. Chem. 1997;272:5606&#x2013;5615.</Citation><ArticleIdList><ArticleId IdType="pubmed">9038169</ArticleId></ArticleIdList></Reference><Reference><Citation>Storrie B., Madden E.A. Isolation of subcellular organelles. Methods Enzymol. 1990;182:203&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pubmed">2156127</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson D.M., Binder L.I. Polymerization of microtubule-associated protein tau under near-physiological conditions. J. Biol. Chem. 1995;270:24306&#x2013;24314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7592641</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackmann M., Wiech H., Mandelkow E. Nonsaturable binding indicates clustering of tau on the microtubule surface in a paired helical filament-like conformation. J. Biol. Chem. 2000;275:30335&#x2013;30343.</Citation><ArticleIdList><ArticleId IdType="pubmed">10869348</ArticleId></ArticleIdList></Reference><Reference><Citation>Barghorn S., Mandelkow E. Toward a unified scheme for the aggregation of tau into Alzheimer paired helical filaments. Biochemistry. 2002;41:14885&#x2013;14896.</Citation><ArticleIdList><ArticleId IdType="pubmed">12475237</ArticleId></ArticleIdList></Reference><Reference><Citation>Chirita C.N., Necula M., Kuret J. Anionic micelles and vesicles induce tau fibrillization in vitro. J. Biol. Chem. 2003;278:25644&#x2013;25650.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730214</ArticleId></ArticleIdList></Reference><Reference><Citation>Aniento F., Roche E., Cuervo A.M., Knecht E. Uptake and degradation of glyceraldehyde-3-phosphate dehydrogenase by rat liver lysosomes. J. Biol. Chem. 1993;268:10463&#x2013;10470.</Citation><ArticleIdList><ArticleId IdType="pubmed">8486700</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar M., Kuret J., Lee G. Two motifs within the tau microtubule-binding domain mediate its association with the hsc70 molecular chaperone. J. Neurosci. Res. 2008;86:2763&#x2013;2773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4271846</ArticleId><ArticleId IdType="pubmed">18500754</ArticleId></ArticleIdList></Reference><Reference><Citation>Massey A.C., Kaushik S., Sovak G., Kiffin R., Cuervo A.M. Consequences of the selective blockage of chaperone-mediated autophagy. Proc. Natl. Acad. Sci. USA. 2006;103:5805&#x2013;5810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1458654</ArticleId><ArticleId IdType="pubmed">16585521</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuervo A.M., Terlecky S.R., Dice J.F., Knecht E. Selective binding and uptake of ribonuclease A and glyceraldehyde-3-phosphate dehydrogenase by isolated rat liver lysosomes. J. Biol. Chem. 1994;269:26374&#x2013;26380.</Citation><ArticleIdList><ArticleId IdType="pubmed">7929357</ArticleId></ArticleIdList></Reference><Reference><Citation>Komatsu M., Chiba T., Mizushima N. [Physiological role in constitutive autophagy] Tanpakushitsu Kakusan Koso. 2006;51:1515&#x2013;1518.</Citation><ArticleIdList><ArticleId IdType="pubmed">16922430</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara T., Nakamura K., Matsui M., Yamamoto A., Nakahara Y., Suzuki-Migishima R., Yokoyama M., Mishima K., Saito I., Okano H., et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature. 2006;441:885&#x2013;889.</Citation><ArticleIdList><ArticleId IdType="pubmed">16625204</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu W.H., Cuervo A.M., Kumar A., Peterhoff C.M., Schmidt S.D., Lee J.H., Mohan P.S., Mercken M., Farmery M.R., Tjernberg L.O., et al. Macroautophagy&#x2013;a novel Beta-amyloid peptide-generating pathway activated in Alzheimer's disease. J. Cell Biol. 2005;171:87&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171227</ArticleId><ArticleId IdType="pubmed">16203860</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb J.L., Ravikumar B., Atkins J., Skepper J.N., Rubinsztein D.C. Alpha-Synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 2003;278:25009&#x2013;25013.</Citation><ArticleIdList><ArticleId IdType="pubmed">12719433</ArticleId></ArticleIdList></Reference><Reference><Citation>Rideout H.J., Lang-Rollin I., Stefanis L. Involvement of macroautophagy in the dissolution of neuronal inclusions. Int. J. Biochem. Cell Biol. 2004;36:2551&#x2013;2562.</Citation><ArticleIdList><ArticleId IdType="pubmed">15325592</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling H., Vamvakas S., Gekle M., Schaefer L., Teschner M., Schaefer R.M., Heidland A. Role of lysosomal cathepsin activities in cell hypertrophy induced by NH4Cl in cultured renal proximal tubule cells. J. Am. Soc. Nephrol. 1996;7:73&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">8808112</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunkes A., Lindenberg K.S., Ben-Haiem L., Weber C., Devys D., Landwehrmeyer G.B., Mandel J.L., Trottier Y. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol. Cell. 2002;10:259&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">12191472</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y.J., Sapp E., Cuiffo B.G., Sobin L., Yoder J., Kegel K.B., Qin Z.H., Detloff P., Aronin N., DiFiglia M. Lysosomal proteases are involved in generation of N-terminal huntingtin fragments. Neurobiol. Dis. 2006;22:346&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">16423528</ArticleId></ArticleIdList></Reference><Reference><Citation>Caughey B., Raymond G.J., Ernst D., Race R.E. N-terminal truncation of the scrapie-associated form of PrP by lysosomal protease(s): implications regarding the site of conversion of PrP to the protease-resistant state. J. Virol. 1991;65:6597&#x2013;6603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC250721</ArticleId><ArticleId IdType="pubmed">1682507</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg S.G., Davies P. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc. Natl Acad. Sci. USA. 1990;87:5827&#x2013;5831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54421</ArticleId><ArticleId IdType="pubmed">2116006</ArticleId></ArticleIdList></Reference><Reference><Citation>Wattiaux R., Wattiaux-De Coninck S., Ronveaux-dupal M.F., Dubois F. Isolation of rat liver lysosomes by isopycnic centrifugation in a metrizamide gradient. J. Cell Biol. 1978;78:349&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2110129</ArticleId><ArticleId IdType="pubmed">211139</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohsumi Y., Ishikawa T., Kato K. A rapid and simplified method for the preparation of lysosomal membranes from rat liver. J. Biochem. 1983;93:547&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pubmed">6841352</ArticleId></ArticleIdList></Reference><Reference><Citation>Marzella L., Ahlberg J., Glaumann H. Isolation of autophagic vacuoles from rat liver: morphological and biochemical characterization. J. Cell Biol. 1982;93:144&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2112104</ArticleId><ArticleId IdType="pubmed">7068752</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18448646</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>18</Issue><PubDate><Year>2008</Year><Month>Apr</Month><Day>30</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Activation of the amyloid cascade in apolipoprotein E4 transgenic mice induces lysosomal activation and neurodegeneration resulting in marked cognitive deficits.</ArticleTitle><Pagination><StartPage>4690</StartPage><EndPage>4701</EndPage><MedlinePgn>4690-701</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5633-07.2008</ELocationID><Abstract><AbstractText>The allele E4 of apolipoprotein E (apoE4), the most prevalent genetic risk factor for Alzheimer's disease, is associated histopathologically with elevated levels of brain amyloid. This led to the suggestion that the pathological effects of apoE4 are mediated by cross-talk interactions with amyloid beta peptide (Abeta), which accentuate the pathological effects of the amyloid cascade. The mechanisms underlying the Abeta-mediated pathological effects of apoE4 are unknown. We have shown recently that inhibition of the Abeta-degrading enzyme neprilysin in brains of wild-type apoE3 and apoE4 mice results in rapid and similar elevations in their total brain Abeta levels. However, the nucleation and aggregation of Abeta in these mice were markedly affected by the apoE genotype and were specifically enhanced in the apoE4 mice. We presently used the neprilysin inhibition paradigm to analyze the neuropathological and cognitive effects that are induced by apoE4 after activation of the amyloid cascade. This revealed that apoE4 stimulates isoform specifically the degeneration of hippocampal CA1 neurons and of entorhinal and septal neurons, which is accompanied by the accumulation of intracellular Abeta and apoE and with lysosomal activation. Furthermore, these neuropathological effects are associated isoform specifically with the occurrence of pronounced cognitive deficits in the ApoE4 mice. These findings provide the first in vivo evidence regarding the cellular mechanisms underlying the pathological cross talk between apoE4 and Abeta, as well as a novel model system of neurodegeneration in vivo that is uniquely suitable for studying the early stages of the amyloid cascade and the effects thereon of apoE4.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Belinson</LastName><ForeName>Haim</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv 69978, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lev</LastName><ForeName>Dimitri</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Michaelson</LastName><ForeName>Daniel M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG10435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG010435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG48440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053318">Apolipoprotein E3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.11</RegistryNumber><NameOfSubstance UI="D015260">Neprilysin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053318" MajorTopicYN="N">Apolipoprotein E3</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005106" MajorTopicYN="N">Exploratory Behavior</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="N">Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046529" MajorTopicYN="N">Microscopy, Electron, Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015260" MajorTopicYN="N">Neprilysin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014868" MajorTopicYN="N">Water Deprivation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>10</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18448646</ArticleId><ArticleId IdType="pmc">PMC3844816</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5633-07.2008</ArticleId><ArticleId IdType="pii">28/18/4690</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer's 1907 paper, &#x201c;Uber eine eigenartige Erkankung der Hirnrinde.&#x201d;. Clin Anat. 1995;8:429&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pubmed">8713166</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T, Schindler C, Bruckner MK, Eschrich K, Bigl V, Zedlick D, Marcova L. Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein &#x3b5;4 allele. J Neurosci. 1997;17:516&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573225</ArticleId><ArticleId IdType="pubmed">8987775</ArticleId></ArticleIdList></Reference><Reference><Citation>Brendza RP, Bales KR, Paul SM, Holtzman DM. Role of apoE/Abeta interactions in Alzheimer's disease: insights from transgenic mouse models. Mol Psychiatry. 2002;7:132&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">11840304</ArticleId></ArticleIdList></Reference><Reference><Citation>Casas C, Sergeant N, Itier JM, Blanchard V, Wirths O, van der Kolk N, Vingtdeux V, van de Steeg E, Ret G, Canton T, Drobecq H, Clark A, Bonici B, Delacourte A, Benavides J, Schmitz C, Tremp G, Bayer TA, Benoit P, Pradier L. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol. 2004;165:1289&#x2013;1300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618627</ArticleId><ArticleId IdType="pubmed">15466394</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Barnett JL, Pieroni C, Nixon RA. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased &#x3b2;-amyloidogenesis. J Neurosci. 1997;17:6142&#x2013;6151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568334</ArticleId><ArticleId IdType="pubmed">9236226</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ, Justice A, McConlogue L, Games D, Freedman SB, Morris RG. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature. 2000;408:975&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140684</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB. Apolipoprotein E dose-dependent modulation of beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. J Mol Neurosci. 2004;23:255&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">15181254</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolev I, Michaelson DM. A nontransgenic mouse model shows inducible amyloid-beta (Abeta) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade. Proc Natl Acad Sci USA. 2004;101:13909&#x2013;13914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC518852</ArticleId><ArticleId IdType="pubmed">15365176</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolev I, Michaelson DM. The nucleation growth and reversibility of Amyloid-beta deposition in vivo. J Alzheimers Dis. 2006;10:291&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">17119294</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol Dis. 2002;9:305&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">11950276</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin KBJ, Paxinos G. Mouse brain in stereotaxic coordinates. San Diego: Academic; 1997.</Citation></Reference><Reference><Citation>Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, Holtzman DM. Human apolipoprotein E4 alters the amyloid-&#x3b2; 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci. 2005;25:2803&#x2013;2810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725147</ArticleId><ArticleId IdType="pubmed">15772340</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukami S, Watanabe K, Iwata N, Haraoka J, Lu B, Gerard NP, Gerard C, Fraser P, Westaway D, St George-Hyslop P, Saido TC. Abeta-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Abeta pathology. Neurosci Res. 2002;43:39&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">12074840</ArticleId></ArticleIdList></Reference><Reference><Citation>Geula C, Mesulam MM. Cholinergic system in Alzheimer disease. In: Terry RD, Katzman R, Bick KL, Sisodia SS, editors. Alzheimer disease. Ed 2. Philadelphia: Lippincott, Williams, and Wilkins; 1999. p. 457.</Citation></Reference><Reference><Citation>Goedert M, Spillantini MG. A century of Alzheimer's disease. Science. 2006;314:777&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">17082447</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimm HS, Beher D, Lichtenthaler SF, Shearman MS, Beyreuther K, Hartmann T. gamma-Secretase cleavage site specificity differs for intracellular and secretory amyloid beta. J Biol Chem. 2003;278:13077&#x2013;13085.</Citation><ArticleIdList><ArticleId IdType="pubmed">12556458</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J. Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. J Alzheimers Dis. 2006;9:151&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914853</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartman RE, Laurer H, Longhi L, Bales KR, Paul SM, McIntosh TK, Holtzman DM. Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease. J Neurosci. 2002;22:10083&#x2013;10087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758744</ArticleId><ArticleId IdType="pubmed">12451108</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof PR, Morrison JH. The cellular basis of cortical disconnection in Alzheimer disease and related dementing conditions. In: Terry RD, Katzman R, Bick KL, Sisodia SS, editors. Alzheimer Disease. Ed 2. Philadelphia: Lippincott, Williams, and Wilkins; 1999. p. 457.</Citation></Reference><Reference><Citation>Holtzman DM. In vivo effects of ApoE and clusterin on amyloid-beta metabolism and neuropathology. J Mol Neurosci. 2004;23:247&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">15181253</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2000;97:2892&#x2013;2897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16026</ArticleId><ArticleId IdType="pubmed">10694577</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Weisgraber KH, Mucke L, Mahley RW. Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease. J Mol Neurosci. 2004;23:189&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">15181247</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji ZS, Miranda RD, Newhouse YM, Weisgraber KH, Huang Y, Mahley RW. Apolipoprotein E4 potentiates amyloid beta peptide-induced lysosomal leakage and apoptosis in neuronal cells. J Biol Chem. 2002;277:21821&#x2013;21828.</Citation><ArticleIdList><ArticleId IdType="pubmed">11912196</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji ZS, Mullendorff K, Cheng IH, Miranda RD, Huang Y, Mahley RW. Reactivity of apolipoprotein E4 and amyloid beta peptide: lysosomal stability and neurodegeneration. J Biol Chem. 2006;281:2683&#x2013;2692.</Citation><ArticleIdList><ArticleId IdType="pubmed">16298992</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan J, Galindo MF, Miller RJ, Reardon CA, Getz GS, LaDu MJ. Isoform-specific effect of apolipoprotein E on cell survival and &#x3b2;-amyloid-induced toxicity in rat hippocampal pyramidal neuronal cultures. J Neurosci. 1998;18:195&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793392</ArticleId><ArticleId IdType="pubmed">9412500</ArticleId></ArticleIdList></Reference><Reference><Citation>LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE. Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem. 1994;269:23403&#x2013;23406.</Citation><ArticleIdList><ArticleId IdType="pubmed">8089103</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci. 2007;8:499&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">17551515</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi O, Jongen-Relo AL, Feldon J, Roses AD, Michaelson DM. ApoE4 impairs hippocampal plasticity isoform-specifically and blocks the environmental stimulation of synaptogenesis and memory. Neurobiol Dis. 2003;13:273&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">12901842</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, Beyreuther K. Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway. Brain. 2006;129:2823&#x2013;2839.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012295</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumori Y, Hong SM, Fan Y, Kayama T, Hsu CY, Weinstein PR, Liu J. Enriched environment and spatial learning enhance hippocampal neurogenesis and salvages ischemic penumbra after focal cerebral ischemia. Neurobiol Dis. 2006;22:187&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">16361108</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori E, Lee K, Yasuda M, Hashimoto M, Kazui H, Hirono N, Matsui M. Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E epsilon4 allele. Ann Neurol. 2002;51:209&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">11835377</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris RG, Frey U. Hippocampal synaptic plasticity: role in spatial learning or the automatic recording of attended experience? Philos Trans R Soc Lond B Biol Sci. 1997;352:1489&#x2013;1503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1692060</ArticleId><ArticleId IdType="pubmed">9368938</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, Cataldo AM. Lysosomal system pathways: genes to neurodegeneration in Alzheimer's disease. J Alzheimers Dis. 2006;9:277&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914867</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Puttfarcken PS, Manelli AM, Falduto MT, Getz GS, LaDu MJ. Effect of apolipoprotein E on neurite outgrowth and beta-amyloid-induced toxicity in developing rat primary hippocampal cultures. J Neurochem. 1997;68:760&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pubmed">9003067</ArticleId></ArticleIdList></Reference><Reference><Citation>Roses AD. On the discovery of the genetic association of apolipoprotein E genotypes and common late-onset Alzheimer disease. J Alzheimers Dis. 2006;9:361&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914873</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, Hulette C, Crain B, Goldgaber D, Roses AD. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:9649&#x2013;9653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47627</ArticleId><ArticleId IdType="pubmed">8415756</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:8098&#x2013;8102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47295</ArticleId><ArticleId IdType="pubmed">8367470</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL, Quarfordt SH, Maeda N. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem. 1997;272:17972&#x2013;17980.</Citation><ArticleIdList><ArticleId IdType="pubmed">9218423</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, Beal MF, Xu H, Greengard P, Gouras GK. Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol. 2002;161:1869&#x2013;1879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850783</ArticleId><ArticleId IdType="pubmed">12414533</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng BP, Kitazawa M, LaFerla FM. Amyloid beta-peptide: the inside story. Curr Alzheimer Res. 2004;1:231&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">15975052</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Zee EA, Compaan JC, de Boer M, Luiten PG. Changes in PKC&#x3b3; immunoreactivity in mouse hippocampus induced by spatial discrimination learning. J Neurosci. 1992;12:4808&#x2013;4815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575776</ArticleId><ArticleId IdType="pubmed">1464769</ArticleId></ArticleIdList></Reference><Reference><Citation>West MJ, Coleman PD, Flood DG, Troncoso JC. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet. 1994;344:769&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pubmed">7916070</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu PT, Gilbert JR, Qiu HL, Ervin J, Rothrock-Christian TR, Hulette C, Schmechel DE. Specific regional transcription of apolipoprotein E in human brain neurons. Am J Pathol. 1999;154:601&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850012</ArticleId><ArticleId IdType="pubmed">10027417</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerbinatti CV, Wahrle SE, Kim H, Cam JA, Bales K, Paul SM, Holtzman DM, Bu G. Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal Abeta42 accumulation in amyloid model mice. J Biol Chem. 2006;281:36180&#x2013;36186.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012232</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16982417</PMID><DateCompleted><Year>2006</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>51</Volume><Issue>6</Issue><PubDate><Year>2006</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease.</ArticleTitle><Pagination><StartPage>703</StartPage><EndPage>714</EndPage><MedlinePgn>703-14</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) may result from the accumulation of amyloid-beta (Abeta) peptides in the brain. The cysteine protease cathepsin B (CatB) is associated with amyloid plaques in AD brains and has been suspected to increase Abeta production. Here, we demonstrate that CatB actually reduces levels of Abeta peptides, especially the aggregation-prone species Abeta1-42, through proteolytic cleavage. Genetic inactivation of CatB in mice with neuronal expression of familial AD-mutant human amyloid precursor protein (hAPP) increased the relative abundance of Abeta1-42, worsening plaque deposition and other AD-related pathologies. Lentivirus-mediated expression of CatB in aged hAPP mice reduced preexisting amyloid deposits, even thioflavin S-positive plaques. Under cell-free conditions, CatB effectively cleaved Abeta1-42, generating C-terminally truncated Abeta peptides that are less amyloidogenic. Thus, CatB likely fulfills antiamyloidogenic and neuroprotective functions. Insufficient CatB activity might promote AD; increasing CatB activity could counteract the neuropathology of this disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mueller-Steiner</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, University of California, San Francisco, 1650 Owens Street, 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yungui</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Arai</LastName><ForeName>Hideaki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik D</ForeName><Initials>ED</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Binggui</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xin</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Guiqiu</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Esposito</LastName><ForeName>Luke</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Mucke</LastName><ForeName>Lennart</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Li</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 NS054811</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG024447</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.1</RegistryNumber><NameOfSubstance UI="D002401">Cathepsin B</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2006 Sep 21;51(6):671-2. doi: 10.1016/j.neuron.2006.09.005.</RefSource><PMID Version="1">16982408</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002401" MajorTopicYN="N">Cathepsin B</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006868" MajorTopicYN="N">Hydrolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018613" MajorTopicYN="N">Microscopy, Confocal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>9</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>11</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>9</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16982417</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2006.07.027</ArticleId><ArticleId IdType="pii">S0896-6273(06)00597-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21976528</PMID><DateCompleted><Year>2011</Year><Month>11</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>40</Issue><PubDate><Year>2011</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Chronic stress exacerbates tau pathology, neurodegeneration, and cognitive performance through a corticotropin-releasing factor receptor-dependent mechanism in a transgenic mouse model of tauopathy.</ArticleTitle><Pagination><StartPage>14436</StartPage><EndPage>14449</EndPage><MedlinePgn>14436-49</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3836-11.2011</ELocationID><Abstract><AbstractText>Because overactivation of the hypothalamic-pituitary-adrenal (HPA) axis occurs in Alzheimer's disease (AD), dysregulation of stress neuromediators may play a mechanistic role in the pathophysiology of AD. However, the effects of stress on tau phosphorylation are poorly understood, and the relationship between corticosterone and corticotropin-releasing factor (CRF) on both &#x3b2;-amyloid (A&#x3b2;) and tau pathology remain unclear. Therefore, we first established a model of chronic stress, which exacerbates A&#x3b2; accumulation in Tg2576 mice and then extended this stress paradigm to a tau transgenic mouse model with the P301S mutation (PS19) that displays tau hyperphosphorylation, insoluble tau inclusions and neurodegeneration. We show for the first time that both Tg2576 and PS19 mice demonstrate a heightened HPA stress profile in the unstressed state. In Tg2576 mice, 1 month of restraint/isolation (RI) stress increased A&#x3b2; levels, suppressed microglial activation, and worsened spatial and fear memory compared with nonstressed mice. In PS19 mice, RI stress promoted tau hyperphosphorylation, insoluble tau aggregation, neurodegeneration, and fear-memory impairments. These effects were not mimicked by chronic corticosterone administration but were prevented by pre-stress administration of a CRF receptor type 1 (CRF(1)) antagonist. The role for a CRF(1)-dependent mechanism was further supported by the finding that mice overexpressing CRF had increased hyperphosphorylated tau compared with wild-type littermates. Together, these results implicate HPA dysregulation in AD neuropathogenesis and suggest that prolonged stress may increase A&#x3b2; and tau hyperphosphorylation. These studies also implicate CRF in AD pathophysiology and suggest that pharmacological manipulation of this neuropeptide may be a potential therapeutic strategy for AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carroll</LastName><ForeName>Jenna C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, School of Medicine and Institute on Aging, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iba</LastName><ForeName>Michiyo</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bangasser</LastName><ForeName>Debra A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Valentino</LastName><ForeName>Rita J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Brunden</LastName><ForeName>Kurt R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M-Y</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG17586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 MH092438</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH40008</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH040008</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018019">Receptors, Corticotropin-Releasing Hormone</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>5CLY6W2H1M</RegistryNumber><NameOfSubstance UI="D000099052">CRF Receptor, Type 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2011 Nov 03;12(12):704. doi: 10.1038/nrn3139.</RefSource><PMID Version="1">22048064</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007030" MajorTopicYN="N">Hypothalamo-Hypophyseal System</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008809" MajorTopicYN="N">Mice, Inbred C3H</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010913" MajorTopicYN="N">Pituitary-Adrenal System</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018019" MajorTopicYN="N">Receptors, Corticotropin-Releasing Hormone</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000099052" MajorTopicYN="N">CRF Receptor, Type 1</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>4</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21976528</ArticleId><ArticleId IdType="mid">NIHMS329879</ArticleId><ArticleId IdType="pmc">PMC3230070</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3836-11.2011</ArticleId><ArticleId IdType="pii">31/40/14436</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alfarez DN, Jo&#xeb;ls M, Krugers HJ. Chronic unpredictable stress impairs long-term potentiation in rat hippocampal CA1 area and dentate gyrus in vitro. Eur J Neurosci. 2003;17:1928&#x2013;1934.</Citation><ArticleIdList><ArticleId IdType="pubmed">12752792</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T, Stieler J, Strijkstra AM, Hut RA, R&#xfc;diger J, Van der Zee EA, Harkany T, Holzer M, H&#xe4;rtig W. Reversible paired helical filament-like phosphorylation of tau is an adaptive process associated with neuronal plasticity in hibernating animals. J Neurosci. 2003;23:6972&#x2013;6981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740664</ArticleId><ArticleId IdType="pubmed">12904458</ArticleId></ArticleIdList></Reference><Reference><Citation>Avila J, Wandosell F, Hern&#xe1;ndez F. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors. Expert Rev Neurother. 2010;10:703&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pubmed">20420491</ArticleId></ArticleIdList></Reference><Reference><Citation>Aznar S, Knudsen GM. Depression and Alzheimer's disease: is stress the initiating factor in a common neuropathological cascade? J Alzheimers Dis. 2011;23:177&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">21098983</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachman DL, Wolf PA, Linn R, Knoefel JE, Cobb J, Belanger A, D'Agostino RB, White LR. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology. 1992;42:115&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">1734291</ArticleId></ArticleIdList></Reference><Reference><Citation>Bale TL, Vale WW. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol. 2004;44:525&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">14744257</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao AM, Meynen G, Swaab DF. The stress system in depression and neurodegeneration: focus on the human hypothalamus. Brain Res Rev. 2008;57:531&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">17524488</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayatti N, Behl C. The neuroprotective actions of CRH. Ageing Res Rev. 2005;4:258&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">16046283</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayatti N, Zschocke J, Behl C. Brain region-specific neuroprotective action and signaling of corticotropin-releasing hormone in primary neurons. Endocrinology. 2003;144:4051&#x2013;4060.</Citation><ArticleIdList><ArticleId IdType="pubmed">12933679</ArticleId></ArticleIdList></Reference><Reference><Citation>Benzing WC, Wujek JR, Ward EK, Shaffer D, Ashe KH, Younkin SG, Brunden KR. Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol Aging. 1999;20:581&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">10674423</ArticleId></ArticleIdList></Reference><Reference><Citation>Biber K, Neumann H, Inoue K, Boddeke HW. Neuronal &#x201c;On&#x201d; and &#x201c;Off&#x201d; signals control microglia. Trends Neurosci. 2007;30:596&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pubmed">17950926</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunden KR, Zhang B, Carroll J, Yao Y, Potuzak JS, Hogan AM, Iba M, James MJ, Xie SX, Ballatore C, Smith AB, 3rd, Lee VM, Trojanowski JQ. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neurosci. 2010;30:13861&#x2013;13866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2958430</ArticleId><ArticleId IdType="pubmed">20943926</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunden KR, Yao Y, Potuzak JS, Ferrer NI, Ballatore C, James MJ, Hogan AM, Trojanowski JQ, Smith AB, 3rd, Lee VM. The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies. Pharmacol Res. 2011;63:341&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3042036</ArticleId><ArticleId IdType="pubmed">21163349</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchanan JB, Sparkman NL, Chen J, Johnson RW. Cognitive and neuroinflammatory consequences of mild repeated stress are exacerbated in aged mice. Psychoneuroendocrinology. 2008;33:755&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2580674</ArticleId><ArticleId IdType="pubmed">18407425</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahill L. Why sex matters for neuroscience. Nat Rev Neurosci. 2006;7:477&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">16688123</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan MJ, Lipinski WJ, Bian F, Durham RA, Pack A, Walker LC. Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. Am J Pathol. 2001;158:1173&#x2013;1177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850367</ArticleId><ArticleId IdType="pubmed">11238065</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll JC, Pike CJ. Selective estrogen receptor modulators differentially regulate Alzheimer-like changes in female 3xTg-AD mice. Endocrinology. 2008;149:2607&#x2013;2611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2329277</ArticleId><ArticleId IdType="pubmed">18276750</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll JC, Rosario ER, Chang L, Stanczyk FZ, Oddo S, LaFerla FM, Pike CJ. Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. J Neurosci. 2007;27:13357&#x2013;13365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673397</ArticleId><ArticleId IdType="pubmed">18045930</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll JC, Rosario ER, Villamagna A, Pike CJ. Continuous and cyclic progesterone differentially interact with estradiol in the regulation of Alzheimer-like pathology in female 3xTransgenic-Alzheimer's disease mice. Endocrinology. 2010;151:2713&#x2013;2722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2875823</ArticleId><ArticleId IdType="pubmed">20410196</ArticleId></ArticleIdList></Reference><Reference><Citation>Csernansky JG, Dong H, Fagan AM, Wang L, Xiong C, Holtzman DM, Morris JC. Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am J Psychiatry. 2006;163:2164&#x2013;2169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1780275</ArticleId><ArticleId IdType="pubmed">17151169</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayas CV, Buller KM, Crane JW, Xu Y, Day TA. Stressor categorization: acute physical and psychological stressors elicit distinctive recruitment patterns in the amygdala and in medullary noradrenergic cell groups. Eur J Neurosci. 2001;14:1143&#x2013;1152.</Citation><ArticleIdList><ArticleId IdType="pubmed">11683906</ArticleId></ArticleIdList></Reference><Reference><Citation>De la Fuente M, Gimenez-Llort L. Models of aging of neuroimmunomodulation: strategies for its improvement. Neuroimmunomodulation. 2010;17:213&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">20134206</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi L, Alldred MJ, Ginsberg SD, Ohno M. Sex- and brain region-specific acceleration of beta-amyloidogenesis following behavioral stress in a mouse model of Alzheimer's disease. Mol Brain. 2010;3:34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2988063</ArticleId><ArticleId IdType="pubmed">21059265</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhabhar FS. Enhancing versus suppressive effects of stress on immune function: implications for immunoprotection and immunopathology. Neuroimmunomodulation. 2009;16:300&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2790771</ArticleId><ArticleId IdType="pubmed">19571591</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong H, Csernansky JG. Effects of stress and stress hormones on amyloid-beta protein and plaque deposition. J Alzheimers Dis. 2009;18:459&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2905685</ArticleId><ArticleId IdType="pubmed">19584430</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott EM, Mattson MP, Vanderklish P, Lynch G, Chang I, Sapolsky RM. Corticosterone exacerbates kainate-induced alterations in hippocampal tau immunoreactivity and spectrin proteolysis in vivo. J Neurochem. 1993;61:57&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">8515288</ArticleId></ArticleIdList></Reference><Reference><Citation>Facci L, Stevens DA, Pangallo M, Franceschini D, Skaper SD, Strijbos PJ. Corticotropin-releasing factor (CRF) and related peptides confer neuroprotection via type 1 CRF receptors. Neuropharmacology. 2003;45:623&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">12941376</ArticleId></ArticleIdList></Reference><Reference><Citation>Farfara D, Lifshitz V, Frenkel D. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J Cell Mol Med. 2008;12:762&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4401126</ArticleId><ArticleId IdType="pubmed">18363841</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Q, Cheng B, Yang R, Sun FY, Zhu CQ. Dynamic changes of phosphorylated tau in mouse hippocampus after cold water stress. Neurosci Lett. 2005;388:13&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">16005567</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueira ML, Ouakinin S. Gender-related endocrinological dysfunction and mental disorders. Curr Opin Psychiatry. 2010;23:369&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">20495459</ArticleId></ArticleIdList></Reference><Reference><Citation>Glezer I, Rivest S. Glucocorticoids: protectors of the brain during innate immune responses. Neuroscientist. 2004;10:538&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">15534039</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold PW, Chrousos GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry. 2002;7:254&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">11920153</ArticleId></ArticleIdList></Reference><Reference><Citation>Green KN, Billings LM, Roozendaal B, McGaugh JL, LaFerla FM. Glucocorticoids increase amyloid-&#x3b2; and tau pathology in a mouse model of Alzheimer's disease. J Neurosci. 2006;26:9047&#x2013;9056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675335</ArticleId><ArticleId IdType="pubmed">16943563</ArticleId></ArticleIdList></Reference><Reference><Citation>Guldiken S, Guldiken B. Subclinical Cushing's syndrome is a potential cause of metabolic dementia and rapidly progressive Alzheimer-type dementia. Med Hypotheses. 2008;71:703&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">18801622</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauger RL, Risbrough V, Oakley RH, Olivares-Reyes JA, Dautzenberg FM. Role of CRF receptor signaling in stress vulnerability, anxiety, and depression. Ann N Y Acad Sci. 2009;1179:120&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3115623</ArticleId><ArticleId IdType="pubmed">19906236</ArticleId></ArticleIdList></Reference><Reference><Citation>Herman JP, Cullinan WE. Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis. Trends Neurosci. 1997;20:78&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">9023876</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann M, Henneicke H, Street J, Modzelewski J, Kalak R, Buttgereit F, Dunstan CR, Zhou H, Seibel MJ. The challenge of continuous exogenous glucocorticoid administration in mice. Steroids. 2009;74:245&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">19071150</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillhouse EW, Grammatopoulos DK. The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology. Endocr Rev. 2006;27:260&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">16484629</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoare SR, Sullivan SK, Schwarz DA, Ling N, Vale WW, Crowe PD, Grigoriadis DE. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists. Biochemistry. 2004;43:3996&#x2013;4011.</Citation><ArticleIdList><ArticleId IdType="pubmed">15049707</ArticleId></ArticleIdList></Reference><Reference><Citation>Holsboer F, Ising M. Central CRH system in depression and anxiety&#x2013;evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol. 2008;583:350&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">18272149</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang HJ, Liang KC, Ke HC, Chang YY, Hsieh-Li HM. Long-term social isolation exacerbates the impairment of spatial working memory in APP/PS1 transgenic mice. Brain Res. 2011;1371:150&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">21114967</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurtado DE, Molina-Porcel L, Iba M, Aboagye AK, Paul SM, Trojanowski JQ, Lee VM. A&#x3b2; accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Am J Pathol. 2010;177:1977&#x2013;1988.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947292</ArticleId><ArticleId IdType="pubmed">20802182</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong YH, Park CH, Yoo J, Shin KY, Ahn SM, Kim HS, Lee SH, Emson PC, Suh YH. Chronic stress accelerates learning and memory impairments and increases amyloid deposition in APPV717I-CT100 transgenic mice, an Alzheimer's disease model. FASEB J. 2006;20:729&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">16467370</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurgens HA, Johnson RW. Dysregulated neuronal-microglial cross-talk during aging, stress and inflammation. Exp Neurol. 2010 doi: 10.1016/j.expneurol.2010.11.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2010.11.014</ArticleId><ArticleId IdType="pmc">PMC3071456</ArticleId><ArticleId IdType="pubmed">21110971</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE, Cirrito JR, Dong H, Csernansky JG, Holtzman DM. Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity. Proc Natl Acad Sci USA. 2007;104:10673&#x2013;10678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1965571</ArticleId><ArticleId IdType="pubmed">17551018</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JJ, Diamond DM. The stressed hippocampus, synaptic plasticity and lost memories. Nat Rev Neurosci. 2002;3:453&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">12042880</ArticleId></ArticleIdList></Reference><Reference><Citation>Korneyev A, Binder L, Bernardis J. Rapid reversible phosphorylation of rat brain tau proteins in response to cold water stress. Neurosci Lett. 1995;191:19&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">7659281</ArticleId></ArticleIdList></Reference><Reference><Citation>Landfield PW, Blalock EM, Chen KC, Porter NM. A new glucocorticoid hypothesis of brain aging: implications for Alzheimer's disease. Curr Alzheimer Res. 2007;4:205&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3573879</ArticleId><ArticleId IdType="pubmed">17430248</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee BK, Glass TA, Wand GS, McAtee MJ, Bandeen-Roche K, Bolla KI, Schwartz BS. Apolipoprotein e genotype, cortisol, and cognitive function in community-dwelling older adults. Am J Psychiatry. 2008;165:1456&#x2013;1464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2579316</ArticleId><ArticleId IdType="pubmed">18593777</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Skovronsky DM, Abtahian F, Doms RW, Lee VM. Secretion and intracellular generation of truncated Abeta in beta-site amyloid-beta precursor protein-cleaving enzyme expressing human neurons. J Biol Chem. 2003;278:4458&#x2013;4466.</Citation><ArticleIdList><ArticleId IdType="pubmed">12480937</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KW, Kim JB, Seo JS, Kim TK, Im JY, Baek IS, Kim KS, Lee JK, Han PL. Behavioral stress accelerates plaque pathogenesis in the brain of Tg2576 mice via generation of metabolic oxidative stress. J Neurochem. 2009;108:165&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">19012747</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HY, Ericsson A, Sawchenko PE. Distinct mechanisms underlie activation of hypothalamic neurosecretory neurons and their medullary catecholaminergic afferents in categorically different stress paradigms. Proc Natl Acad Sci USA. 1996;93:2359&#x2013;2364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39801</ArticleId><ArticleId IdType="pubmed">8637878</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L, Louis JC, Yan Q, Richards WG, Citron M, Vassar R. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci. 2001;4:231&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224535</ArticleId></ArticleIdList></Reference><Reference><Citation>Magari&#xf1;os AM, McEwen BS. Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: comparison of stressors. Neuroscience. 1995;69:83&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">8637635</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwen BS. Stress and hippocampal plasticity. Annu Rev Neurosci. 1999;22:105&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">10202533</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwen BS. Sex, stress and the hippocampus: allostasis, allostatic load and the aging process. Neurobiol Aging. 2002;23:921&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pubmed">12392796</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa Y, Nakamura M, McIntosh TK, Rodriguez A, Berlin JA, Smith DH, Saatman KE, Raghupathi R, Clemens J, Saido TC, Schmidt ML, Lee VM, Trojanowski JQ. Traumatic brain injury in young, amyloid-beta peptide overexpressing transgenic mice induces marked ipsilateral hippocampal atrophy and diminished Abeta deposition during aging. J Comp Neurol. 1999;411:390&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">10413774</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann H. Control of glial immune function by neurons. Glia. 2001;36:191&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">11596127</ArticleId></ArticleIdList></Reference><Reference><Citation>Nithianantharajah J, Hannan AJ. Enriched environments, experience-dependent plasticity and disorders of the nervous system. Nat Rev Neurosci. 2006;7:697&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pubmed">16924259</ArticleId></ArticleIdList></Reference><Reference><Citation>Papasozomenos SC. Heat shock induces rapid dephosphorylation of tau in both female and male rats followed by hyperphosphorylation only in female rats: implications for Alzheimer's disease. J Neurochem. 1996;66:1140&#x2013;1149.</Citation><ArticleIdList><ArticleId IdType="pubmed">8769877</ArticleId></ArticleIdList></Reference><Reference><Citation>Patil SS, Sunyer B, H&#xf6;ger H, Lubec G. Evaluation of spatial memory of C57BL/6J and CD1 mice in the Barnes maze, the Multiple T-maze and in the Morris water maze. Behav Brain Res. 2009;198:58&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">19022298</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen WA, McCullers D, Culmsee C, Haughey NJ, Herman JP, Mattson MP. Corticotropin-releasing hormone protects neurons against insults relevant to the pathogenesis of Alzheimer's disease. Neurobiol Dis. 2001;8:492&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">11442356</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen WA, Wan R, Zhang P, Mattson MP. Urocortin, but not urocortin II, protects cultured hippocampal neurons from oxidative and excitotoxic cell death via corticotropin-releasing hormone receptor type I. J Neurosci. 2002;22:404&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758668</ArticleId><ArticleId IdType="pubmed">11784785</ArticleId></ArticleIdList></Reference><Reference><Citation>Pervanidou P, Chrousos GP. Neuroendocrinology of post-traumatic stress disorder. Prog Brain Res. 2010;182:149&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">20541663</ArticleId></ArticleIdList></Reference><Reference><Citation>Planel E, Yasutake K, Fujita SC, Ishiguro K. Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse. J Biol Chem. 2001;276:34298&#x2013;34306.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441005</ArticleId></ArticleIdList></Reference><Reference><Citation>Pocock JM, Kettenmann H. Neurotransmitter receptors on microglia. Trends Neurosci. 2007;30:527&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pubmed">17904651</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian W, Yin X, Hu W, Shi J, Gu J, Grundke-Iqbal I, Iqbal K, Gong CX, Liu F. Activation of protein phosphatase 2B and hyperphosphorylation of tau in Alzheimer's disease. J Alzheimers Dis. 2011;23:617&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3377165</ArticleId><ArticleId IdType="pubmed">21157033</ArticleId></ArticleIdList></Reference><Reference><Citation>Radak Z, Hart N, Sarga L, Koltai E, Atalay M, Ohno H, Boldogh I. Exercise plays a preventive role against Alzheimer's disease. J Alzheimers Dis. 2010;20:777&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pubmed">20182027</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissman RA, Lee KF, Vale W, Sawchenko PE. Corticotropin-releasing factor receptors differentially regulate stress-induced tau phosphorylation. J Neurosci. 2007;27:6552&#x2013;6562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672442</ArticleId><ArticleId IdType="pubmed">17567816</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman SM, Mattson MP. Adverse stress, hippocampal networks, and Alzheimer's disease. Neuromolecular Med. 2010;12:56&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2833224</ArticleId><ArticleId IdType="pubmed">19943124</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruitenberg A, Ott A, van Swieten JC, Hofman A, Breteler MM. Incidence of dementia: does gender make a difference? Neurobiol Aging. 2001;22:575&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">11445258</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapolsky RM, Krey LC, McEwen BS. Prolonged glucocorticoid exposure reduces hippocampal neuron number: implications for aging. J Neurosci. 1985;5:1222&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6565052</ArticleId><ArticleId IdType="pubmed">3998818</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawchenko PE, Li HY, Ericsson A. Circuits and mechanisms governing hypothalamic responses to stress: a tale of two paradigms. Prog Brain Res. 2000;122:61&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">10737051</ArticleId></ArticleIdList></Reference><Reference><Citation>Scales TM, Derkinderen P, Leung KY, Byers HL, Ward MA, Price C, Bird IN, Perera T, Kellie S, Williamson R, Anderton BH, Reynolds CH. Tyrosine phosphorylation of tau by the SRC family kinases lck and fyn. Mol Neurodegener. 2011;6:12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3037338</ArticleId><ArticleId IdType="pubmed">21269457</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorrells SF, Sapolsky RM. An inflammatory review of glucocorticoid actions in the CNS. Brain Behav Immun. 2007;21:259&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1997278</ArticleId><ArticleId IdType="pubmed">17194565</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein-Behrens B, Mattson MP, Chang I, Yeh M, Sapolsky R. Stress exacerbates neuron loss and cytoskeletal pathology in the hippocampus. J Neurosci. 1994;14:5373&#x2013;5380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577078</ArticleId><ArticleId IdType="pubmed">8083742</ArticleId></ArticleIdList></Reference><Reference><Citation>Stengel A, Tach&#xe9; Y. Corticotropin-releasing factor signaling and visceral response to stress. Exp Biol Med (Maywood) 2010;235:1168&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169435</ArticleId><ArticleId IdType="pubmed">20881321</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenzel-Poore MP, Cameron VA, Vaughan J, Sawchenko PE, Vale W. Development of Cushing's syndrome in corticotropin-releasing factor transgenic mice. Endocrinology. 1992;130:3378&#x2013;3386.</Citation><ArticleIdList><ArticleId IdType="pubmed">1597149</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaab DF, Bao AM, Lucassen PJ. The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev. 2005;4:141&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15996533</ArticleId></ArticleIdList></Reference><Reference><Citation>Teegarden SL, Bale TL. Effects of stress on dietary preference and intake are dependent on access and stress sensitivity. Physiol Behav. 2008;93:713&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2483328</ArticleId><ArticleId IdType="pubmed">18155095</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe Y, Gould E, McEwen BS. Stress induces atrophy of apical dendrites of hippocampal CA3 pyramidal neurons. Brain Res. 1992;588:341&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">1393587</ArticleId></ArticleIdList></Reference><Reference><Citation>Wellman CL, Izquierdo A, Garrett JE, Martin KP, Carroll J, Millstein R, Lesch KP, Murphy DL, Holmes A. Impaired stress-coping and fear extinction and abnormal corticolimbic morphology in serotonin transporter knock-out mice. J Neurosci. 2007;27:684&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672805</ArticleId><ArticleId IdType="pubmed">17234600</ArticleId></ArticleIdList></Reference><Reference><Citation>West MJ, Slomianka L, Gundersen HJ. Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat Rec. 1991;231:482&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">1793176</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Arnold SE, Schneider JA, Kelly JF, Tang Y, Bennett DA. Chronic psychological distress and risk of Alzheimer's disease in old age. Neuroepidemiology. 2006;27:143&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">16974109</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanagisawa M, Planel E, Ishiguro K, Fujita SC. Starvation induces tau hyperphosphorylation in mouse brain: implications for Alzheimer's disease. FEBS Lett. 1999;461:329&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pubmed">10567721</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan J, Sun XB, Wang HQ, Zhao H, Zhao XY, Xu YX, Guo JC, Zhu CQ. Chronic restraint stress alters the expression and distribution of phosphorylated tau and MAP2 in cortex and hippocampus of rat brain. Brain Res. 2010;1347:132&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">20513368</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang LF, Shi L, Liu H, Meng FT, Liu YJ, Wu HM, Du X, Zhou JN. Increased hippocampal tau phosphorylation and axonal mitochondrial transport in a mouse model of chronic stress. Int J Neuropsychopharmacol. 2011;22:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">21418733</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">14642273</PMID><DateCompleted><Year>2004</Year><Month>01</Month><Day>05</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>40</Volume><Issue>3</Issue><PubDate><Year>2003</Year><Month>Oct</Month><Day>30</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.</ArticleTitle><Pagination><StartPage>471</StartPage><EndPage>483</EndPage><MedlinePgn>471-83</MedlinePgn></Pagination><Abstract><AbstractText>Cyclin-dependent kinase 5 (Cdk5) and its regulatory subunit p35 are integral players in the proper development of the mammalian central nervous system. Proteolytic cleavage of p35 generates p25, leading to aberrant Cdk5 activation. The accumulation of p25 is implicated in several neurodegenerative diseases. In primary neurons, p25 causes apoptosis and tau hyperphosphorylation. Current mouse models expressing p25, however, fail to rigorously recapitulate these phenotypes in vivo. Here, we generated inducible transgenic mouse lines overexpressing p25 in the postnatal forebrain. Induction of p25 preferentially directed Cdk5 to pathological substrates. These animals exhibited neuronal loss in the cortex and hippocampus, accompanied by forebrain atrophy, astrogliosis, and caspase-3 activation. Endogenous tau was hyperphosphorylated at many epitopes, aggregated tau accumulated, and neurofibrillary pathology developed progressively in these animals. Our cumulative findings provide compelling evidence that in vivo deregulation of Cdk5 by p25 plays a causative role in neurodegeneration and the development of neurofibrillary pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>Jonathan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Pathology, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115, USA. jonathan_cruz@hms.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>Huang-Chun</ForeName><Initials>HC</Initials></Author><Author ValidYN="Y"><LastName>Goldman</LastName><ForeName>Joseph A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Shih</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Li-Huei</ForeName><Initials>LH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003902">Detergents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008164">Luminescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C089495">neuronal Cdk5 activator (p25-p35)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>632GS99618</RegistryNumber><NameOfSubstance UI="C025231">sarkosyl</NameOfSubstance></Chemical><Chemical><RegistryNumber>9DLQ4CIU6V</RegistryNumber><NameOfSubstance UI="D011392">Proline</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051360">Cyclin-Dependent Kinase 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.22</RegistryNumber><NameOfSubstance UI="C495905">CDK5 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.22</RegistryNumber><NameOfSubstance UI="C495906">Cdk5 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.22</RegistryNumber><NameOfSubstance UI="D018844">Cyclin-Dependent Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C505407">CASP3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C505409">Casp3 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D020169">Caspases</NameOfSubstance></Chemical><Chemical><RegistryNumber>GMW67QNF9C</RegistryNumber><NameOfSubstance UI="D007930">Leucine</NameOfSubstance></Chemical><Chemical><RegistryNumber>Z711V88R5F</RegistryNumber><NameOfSubstance UI="D012521">Sarcosine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002458" MajorTopicYN="N">Cell Fractionation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051360" MajorTopicYN="N">Cyclin-Dependent Kinase 5</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018844" MajorTopicYN="N">Cyclin-Dependent Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003902" MajorTopicYN="N">Detergents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015151" MajorTopicYN="N">Immunoblotting</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007930" MajorTopicYN="N">Leucine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008164" MajorTopicYN="N">Luminescent Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016253" MajorTopicYN="N">Microscopy, Immunoelectron</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011392" MajorTopicYN="N">Proline</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012521" MajorTopicYN="N">Sarcosine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>12</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>1</Month><Day>6</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>12</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14642273</ArticleId><ArticleId IdType="doi">10.1016/s0896-6273(03)00627-5</ArticleId><ArticleId IdType="pii">S0896627303006275</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10408445</PMID><DateCompleted><Year>1999</Year><Month>07</Month><Day>23</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-0836</ISSN><JournalIssue CitedMedium="Print"><Volume>400</Volume><Issue>6740</Issue><PubDate><Year>1999</Year><Month>Jul</Month><Day>08</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.</ArticleTitle><Pagination><StartPage>173</StartPage><EndPage>177</EndPage><MedlinePgn>173-7</MedlinePgn></Pagination><Abstract><AbstractText>Amyloid-beta peptide (Abeta) seems to have a central role in the neuropathology of Alzheimer's disease (AD). Familial forms of the disease have been linked to mutations in the amyloid precursor protein (APP) and the presenilin genes. Disease-linked mutations in these genes result in increased production of the 42-amino-acid form of the peptide (Abeta42), which is the predominant form found in the amyloid plaques of Alzheimer's disease. The PDAPP transgenic mouse, which overexpresses mutant human APP (in which the amino acid at position 717 is phenylalanine instead of the normal valine), progressively develops many of the neuropathological hallmarks of Alzheimer's disease in an age- and brain-region-dependent manner. In the present study, transgenic animals were immunized with Abeta42, either before the onset of AD-type neuropathologies (at 6 weeks of age) or at an older age (11 months), when amyloid-beta deposition and several of the subsequent neuropathological changes were well established. We report that immunization of the young animals essentially prevented the development of beta-amyloid-plaque formation, neuritic dystrophy and astrogliosis. Treatment of the older animals also markedly reduced the extent and progression of these AD-like neuropathologies. Our results raise the possibility that immunization with amyloid-beta may be effective in preventing and treating Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schenk</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Elan Pharmaceuticals, South San Francisco, California 94080, USA. dschenk@elanpharma.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbour</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Dunn</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Grajeda</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Guido</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Johnson-Wood</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kholodenko</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Lieberburg</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Motter</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Mutter</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Soriano</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Shopp</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Vasquez</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Vandevert</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wogulis</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Yednock</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Games</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Seubert</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002021">Buffers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000683">Serum Amyloid P-Component</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-81-2</RegistryNumber><NameOfSubstance UI="D005620">Freund's Adjuvant</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 1999 Jul 8;400(6740):116-7. doi: 10.1038/22006.</RefSource><PMID Version="1">10408433</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2002 Apr 18;416(6882):677. doi: 10.1038/416677d.</RefSource><PMID Version="1">11961526</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002021" MajorTopicYN="N">Buffers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005620" MajorTopicYN="N">Freund's Adjuvant</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017354" MajorTopicYN="N">Point Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000683" MajorTopicYN="N">Serum Amyloid P-Component</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>7</Month><Day>17</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>23</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>7</Month><Day>17</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId><ArticleId IdType="doi">10.1038/22124</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11140686</PMID><DateCompleted><Year>2001</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-0836</ISSN><JournalIssue CitedMedium="Print"><Volume>408</Volume><Issue>6815</Issue><PubDate><MedlineDate>2000 Dec 21-28</MedlineDate></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>982</StartPage><EndPage>985</EndPage><MedlinePgn>982-5</MedlinePgn></Pagination><Abstract><AbstractText>Vaccinations with amyloid-beta peptide (A beta) can dramatically reduce amyloid deposition in a transgenic mouse model of Alzheimer's disease. To determine if the vaccinations had deleterious or beneficial functional consequences, we tested eight months of A beta vaccination in a different transgenic model for Alzheimer's disease in which mice develop learning deficits as amyloid accumulates. Here we show that vaccination with A beta protects transgenic mice from the learning and age-related memory deficits that normally occur in this mouse model for Alzheimer's disease. During testing for potential deleterious effects of the vaccine, all mice performed superbly on the radial-arm water-maze test of working memory. Later, at an age when untreated transgenic mice show memory deficits, the A beta-vaccinated transgenic mice showed cognitive performance superior to that of the control transgenic mice and, ultimately, performed as well as nontransgenic mice. The A beta-vaccinated mice also had a partial reduction in amyloid burden at the end of the study. This therapeutic approach may thus prevent and, possibly, treat Alzheimer's dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of South Florida, Tampa 33612, USA. dmorgan@hsc.usf.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diamond</LastName><ForeName>D M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Gottschall</LastName><ForeName>P E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Ugen</LastName><ForeName>K E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Dickey</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Duff</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Jantzen</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>DiCarlo</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Wilcock</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Connor</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hatcher</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hope</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Arendash</LastName><ForeName>G W</ForeName><Initials>GW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nature 2001 Aug 9;412(6847):660</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2000 Dec 21-28;408(6815):915-6. doi: 10.1038/35050179.</RefSource><PMID Version="1">11140660</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2002 Apr 18;416(6882):677. doi: 10.1038/416677d.</RefSource><PMID Version="1">11961526</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>1</Month><Day>5</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>1</Month><Day>5</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11140686</ArticleId><ArticleId IdType="doi">10.1038/35050116</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11140685</PMID><DateCompleted><Year>2001</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-0836</ISSN><JournalIssue CitedMedium="Print"><Volume>408</Volume><Issue>6815</Issue><PubDate><MedlineDate>2000 Dec 21-28</MedlineDate></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>979</StartPage><EndPage>982</EndPage><MedlinePgn>979-82</MedlinePgn></Pagination><Abstract><AbstractText>Much evidence indicates that abnormal processing and extracellular deposition of amyloid-beta peptide (A beta), a proteolytic derivative of the beta-amyloid precursor protein (betaAPP), is central to the pathogenesis of Alzheimer's disease (reviewed in ref. 1). In the PDAPP transgenic mouse model of Alzheimer's disease, immunization with A beta causes a marked reduction in burden of the brain amyloid. Evidence that A beta immunization also reduces cognitive dysfunction in murine models of Alzheimer's disease would support the hypothesis that abnormal A beta processing is essential to the pathogenesis of Alzheimer's disease, and would encourage the development of other strategies directed at the 'amyloid cascade'. Here we show that A beta immunization reduces both deposition of cerebral fibrillar A beta and cognitive dysfunction in the TgCRND8 murine model of Alzheimer's disease without, however, altering total levels of A beta in the brain. This implies that either a approximately 50% reduction in dense-cored A beta plaques is sufficient to affect cognition, or that vaccination may modulate the activity/abundance of a small subpopulation of especially toxic A beta species.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Janus</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre for Research in Neurodegenerative Diseases, Department of Medicine, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pearson</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>McLaurin</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mathews</LastName><ForeName>P M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>S D</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Chishti</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Horne</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Heslin</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>French</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mount</LastName><ForeName>H T</ForeName><Initials>HT</Initials></Author><Author ValidYN="Y"><LastName>Nixon</LastName><ForeName>R A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Mercken</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bergeron</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Fraser</LastName><ForeName>P E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>St George-Hyslop</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Westaway</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058228">Islet Amyloid Polypeptide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2000 Dec 21-28;408(6815):915-6. doi: 10.1038/35050179.</RefSource><PMID Version="1">11140660</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2002 Apr 18;416(6882):677. doi: 10.1038/416677d.</RefSource><PMID Version="1">11961526</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058228" MajorTopicYN="N">Islet Amyloid Polypeptide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008647" MajorTopicYN="N">Mesocricetus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008809" MajorTopicYN="N">Mice, Inbred C3H</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>1</Month><Day>5</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>1</Month><Day>5</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11140685</ArticleId><ArticleId IdType="doi">10.1038/35050110</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10932230</PMID><DateCompleted><Year>2000</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1078-8956</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>8</Issue><PubDate><Year>2000</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease.</ArticleTitle><Pagination><StartPage>916</StartPage><EndPage>919</EndPage><MedlinePgn>916-9</MedlinePgn></Pagination><Abstract><AbstractText>One hallmark of Alzheimer disease is the accumulation of amyloid beta-peptide in the brain and its deposition as plaques. Mice transgenic for an amyloid beta precursor protein (APP) mini-gene driven by a platelet-derived (PD) growth factor promoter (PDAPP mice), which overexpress one of the disease-linked mutant forms of the human amyloid precursor protein, show many of the pathological features of Alzheimer disease, including extensive deposition of extracellular amyloid plaques, astrocytosis and neuritic dystrophy. Active immunization of PDAPP mice with human amyloid beta-peptide reduces plaque burden and its associated pathologies. Several hypotheses have been proposed regarding the mechanism of this response. Here we report that peripheral administration of antibodies against amyloid beta-peptide, was sufficient to reduce amyloid burden. Despite their relatively modest serum levels, the passively administered antibodies were able to enter the central nervous system, decorate plaques and induce clearance of preexisting amyloid. When examined in an ex vivo assay with sections of PDAPP or Alzheimer disease brain tissue, antibodies against amyloid beta-peptide triggered microglial cells to clear plaques through Fc receptor-mediated phagocytosis and subsequent peptide degradation. These results indicate that antibodies can cross the blood-brain barrier to act directly in the central nervous system and should be considered as a therapeutic approach for the treatment of Alzheimer disease and other neurological disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bard</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Elan Pharmaceuticals, 800 Gateway Boulevard, South San Francisco, California 94080, USA. fbard@elanpharma.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cannon</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Barbour</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>R L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Games</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Grajeda</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Guido</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Johnson-Wood</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kholodenko</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lieberburg</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Motter</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Soriano</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Vasquez</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Welch</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Seubert</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Schenk</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Yednock</LastName><ForeName>T</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>8</Month><Day>10</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>9</Month><Day>2</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>8</Month><Day>10</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId><ArticleId IdType="doi">10.1038/78682</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11438712</PMID><DateCompleted><Year>2001</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>98</Volume><Issue>15</Issue><PubDate><Year>2001</Year><Month>Jul</Month><Day>17</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>8850</StartPage><EndPage>8855</EndPage><MedlinePgn>8850-5</MedlinePgn></Pagination><Abstract><AbstractText>Active immunization with the amyloid beta (A beta) peptide has been shown to decrease brain A beta deposition in transgenic mouse models of Alzheimer's disease and certain peripherally administered anti-A beta antibodies were shown to mimic this effect. In exploring factors that alter A beta metabolism and clearance, we found that a monoclonal antibody (m266) directed against the central domain of A beta was able to bind and completely sequester plasma A beta. Peripheral administration of m266 to PDAPP transgenic mice, in which A beta is generated specifically within the central nervous system (CNS), results in a rapid 1,000-fold increase in plasma A beta, due, in part, to a change in A beta equilibrium between the CNS and plasma. Although peripheral administration of m266 to PDAPP mice markedly reduces A beta deposition, m266 did not bind to A beta deposits in the brain. Thus, m266 appears to reduce brain A beta burden by altering CNS and plasma A beta clearance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>DeMattos</LastName><ForeName>R B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>The Center for the Study of Nervous System Injury, Washington University School of Medicine, 660 South Euclid Avenue, Box 8111, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bales</LastName><ForeName>K R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Cummins</LastName><ForeName>D J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Dodart</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>S M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>D M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2001</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):8931-2. doi: 10.1073/pnas.171311798.</RefSource><PMID Version="1">11481462</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>7</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>8</Month><Day>31</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>7</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>1</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11438712</ArticleId><ArticleId IdType="pmc">PMC37524</ArticleId><ArticleId IdType="doi">10.1073/pnas.151261398</ArticleId><ArticleId IdType="pii">151261398</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe D J. Science. 1997;275:630&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pubmed">9019820</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde T E, Eckman C B, Younkin S G. Biochim Biophys Acta. 2000;1502:172&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">10899442</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A, Chartier-Harlon M C, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, et al. Nature (London) 1991;349:704&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>St. George-Hyslop P H, Levesque G, Levesque L, Rommens J, Westaway D, Fraser P E. Cold Spring Harbor Symp Quant Biol. 1996;61:559&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">9246482</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim T W, Tanzi R E. Curr Opin Neurobiol. 1997;7:683&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">9384549</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G. J Clin Invest. 1999;104:1321&#x2013;1327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC409849</ArticleId><ArticleId IdType="pubmed">10562290</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Marishima M, Lee H-J, Hama E, Sekine-Aizawa Y, Saido T C. Nat Med. 2000;6:143&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">10655101</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghersi-Egea J-F, Gorevic P D, Ghiso J, Frangione B, Patlak C S, Fensternacher J D. J Neurochem. 1996;67:880&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pubmed">8764620</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata M, Yamada S, Kumar S R, Calero M, Bading J, Frangione B, Holtzman D M, Miller C A, Strickland D K, Ghiso J, Zlokovic B V. J Clin Invest. 2000;106:1489&#x2013;1499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC387254</ArticleId><ArticleId IdType="pubmed">11120756</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski T, Ghiso J, Frangione B. Neurobiol Dis. 1997;4:313&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">9440120</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter W J, Roses A D. Annu Rev Neurosci. 1996;19:53&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">8833436</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y, Ni B, Glinn M, Dodel R C, Bales K R, Zhang Z, Hyslop P, Paul S M. J Neurochem. 1997;69:299&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">9202323</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales K R, Verina T, Dodel R C, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone E M, Little S P, Cummins D J, et al. Nat Genet. 1997;17:263&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354781</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo C, Angelini G, Dapino D, Piccini A, Piombo G, Schettini G, Chen S, Teller J K, Zaccheo D, Gambetti P, Tabaton M. Proc Natl Acad Sci USA. 1998;95:15598&#x2013;15602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC28089</ArticleId><ArticleId IdType="pubmed">9861015</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman D M, Bales K R, Wu S, Bhat P, Parsadanian M, Fagan A M, Chang L K, Sun Y, Paul S M. J Clin Invest. 1999;103:R15&#x2013;R21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC408154</ArticleId><ArticleId IdType="pubmed">10079115</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales K R, Verina T, Cummins D J, Du Y, Dodel J C, Saura J, Fishman C E, DeLong C A, Piccardo P, Petegnief V, et al. Proc Natl Acad Sci USA. 1999;96:15233&#x2013;15238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24803</ArticleId><ArticleId IdType="pubmed">10611368</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman D M, Bales K R, Tenkova T, Fagan A M, Parsadanian M, Sartorius L J, Mackey B, Olney J, McKeel D, Wozniak D, Paul S M. Proc Natl Acad Sci USA. 2000;97:2892&#x2013;2897. . (First Published February 29, 2000; 10.1073/pnas.050004797)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16026</ArticleId><ArticleId IdType="pubmed">10694577</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic B V, Martel C L, Mackic J B, Matsubara E, Wisniewski T, McComb J G, Frangione B, Ghiso J. Biochem Biophys Res Commun. 1994;205:1431&#x2013;1437.</Citation><ArticleIdList><ArticleId IdType="pubmed">7802679</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic B V, Martel C L, Matsubara E, McComb J G, Zheng G, McCluskey R T, Frangione B, Ghiso J. Proc Natl Acad Sci USA. 1996;93:4229&#x2013;4234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39517</ArticleId><ArticleId IdType="pubmed">8633046</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, et al. Proc Natl Acad Sci USA. 1997;94:1550&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19829</ArticleId><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference><Reference><Citation>Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, David D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, et al. Nature (London) 1992;359:325&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">1406936</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos R B, Curtiss L K, Williams D L. J Biol Chem. 1998;273:4206&#x2013;4212.</Citation><ArticleIdList><ArticleId IdType="pubmed">9461617</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Wu S, Bu G, Onifade M K, Patel S N, LaDu M J, Fagan A M, Holtzman D M. J Neurosci. 1998;18:3261&#x2013;3272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792658</ArticleId><ArticleId IdType="pubmed">9547235</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, Permanne B, Zlokovic B, Smith J D, Ladu M J, Rostagno A, et al. Biochem J. 2000;348:359&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1221074</ArticleId><ArticleId IdType="pubmed">10816430</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, Burke R-L, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, et al. Nat Med. 2000;6:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, et al. Nature (London) 1995;373:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic B V, Ghiso J, Mackic J B, McComb J G, Weiss M H, Frangione B. Biochem Biophys Res Commun. 1993;197:1034&#x2013;1040.</Citation><ArticleIdList><ArticleId IdType="pubmed">8280117</ArticleId></ArticleIdList></Reference><Reference><Citation>Motter R, Vigopelfrey C, Kholodenko D, Barbour R, Johnsonwood K, Galasko D, Chang L, Miller B, Clark C, Green R, et al. Ann Neurol. 1995;38:643&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">7574461</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Dickson D W, Trojanowski J Q, Lee V M Y. Exp Neurol. 1999;158:328&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">10415140</ArticleId></ArticleIdList></Reference><Reference><Citation>Knauer M F, Soreghan B, Burdick D, Kosmoski J, Glabe C G. Proc Natl Acad Sci USA. 1992;89:7437&#x2013;7441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC49725</ArticleId><ArticleId IdType="pubmed">1502155</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang A J, Chandswangbhuvana D, Shu T, Henschen A, Glabe C G. J Biol Chem. 1999;274:20650&#x2013;20656.</Citation><ArticleIdList><ArticleId IdType="pubmed">10400697</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D M, Tseng B P, Rydel R E, Podlisny M B, Selkoe D J. Biochemistry. 2000;39:10831&#x2013;10839.</Citation><ArticleIdList><ArticleId IdType="pubmed">10978169</ArticleId></ArticleIdList></Reference><Reference><Citation>Ditaranto K, Tekirian T L, Yang A J. Neurobiol Dis. 2001;8:19&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">11162237</ArticleId></ArticleIdList></Reference><Reference><Citation>Backsai B J, Kajdasz S T, Christie R H, Carter C, Games D, Seubert P, Schenk D, Hyman B T. Nat Med. 2001;7:369&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">11231639</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman D M, Fagan A M, Mackey B, Tenkova T, Sartorius L, Paul S M, Bales K, Ashe K H, Irizzary M C, Hyman B T. Ann Neurol. 2000;47:739&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">10852539</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18461171</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>5</Issue><PubDate><Year>2008</Year><Month>May</Month><Day>07</Day></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy.</ArticleTitle><Pagination><StartPage>e2124</StartPage><MedlinePgn>e2124</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2124</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0002124</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The development of a safe and effective AD vaccine requires a delicate balance between providing an adequate anti-Abeta antibody response sufficient to provide therapeutic benefit, while eliminating an adverse T cell-mediated proinflammatory autoimmune response. To achieve this goal we have designed a prototype chemokine-based DNA epitope vaccine expressing a fusion protein that consists of 3 copies of the self-B cell epitope of Abeta(42) (Abeta(1-11)) , a non-self T helper cell epitope (PADRE), and macrophage-derived chemokine (MDC/CCL22) as a molecular adjuvant to promote a strong anti-inflammatory Th2 phenotype.</AbstractText><AbstractText Label="METHODS AND FINDINGS" NlmCategory="RESULTS">We generated pMDC-3Abeta(1-11)-PADRE construct and immunized 3xTg-AD mouse model starting at age of 3-4 months old. We demonstrated that prophylactic immunizations with the DNA epitope vaccine generated a robust Th2 immune response that induced high titers of anti-Abeta antibody, which in turn inhibited accumulation of Abeta pathology in the brains of older mice. Importantly, vaccination reduced glial activation and prevented the development of behavioral deficits in aged animals without increasing the incidence of microhemorrhages.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Data from this transitional pre-clinical study suggest that our DNA epitope vaccine could be used as a safe and effective strategy for AD therapy. Future safety and immunology studies in large animals with the goal to achieve effective humoral immunity without adverse effects should help to translate this study to human clinical trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Movsesyan</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghochikyan</LastName><ForeName>Anahit</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mkrtichyan</LastName><ForeName>Mikayel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Petrushina</LastName><ForeName>Irina</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Davtyan</LastName><ForeName>Hayk</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Olkhanud</LastName><ForeName>Purevdorj B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Head</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Biragyn</LastName><ForeName>Arya</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Cribbs</LastName><ForeName>David H</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Agadjanyan</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG20241</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG000538</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG00096</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG16573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG020241</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS050895</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG00538</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000096</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020241</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS50895</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS057395</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS057395</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>05</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017780">Malaria Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C401223">PADRE 45</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019444">Vaccines, DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017780" MajorTopicYN="N">Malaria Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019444" MajorTopicYN="N">Vaccines, DNA</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>5</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18461171</ArticleId><ArticleId IdType="pmc">PMC2358976</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0002124</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256:184&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse [see comments]. Nature. 1999;400:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000;408:979&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140685</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408:982&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 2002;5:452&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">11941374</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, Burke RL, Games D, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, et al. Antibodies against beta-Amyloid Slow Cognitive Decline in Alzheimer's Disease. Neuron. 2003;38:547&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">12765607</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I, Rovira MB, Guerra MLS, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004;14:11&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095815</ArticleId><ArticleId IdType="pubmed">14997933</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003;9:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">12640446</ArticleId></ArticleIdList></Reference><Reference><Citation>Orgogozo JM, Gilman S, Dartigues JM, Laurent B, Puel M, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61(1):46&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">12847155</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Hansen L, Adame A, Crews L, Bard F, et al. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology. 2005;64:129&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642916</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology. 2005;64:94&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642910</ArticleId></ArticleIdList></Reference><Reference><Citation>Patton RL, Kalback WM, Esh CL, Kokjohn TA, Van Vickle GD, et al. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol. 2006;169:1048&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698828</ArticleId><ArticleId IdType="pubmed">16936277</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, et al. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol. 2006;65:1040&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pubmed">17086100</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D. Opinion: Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci. 2002;3:824&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">12360327</ArticleId></ArticleIdList></Reference><Reference><Citation>Cribbs DH, Agadjanyan MG. Immunotherapy for Alzheimer's Disease: Potential Problems and Possible Solutions. Current Immunology Reviews. 2005;1:139&#x2013;155.</Citation></Reference><Reference><Citation>Lemere CA, Maier M, Jiang L, Peng Y, Seabrook TJ. Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. Rejuvenation Res. 2006;9:77&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">16608400</ArticleId></ArticleIdList></Reference><Reference><Citation>Agadjanyan MG, Ghochikyan A, Petrushina I, Vasilevko V, Movsesyan N, et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol. 2005;174:1580&#x2013;1586.</Citation><ArticleIdList><ArticleId IdType="pubmed">15661919</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamikonyan G, Necula M, Mkrtichyan M, Ghochikyan A, Petrushina I, et al. Anti-Abeta 1&#x2013;11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils, but not the most toxic oligomers. J Biol Chem. 2007;282:22376&#x2013;22386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2435219</ArticleId><ArticleId IdType="pubmed">17545160</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrushina I, Ghochikyan A, Mktrichyan M, Mamikonyan G, Movsesyan N, et al. Alzheimer's Disease Peptide Epitope Vaccine Reduces Insoluble But Not Soluble/Oligomeric A{beta} Species in Amyloid Precursor Protein Transgenic Mice. J Neurosci. 2007;27:12721&#x2013;12731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2366938</ArticleId><ArticleId IdType="pubmed">18003852</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity. 1994;1:751&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pubmed">7895164</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghochikyan A, Mkrtichyan M, Petrushina I, Movsesyan N, Karapetyan A, et al. Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch. Vaccine. 2006;24:2275&#x2013;2282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2081151</ArticleId><ArticleId IdType="pubmed">16368167</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghochikyan A, Vasilevko V, Petrushina I, Tran M, Sadzikava N, et al. Generation and chracterization of the humoral immune response to DNA immunization with a chimeric &#x3b2;-amyloid-interleukin-4 minigene. Eur J Immunol. 2003;33:3232&#x2013;3241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1524857</ArticleId><ArticleId IdType="pubmed">14635031</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu B, Rosenberg RN, Li L, Boyer PJ, Johnston SA. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch Neurol. 2004;61:1859&#x2013;1864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1482312</ArticleId><ArticleId IdType="pubmed">15596606</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz JG, Salzer U, Mohajeri MH, Franke D, Heinrich J, et al. Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimer's disease. J Mol Med. 2004;82:706&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">15241501</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutzler MA, Cao C, Bai Y, Dong H, Choe PY, et al. Mapping of immune responses following wild-type and mutant ABeta42 plasmid or peptide vaccination in different mouse haplotypes and HLA Class II transgenic mice. Vaccine. 2006;24:4630&#x2013;4639.</Citation><ArticleIdList><ArticleId IdType="pubmed">16157426</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HD, Jin JJ, Maxwell JA, Fukuchi K. Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease. Immunol Lett. 2007;112:30&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2001313</ArticleId><ArticleId IdType="pubmed">17686533</ArticleId></ArticleIdList></Reference><Reference><Citation>Biragyn A, Belyakov IM, Chow YH, Dimitrov DS, Berzofsky JA, et al. DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood. 2002;100:1153&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">12149191</ArticleId></ArticleIdList></Reference><Reference><Citation>Biragyn A, Surenhu M, Yang D, Ruffini PA, Haines BA, et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol. 2001;167:6644&#x2013;6653.</Citation><ArticleIdList><ArticleId IdType="pubmed">11714836</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsonego A, Maron R, Zota V, Selkoe DJ, Weiner HL. Immune hyporespobnsivness to amyloid b-peptide in amyloid precursor protein transgenic mice: mplications for the pathogenesis and treatment of Alzheimer's disease. Proc Nat Acad Sci, USA, 2001;98:10273&#x2013;10278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC56951</ArticleId><ArticleId IdType="pubmed">11517335</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrushina I, Tran M, Sadzikava N, Ghochikyan A, Vasilevko V, et al. Importance of IgG2c isotype in the immune response to b-amyloid in APP/Tg mice. Neurosci Letters. 2003;338:5&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12565127</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Gordon M, Cao C, Ugen KE, Morgan D. Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Abeta antibodies. BMC Neurosci. 2007;8:22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1845169</ArticleId><ArticleId IdType="pubmed">17374155</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasquali JL, Soulas-Sprauel P, Korganow AS, Martin T. Auto-reactive B cells in transgenic mice. J Autoimmun. 2007;29:250&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">17845841</ArticleId></ArticleIdList></Reference><Reference><Citation>Snapper CM, Paul WE. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science. 1987;236:944&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pubmed">3107127</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings LM, Oddo S, Green KN, McGaugh JL, Laferla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 2005;45:675&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748844</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci. 2007;8:663&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, Dickson DW, Lin W-L, Chisholm L, Corral A, et al. Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP. Science. 2001;293:1487&#x2013;1491.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520987</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging. 2003;24:1063&#x2013;1070.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643377</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, et al. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem 2006</Citation><ArticleIdList><ArticleId IdType="pubmed">17056594</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science. 2002;298:1379.</Citation><ArticleIdList><ArticleId IdType="pubmed">12434053</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Jantzen PT, Li Q, Morgan D, Gordon MN. Amyloid-b vaccination, but not nitro-NSAID treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience. 2007 in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1857306</ArticleId><ArticleId IdType="pubmed">17137722</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Chen KS, Kobayashi D, Barbour R, Motter R, et al. Active beta-amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of beta-amyloid. J Neurosci. 2007;27:2654&#x2013;2662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672499</ArticleId><ArticleId IdType="pubmed">17344403</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med. 1998;187:129&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2199181</ArticleId><ArticleId IdType="pubmed">9419219</ArticleId></ArticleIdList></Reference><Reference><Citation>Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med. 1998;187:875&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2212187</ArticleId><ArticleId IdType="pubmed">9500790</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai T, Nagira M, Takagi S, Kakizaki M, Nishimura M, et al. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol. 1999;11:81&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">10050676</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaliauskiene L, Kang S, Sparks K, Zinn KR, Schwiebert LM, et al. Enhancement of MHC class II-restricted responses by receptor-mediated uptake of peptide antigens. J Immunol. 2002;169:2337&#x2013;2345.</Citation><ArticleIdList><ArticleId IdType="pubmed">12193699</ArticleId></ArticleIdList></Reference><Reference><Citation>Biragyn A, Ruffini PA, Coscia M, Harvey LK, Neelapu SS, et al. Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood. 2004;104:1961&#x2013;1969.</Citation><ArticleIdList><ArticleId IdType="pubmed">15191951</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiavo R, Baatar D, Olkhanud P, Indig FE, Restifo N, et al. Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses. Blood. 2006;107:4597&#x2013;4605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1895803</ArticleId><ArticleId IdType="pubmed">16514063</ArticleId></ArticleIdList></Reference><Reference><Citation>Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. Nature Rev Immunol. 2001;1:209&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">11905830</ArticleId></ArticleIdList></Reference><Reference><Citation>Okura Y, Miyakoshi A, Kohyama K, Park IK, Staufenbiel M, et al. Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety. Proc Natl Acad Sci U S A. 2006;103:9619&#x2013;9624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1480456</ArticleId><ArticleId IdType="pubmed">16769900</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsonego A, Zota V, Karni A, Krieger JI, Bar-Or A, et al. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest. 2003;112(3):415&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC166296</ArticleId><ArticleId IdType="pubmed">12897209</ArticleId></ArticleIdList></Reference><Reference><Citation>Cribbs DH, Ghochikyan A, Tran M, Vasilevko V, Petrushina I, et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol. 2003;15:505&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1483061</ArticleId><ArticleId IdType="pubmed">12663680</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18003852</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>46</Issue><PubDate><Year>2007</Year><Month>Nov</Month><Day>14</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice.</ArticleTitle><Pagination><StartPage>12721</StartPage><EndPage>12731</EndPage><MedlinePgn>12721-31</MedlinePgn></Pagination><Abstract><AbstractText>Active vaccination of elderly Alzheimer's disease (AD) patients with fibrillar amyloid-beta peptide (Abeta42), even in the presence of a potent Th1 adjuvant, induced generally low titers of antibodies in a small fraction (approximately 20% responders) of those that received the AN-1792 vaccine. To improve the immunogenicity and reduce the likelihood of inducing adverse autoreactive T-cells specific for Abeta42, we previously tested in wild-type mice an alternative approach for active immunization: an epitope vaccine that selectively initiate B cell responses toward an immunogenic self-epitope of Abeta in the absence of anti-Abeta T cell responses. Here, we describe a second generation epitope vaccine composed of two copies of Abeta(1-11) fused with the promiscuous nonself T cell epitope, PADRE (pan human leukocyte antigen DR-binding peptide) that completely eliminates the autoreactive T cell responses and induces humoral immune responses in amyloid precursor protein transgenic 2576 mice with pre-existing AD-like pathology. Based on the titers of anti-Abeta(1-11) antibody experimental mice were divided into low, moderate and high responders, and for the first time we report a positive correlation between the concentration of anti-Abeta(1-11) antibody and a reduction of insoluble, cerebral Abeta plaques. The reduction of insoluble Abeta deposition was not associated with adverse events, such as CNS T cell or macrophage infiltration or microhemorrhages. Surprisingly, vaccination did not alter the levels of soluble Abeta. Alternatively, early protective immunization before substantial neuropathology, neuronal loss and cognitive deficits have become firmly established may be more beneficial and safer for potential patients, especially if they can be identified in a preclinical stage by the development of antecedent biomarkers of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Petrushina</LastName><ForeName>Irina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>The Institute for Brain Aging and Dementia, University of California, Irvine, Irvine, California 92697-4540, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghochikyan</LastName><ForeName>Anahit</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mktrichyan</LastName><ForeName>Mikayel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mamikonyan</LastName><ForeName>Gregory</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Movsesyan</LastName><ForeName>Nina</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Davtyan</LastName><ForeName>Hayk</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Archita</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Head</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Cribbs</LastName><ForeName>David H</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Agadjanyan</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG20241</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG00096</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG16573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG020241</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS050895</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000096</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020241</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS50895</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D023582">Alzheimer Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017780">Malaria Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C401223">PADRE 45</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023582" MajorTopicYN="N">Alzheimer Vaccines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017780" MajorTopicYN="N">Malaria Vaccines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>5</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18003852</ArticleId><ArticleId IdType="mid">NIHMS47180</ArticleId><ArticleId IdType="pmc">PMC2366938</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3201-07.2007</ArticleId><ArticleId IdType="pii">27/46/12721</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Agadjanyan MG, Ghochikyan A, Petrushina I, Vasilevko V, Movsesyan N, Mkrtichyan M, Saing T, Cribbs DH. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol. 2005;174:1580&#x2013;1586.</Citation><ArticleIdList><ArticleId IdType="pubmed">15661919</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, Snoke K, Serra HM, Kubo RT, Sette A, Grey HM. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity. 1994;1:751&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pubmed">7895164</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, et al. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA. 2003;100:2023&#x2013;2028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC149952</ArticleId><ArticleId IdType="pubmed">12566568</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology. 2005;64:94&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642910</ArticleId></ArticleIdList></Reference><Reference><Citation>Boche D, DeBeer S, Cox A, Wilkinson D, Holmes C, Neal J, Love S, Esiri M, Bridges L, Weller R, Nicoll JA. Eighth International Conference Alzheimer's and Parkinson's Disease: Progress and New Perspectives. Salzburg, Austria: Kenes; 2007. Evidence of a transient increase in cerebral amyloid angiopathy after Abeta42 immunization in human Alzheimer's disease.</Citation></Reference><Reference><Citation>Chai SK, Clavijo P, Tam JP, Zavala F. Immunogenic properties of multiple antigen peptide systems containing defined T and B epitopes. J Immunol. 1992;149:2385&#x2013;2390.</Citation><ArticleIdList><ArticleId IdType="pubmed">1382101</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ, Justice A, McConlogue L, Games D, Freedman SB, Morris RGM. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature. 2000;408:975&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140684</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005;8:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Cribbs DH, Ghochikyan A, Tran M, Vasilevko V, Petrushina I, Sadzikava N, Kesslak P, Kieber-Emmons T, Cotman CW, Agadjanyan MG. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol. 2003;15:505&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1483061</ArticleId><ArticleId IdType="pubmed">12663680</ArticleId></ArticleIdList></Reference><Reference><Citation>Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE. Reduced effectiveness of Abeta1&#x2013;42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging. 2001;22:721&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">11705631</ArticleId></ArticleIdList></Reference><Reference><Citation>Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE. Amyloid-&#x3b2; immunization effectively reduces amyloid deposition in FcR&#x3b3;&#x2212;/&#x2212; knock-out mice. J Neurosci. 2003;23:8532&#x2013;8538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740360</ArticleId><ArticleId IdType="pubmed">13679422</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jong D, Jansen RW, Kremer BP, Verbeek MM. Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. J Gerontol A Biol Sci Med Sci. 2006;61:755&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">16870640</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2001;98:8850&#x2013;8855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC37524</ArticleId><ArticleId IdType="pubmed">11438712</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM. Immunization reverses memory deficits without reducing brain A&#x3b2; burden in Alzheimer's disease model. Nat Neurosci. 2002;5:452&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">11941374</ArticleId></ArticleIdList></Reference><Reference><Citation>Eng LF, Ghirnikar RS, Lee YL. Glial fibrillary acidic protein: GFAP-thirty-one years (1969&#x2013;2000) Neurochem Res. 2000;25:1439&#x2013;1451.</Citation><ArticleIdList><ArticleId IdType="pubmed">11059815</ArticleId></ArticleIdList></Reference><Reference><Citation>Esler WP, Wolfe MS. A portrait of Alzheimer secretases-new features and familiar faces. Science. 2001;293:1449&#x2013;1454.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520976</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Eighth International Conference Alzheimer's and Parkinson's Disease: Progress and New Perspectives. Salzburg, Austria: Kenes; 2007a. Cerebrospinal fluid biomarkers of early stage Alzheimer disease.</Citation></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007b;64:343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I, Rovira MB, Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004;14:11&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095815</ArticleId><ArticleId IdType="pubmed">14997933</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005;64:1563&#x2013;1572.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883317</ArticleId></ArticleIdList></Reference><Reference><Citation>Furlan R, Brambilla E, Sanvito F, Roccatagliata L, Olivieri S, Bergami A, Pluchino S, Uccelli A, Comi G, Martino G. Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain. 2003;126:285&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">12538398</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghochikyan A, Vasilevko V, Petrushina I, Tran M, Sadzikava N, Babikyan D, Movsesyan N, Tian W, Ross TM, Cribbs DH, Agadjanyan MG. Generation and chracterization of the humoral immune response to DNA immunization with a chimeric &#x3b2;-amyloid-interleukin-4 minigene. Eur J Immunol. 2003;33:3232&#x2013;3241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1524857</ArticleId><ArticleId IdType="pubmed">14635031</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM. Clinical effects of A&#x3b2; immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883316</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA. 2003;100:10417&#x2013;10422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC193576</ArticleId><ArticleId IdType="pubmed">12925731</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256:184&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Head E, Garzon-Rodriguez W, Johnson JK, Lott IT, Cotman CW, Glabe C. Oxidation of A&#x3b2; and plaque biogenesis in Alzheimer's disease and Down syndrome. Neurobiol Dis. 2001;8:792&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">11592849</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 2003;38:547&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">12765607</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, A&#x3b2; elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000;408:979&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140685</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid &#x3b2; protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763819</ArticleId><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamoto T, Ogomori K, Tateishi J, Prusiner SB. Formic acid pretreatment enhances immunostaining of cerebral and systemic amyloids. Lab Invest. 1987;57:230&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">2441141</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL, Krafft GA, Finch CE. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 2001;24:219&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">11250006</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med. 2005;11:556&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834427</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Loo DT, Copani A, Pike CJ, Whittemore ER, Walencewicz AJ, Cotman CW. Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci USA. 1993;90:7951&#x2013;7955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47265</ArticleId><ArticleId IdType="pubmed">8367446</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci USA. 1994;91:12243&#x2013;12247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45413</ArticleId><ArticleId IdType="pubmed">7991613</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamikonyan G, Necula M, Mkrtichyan M, Ghochikyan A, Petrushina I, Movsesyan N, Mina E, Kiyatkin A, Glabe C, Cribbs DH, Agadjanyan MG. Anti-Abeta 1&#x2013;11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils, but not the most toxic oligomers. J Biol Chem. 2007;282:22376&#x2013;22386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2435219</ArticleId><ArticleId IdType="pubmed">17545160</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology. 2005;64:129&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642916</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M, French JE, Lambermon MH, Darabie AA, Brown ME, Janus C, Chishti MA, Horne P, Westaway D, Fraser PE, Mount HT, Przybylski M, St George-Hyslop P. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4&#x2013;10 and inhibit cytotoxicity and fibrillogenesis. Nat Med. 2002;8:1263&#x2013;1269.</Citation><ArticleIdList><ArticleId IdType="pubmed">12379850</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408:982&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolic WV, Bai Y, Obregon D, Hou H, Mori T, Zeng J, Ehrhart J, Shytle RD, Giunta B, Morgan D, Town T, Tan T. Transcutaneous &#x3b2;-amyloid peptide immunization of transgenic Alzheimer's mice results in reduced cerebral b-amyloid deposits in the absence of T cell infiltration and microhemorrhage. Proc Natl Acad Sci USA. 2007;104:2507&#x2013;2512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1892920</ArticleId><ArticleId IdType="pubmed">17264212</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003;9:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">12640446</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, Vlachouli C, Wilkinson D, Bayer A, Games D, Seubert P, Schenk D, Holmes C. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol. 2006;65:1040&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pubmed">17086100</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsch RM, Hock C. Eighth International Conference Alzheimer's and Parkinson's Disease: Progress and New Perspectives. Salzburg, Austria: Kenes; 2007. Immunotherapy against beta-amyloid in Alzheimer's disease.</Citation></Reference><Reference><Citation>Orgogozo JM, Gilman S, Dartigues JM, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61:46&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">12847155</ArticleId></ArticleIdList></Reference><Reference><Citation>Pala P, Hussell T, Openshaw PJ. Flow cytometric measurement of intracellular cytokines. J Immunol Methods. 2000;243:107&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">10986410</ArticleId></ArticleIdList></Reference><Reference><Citation>Patton RL, Kalback WM, Esh CL, Kokjohn TA, Van Vickle GD, Luehrs DC, Kuo YM, Lopez J, Brune D, Ferrer I, Masliah E, Newel AJ, Beach TG, Castano EM, Roher AE. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol. 2006;169:1048&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698828</ArticleId><ArticleId IdType="pubmed">16936277</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrushina I, Tran M, Sadzikava N, Ghochikyan A, Vasilevko V, Agadjanyan MG, Cribbs DH. Importance of IgG2c isotype in the immune response to b-amyloid in APP Tg mice. Neurosci Lett. 2003;338:5&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12565127</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science. 2002;298:1379.</Citation><ArticleIdList><ArticleId IdType="pubmed">12434053</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW. Aggregation-related toxicity of synthetic &#x3b2;-amyloid protein in hippocampal cultures. Euro J Pharm. 1991;207:367&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">1783006</ArticleId></ArticleIdList></Reference><Reference><Citation>Price DL, Sisodia SS. Cellular and molecular biology of Alzheimer's disease and animal models. Annu Rev Med. 1994;45:435&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">8198393</ArticleId></ArticleIdList></Reference><Reference><Citation>Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid &#x3b2;. J Neurosci. 2005;25:629&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725332</ArticleId><ArticleId IdType="pubmed">15659599</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D. Opinion: amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci. 2002;3:824&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">12360327</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse [see comments] Nature. 1999;400:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt ML, Robinson KA, Lee VM, Trojanowski JQ. Chemical and immunological heterogeneity of fibrillar amyloid in plaques of Alzheimer's disease and Down's syndrome brains revealed by confocal microscopy. Am J Pathol. 1995;147:503&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1869826</ArticleId><ArticleId IdType="pubmed">7639340</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron. 1991;6:487&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">1673054</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol. 1994;53:438&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">8083687</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam JP. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci USA. 1988;85:5409&#x2013;5413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC281766</ArticleId><ArticleId IdType="pubmed">3399498</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner HL, Selkoe DJ. Inflammation and therapeutic vaccination in CNS diseases. Nature. 2002;420:879&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">12490962</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, Carlson GA, Younkin SG, Ashe KH. The relationship between A&#x3b2; and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2002;22:1858&#x2013;1867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758862</ArticleId><ArticleId IdType="pubmed">11880515</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 2004;1:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC539292</ArticleId><ArticleId IdType="pubmed">15588287</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Jantzen PT, Li Q, Morgan D, Gordon MN. Amyloid-beta vaccination, but not nitro-NSAID treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience. 2007;144:950&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1857306</ArticleId><ArticleId IdType="pubmed">17137722</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">12847155</PMID><DateCompleted><Year>2004</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>1</Issue><PubDate><Year>2003</Year><Month>Jul</Month><Day>08</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization.</ArticleTitle><Pagination><StartPage>46</StartPage><EndPage>54</EndPage><MedlinePgn>46-54</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">AD is characterized by cerebral deposition of beta-amyloid plaques with amyloid beta-peptide (Abeta) 42 as the major peptide constituent, along with neurofibrillary tangles and neuronal loss. In transgenic mice, active immunization against Abeta42 removes these plaques and improves cognitive function. A Phase I study in AD patients demonstrated good safety and tolerability of multiple injections of aggregated Abeta42 (AN1792) with QS-21 as adjuvant.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Three hundred seventy-two patients with mild to moderate AD were randomized to receive IM injections of AN1792 or placebo (4:1) at baseline and at months 1, 3, 6, 9, and 12 in a multicenter Phase II safety, tolerability, and pilot efficacy study. Dosing was terminated after four early reports of meningoencephalitis, but follow-up continued. The study remains blinded, and further results will be reported after its termination.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Symptoms and laboratory findings consistent with meningoencephalitis occurred in 18 of 298 (6%) patients treated with AN1792 compared with 0 of 74 on placebo (p = 0.020). Sixteen of the 18 had received two doses, one had received one dose, and one had received three doses of the study drug before symptoms occurred. The median latency from the first and last injections to symptoms was 75 and 40 days. No case occurred later than 6 months after the first immunization. Anti-Abeta42 antibody titers were not correlated with the occurrence or severity of symptoms or relapses. Twelve patients recovered to or close to baseline within weeks, whereas six remain with disabling cognitive or neurologic sequelae. All 18 patients remain alive to date (December 31, 2002), 6 months to &gt;1 year after symptom onset.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Postvaccination meningoencephalitis occurred without clear relation to serum anti-Abeta42 antibody titers. Potential mechanisms such as T-cell and microglial activation may be responsible and are under consideration to develop a safer anti-Abeta immunotherapy for AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Orgogozo</LastName><ForeName>J-M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Federation of Neurology, CHU Pellegrin, Bordeaux, France. j.m.orgogozo@neuro.u-bordeaux2.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilman</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Dartigues</LastName><ForeName>J-F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Laurent</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Puel</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kirby</LastName><ForeName>L C</ForeName><Initials>LC</Initials></Author><Author ValidYN="Y"><LastName>Jouanny</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Eisner</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Flitman</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Michel</LastName><ForeName>B F</ForeName><Initials>BF</Initials></Author><Author ValidYN="Y"><LastName>Boada</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Frank</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hock</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C437846">AN-1792</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D023582">Alzheimer Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2003 Jul 8;61(1):7-8. doi: 10.1212/wnl.61.1.7.</RefSource><PMID Version="1">12847147</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023582" MajorTopicYN="N">Alzheimer Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008590" MajorTopicYN="N">Meningoencephalitis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010956" MajorTopicYN="N">Plasmapheresis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012449" MajorTopicYN="N">Safety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>7</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>1</Month><Day>30</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>7</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12847155</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000073623.84147.a8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">12640446</PMID><DateCompleted><Year>2003</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1078-8956</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>2003</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.</ArticleTitle><Pagination><StartPage>448</StartPage><EndPage>452</EndPage><MedlinePgn>448-52</MedlinePgn></Pagination><Abstract><AbstractText>Amyloid-beta peptide (Abeta) has a key role in the pathogenesis of Alzheimer disease (AD). Immunization with Abeta in a transgenic mouse model of AD reduces both age-related accumulation of Abeta in the brain and associated cognitive impairment. Here we present the first analysis of human neuropathology after immunization with Abeta (AN-1792). Comparison with unimmunized cases of AD (n = 7) revealed the following unusual features in the immunized case, despite diagnostic neuropathological features of AD: (i) there were extensive areas of neocortex with very few Abeta plaques; (ii) those areas of cortex that were devoid of Abeta plaques contained densities of tangles, neuropil threads and cerebral amyloid angiopathy (CAA) similar to unimmunized AD, but lacked plaque-associated dystrophic neurites and astrocyte clusters; (iii) in some regions devoid of plaques, Abeta-immunoreactivity was associated with microglia; (iv) T-lymphocyte meningoencephalitis was present; and (v) cerebral white matter showed infiltration by macrophages. Findings (i)-(iii) strongly resemble the changes seen after Abeta immunotherapy in mouse models of AD and suggest that the immune response generated against the peptide elicited clearance of Abeta plaques in this patient. The T-lymphocyte meningoencephalitis is likely to correspond to the side effect seen in some other patients who received AN-1792 (refs. 7-9).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nicoll</LastName><ForeName>James A R</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Division of Clinical Neurosciences, University of Southampton, Southampton, UK. J.Nicoll@soton.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilkinson</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Clive</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Steart</LastName><ForeName>Phil</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Markham</LastName><ForeName>Hannah</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Weller</LastName><ForeName>Roy O</ForeName><Initials>RO</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2003</Year><Month>03</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D023582">Alzheimer Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2003 Apr;9(4):389-90. doi: 10.1038/nm847.</RefSource><PMID Version="1">12640449</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2004 Feb;10(2):117-8; author reply 118-9. doi: 10.1038/nm0204-117.</RefSource><PMID Version="1">14760408</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023582" MajorTopicYN="N">Alzheimer Vaccines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008590" MajorTopicYN="N">Meningoencephalitis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2002</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2003</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>3</Month><Day>18</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>5</Month><Day>31</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>3</Month><Day>18</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12640446</ArticleId><ArticleId IdType="doi">10.1038/nm840</ArticleId><ArticleId IdType="pii">nm840</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15883317</PMID><DateCompleted><Year>2006</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>9</Issue><PubDate><Year>2005</Year><Month>May</Month><Day>10</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.</ArticleTitle><Pagination><StartPage>1563</StartPage><EndPage>1572</EndPage><MedlinePgn>1563-72</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Alzheimer disease (AD) is characterized by progressive cerebral atrophy that may be measured using MRI. Reported are MRI findings of a Phase IIa immunotherapy trial in AD prematurely terminated owing to meningoencephalitis in a subset of patients.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess cerebral volume changes in patients immunized with AN1792 (beta-amyloid [Abeta] 1 to 42) who were antibody responders (anti-AN1792 IgG titer of &gt; or =1:2,200) compared with placebo patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This randomized, multicenter, placebo-controlled, double-blind trial of AN1792 225 mug plus QS-21 50 mug included 372 patients with probable AD. Patients received one to three injections of AN1792/QS-21 or saline and were assessed for 12 months. Volumetric MRI was performed pre dose and at month 12 or early termination. Brain, ventricular, and hippocampal volume changes were measured from registered scan pairs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Two hundred eighty-eight patients had paired scans (mean interval 10.9 months). Antibody responders (n = 45) had greater brain volume decrease (3.12 +/- 1.98 vs 2.04 +/- 1.74%; p = 0.007), greater ventricular enlargement as a percentage of baseline brain volume (1.10 +/- 0.75 vs 0.48 +/- 0.40%; p &lt; 0.001), and a nonsignificant greater hippocampal volume decrease (3.78 +/- 2.63 vs 2.86 +/- 3.19%; p = 0.124) than placebo patients (n = 57). Increased losses in brain volume were not reflected in worsening cognitive performance; a composite z score across a Neuropsychological Test Battery showed differences favoring antibody responders over placebo (0.03 +/- 0.39 vs -0.24 +/- 0.45; p = 0.008).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A dissociation between brain volume loss and cognitive function was observed in AN1792/QS-21 antibody responders. The reasons for this remain unclear but include the possibility that volume changes were due to amyloid removal and associated cerebral fluid shifts.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>N C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Institute of Neurology, London, UK. nfox@dementia.ion.ucl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>R S</ForeName><Initials>RS</Initials></Author><Author ValidYN="Y"><LastName>Gilman</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Rossor</LastName><ForeName>M N</ForeName><Initials>MN</Initials></Author><Author ValidYN="Y"><LastName>Griffith</LastName><ForeName>S G</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>Jenkins</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Koller</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><CollectiveName>AN1792(QS-21)-201 Study</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G116/143</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002555" MajorTopicYN="N">Cerebrospinal Fluid</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016233" MajorTopicYN="N">Immunotherapy, Active</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020547" MajorTopicYN="N">Lateral Ventricles</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="N">Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>5</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>1</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>5</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15883317</ArticleId><ArticleId IdType="doi">10.1212/01.WNL.0000159743.08996.99</ArticleId><ArticleId IdType="pii">64/9/1563</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18640458</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>372</Volume><Issue>9634</Issue><PubDate><Year>2008</Year><Month>Jul</Month><Day>19</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.</ArticleTitle><Pagination><StartPage>216</StartPage><EndPage>223</EndPage><MedlinePgn>216-23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(08)61075-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Immunisation of patients with Alzheimer's disease with full-length amyloid-beta peptide (Abeta(42)) can clear amyloid plaques from the brain. Our aim was to assess the relation between Abeta(42) immune response, degree of plaque removal, and long-term clinical outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In June, 2003, consent for long-term clinical follow-up, post-mortem neuropathological examination, or both, was sought from 80 patients (or their carers) who had entered a phase I randomised, placebo-controlled trial of immunisation with Abeta(42) (AN1792, Elan Pharmaceuticals) in September, 2000. The follow-up study was completed in September, 2006. Plaques were assessed in terms of the percentage area of the cortex with Abeta immunostaining (Abeta load) and in terms of characteristic histological features reflecting plaque removal. Survival of all 80 individuals until severe dementia or death was assessed with a Cox proportional hazard model.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">20 participants--15 in the AN1792 group, five in the placebo group--died before follow-up started. A further 22 patients--19 in the AN1792 group, three in the placebo group--died during follow-up. Nine of the deceased patients, all in the AN1792 group, had given consent for post-mortem analysis; one of these who did not die with Alzheimer's disease was excluded. In the remaining eight participants who received immunisation and who were examined neuropathologically, mean Abeta load was lower than in an unimmunised control group that was matched for age at death (2.1% [SE 0.7] in treated participants vs 5.1% [0.9] in controls; mean difference 3.0%, 95% CI 0.6-5.4; p=0.02). Although there was considerable variation in Abeta load and degree of plaque removal among immunised participants, the degree of plaque removal varied significantly with mean antibody response attained during the treatment study period (Kruskal-Wallis p=0.02). Seven of the eight immunised patients who underwent post-mortem assessment, including those with virtually complete plaque removal, had severe end stage dementia before death. In the whole cohort, there was no evidence of improved survival (hazard ratio 0.93, 95% CI 0.43-3.11; p=0.86) or of an improvement in the time to severe dementia (1.18, 0.45-3.11; p=0.73) in the AN1792 group versus the placebo group.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Although immunisation with Abeta(42) resulted in clearance of amyloid plaques in patients with Alzheimer's disease, this clearance did not prevent progressive neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Clive</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Clinical Neurosciences, University of Southampton, Southampton, UK; Moorgreen Hospital, Hampshire Partnership Trust, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boche</LastName><ForeName>Delphine</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Wilkinson</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Yadegarfar</LastName><ForeName>Ghasem</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Hopkins</LastName><ForeName>Vivienne</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Bayer</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Roy W</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>Bullock</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Love</LastName><ForeName>Seth</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Neal</LastName><ForeName>James W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Zotova</LastName><ForeName>Elina</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Nicoll</LastName><ForeName>James A R</ForeName><Initials>JA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0501033</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C437846">AN-1792</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2008 Jul 19;372(9634):180-2. doi: 10.1016/S0140-6736(08)61047-8.</RefSource><PMID Version="1">18640437</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2008 Oct 18;372(9647):1381; author reply 1381-2. doi: 10.1016/S0140-6736(08)61579-2.</RefSource><PMID Version="1">18940458</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2008 Oct 18;372(9647):1381; author reply 1381-2. doi: 10.1016/S0140-6736(08)61578-0.</RefSource><PMID Version="1">18940459</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017321" MajorTopicYN="N">Clinical Trials, Phase I as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>7</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>7</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18640458</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(08)61075-2</ArticleId><ArticleId IdType="pii">S0140-6736(08)61075-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">5662937</PMID><DateCompleted><Year>1968</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1250</ISSN><JournalIssue CitedMedium="Print"><Volume>114</Volume><Issue>512</Issue><PubDate><Year>1968</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.</ArticleTitle><Pagination><StartPage>797</StartPage><EndPage>811</EndPage><MedlinePgn>797-811</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Blessed</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Tomlinson</LastName><ForeName>B E</ForeName><Initials>BE</Initials></Author><Author ValidYN="Y"><LastName>Roth</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003693" MajorTopicYN="N">Delirium</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007360" MajorTopicYN="N">Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="N">Personality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011581" MajorTopicYN="N">Psychological Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1968</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1968</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1968</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">5662937</ArticleId><ArticleId IdType="doi">10.1192/bjp.114.512.797</ArticleId><ArticleId IdType="pii">S000712500009958X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17965777</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9738</ISSN><JournalIssue CitedMedium="Print"><Volume>117</Volume><Issue>11</Issue><PubDate><Year>2007</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Journal of clinical investigation</Title><ISOAbbreviation>J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease.</ArticleTitle><Pagination><StartPage>3393</StartPage><EndPage>3402</EndPage><MedlinePgn>3393-402</MedlinePgn></Pagination><Abstract><AbstractText>Recent epidemiological evidence suggests that some antihypertensive medications may reduce the risk for Alzheimer disease (AD). We screened 55 clinically prescribed antihypertensive medications for AD-modifying activity using primary cortico-hippocampal neuron cultures generated from the Tg2576 AD mouse model. These agents represent all drug classes used for hypertension pharmacotherapy. We identified 7 candidate antihypertensive agents that significantly reduced AD-type beta-amyloid protein (Abeta) accumulation. Through in vitro studies, we found that only 1 of the candidate drugs, valsartan, was capable of attenuating oligomerization of Abeta peptides into high-molecular-weight (HMW) oligomeric peptides, known to be involved in cognitive deterioration. We found that preventive treatment of Tg2576 mice with valsartan significantly reduced AD-type neuropathology and the content of soluble HMW extracellular oligomeric Abeta peptides in the brain. Most importantly, valsartan administration also attenuated the development of Abeta-mediated cognitive deterioration, even when delivered at a dose about 2-fold lower than that used for hypertension treatment in humans. These preclinical studies suggest that certain antihypertensive drugs may have AD-modifying activity and may protect against progressive Abeta-related memory deficits in subjects with AD or in those at high risk of developing AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Lap</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Linghong</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Zhong</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Xianjuan</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Humala</LastName><ForeName>Nelson</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Seror</LastName><ForeName>Ilana</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Bartholomew</LastName><ForeName>Sadie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Rosendorff</LastName><ForeName>Clive</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Pasinetti</LastName><ForeName>Giulio Maria</ForeName><Initials>GM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG002219</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG02219</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Invest</MedlineTA><NlmUniqueID>7802877</NlmUniqueID><ISSNLinking>0021-9738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013777">Tetrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>80M03YXJ7I</RegistryNumber><NameOfSubstance UI="D000068756">Valsartan</NameOfSubstance></Chemical><Chemical><RegistryNumber>HG18B9YRS7</RegistryNumber><NameOfSubstance UI="D014633">Valine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="Y">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="Y">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020836" MajorTopicYN="N">Protein Structure, Quaternary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011897" MajorTopicYN="N">Random Allocation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013028" MajorTopicYN="Y">Space Perception</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013777" MajorTopicYN="Y">Tetrazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014633" MajorTopicYN="N">Valine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068756" MajorTopicYN="N">Valsartan</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17965777</ArticleId><ArticleId IdType="pmc">PMC2040315</ArticleId><ArticleId IdType="doi">10.1172/JCI31547</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lopez-Arrieta J.M., Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst. Rev. 2002;3:CD000147.</Citation><ArticleIdList><ArticleId IdType="pubmed">11279679</ArticleId></ArticleIdList></Reference><Reference><Citation>Khachaturian A.S., et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County study. Arch. Neurol. 2006;63:686&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pubmed">16533956</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Z.C., Viitanen M., Winblad B., Fratiglioni L. Low blood pressure and incidence of dementia in a very old sample: dependent on initial cognition. J. Am. Geriatr. Soc. 1999;47:723&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">10366174</ArticleId></ArticleIdList></Reference><Reference><Citation>Forette F., et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch. Intern. Med. 2002;162:2046&#x2013;2052.</Citation><ArticleIdList><ArticleId IdType="pubmed">12374512</ArticleId></ArticleIdList></Reference><Reference><Citation>in&#x2019;t Veld B.A., Ruitenberg A., Hofman A., Stricker B.H., Breteler M.M. Antihypertensive drugs and incidence of dementia: the Rotterdam study. Neurobiol. Aging. 2000;54:A397.</Citation><ArticleIdList><ArticleId IdType="pubmed">11378246</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer R.B. Stroke in the elderly treated for systolic hypertension (SHEP). J. Insur. Med. 1991;23:265&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">10148513</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M.J., Bird A.S., Blizard R.A., Mann A.H. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council&#x2019;s treatment trial of hypertension in older adults. BMJ. 1996;312:801&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2350726</ArticleId><ArticleId IdType="pubmed">8608285</ArticleId></ArticleIdList></Reference><Reference><Citation>Lithell H., et al. The Study on Cognition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J. Hypertens. 2004;22:1605&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pubmed">15257185</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D.J. Alzheimer&#x2019;s disease: genes, proteins, and therapy. Physiol. Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Busciglio J., Gabuzda D.H., Matsudaira P., Yankner B.A. Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc. Natl. Acad. Sci. U. S. A. 1993;90:2092&#x2013;2096.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46027</ArticleId><ArticleId IdType="pubmed">8446635</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C., et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature. 1992;359:322&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">1383826</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoji M., et al. Production of the Alzheimer amyloid-beta protein by normal proteolytic processing. Science. 1992;258:126&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">1439760</ArticleId></ArticleIdList></Reference><Reference><Citation>Esch F.S., et al. Cleavage of amyloid-beta peptide during constitutive processing of its precursor. Science. 1990;248:1122&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">2111583</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D.M., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S., et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotilinek L.A., et al. Reversible memory loss in a mouse transgenic model of Alzheimer&#x2019;s disease. J. Neurosci. 2002;22:6331&#x2013;6335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758140</ArticleId><ArticleId IdType="pubmed">12151510</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen J.S., et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. U. S. A. 2006;103:5161&#x2013;5166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1405622</ArticleId><ArticleId IdType="pubmed">16549764</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary J.P., et al. Natural oligomers of the amyloid-[beta] protein specifically disrupt cognitive function. Nat. Neurosci. 2005;8:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I., et al. Amyloid beta protein immunotherapy neutralizes A beta oligomers that disrupt synaptic plasticity in vivo. Nat. Med. 2005;11:556&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834427</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirjany M., Ho L., Pasinetti G.M. Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity. J. Pharmacol. Exp. Ther. 2002;301:494&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">11961048</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein W.L. Abeta toxicity in Alzheimer&#x2019;s disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 2002;41:345&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">12176077</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaurin J., et al. Therapeutically effective antibodies against amyloid-[beta] peptide target amyloid-[beta] residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 2002;8:1263&#x2013;1269.</Citation><ArticleIdList><ArticleId IdType="pubmed">12379850</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto S., et al. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist &#x2014; 1st communication: antihypertensive effects of valsartan in hypertensive models. Arzneimittelforschung. 1997;47:604&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pubmed">9205773</ArticleId></ArticleIdList></Reference><Reference><Citation>PDR.net. http://www.pdr.net.</Citation></Reference><Reference><Citation>Hsiao K., et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods. 1984;11:47&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">6471907</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D. Mechanisms of A beta plaque clearance following passive A beta immunization. Neurodegener. Dis. 2005;2:261&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">16909007</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z., et al. Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer&#x2019;s disease. Neurobiol. Aging. 2007;28:824&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pubmed">16769157</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., et al. Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease. Faseb J. 2005;19:659&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">15650008</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T., et al. Age-dependent changes in brain, CSF, and plasma amyloid {beta} protein in the Tg2576 transgenic mouse model of Alzheimer&#x2019;s disease. J. Neurosci. 2001;21:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763819</ArticleId><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda K., et al. Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency. J. Endocrinol. 2003;176:237&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">12553872</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaurin J., et al. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. 2006;12:801&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">16767098</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallet P.G., et al. A comparative study of histological and immunohistochemical methods for neurofibrillary tangles and senile plaques in Alzheimer&#x2019;s disease. Acta Neuropathologica. 1992;83:170&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">1373017</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho L., et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer&#x2019;s disease. FASEB J. 2004;18:902&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">15033922</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu W.Q., et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem. 1998;273:32730&#x2013;32738.</Citation><ArticleIdList><ArticleId IdType="pubmed">9830016</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z., et al. Connective tissue growth factor (CTGF) expression in the brain is a downstream effector of insulin resistance- associated promotion of Alzheimer&#x2019;s disease beta-amyloid neuropathology. FASEB J. 2005;19:2081&#x2013;2082.</Citation><ArticleIdList><ArticleId IdType="pubmed">16186174</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Ongil S., et al. Crosstalk between mesangial and endothelial cells: angiotensin II down-regulates endothelin-converting enzyme 1. Cell. Physiol. Biochem. 2005;15:135&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">15665524</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi M., et al. Localization of rat endothelin-converting enzyme to vascular endothelial cells and some secretory cells. Biochem. J. 1995;311:657&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1136050</ArticleId><ArticleId IdType="pubmed">7487910</ArticleId></ArticleIdList></Reference><Reference><Citation>Martindale. 2007. The complete drug reference. The Pharmaceutical Press. http://www.medicinescomplete.com/mc/martindale/current/contents.htm.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22753410</PMID><DateCompleted><Year>2012</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN><JournalIssue CitedMedium="Internet"><Volume>287</Volume><Issue>36</Issue><PubDate><Year>2012</Year><Month>Aug</Month><Day>31</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Swedish Alzheimer mutation induces mitochondrial dysfunction mediated by HSP60 mislocalization of amyloid precursor protein (APP) and beta-amyloid.</ArticleTitle><Pagination><StartPage>30317</StartPage><EndPage>30327</EndPage><MedlinePgn>30317-27</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M112.365890</ELocationID><Abstract><AbstractText>Alzheimer disease (AD) is a complex disorder that involves numerous cellular and subcellular alterations including impairments in mitochondrial homeostasis. To better understand the role of mitochondrial dysfunction in the pathogenesis of AD, we analyzed brains from clinically well-characterized human subjects and from the 3xTg-AD mouse model of AD. We find A&#x3b2; and critical components of the &#x3b3;-secretase complex, presenilin-1, -2, and nicastrin, accumulate in the mitochondria. We used a proteomics approach to identify binding partners and show that heat shock protein 60 (HSP60), a molecular chaperone localized to mitochondria and the plasma membrane, specifically associates with APP. We next generated stable neural cell lines expressing human wild-type or Swedish APP, and provide corroborating in vitro evidence that HSP60 mediates translocation of APP to the mitochondria. Viral-mediated shRNA knockdown of HSP60 attenuates APP and A&#x3b2; mislocalization to the mitochondria. Our findings identify a novel interaction between APP and HSP60, which accounts for its translocation to the mitochondria.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Walls</LastName><ForeName>Ken Carlson</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, CA 92697-4545, USA. kwalls@uci.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coskun</LastName><ForeName>Pinar</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Gallegos-Perez</LastName><ForeName>Jose Luis</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Zadourian</LastName><ForeName>Nineli</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Freude</LastName><ForeName>Kristine</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Rasool</LastName><ForeName>Suhail</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Blurton-Jones</LastName><ForeName>Mathew</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Kim Nicholas</ForeName><Initials>KN</Initials></Author><Author ValidYN="Y"><LastName>LaFerla</LastName><ForeName>Frank Michael</ForeName><Initials>FM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG027544</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027544</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>021928</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>06</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018834">Chaperonin 60</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C557066">Hspd1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018834" MajorTopicYN="N">Chaperonin 60</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>8</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22753410</ArticleId><ArticleId IdType="pmc">PMC3436283</ArticleId><ArticleId IdType="doi">10.1074/jbc.M112.365890</ArticleId><ArticleId IdType="pii">S0021-9258(20)63133-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Reddy P. H., Beal M. F. (2005) Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Res. Brain Res. Rev. 49, 618&#x2013;632</Citation><ArticleIdList><ArticleId IdType="pubmed">16269322</ArticleId></ArticleIdList></Reference><Reference><Citation>Coskun P., Wyrembak J., Schriner S., Chen H. W., Marciniack C., Laferla F., Wallace D. C. (2011) A mitochondrial etiology of Alzheimer and Parkinson disease. Biochim. Biophys. Acta 1820, 553&#x2013;564</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270155</ArticleId><ArticleId IdType="pubmed">21871538</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow R. H. (2007) Pathogenesis of Alzheimer's disease. Clin. Interv. Aging 2, 347&#x2013;359</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2685260</ArticleId><ArticleId IdType="pubmed">18044185</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao J., Irwin R. W., Zhao L., Nilsen J., Hamilton R. T., Brinton R. D. (2009) Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 106, 14670&#x2013;14675</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732886</ArticleId><ArticleId IdType="pubmed">19667196</ArticleId></ArticleIdList></Reference><Reference><Citation>Takuma K., Yao J., Huang J., Xu H., Chen X., Luddy J., Trillat A. C., Stern D. M., Arancio O., Yan S. S. (2005) ABAD enhances A&#x3b2;-induced cell stress via mitochondrial dysfunction. FASEB J. 19, 597&#x2013;598</Citation><ArticleIdList><ArticleId IdType="pubmed">15665036</ArticleId></ArticleIdList></Reference><Reference><Citation>Manczak M., Anekonda T. S., Henson E., Park B. S., Quinn J., Reddy P. H. (2006) Mitochondria are a direct site of A&#x3b2; accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 15, 1437&#x2013;1449</Citation><ArticleIdList><ArticleId IdType="pubmed">16551656</ArticleId></ArticleIdList></Reference><Reference><Citation>Caspersen C., Wang N., Yao J., Sosunov A., Chen X., Lustbader J. W., Xu H. W., Stern D., McKhann G., Yan S. D. (2005) Mitochondrial A&#x3b2;: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J. 19, 2040&#x2013;2041</Citation><ArticleIdList><ArticleId IdType="pubmed">16210396</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillardon F., Rist W., Kussmaul L., Vogel J., Berg M., Danzer K., Kraut N., Hengerer B. (2007) Proteomic and functional alterations in brain mitochondria from Tg2576 mice occur before amyloid plaque deposition. Proteomics 7, 605&#x2013;616</Citation><ArticleIdList><ArticleId IdType="pubmed">17309106</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardoso S. M., Santana I., Swerdlow R. H., Oliveira C. R. (2004) Mitochondria dysfunction of Alzheimer's disease cybrids enhances A&#x3b2; toxicity. J. Neurochem. 89, 1417&#x2013;1426</Citation><ArticleIdList><ArticleId IdType="pubmed">15189344</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow R. H., Kish S. J. (2002) Mitochondria in Alzheimer's disease. Int. Rev. Neurobiol. 53, 341&#x2013;385</Citation><ArticleIdList><ArticleId IdType="pubmed">12512346</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Su B., Siedlak S. L., Moreira P. I., Fujioka H., Wang Y., Casadesus G., Zhu X. (2008) Amyloid-&#x3b2; overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc. Natl. Acad. Sci. U.S.A. 105, 19318&#x2013;19323</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2614759</ArticleId><ArticleId IdType="pubmed">19050078</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardoso S. M., Santos S., Swerdlow R. H., Oliveira C. R. (2001) Functional mitochondria are required for amyloid &#x3b2;-mediated neurotoxicity. FASEB J. 15, 1439&#x2013;1441</Citation><ArticleIdList><ArticleId IdType="pubmed">11387250</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi L., Prabhu B. M., Galati D. F., Avadhani N. G., Anandatheerthavarada H. K. (2006) Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J. Neurosci. 26, 9057&#x2013;9068</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675337</ArticleId><ArticleId IdType="pubmed">16943564</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson C. A., Frykman S., Farmery M. R., Tjernberg L. O., Nilsberth C., Pursglove S. E., Ito A., Winblad B., Cowburn R. F., Thyberg J., Ankarcrona M. (2004) Nicastrin, presenilin, APH-1, and PEN-2 form active &#x3b3;-secretase complexes in mitochondria. J. Biol. Chem. 279, 51654&#x2013;51660</Citation><ArticleIdList><ArticleId IdType="pubmed">15456764</ArticleId></ArticleIdList></Reference><Reference><Citation>Du H., Guo L., Fang F., Chen D., Sosunov A. A., McKhann G. M., Yan Y., Wang C., Zhang H., Molkentin J. D., Gunn-Moore F. J., Vonsattel J. P., Arancio O., Chen J. X., Yan S. D. (2008) Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat. Med. 14, 1097&#x2013;1105</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789841</ArticleId><ArticleId IdType="pubmed">18806802</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin J., Hulette C., Wang Y., Zhang T., Pan C., Wadhwa R., Zhang J. (2006) Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: relevance to Parkinson disease. Mol. Cell Proteomics 5, 1193&#x2013;1204</Citation><ArticleIdList><ArticleId IdType="pubmed">16565515</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakahira H., Breuer P., Hayer-Hartl M. K., Hartl F. U. (2002) Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity. Proc. Natl. Acad. Sci. U.S.A. 99, 16412&#x2013;16418</Citation><ArticleIdList><ArticleId IdType="pmc">PMC139902</ArticleId><ArticleId IdType="pubmed">12189209</ArticleId></ArticleIdList></Reference><Reference><Citation>Dou F., Netzer W. J., Tanemura K., Li F., Hartl F. U., Takashima A., Gouras G. K., Greengard P., Xu H. (2003) Chaperones increase association of tau protein with microtubules. Proc. Natl. Acad. Sci. U.S.A. 100, 721&#x2013;726</Citation><ArticleIdList><ArticleId IdType="pmc">PMC141063</ArticleId><ArticleId IdType="pubmed">12522269</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta R. S., Ramachandra N. B., Bowes T., Singh B. (2008) Unusual cellular disposition of the mitochondrial molecular chaperones Hsp60, Hsp70 and Hsp10. Novartis Found Symp. 291, 59&#x2013;68; discussion 69&#x2013;73, 137&#x2013;140</Citation><ArticleIdList><ArticleId IdType="pubmed">18575266</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanju&#xe1;n Szklarz L. K., Guiard B., Rissler M., Wiedemann N., Kozjak V., van der Laan M., Lohaus C., Marcus K., Meyer H. E., Chacinska A., Pfanner N., Meisinger C. (2005) Inactivation of the mitochondrial heat shock protein zim17 leads to aggregation of matrix hsp70s followed by pleiotropic effects on morphology and protein biogenesis. J. Mol. Biol. 351, 206&#x2013;218</Citation><ArticleIdList><ArticleId IdType="pubmed">15992824</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S., Caccamo A., Shepherd J. D., Murphy M. P., Golde T. E., Kayed R., Metherate R., Mattson M. P., Akbari Y., LaFerla F. M. (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular A&#x3b2; and synaptic dysfunction. Neuron 39, 409&#x2013;421</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder E. Y., Deitcher D. L., Walsh C., Arnold-Aldea S., Hartwieg E. A., Cepko C. L. (1992) Multipotent neural cell lines can engraft and participate in development of mouse cerebellum. Cell 68, 33&#x2013;51</Citation><ArticleIdList><ArticleId IdType="pubmed">1732063</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultan A. S., Miyoshi E., Ihara Y., Nishikawa A., Tsukada Y., Taniguchi N. (1997) Bisecting GlcNAc structures act as negative sorting signals for cell surface glycoproteins in forskolin-treated rat hepatoma cells. J. Biol. Chem. 272, 2866&#x2013;2872</Citation><ArticleIdList><ArticleId IdType="pubmed">9006930</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls K. C., Ghosh A. P., Ballestas M. E., Klocke B. J., Roth K. A. (2009) bcl-2/Adenovirus E1B 19-kd interacting protein 3 (BNIP3) regulates hypoxia-induced neural precursor cell death. J. Neuropathol. Exp. Neurol. 68, 1326&#x2013;1338</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2791349</ArticleId><ArticleId IdType="pubmed">19915483</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls K. C., Ghosh A. P., Franklin A. V., Klocke B. J., Ballestas M., Shacka J. J., Zhang J., Roth K. A. (2010) Lysosome dysfunction triggers Atg7-dependent neural apoptosis. J. Biol. Chem. 285, 10497&#x2013;10507</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856257</ArticleId><ArticleId IdType="pubmed">20123985</ArticleId></ArticleIdList></Reference><Reference><Citation>Freude K. K., Penjwini M., Davis J. L., LaFerla F. M., Blurton-Jones M. (2011) Soluble amyloid precursor protein induces rapid neural differentiation of human embryonic stem cells. J. Biol. Chem. 286, 24264-24274</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3129207</ArticleId><ArticleId IdType="pubmed">21606494</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R., Head E., Sarsoza F., Saing T., Cotman C. W., Necula M., Margol L., Wu J., Breydo L., Thompson J. L., Rasool S., Gurlo T., Butler P., Glabe C. G. (2007) Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neurodegener. 2, 18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2100048</ArticleId><ArticleId IdType="pubmed">17897471</ArticleId></ArticleIdList></Reference><Reference><Citation>Blass J. P., Sheu R. K., Gibson G. E. (2000) Inherent abnormalities in energy metabolism in Alzheimer disease. Interaction with cerebrovascular compromise. Ann. N.Y. Acad. Sci. 903, 204&#x2013;221</Citation><ArticleIdList><ArticleId IdType="pubmed">10818509</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhein V., Song X., Wiesner A., Ittner L. M., Baysang G., Meier F., Ozmen L., Bluethmann H., Dr&#xf6;se S., Brandt U., Savaskan E., Czech C., G&#xf6;tz J., Eckert A. (2009) Amyloid-&#x3b2; and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc. Natl. Acad. Sci. U.S.A. 106, 20057&#x2013;20062</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774257</ArticleId><ArticleId IdType="pubmed">19897719</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton M. J., Lee E. B., Sun E., Wong M. M., Leight S., Zhang B., Trojanowski J. Q., Lee V. M. (2011) Intraneuronal APP, not free A&#x3b2; peptides in 3xTg-AD mice: implications for tau versus A&#x3b2;-mediated Alzheimer neurodegeneration. J. Neurosci. 31, 7691&#x2013;7699</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3118598</ArticleId><ArticleId IdType="pubmed">21613482</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta R. S. (1990) Mitochondria, molecular chaperone proteins and the in vivo assembly of microtubules. Trends Biochem. Sci. 15, 415&#x2013;418</Citation><ArticleIdList><ArticleId IdType="pubmed">1980553</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi L., Ohno M. (2011) Mitochondrial dysfunction and accumulation of the beta-secretase-cleaved C-terminal fragment of APP in Alzheimer's disease transgenic mice. Neurobiol. Dis. 45, 417&#x2013;424</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3225635</ArticleId><ArticleId IdType="pubmed">21933711</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T. T., Hsu C. T., Kuo Y. M. (2009) Amyloid precursor protein, heat-shock proteins, and Bcl-2 form a complex in mitochondria and modulate mitochondria function and apoptosis in N2a cells. Mech. Ageing Dev. 130, 592&#x2013;601</Citation><ArticleIdList><ArticleId IdType="pubmed">19622370</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaden D., Voigt P., Munter L. M., Bobowski K. D., Schaefer M., Multhaup G. (2009) Subcellular localization and dimerization of APLP1 are strikingly different from APP and APLP2. J. Cell Sci. 122, 368&#x2013;377</Citation><ArticleIdList><ArticleId IdType="pubmed">19126676</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra D., Choy G., Tang D. G. (2007) Cytosolic accumulation of HSP60 during apoptosis with or without apparent mitochondrial release: evidence that its pro-apoptotic or pro-survival functions involve differential interactions with caspase-3. J. Biol. Chem. 282, 31289&#x2013;31301</Citation><ArticleIdList><ArticleId IdType="pubmed">17823127</ArticleId></ArticleIdList></Reference><Reference><Citation>Xanthoudakis S., Roy S., Rasper D., Hennessey T., Aubin Y., Cassady R., Tawa P., Ruel R., Rosen A., Nicholson D. W. (1999) Hsp60 accelerates the maturation of pro-caspase-3 by upstream activator proteases during apoptosis. EMBO J. 18, 2049&#x2013;2056</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1171289</ArticleId><ArticleId IdType="pubmed">10205159</ArticleId></ArticleIdList></Reference><Reference><Citation>Veereshwarayya V., Kumar P., Rosen K. M., Mestril R., Querfurth H. W. (2006) Differential effects of mitochondrial heat shock protein 60 and related molecular chaperones to prevent intracellular &#x3b2;-amyloid-induced inhibition of complex IV and limit apoptosis. J. Biol. Chem. 281, 29468&#x2013;29478</Citation><ArticleIdList><ArticleId IdType="pubmed">16887805</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22042871</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>108</Volume><Issue>49</Issue><PubDate><Year>2011</Year><Month>Dec</Month><Day>06</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease and has therapeutic implications for neurocognitive disorders.</ArticleTitle><Pagination><StartPage>E1339</StartPage><EndPage>E1348</EndPage><MedlinePgn>E1339-48</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1102349108</ELocationID><Abstract><AbstractText>The adult hippocampus plays a central role in memory formation, synaptic plasticity, and neurogenesis. The subgranular zone of the dentate gyrus contains neural progenitor cells with self-renewal and multilineage potency. Transgene expression of familial Alzheimer's disease-linked mutants of &#x3b2;-amyloid precursor protein (APP) and presenilin-1 leads to a significant inhibition of neurogenesis, which is potentially linked to age-dependent memory loss. To investigate the effect of neurogenesis on cognitive function in a relevant disease model, FGF2 gene is delivered bilaterally to the hippocampi of APP+presenilin-1 bigenic mice via an adenoassociated virus serotype 2/1 hybrid (AAV2/1-FGF2). Animals injected with AAV2/1-FGF2 at a pre- or postsymptomatic stage show significantly improved spatial learning in the radial arm water maze test. A neuropathological investigation demonstrates that AAV2/1-FGF2 injection enhances the number of doublecortin, BrdU/NeuN, and c-fos-positive cells in the dentate gyrus, and the clearance of fibrillar amyloid-&#x3b2; peptide (A&#x3b2;) in the hippocampus. AAV2/1-FGF2 injection also enhances long-term potentiation in another APP mouse model (J20) compared with control AAV2/1-GFP-injected littermates. An in vitro study confirmed the enhanced neurogenesis of mouse neural stem cells by direct AAV2/1-FGF2 infection in an A&#x3b2; oligomer-sensitive manner. Further, FGF2 enhances A&#x3b2; phagocytosis in primary cultured microglia, and reduces A&#x3b2; production from primary cultured neurons after AAV2/1-FGF2 infection. Thus, our data indicate that virus-mediated FGF2 gene delivery has potential as an alternative therapy of Alzheimer's disease and possibly other neurocognitive disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kiyota</LastName><ForeName>Tomomi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of Nebraska Medical Center, Omaha, NE 68198, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingraham</LastName><ForeName>Kaitlin L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Jacobsen</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Huangui</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ikezu</LastName><ForeName>Tsuneya</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 NS043985</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG032600</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG032600</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS043985</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016760">Proto-Oncogene Proteins c-fos</NameOfSubstance></Chemical><Chemical><RegistryNumber>103107-01-3</RegistryNumber><NameOfSubstance UI="D016222">Fibroblast Growth Factor 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21282</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="N">Dentate Gyrus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000229" MajorTopicYN="N">Dependovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016222" MajorTopicYN="N">Fibroblast Growth Factor 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057507" MajorTopicYN="N">Mice, 129 Strain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016760" MajorTopicYN="N">Proto-Oncogene Proteins c-fos</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>10</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22042871</ArticleId><ArticleId IdType="pmc">PMC3241747</ArticleId><ArticleId IdType="doi">10.1073/pnas.1102349108</ArticleId><ArticleId IdType="pii">1102349108</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Martin JB. Molecular basis of the neurodegenerative disorders. N Engl J Med. 1999;340:1970&#x2013;1980.</Citation><ArticleIdList><ArticleId IdType="pubmed">10379022</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: A decade of discoveries paves the way for therapeutic breakthroughs. Nat Med. 2004;10:1055&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pubmed">15459709</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004;430:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006;368:387&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408:982&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, et al. Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA. 2003;100:2023&#x2013;2028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC149952</ArticleId><ArticleId IdType="pubmed">12566568</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock C, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 2003;38:547&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">12765607</ArticleId></ArticleIdList></Reference><Reference><Citation>Birmingham K, Frantz S. Set back to Alzheimer vaccine studies. Nat Med. 2002;8:199&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">11875473</ArticleId></ArticleIdList></Reference><Reference><Citation>Check E. Nerve inflammation halts trial for Alzheimer's drug. Nature. 2002;415:462.</Citation><ArticleIdList><ArticleId IdType="pubmed">11823817</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson C, et al. Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab. Alzheimers Dement. 2011;7:396&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">21784350</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbimbo BP, Giardina GA. &#x3b3;-secretase inhibitors and modulators for the treatment of Alzheimer's disease: Disappointments and hopes. Curr Top Med Chem. 2011;11:1555&#x2013;1570.</Citation><ArticleIdList><ArticleId IdType="pubmed">21510832</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuszynski MH, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med. 2005;11:551&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15852017</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagahara AH, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med. 2009;15:331&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838375</ArticleId><ArticleId IdType="pubmed">19198615</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishop KM, et al. Therapeutic potential of CERE-110 (AAV2-NGF): Targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons. Exp Neurol. 2008;211:574&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2709503</ArticleId><ArticleId IdType="pubmed">18439998</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K, et al. AAV2/5-mediated NGF gene delivery protects septal cholinergic neurons following axotomy. Brain Res. 2005;1061:107&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">16226726</ArticleId></ArticleIdList></Reference><Reference><Citation>Mud&#xf2; G, et al. The FGF-2/FGFRs neurotrophic system promotes neurogenesis in the adult brain. J Neural Transm. 2009;116:995&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pubmed">19291360</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K, et al. Neurogenesis and aging: FGF-2 and HB-EGF restore neurogenesis in hippocampus and subventricular zone of aged mice. Aging Cell. 2003;2:175&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">12882410</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn HG, Winkler J, Kempermann G, Thal LJ, Gage FH. Epidermal growth factor and fibroblast growth factor-2 have different effects on neural progenitors in the adult rat brain. J Neurosci. 1997;17:5820&#x2013;5829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573198</ArticleId><ArticleId IdType="pubmed">9221780</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao Y, Black IB, DiCicco-Bloom E. In vivo neurogenesis is inhibited by neutralizing antibodies to basic fibroblast growth factor. J Neurobiol. 1997;33:289&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">9298766</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldauf K, Reymann KG. Influence of EGF/bFGF treatment on proliferation, early neurogenesis and infarct volume after transient focal ischemia. Brain Res. 2005;1056:158&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">16125154</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapieha PS, Peltier M, Rendahl KG, Manning WC, Di Polo A. Fibroblast growth factor-2 gene delivery stimulates axon growth by adult retinal ganglion cells after acute optic nerve injury. Mol Cell Neurosci. 2003;24:656&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">14664816</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuettauf F, et al. Adeno-associated viruses containing bFGF or BDNF are neuroprotective against excitotoxicity. Curr Eye Res. 2004;29:379&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">15764082</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K, Henry RA, Hughes SM, Connor B. Creating a neurogenic environment: The role of BDNF and FGF2. Mol Cell Neurosci. 2007;36:108&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">17656107</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Tung YC, Li B, Iqbal K, Grundke-Iqbal I. Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis. Neurobiol Aging. 2007;28:1148&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pubmed">16859812</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings BJ, Su JH, Cotman CW. Neuritic involvement within bFGF immunopositive plaques of Alzheimer's disease. Exp Neurol. 1993;124:315&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">8287930</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiyota T, et al. CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic mice. FASEB J. 2010;24:3093&#x2013;3102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2909296</ArticleId><ArticleId IdType="pubmed">20371618</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiyota T, et al. AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice. Gene Ther. 2011 10.1038/gt.2011.126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241853</ArticleId><ArticleId IdType="pubmed">21918553</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiyota T, et al. AAV1/2-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses gliosis, beta-amyloidosis, and learning impairment of APP/PS1 mice. Mol Ther. 2009;17:803&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2709991</ArticleId><ArticleId IdType="pubmed">19277012</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 2004;1:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC539292</ArticleId><ArticleId IdType="pubmed">15588287</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner JP, Black IB, DiCicco-Bloom E. Stimulation of neonatal and adult brain neurogenesis by subcutaneous injection of basic fibroblast growth factor. J Neurosci. 1999;19:6006&#x2013;6016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6783097</ArticleId><ArticleId IdType="pubmed">10407038</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao MS, Shetty AK. Efficacy of doublecortin as a marker to analyse the absolute number and dendritic growth of newly generated neurons in the adult dentate gyrus. Eur J Neurosci. 2004;19:234&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">14725617</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham WC, et al. Correlations between immediate early gene induction and the persistence of long-term potentiation. Neuroscience. 1993;56:717&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">8255430</ArticleId></ArticleIdList></Reference><Reference><Citation>Worley PF, et al. Thresholds for synaptic activation of transcription factors in hippocampus: correlation with long-term enhancement. J Neurosci. 1993;13:4776&#x2013;4786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576344</ArticleId><ArticleId IdType="pubmed">8229198</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeds NW, Williams BL, Bickford PC. Tissue plasminogen activator induction in Purkinje neurons after cerebellar motor learning. Science. 1995;270:1992&#x2013;1994.</Citation><ArticleIdList><ArticleId IdType="pubmed">8533091</ArticleId></ArticleIdList></Reference><Reference><Citation>Vann SD, Brown MW, Aggleton JP. Fos expression in the rostral thalamic nuclei and associated cortical regions in response to different spatial memory tests. Neuroscience. 2000;101:983&#x2013;991.</Citation><ArticleIdList><ArticleId IdType="pubmed">11113347</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson HA. Immediate-early genes, neuronal plasticity, and memory. Biochem Cell Biol. 1992;70:729&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pubmed">1482550</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragunow M. A role for immediate-early transcription factors in learning and memory. Behav Genet. 1996;26:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">8754252</ArticleId></ArticleIdList></Reference><Reference><Citation>Malenka RC, Bear MF. LTP and LTD: An embarrassment of riches. Neuron. 2004;44:5&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450156</ArticleId></ArticleIdList></Reference><Reference><Citation>Saganich MJ, et al. Deficits in synaptic transmission and learning in amyloid precursor protein (APP) transgenic mice require C-terminal cleavage of APP. J Neurosci. 2006;26:13428&#x2013;13436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674728</ArticleId><ArticleId IdType="pubmed">17192425</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiyota T, et al. CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PLoS ONE. 2009;4:e6197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2703798</ArticleId><ArticleId IdType="pubmed">19593388</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin BK, et al. ADAPT Research Group Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): Results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol. 2008;65:896&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2925195</ArticleId><ArticleId IdType="pubmed">18474729</ArticleId></ArticleIdList></Reference><Reference><Citation>Shors TJ, et al. Neurogenesis in the adult is involved in the formation of trace memories. Nature. 2001;410:372&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">11268214</ArticleId></ArticleIdList></Reference><Reference><Citation>Aimone JB, Wiles J, Gage FH. Computational influence of adult neurogenesis on memory encoding. Neuron. 2009;61:187&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2670434</ArticleId><ArticleId IdType="pubmed">19186162</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasaki TR, et al. Neural stem cells improve memory in an inducible mouse model of neuronal loss. J Neurosci. 2007;27:11925&#x2013;11933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673368</ArticleId><ArticleId IdType="pubmed">17978032</ArticleId></ArticleIdList></Reference><Reference><Citation>Donovan MH, et al. Decreased adult hippocampal neurogenesis in the PDAPP mouse model of Alzheimer's disease. J Comp Neurol. 2006;495:70&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">16432899</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng R, et al. Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces. Neuron. 2001;32:911&#x2013;926.</Citation><ArticleIdList><ArticleId IdType="pubmed">11738035</ArticleId></ArticleIdList></Reference><Reference><Citation>Haughey NJ, et al. Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. J Neurochem. 2002;83:1509&#x2013;1524.</Citation><ArticleIdList><ArticleId IdType="pubmed">12472904</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen PH, et al. The presenilin-1 familial Alzheimer disease mutant P117L impairs neurogenesis in the hippocampus of adult mice. Exp Neurol. 2004;188:224&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">15246822</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K, et al. Enhanced neurogenesis in Alzheimer's disease transgenic (PDGF-APPSw,Ind) mice. Proc Natl Acad Sci USA. 2004;101:13363&#x2013;13367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC516572</ArticleId><ArticleId IdType="pubmed">15340159</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JM, et al. Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2010;107:6498&#x2013;6503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2851948</ArticleId><ArticleId IdType="pubmed">20231471</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnus T, Chan A, Savill J, Toyka KV, Gold R. Phagocytotic removal of apoptotic, inflammatory lymphocytes in the central nervous system by microglia and its functional implications. J Neuroimmunol. 2002;130:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12225883</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldau B, Shetty AK. Behavior of neural stem cells in the Alzheimer brain. Cell Mol Life Sci. 2008;65:2372&#x2013;2384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3612503</ArticleId><ArticleId IdType="pubmed">18500448</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian X, Davis AA, Goderie SK, Temple S. FGF2 concentration regulates the generation of neurons and glia from multipotent cortical stem cells. Neuron. 1997;18:81&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">9010207</ArticleId></ArticleIdList></Reference><Reference><Citation>Stachowiak MK, Maher PA, Joy A, Mordechai E, Stachowiak EK. Nuclear localization of functional FGF receptor 1 in human astrocytes suggests a novel mechanism for growth factor action. Brain Res Mol Brain Res. 1996;38:161&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">8737680</ArticleId></ArticleIdList></Reference><Reference><Citation>Stachowiak MK, Maher PA, Stachowiak EK. Integrative nuclear signaling in cell development&#x2014;a role for FGF receptor-1. DNA Cell Biol. 2007;26:811&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pubmed">18021009</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunham-Ems SM, et al. Fibroblast growth factor receptor-1 (FGFR1) nuclear dynamics reveal a novel mechanism in transcription control. Mol Biol Cell. 2009;20:2401&#x2013;2412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2675620</ArticleId><ArticleId IdType="pubmed">19261810</ArticleId></ArticleIdList></Reference><Reference><Citation>Stachowiak EK, Fang X, Myers J, Dunham S, Stachowiak MK. cAMP-induced differentiation of human neuronal progenitor cells is mediated by nuclear fibroblast growth factor receptor-1 (FGFR1) J Neurochem. 2003;84:1296&#x2013;1312.</Citation><ArticleIdList><ArticleId IdType="pubmed">12614330</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:710&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">8878479</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein RL, et al. Measurements of vector-derived neurotrophic factor and green fluorescent protein levels in the brain. Methods. 2002;28:286&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">12413428</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao W, et al. Gene therapy vectors based on adeno-associated virus type 1. J Virol. 1999;73:3994&#x2013;4003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC104178</ArticleId><ArticleId IdType="pubmed">10196295</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao X, Li J, McCown TJ, Samulski RJ. Gene transfer by adeno-associated virus vectors into the central nervous system. Exp Neurol. 1997;144:113&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">9126160</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto M, et al. Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am J Pathol. 2005;166:1475&#x2013;1485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1606401</ArticleId><ArticleId IdType="pubmed">15855647</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto M, et al. Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol. 2007;170:680&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851864</ArticleId><ArticleId IdType="pubmed">17255335</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson ER, et al. Hippocampal synaptic dysfunction in a murine model of human immunodeficiency virus type 1 encephalitis. Neuroscience. 2003;118:359&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">12699772</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson ER, Gendelman HE, Xiong H. Memantine protects hippocampal neuronal function in murine human immunodeficiency virus type 1 encephalitis. J Neurosci. 2004;24:7194&#x2013;7198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729180</ArticleId><ArticleId IdType="pubmed">15306653</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato S, et al. Spatial learning impairment, enhanced CDK5/p35 activity, and downregulation of NMDA receptor expression in transgenic mice expressing tau-tubulin kinase 1. J Neurosci. 2008;28:14511&#x2013;14521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671237</ArticleId><ArticleId IdType="pubmed">19118186</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan X, et al. HIV-1 reduces Abeta-degrading enzymatic activities in primary human mononuclear phagocytes. J Immunol. 2011;186:6925&#x2013;6932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3110566</ArticleId><ArticleId IdType="pubmed">21551363</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, et al. Actin interaction and regulation of cyclin-dependent kinase 5/p35 complex activity. J Neurochem. 2010;116:192&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2957558</ArticleId><ArticleId IdType="pubmed">20492361</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokuraku K, Marquardt M, Ikezu T. Real-time imaging and quantification of amyloid-beta peptide aggregates by novel quantum-dot nanoprobes. PLoS ONE. 2009;4:e8492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2794548</ArticleId><ArticleId IdType="pubmed">20041162</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuszynski MH, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med. 2005;11:551&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15852017</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagahara AH, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med. 2009;15:331&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838375</ArticleId><ArticleId IdType="pubmed">19198615</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn HG, Winkler J, Kempermann G, Thal LJ, Gage FH. Epidermal growth factor and fibroblast growth factor-2 have different effects on neural progenitors in the adult rat brain. J Neurosci. 1997;17:5820&#x2013;5829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573198</ArticleId><ArticleId IdType="pubmed">9221780</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Tung YC, Li B, Iqbal K, Grundke-Iqbal I. Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis. Neurobiol Aging. 2007;28:1148&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pubmed">16859812</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings BJ, Su JH, Cotman CW. Neuritic involvement within bFGF immunopositive plaques of Alzheimer's disease. Exp Neurol. 1993;124:315&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">8287930</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22824372</PMID><DateCompleted><Year>2013</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1742-2094</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2012</Year><Month>Jul</Month><Day>23</Day></PubDate></JournalIssue><Title>Journal of neuroinflammation</Title><ISOAbbreviation>J Neuroinflammation</ISOAbbreviation></Journal><ArticleTitle>Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study.</ArticleTitle><Pagination><StartPage>179</StartPage><MedlinePgn>179</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1742-2094-9-179</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study undertakes a systematic and comprehensive analysis of brain gene expression profiles of immune/inflammation-related genes in aging and Alzheimer's disease (AD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In a well-powered microarray study of young (20 to 59 years), aged (60 to 99 years), and AD (74 to 95 years) cases, gene responses were assessed in the hippocampus, entorhinal cortex, superior frontal gyrus, and post-central gyrus.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Several novel concepts emerge. First, immune/inflammation-related genes showed major changes in gene expression over the course of cognitively normal aging, with the extent of gene response far greater in aging than in AD. Of the 759 immune-related probesets interrogated on the microarray, approximately 40% were significantly altered in the SFG, PCG and HC with increasing age, with the majority upregulated (64 to 86%). In contrast, far fewer immune/inflammation genes were significantly changed in the transition to AD (approximately 6% of immune-related probesets), with gene responses primarily restricted to the SFG and HC. Second, relatively few significant changes in immune/inflammation genes were detected in the EC either in aging or AD, although many genes in the EC showed similar trends in responses as in the other brain regions. Third, immune/inflammation genes undergo gender-specific patterns of response in aging and AD, with the most pronounced differences emerging in aging. Finally, there was widespread upregulation of genes reflecting activation of microglia and perivascular macrophages in the aging brain, coupled with a downregulation of select factors (TOLLIP, fractalkine) that when present curtail microglial/macrophage activation. Notably, essentially all pathways of the innate immune system were upregulated in aging, including numerous complement components, genes involved in toll-like receptor signaling and inflammasome signaling, as well as genes coding for immunoglobulin (Fc) receptors and human leukocyte antigens I and II.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Unexpectedly, the extent of innate immune gene upregulation in AD was modest relative to the robust response apparent in the aged brain, consistent with the emerging idea of a critical involvement of inflammation in the earliest stages, perhaps even in the preclinical stage, of AD. Ultimately, our data suggest that an important strategy to maintain cognitive health and resilience involves reducing chronic innate immune activation that should be initiated in late midlife.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cribbs</LastName><ForeName>David H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, 1226 Gillespie NRF, Irvine, CA 92697, USA. cribbs@uci.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berchtold</LastName><ForeName>Nicole C</ForeName><Initials>NC</Initials></Author><Author ValidYN="Y"><LastName>Perreau</LastName><ForeName>Victoria</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Coleman</LastName><ForeName>Paul D</ForeName><Initials>PD</Initials></Author><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Tenner</LastName><ForeName>Andrea J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Cotman</LastName><ForeName>Carl W</ForeName><Initials>CW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG034667</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG000538</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG023173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG16573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neuroinflammation</MedlineTA><NlmUniqueID>101222974</NlmUniqueID><ISSNLinking>1742-2094</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="Y">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040081" MajorTopicYN="N">Protein Array Analysis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>7</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22824372</ArticleId><ArticleId IdType="pmc">PMC3419089</ArticleId><ArticleId IdType="doi">10.1186/1742-2094-9-179</ArticleId><ArticleId IdType="pii">1742-2094-9-179</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rogers J, Webster S, Lue LF, Brachova L, Civin WH, Emmerling M, Shivers B, Walker D, McGeer P. Inflammation and Alzheimer&#x2019;s disease pathogenesis. Neurobiol Aging. 1996;17:681&#x2013;686. doi: 10.1016/0197-4580(96)00115-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(96)00115-7</ArticleId><ArticleId IdType="pubmed">8892340</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I. et al.Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383&#x2013;421. doi: 10.1016/S0197-4580(00)00124-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(00)00124-X</ArticleId><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Rogers J, McGeer EG. Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12&#x2009;years. J Alzheimers Dis. 2006;9:271&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914866</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006;12:1005&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pubmed">16960575</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging. 2007;28:639&#x2013;647. doi: 10.1016/j.neurobiolaging.2006.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.03.013</ArticleId><ArticleId IdType="pubmed">16697488</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol. 2007;184:69&#x2013;91. doi: 10.1016/j.jneuroim.2006.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2006.11.017</ArticleId><ArticleId IdType="pubmed">17222916</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao X, Cummins DJ, Paul SM. Neuroinflammation-induced acceleration of amyloid deposition in the APPV717F transgenic mouse. Eur J Neurosci. 2001;14:474&#x2013;482. doi: 10.1046/j.0953-816x.2001.01666.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0953-816x.2001.01666.x</ArticleId><ArticleId IdType="pubmed">11553297</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Bora SH, Xu G, Borchelt DR, Price DL, Koliatsos VE. Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol Dis. 2003;14:133&#x2013;145. doi: 10.1016/S0969-9961(03)00069-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0969-9961(03)00069-X</ArticleId><ArticleId IdType="pubmed">13678674</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci. 2005;25:8843&#x2013;8853. doi: 10.1523/JNEUROSCI.2868-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2868-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725603</ArticleId><ArticleId IdType="pubmed">16192374</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlpine FE, Lee JK, Harms AS, Ruhn KA, Blurton-Jones M, Hong J, Das P, Golde TE, LaFerla FM, Oddo S, Blesch A, Tansey MG. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis. 2009;34:163&#x2013;177. doi: 10.1016/j.nbd.2009.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2009.01.006</ArticleId><ArticleId IdType="pmc">PMC2948857</ArticleId><ArticleId IdType="pubmed">19320056</ArticleId></ArticleIdList></Reference><Reference><Citation>DiCarlo G, Wilcock D, Henderson D, Gordon M, Morgan D. Intrahippocampal LPS injections reduce Abeta load in APP&#x2009;+&#x2009;PS1 transgenic mice. Neurobiol Aging. 2001;22:1007&#x2013;1012. doi: 10.1016/S0197-4580(01)00292-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(01)00292-5</ArticleId><ArticleId IdType="pubmed">11755009</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, O'Banion MK. Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest. 2007;117:1595&#x2013;1604. doi: 10.1172/JCI31450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI31450</ArticleId><ArticleId IdType="pmc">PMC1878531</ArticleId><ArticleId IdType="pubmed">17549256</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkes CA, McLaurin J. Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc Natl Acad Sci USA. 2009;106:1261&#x2013;1266. doi: 10.1073/pnas.0805453106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0805453106</ArticleId><ArticleId IdType="pmc">PMC2633563</ArticleId><ArticleId IdType="pubmed">19164591</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer LJ, Hoes AW, Ott A, Hofman A, Breteler MM, Stricker BH. in 't Veld BA. NSAIDs and incident Alzheimer's disease. The Rotterdam Study. Neurobiol Aging. 1998;19:607&#x2013;611. doi: 10.1016/S0197-4580(98)00096-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(98)00096-7</ArticleId><ArticleId IdType="pubmed">10192221</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvanitakis Z, Grodstein F, Bienias JL, Schneider JA, Wilson RS, Kelly JF, Evans DA, Bennett DA. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology. 2008;70:2219&#x2013;2225. doi: 10.1212/01.wnl.0000313813.48505.86.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000313813.48505.86</ArticleId><ArticleId IdType="pubmed">18519870</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, Cole GM. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci. 2000;20:5709&#x2013;5714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772529</ArticleId><ArticleId IdType="pubmed">10908610</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL, Citron M, Landreth G. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci. 2003;23:7504&#x2013;7509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740758</ArticleId><ArticleId IdType="pubmed">12930788</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O'Banion K, Klockgether T, Van Leuven F, Landreth GE. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain. 2005;128:1442&#x2013;1453. doi: 10.1093/brain/awh452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh452</ArticleId><ArticleId IdType="pubmed">15817521</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitner JC, Zandi PP. Do nonsteroidal antiinflammatory drugs reduce the risk of Alzheimer's disease? N Engl J Med. 2001;345:1567&#x2013;1568. doi: 10.1056/NEJM200111223452110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200111223452110</ArticleId><ArticleId IdType="pubmed">11794225</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS. The inflammatory hypothesis of Alzheimer disease: dead or alive? Alzheimer Dis Assoc Disord. 2008;22:4&#x2013;5. doi: 10.1097/WAD.0b013e318166ca4c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e318166ca4c</ArticleId><ArticleId IdType="pubmed">18317241</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinert CL, McCaffrey LD, Breitner JC. Alzheimer's Disease anti-inflammatory prevention trial: design, methods, and baseline results. Alzheimers Dement. 2009;5:93&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866447</ArticleId><ArticleId IdType="pubmed">19328435</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitner JC, Haneuse SJ, Walker R, Dublin S, Crane PK, Gray SL, Larson EB. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology. 2009;72:1899&#x2013;1905. doi: 10.1212/WNL.0b013e3181a18691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181a18691</ArticleId><ArticleId IdType="pmc">PMC2690966</ArticleId><ArticleId IdType="pubmed">19386997</ArticleId></ArticleIdList></Reference><Reference><Citation>Arends YM, Duyckaerts C, Rozemuller JM, Eikelenboom P, Hauw JJ. Microglia, amyloid and dementia in Alzheimer disease. A correlative study. Neurobiol Aging. 2000;21:39&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">10794847</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoozemans JJ, van Haastert ES, Veerhuis R, Arendt T, Scheper W, Eikelenboom P, Rozemuller AJ. Maximal COX-2 and ppRb expression in neurons occurs during early Braak stages prior to the maximal activation of astrocytes and microglia in Alzheimer's disease. J Neuroinflammation. 2005;2:27. doi: 10.1186/1742-2094-2-27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-2-27</ArticleId><ArticleId IdType="pmc">PMC1308853</ArticleId><ArticleId IdType="pubmed">16300681</ArticleId></ArticleIdList></Reference><Reference><Citation>Vehmas AK, Kawas CH, Stewart WF, Troncoso JC. Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiol Aging. 2003;24:321&#x2013;331. doi: 10.1016/S0197-4580(02)00090-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(02)00090-8</ArticleId><ArticleId IdType="pubmed">12498966</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoozemans JJ, Veerhuis R, Rozemuller JM, Eikelenboom P. Soothing the inflamed brain: effect of non-steroidal anti-inflammatory drugs on Alzheimer's disease pathology. CNS Neurol Disord Drug Targets. 2011;10:57&#x2013;67. doi: 10.2174/187152711794488665.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/187152711794488665</ArticleId><ArticleId IdType="pubmed">21143138</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelenboom P, Veerhuis R, van Exel E, Hoozemans JJ, Rozemuller AJ, van Gool WA. The early involvement of the innate immunity in the pathogenesis of late-onset Alzheimer's disease: neuropathological, epidemiological and genetic evidence. Curr Alzheimer Res. 2011;8:142&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">21345167</ArticleId></ArticleIdList></Reference><Reference><Citation>Berchtold NC, Cribbs DH, Coleman PD, Rogers J, Head E, Kim R, Beach T, Miller C, Troncoso J, Trojanowski JQ, Zielke HR, Cotman CW. Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci USA. 2008;105:15605&#x2013;15610. doi: 10.1073/pnas.0806883105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0806883105</ArticleId><ArticleId IdType="pmc">PMC2563070</ArticleId><ArticleId IdType="pubmed">18832152</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J Neurosci. 2005;25:9275&#x2013;9284. doi: 10.1523/JNEUROSCI.2614-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2614-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725757</ArticleId><ArticleId IdType="pubmed">16207887</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol. 2007;7:161&#x2013;167. doi: 10.1038/nri2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2015</ArticleId><ArticleId IdType="pubmed">17220915</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, Culliford D, Perry VH. Systemic inflammation and disease progression in Alzheimer disease. Neurology. 2009;73:768&#x2013;774. doi: 10.1212/WNL.0b013e3181b6bb95.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181b6bb95</ArticleId><ArticleId IdType="pmc">PMC2848584</ArticleId><ArticleId IdType="pubmed">19738171</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31:e15. doi: 10.1093/nar/gng015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gng015</ArticleId><ArticleId IdType="pmc">PMC150247</ArticleId><ArticleId IdType="pubmed">12582260</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4:249&#x2013;264. doi: 10.1093/biostatistics/4.2.249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biostatistics/4.2.249</ArticleId><ArticleId IdType="pubmed">12925520</ArticleId></ArticleIdList></Reference><Reference><Citation>McClintick JN, Edenberg HJ. Effects of filtering by Present call on analysis of microarray experiments. BMC Bioinformatics. 2006;7:49. doi: 10.1186/1471-2105-7-49.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-7-49</ArticleId><ArticleId IdType="pmc">PMC1409797</ArticleId><ArticleId IdType="pubmed">16448562</ArticleId></ArticleIdList></Reference><Reference><Citation>Fearon DT. Innate immunity - beginning to fulfill its promise? Nat Immunol. 2000;1:102&#x2013;103. doi: 10.1038/77773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/77773</ArticleId><ArticleId IdType="pubmed">11248799</ArticleId></ArticleIdList></Reference><Reference><Citation>Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001;1:135&#x2013;145. doi: 10.1038/35100529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35100529</ArticleId><ArticleId IdType="pubmed">11905821</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P, Lieberburg I. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci USA. 1992;89:10016&#x2013;10020. doi: 10.1073/pnas.89.21.10016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.89.21.10016</ArticleId><ArticleId IdType="pmc">PMC50268</ArticleId><ArticleId IdType="pubmed">1438191</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradt BM, Kolb WP, Cooper NR. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J Exp Med. 1998;188:431&#x2013;438. doi: 10.1084/jem.188.3.431.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.188.3.431</ArticleId><ArticleId IdType="pmc">PMC2212467</ArticleId><ArticleId IdType="pubmed">9687521</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Walter S, Stagi M, Cherny D, Letiembre M, Schulz-Schaeffer W, Heine H, Penke B, Neumann H, Fassbender K. LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. Brain. 2005;128:1778&#x2013;1789. doi: 10.1093/brain/awh531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh531</ArticleId><ArticleId IdType="pubmed">15857927</ArticleId></ArticleIdList></Reference><Reference><Citation>Fassbender K, Walter S, Kuhl S, Landmann R, Ishii K, Bertsch T, Stalder AK, Muehlhauser F, Liu Y, Ulmer AJ, Rivest S, Lentschat A, Gulbins E, Jucker M, Staufenbiel M, Brechtel K, Walter J, Multhaup G, Penke B, Adachi Y, Hartmann T, Beyreuther K. The LPS receptor (CD14) links innate immunity with Alzheimer's disease. FASEB J. 2004;18:203&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">14597556</ArticleId></ArticleIdList></Reference><Reference><Citation>Bate C, Veerhuis R, Eikelenboom P, Williams A. Microglia kill amyloid-beta1-42 damaged neurons by a CD14-dependent process. Neuroreport. 2004;15:1427&#x2013;1430. doi: 10.1097/01.wnr.0000132203.76836.16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.wnr.0000132203.76836.16</ArticleId><ArticleId IdType="pubmed">15194867</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K, Iribarren P, Hu J, Chen J, Gong W, Cho EH, Lockett S, Dunlop NM, Wang JM. Activation of Toll-like receptor 2 on microglia promotes cell uptake of Alzheimer disease-associated amyloid beta peptide. J Biol Chem. 2006;281:3651&#x2013;3659.</Citation><ArticleIdList><ArticleId IdType="pubmed">16339765</ArticleId></ArticleIdList></Reference><Reference><Citation>Tahara K, Kim HD, Jin JJ, Maxwell JA, Li L, Fukuchi K. Role of toll-like receptor signalling in Abeta uptake and clearance. Brain. 2006;129:3006&#x2013;3019. doi: 10.1093/brain/awl249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl249</ArticleId><ArticleId IdType="pmc">PMC2445613</ArticleId><ArticleId IdType="pubmed">16984903</ArticleId></ArticleIdList></Reference><Reference><Citation>Udan ML, Ajit D, Crouse NR, Nichols MR. Toll-like receptors 2 and 4 mediate Abeta(1&#x2013;42) activation of the innate immune response in a human monocytic cell line. J Neurochem. 2008;104:524&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">17986235</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin JJ, Kim HD, Maxwell JA, Li L, Fukuchi K. Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation. 2008;5:23. doi: 10.1186/1742-2094-5-23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-5-23</ArticleId><ArticleId IdType="pmc">PMC2430555</ArticleId><ArticleId IdType="pubmed">18510752</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang SC, Lathia JD, Selvaraj PK, Jo DG, Mughal MR, Cheng A, Siler DA, Markesbery WR, Arumugam TV, Mattson MP. Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Exp Neurol. 2008;213:114&#x2013;121. doi: 10.1016/j.expneurol.2008.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2008.05.014</ArticleId><ArticleId IdType="pmc">PMC2597513</ArticleId><ArticleId IdType="pubmed">18586243</ArticleId></ArticleIdList></Reference><Reference><Citation>Landreth GE, Reed-Geaghan EG. Toll-like receptors in Alzheimer's disease. Curr Top Microbiol Immunol. 2009;336:137&#x2013;153. doi: 10.1007/978-3-642-00549-7_8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-642-00549-7_8</ArticleId><ArticleId IdType="pmc">PMC3032986</ArticleId><ArticleId IdType="pubmed">19688332</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE. CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J Neurosci. 2009;29:11982&#x2013;11992. doi: 10.1523/JNEUROSCI.3158-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3158-09.2009</ArticleId><ArticleId IdType="pmc">PMC2778845</ArticleId><ArticleId IdType="pubmed">19776284</ArticleId></ArticleIdList></Reference><Reference><Citation>Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, Fitzgerald KA, Latz E, Moore KJ, Golenbock DT. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol. 2008;9:857&#x2013;865. doi: 10.1038/ni.1636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1636</ArticleId><ArticleId IdType="pmc">PMC3101478</ArticleId><ArticleId IdType="pubmed">18604209</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenner AJ. Complement in Alzheimer's disease: opportunities for modulating protective and pathogenic events. Neurobiol Aging. 2001;22:849&#x2013;861. doi: 10.1016/S0197-4580(01)00301-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(01)00301-3</ArticleId><ArticleId IdType="pubmed">11754992</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, Quigg RJ, Masliah E. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci USA. 2002;99:10837&#x2013;10842. doi: 10.1073/pnas.162350199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.162350199</ArticleId><ArticleId IdType="pmc">PMC125059</ArticleId><ArticleId IdType="pubmed">12119423</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Li R, Mastroeni D, Grover A, Leonard B, Ahern G, Cao P, Kolody H, Vedders L, Kolb WP, Sabbagh M. Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes. Neurobiol Aging. 2006;27:1733&#x2013;1739. doi: 10.1016/j.neurobiolaging.2005.09.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2005.09.043</ArticleId><ArticleId IdType="pubmed">16290270</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucin KM, Wyss-Coray T. Immune activation in brain aging and neurodegeneration: too much or too little? Neuron. 2009;64:110&#x2013;122. doi: 10.1016/j.neuron.2009.08.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.08.039</ArticleId><ArticleId IdType="pmc">PMC2834890</ArticleId><ArticleId IdType="pubmed">19840553</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivest S. Regulation of innate immune responses in the brain. Nat Rev Immunol. 2009;9:429&#x2013;439. doi: 10.1038/nri2565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2565</ArticleId><ArticleId IdType="pubmed">19461673</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol. 1982;57:239&#x2013;242. doi: 10.1007/BF00685397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00685397</ArticleId><ArticleId IdType="pubmed">6812382</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelenboom P, Veerhuis R. The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiol Aging. 1996;17:673&#x2013;680. doi: 10.1016/0197-4580(96)00108-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(96)00108-X</ArticleId><ArticleId IdType="pubmed">8892339</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster S, Lue LF, Brachova L, Tenner AJ, McGeer PL, Terai K, Walker DG, Bradt B, Cooper NR, Rogers J. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol Aging. 1997;18:415&#x2013;421. doi: 10.1016/S0197-4580(97)00042-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(97)00042-0</ArticleId><ArticleId IdType="pubmed">9330973</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca MI, Ager RR, Chu SH, Yazan O, Sanderson SD, LaFerla FM, Taylor SM, Woodruff TM, Tenner AJ. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol. 2009;183:1375&#x2013;1383. doi: 10.4049/jimmunol.0901005.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0901005</ArticleId><ArticleId IdType="pmc">PMC4067320</ArticleId><ArticleId IdType="pubmed">19561098</ArticleId></ArticleIdList></Reference><Reference><Citation>Tacnet-Delorme P, Chevallier S, Arlaud GJ. Beta-amyloid fibrils activate the C1 complex of complement under physiological conditions: evidence for a binding site for A beta on the C1q globular regions. J Immunol. 2001;167:6374&#x2013;6381.</Citation><ArticleIdList><ArticleId IdType="pubmed">11714802</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiyaz M, Lupton MK, Proitsi P, Powell JF, Lovestone S. Complement activation as a biomarker for Alzheimer's disease. Immunobiology. 2012;217:204&#x2013;215. doi: 10.1016/j.imbio.2011.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2011.07.023</ArticleId><ArticleId IdType="pubmed">21856034</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol. 2004;5:987&#x2013;995. doi: 10.1038/ni1112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1112</ArticleId><ArticleId IdType="pubmed">15454922</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol. 2004;76:514&#x2013;519. doi: 10.1189/jlb.0304127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.0304127</ArticleId><ArticleId IdType="pubmed">15178705</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner H. Endogenous TLR ligands and autoimmunity. Adv Immunol. 2006;91:159&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">16938540</ArticleId></ArticleIdList></Reference><Reference><Citation>Zedler S, Faist E. The impact of endogenous triggers on trauma-associated inflammation. Curr Opin Crit Care. 2006;12:595&#x2013;601. doi: 10.1097/MCC.0b013e3280106806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCC.0b013e3280106806</ArticleId><ArticleId IdType="pubmed">17077693</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol. 2009;86:557&#x2013;566. doi: 10.1189/jlb.1008647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.1008647</ArticleId><ArticleId IdType="pubmed">19451397</ArticleId></ArticleIdList></Reference><Reference><Citation>Pineau I, Lacroix S. Endogenous signals initiating inflammation in the injured nervous system. Glia. 2009;57:351&#x2013;361. doi: 10.1002/glia.20763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.20763</ArticleId><ArticleId IdType="pubmed">18803306</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007;81:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">17032697</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, Nacken W, Foell D, van der Poll T, Sorg C, Roth J. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 2007;13:1042&#x2013;1049. doi: 10.1038/nm1638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1638</ArticleId><ArticleId IdType="pubmed">17767165</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyette J, Geczy CL. Inflammation-associated S100 proteins: new mechanisms that regulate function. Amino Acids. 2011;41:821&#x2013;842. doi: 10.1007/s00726-010-0528-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00726-010-0528-0</ArticleId><ArticleId IdType="pubmed">20213444</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehnardt S. Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury. Glia. 2010;58:253&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">19705460</ArticleId></ArticleIdList></Reference><Reference><Citation>Arroyo DS, Soria JA, Gaviglio EA, Rodriguez-Galan MC, Iribarren P. Toll-like receptors are key players in neurodegeneration. Int Immunopharmacol. 2011;11:1415&#x2013;1421. doi: 10.1016/j.intimp.2011.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2011.05.006</ArticleId><ArticleId IdType="pmc">PMC3183240</ArticleId><ArticleId IdType="pubmed">21616174</ArticleId></ArticleIdList></Reference><Reference><Citation>Tschopp J, Schroder K. NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production? Nat Rev Immunol. 2010;10:210&#x2013;215. doi: 10.1038/nri2725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2725</ArticleId><ArticleId IdType="pubmed">20168318</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140:821&#x2013;832. doi: 10.1016/j.cell.2010.01.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.01.040</ArticleId><ArticleId IdType="pubmed">20303873</ArticleId></ArticleIdList></Reference><Reference><Citation>Kufer TA, Sansonetti PJ. NLR functions beyond pathogen recognition. Nat Immunol. 2011;12:121&#x2013;128. doi: 10.1038/ni.1985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1985</ArticleId><ArticleId IdType="pubmed">21245903</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin WS, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI, Roberts GW, Mrak RE. Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol. 1998;8:65&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098321</ArticleId><ArticleId IdType="pubmed">9458167</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin WS, Mrak RE. Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease. J Leukoc Biol. 2002;72:233&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3835694</ArticleId><ArticleId IdType="pubmed">12149413</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Mastroeni D, Leonard B, Joyce J, Grover A. Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder? Int Rev Neurobiol. 2007;82:235&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">17678964</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin WS, Nicoll JA, Grimaldi LM, Sheng JG, Mrak RE. The pervasiveness of interleukin-1 in Alzheimer pathogenesis: a role for specific polymorphisms in disease risk. Exp Gerontol. 2000;35:481&#x2013;487. doi: 10.1016/S0531-5565(00)00110-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0531-5565(00)00110-8</ArticleId><ArticleId IdType="pmc">PMC3833595</ArticleId><ArticleId IdType="pubmed">10959036</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutterwala FS, Ogura Y, Flavell RA. The inflammasome in pathogen recognition and inflammation. J Leukoc Biol. 2007;82:259&#x2013;264. doi: 10.1189/jlb.1206755.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.1206755</ArticleId><ArticleId IdType="pubmed">17470531</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao HM, Liu B, Zhang W, Hong JS. Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci. 2003;24:395&#x2013;401. doi: 10.1016/S0165-6147(03)00176-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-6147(03)00176-7</ArticleId><ArticleId IdType="pubmed">12915048</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrekar-Colucci S, Landreth GE. Microglia and inflammation in Alzheimer's disease. CNS Neurol Disord Drug Targets. 2010;9:156&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653290</ArticleId><ArticleId IdType="pubmed">20205644</ArticleId></ArticleIdList></Reference><Reference><Citation>Okun E, Mattson MP, Arumugam TV. Involvement of Fc receptors in disorders of the central nervous system. Neuromolecular Med. 2010;12:164&#x2013;178. doi: 10.1007/s12017-009-8099-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-009-8099-5</ArticleId><ArticleId IdType="pmc">PMC2878892</ArticleId><ArticleId IdType="pubmed">19844812</ArticleId></ArticleIdList></Reference><Reference><Citation>Peress NS, Fleit HB, Perillo E, Kuljis R, Pezzullo C. Identification of Fc gamma RI, II and III on normal human brain ramified microglia and on microglia in senile plaques in Alzheimer's disease. J Neuroimmunol. 1993;48:71&#x2013;79. doi: 10.1016/0165-5728(93)90060-C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-5728(93)90060-C</ArticleId><ArticleId IdType="pubmed">8227309</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34&#x2013;47. doi: 10.1038/nri2206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2206</ArticleId><ArticleId IdType="pubmed">18064051</ArticleId></ArticleIdList></Reference><Reference><Citation>van Lent PL, Grevers LC, Schelbergen R, Blom A, Geurts J, Sloetjes A, Vogl T, Roth J, van den Berg WB. S100A8 causes a shift toward expression of activatory Fcgamma receptors on macrophages via toll-like receptor 4 and regulates Fcgamma receptor expression in synovium during chronic experimental arthritis. Arthritis Rheum. 2010;62:3353&#x2013;3364. doi: 10.1002/art.27654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27654</ArticleId><ArticleId IdType="pubmed">20662072</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK, Streit WJ, Salafranca MN, Adhikari S, Thompson DA, Botti P, Bacon KB, Feng L. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci USA. 1998;95:10896&#x2013;10901. doi: 10.1073/pnas.95.18.10896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.18.10896</ArticleId><ArticleId IdType="pmc">PMC27992</ArticleId><ArticleId IdType="pubmed">9724801</ArticleId></ArticleIdList></Reference><Reference><Citation>Moestrup SK, Moller HJ. CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann Med. 2004;36:347&#x2013;354. doi: 10.1080/07853890410033171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890410033171</ArticleId><ArticleId IdType="pubmed">15478309</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabriek BO, Dijkstra CD, van den Berg TK. The macrophage scavenger receptor CD163. Immunobiology. 2005;210:153&#x2013;160. doi: 10.1016/j.imbio.2005.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2005.05.010</ArticleId><ArticleId IdType="pubmed">16164022</ArticleId></ArticleIdList></Reference><Reference><Citation>Philippidis P, Mason JC, Evans BJ, Nadra I, Taylor KM, Haskard DO, Landis RC. Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: antiinflammatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res. 2004;94:119&#x2013;126. doi: 10.1161/01.RES.0000109414.78907.F9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.RES.0000109414.78907.F9</ArticleId><ArticleId IdType="pubmed">14656926</ArticleId></ArticleIdList></Reference><Reference><Citation>Colton CA, Mott RT, Sharpe H, Xu Q, Van Nostrand WE, Vitek MP. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J Neuroinflammation. 2006;3:27. doi: 10.1186/1742-2094-3-27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-3-27</ArticleId><ArticleId IdType="pmc">PMC1609108</ArticleId><ArticleId IdType="pubmed">17005052</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Kawamata T, Walker DG, Akiyama H, Tooyama I, McGeer EG. Microglia in degenerative neurological disease. Glia. 1993;7:84&#x2013;92. doi: 10.1002/glia.440070114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.440070114</ArticleId><ArticleId IdType="pubmed">8423066</ArticleId></ArticleIdList></Reference><Reference><Citation>Popovic M, Caballero-Bleda M, Puelles L, Popovic N. Importance of immunological and inflammatory processes in the pathogenesis and therapy of Alzheimer's disease. Int J Neurosci. 1998;95:203&#x2013;236. doi: 10.3109/00207459809003341.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00207459809003341</ArticleId><ArticleId IdType="pubmed">9777440</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry VH. A revised view of the central nervous system microenvironment and major histocompatibility complex class II antigen presentation. J Neuroimmunol. 1998;90:113&#x2013;121. doi: 10.1016/S0165-5728(98)00145-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-5728(98)00145-3</ArticleId><ArticleId IdType="pubmed">9817438</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Keefe GM, Nguyen VT, Benveniste EN. Regulation and function of class II major histocompatibility complex, CD40, and B7 expression in macrophages and microglia: Implications in neurological diseases. J Neurovirol. 2002;8:496&#x2013;512. doi: 10.1080/13550280290100941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13550280290100941</ArticleId><ArticleId IdType="pubmed">12476345</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuello AC, Ferretti MT, Leon WC, Iulita MF, Melis T, Ducatenzeiler A, Bruno MA, Canneva F. Early-stage inflammation and experimental therapy in transgenic models of the Alzheimer-like amyloid pathology. Neurodegener Dis. 2010;7:96&#x2013;98. doi: 10.1159/000285514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000285514</ArticleId><ArticleId IdType="pubmed">20173335</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiendl H, Feger U, Mittelbronn M, Jack C, Schreiner B, Stadelmann C, Antel J, Brueck W, Meyermann R, Bar-Or A, Kieseier BC, Weller M. Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. Brain. 2005;128:2689&#x2013;2704. doi: 10.1093/brain/awh609.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh609</ArticleId><ArticleId IdType="pubmed">16123145</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer EG, McGeer PL. Innate immunity in Alzheimer's disease: a model for local inflammatory reactions. Mol Interv. 2001;1:22&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">14993335</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen MD, Julien JP, Rivest S. Innate immunity: the missing link in neuroprotection and neurodegeneration? Nat Rev Neurosci. 2002;3:216&#x2013;227. doi: 10.1038/nrn752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn752</ArticleId><ArticleId IdType="pubmed">11994753</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry VH, Newman TA, Cunningham C. The impact of systemic infection on the progression of neurodegenerative disease. Nat Rev Neurosci. 2003;4:103&#x2013;112. doi: 10.1038/nrn1032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1032</ArticleId><ArticleId IdType="pubmed">12563281</ArticleId></ArticleIdList></Reference><Reference><Citation>Turrin NP, Rivest S. Innate immune reaction in response to seizures: implications for the neuropathology associated with epilepsy. Neurobiol Dis. 2004;16:321&#x2013;334. doi: 10.1016/j.nbd.2004.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2004.03.010</ArticleId><ArticleId IdType="pubmed">15193289</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehnardt S, Massillon L, Follett P, Jensen FE, Ratan R, Rosenberg PA, Volpe JJ, Vartanian T. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci USA. 2003;100:8514&#x2013;8519. doi: 10.1073/pnas.1432609100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1432609100</ArticleId><ArticleId IdType="pmc">PMC166260</ArticleId><ArticleId IdType="pubmed">12824464</ArticleId></ArticleIdList></Reference><Reference><Citation>Konat GW, Kielian T, Marriott I. The role of Toll-like receptors in CNS response to microbial challenge. J Neurochem. 2006;99:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2423668</ArticleId><ArticleId IdType="pubmed">16899072</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe O, Yamasue H, Yamada H, Masutani Y, Kabasawa H, Sasaki H, Takei K, Suga M, Kasai K, Aoki S, Ohtomo K. Sex dimorphism in gray/white matter volume and diffusion tensor during normal aging. NMR Biomed. 2010;23:446&#x2013;458. doi: 10.1002/nbm.1479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/nbm.1479</ArticleId><ArticleId IdType="pubmed">20310078</ArticleId></ArticleIdList></Reference><Reference><Citation>Taki Y, Kinomura S, Sato K, Goto R, Kawashima R, Fukuda H. A longitudinal study of gray matter volume decline with age and modifying factors. Neurobiol Aging. 2011;32:907&#x2013;915. doi: 10.1016/j.neurobiolaging.2009.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.05.003</ArticleId><ArticleId IdType="pubmed">19497638</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong G, Rosa-Neto P, Carbonell F, Chen ZJ, He Y, Evans AC. Age- and gender-related differences in the cortical anatomical network. J Neurosci. 2009;29:15684&#x2013;15693. doi: 10.1523/JNEUROSCI.2308-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2308-09.2009</ArticleId><ArticleId IdType="pmc">PMC2831804</ArticleId><ArticleId IdType="pubmed">20016083</ArticleId></ArticleIdList></Reference><Reference><Citation>Douglas PM, Dillin A. Protein homeostasis and aging in neurodegeneration. J Cell Biol. 2010;190:719&#x2013;729. doi: 10.1083/jcb.201005144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201005144</ArticleId><ArticleId IdType="pmc">PMC2935559</ArticleId><ArticleId IdType="pubmed">20819932</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickford F, Masliah E, Britschgi M, Lucin K, Narasimhan R, Jaeger PA, Small S, Spencer B, Rockenstein E, Levine B, Wyss-Coray T. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest. 2008;118:2190&#x2013;2199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2391284</ArticleId><ArticleId IdType="pubmed">18497889</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaeger PA, Pickford F, Sun CH, Lucin KM, Masliah E, Wyss-Coray T. Regulation of amyloid precursor protein processing by the Beclin 1 complex. PLoS One. 2010;5:e11102. doi: 10.1371/journal.pone.0011102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0011102</ArticleId><ArticleId IdType="pmc">PMC2886067</ArticleId><ArticleId IdType="pubmed">20559548</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaeger PA, Wyss-Coray T. Beclin 1 complex in autophagy and Alzheimer disease. Arch Neurol. 2010;67:1181&#x2013;1184. doi: 10.1001/archneurol.2010.258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.258</ArticleId><ArticleId IdType="pubmed">20937944</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter S, Letiembre M, Liu Y, Heine H, Penke B, Hao W, Bode B, Manietta N, Walter J, Schulz-Schuffer W, Fassbender K. Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cell Physiol Biochem. 2007;20:947&#x2013;956. doi: 10.1159/000110455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000110455</ArticleId><ArticleId IdType="pubmed">17982277</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9:119&#x2013;128. doi: 10.1016/S1474-4422(09)70299-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(09)70299-6</ArticleId><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK. Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology. 2011;77:1619&#x2013;1628. doi: 10.1212/WNL.0b013e3182343314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182343314</ArticleId><ArticleId IdType="pmc">PMC3198979</ArticleId><ArticleId IdType="pubmed">21998317</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller M, Ruegg A, Werner S, Beer HD. Active caspase-1 is a regulator of unconventional protein secretion. Cell. 2008;132:818&#x2013;831. doi: 10.1016/j.cell.2007.12.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.12.040</ArticleId><ArticleId IdType="pubmed">18329368</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis BK, Ting JP. NLRP3 has a sweet tooth. Nat Immunol. 2010;11:105&#x2013;106. doi: 10.1038/ni0210-105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni0210-105</ArticleId><ArticleId IdType="pubmed">20084064</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem. 2009;284:12845&#x2013;12852. doi: 10.1074/jbc.M808759200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M808759200</ArticleId><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci. 2010;11:155&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3648341</ArticleId><ArticleId IdType="pubmed">20029438</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, Huang D, Kidd G, Dombrowski S, Dutta R, Lee JC, Cook DN, Jung S, Lira SA, Littman DR, Ransohoff RM. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci. 2006;9:917&#x2013;924. doi: 10.1038/nn1715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1715</ArticleId><ArticleId IdType="pubmed">16732273</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers JT, Morganti JM, Bachstetter AD, Hudson CE, Peters MM, Grimmig BA, Weeber EJ, Bickford PC, Gemma C. CX3CR1 deficiency leads to impairment of hippocampal cognitive function and synaptic plasticity. J Neurosci. 2011;31:16241&#x2013;16250. doi: 10.1523/JNEUROSCI.3667-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3667-11.2011</ArticleId><ArticleId IdType="pmc">PMC3236509</ArticleId><ArticleId IdType="pubmed">22072675</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasilevko V, Passos GF, Quiring D, Head E, Kim RC, Fisher M, Cribbs DH. Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy. Ann NY Acad Sci. 2010;1207:58&#x2013;70. doi: 10.1111/j.1749-6632.2010.05786.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2010.05786.x</ArticleId><ArticleId IdType="pmc">PMC2958685</ArticleId><ArticleId IdType="pubmed">20955427</ArticleId></ArticleIdList></Reference><Reference><Citation>Cribbs DH. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention. CNS Neurol Disord Drug Targets. 2010;9:207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3153446</ArticleId><ArticleId IdType="pubmed">20205639</ArticleId></ArticleIdList></Reference><Reference><Citation>Afagh A, Cummings BJ, Cribbs DH, Cotman CW, Tenner AJ. Localization and cell association of C1q in Alzheimer's disease brain. Exp Neurol. 1996;138:22&#x2013;32. doi: 10.1006/exnr.1996.0043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.1996.0043</ArticleId><ArticleId IdType="pubmed">8593893</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer EG, McGeer PL. Chronic inflammation in Alzheimer's disease offers therapeutic opportunities. Expert Rev Neurother. 2001;1:53&#x2013;60. doi: 10.1586/14737175.1.1.53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737175.1.1.53</ArticleId><ArticleId IdType="pubmed">19811046</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, Brandt J, Craft S, Evans DE, Green RC, Ismail MS, Martin BK, Mullan MJ, Sabbagh M, Tariot PN. ADAPT Research Group. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement. 2011;7:402&#x2013;411. doi: 10.1016/j.jalz.2010.12.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2010.12.014</ArticleId><ArticleId IdType="pmc">PMC3149804</ArticleId><ArticleId IdType="pubmed">21784351</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong L, Balazs R, Soiampornkul R, Thangnipon W, Cotman CW. Interleukin-1 beta impairs brain derived neurotrophic factor-induced signal transduction. Neurobiol Aging. 2008;29:1380&#x2013;1393. doi: 10.1016/j.neurobiolaging.2007.02.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.02.027</ArticleId><ArticleId IdType="pmc">PMC4052889</ArticleId><ArticleId IdType="pubmed">17467122</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrup K. Reimagining Alzheimer's disease - an age-based hypothesis. J Neurosci. 2010;30:16755&#x2013;16762. doi: 10.1523/JNEUROSCI.4521-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4521-10.2010</ArticleId><ArticleId IdType="pmc">PMC3004746</ArticleId><ArticleId IdType="pubmed">21159946</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20817278</PMID><DateCompleted><Year>2010</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>142</Volume><Issue>6</Issue><PubDate><Year>2010</Year><Month>Sep</Month><Day>17</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Iron-export ferroxidase activity of &#x3b2;-amyloid precursor protein is inhibited by zinc in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>857</StartPage><EndPage>867</EndPage><MedlinePgn>857-67</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2010.08.014</ELocationID><Abstract><AbstractText>Alzheimer's Disease (AD) is complicated by pro-oxidant intraneuronal Fe(2+) elevation as well as extracellular Zn(2+) accumulation within amyloid plaque. We found that the AD &#x3b2;-amyloid protein precursor (APP) possesses ferroxidase activity mediated by a conserved H-ferritin-like active site, which is inhibited specifically by Zn(2+). Like ceruloplasmin, APP catalytically oxidizes Fe(2+), loads Fe(3+) into transferrin, and has a major interaction with ferroportin in HEK293T cells (that lack ceruloplasmin) and in human cortical tissue. Ablation of APP in HEK293T cells and primary neurons induces marked iron retention, whereas increasing APP695 promotes iron export. Unlike normal mice, APP(-/-) mice are vulnerable to dietary iron exposure, which causes Fe(2+) accumulation and oxidative stress in cortical neurons. Paralleling iron accumulation, APP ferroxidase activity in AD postmortem neocortex is inhibited by endogenous Zn(2+), which we demonstrate can originate from Zn(2+)-laden amyloid aggregates and correlates with A&#x3b2; burden. Abnormal exchange of cortical zinc may link amyloid pathology with neuronal iron accumulation in AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2010 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Duce</LastName><ForeName>James A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Mental Health Research Institute, The University of Melbourne, Parkville, Victoria 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsatsanis</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Cater</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Simon A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Robb</LastName><ForeName>Elysia</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Wikhe</LastName><ForeName>Krutika</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Leong</LastName><ForeName>Su Ling</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Perez</LastName><ForeName>Keyla</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Johanssen</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Greenough</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Hyun-Hee</ForeName><Initials>HH</Initials></Author><Author ValidYN="Y"><LastName>Galatis</LastName><ForeName>Denise</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Moir</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>McLean</LastName><ForeName>Catriona</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Cappai</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Barnham</LastName><ForeName>Kevin J</ForeName><Initials>KJ</Initials></Author><Author ValidYN="Y"><LastName>Ciccotosto</LastName><ForeName>Giuseppe D</ForeName><Initials>GD</Initials></Author><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>Jack T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Bush</LastName><ForeName>Ashley I</ForeName><Initials>AI</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG012686</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01AG12686</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>E1UOL152H7</RegistryNumber><NameOfSubstance UI="D007501">Iron</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.16.3.1</RegistryNumber><NameOfSubstance UI="D002570">Ceruloplasmin</NameOfSubstance></Chemical><Chemical><RegistryNumber>J41CSQ7QDS</RegistryNumber><NameOfSubstance UI="D015032">Zinc</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002570" MajorTopicYN="N">Ceruloplasmin</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015032" MajorTopicYN="N">Zinc</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>9</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20817278</ArticleId><ArticleId IdType="mid">NIHMS230633</ArticleId><ArticleId IdType="pmc">PMC2943017</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2010.08.014</ArticleId><ArticleId IdType="pii">S0092-8674(10)00938-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, et al. Rapid restoration of cognition in Alzheimer&#x2019;s transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron. 2008;59:43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">18614028</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker GR, Boyer RF. Iron incorporation into apoferritin. The role of apoferritin as a ferroxidase. J Biol Chem. 1986;261:13182&#x2013;13185.</Citation><ArticleIdList><ArticleId IdType="pubmed">3759957</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartzokis G, Mintz J, Sultzer D, Marx P, Herzberg JS, Phelan CK, Marder SR. In vivo MR evaluation of age-related increases in brain iron. AJNR Am J Neuroradiol. 1994a;15:1129&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8333472</ArticleId><ArticleId IdType="pubmed">8073983</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartzokis G, Sultzer D, Mintz J, Holt LE, Marx P, Phelan CK, Marder SR. In vivo evaluation of brain iron in Alzheimer&#x2019;s disease and normal subjects using MRI. Biol Psychiatry. 1994b;35:480&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">8018799</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartzokis G, Tishler TA. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer&#x2019;s and Huntingon&#x2019;s disease. Cell Mol Biol (Noisy-le-grand) 2000;46:821&#x2013;833.</Citation><ArticleIdList><ArticleId IdType="pubmed">10875443</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodovitz S, Falduto MT, Frail DE, Klein WL. Iron levels modulate alpha-secretase cleavage of amyloid precursor protein. J Neurochem. 1995;64:307&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">7798927</ArticleId></ArticleIdList></Reference><Reference><Citation>Bush AI, Pettingell WH, Multhaup G, d Paradis M, Vonsattel JP, Gusella JF, Beyreuther K, Masters CL, Tanzi RE. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science. 1994;265:1464&#x2013;1467.</Citation><ArticleIdList><ArticleId IdType="pubmed">8073293</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer&#x2019;s disease transgenic mice. Neuron. 2001;30:665&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">11430801</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherny RA, Legg JT, McLean CA, Fairlie D, Huang X, Atwood CS, Beyreuther K, Tanzi RE, Masters CL, Bush AI. Aqueous dissolution of Alzheimer&#x2019;s disease A&#x3b2; amyloid deposits by biometal depletion. Journal of Biological Chemistry. 1999;274:23223&#x2013;23228.</Citation><ArticleIdList><ArticleId IdType="pubmed">10438495</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinnery PF, Crompton DE, Birchall D, Jackson MJ, Coulthard A, Lombes A, Quinn N, Wills A, Fletcher N, Mottershead JP, et al. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain. 2007;130:110&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">17142829</ArticleId></ArticleIdList></Reference><Reference><Citation>Cras P, Kawai M, Lowery D, Gonzalez-DeWhitt P, Greenberg B, Perry G. Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. Proc Natl Acad Sci U S A. 1991;88:7552&#x2013;7556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC52339</ArticleId><ArticleId IdType="pubmed">1652752</ArticleId></ArticleIdList></Reference><Reference><Citation>De Domenico I, Nemeth E, Nelson JM, Phillips JD, Ajioka RS, Kay MS, Kushner JP, Ganz T, Ward DM, Kaplan J. The hepcidin-binding site on ferroportin is evolutionarily conserved. Cell Metab. 2008;8:146&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2660598</ArticleId><ArticleId IdType="pubmed">18680715</ArticleId></ArticleIdList></Reference><Reference><Citation>De Domenico I, Ward DM, di Patti MC, Jeong SY, David S, Musci G, Kaplan J. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin. EMBO J. 2007;26:2823&#x2013;2831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1894773</ArticleId><ArticleId IdType="pubmed">17541408</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding B, Chen KM, Ling HW, Sun F, Li X, Wan T, Chai WM, Zhang H, Zhan Y, Guan YJ. Correlation of iron in the hippocampus with MMSE in patients with Alzheimer&#x2019;s disease. J Magn Reson Imaging. 2009;29:793&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pubmed">19306401</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong J, Atwood CS, Anderson VE, Siedlak SL, Smith MA, Perry G, Carey PR. Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry. 2003;42:2768&#x2013;2773.</Citation><ArticleIdList><ArticleId IdType="pubmed">12627941</ArticleId></ArticleIdList></Reference><Reference><Citation>El Tannir El Tayara N, Delatour B, Le Cudennec C, Guegan M, Volk A, Dhenain M. Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer&#x2019;s disease. Neurobiol Dis. 2006;22:199&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">16337798</ArticleId></ArticleIdList></Reference><Reference><Citation>Falangola MF, Lee SP, Nixon RA, Duff K, Helpern JA. Histological co-localization of iron in Abeta plaques of PS/APP transgenic mice. Neurochem Res. 2005;30:201&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959869</ArticleId><ArticleId IdType="pubmed">15895823</ArticleId></ArticleIdList></Reference><Reference><Citation>Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harrison J, Lannfelt L, Blennow K, Zetterberg H, et al. PBT2 Rapidly Improves Cognition in Alzheimer&#x2019;s Disease: Additional Phase II Analyses. J Alzheimers Dis. 2010;20:509&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">20164561</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa K, Sopher BL, Rydel RE, Begley JG, Pham DG, Martin GM, Fox M, Mattson MP. Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. J Neurochem. 1996;67:1882&#x2013;1896.</Citation><ArticleIdList><ArticleId IdType="pubmed">8863493</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Cuyar LF, Perry G, Miyajima H, Atwood CS, Riveros-Angel M, Lyons PF, Siedlak SL, Smith MA, Castellani RJ. Redox active iron accumulation in aceruloplasminemia. Neuropathology. 2008;28:466&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pubmed">18282164</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray CW, Patel AJ. Induction of beta-amyloid precursor protein isoform mRNAs by bFGF in astrocytes. Neuroreport. 1993;4:811&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pubmed">8347831</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundke-Iqbal I, Fleming J, Tung YC, Lassmann H, Iqbal K, Joshi JG. Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia. Acta Neuropathol. 1990;81:105&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">2082650</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez JA, Yu J, Rivera S, Wessling-Resnick M. Functional expression cloning and characterization of SFT, a stimulator of Fe transport. J Cell Biol. 1997;139:895&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2139974</ArticleId><ArticleId IdType="pubmed">9362508</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallgren B, Sourander P. The effect of age on the non-haemin iron in the human brain. J Neurochem. 1958;3:41&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">13611557</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Q, Maret W. Imbalance between pro-oxidant and pro-antioxidant functions of zinc in disease. J Alzheimers Dis. 2005;8:161&#x2013;170. discussion 209&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">16308485</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris ZL, Takahashi Y, Miyajima H, Serizawa M, MacGillivray RT, Gitlin JD. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci U S A. 1995;92:2539&#x2013;2543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC42253</ArticleId><ArticleId IdType="pubmed">7708681</ArticleId></ArticleIdList></Reference><Reference><Citation>Honda K, Smith MA, Zhu X, Baus D, Merrick WC, Tartakoff AM, Hattier T, Harris PL, Siedlak SL, Fujioka H, et al. Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J Biol Chem. 2005;280:20978&#x2013;20986.</Citation><ArticleIdList><ArticleId IdType="pubmed">15767256</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Wengenack TM, Reyes DA, Garwood M, Curran GL, Borowski BJ, Lin J, Preboske GM, Holasek SS, Adriany G, et al. In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer&#x2019;s transgenic mice. J Neurosci. 2005;25:10041&#x2013;10048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744887</ArticleId><ArticleId IdType="pubmed">16251453</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong SY, David S. Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J Biol Chem. 2003;278:27144&#x2013;27148.</Citation><ArticleIdList><ArticleId IdType="pubmed">12743117</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong SY, David S. Age-related changes in iron homeostasis and cell death in the cerebellum of ceruloplasmin-deficient mice. J Neurosci. 2006;26:9810&#x2013;9819.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674433</ArticleId><ArticleId IdType="pubmed">16988052</ArticleId></ArticleIdList></Reference><Reference><Citation>Klausner RD, Rouault TA, Harford JB. Regulating the fate of mRNA: the control of cellular iron metabolism. Cell. 1993;72:19&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">8380757</ArticleId></ArticleIdList></Reference><Reference><Citation>Klomp LW, Farhangrazi ZS, Dugan LL, Gitlin JD. Ceruloplasmin gene expression in the murine central nervous system. J Clin Invest. 1996;98:207&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC507418</ArticleId><ArticleId IdType="pubmed">8690795</ArticleId></ArticleIdList></Reference><Reference><Citation>Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer&#x2019;s disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2008;7:779&#x2013;786.</Citation><ArticleIdList><ArticleId IdType="pubmed">18672400</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawson DM, Artymiuk PJ, Yewdall SJ, Smith JM, Livingstone JC, Treffry A, Luzzago A, Levi S, Arosio P, Cesareni G, et al. Solving the structure of human H ferritin by genetically engineering intermolecular crystal contacts. Nature. 1991;349:541&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pubmed">1992356</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawson DM, Treffry A, Artymiuk PJ, Harrison PM, Yewdall SJ, Luzzago A, Cesareni G, Levi S, Arosio P. Identification of the ferroxidase centre in ferritin. FEBS Lett. 1989;254:207&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">2776883</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Cole TB, Palmiter RD, Suh SW, Koh JY. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc Natl Acad Sci U S A. 2002;99:7705&#x2013;7710.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124328</ArticleId><ArticleId IdType="pubmed">12032347</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer&#x2019;s disease senile plaques. J Neurol Sci. 1998;158:47&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">9667777</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovan MC, Martinuzzi A, Squarzanti F, Bolla A, Silvestri I, Liessi G, Macchi C, Ruzza G, Trevisan CP, Angelini C. Exploring mental status in Friedreich&#x2019;s ataxia: a combined neuropsychological, behavioral and neuroimaging study. Eur J Neurol. 2006;13:827&#x2013;835.</Citation><ArticleIdList><ArticleId IdType="pubmed">16879292</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I, Rydel RE. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the &#x3b2;-amyloid precursor protein. Neuron. 1993;10:243&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">8094963</ArticleId></ArticleIdList></Reference><Reference><Citation>Maynard CJ, Cappai R, Volitakis I, Cherny RA, White AR, Beyreuther K, Masters CL, Bush AI, Li QX. Overexpression of Alzheimer&#x2019;s disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem. 2002;277:44670&#x2013;44676.</Citation><ArticleIdList><ArticleId IdType="pubmed">12215434</ArticleId></ArticleIdList></Reference><Reference><Citation>Meloni G, Sonois V, Delaine T, Guilloreau L, Gillet A, Teissie J, Faller P, Vasak M. Metal swap between Zn7-metallothionein-3 and amyloid-beta-Cu protects against amyloid-beta toxicity. Nat Chem Biol. 2008;4:366&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">18454142</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller LM, Wang Q, Telivala TP, Smith RJ, Lanzirotti A, Miklossy J. Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer&#x2019;s disease. Journal of structural biology. 2006;155:30&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">16325427</ArticleId></ArticleIdList></Reference><Reference><Citation>Mita S, Schon EA, Herbert J. Widespread expression of amyloid beta-protein precursor gene in rat brain. Am J Pathol. 1989;134:1253&#x2013;1261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1879949</ArticleId><ArticleId IdType="pubmed">2502926</ArticleId></ArticleIdList></Reference><Reference><Citation>Ninomiya H, Roch JM, Sundsmo MP, Otero DA, Saitoh T. Amino acid sequence RERMS represents the active domain of amyloid beta/A4 protein precursor that promotes fibroblast growth. J Cell Biol. 1993;121:879&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2119788</ArticleId><ArticleId IdType="pubmed">8491779</ArticleId></ArticleIdList></Reference><Reference><Citation>Opazo C, Huang X, Cherny R, Moir R, Roher A, White A, Cappai R, Masters C, Tanzi R, Inestrosa N, et al. Metalloenzyme-like activity of Alzheimer&#x2019;s disease &#x3b2;-amyloid: Cu-dependent catalytic conversion of dopamine, cholesterol and biological reducing agents to neurotoxic H2O2. Journal of Biological Chemistry. 2002;277:40302&#x2013;40308.</Citation><ArticleIdList><ArticleId IdType="pubmed">12192006</ArticleId></ArticleIdList></Reference><Reference><Citation>Osaki S. Kinetic studies of ferrous ion oxidation with crystalline human ferroxidase (ceruloplasmin) J Biol Chem. 1966;241:5053&#x2013;5059.</Citation><ArticleIdList><ArticleId IdType="pubmed">5925868</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel BN, Dunn RJ, Jeong SY, Zhu Q, Julien JP, David S. Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. J Neurosci. 2002;22:6578&#x2013;6586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758125</ArticleId><ArticleId IdType="pubmed">12151537</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian ZM, Chang YZ, Leung G, Du JR, Zhu L, Wang Q, Niu L, Xu YJ, Yang L, Ho KP, et al. Expression of ferroportin1, hephaestin and ceruloplasmin in rat heart. Biochim Biophys Acta. 2007;1772:527&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">17383861</ArticleId></ArticleIdList></Reference><Reference><Citation>Religa D, Strozyk D, Cherny RA, Volitakis I, Haroutunian V, Winblad B, Naslund J, Bush AI. Elevated cortical zinc in Alzheimer disease. Neurology. 2006;67:69&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">16832080</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol. 2003;60:1685&#x2013;1691.</Citation><ArticleIdList><ArticleId IdType="pubmed">14676042</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson SR, Noone DF, Kril J, Halliday GM. Most amyloid plaques contain ferritin-rich cells. Alzheimer&#x2019;s Research. 1995;1:191&#x2013;196.</Citation></Reference><Reference><Citation>Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, Leiter L, McPhee J, Sarang SS, Utsuki T, et al. An iron-responsive element type II in the 5&#x2032;-untranslated region of the Alzheimer&#x2019;s amyloid precursor protein transcript. J Biol Chem. 2002;277:45518&#x2013;45528.</Citation><ArticleIdList><ArticleId IdType="pubmed">12198135</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohan de Silva HA, Jen A, Wickenden C, Jen LS, Wilkinson SL, Patel AJ. Cell-specific expression of beta-amyloid precursor protein isoform mRNAs and proteins in neurons and astrocytes. Brain Res Mol Brain Res. 1997;47:147&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">9221912</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossjohn J, Cappai R, Feil SC, Henry A, McKinstry WJ, Galatis D, Hesse L, Multhaup G, Beyreuther K, Masters CL, et al. Crystal structure of the N-terminal, growth factor-like domain of Alzheimer amyloid precursor protein. Nat Struct Biol. 1999;6:327&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">10201399</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A. 1997;94:9866&#x2013;9868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23283</ArticleId><ArticleId IdType="pubmed">9275217</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh SW, Jensen KB, Jensen MS, Silva DS, Kesslak PJ, Danscher G, Frederickson CJ. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer&#x2019;s diseased brains. Brain Res. 2000;852:274&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">10678753</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi M, Dore S, Ferris CD, Tomita T, Sawa A, Wolosker H, Borchelt DR, Iwatsubo T, Kim SH, Thinakaran G, et al. Amyloid precursor proteins inhibit heme oxygenase activity and augment neurotoxicity in Alzheimer&#x2019;s disease. Neuron. 2000;28:461&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">11144356</ArticleId></ArticleIdList></Reference><Reference><Citation>Toussaint L, Bertrand L, Hue L, Crichton RR, Declercq JP. High-resolution X-ray structures of human apoferritin H-chain mutants correlated with their activity and metal-binding sites. J Mol Biol. 2007;365:440&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">17070541</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida Y, Takio K, Titani K, Ihara Y, Tomonaga M. The growth-inhibitory factor that is deficient in the Alzheimer&#x2019;s disease brain is a 68-amino acid metallothionein-like protein. Neuron. 1991;7:337&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">1873033</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser CC, Voorwinden LH, Crommelin DJ, Danhof M, de Boer AG. Characterization and modulation of the transferrin receptor on brain capillary endothelial cells. Pharm Res. 2004;21:761&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pubmed">15180331</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Ha Y. The X-ray structure of an antiparallel dimer of the human amyloid precursor protein E2 domain. Mol Cell. 2004;15:343&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">15304215</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto A, Shin RW, Hasegawa K, Naiki H, Sato H, Yoshimasu F, Kitamoto T. Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer&#x2019;s disease. J Neurochem. 2002;82:1137&#x2013;1147.</Citation><ArticleIdList><ArticleId IdType="pubmed">12358761</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Chen-Barrett Y, Arosio P, Chasteen ND. Reaction paths of iron oxidation and hydrolysis in horse spleen and recombinant human ferritins. Biochemistry. 1998;37:9743&#x2013;9750.</Citation><ArticleIdList><ArticleId IdType="pubmed">9657687</ArticleId></ArticleIdList></Reference><Reference><Citation>Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 2004;5:863&#x2013;873.</Citation><ArticleIdList><ArticleId IdType="pubmed">15496864</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21148344</PMID><DateCompleted><Year>2011</Year><Month>01</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>330</Volume><Issue>6012</Issue><PubDate><Year>2010</Year><Month>Dec</Month><Day>24</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Decreased clearance of CNS beta-amyloid in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1774</StartPage><MedlinePgn>1774</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1197623</ELocationID><Abstract><AbstractText>Alzheimer's disease is hypothesized to be caused by an imbalance between &#x3b2;-amyloid (A&#x3b2;) production and clearance that leads to A&#x3b2; accumulation in the central nervous system (CNS). A&#x3b2; production and clearance are key targets in the development of disease-modifying therapeutic agents for Alzheimer's disease. However, there has not been direct evidence of altered A&#x3b2; production or clearance in Alzheimer's disease. By using metabolic labeling, we measured A&#x3b2;42 and A&#x3b2;40 production and clearance rates in the CNS of participants with Alzheimer's disease and cognitively normal controls. Clearance rates for both A&#x3b2;42 and A&#x3b2;40 were impaired in Alzheimer's disease compared with controls. On average, there were no differences in A&#x3b2;40 or A&#x3b2;42 production rates. Thus, the common late-onset form of Alzheimer's disease is characterized by an overall impairment in A&#x3b2; clearance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mawuenyega</LastName><ForeName>Kwasi G</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sigurdson</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Ovod</LastName><ForeName>Vitaliy</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Munsell</LastName><ForeName>Ling</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Kasten</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Yarasheski</LastName><ForeName>Kevin E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS065667</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK056341</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 GM103422</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG030946</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P60 DK020579</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG027091</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 RR000954</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R24 GM136766</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR024992</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>12</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Biomark Med. 2011 Apr;5(2):202.</RefSource><PMID Version="1">21614802</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>12</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21148344</ArticleId><ArticleId IdType="mid">NIHMS266465</ArticleId><ArticleId IdType="pmc">PMC3073454</ArticleId><ArticleId IdType="doi">10.1126/science.1197623</ArticleId><ArticleId IdType="pii">science.1197623</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J, Selkoe DJ. Science. 2002 Jul 19;297:353.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL. N Engl J Med. 2004 Jul 1;351:56.</Citation><ArticleIdList><ArticleId IdType="pubmed">15229308</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, et al. Nat Med. 1996 Aug;2:864.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, et al. Nat Med. 2006 Jul;12:856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2983090</ArticleId><ArticleId IdType="pubmed">16799555</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, et al. Annals of Neurology. 2009;66:48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730994</ArticleId><ArticleId IdType="pubmed">19360898</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, et al. Neuron. 2004 Jan 22;41:193.</Citation><ArticleIdList><ArticleId IdType="pubmed">14741101</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis RJ, et al. Neurology. 1996 Jun;46:1592.</Citation><ArticleIdList><ArticleId IdType="pubmed">8649554</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19734903</PMID><DateCompleted><Year>2009</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>10</Issue><PubDate><Year>2009</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1094</StartPage><EndPage>1099</EndPage><MedlinePgn>1094-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.439</ELocationID><Abstract><AbstractText>The gene encoding apolipoprotein E (APOE) on chromosome 19 is the only confirmed susceptibility locus for late-onset Alzheimer's disease. To identify other risk loci, we conducted a large genome-wide association study of 2,032 individuals from France with Alzheimer's disease (cases) and 5,328 controls. Markers outside APOE with suggestive evidence of association (P &lt; 10(-5)) were examined in collections from Belgium, Finland, Italy and Spain totaling 3,978 Alzheimer's disease cases and 3,297 controls. Two loci gave replicated evidence of association: one within CLU (also called APOJ), encoding clusterin or apolipoprotein J, on chromosome 8 (rs11136000, OR = 0.86, 95% CI 0.81-0.90, P = 7.5 x 10(-9) for combined data) and the other within CR1, encoding the complement component (3b/4b) receptor 1, on chromosome 1 (rs6656401, OR = 1.21, 95% CI 1.14-1.29, P = 3.7 x 10(-9) for combined data). Previous biological studies support roles of CLU and CR1 in the clearance of beta amyloid (Abeta) peptide, the principal constituent of amyloid plaques, which are one of the major brain lesions of individuals with Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Jean-Charles</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Inserm U744, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heath</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Even</LastName><ForeName>Gael</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Campion</LastName><ForeName>Dominique</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sleegers</LastName><ForeName>Kristel</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hiltunen</LastName><ForeName>Mikko</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Combarros</LastName><ForeName>Onofre</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Zelenika</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Bullido</LastName><ForeName>Maria J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Tavernier</LastName><ForeName>B&#xe9;atrice</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Letenneur</LastName><ForeName>Luc</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Bettens</LastName><ForeName>Karolien</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Berr</LastName><ForeName>Claudine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Pasquier</LastName><ForeName>Florence</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Fi&#xe9;vet</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Barberger-Gateau</LastName><ForeName>Pascale</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Engelborghs</LastName><ForeName>Sebastiaan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>De Deyn</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Mateo</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Franck</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Helisalmi</LastName><ForeName>Seppo</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Porcellini</LastName><ForeName>Elisa</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Hanon</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><CollectiveName>European Alzheimer's Disease Initiative Investigators</CollectiveName></Author><Author ValidYN="Y"><LastName>de Pancorbo</LastName><ForeName>Marian M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Lendon</LastName><ForeName>Corinne</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Dufouil</LastName><ForeName>Carole</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Jaillard</LastName><ForeName>C&#xe9;line</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Leveillard</LastName><ForeName>Thierry</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Alvarez</LastName><ForeName>Victoria</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Bosco</LastName><ForeName>Paolo</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Mancuso</LastName><ForeName>Michelangelo</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Panza</LastName><ForeName>Francesco</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Nacmias</LastName><ForeName>Benedetta</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Boss&#xf9;</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Piccardi</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Annoni</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Seripa</LastName><ForeName>Davide</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Galimberti</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Hannequin</LastName><ForeName>Didier</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Licastro</LastName><ForeName>Federico</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Soininen</LastName><ForeName>Hilkka</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ritchie</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Blanch&#xe9;</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Dartigues</LastName><ForeName>Jean-Fran&#xe7;ois</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Tzourio</LastName><ForeName>Christophe</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Gut</LastName><ForeName>Ivo</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Van Broeckhoven</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Alp&#xe9;rovitch</LastName><ForeName>Annick</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lathrop</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Amouyel</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495242">CLU protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C509991">CR1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051152">Clusterin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017463">Receptors, Complement 3b</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Genet. 2009 Oct;41(10):1047-8. doi: 10.1038/ng1009-1047.</RefSource><PMID Version="1">19786950</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Clin Genet. 2010 Apr;77(4):330-2. doi: 10.1111/j.1399-0004.2009.01366_3.x.</RefSource><PMID Version="1">20095981</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051152" MajorTopicYN="N">Clusterin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017463" MajorTopicYN="N">Receptors, Complement 3b</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">White People</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Arosio</LastName><ForeName>Beatrice</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coto</LastName><ForeName>Eliecer</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Del Zompo</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deramecourt</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Epelbaum</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forti</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brice</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferri</LastName><ForeName>Raffaele</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scarpini</LastName><ForeName>Elio</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Siciliano</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Solfrizzi</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sorbi</LastName><ForeName>Sandro</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spalletta</LastName><ForeName>Gianfranco</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ravaglia</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sahel</LastName><ForeName>Jos&#xe9;</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valdivieso</LastName><ForeName>Fernando</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Veps&#xe4;l&#xe4;inen</LastName><ForeName>Saila</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pilotto</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId><ArticleId IdType="doi">10.1038/ng.439</ArticleId><ArticleId IdType="pii">ng.439</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2000 Feb 24;268(3):750-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10679277</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1997 Oct 22-29;278(16):1349-56</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2002 Jul 19;297(5580):353-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1999 Sep;65(3):664-70</Citation><ArticleIdList><ArticleId IdType="pubmed">10441572</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2009 Jul;30(7):1037-47</Citation><ArticleIdList><ArticleId IdType="pubmed">19362756</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4229-34</Citation><ArticleIdList><ArticleId IdType="pubmed">8633046</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Immunol. 2009 Feb;46(5):761-72</Citation><ArticleIdList><ArticleId IdType="pubmed">19004497</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2004 Jan 22;41(2):193-202</Citation><ArticleIdList><ArticleId IdType="pubmed">14741101</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 1993 Jul 1;293 ( Pt 1):27-30</Citation><ArticleIdList><ArticleId IdType="pubmed">8328966</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 1978 Oct;108(4):299-307</Citation><ArticleIdList><ArticleId IdType="pubmed">727199</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2006 Aug;38(8):904-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16862161</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Hum Genet. 2004 Nov;12(11):971-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15241485</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2002 Jun;4(3):169-77</Citation><ArticleIdList><ArticleId IdType="pubmed">12226536</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1979 Sep;76(9):4646-9</Citation><ArticleIdList><ArticleId IdType="pubmed">291993</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10837-42</Citation><ArticleIdList><ArticleId IdType="pubmed">12119423</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2009 Jan;84(1):35-43</Citation><ArticleIdList><ArticleId IdType="pubmed">19118814</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cereb Blood Flow Metab. 2007 May;27(5):909-18</Citation><ArticleIdList><ArticleId IdType="pubmed">17077814</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2009 Oct;41(10):1088-93</Citation><ArticleIdList><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1997 Jul;69(1):388-98</Citation><ArticleIdList><ArticleId IdType="pubmed">9202333</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 1982 May 1;155(5):1427-38</Citation><ArticleIdList><ArticleId IdType="pubmed">6978375</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Hum Genet. 2008 Dec;16(12):1413-29</Citation><ArticleIdList><ArticleId IdType="pubmed">19020537</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 1999 Mar;103(6):R15-R21</Citation><ArticleIdList><ArticleId IdType="pubmed">10079115</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2008 Nov;83(5):623-32</Citation><ArticleIdList><ArticleId IdType="pubmed">18976728</ArticleId></ArticleIdList></Reference><Reference><Citation>Microsc Res Tech. 2000 Aug 15;50(4):305-15</Citation><ArticleIdList><ArticleId IdType="pubmed">10936885</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 2007 Aug;32 Suppl 1:S62-70</Citation><ArticleIdList><ArticleId IdType="pubmed">17659844</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunopharmacology. 2000 Aug;49(1-2):187-98</Citation><ArticleIdList><ArticleId IdType="pubmed">10904117</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2007 Jun 7;54(5):713-20</Citation><ArticleIdList><ArticleId IdType="pubmed">17553421</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2008 Dec 11;456(7223):728-31</Citation><ArticleIdList><ArticleId IdType="pubmed">19079049</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1990 Dec;5(6):831-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1702645</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2009 Feb;41(2):192-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19136949</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10843-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12145324</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2005 Jan 15;21(2):263-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15297300</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Neurosci. 2004;23(3):247-54</Citation><ArticleIdList><ArticleId IdType="pubmed">15181253</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 1992 Oct;15(10):391-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1279864</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2006 Dec;27(12):1733-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16290270</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2008 Jan;65(1):45-53</Citation><ArticleIdList><ArticleId IdType="pubmed">17998437</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2008 Sep;106(5):2080-92</Citation><ArticleIdList><ArticleId IdType="pubmed">18624920</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2008 Nov 6;456(7218):18-21</Citation><ArticleIdList><ArticleId IdType="pubmed">18987709</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2007 Jan;39(1):17-23</Citation><ArticleIdList><ArticleId IdType="pubmed">17192785</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2008 Nov 26;60(4):534-42</Citation><ArticleIdList><ArticleId IdType="pubmed">19038212</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Feb;63(2):168-74</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">12702875</PMID><DateCompleted><Year>2003</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>300</Volume><Issue>5618</Issue><PubDate><Year>2003</Year><Month>Apr</Month><Day>18</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.</ArticleTitle><Pagination><StartPage>486</StartPage><EndPage>489</EndPage><MedlinePgn>486-9</MedlinePgn></Pagination><Abstract><AbstractText>Soluble oligomers are common to most amyloids and may represent the primary toxic species of amyloids, like the Abeta peptide in Alzheimer's disease (AD). Here we show that all of the soluble oligomers tested display a common conformation-dependent structure that is unique to soluble oligomers regardless of sequence. The in vitro toxicity of soluble oligomers is inhibited by oligomer-specific antibody. Soluble oligomers have a unique distribution in human AD brain that is distinct from fibrillar amyloid. These results indicate that different types of soluble amyloid oligomers have a common structure and suggest they share a common mechanism of toxicity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kayed</LastName><ForeName>Rakez</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697-3900, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Head</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>McIntire</LastName><ForeName>Theresa M</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>Milton</LastName><ForeName>Saskia C</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Cotman</LastName><ForeName>Carl W</ForeName><Initials>CW</Initials></Author><Author ValidYN="Y"><LastName>Glabe</LastName><ForeName>Charles G</ForeName><Initials>CG</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG00538</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG16573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS31230</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001704">Biopolymers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2003 Sep 26;301(5641):1847-9. doi: 10.1126/science.301.5641.1847.</RefSource><PMID Version="1">14512605</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001704" MajorTopicYN="N">Biopolymers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018613" MajorTopicYN="N">Microscopy, Confocal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018716" MajorTopicYN="N">Molecular Mimicry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>4</Month><Day>19</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>5</Month><Day>13</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>4</Month><Day>19</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId><ArticleId IdType="doi">10.1126/science.1079469</ArticleId><ArticleId IdType="pii">300/5618/486</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22896675</PMID><DateCompleted><Year>2013</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>147</Issue><PubDate><Year>2012</Year><Month>Aug</Month><Day>15</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid &#x3b2;.</ArticleTitle><Pagination><StartPage>147ra111</StartPage><MedlinePgn>147ra111</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.3003748</ELocationID><Abstract><AbstractText>Because it lacks a lymphatic circulation, the brain must clear extracellular proteins by an alternative mechanism. The cerebrospinal fluid (CSF) functions as a sink for brain extracellular solutes, but it is not clear how solutes from the brain interstitium move from the parenchyma to the CSF. We demonstrate that a substantial portion of subarachnoid CSF cycles through the brain interstitial space. On the basis of in vivo two-photon imaging of small fluorescent tracers, we showed that CSF enters the parenchyma along paravascular spaces that surround penetrating arteries and that brain interstitial fluid is cleared along paravenous drainage pathways. Animals lacking the water channel aquaporin-4 (AQP4) in astrocytes exhibit slowed CSF influx through this system and a ~70% reduction in interstitial solute clearance, suggesting that the bulk fluid flow between these anatomical influx and efflux routes is supported by astrocytic water transport. Fluorescent-tagged amyloid &#x3b2;, a peptide thought to be pathogenic in Alzheimer's disease, was transported along this route, and deletion of the Aqp4 gene suppressed the clearance of soluble amyloid &#x3b2;, suggesting that this pathway may remove amyloid &#x3b2; from the central nervous system. Clearance through paravenous flow may also regulate extracellular levels of proteins involved with neurodegenerative conditions, its impairment perhaps contributing to the mis-accumulation of soluble proteins.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iliff</LastName><ForeName>Jeffrey J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Center for Translational Neuromedicine, Department of Neurosurgery, University of Rochester Medical Center, Rochester, NY 14642, USA. jeffrey_iliff@urmc.rochester.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Minghuan</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Yonghong</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Plogg</LastName><ForeName>Benjamin A</ForeName><Initials>BA</Initials></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Weiguo</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Gundersen</LastName><ForeName>Georg A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Benveniste</LastName><ForeName>Helene</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Vates</LastName><ForeName>G Edward</ForeName><Initials>GE</Initials></Author><Author ValidYN="Y"><LastName>Deane</LastName><ForeName>Rashid</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Goldman</LastName><ForeName>Steven A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Nagelhus</LastName><ForeName>Erlend A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Nedergaard</LastName><ForeName>Maiken</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS078167</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS078304</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS075345</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS052534</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS075177</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051401">Aquaporin 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>059QF0KO0R</RegistryNumber><NameOfSubstance UI="D014867">Water</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Invest Ophthalmol Vis Sci. 2015 Jun;56(6):3955-6. doi: 10.1167/iovs.15-17243.</RefSource><PMID Version="1">26087361</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051401" MajorTopicYN="N">Aquaporin 4</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001692" MajorTopicYN="N">Biological Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002552" MajorTopicYN="N">Cerebral Ventricles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002555" MajorTopicYN="N">Cerebrospinal Fluid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045604" MajorTopicYN="N">Extracellular Fluid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021621" MajorTopicYN="N">Imaging, Three-Dimensional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036641" MajorTopicYN="N">Microscopy, Fluorescence, Multiphoton</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014867" MajorTopicYN="N">Water</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>8</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22896675</ArticleId><ArticleId IdType="mid">NIHMS432693</ArticleId><ArticleId IdType="pmc">PMC3551275</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.3003748</ArticleId><ArticleId IdType="pii">4/147/147ra111</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aukland K, Reed RK. Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. Physiol Rev. 1993;73:1&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">8419962</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid-Sch&#xf6;nbein GW. Microlymphatics and lymph flow. Physiol Rev. 1990;70:987&#x2013;1028.</Citation><ArticleIdList><ArticleId IdType="pubmed">2217560</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott NJ. Evidence for bulk flow of brain interstitial fluid: Significance for physiology and pathology. Neurochem Int. 2004;45:545&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">15186921</ArticleId></ArticleIdList></Reference><Reference><Citation>Cserr HF, Cooper DN, Suri PK, Patlak CS. Efflux of radiolabeled polyethylene glycols and albumin from rat brain. Am J Physiol. 1981;240:F319&#x2013;F328.</Citation><ArticleIdList><ArticleId IdType="pubmed">7223889</ArticleId></ArticleIdList></Reference><Reference><Citation>Cserr HF, Harling-Berg CJ, Knopf PM. Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance. Brain Pathol. 1992;2:269&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">1341962</ArticleId></ArticleIdList></Reference><Reference><Citation>Flexner LB. Some problems of the origin, circulation and absorption of the cerebrospinal fluid. Q Rev Biol. 1933;8:397&#x2013;422.</Citation></Reference><Reference><Citation>Praetorius J. Water and solute secretion by the choroid plexus. Pflugers Arch. 2007;454:1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">17120021</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh L, Zakharov A, Johnston M. Integration of the subarachnoid space and lymphatics: Is it time to embrace a new concept of cerebrospinal fluid absorption? Cerebrospinal Fluid Res. 2005;2:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1266390</ArticleId><ArticleId IdType="pubmed">16174293</ArticleId></ArticleIdList></Reference><Reference><Citation>Sykov&#xe1; E, Nicholson C. Diffusion in brain extracellular space. Physiol Rev. 2008;88:1277&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785730</ArticleId><ArticleId IdType="pubmed">18923183</ArticleId></ArticleIdList></Reference><Reference><Citation>Proescholdt MG, Hutto B, Brady LS, Herkenham M. Studies of cerebrospinal fluid flow and penetration into brain following lateral ventricle and cisterna magna injections of the tracer [14C]inulin in rat. Neuroscience. 2000;95:577&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pubmed">10658638</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichimura T, Fraser PA, Cserr HF. Distribution of extracellular tracers in perivascular spaces of the rat brain. Brain Res. 1991;545:103&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">1713524</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller RO. Microscopic morphology and histology of the human meninges. Morphologie. 2005;89:22&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">15943078</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadaczek P, Yamashita Y, Mirek H, Tamas L, Bohn MC, Noble C, Park JW, Bankiewicz K. The &#x201c;perivascular pump&#x201d; driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol Ther. 2006;14:69&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730223</ArticleId><ArticleId IdType="pubmed">16650807</ArticleId></ArticleIdList></Reference><Reference><Citation>Schley D, Carare-Nnadi R, Please CP, Perry VH, Weller RO. Mechanisms to explain the reverse perivascular transport of solutes out of the brain. J Theor Biol. 2006;238:962&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pubmed">16112683</ArticleId></ArticleIdList></Reference><Reference><Citation>Rennels ML, Blaumanis OR, Grady PA. Rapid solute transport throughout the brain via paravascular fluid pathways. Adv Neurol. 1990;52:431&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">2396537</ArticleId></ArticleIdList></Reference><Reference><Citation>Cserr HF. Physiology of the choroid plexus. Physiol Rev. 1971;51:273&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">4930496</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathiisen TM, Lehre KP, Danbolt NC, Ottersen OP. The perivascular astroglial sheath provides a complete covering of the brain microvessels: An electron microscopic 3D reconstruction. Glia. 2010;58:1094&#x2013;1103.</Citation><ArticleIdList><ArticleId IdType="pubmed">20468051</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, Holtzman DM. Neuronal activity regulates the regional vulnerability to amyloid-&#x3b2; deposition. Nat Neurosci. 2011;14:750&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV, Deane R, Sagare AP, Bell RD, Winkler EA. Low-density lipoprotein receptor-related protein-1: A serial clearance homeostatic mechanism controlling Alzheimer&#x2019;s amyloid &#x3b2;-peptide elimination from the brain. J Neurochem. 2010;115:1077&#x2013;1089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2972355</ArticleId><ArticleId IdType="pubmed">20854368</ArticleId></ArticleIdList></Reference><Reference><Citation>Crossgrove JS, Li GJ, Zheng W. The choroid plexus removes &#x3b2;-amyloid from brain cerebrospinal fluid. Exp Biol Med. 2005;230:771&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3982214</ArticleId><ArticleId IdType="pubmed">16246905</ArticleId></ArticleIdList></Reference><Reference><Citation>Serot JM, Zmudka J, Jouanny P. A possible role for CSF turnover and choroid plexus in the pathogenesis of late onset Alzheimer&#x2019;s disease. J Alzheimers Dis. 2012;30:17&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">22349684</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradbury MW, Westrop RJ. Factors influencing exit of substances from cerebrospinal fluid into deep cervical lymph of the rabbit. J Physiol. 1983;339:519&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1199176</ArticleId><ArticleId IdType="pubmed">6411905</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulton M, Young A, Hay J, Armstrong D, Flessner M, Schwartz M, Johnston M. Drainage of CSF through lymphatic pathways and arachnoid villi in sheep: Measurement of 125I-albumin clearance. Neuropathol Appl Neurobiol. 1996;22:325&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pubmed">8875467</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston M, Zakharov A, Papaiconomou C, Salmasi G, Armstrong D. Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species. Cerebrospinal Fluid Res. 2004;1:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC546409</ArticleId><ArticleId IdType="pubmed">15679948</ArticleId></ArticleIdList></Reference><Reference><Citation>Weed LH. The absorption of cerebrospinal fluid into the venous system. Am J Anat. 1923;31:191&#x2013;221.</Citation></Reference><Reference><Citation>Szentistv&#xe1;nyi I, Patlak CS, Ellis RA, Cserr HF. Drainage of interstitial fluid from different regions of rat brain. Am J Physiol. 1984;246:F835&#x2013;F844.</Citation><ArticleIdList><ArticleId IdType="pubmed">6742132</ArticleId></ArticleIdList></Reference><Reference><Citation>Carare RO, Bernardes-Silva M, Newman TA, Page AM, Nicoll JA, Perry VH, Weller RO. Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: Significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol Appl Neurobiol. 2008;34:131&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">18208483</ArticleId></ArticleIdList></Reference><Reference><Citation>Rennels ML, Gregory TF, Blaumanis OR, Fujimoto K, Grady PA. Evidence for a &#x2018;paravascular&#x2019; fluid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space. Brain Res. 1985;326:47&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">3971148</ArticleId></ArticleIdList></Reference><Reference><Citation>Pullen RG, DePasquale M, Cserr HF. Bulk flow of cerebrospinal fluid into brain in response to acute hyperosmolality. Am J Physiol. 1987;253:F538&#x2013;F545.</Citation><ArticleIdList><ArticleId IdType="pubmed">3115117</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadopoulos MC, Verkman AS. Aquaporin-4 and brain edema. Pediatr Nephrol. 2007;22:778&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6904420</ArticleId><ArticleId IdType="pubmed">17347837</ArticleId></ArticleIdList></Reference><Reference><Citation>Haj-Yasein NN, Vindedal GF, Eilert-Olsen M, Gundersen GA, Skare &#xd8;, Laake P, Klungland A, Thor&#xe9;n AE, Burkhardt JM, Ottersen OP, Nagelhus EA. Glial-conditional deletion of aquaporin-4 (Aqp4) reduces blood&#x2013;brain water uptake and confers barrier function on perivascular astrocyte endfeet. Proc Natl Acad Sci USA. 2011;108:17815&#x2013;17820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203818</ArticleId><ArticleId IdType="pubmed">21990350</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen S, Nagelhus EA, Amiry-Moghaddam M, Bourque C, Agre P, Ottersen OP. Specialized membrane domains for water transport in glial cells: High-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci. 1997;17:171&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793699</ArticleId><ArticleId IdType="pubmed">8987746</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorr A, Sled JG, Kabani N. Three-dimensional cerebral vasculature of the CBA mouse brain: A magnetic resonance imaging and micro computed tomography study. Neuroimage. 2007;35:1409&#x2013;1423.</Citation><ArticleIdList><ArticleId IdType="pubmed">17369055</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao X, Hrabetov&#xe1; S, Nicholson C, Manley GT. Aquaporin-4-deficient mice have increased extracellular space without tortuosity change. J Neurosci. 2008;28:5460&#x2013;5464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659334</ArticleId><ArticleId IdType="pubmed">18495879</ArticleId></ArticleIdList></Reference><Reference><Citation>Amiry-Moghaddam M, Otsuka T, Hurn PD, Traystman RJ, Haug FM, Froehner SC, Adams ME, Neely JD, Agre P, Ottersen OP, Bhardwaj A. An &#x3b1;-syntrophin-dependent pool of AQP4 in astroglial end-feet confers bidirectional water flow between blood and brain. Proc Natl Acad Sci USA. 2003;100:2106&#x2013;2111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC149966</ArticleId><ArticleId IdType="pubmed">12578959</ArticleId></ArticleIdList></Reference><Reference><Citation>Frigeri A, Nicchia GP, Nico B, Quondamatteo F, Herken R, Roncali L, Svelto M. Aquaporin-4 deficiency in skeletal muscle and brain of dystrophic mdx mice. FASEB J. 2001;15:90&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">11149896</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Kong H, Hua X, Xiao M, Ding J, Hu G. Altered blood-brain barrier integrity in adult aquaporin-4 knockout mice. Neuroreport. 2008;19:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">18281883</ArticleId></ArticleIdList></Reference><Reference><Citation>Eilert-Olsen M, Haj-Yasein NN, Vindedal GF, Enger R, Gundersen GA, Hoddevik EH, Petersen PH, Haug FM, Skare &#xd8;, Adams ME, Froehner SC, Burkhardt JM, Thoren AE, Nagelhus EA. Deletion of aquaporin-4 changes the perivascular glial protein scaffold without disrupting the brain endothelial barrier. Glia. 2012;60:432&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">22131281</ArticleId></ArticleIdList></Reference><Reference><Citation>Saadoun S, Tait MJ, Reza A, Davies DC, Bell BA, Verkman AS, Papadopoulos MC. AQP4 gene deletion in mice does not alter blood&#x2013;brain barrier integrity or brain morphology. Neuroscience. 2009;161:764&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pubmed">19345723</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball KK, Cruz NF, Mrak RE, Dienel GA. Trafficking of glucose, lactate, and amyloid-&#x3b2; from the inferior colliculus through perivascular routes. J Cereb Blood Flow Metab. 2010;30:162&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2801760</ArticleId><ArticleId IdType="pubmed">19794399</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. Perivascular drainage of amyloid-&#x3b2; peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer&#x2019;s disease. Brain Pathol. 2008;18:253&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095597</ArticleId><ArticleId IdType="pubmed">18363936</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross GW, O&#x2019;Callaghan JP, Sharp DS, Petrovitch H, Miller DB, Abbott RD, Nelson J, Launer LJ, Foley DJ, Burchfiel CM, Hardman J, White LR. Quantification of regional glial fibrillary acidic protein levels in Alzheimer&#x2019;s disease. Acta Neurol Scand. 2003;107:318&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">12713522</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Callaghan JP, Miller DB. The concentration of glial fibrillary acidic protein increases with age in the mouse and rat brain. Neurobiol Aging. 1991;12:171&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">1904995</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkhratsky A, Parpura V. Recent advances in (patho)physiology of astroglia. Acta Pharmacol Sin. 2010;31:1044&#x2013;1054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4002299</ArticleId><ArticleId IdType="pubmed">20694024</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamby ME, Sofroniew MV. Reactive astrocytes as therapeutic targets for CNS disorders. Neurotherapeutics. 2010;7:494&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2952540</ArticleId><ArticleId IdType="pubmed">20880511</ArticleId></ArticleIdList></Reference><Reference><Citation>Groothuis DR, Vavra MW, Schlageter KE, Kang EW, Itskovich AC, Hertzler S, Allen CV, Lipton HL. Efflux of drugs and solutes from brain: The interactive roles of diffusional transcapillary transport, bulk flow and capillary transporters. J Cereb Blood Flow Metab. 2007;27:43&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">16639426</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of amyloid-&#x3b2; peptide across the blood-brain barrier: Implication for therapies in Alzheimer&#x2019;s disease. CNS Neurol Disord Drug Targets. 2009;8:16&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2872930</ArticleId><ArticleId IdType="pubmed">19275634</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvira-Botero X, Carro EM. Clearance of amyCloid-&#x3b2; peptide across the choroid plexus in Alzheimer&#x2019;s disease. Curr Aging Sci. 2010;3:219&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">20735345</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM, Kivis&#xe4;kk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol. 2003;3:569&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pubmed">12876559</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Zhang H, Varrin-Doyer M, Zamvil SS, Verkman AS. Proinflammatory role of aquaporin-4 in autoimmune neuroinflammation. FASEB J. 2011;25:1556&#x2013;1566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3079299</ArticleId><ArticleId IdType="pubmed">21257712</ArticleId></ArticleIdList></Reference><Reference><Citation>Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, Herms J, Winkler F. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med. 2010;16:116&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">20023634</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman SA, Chen Z. Perivascular instruction of cell genesis and fate in the adult brain. Nat Neurosci. 2011;14:1382&#x2013;1389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3655803</ArticleId><ArticleId IdType="pubmed">22030549</ArticleId></ArticleIdList></Reference><Reference><Citation>Thrane AS, Rappold PM, Fujita T, Torres A, Bekar LK, Takano T, Peng W, Wang F, Thrane VR, Enger R, Haj-Yasein NN, Skare &#xd8;, Holen T, Klungland A, Ottersen OP, Nedergaard M, Nagelhus EA. Critical role of aquaporin-4 (AQP4) in astrocytic Ca2+ signaling events elicited by cerebral edema. Proc Natl Acad Sci USA. 2011;108:846&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3021020</ArticleId><ArticleId IdType="pubmed">21187412</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Bergles DE, Nishiyama A. NG2 cells generate both oligodendrocytes and gray matter astrocytes. Development. 2008;135:145&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">18045844</ArticleId></ArticleIdList></Reference><Reference><Citation>Takano T, Tian GF, Peng W, Lou N, Libionka W, Han X, Nedergaard M. Astrocyte-mediated control of cerebral blood flow. Nat Neurosci. 2006;9:260&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">16388306</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehre KP, Levy LM, Ottersen OP, Storm-Mathisen J, Danbolt NC. Differential expression of two glial glutamate transporters in the rat brain: Quantitative and immunocytochemical observations. J Neurosci. 1995;15:1835&#x2013;1853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578153</ArticleId><ArticleId IdType="pubmed">7891138</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11406613</PMID><DateCompleted><Year>2001</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0964-6906</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>12</Issue><PubDate><Year>2001</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Human molecular genetics</Title><ISOAbbreviation>Hum Mol Genet</ISOAbbreviation></Journal><ArticleTitle>BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.</ArticleTitle><Pagination><StartPage>1317</StartPage><EndPage>1324</EndPage><MedlinePgn>1317-24</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) is a neurodegenerative disorder characterized by accumulation of amyloid plaques and neurofibrillary tangles in the brain. The major components of plaque, beta-amyloid peptides (Abetas), are produced from amyloid precursor protein (APP) by the activity of beta- and gamma-secretases. beta-secretase activity cleaves APP to define the N-terminus of the Abeta1-x peptides and, therefore, has been a long- sought therapeutic target for treatment of AD. The gene encoding a beta-secretase for beta-site APP cleaving enzyme (BACE) was identified recently. However, it was not known whether BACE was the primary beta-secretase in mammalian brain nor whether inhibition of beta-secretase might have effects in mammals that would preclude its utility as a therapeutic target. In the work described herein, we generated two lines of BACE knockout mice and characterized them for pathology, beta-secretase activity and Abeta production. These mice appeared to develop normally and showed no consistent phenotypic differences from their wild-type littermates, including overall normal tissue morphology and brain histochemistry, normal blood and urine chemistries, normal blood-cell composition, and no overt behavioral and neuromuscular effects. Brain and primary cortical cultures from BACE knockout mice showed no detectable beta-secretase activity, and primary cortical cultures from BACE knockout mice produced much less Abeta from APP. The findings that BACE is the primary beta-secretase activity in brain and that loss of beta-secretase activity produces no profound phenotypic defects with a concomitant reduction in beta-amyloid peptide clearly indicate that BACE is an excellent therapeutic target for treatment of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Roberds</LastName><ForeName>S L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Genomics, Pharmacia Corp., 301 Henrietta Street, Kalamazoo, MI 49007, USA. steven.l.roberds@pharmacia.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Basi</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Bienkowski</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Branstetter</LastName><ForeName>D G</ForeName><Initials>DG</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>K S</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Freedman</LastName><ForeName>S B</ForeName><Initials>SB</Initials></Author><Author ValidYN="Y"><LastName>Frigon</LastName><ForeName>N L</ForeName><Initials>NL</Initials></Author><Author ValidYN="Y"><LastName>Games</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Johnson-Wood</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kappenman</LastName><ForeName>K E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Kawabe</LastName><ForeName>T T</ForeName><Initials>TT</Initials></Author><Author ValidYN="Y"><LastName>Kola</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Kuehn</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Motter</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Nichols</LastName><ForeName>N F</ForeName><Initials>NF</Initials></Author><Author ValidYN="Y"><LastName>Power</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Robertson</LastName><ForeName>D W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Schenk</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Schoor</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Shopp</LastName><ForeName>G M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Shuck</LastName><ForeName>M E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Sinha</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Svensson</LastName><ForeName>K A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Tatsuno</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Tintrup</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Wijsman</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>McConlogue</LastName><ForeName>L</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hum Mol Genet</MedlineTA><NlmUniqueID>9208958</NlmUniqueID><ISSNLinking>0964-6906</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046508" MajorTopicYN="N">Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008808" MajorTopicYN="N">Mice, Inbred CBA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>6</Month><Day>15</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>10</Month><Day>19</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>6</Month><Day>15</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11406613</ArticleId><ArticleId IdType="doi">10.1093/hmg/10.12.1317</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20080541</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>4</Issue><PubDate><Year>2010</Year><Month>Jan</Month><Day>26</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition.</ArticleTitle><Pagination><StartPage>1630</StartPage><EndPage>1635</EndPage><MedlinePgn>1630-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0908953107</ELocationID><Abstract><AbstractText>An additional copy of the beta-amyloid precursor protein (APP) gene causes early-onset Alzheimer's disease (AD) in trisomy 21 (DS). Endosome dysfunction develops very early in DS and AD and has been implicated in the mechanism of neurodegeneration. Here, we show that morphological and functional endocytic abnormalities in fibroblasts from individuals with DS are reversed by lowering the expression of APP or beta-APP-cleaving enzyme 1 (BACE-1) using short hairpin RNA constructs. By contrast, endosomal pathology can be induced in normal disomic (2N) fibroblasts by overexpressing APP or the C-terminal APP fragment generated by BACE-1 (betaCTF), all of which elevate the levels of betaCTFs. Expression of a mutant form of APP that cannot undergo beta-cleavage had no effect on endosomes. Pharmacological inhibition of APP gamma-secretase, which markedly reduced Abeta production but raised betaCTF levels, also induced AD-like endosome dysfunction in 2N fibroblasts and worsened this pathology in DS fibroblasts. These findings strongly implicate APP and the betaCTF of APP, and exclude Abeta and the alphaCTF, as the cause of endocytic pathway dysfunction in DS and AD, underscoring the potential multifaceted value of BACE-1 inhibition in AD therapeutics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan Kline Institute, Orangeburg, NY 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mullaney</LastName><ForeName>Kerry A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Peterhoff</LastName><ForeName>Corrinne M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Che</LastName><ForeName>Shaoli</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Stephen D</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Boyer-Boiteau</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ginsberg</LastName><ForeName>Stephen D</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Cataldo</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Mathews</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Nixon</LastName><ForeName>Ralph A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG014449</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG043375</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG017617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>12</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1263-4. doi: 10.1073/pnas.0913922107.</RefSource><PMID Version="1">20133888</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011992" MajorTopicYN="N">Endosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034622" MajorTopicYN="Y">RNA Interference</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>7</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20080541</ArticleId><ArticleId IdType="pmc">PMC2824382</ArticleId><ArticleId IdType="doi">10.1073/pnas.0908953107</ArticleId><ArticleId IdType="pii">0908953107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Haass C, et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature. 1992;359:322&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">1383826</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, Estus S, Younkin LH, Selkoe DJ, Younkin SG. Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science. 1992;255:728&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">1738847</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia SS, Price DL. Role of the beta-amyloid protein in Alzheimer&#x2019;s disease. FASEB J. 1995;9:366&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">7896005</ArticleId></ArticleIdList></Reference><Reference><Citation>Athan ES, Lee JH, Arriaga A, Mayeux RP, Tycko B. Polymorphisms in the promoter of the human APP gene: Functional evaluation and allele frequencies in Alzheimer disease. Arch Neurol. 2002;59:1793&#x2013;1799.</Citation><ArticleIdList><ArticleId IdType="pubmed">12433268</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovelet-Lecrux A, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006;38:24&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">16369530</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K, et al. APP duplication is sufficient to cause early onset Alzheimer&#x2019;s dementia with cerebral amyloid angiopathy. Brain. 2006;129:2977&#x2013;2983.</Citation><ArticleIdList><ArticleId IdType="pubmed">16921174</ArticleId></ArticleIdList></Reference><Reference><Citation>Margallo-Lana M, et al. Influence of the amyloid precursor protein locus on dementia in Down syndrome. Neurology. 2004;62:1996&#x2013;1998.</Citation><ArticleIdList><ArticleId IdType="pubmed">15184603</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. Niemann-Pick Type C disease and Alzheimer&#x2019;s disease: The APP-endosome connection fattens up. Am J Pathol. 2004;164:757&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1613265</ArticleId><ArticleId IdType="pubmed">14982829</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, et al. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer&#x2019;s disease and Down syndrome: Differential effects of APOE genotype and presenilin mutations. Am J Pathol. 2000;157:277&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850219</ArticleId><ArticleId IdType="pubmed">10880397</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, et al. Down syndrome fibroblast model of Alzheimer-related endosome pathology: Accelerated endocytosis promotes late endocytic defects. Am J Pathol. 2008;173:370&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2475775</ArticleId><ArticleId IdType="pubmed">18535180</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbel M, Yacoby I, Solomon B. Inhibition of amyloid precursor protein processing by &#x3b2;-secretase through site-directed antibodies. Proc Natl Acad Sci USA. 2005;102:7718&#x2013;7723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1140443</ArticleId><ArticleId IdType="pubmed">15894613</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajendran L, et al. Efficient inhibition of the Alzheimer&#x2019;s disease &#x3b2;-secretase by membrane targeting. Science. 2008;320:520&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">18436784</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: Progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia SS. Beta-amyloid precursor protein cleavage by a membrane-bound protease. Proc Natl Acad Sci USA. 1992;89:6075&#x2013;6079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC49440</ArticleId><ArticleId IdType="pubmed">1631093</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, et al. Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc Natl Acad Sci USA. 1996;93:13333&#x2013;13338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24093</ArticleId><ArticleId IdType="pubmed">8917591</ArticleId></ArticleIdList></Reference><Reference><Citation>Salehi A, et al. Increased App expression in a mouse model of Down&#x2019;s syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron. 2006;51:29&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">16815330</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, et al. App gene dosage modulates endosomal abnormalities of Alzheimer&#x2019;s disease in a segmental trisomy 16 mouse model of Down syndrome. J Neurosci. 2003;23:6788&#x2013;6792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740714</ArticleId><ArticleId IdType="pubmed">12890772</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathews PM, et al. Alzheimer&#x2019;s disease-related overexpression of the cation-dependent mannose 6-phosphate receptor increases A&#x3b2; secretion: Role for altered lysosomal hydrolase distribution in beta-amyloidogenesis. J Biol Chem. 2002;277:5299&#x2013;5307.</Citation><ArticleIdList><ArticleId IdType="pubmed">11551970</ArticleId></ArticleIdList></Reference><Reference><Citation>Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296:550&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">11910072</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Teplow DB, Selkoe DJ. Generation of amyloid beta protein from its precursor is sequence specific. Neuron. 1995;14:661&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">7695913</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi JH, et al. Age-dependent dysregulation of brain amyloid precursor protein in the Ts65Dn Down syndrome mouse model. J Neurochem. 2009;110:1818&#x2013;1827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744432</ArticleId><ArticleId IdType="pubmed">19619138</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, Esler WP, Das C. Continuing strategies for inhibiting Alzheimer&#x2019;s gamma-secretase. J Mol Neurosci. 2002;19:83&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">12212799</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaether C, Schmitt S, Willem M, Haass C. Amyloid precursor protein and Notch intracellular domains are generated after transport of their precursors to the cell surface. Traffic. 2006;7:408&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">16536739</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao SC, Krichevsky AM, Kosik KS, Tsai LH. BACE1 suppression by RNA interference in primary cortical neurons. J Biol Chem. 2004;279:1942&#x2013;1949.</Citation><ArticleIdList><ArticleId IdType="pubmed">14600149</ArticleId></ArticleIdList></Reference><Reference><Citation>Geller LN, Potter H. Chromosome missegregation and trisomy 21 mosaicism in Alzheimer&#x2019;s disease. Neurobiol Dis. 1999;6:167&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408806</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. Endosome function and dysfunction in Alzheimer&#x2019;s disease and other neurodegenerative diseases. Neurobiol Aging. 2005;26:373&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">15639316</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci. 2007;120:4081&#x2013;4091.</Citation><ArticleIdList><ArticleId IdType="pubmed">18032783</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin LW, Shie FS, Maezawa I, Vincent I, Bird T. Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. Am J Pathol. 2004;164:975&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1614713</ArticleId><ArticleId IdType="pubmed">14982851</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HS, et al. Carboxyl-terminal fragment of Alzheimer&#x2019;s APP destabilizes calcium homeostasis and renders neuronal cells vulnerable to excitotoxicity. FASEB J. 2000;14:1508&#x2013;1517.</Citation><ArticleIdList><ArticleId IdType="pubmed">10928985</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer O, et al. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci. 2005;8:1343&#x2013;1349.</Citation><ArticleIdList><ArticleId IdType="pubmed">16136043</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, et al. Beta-secretase cleavage of Alzheimer&#x2019;s amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Nistor M, et al. Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain. Neurobiol Aging. 2007;28:1493&#x2013;1506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375834</ArticleId><ArticleId IdType="pubmed">16904243</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD, Che S, Wuu J, Counts SE, Mufson EJ. Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer&#x2019;s disease. J Neurochem. 2006;97:475&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">16539663</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathews PM, et al. Calpain activity regulates the cell surface distribution of amyloid precursor protein: Inhibition of calpains enhances endosomal generation of beta-cleaved C-terminal APP fragments. J Biol Chem. 2002;277:36415&#x2013;36424.</Citation><ArticleIdList><ArticleId IdType="pubmed">12087104</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19935655</PMID><DateCompleted><Year>2009</Year><Month>12</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>12</Issue><PubDate><Year>2009</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses.</ArticleTitle><Pagination><StartPage>1567</StartPage><EndPage>1576</EndPage><MedlinePgn>1567-76</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.2433</ELocationID><Abstract><AbstractText>Accumulation of cerebral amyloid-beta peptide (Abeta) is essential for developing synaptic and cognitive deficits in Alzheimer's disease. However, the physiological functions of Abeta, as well as the primary mechanisms that initiate early Abeta-mediated synaptic dysfunctions, remain largely unknown. Here we examine the acute effects of endogenously released Abeta peptides on synaptic transfer at single presynaptic terminals and synaptic connections in rodent hippocampal cultures and slices. Increasing extracellular Abeta by inhibiting its degradation enhanced release probability, boosting ongoing activity in the hippocampal network. Presynaptic enhancement mediated by Abeta was found to depend on the history of synaptic activation, with lower impact at higher firing rates. Notably, both elevation and reduction in Abeta levels attenuated short-term synaptic facilitation during bursts in excitatory synaptic connections. These observations suggest that endogenous Abeta peptides have a crucial role in activity-dependent regulation of synaptic vesicle release and might point to the primary pathological events that lead to compensatory synapse loss in Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abramov</LastName><ForeName>Efrat</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dolev</LastName><ForeName>Iftach</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Fogel</LastName><ForeName>Hilla</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ciccotosto</LastName><ForeName>Giuseppe D</ForeName><Initials>GD</Initials></Author><Author ValidYN="Y"><LastName>Ruff</LastName><ForeName>Eyal</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Slutsky</LastName><ForeName>Inna</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026941">Sodium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>4368-28-9</RegistryNumber><NameOfSubstance UI="D013779">Tetrodotoxin</NameOfSubstance></Chemical><Chemical><RegistryNumber>B79L7B5X3Z</RegistryNumber><NameOfSubstance UI="D015244">Thiorphan</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.11</RegistryNumber><NameOfSubstance UI="D015260">Neprilysin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056547" MajorTopicYN="N">CA1 Region, Hippocampal</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019706" MajorTopicYN="N">Excitatory Postsynaptic Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008564" MajorTopicYN="N">Membrane Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015260" MajorTopicYN="N">Neprilysin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009433" MajorTopicYN="N">Neural Inhibition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009924" MajorTopicYN="N">Organ Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017729" MajorTopicYN="N">Presynaptic Terminals</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026941" MajorTopicYN="N">Sodium Channel Blockers</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013572" MajorTopicYN="N">Synaptic Vesicles</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013779" MajorTopicYN="N">Tetrodotoxin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015244" MajorTopicYN="N">Thiorphan</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19935655</ArticleId><ArticleId IdType="doi">10.1038/nn.2433</ArticleId><ArticleId IdType="pii">nn.2433</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Science. 2001 May 25;292(5521):1550-2</Citation><ArticleIdList><ArticleId IdType="pubmed">11375493</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Physiol. 2002;64:355-405</Citation><ArticleIdList><ArticleId IdType="pubmed">11826273</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 1990 May;27(5):457-64</Citation><ArticleIdList><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3228-33</Citation><ArticleIdList><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Ther. 2005 Nov;108(2):129-48</Citation><ArticleIdList><ArticleId IdType="pubmed">16112736</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2008 Jan 23;28(4):788-97</Citation><ArticleIdList><ArticleId IdType="pubmed">18216187</ArticleId></ArticleIdList></Reference><Reference><Citation>J Physiol. 1996 Feb 15;491 ( Pt 1):163-76</Citation><ArticleIdList><ArticleId IdType="pubmed">9011608</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2004 Jan 8;41(1):27-33</Citation><ArticleIdList><ArticleId IdType="pubmed">14715132</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2005 Dec 22;48(6):913-22</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 1991 Oct;30(4):572-80</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2004 Jan 28;24(4):991-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14749444</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1997 Jun;18(6):995-1008</Citation><ArticleIdList><ArticleId IdType="pubmed">9208866</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2004 Aug 19;366(3):320-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15288443</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2002 Oct 25;298(5594):789-91</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2007 Aug;8(8):597-609</Citation><ArticleIdList><ArticleId IdType="pubmed">17637801</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2004 Dec 2;44(5):835-49</Citation><ArticleIdList><ArticleId IdType="pubmed">15572114</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):5161-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16549764</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2004 Apr 8;42(1):23-36</Citation><ArticleIdList><ArticleId IdType="pubmed">15066262</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1992 Sep 24;359(6393):325-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1406936</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 2004 Feb 11;23(3):483-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14749724</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2005 Aug 24;25(34):7709-17</Citation><ArticleIdList><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Sci. 2000 Jun;113 ( Pt 11):1857-70</Citation><ArticleIdList><ArticleId IdType="pubmed">10806097</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1995 May 19;81(4):525-31</Citation><ArticleIdList><ArticleId IdType="pubmed">7758106</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1987 May;6(5):1317-22</Citation><ArticleIdList><ArticleId IdType="pubmed">2440677</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2001 Oct 25;32(2):177-80</Citation><ArticleIdList><ArticleId IdType="pubmed">11683988</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1990 Jan-Feb;11(1):29-37</Citation><ArticleIdList><ArticleId IdType="pubmed">2325814</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2008 Aug;14(8):837-42</Citation><ArticleIdList><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2007 Sep 6;55(5):697-711</Citation><ArticleIdList><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2005 May 26;435(7041):497-501</Citation><ArticleIdList><ArticleId IdType="pubmed">15917809</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2006 Mar 16;440(7082):352-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2004 Oct 14;431(7010):796-803</Citation><ArticleIdList><ArticleId IdType="pubmed">15483601</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2001 Jun 15;276(24):21895-901</Citation><ArticleIdList><ArticleId IdType="pubmed">11278416</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 1999 Mar;38(3):349-59</Citation><ArticleIdList><ArticleId IdType="pubmed">10219973</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1992 Oct 2;258(5079):126-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1439760</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 1999 Apr;90(1):1-13</Citation><ArticleIdList><ArticleId IdType="pubmed">10188929</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 1997 Jan;20(1):38-43</Citation><ArticleIdList><ArticleId IdType="pubmed">9004418</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1997 Apr;18(4):599-612</Citation><ArticleIdList><ArticleId IdType="pubmed">9136769</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1999 Oct 15;19(20):8876-84</Citation><ArticleIdList><ArticleId IdType="pubmed">10516307</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2003 Mar 27;37(6):925-37</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Biol Cell. 2000 Apr;11(4):1213-24</Citation><ArticleIdList><ArticleId IdType="pubmed">10749925</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2007 Mar 14;27(11):2866-75</Citation><ArticleIdList><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2008 Aug 29;321(5893):1221-4</Citation><ArticleIdList><ArticleId IdType="pubmed">18755980</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2008 Apr 10;58(1):42-51</Citation><ArticleIdList><ArticleId IdType="pubmed">18400162</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1992 Sep 24;359(6393):322-5</Citation><ArticleIdList><ArticleId IdType="pubmed">1383826</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2001 Jul;4(7):711-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11426227</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2008 Dec 31;28(53):14537-45</Citation><ArticleIdList><ArticleId IdType="pubmed">19118188</ArticleId></ArticleIdList></Reference><Reference><Citation>J Physiol. 1968 Mar;195(2):481-92</Citation><ArticleIdList><ArticleId IdType="pubmed">4296699</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1993 Oct;11(4):713-24</Citation><ArticleIdList><ArticleId IdType="pubmed">8398156</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2006 Dec 7;52(5):831-43</Citation><ArticleIdList><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2000 Feb;6(2):143-50</Citation><ArticleIdList><ArticleId IdType="pubmed">10655101</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11700559</PMID><DateCompleted><Year>2001</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-0836</ISSN><JournalIssue CitedMedium="Print"><Volume>414</Volume><Issue>6860</Issue><PubDate><Year>2001</Year><Month>Nov</Month><Day>08</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity.</ArticleTitle><Pagination><StartPage>212</StartPage><EndPage>216</EndPage><MedlinePgn>212-6</MedlinePgn></Pagination><Abstract><AbstractText>Epidemiological studies have documented a reduced prevalence of Alzheimer's disease among users of nonsteroidal anti-inflammatory drugs (NSAIDs). It has been proposed that NSAIDs exert their beneficial effects in part by reducing neurotoxic inflammatory responses in the brain, although this mechanism has not been proved. Here we report that the NSAIDs ibuprofen, indomethacin and sulindac sulphide preferentially decrease the highly amyloidogenic Abeta42 peptide (the 42-residue isoform of the amyloid-beta peptide) produced from a variety of cultured cells by as much as 80%. This effect was not seen in all NSAIDs and seems not to be mediated by inhibition of cyclooxygenase (COX) activity, the principal pharmacological target of NSAIDs. Furthermore, short-term administration of ibuprofen to mice that produce mutant beta-amyloid precursor protein (APP) lowered their brain levels of Abeta42. In cultured cells, the decrease in Abeta42 secretion was accompanied by an increase in the Abeta(1-38) isoform, indicating that NSAIDs subtly alter gamma-secretase activity without significantly perturbing other APP processing pathways or Notch cleavage. Our findings suggest that NSAIDs directly affect amyloid pathology in the brain by reducing Abeta42 peptide levels independently of COX activity and that this Abeta42-lowering activity could be optimized to selectively target the pathogenic Abeta42 species.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weggen</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California San Diego, La Jolla, California 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eriksen</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Sagi</LastName><ForeName>S A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Pietrzik</LastName><ForeName>C U</ForeName><Initials>CU</Initials></Author><Author ValidYN="Y"><LastName>Findlay</LastName><ForeName>K A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>T E</ForeName><Initials>TE</Initials></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>M P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Bulter</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>D E</ForeName><Initials>DE</Initials></Author><Author ValidYN="Y"><LastName>Marquez-Sterling</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Golde</LastName><ForeName>T E</ForeName><Initials>TE</Initials></Author><Author ValidYN="Y"><LastName>Koo</LastName><ForeName>E H</ForeName><Initials>EH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>184SNS8VUH</RegistryNumber><NameOfSubstance UI="D013467">Sulindac</NameOfSubstance></Chemical><Chemical><RegistryNumber>6UVA8S2DEY</RegistryNumber><NameOfSubstance UI="C025462">sulindac sulfide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.99.1</RegistryNumber><NameOfSubstance UI="D011451">Prostaglandin-Endoperoxide Synthases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>WK2XYI10QM</RegistryNumber><NameOfSubstance UI="D007052">Ibuprofen</NameOfSubstance></Chemical><Chemical><RegistryNumber>XXE1CET956</RegistryNumber><NameOfSubstance UI="D007213">Indomethacin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2001 Nov 8;414(6860):159-60. doi: 10.1038/35102656.</RefSource><PMID Version="1">11700538</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007052" MajorTopicYN="N">Ibuprofen</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007213" MajorTopicYN="N">Indomethacin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011451" MajorTopicYN="N">Prostaglandin-Endoperoxide Synthases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013467" MajorTopicYN="N">Sulindac</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>11</Month><Day>9</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>11</Month><Day>9</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11700559</ArticleId><ArticleId IdType="doi">10.1038/35102591</ArticleId><ArticleId IdType="pii">35102591</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22323718</PMID><DateCompleted><Year>2012</Year><Month>03</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>6</Issue><PubDate><Year>2012</Year><Month>Feb</Month><Day>08</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Differential effects between &#x3b3;-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice.</ArticleTitle><Pagination><StartPage>2037</StartPage><EndPage>2050</EndPage><MedlinePgn>2037-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4264-11.2012</ELocationID><Abstract><AbstractText>&#x3b3;-Secretase inhibitors (GSIs) reduce amyloid-&#x3b2; (A&#x3b2;) peptides but inevitably increase the &#x3b2;-C-terminal fragment (&#x3b2;-CTF) of amyloid precursor protein (APP), potentially having undesirable effects on synapses. In contrast, &#x3b3;-secretase modulators (GSMs) reduce A&#x3b2;42 without increasing &#x3b2;-CTF. Although the A&#x3b2;-lowering effects of these compounds have been extensively studied, little effort has been made to investigate their effects on cognition. Here, we compared the effects of two GSIs--(2S)-2-hydroxy-3-methyl-N-[(2S)-1-{[(1S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-3-benzazepin-1-yl]amino}-1-oxopropan-2-yl]butanamide (LY450139, semagacestat) and (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxazol-3-yl)phenyl]methyl]amino-5,5,5-trifluoropentanamide (BMS-708163)--and a second-generation GSM [{(2S,4R)-1-[(4R)-1,1,1-trifluoro-7-methyloctan-4-yl]-2-[4-(trifluoromethyl)phenyl]piperidin-4-yl}acetic acid (GSM-2)] on spatial working memory in APP-transgenic (Tg2576) and nontransgenic mice using the Y-maze task. While acute dosing with either GSI ameliorated memory deficits in 5.5-month-old Tg2576 mice, these effects disappeared after 8 d subchronic dosing. Subchronic dosing with either GSI rather impaired normal cognition in 3-month-old Tg2576 mice, with no inhibition on the processing of other &#x3b3;-secretase substrates, such as Notch, N-cadherin, or EphA4, in the brain. LY450139 also impaired normal cognition in wild-type mice; however, the potency was 10-fold lower than that in Tg2576 mice, indicating an APP-dependent mechanism likely with &#x3b2;-CTF accumulation. Immunofluorescence studies revealed that the &#x3b2;-CTF accumulation was localized in the presynaptic terminals of the hippocampal stratum lucidum and dentate hilus, implying an effect on presynaptic function in the mossy fibers. In contrast, both acute and subchronic dosing with GSM-2 significantly ameliorated memory deficits in Tg2576 mice and did not affect normal cognition in wild-type mice. We demonstrated a clear difference between GSI and GSM in effects on functional consequences, providing new insights into strategies for developing these drugs against Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mitani</LastName><ForeName>Yasuyuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Pharmacology Research Laboratories, Astellas Pharma, Inc., Tsukuba, Ibaraki 305-8585, Japan. yasuyuki.mitani@astellas.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yarimizu</LastName><ForeName>Junko</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Saita</LastName><ForeName>Kyoko</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Uchino</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Akashiba</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Shitaka</LastName><ForeName>Yoshitsugu</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Ni</LastName><ForeName>Keni</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Matsuoka</LastName><ForeName>Nobuya</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001381">Azepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C484278">N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001381" MajorTopicYN="N">Azepines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>8</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22323718</ArticleId><ArticleId IdType="pmc">PMC6621706</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4264-11.2012</ArticleId><ArticleId IdType="pii">32/6/2037</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alberi L, Liu S, Wang Y, Badie R, Smith-Hicks C, Wu J, Pierfelice TJ, Abazyan B, Mattson MP, Kuhl D, Pletnikov M, Worley PF, Gaiano N. Activity-induced Notch signaling in neurons requires Arc/Arg3.1 and is essential for synaptic plasticity in hippocampal networks. Neuron. 2011;69:437&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056341</ArticleId><ArticleId IdType="pubmed">21315255</ArticleId></ArticleIdList></Reference><Reference><Citation>Allison JG, Das PM, Ma J, Inglis FM, Jones FE. The ERBB4 intracellular domain (4ICD) regulates NRG1-induced gene expression in hippocampal neurons. Neurosci Res. 2011;70:155&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">21352860</ArticleId></ArticleIdList></Reference><Reference><Citation>Beher D, Wrigley JD, Owens AP, Shearman MS. Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity. J Neurochem. 2002;82:563&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pubmed">12153480</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittner T, Fuhrmann M, Burgold S, Jung CK, Volbracht C, Steiner H, Mitteregger G, Kretzschmar HA, Haass C, Herms J. &#x3b3;-Secretase inhibition reduces spine density in vivo via an amyloid precursor protein-dependent pathway. J Neurosci. 2009;29:10405&#x2013;10409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665795</ArticleId><ArticleId IdType="pubmed">19692615</ArticleId></ArticleIdList></Reference><Reference><Citation>Bot N, Schweizer C, Ben Halima S, Fraering PC. Processing of the synaptic cell adhesion molecule Neurexin-3&#x3b2; by Alzheimer disease &#x3b1;- and &#x3b3;-secretases. J Biol Chem. 2011;286:2762&#x2013;2773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3024772</ArticleId><ArticleId IdType="pubmed">21084300</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-&#x3b2; metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Comery TA, Martone RL, Aschmies S, Atchison KP, Diamantidis G, Gong X, Zhou H, Kreft AF, Pangalos MN, Sonnenberg-Reines J, Jacobsen JS, Marquis KL. Acute &#x3b3;-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2005;25:8898&#x2013;8902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725598</ArticleId><ArticleId IdType="pubmed">16192379</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook JJ, Wildsmith KR, Gilberto DB, Holahan MA, Kinney GG, Mathers PD, Michener MS, Price EA, Shearman MS, Simon AJ, Wang JX, Wu G, Yarasheski KE, Bateman RJ. Acute &#x3b3;-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-&#x3b2; production to alternative APP fragments without amyloid-&#x3b2; rebound. J Neurosci. 2010;30:6743&#x2013;6750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2913973</ArticleId><ArticleId IdType="pubmed">20463236</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa RM, Honjo T, Silva AJ. Learning and memory deficits in Notch mutant mice. Curr Biol. 2003;13:1348&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pubmed">12906797</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998;391:387&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">9450754</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH, Schrijvers V, Wolfe MS, Ray WJ, Goate A, Kopan R. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999;398:518&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206645</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewachter I, Revers&#xe9; D, Caluwaerts N, Ris L, Kuip&#xe9;ri C, Van den Haute C, Spittaels K, Umans L, Serneels L, Thiry E, Moechars D, Mercken M, Godaux E, Van Leuven F. Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice. J Neurosci. 2002;22:3445&#x2013;3453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758348</ArticleId><ArticleId IdType="pubmed">11978821</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, Golde TE. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest. 2003;112:440&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC166298</ArticleId><ArticleId IdType="pubmed">12897211</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008;65:1031&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2682361</ArticleId><ArticleId IdType="pubmed">18695053</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillman KW, Starrett JE, Parker MF, Xie K, Bronson JJ, Marcin LR, McElhone KE, Bergstrom CP, Mate RA, Williams R, Meredith JE, Burton CR, Barten DM, Toyn JH, Roberts SB, Lentz KA, Houston JG, Zaczek R, Albright CF, Decicco CP, et al. Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable &#x3b3;-secretase inhibitor. ACS Med Chem Lett. 2010;1:120&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4007960</ArticleId><ArticleId IdType="pubmed">24900185</ArticleId></ArticleIdList></Reference><Reference><Citation>Henley DB, May PC, Dean RA, Siemers ER. Development of semagacestat (LY450139), a functional &#x3b3;-secretase inhibitor, for the treatment of Alzheimer's disease. Expert Opin Pharmacother. 2009;10:1657&#x2013;1664.</Citation><ArticleIdList><ArticleId IdType="pubmed">19527190</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, Morgan D. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav Genet. 1999;29:177&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">10547924</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, A&#x3b2; elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbimbo BP, Hutter-Paier B, Villetti G, Facchinetti F, Cenacchi V, Volta R, Lanzillotta A, Pizzi M, Windisch M. CHF5074, a novel &#x3b3;-secretase modulator, attenuates brain &#x3b2;-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. Br J Pharmacol. 2009;156:982&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2697723</ArticleId><ArticleId IdType="pubmed">19239474</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue E, Deguchi-Tawarada M, Togawa A, Matsui C, Arita K, Katahira-Tayama S, Sato T, Yamauchi E, Oda Y, Takai Y. Synaptic activity prompts gamma-secretase-mediated cleavage of EphA4 and dendritic spine formation. J Cell Biol. 2009;185:551&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700400</ArticleId><ArticleId IdType="pubmed">19414612</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43) Neuron. 1994;13:45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">8043280</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett JT, Berger EP, Lansbury PT., Jr The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 1993;32:4693&#x2013;4697.</Citation><ArticleIdList><ArticleId IdType="pubmed">8490014</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Mullaney KA, Peterhoff CM, Che S, Schmidt SD, Boyer-Boiteau A, Ginsberg SD, Cataldo AM, Mathews PM, Nixon RA. Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc Natl Acad Sci U S A. 2010;107:1630&#x2013;1635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824382</ArticleId><ArticleId IdType="pubmed">20080541</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinno S, Araki K, Matsumoto Y, Suh YH, Yamamoto T. Selective apoptosis induction in the hippocampal mossy fiber pathway by exposure to CT105, the C-terminal fragment of Alzheimer's amyloid precursor protein. Brain Res. 2009;1249:68&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">19007761</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T, Shoji M, Younkin LH, Wen-Lang L, Dickson DW, Murakami T, Matsubara E, Abe K, Ashe KH, Younkin SG. Dimeric amyloid &#x3b2; protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2004;24:3801&#x2013;3809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729359</ArticleId><ArticleId IdType="pubmed">15084661</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Suh YH, Lee MH, Ryu PD. Cation selective channels formed by a C-terminal fragment of beta-amyloid precursor protein. Neuroreport. 1999;10:1427&#x2013;1431.</Citation><ArticleIdList><ArticleId IdType="pubmed">10380958</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Suh YH. Neurotoxicity of a carboxyl-terminal fragment of the Alzheimer's amyloid precursor protein. J Neurochem. 1996;67:1172&#x2013;1182.</Citation><ArticleIdList><ArticleId IdType="pubmed">8752124</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopan R, Ilagan MX. Gamma-secretase: proteasome of the membrane? Nat Rev Mol Cell Biol. 2004;5:499&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">15173829</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopan R, Schroeter EH, Weintraub H, Nye JS. Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain. Proc Natl Acad Sci U S A. 1996;93:1683&#x2013;1688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40002</ArticleId><ArticleId IdType="pubmed">8643690</ArticleId></ArticleIdList></Reference><Reference><Citation>Kounnas MZ, Danks AM, Cheng S, Tyree C, Ackerman E, Zhang X, Ahn K, Nguyen P, Comer D, Mao L, Yu C, Pleynet D, Digregorio PJ, Velicelebi G, Stauderman KA, Comer WT, Mobley WC, Li YM, Sisodia SS, Tanzi RE, et al. Modulation of &#x3b3;-secretase reduces &#x3b2;-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron. 2010;67:769&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947312</ArticleId><ArticleId IdType="pubmed">20826309</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreft AF, Martone R, Porte A. Recent advances in the identification of &#x3b3;-secretase inhibitors to clinically test the A&#x3b2; oligomer hypothesis of Alzheimer's disease. J Med Chem. 2009;52:6169&#x2013;6188.</Citation><ArticleIdList><ArticleId IdType="pubmed">19694467</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukar T, Prescott S, Eriksen JL, Holloway V, Murphy MP, Koo EH, Golde TE, Nicolle MM. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci. 2007;8:54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1948891</ArticleId><ArticleId IdType="pubmed">17650315</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, Vandersteen A, Segers-Nolten I, Van Der Werf K, Subramaniam V, Braeken D, Callewaert G, Bartic C, D'Hooge R, Martins IC, Rousseau F, Schymkowitz J, De Strooper B. Neurotoxicity of Alzheimer's disease Abeta peptides is induced by small changes in the Abeta42 to Abeta40 ratio. EMBO J. 2010;29:3408&#x2013;3420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2957213</ArticleId><ArticleId IdType="pubmed">20818335</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL. A&#x3b2; oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007;27:796&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, Chiang HC, Xu G, Koliatsos VE, Borchelt DR, Price DL, Lee HK, Wong PC. BACE1, a major determinant of selective vulnerability of the brain to amyloid-&#x3b2; amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci. 2005;25:11693&#x2013;11709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2564291</ArticleId><ArticleId IdType="pubmed">16354928</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MK, Slunt HH, Martin LJ, Thinakaran G, Kim G, Gandy SE, Seeger M, Koo E, Price DL, Sisodia SS. Expression of presenilin 1 and 2 (PS1 and PS2) in human and murine tissues. J Neurosci. 1996;16:7513&#x2013;7525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579112</ArticleId><ArticleId IdType="pubmed">8922407</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999;155:853&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>Marambaud P, Wen PH, Dutt A, Shioi J, Takashima A, Siman R, Robakis NK. A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell. 2003;114:635&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">13678586</ArticleId></ArticleIdList></Reference><Reference><Citation>Martone RL, Zhou H, Atchison K, Comery T, Xu JZ, Huang X, Gong X, Jin M, Kreft A, Harrison B, Mayer SC, Aschmies S, Gonzales C, Zaleska MM, Riddell DR, Wagner E, Lu P, Sun SC, Sonnenberg-Reines J, Oganesian A, et al. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther. 2009;331:598&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">19671883</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy JV, Twomey C, Wujek P. Presenilin-dependent regulated intramembrane proteolysis and gamma-secretase activity. Cell Mol Life Sci. 2009;66:1534&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11131470</ArticleId><ArticleId IdType="pubmed">19189053</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005;47:191&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1373682</ArticleId><ArticleId IdType="pubmed">16039562</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999;46:860&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, Jacobs RT, Zacco A, Greenberg B, Ciaccio PJ. Modulation of Notch processing by &#x3b3;-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci. 2004;82:341&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">15319485</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of A&#x3b2; 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbantoglu J, Tirado-Santiago G, Lahsa&#xef;ni A, Poirier J, Goncalves O, Verge G, Momoli F, Welner SA, Massicotte G, Julien JP, Shapiro ML. Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature. 1997;387:500&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">9168112</ArticleId></ArticleIdList></Reference><Reference><Citation>Oehlrich D, Berthelot DJC, Gijsen HJ. &#x3b3;-Secretase modulators as potential disease modifying anti-Alzheimer's drugs. J Med Chem. 2011;54:669&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pubmed">21141968</ArticleId></ArticleIdList></Reference><Reference><Citation>Oster-Granite ML, McPhie DL, Greenan J, Neve RL. Age-dependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid precursor protein. J Neurosci. 1996;16:6732&#x2013;6741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579256</ArticleId><ArticleId IdType="pubmed">8824314</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L, Roberson ED. Quantifying biomarkers of cognitive dysfunction and neuronal network hyperexcitability in mouse models of Alzheimer's disease: depletion of calcium-dependent proteins and inhibitory hippocampal remodeling. Methods Mol Biol. 2011;670:245&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8153735</ArticleId><ArticleId IdType="pubmed">20967595</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, Westman-Brinkmalm A, Zetterberg H, Simon AJ, Blennow K. A novel pathway for amyloid precursor protein processing. Neurobiol Aging. 2011;32:1090&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">19604603</ArticleId></ArticleIdList></Reference><Reference><Citation>Pu YJ, Vaid RK, Boini SK, Towsley RW, Doecke CW, Mitchell D. A practical method for functionalized peptide or amide bond formation in aqueous-ethanol media with EDC as activator. Org Process Res Dev. 2008;13:310&#x2013;314.</Citation></Reference><Reference><Citation>Rushworth JV, Hooper NM. Lipid rafts: linking Alzheimer's amyloid-beta production, aggregation, and toxicity at neuronal membranes. Int J Alzheimers Dis. 2010;2011:603052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3014710</ArticleId><ArticleId IdType="pubmed">21234417</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Chen G, Malkani S, Choi SY, Takahashi RH, Zhang D, Gouras GK, Kirkwood A, Morris RG, Shen J. Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. J Neurosci. 2005;25:6755&#x2013;6764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725351</ArticleId><ArticleId IdType="pubmed">16033885</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemers E, Henley D, Sundell K, Sethuraman G, Dean R, Wrobleski K, Mohs R. Evaluating semagacestat, a gamma-secretase inhibitor, in a phase III trial. Alzheimers Dement. 2011;7:S484&#x2013;S485.</Citation></Reference><Reference><Citation>Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature. 1999;402:537&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591214</ArticleId></ArticleIdList></Reference><Reference><Citation>Struhl G, Greenwald I. Presenilin is required for activity and nuclear access of Notch in Drosophila. Nature. 1999;398:522&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206646</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh YH, Kim HS, Lee JP, Park CH, Jeong SJ, Kim SS, Rah JC, Seo JH, Kim SS. Roles of A beta and carboxyl terminal peptide fragments of amyloid precursor protein in Alzheimer disease. J Neural Transm Suppl. 2000;2000:65&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">11128614</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M, Qu Y, Gray A, Wu Z, Seto T, Hutton M, Shearman MS, Middleton RE. Oral treatment with a gamma-secretase inhibitor improves long-term potentiation in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther. 2010;333:110&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">20056779</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dam D, D'Hooge R, Staufenbiel M, Van Ginneken C, Van Meir F, De Deyn PP. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci. 2003;17:388&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">12542676</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Chan SL, Miele L, Yao PJ, Mackes J, Ingram DK, Mattson MP, Furukawa K. Involvement of Notch signaling in hippocampal synaptic plasticity. Proc Natl Acad Sci U S A. 2004;101:9458&#x2013;9462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC438998</ArticleId><ArticleId IdType="pubmed">15190179</ArticleId></ArticleIdList></Reference><Reference><Citation>Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH. A subset of NSAIDs lower amyloidogenic A&#x3b2;42 independently of cyclooxygenase activity. Nature. 2001;414:212&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">11700559</ArticleId></ArticleIdList></Reference><Reference><Citation>Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Golde TE, Koo EH. A&#x3b2;42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J Biol Chem. 2003;278:30748&#x2013;30754.</Citation><ArticleIdList><ArticleId IdType="pubmed">12777371</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Nguyen LN, Kessels HW, Hagiwara H, Sisodia S, Malinow R. Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat Neurosci. 2010;13:190&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3310198</ArticleId><ArticleId IdType="pubmed">20037574</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and &#x3b3;-secretase activity. Nature. 1999;398:513&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee HJ, Zhang L, Higgins GA, Parker EM. Chronic treatment with the &#x3b3;-secretase inhibitor LY-411,575 inhibits &#x3b2;-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004;279:12876&#x2013;12882.</Citation><ArticleIdList><ArticleId IdType="pubmed">14709552</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, Carter DB, Tomasselli AG, Parodi LA, Heinrikson RL, Gurney ME. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature. 1999;402:533&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591213</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan XX, Li T, Rominger CM, Prakash SR, Wong PC, Olson RE, Zaczek R, Li YW. Binding sites of &#x3b3;-secretase inhibitors in rodent brain: distribution, postnatal development, and effect of deafferentation. J Neurosci. 2004;24:2942&#x2013;2952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729845</ArticleId><ArticleId IdType="pubmed">15044533</ArticleId></ArticleIdList></Reference><Reference><Citation>Younkin SG. The role of A beta 42 in Alzheimer's disease. J Physiol Paris. 1998;92:289&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">9789825</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16990514</PMID><DateCompleted><Year>2006</Year><Month>11</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>314</Volume><Issue>5799</Issue><PubDate><Year>2006</Year><Month>Oct</Month><Day>27</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Control of peripheral nerve myelination by the beta-secretase BACE1.</ArticleTitle><Pagination><StartPage>664</StartPage><EndPage>666</EndPage><MedlinePgn>664-6</MedlinePgn></Pagination><Abstract><AbstractText>Although BACE1 (beta-site amyloid precursor protein-cleaving enzyme 1) is essential for the generation of amyloid-b peptide in Alzheimer's disease, its physiological function is unclear. We found that very high levels of BACE1 were expressed at time points when peripheral nerves become myelinated. Deficiency of BACE1 resulted in the accumulation of unprocessed neuregulin 1 (NRG1), an axonally expressed factor required for glial cell development and myelination. BACE1-/- mice displayed hypomyelination of peripheral nerves and aberrant axonal segregation of small-diameter afferent fibers, very similar to that seen in mice with mutations in type III NRG1 or Schwann cell-specific ErbB2 knockouts. Thus, BACE1 is required for myelination and correct bundling of axons by Schwann cells, probably through processing of type III NRG1.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Willem</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Adolf Butenandt-Institute, Department of Biochemistry, Laboratory for Alzheimer's and Parkinson's Disease Research, Schillerstrasse 44, Ludwig-Maximilians-University, 80336 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garratt</LastName><ForeName>Alistair N</ForeName><Initials>AN</Initials></Author><Author ValidYN="Y"><LastName>Novak</LastName><ForeName>Bozidar</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Citron</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kaufmann</LastName><ForeName>Steve</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Rittger</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>DeStrooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Saftig</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Birchmeier</LastName><ForeName>Carmen</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020890">Neuregulin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C490581">Nrg1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2006 Oct 27;314(5799):602-3. doi: 10.1126/science.1135043.</RefSource><PMID Version="1">17068248</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005727" MajorTopicYN="N">Ganglia, Spinal</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009186" MajorTopicYN="N">Myelin Sheath</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020890" MajorTopicYN="N">Neuregulin-1</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009475" MajorTopicYN="N">Neurons, Afferent</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="N">Protein Processing, Post-Translational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012583" MajorTopicYN="N">Schwann Cells</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012584" MajorTopicYN="N">Sciatic Nerve</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>9</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>11</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>9</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16990514</ArticleId><ArticleId IdType="doi">10.1126/science.1132341</ArticleId><ArticleId IdType="pii">1132341</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20864679</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-2191</ISSN><JournalIssue CitedMedium="Internet"><Volume>177</Volume><Issue>5</Issue><PubDate><Year>2010</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The American journal of pathology</Title><ISOAbbreviation>Am J Pathol</ISOAbbreviation></Journal><ArticleTitle>CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models.</ArticleTitle><Pagination><StartPage>2549</StartPage><EndPage>2562</EndPage><MedlinePgn>2549-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2353/ajpath.2010.100265</ELocationID><Abstract><AbstractText>Microglia, the primary immune effector cells in the brain, continually monitor the tissue parenchyma for pathological alterations and become activated in Alzheimer's disease. Loss of signaling between neurons and microglia via deletion of the microglial receptor, CX3CR1, worsens phenotypes in various models of neurodegenerative diseases. In contrast, CX3CR1 deficiency ameliorates pathology in murine stroke models. To examine the role of CX3CR1 in Alzheimer's disease-related &#x3b2;-amyloid pathology, we generated APPPS1 and R1.40 transgenic mouse models of Alzheimer's disease deficient for CX3CR1. Surprisingly, CX3CR1 deficiency resulted in a gene dose-dependent reduction in &#x3b2;-amyloid deposition in both the APPPS1 and R1.40 mouse models of AD. Immunohistochemical analysis revealed reduced staining for CD68, a marker of microglial activation. Furthermore, quantitative immunohistochemical analysis revealed reduced numbers of microglia surrounding &#x3b2;-amyloid deposits in the CX3CR1-deficient APPPS1 animals. The reduced &#x3b2;-amyloid pathology correlated with reduced levels of TNF&#x3b1; and CCL2 mRNAs, but elevated IL1&#x3b2; mRNA levels, suggesting an altered neuroinflammatory milieu. Finally, to account for these seemingly disparate results, both in vitro and in vivo studies provided evidence that CX3CL1/CX3CR1 signaling alters the phagocytic capacity of microglia, including the uptake of A&#x3b2; fibrils. Taken together, these results demonstrate that loss of neuron-microglial fractalkine signaling leads to reduced &#x3b2;-amyloid deposition in mouse models of AD that is potentially mediated by altered activation and phagocytic capability of CX3CR1-deficient microglia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sungho</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Lerner Research Institute, The Cleveland Clinic, Department of Neurosciences, Case Western Reserve University School of Medicine, 9500 Euclid Avenue, NC30, Cleveland, OH 44195-0001, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varvel</LastName><ForeName>Nicholas H</ForeName><Initials>NH</Initials></Author><Author ValidYN="Y"><LastName>Konerth</LastName><ForeName>Megan E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Guixiang</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Cardona</LastName><ForeName>Astrid E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Ransohoff</LastName><ForeName>Richard M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Lamb</LastName><ForeName>Bruce T</ForeName><Initials>BT</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG023012</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30NS068003</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30 NS068003</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG023012</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007250</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Pathol</MedlineTA><NlmUniqueID>0370502</NlmUniqueID><ISSNLinking>0002-9440</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073883">CX3C Chemokine Receptor 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054428">Chemokine CX3CL1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C471885">Cx3cr1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019707">Receptors, Chemokine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073883" MajorTopicYN="N">CX3C Chemokine Receptor 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054428" MajorTopicYN="N">Chemokine CX3CL1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019707" MajorTopicYN="N">Receptors, Chemokine</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20864679</ArticleId><ArticleId IdType="pmc">PMC2966811</ArticleId><ArticleId IdType="doi">10.2353/ajpath.2010.100265</ArticleId><ArticleId IdType="pii">S0002-9440(10)60305-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease&#x2013;a double-edged sword. Neuron. 2002;35:419&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">12165466</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T. Inflammation and Alzheimer&#x2019;s disease. Neurobiol Aging. 2000;21:383&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenigsknecht-Talboo J, Meyer-Luehmann M, Parsadanian M, Garcia-Alloza M, Finn MB, Hyman BT, Bacskai BJ, Holtzman DM. Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J Neurosci. 2008;28:14156&#x2013;14164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743894</ArticleId><ArticleId IdType="pubmed">19109498</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, Klunk WE, Kohsaka S, Jucker M, Calhoun ME. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci. 2008;28:4283&#x2013;4292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3844768</ArticleId><ArticleId IdType="pubmed">18417708</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer&#x2019;s disease. Nature. 2008;451:720&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Gordon MN, Tan J, Wilcock D, Rojiani AM. Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J Neuropathol Exp Neurol. 2005;64:743&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pubmed">16141783</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto M, Horiba M, Buescher JL, Huang D, Gendelman HE, Ransohoff RM, Ikezu T. Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am J Pathol. 2005;166:1475&#x2013;1485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1606401</ArticleId><ArticleId IdType="pubmed">15855647</ArticleId></ArticleIdList></Reference><Reference><Citation>Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, Duman RS, Flavell RA. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med. 2008;14:681&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2649699</ArticleId><ArticleId IdType="pubmed">18516051</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, O'Banion MK. Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest. 2007;117:1595&#x2013;1604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1878531</ArticleId><ArticleId IdType="pubmed">17549256</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Z, Ho L, Yemul S, Zhao Z, Qing W, Pompl P, Kelley K, Dang A, Teplow D, Pasinetti GM. Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer&#x2019;s disease neuropathology. Gene Expr. 2002;10:271&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5977525</ArticleId><ArticleId IdType="pubmed">12450219</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci. 2008;28:6333&#x2013;6341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329761</ArticleId><ArticleId IdType="pubmed">18562603</ArticleId></ArticleIdList></Reference><Reference><Citation>Limatola C, Lauro C, Catalano M, Ciotti MT, Bertollini C, Di Angelantonio S, Ragozzino D, Eusebi F. Chemokine CX3CL1 protects rat hippocampal neurons against glutamate-mediated excitotoxicity. J Neuroimmunol. 2005;166:19&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">16019082</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, Huang D, Kidd G, Dombrowski S, Dutta R, Lee JC, Cook DN, Jung S, Lira SA, Littman DR, Ransohoff RM. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci. 2006;9:917&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">16732273</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK, Streit WJ, Salafranca MN, Adhikari S, Thompson DA, Botti P, Bacon KB, Feng L. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia, Proc Natl Acad Sci USA. 1998;95:10896&#x2013;10901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27992</ArticleId><ArticleId IdType="pubmed">9724801</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, Littman DR. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol. 2000;20:4106&#x2013;4114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC85780</ArticleId><ArticleId IdType="pubmed">10805752</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385:640&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pubmed">9024663</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuo J, Smith BC, Bojanowski CM, Meleth AD, Gery I, Csaky KG, Chew EY, Chan CC. The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age-related macular degeneration. FASEB J. 2004;18:1297&#x2013;1299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1971128</ArticleId><ArticleId IdType="pubmed">15208270</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan CC, Tuo J, Bojanowski CM, Csaky KG, Green WR. Detection of CX3CR1 single nucleotide polymorphism and expression on archived eyes with age-related macular degeneration. Histol Histopathol. 2005;20:857&#x2013;863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1930145</ArticleId><ArticleId IdType="pubmed">15944936</ArticleId></ArticleIdList></Reference><Reference><Citation>Denes A, Ferenczi S, Halasz J, Kornyei Z, Kovacs KJ. Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. J Cereb Blood Flow Metab. 2008;28:1707&#x2013;1721.</Citation><ArticleIdList><ArticleId IdType="pubmed">18575457</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano SG, Amaravadi LS, Wang YF, Zhou H, Yu GX, Tonra JR, Fairchild-Huntress V, Fang Q, Dunmore JH, Huszar D, Pan Y. Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. J Neuroimmunol. 2002;125:59&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">11960641</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, Jaggi F, Wolburg H, Gengler S, Haass C, Ghetti B, Czech C, Holscher C, Mathews PM, Jucker M. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7:940&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb BT, Sisodia SS, Lawler AM, Slunt HH, Kitt CA, Kearns WG, Pearson PL, Price DL, Gearhart JD. Introduction and expression of the 400 kilobase amyloid precursor protein gene in transgenic mice [corrected]. Nat Genet. 1993;5:22&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">8220418</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb BT, Call LM, Slunt HH, Bardel KA, Lawler AM, Eckman CB, Younkin SG, Holtz G, Wagner SL, Price DL, Sisodia SS, Gearhart JD. Altered metabolism of familial Alzheimer&#x2019;s disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice. Hum Mol Genet. 1997;6:1535&#x2013;1541.</Citation><ArticleIdList><ArticleId IdType="pubmed">9285791</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehman EJH, Kulnane LS, Lamb BT. Alterations in &#x3b2;-amyloid production and deposition in brain regions of two transgenic models. Neurobiol Aging. 2003;24:645&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pubmed">12885572</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehman EJ, Kulnane LS, Gao Y, Petriello MC, Pimpis KM, Younkin L, Dolios G, Wang R, Younkin SG, Lamb BT. Genetic background regulates &#x3b2;-amyloid precursor protein processing and &#x3b2;-amyloid deposition in the mouse. Hum Mol Genet. 2003;12:2949&#x2013;2956.</Citation><ArticleIdList><ArticleId IdType="pubmed">14506131</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin LJ, Sisodia SS, Koo EH, Cork LC, Dellovade TL, Weidemann A, Beyreuther K, Masters C, Price DL. Amyloid precursor protein in aged nonhuman primates. Proc Natl Acad Sci USA. 1991;88:1461&#x2013;1465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC51038</ArticleId><ArticleId IdType="pubmed">1899927</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Varvel NH, Lamb BT, Herrup K. Ectopic cell cycle events link human Alzheimer&#x2019;s disease and amyloid precursor protein transgenic mouse models. J Neurosci. 2006;26:775&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675370</ArticleId><ArticleId IdType="pubmed">16421297</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci. 2005;25:5446&#x2013;5454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725006</ArticleId><ArticleId IdType="pubmed">15930395</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE. CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J Neurosci. 2009;29:11982&#x2013;11992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2778845</ArticleId><ArticleId IdType="pubmed">19776284</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura J, Tusell JM, Serratosa J. High-yield isolation of murine microglia by mild trypsinization. Glia. 2003;44:183&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">14603460</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenigsknecht J, Landreth G. Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism. J Neurosci. 2004;24:9838&#x2013;9846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730228</ArticleId><ArticleId IdType="pubmed">15525768</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DC, Kim SH, Jeong MW, Baek NI, Kim KT. Effect of rottlerin, a PKC-delta inhibitor, on TLR-4-dependent activation of murine microglia. Biochem Biophys Res Commun. 2005;337:110&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">16182255</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenigsknecht-Talboo J, Landreth GE. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci. 2005;25:8240&#x2013;8249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725530</ArticleId><ArticleId IdType="pubmed">16148231</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehme SA, Lio FM, Maciejewski-Lenoir D, Bacon KB, Conlon PJ. The chemokine fractalkine inhibits Fas-mediated cell death of brain microglia. J Immunol. 2000;165:397&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">10861077</ArticleId></ArticleIdList></Reference><Reference><Citation>Haskell CA, Hancock WW, Salant DJ, Gao W, Csizmadia V, Peters W, Faia K, Fituri O, Rottman JB, Charo IF. Targeted deletion of CX(3)CR1 reveals a role for fractalkine in cardiac allograft rejection. J Clin Invest. 2001;108:679&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC209384</ArticleId><ArticleId IdType="pubmed">11544273</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulnane LS, Lamb BT. Neuropathological characterization of mutant amyloid precursor protein yeast artificial chromosome transgenic mice. Neurobiol Dis. 2001;8:982&#x2013;992.</Citation><ArticleIdList><ArticleId IdType="pubmed">11741394</ArticleId></ArticleIdList></Reference><Reference><Citation>Combadiere C, Feumi C, Raoul W, Keller N, Rodero M, Pezard A, Lavalette S, Houssier M, Jonet L, Picard E, Debre P, Sirinyan M, Deterre P, Ferroukhi T, Cohen SY, Chauvaud D, Jeanny JC, Chemtob S, Behar-Cohen F, Sennlaub F. CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. J Clin Invest. 2007;117:2920&#x2013;2928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1994614</ArticleId><ArticleId IdType="pubmed">17909628</ArticleId></ArticleIdList></Reference><Reference><Citation>Raoul W, Keller N, Rodero M, Behar-Cohen F, Sennlaub F, Combadiere C. Role of the chemokine receptor CX3CR1 in the mobilization of phagocytic retinal microglial cells. J Neuroimmunol. 2008;198:56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">18508131</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishizuka K, Kimura T, Igata-yi R, Katsuragi S, Takamatsu J, Miyakawa T. Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer&#x2019;s disease. Psychiatry Clin Neurosci. 1997;51:135&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225377</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer&#x2019;s disease. Neuron. 2006;49:489&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">16476660</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Sastre M, Dumitrescu-Ozimek L, Dewachter I, Walter J, Klockgether T, Van Leuven F. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J Neuroinflammation. 2005;2:22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1274341</ArticleId><ArticleId IdType="pubmed">16212664</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelsins MC, Mastrangelo MA, Oddo S, LaFerla FM, Federoff HJ, Bowers WJ. Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer&#x2019;s disease mice. J Neuroinflammation. 2005;2:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1276812</ArticleId><ArticleId IdType="pubmed">16232318</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman GA, Moores K, Harrison D, Campbell CA, Stewart BR, Strijbos PJ. Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. J Neurosci. 2000;20:RC87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772533</ArticleId><ArticleId IdType="pubmed">10899174</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend KP, Town T, Mori T, Lue LF, Shytle D, Sanberg PR, Morgan D, Fernandez F, Flavell RA, Tan J. CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid beta-peptide. Eur J Immunol. 2005;35:901&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pubmed">15688347</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelcer N, Khanlou N, Clare R, Jiang Q, Reed-Geaghan EG, Landreth GE, Vinters HV, Tontonoz P. Attenuation of neuroinflammation and Alzheimer&#x2019;s disease pathology by liver x receptors. Proc Natl Acad Sci USA. 2007;104:10601&#x2013;10606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1890560</ArticleId><ArticleId IdType="pubmed">17563384</ArticleId></ArticleIdList></Reference><Reference><Citation>Boissonneault V, Filali M, Lessard M, Relton J, Wong G, Rivest S. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer&#x2019;s disease. Brain. 2009;132:1078&#x2013;1092.</Citation><ArticleIdList><ArticleId IdType="pubmed">19151372</ArticleId></ArticleIdList></Reference><Reference><Citation>Shie FS, Montine KS, Breyer RM, Montine TJ. Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity. Glia. 2005;52:70&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">15920732</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol. 2009;27:119&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">19302036</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez S, Baglietto-Vargas D, Caballero C, Moreno-Gonzalez I, Torres M, Sanchez-Varo R, Ruano D, Vizuete M, Gutierrez A, Vitorica J. Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer&#x2019;s disease: age-dependent switch in the microglial phenotype from alternative to classic. J Neurosci. 2008;28:11650&#x2013;11661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671312</ArticleId><ArticleId IdType="pubmed">18987201</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsonego A, Zota V, Karni A, Krieger JI, Bar-Or A, Bitan G, Budson AE, Sperling R, Selkoe DJ, Weiner HL. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest. 2003;112:415&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC166296</ArticleId><ArticleId IdType="pubmed">12897209</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto M, Kiyota T, Walsh SM, Liu J, Kipnis J, Ikezu T. Cytokine-mediated inhibition of fibrillar amyloid-beta peptide degradation by human mononuclear phagocytes. J Immunol. 2008;181:3877&#x2013;3886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2603577</ArticleId><ArticleId IdType="pubmed">18768842</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu E, Kawahara K, Kajizono M, Sawada M, Nakayama H. IL-4-induced selective clearance of oligomeric beta-amyloid peptide(1-42) by rat primary type 2 microglia. J Immunol. 2008;181:6503&#x2013;6513.</Citation><ArticleIdList><ArticleId IdType="pubmed">18941241</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn J, Montine T, Morrow J, Woodward WR, Kulhanek D, Eckenstein F. Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer&#x2019;s disease. J Neuroimmunol. 2003;137:32&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">12667645</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiyota T, Yamamoto M, Xiong H, Lambert MP, Klein WL, Gendelman HE, Ransohoff RM, Ikezu T. CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PLoS One. 2009;4:e6197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2703798</ArticleId><ArticleId IdType="pubmed">19593388</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajetto A, Bonavia R, Barbero S, Florio T, Schettini G. Chemokines and their receptors in the central nervous system. Front Neuroendocrinol. 2001;22:147&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">11456467</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowing G, Lalancette-Hebert M, Audet JN, Dequen F, Julien JP. Macrophage colony stimulating factor (M-CSF) exacerbates ALS disease in a mouse model through altered responses of microglia expressing mutant superoxide dismutase. Exp Neurol. 2009;220:267&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">19733170</ArticleId></ArticleIdList></Reference><Reference><Citation>Grathwohl SA, Kalin RE, Bolmont T, Prokop S, Winkelmann G, Kaeser SA, Odenthal J, Radde R, Eldh T, Gandy S, Aguzzi A, Staufenbiel M, Mathews PM, Wolburg H, Heppner FL, Jucker M. Formation and maintenance of Alzheimer&#x2019;s disease beta-amyloid plaques in the absence of microglia. Nat Neurosci. 2009;12:1361&#x2013;1363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4721582</ArticleId><ArticleId IdType="pubmed">19838177</ArticleId></ArticleIdList></Reference><Reference><Citation>Manczak M, Mao P, Nakamura K, Bebbington C, Park B, Reddy PH. Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1&#x2013;42 and suppresses microglial activity in a transgenic mouse model of Alzheimer&#x2019;s disease. Hum Mol Genet. 2009;18:3876&#x2013;3893.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748895</ArticleId><ArticleId IdType="pubmed">19617638</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med. 2007;13:432&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pubmed">17351623</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondolfi L, Calhoun M, Ermini F, Kuhn HG, Wiederhold KH, Walker L, Staufenbiel M, Jucker M. Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J Neurosci. 2002;22:515&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758656</ArticleId><ArticleId IdType="pubmed">11784797</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuhrmann M, Bittner T, Jung CK, Burgold S, Page RM, Mitteregger G, Haass C, LaFerla FM, Kretzschmar H, Herms J. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer&#x2019;s disease. Nat Neurosci. 13:411&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4072212</ArticleId><ArticleId IdType="pubmed">20305648</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes JP, Blurton-Jones M, Yamasaki TR, Agostinho P, LaFerla FM. Activation of cell cycle proteins in transgenic mice in response to neuronal loss but not amyloid-beta and tau pathology. J Alzheimers Dis. 2009;16:541&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pubmed">19276549</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20920788</PMID><DateCompleted><Year>2010</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Month>Oct</Month><Day>06</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Regulation of tau pathology by the microglial fractalkine receptor.</ArticleTitle><Pagination><StartPage>19</StartPage><EndPage>31</EndPage><MedlinePgn>19-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2010.08.023</ELocationID><Abstract><AbstractText>Aggregates of the hyperphosphorylated microtubule-associated protein tau (MAPT) are an invariant neuropathological feature of tauopathies. Here, we show that microglial neuroinflammation promotes MAPT phosphorylation and aggregation. First, lipopolysaccharide-induced microglial activation promotes hyperphosphorylation of endogenous mouse MAPT in nontransgenic mice that is further enhanced in mice lacking the microglial-specific fractalkine receptor (CX3CR1) and is dependent upon functional toll-like receptor 4 and interleukin-1 (IL-1) receptors. Second, humanized MAPT transgenic mice lacking CX3CR1 exhibited enhanced MAPT phosphorylation and aggregation as well as behavioral impairments that correlated with increased levels of active p38 MAPK. Third, in&#xa0;vitro experiments demonstrate that microglial activation elevates the level of active p38 MAPK and enhances MAPT hyperphosphorylation within neurons that can be blocked by administration of an interleukin-1 receptor antagonist and a specific p38 MAPK inhibitor. Taken together, our results suggest that CX3CR1 and IL-1/p38 MAPK may serve as novel therapeutic targets for human tauopathies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2010 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bhaskar</LastName><ForeName>Kiran</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konerth</LastName><ForeName>Megan</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kokiko-Cochran</LastName><ForeName>Olga N</ForeName><Initials>ON</Initials></Author><Author ValidYN="Y"><LastName>Cardona</LastName><ForeName>Astrid</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ransohoff</LastName><ForeName>Richard M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Lamb</LastName><ForeName>Bruce T</ForeName><Initials>BT</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG023012</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG023012</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015214">Antigens, Differentiation, Myelomonocytic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C067980">CD68 antigen, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073883">CX3C Chemokine Receptor 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017077">Culture Media, Conditioned</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C471885">Cx3cr1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011725">Pyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019707">Receptors, Chemokine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017472">Receptors, Interleukin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493487">Tlr4 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>OU13V1EYWQ</RegistryNumber><NameOfSubstance UI="C093642">SB 203580</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015214" MajorTopicYN="N">Antigens, Differentiation, Myelomonocytic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073883" MajorTopicYN="N">CX3C Chemokine Receptor 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017077" MajorTopicYN="N">Culture Media, Conditioned</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019707" MajorTopicYN="N">Receptors, Chemokine</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017472" MajorTopicYN="N">Receptors, Interleukin-1</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016622" MajorTopicYN="N">Silver Staining</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051197" MajorTopicYN="N">Toll-Like Receptor 4</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048051" MajorTopicYN="N">p38 Mitogen-Activated Protein Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>10</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20920788</ArticleId><ArticleId IdType="mid">NIHMS231562</ArticleId><ArticleId IdType="pmc">PMC2950825</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2010.08.023</ArticleId><ArticleId IdType="pii">S0896-6273(10)00633-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci. 2005;25:5446&#x2013;5454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725006</ArticleId><ArticleId IdType="pubmed">15930395</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, Duff K, Davies P. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem. 2003;86:582&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">12859672</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaskar K, Miller M, Chludzinski A, Herrup K, Zagorski M, Lamb BT. The PI3K-Akt-mTOR pathway regulates Abeta oligomer induced neuronal cell cycle events. Mol Neurodegener. 2009;4:14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663563</ArticleId><ArticleId IdType="pubmed">19291319</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1991;1:213&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">1669710</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, Huang D, Kidd G, Dombrowski S, Dutta R, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci. 2006;9:917&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">16732273</ArticleId></ArticleIdList></Reference><Reference><Citation>Combadiere C, Feumi C, Raoul W, Keller N, Rodero M, Pezard A, Lavalette S, Houssier M, Jonet L, Picard E, et al. CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. J Clin Invest. 2007;117:2920&#x2013;2928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1994614</ArticleId><ArticleId IdType="pubmed">17909628</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR, Lee JC. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 1995;364:229&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">7750577</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham C, Campion S, Lunnon K, Murray CL, Woods JF, Deacon RM, Rawlins JN, Perry VH. Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol Psychiatry. 2009;65:304&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2633437</ArticleId><ArticleId IdType="pubmed">18801476</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J Neurosci. 2005;25:9275&#x2013;9284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725757</ArticleId><ArticleId IdType="pubmed">16207887</ArticleId></ArticleIdList></Reference><Reference><Citation>Denes A, Ferenczi S, Halasz J, Kornyei Z, Kovacs KJ. Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. J Cereb Blood Flow Metab. 2008;28:1707&#x2013;1721.</Citation><ArticleIdList><ArticleId IdType="pubmed">18575457</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuhrmann M, Bittner T, Jung CK, Burgold S, Page RM, Mitteregger G, Haass C, LaFerla FM, Kretzschmar H, Herms J. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer&#x2019;s disease. Nat Neurosci. 2010;13:411&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4072212</ArticleId><ArticleId IdType="pubmed">20305648</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebicke-Haerter PJ. Microglia in neurodegeneration: molecular aspects. Microsc Res Tech. 2001;54:47&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">11526957</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerhard A, Trender-Gerhard I, Turkheimer F, Quinn NP, Bhatia KP, Brooks DJ. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. Mov Disord. 2006;21:89&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">16108021</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Hasegawa M, Jakes R, Lawler S, Cuenda A, Cohen P. Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases. FEBS Lett. 1997;409:57&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">9199504</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SG, Davies P. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci U S A. 1990;87:5827&#x2013;5831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54421</ArticleId><ArticleId IdType="pubmed">2116006</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK, Streit WJ, Salafranca MN, Adhikari S, Thompson DA, et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A. 1998;95:10896&#x2013;10901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27992</ArticleId><ArticleId IdType="pubmed">9724801</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartzler AW, Zhu X, Siedlak SL, Castellani RJ, Avila J, Perry G, Smith MA. The p38 pathway is activated in Pick disease and progressive supranuclear palsy: a mechanistic link between mitogenic pathways, oxidative stress, and tau. Neurobiol Aging. 2002;23:855&#x2013;859.</Citation><ArticleIdList><ArticleId IdType="pubmed">12392790</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauss-Wegrzyniak B, Lukovic L, Bigaud M, Stoeckel ME. Brain inflammatory response induced by intracerebroventricular infusion of lipopolysaccharide: an immunohistochemical study. Brain Res. 1998;794:211&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">9622633</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley K, Floyd RA, Zheng NY, Nael R, Robinson KA, Nguyen X, Pye QN, Stewart CA, Geddes J, Markesbery WR, et al. p38 kinase is activated in the Alzheimer&#x2019;s disease brain. J Neurochem. 1999;72:2053&#x2013;2058.</Citation><ArticleIdList><ArticleId IdType="pubmed">10217284</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes RN. The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory. Neurosci Biobehav Rev. 2004;28:497&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">15465137</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishizawa K, Dickson DW. Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration. J Neuropathol Exp Neurol. 2001;60:647&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pubmed">11398841</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez-Andrade JM, Peters CM, Mejia NA, Ghilardi JR, Kuskowski MA, Mantyh PW. Sensory neurons and their supporting cells located in the trigeminal, thoracic and lumbar ganglia differentially express markers of injury following intravenous administration of paclitaxel in the rat. Neurosci Lett. 2006;405:62&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">16854522</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, Littman DR. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol. 2000;20:4106&#x2013;4114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC85780</ArticleId><ArticleId IdType="pubmed">10805752</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelleher I, Garwood C, Hanger DP, Anderton BH, Noble W. Kinase activities increase during the development of tauopathy in htau mice. J Neurochem. 2007;103:2256&#x2013;2267.</Citation><ArticleIdList><ArticleId IdType="pubmed">17908241</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer&#x2019;s disease. J Neurosci. 2005;25:8843&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725603</ArticleId><ArticleId IdType="pubmed">16192374</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 1994;372:739&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">7997261</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Varvel NH, Konerth ME, Xu G, Cardona AE, Ransohoff RM, Lamb BT. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer&#x2019;s Disease mouse models. Am J Pathol. 2010 In Press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2966811</ArticleId><ArticleId IdType="pubmed">20864679</ArticleId></ArticleIdList></Reference><Reference><Citation>Lew J, Huang QQ, Qi Z, Winkfein RJ, Aebersold R, Hunt T, Wang JH. A brain-specific activator of cyclin-dependent kinase 5. Nature. 1994;371:423&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">8090222</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Liu L, Barger SW, Griffin WS. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci. 2003;23:1605&#x2013;1611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3833596</ArticleId><ArticleId IdType="pubmed">12629164</ArticleId></ArticleIdList></Reference><Reference><Citation>Lien E, Means TK, Heine H, Yoshimura A, Kusumoto S, Fukase K, Fenton MJ, Oikawa M, Qureshi N, Monks B, et al. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest. 2000;105:497&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC289161</ArticleId><ArticleId IdType="pubmed">10683379</ArticleId></ArticleIdList></Reference><Reference><Citation>Masocha W. Systemic lipopolysaccharide (LPS)-induced microglial activation results in different temporal reduction of CD200 and CD200 receptor gene expression in the brain. J Neuroimmunol. 2009;214:78&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">19656578</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan E, Eriksen J, Hutton M. A decade of modeling Alzheimer&#x2019;s disease in transgenic mice. Trends Genet. 2006;22:281&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">16567017</ArticleId></ArticleIdList></Reference><Reference><Citation>Meucci O, Fatatis A, Simen AA, Bushell TJ, Gray PW, Miller RJ. Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc Natl Acad Sci U S A. 1998;95:14500&#x2013;14505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24402</ArticleId><ArticleId IdType="pubmed">9826729</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno T, Kawanokuchi J, Numata K, Suzumura A. Production and neuroprotective functions of fractalkine in the central nervous system. Brain Res. 2003;979:65&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">12850572</ArticleId></ArticleIdList></Reference><Reference><Citation>Mocanu MM, Nissen A, Eckermann K, Khlistunova I, Biernat J, Drexler D, Petrova O, Schonig K, Bujard H, Mandelkow E, et al. The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy. J Neurosci. 2008;28:737&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670355</ArticleId><ArticleId IdType="pubmed">18199773</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble W, Garwood C, Stephenson J, Kinsey AM, Hanger DP, Anderton BH. Minocycline reduces the development of abnormal tau species in models of Alzheimer&#x2019;s disease. FASEB J. 2009;23:739&#x2013;750.</Citation><ArticleIdList><ArticleId IdType="pubmed">19001528</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer&#x2019;s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer&#x2019;s disease. Nature. 2009;461:916&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810658</ArticleId><ArticleId IdType="pubmed">19829371</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, Knapp DJ, Crews FT. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. 2007;55:453&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2871685</ArticleId><ArticleId IdType="pubmed">17203472</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintanilla RA, Orellana DI, Gonzalez-Billault C, Maccioni RB. Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res. 2004;295:245&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">15051507</ArticleId></ArticleIdList></Reference><Reference><Citation>Saez TE, Pehar M, Vargas M, Barbeito L, Maccioni RB. Astrocytic nitric oxide triggers tau hyperphosphorylation in hippocampal neurons. In Vivo. 2004;18:275&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">15341183</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura J, Tusell JM, Serratosa J. High-yield isolation of murine microglia by mild trypsinization. Glia. 2003;44:183&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">14603460</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Jones RA, Zhou XQ, McGinness JM, Van Eldik LJ, Mrak RE, Griffin WS. Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer&#x2019;s disease: potential significance for tau protein phosphorylation. Neurochem Int. 2001;39:341&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3833633</ArticleId><ArticleId IdType="pubmed">11578769</ArticleId></ArticleIdList></Reference><Reference><Citation>Soltys Z, Ziaja M, Pawlinski R, Setkowicz Z, Janeczko K. Morphology of reactive microglia in the injured cerebral cortex. Fractal analysis and complementary quantitative methods. J Neurosci Res. 2001;63:90&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">11169618</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun A, Liu M, Nguyen XV, Bing G. P38 MAP kinase is activated at early stages in Alzheimer&#x2019;s disease brain. Exp Neurol. 2003;183:394&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">14552880</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutherland C, Leighton IA, Cohen P. Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem J. 1993;296(Pt 1):15&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1137648</ArticleId><ArticleId IdType="pubmed">8250835</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai LH, Delalle I, Caviness VS, Jr, Chae T, Harlow E. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature. 1994;371:419&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">8090221</ArticleId></ArticleIdList></Reference><Reference><Citation>Varvel NH, Bhaskar K, Kounnas MZ, Wagner SL, Yang Y, Lamb BT, Herrup K. NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. J Clin Invest. 2009;119:3692&#x2013;3702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2786797</ArticleId><ArticleId IdType="pubmed">19907078</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17023659</PMID><DateCompleted><Year>2006</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>314</Volume><Issue>5796</Issue><PubDate><Year>2006</Year><Month>Oct</Month><Day>06</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>130</StartPage><EndPage>133</EndPage><MedlinePgn>130-3</MedlinePgn></Pagination><Abstract><AbstractText>Ubiquitin-positive, tau- and alpha-synuclein-negative inclusions are hallmarks of frontotemporal lobar degeneration with ubiquitin-positive inclusions and amyotrophic lateral sclerosis. Although the identity of the ubiquitinated protein specific to either disorder was unknown, we showed that TDP-43 is the major disease protein in both disorders. Pathologic TDP-43 was hyper-phosphorylated, ubiquitinated, and cleaved to generate C-terminal fragments and was recovered only from affected central nervous system regions, including hippocampus, neocortex, and spinal cord. TDP-43 represents the common pathologic substrate linking these neurodegenerative disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sampathu</LastName><ForeName>Deepak M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Kwong</LastName><ForeName>Linda K</ForeName><Initials>LK</Initials></Author><Author ValidYN="Y"><LastName>Truax</LastName><ForeName>Adam C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Micsenyi</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Chou</LastName><ForeName>Thomas T</ForeName><Initials>TT</Initials></Author><Author ValidYN="Y"><LastName>Bruce</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Schuck</LastName><ForeName>Theresa</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Grossman</LastName><ForeName>Murray</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>McCluskey</LastName><ForeName>Leo F</ForeName><Initials>LF</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Mackenzie</LastName><ForeName>Ian R</ForeName><Initials>IR</Initials></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Feiden</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Kretzschmar</LastName><ForeName>Hans A</ForeName><Initials>HA</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M-Y</ForeName><Initials>VM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG10124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG17586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG00255</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025801">Ubiquitin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2006 Oct 6;314(5796):42-3. doi: 10.1126/science.314.5796.42.</RefSource><PMID Version="1">17023628</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="Y">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015151" MajorTopicYN="N">Immunoblotting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025801" MajorTopicYN="N">Ubiquitin</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>10</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>10</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>10</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pii">314/5796/130</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19828810</PMID><DateCompleted><Year>2009</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>41</Issue><PubDate><Year>2009</Year><Month>Oct</Month><Day>14</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling.</ArticleTitle><Pagination><StartPage>12957</StartPage><EndPage>12969</EndPage><MedlinePgn>12957-69</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1064-09.2009</ELocationID><Abstract><AbstractText>Upon activation by calcineurin, the nuclear factor of activated T-cells (NFAT) translocates to the nucleus and guides the transcription of numerous molecules involved in inflammation and Ca(2+) dysregulation, both of which are prominent features of Alzheimer's disease (AD). However, NFAT signaling in AD remains relatively uninvestigated. Using isolated cytosolic and nuclear fractions prepared from rapid-autopsy postmortem human brain tissue, we show that NFATs 1 and 3 shifted to nuclear compartments in the hippocampus at different stages of neuropathology and cognitive decline, whereas NFAT2 remained unchanged. NFAT1 exhibited greater association with isolated nuclear fractions in subjects with mild cognitive impairment (MCI), whereas NFAT3 showed a strong nuclear bias in subjects with severe dementia and AD. Similar to NFAT1, calcineurin-Aalpha also exhibited a nuclear bias in the early stages of cognitive decline. But, unlike NFAT1 and similar to NFAT3, the nuclear bias for calcineurin became more pronounced as cognition worsened. Changes in calcineurin/NFAT3 were directly correlated to soluble amyloid-beta (Abeta((1-42))) levels in postmortem hippocampus, and oligomeric Abeta, in particular, robustly stimulated NFAT activation in primary rat astrocyte cultures. Oligomeric Abeta also caused a significant reduction in excitatory amino acid transporter 2 (EAAT2) protein levels in astrocyte cultures, which was blocked by NFAT inhibition. Moreover, inhibition of astrocytic NFAT activity in mixed cultures ameliorated Abeta-dependent elevations in glutamate and neuronal death. The results suggest that NFAT signaling is selectively altered in AD and may play an important role in driving Abeta-mediated neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abdul</LastName><ForeName>Hafiz Mohmmad</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>The Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky 40536, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sama</LastName><ForeName>Michelle A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Furman</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Mathis</LastName><ForeName>Diana M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Beckett</LastName><ForeName>Tina L</ForeName><Initials>TL</Initials></Author><Author ValidYN="Y"><LastName>Weidner</LastName><ForeName>Adam M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Ela S</ForeName><Initials>ES</Initials></Author><Author ValidYN="Y"><LastName>Baig</LastName><ForeName>Irfan</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>M Paul</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>LeVine</LastName><ForeName>Harry</ForeName><Initials>H</Initials><Suffix>3rd</Suffix></Author><Author ValidYN="Y"><LastName>Kraner</LastName><ForeName>Susan D</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Norris</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG027297</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG027297</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG010836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG024190</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005144</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG024190</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG010836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG02797</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005904">Glial Fibrillary Acidic Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050778">NFATC Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C485184">enhanced green fluorescent protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.16</RegistryNumber><NameOfSubstance UI="D019703">Calcineurin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019703" MajorTopicYN="N">Calcineurin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005904" MajorTopicYN="N">Glial Fibrillary Acidic Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050778" MajorTopicYN="N">NFATC Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>4</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19828810</ArticleId><ArticleId IdType="mid">NIHMS158049</ArticleId><ArticleId IdType="pmc">PMC2782445</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1064-09.2009</ArticleId><ArticleId IdType="pii">29/41/12957</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abbott KL, Friday BB, Thaloor D, Murphy TJ, Pavlath GK. Activation and cellular localization of the cyclosporine A-sensitive transcription factor NF-AT in skeletal muscle cells. Mol Biol Cell. 1998;9:2905&#x2013;2916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25565</ArticleId><ArticleId IdType="pubmed">9763451</ArticleId></ArticleIdList></Reference><Reference><Citation>Agostinho P, Lopes JP, Velez Z, Oliveira CR. Overactivation of calcineurin induced by amyloid-beta and prion proteins. Neurochem Int. 2008;52:1226&#x2013;1233.</Citation><ArticleIdList><ArticleId IdType="pubmed">18295934</ArticleId></ArticleIdList></Reference><Reference><Citation>Akama KT, Van Eldik LJ. Beta-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1beta- and tumor necrosis factor-alpha (TNFalpha)-dependent, and involves a TNFalpha receptor-associated factor- and NFkappaB-inducing kinase-dependent signaling mechanism. J Biol Chem. 2000;275:7918&#x2013;7924.</Citation><ArticleIdList><ArticleId IdType="pubmed">10713108</ArticleId></ArticleIdList></Reference><Reference><Citation>Akama KT, Albanese C, Pestell RG, Van Eldik LJ. Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NFkappaB-dependent mechanism. Proc Natl Acad Sci U S A. 1998;95:5795&#x2013;5800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20459</ArticleId><ArticleId IdType="pubmed">9576964</ArticleId></ArticleIdList></Reference><Reference><Citation>Aramburu J, Yaffe MB, L&#xf3;pez-Rodr&#xed;guez C, Cantley LC, Hogan PG, Rao A. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science. 1999;285:2129&#x2013;2133.</Citation><ArticleIdList><ArticleId IdType="pubmed">10497131</ArticleId></ArticleIdList></Reference><Reference><Citation>Arispe N, Rojas E, Pollard HB. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci U S A. 1993;90:567&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45704</ArticleId><ArticleId IdType="pubmed">8380642</ArticleId></ArticleIdList></Reference><Reference><Citation>Blalock EM, Chen KC, Sharrow K, Herman JP, Porter NM, Foster TC, Landfield PW. Gene microarrays in hippocampal aging: statistical profiling identifies novel processes correlated with cognitive impairment. J Neurosci. 2003;23:3807&#x2013;3819.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742177</ArticleId><ArticleId IdType="pubmed">12736351</ArticleId></ArticleIdList></Reference><Reference><Citation>Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A. 2004;101:2173&#x2013;2178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC357071</ArticleId><ArticleId IdType="pubmed">14769913</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasko I, Apochal A, Boeck G, Hartmann T, Grubeck-Loebenstein B, Ransmayr G. Ibuprofen decreases cytokine-induced amyloid beta production in neuronal cells. Neurobiol Dis. 2001;8:1094&#x2013;1101.</Citation><ArticleIdList><ArticleId IdType="pubmed">11741404</ArticleId></ArticleIdList></Reference><Reference><Citation>Canellada A, Ramirez BG, Minami T, Redondo JM, Cano E. Calcium/calcineurin signaling in primary cortical astrocyte cultures: Rcan1-4 and cyclooxygenase-2 as NFAT target genes. Glia. 2008;56:709&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pubmed">18293408</ArticleId></ArticleIdList></Reference><Reference><Citation>Celsi F, Svedberg M, Unger C, Cotman CW, Carr&#xec; MT, Ottersen OP, Nordberg A, Torp R. Beta-amyloid causes downregulation of calcineurin in neurons through induction of oxidative stress. Neurobiol Dis. 2007;26:342&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">17344052</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen QS, Wei WZ, Shimahara T, Xie CW. Alzheimer amyloid beta-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus. Neurobiol Learn Mem. 2002;77:354&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pubmed">11991763</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho HJ, Jin SM, Youn HD, Huh K, Mook-Jung I. Disrupted intracellular calcium regulates BACE1 gene expression via nuclear factor of activated T cells 1 (NFAT 1) signaling. Aging Cell. 2008;7:137&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">18081741</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook CN, Hejna MJ, Magnuson DJ, Lee JM. Expression of calcipressin1, an inhibitor of the phosphatase calcineurin, is altered with aging and Alzheimer's disease. J Alzheimers Dis. 2005;8:63&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">16155351</ArticleId></ArticleIdList></Reference><Reference><Citation>Crabtree GR, Olson EN. NFAT signaling: choreographing the social lives of cells. Cell. 2002;109(Suppl):S67&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">11983154</ArticleId></ArticleIdList></Reference><Reference><Citation>Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem. 2005;280:17294&#x2013;17300.</Citation><ArticleIdList><ArticleId IdType="pubmed">15722360</ArticleId></ArticleIdList></Reference><Reference><Citation>Dineley KT, Hogan D, Zhang WR, Taglialatela G. Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice. Neurobiol Learn Mem. 2007;88:217&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2031869</ArticleId><ArticleId IdType="pubmed">17521929</ArticleId></ArticleIdList></Reference><Reference><Citation>Ermak G, Morgan TE, Davies KJ. Chronic overexpression of the calcineurin inhibitory gene DSCR1 (Adapt78) is associated with Alzheimer's disease. J Biol Chem. 2001;276:38787&#x2013;38794.</Citation><ArticleIdList><ArticleId IdType="pubmed">11483593</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez AM, Fernandez S, Carrero P, Garcia-Garcia M, Torres-Aleman I. Calcineurin in reactive astrocytes plays a key role in the interplay between proinflammatory and anti-inflammatory signals. J Neurosci. 2007;27:8745&#x2013;8756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672188</ArticleId><ArticleId IdType="pubmed">17699657</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraccioli GF, Tomietto P, De Santis M. Rationale for T cell inhibition by cyclosporin A in major autoimmune diseases. Ann N Y Acad Sci. 2005;1051:658&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pubmed">16127006</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster TC, Sharrow KM, Masse JR, Norris CM, Kumar A. Calcineurin links Ca2+ dysregulation with brain aging. J Neurosci. 2001;21:4066&#x2013;4073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201477</ArticleId><ArticleId IdType="pubmed">11356894</ArticleId></ArticleIdList></Reference><Reference><Citation>Genoux D, Haditsch U, Knobloch M, Michalon A, Storm D, Mansuy IM. Protein phosphatase 1 is a molecular constraint on learning and memory. Nature. 2002;418:970&#x2013;975.</Citation><ArticleIdList><ArticleId IdType="pubmed">12198546</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong CX, Singh TJ, Grundke-Iqbal I, Iqbal K. Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem. 1993;61:921&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">8395566</ArticleId></ArticleIdList></Reference><Reference><Citation>Graef IA, Mermelstein PG, Stankunas K, Neilson JR, Deisseroth K, Tsien RW, Crabtree GR. L-type calcium channels and GSK-3 regulate the activity of NF-ATc4 in hippocampal neurons. Nature. 1999;401:703&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pubmed">10537109</ArticleId></ArticleIdList></Reference><Reference><Citation>Groth RD, Dunbar RL, Mermelstein PG. Calcineurin regulation of neuronal plasticity. Biochem Biophys Res Commun. 2003;311:1159&#x2013;1171.</Citation><ArticleIdList><ArticleId IdType="pubmed">14623302</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris ME, Carney JM, Cole PS, Hensley K, Howard BJ, Martin L, Bummer P, Wang Y, Pedigo NW, Jr, Butterfield DA. beta-Amyloid peptide-derived, oxygen-dependent free radicals inhibit glutamate uptake in cultured astrocytes: implications for Alzheimer's disease. Neuroreport. 1995;6:1875&#x2013;1879.</Citation><ArticleIdList><ArticleId IdType="pubmed">8547588</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris ME, Wang Y, Pedigo NW, Jr, Hensley K, Butterfield DA, Carney JM. Amyloid beta peptide (25&#x2013;35) inhibits Na+-dependent glutamate uptake in rat hippocampal astrocyte cultures. J Neurochem. 1996;67:277&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">8667003</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto T, Kawamata T, Saito N, Sasaki M, Nakai M, Niu S, Taniguchi T, Terashima A, Yasuda M, Maeda K, Tanaka C. Isoform-specific redistribution of calcineurin A alpha and A beta in the hippocampal CA1 region of gerbils after transient ischemia. J Neurochem. 1998;70:1289&#x2013;1298.</Citation><ArticleIdList><ArticleId IdType="pubmed">9489752</ArticleId></ArticleIdList></Reference><Reference><Citation>Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol. 2006;7:589&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">16936699</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilioti Z, Gallagher DA, Low-Nam ST, Ramaswamy P, Gajer P, Kingsbury TJ, Birchwood CJ, Levchenko A, Cunningham KW. GSK-3 kinases enhance calcineurin signaling by phosphorylation of RCNs. Genes Dev. 2004;18:35&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314273</ArticleId><ArticleId IdType="pubmed">14701880</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogan PG, Chen L, Nardone J, Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev. 2003;17:2205&#x2013;2232.</Citation><ArticleIdList><ArticleId IdType="pubmed">12975316</ArticleId></ArticleIdList></Reference><Reference><Citation>Horsley V, Pavlath GK. NFAT: ubiquitous regulator of cell differentiation and adaptation. J Cell Biol. 2002;156:771&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173310</ArticleId><ArticleId IdType="pubmed">11877454</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaminuma O. Selective inhibitors of nuclear factor of activated T cells: potential therapeutic drugs for the treatment of immunological and inflammatory diseases. Inflamm Allergy Drug Targets. 2008;7:35&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">18473899</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara M, Kuroda Y. Molecular mechanism of neurodegeneration induced by Alzheimer's beta-amyloid protein: channel formation and disruption of calcium homeostasis. Brain Res Bull. 2000;53:389&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">11136994</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, Glabe CG. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem. 2004;279:46363&#x2013;46366.</Citation><ArticleIdList><ArticleId IdType="pubmed">15385542</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller JN, Pang Z, Geddes JW, Begley JG, Germeyer A, Waeg G, Mattson MP. Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: role of the lipid peroxidation product 4-hydroxynonenal. J Neurochem. 1997;69:273&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">9202320</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchibhotla KV, Goldman ST, Lattarulo CR, Wu HY, Hyman BT, Bacskai BJ. Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron. 2008;59:214&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2578820</ArticleId><ArticleId IdType="pubmed">18667150</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladner CJ, Czech J, Maurice J, Lorens SA, Lee JM. Reduction of calcineurin enzymatic activity in Alzheimer's disease: correlation with neuropathologic changes. J Neuropathol Exp Neurol. 1996;55:924&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pubmed">8759782</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange AW, Molkentin JD, Yutzey KE. DSCR1 gene expression is dependent on NFATc1 during cardiac valve formation and colocalizes with anomalous organ development in trisomy 16 mice. Dev Biol. 2004;266:346&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">14738882</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y, Messing A, Su M, Brenner M. GFAP promoter elements required for region-specific and astrocyte-specific expression. Glia. 2008;56:481&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">18240313</ArticleId></ArticleIdList></Reference><Reference><Citation>LeVine H., 3rd Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 1999;309:274&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">10507030</ArticleId></ArticleIdList></Reference><Reference><Citation>LeVine H., 3rd Alzheimer's beta-peptide oligomer formation at physiologic concentrations. Anal Biochem. 2004;335:81&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">15519574</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D. Soluble oligomers of amyloid beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron. 2009;62:788&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702854</ArticleId><ArticleId IdType="pubmed">19555648</ArticleId></ArticleIdList></Reference><Reference><Citation>Lian Q, Ladner CJ, Magnuson D, Lee JM. Selective changes of calcineurin (protein phosphatase 2B) activity in Alzheimer's disease cerebral cortex. Exp Neurol. 2001;167:158&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11161603</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Grundke-Iqbal I, Iqbal K, Oda Y, Tomizawa K, Gong CX. Truncation and activation of calcineurin A by calpain I in Alzheimer disease brain. J Biol Chem. 2005;280:37755&#x2013;37762.</Citation><ArticleIdList><ArticleId IdType="pubmed">16150694</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Busby JC, Molkentin JD. Interaction between TAK1-TAB1-TAB2 and RCAN1-calcineurin defines a signalling nodal control point. Nat Cell Biol. 2009;11:154&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656285</ArticleId><ArticleId IdType="pubmed">19136967</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund P. l-Glutamine and l-glutamate: UV-method with glutaminase and glutamate dehydrogenase. In: Bergmeyer HU, editor. Methods of enzymatic analysis. Vol 8. Weinheim, Germany: VCH Verlagsgesellschaft; 1986.</Citation></Reference><Reference><Citation>Luoma JI, Zirpel L. Deafferentation-induced activation of NFAT (nuclear factor of activated T-cells) in cochlear nucleus neurons during a developmental critical period: a role for NFATc4-dependent apoptosis in the CNS. J Neurosci. 2008;28:3159&#x2013;3169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670723</ArticleId><ArticleId IdType="pubmed">18354019</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005;47:191&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1373682</ArticleId><ArticleId IdType="pubmed">16039562</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Morihara T, Chu T, Ubeda O, Beech W, Cole GM. Selective inhibition of Abeta42 production by NSAID R-enantiomers. J Neurochem. 2002;83:1009&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pubmed">12421374</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrak RE, Griffin WS. Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging. 2005a;26:349&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">15639313</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrak RE, Griffin WS. Potential inflammatory biomarkers in Alzheimer's disease. J Alzheimers Dis. 2005b;8:369&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">16556968</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy MP, Beckett TL, Ding Q, Patel E, Markesbery WR, St Clair DK, LeVine H, 3rd, Keller JN. Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. Neurobiol Dis. 2007;27:301&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">17651976</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging. 1997;18:S1&#x2013;S2.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330978</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Jicha GA, Schmitt FA, Liu H, Davis DG, Mendiondo MS, Abner EL, Markesbery WR. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles &#x201c;do count&#x201d; when staging disease severity. J Neuropathol Exp Neurol. 2007;66:1136&#x2013;1146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034246</ArticleId><ArticleId IdType="pubmed">18090922</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen T, Di Giovanni S. NFAT signaling in neural development and axon growth. Int J Dev Neurosci. 2008;26:141&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2267928</ArticleId><ArticleId IdType="pubmed">18093786</ArticleId></ArticleIdList></Reference><Reference><Citation>Noguchi H, Matsushita M, Okitsu T, Moriwaki A, Tomizawa K, Kang S, Li ST, Kobayashi N, Matsumoto S, Tanaka K, Tanaka N, Matsui H. A new cell-permeable peptide allows successful allogeneic islet transplantation in mice. Nat Med. 2004;10:305&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">14770176</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris CM, Blalock EM, Chen KC, Porter NM, Landfield PW. Calcineurin enhances L-type Ca(2+) channel activity in hippocampal neurons: increased effect with age in culture. Neuroscience. 2002;110:213&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1473990</ArticleId><ArticleId IdType="pubmed">11958864</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris CM, Kadish I, Blalock EM, Chen KC, Thibault V, Porter NM, Landfield PW, Kraner SD. Calcineurin triggers reactive/inflammatory processes in astrocytes and is upregulated in aging and Alzheimer's models. J Neurosci. 2005;25:4649&#x2013;4658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201418</ArticleId><ArticleId IdType="pubmed">15872113</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris CM, Blalock EM, Thibault O, Brewer LD, Clodfelter GV, Porter NM, Landfield PW. Electrophysiological mechanisms of delayed excitotoxicity: positive feedback loop between NMDA receptor current and depolarization-mediated glutamate release. J Neurophysiol. 2006;96:2488&#x2013;2500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756090</ArticleId><ArticleId IdType="pubmed">16914613</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris CM, Blalock EM, Chen KC, Porter NM, Thibault O, Kraner SD, Landfield PW. Hippocampal &#x2018;zipper&#x2019; slice studies reveal a necessary role for calcineurin in the increased activity of L-type Ca(2+) channels with aging. Neurobiol Aging. 2008 doi: 10.1016/j.neurobiolaging.2008.03.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2008.03.026</ArticleId><ArticleId IdType="pmc">PMC2795015</ArticleId><ArticleId IdType="pubmed">18471936</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohlsson H, Edlund T. Sequence-specific interactions of nuclear factors with the insulin gene enhancer. Cell. 1986;45:35&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">3006925</ArticleId></ArticleIdList></Reference><Reference><Citation>Parpura-Gill A, Beitz D, Uemura E. The inhibitory effects of beta-amyloid on glutamate and glucose uptakes by cultured astrocytes. Brain Res. 1997;754:65&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">9134960</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Pihlaja R, Koistinaho J, Malm T, Sikkil&#xe4; H, Vainio S, Koistinaho M. Transplanted astrocytes internalize deposited beta-amyloid peptides in a transgenic mouse model of Alzheimer's disease. Glia. 2008;56:154&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">18004725</ArticleId></ArticleIdList></Reference><Reference><Citation>Porter NM, Thibault O, Thibault V, Chen KC, Landfield PW. Calcium channel density and hippocampal cell death with age in long-term culture. J Neurosci. 1997;17:5629&#x2013;5639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793822</ArticleId><ArticleId IdType="pubmed">9204944</ArticleId></ArticleIdList></Reference><Reference><Citation>Reese LC, Zhang W, Dineley KT, Kayed R, Taglialatela G. Selective induction of calcineurin activity and signaling by oligomeric amyloid beta. Aging Cell. 2008;7:824&#x2013;835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2954114</ArticleId><ArticleId IdType="pubmed">18782350</ArticleId></ArticleIdList></Reference><Reference><Citation>Sama MA, Mathis DM, Furman JL, Abdul HM, Artiushin IA, Kraner SD, Norris CM. Interleukin-1beta-dependent signaling between astrocytes and neurons depends critically on astrocytic calcineurin/NFAT activity. J Biol Chem. 2008;283:21953&#x2013;21964.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2494911</ArticleId><ArticleId IdType="pubmed">18541537</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanna B, Brandt EB, Kaiser RA, Pfluger P, Witt SA, Kimball TR, van Rooij E, De Windt LJ, Rothenberg ME, Tschop MH, Benoit SC, Molkentin JD. Modulatory calcineurin-interacting proteins 1 and 2 function as calcineurin facilitators in vivo. Proc Natl Acad Sci U S A. 2006;103:7327&#x2013;7332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1464340</ArticleId><ArticleId IdType="pubmed">16648267</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Shioda N, Han F, Moriguchi S, Fukunaga K. Constitutively active calcineurin mediates delayed neuronal death through Fas-ligand expression via activation of NFAT and FKHR transcriptional activities in mouse brain ischemia. J Neurochem. 2007;102:1506&#x2013;1517.</Citation><ArticleIdList><ArticleId IdType="pubmed">17662023</ArticleId></ArticleIdList></Reference><Reference><Citation>Sierra-Paredes G, Sierra-Marcu&#xf1;o G. Ascomycin and FK506: pharmacology and therapeutic potential as anticonvulsants and neuroprotectants. CNS Neurosci Ther. 2008;14:36&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6494028</ArticleId><ArticleId IdType="pubmed">18482098</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson JE, Ince PG, Lace G, Forster G, Shaw PJ, Matthews F, Savva G, Brayne C, Wharton SB. Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiol Aging. 2008 doi: 10.1016/j.neurobiolaging.2008.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2008.05.015</ArticleId><ArticleId IdType="pubmed">18586353</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokolov Y, Kozak JA, Kayed R, Chanturiya A, Glabe C, Hall JE. Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J Gen Physiol. 2006;128:637&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2151594</ArticleId><ArticleId IdType="pubmed">17101816</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Eldik LJ, Thompson WL, Ralay Ranaivo H, Behanna HA, Martin Watterson D. Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches. Int Rev Neurobiol. 2007;82:277&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">17678967</ArticleId></ArticleIdList></Reference><Reference><Citation>Vihma H, Pruunsild P, Timmusk T. Alternative splicing and expression of human and mouse NFAT genes. Genomics. 2008;92:279&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577130</ArticleId><ArticleId IdType="pubmed">18675896</ArticleId></ArticleIdList></Reference><Reference><Citation>Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001;414:212&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">11700559</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res. 2004;94:110&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">14656927</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006;12:1005&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pubmed">16960575</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, Silverstein SC, Husemann J. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med. 2003;9:453&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">12612547</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL, Citron M, Landreth G. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci. 2003;23:7504&#x2013;7509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740758</ArticleId><ArticleId IdType="pubmed">12930788</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, McKeon F. NF-AT activation requires suppression of Crm1-dependent export by calcineurin. Nature. 1999;398:256&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">10094050</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21085570</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>11</Issue><PubDate><Year>2010</Year><Month>Nov</Month><Day>15</Day></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>e13950</StartPage><MedlinePgn>e13950</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e13950</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0013950</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Late Onset Alzheimer's disease (LOAD) is the leading cause of dementia. Recent large genome-wide association studies (GWAS) identified the first strongly supported LOAD susceptibility genes since the discovery of the involvement of APOE in the early 1990s. We have now exploited these GWAS datasets to uncover key LOAD pathophysiological processes.</AbstractText><AbstractText Label="METHODOLOGY" NlmCategory="METHODS">We applied a recently developed tool for mining GWAS data for biologically meaningful information to a LOAD GWAS dataset. The principal findings were then tested in an independent GWAS dataset.</AbstractText><AbstractText Label="PRINCIPAL FINDINGS" NlmCategory="RESULTS">We found a significant overrepresentation of association signals in pathways related to cholesterol metabolism and the immune response in both of the two largest genome-wide association studies for LOAD.</AbstractText><AbstractText Label="SIGNIFICANCE" NlmCategory="CONCLUSIONS">Processes related to cholesterol metabolism and the innate immune response have previously been implicated by pathological and epidemiological studies of Alzheimer's disease, but it has been unclear whether those findings reflected primary aetiological events or consequences of the disease process. Our independent evidence from two large studies now demonstrates that these processes are aetiologically relevant, and suggests that they may be suitable targets for novel and existing therapeutic approaches.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Lesley</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine and Neurology, School of Medicine, Cardiff University, Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Cardiff, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmans</LastName><ForeName>Peter A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Hamshere</LastName><ForeName>Marian L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Harold</LastName><ForeName>Denise</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Moskvina</LastName><ForeName>Valentina</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Ivanov</LastName><ForeName>Dobril</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Pocklington</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Abraham</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Hollingworth</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Sims</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Gerrish</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Pahwa</LastName><ForeName>Jaspreet Singh</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Stretton</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>Angharad R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Lovestone</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Proitsi</LastName><ForeName>Petroula</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lupton</LastName><ForeName>Michelle K</ForeName><Initials>MK</Initials></Author><Author ValidYN="Y"><LastName>Brayne</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Rubinsztein</LastName><ForeName>David C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lawlor</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Aoibhinn</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Kristelle S</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Passmore</LastName><ForeName>Peter A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>McGuinness</LastName><ForeName>Bernadette</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Todd</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Clive</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Mann</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>A David</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Love</LastName><ForeName>Seth</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kehoe</LastName><ForeName>Patrick G</ForeName><Initials>PG</Initials></Author><Author ValidYN="Y"><LastName>Mead</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Collinge</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Maier</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Jessen</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Sch&#xfc;rmann</LastName><ForeName>Britta</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Heun</LastName><ForeName>Reinhard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>K&#xf6;lsch</LastName><ForeName>Heike</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>van den Bussche</LastName><ForeName>Hendrik</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Heuser</LastName><ForeName>Isabella</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Kornhuber</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wiltfang</LastName><ForeName>Jens</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Dichgans</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Fr&#xf6;lich</LastName><ForeName>Lutz</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>Harald</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>H&#xfc;ll</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Rujescu</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Kauwe</LastName><ForeName>John S K</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Nowotny</LastName><ForeName>Petra</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Mayo</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Livingston</LastName><ForeName>Gill</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Bass</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials></Author><Author ValidYN="Y"><LastName>Gurling</LastName><ForeName>Hugh</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>McQuillin</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Gwilliam</LastName><ForeName>Rhian</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Deloukas</LastName><ForeName>Panos</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Guerreiro</LastName><ForeName>Rita</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>M&#xfc;hleisen</LastName><ForeName>Thomas W</ForeName><Initials>TW</Initials></Author><Author ValidYN="Y"><LastName>N&#xf6;then</LastName><ForeName>Markus M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Moebus</LastName><ForeName>Susanne</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>J&#xf6;ckel</LastName><ForeName>Karl-Heinz</ForeName><Initials>KH</Initials></Author><Author ValidYN="Y"><LastName>Klopp</LastName><ForeName>Norman</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Wichmann</LastName><ForeName>H-Erich</ForeName><Initials>HE</Initials></Author><Author ValidYN="Y"><LastName>R&#xfc;ther</LastName><ForeName>Eckhard</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Carrasquillo</LastName><ForeName>Minerva M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Pankratz</LastName><ForeName>V Shane</ForeName><Initials>VS</Initials></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>O'Donovan</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Owen</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U123192748</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U123160651</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0600974</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0300429</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>Z01 AG000950</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0900688</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0601846</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>Z01 AG000950-06</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0801418</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>11</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>PLoS One. 2011;6(2). doi:10.1371/annotation/a0bb886d-d345-4a20-a82e-adce9b047798</RefSource><Note>Heun, Reinhard [added]; K&#xf6;lsch, Heike [added]</Note></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015894" MajorTopicYN="N">Genome, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007107" MajorTopicYN="N">Immune System</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>Profs Owen, J Williams and Dr Harold have a patent application in respect of genes identified in the GWAS Harold et al. Nature Genetics 2009;41(10):1088&#x2013;93; this study provided data for this manuscript and was funded by the MRC and the Wellcome Trust. Dr Passmore has consulted for Pfizer and received compensation. Dr Hull has been funded by Wyeth and consulted for Pfizer, Wyeth and Merz; he has a patent pending for AD diagnostic tests. Dr Lynch has received travel expenses from Pfizer and Novartis. Prof Goate's work has been funded by NIH and AHAF. Prof Fox is a board member of the Alzheimer's Research Forum, has consulted for Abbott Laboratories and has received compensation for consulting for GE Healthcare. He has a patent for QA Box that did not arise from this work which contributes funds to his institution. Dr Morris is funded by NIA. Dr Livingston has received compensation from Lundbeck sa. Ms Stretton holds a CASE PhD studentship jointly funded by MRC and GSK. The remaining authors declare no potential conflict of interest. This does not alter the authors' adherence to all the PloS ONE policies on sharing data and materials.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>11</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21085570</ArticleId><ArticleId IdType="pmc">PMC2981526</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0013950</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925369</ArticleId></ArticleIdList></Reference><Reference><Citation>Wancata J, Musalek M, Alexandrowicz R, Krautgartner M. Number of dementia sufferers in Europe between the years 2000 and 2050. Eur Psychiatry. 2003;18:306&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pubmed">14611926</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63:168&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006;368:387&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem. 2009;110:1129&#x2013;1134.</Citation><ArticleIdList><ArticleId IdType="pubmed">19457065</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L. Alzheimer's disease genetics current status and future perspectives. Int Rev Neurobiol. 2009;84:167&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">19501718</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics. 2009;41:1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J-C, Heath S, Even G, Campion D, Sleegers K, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature Genetics. 2009;41:1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Corneveaux JJ, Myers AJ, Allen AN, Pruzin JJ, Ramirez M, et al. Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet 2010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2908469</ArticleId><ArticleId IdType="pubmed">20534741</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasquillo MM, Belbin O, Hunter TA, Ma L, Bisceglio GD, et al. Replication of CLU, CR1, and PICALM Associations With Alzheimer Disease. Arch Neurol 2010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919638</ArticleId><ArticleId IdType="pubmed">20554627</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Benyamin B, McEvoy BP, Gordon S, Henders AK, et al. Common SNPs explain a large proportion of the heritability for human height. Nat Genet 2010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3232052</ArticleId><ArticleId IdType="pubmed">20562875</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschhorn JN. Genomewide association studies&#x2013;illuminating biologic pathways. N Engl J Med. 2009;360:1699&#x2013;1701.</Citation><ArticleIdList><ArticleId IdType="pubmed">19369661</ArticleId></ArticleIdList></Reference><Reference><Citation>Baranzini SE, Galwey NW, Wang J, Khankhanian P, Lindberg R, et al. Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet. 2009;18:2078&#x2013;2090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678928</ArticleId><ArticleId IdType="pubmed">19286671</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie MD. Using prior knowledge and genome-wide association to identify pathways involved in multiple sclerosis. Genome Med. 2009;1:65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2703874</ArticleId><ArticleId IdType="pubmed">19566917</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Li M, Bucan M. Pathway-Based Approaches for Analysis of Genomewide Association Studies. Am J Hum Genet. 2007;81</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2276352</ArticleId><ArticleId IdType="pubmed">17966091</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmans P, Green EK, Pahwa JS, Ferreira MA, Purcell SM, et al. Gene ontology analysis of GWA study data sets provides insights into the biology of bipolar disorder. Am J Hum Genet. 2009;85:13&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2706963</ArticleId><ArticleId IdType="pubmed">19539887</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Moskvina V, Schmidt KM. On multiple-testing correction in genome-wide association studies. Genet Epidemiol. 2008;32:567&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pubmed">18425821</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris MA, Clark J, Ireland A, Lomax J, Ashburner M, et al. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res. 2004;32:D258&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC308770</ArticleId><ArticleId IdType="pubmed">14681407</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, et al. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res. 2006;34:D354&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1347464</ArticleId><ArticleId IdType="pubmed">16381885</ArticleId></ArticleIdList></Reference><Reference><Citation>Bult CJ, Eppig JT, Kadin JA, Richardson JE, Blake JA. The Mouse Genome Database (MGD): mouse biology and model systems. Nucleic Acids Res. 2008;36:D724&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2238849</ArticleId><ArticleId IdType="pubmed">18158299</ArticleId></ArticleIdList></Reference><Reference><Citation>Simes RJ. Am improved Bonferroni-type procedure for multiple tests of significance. Biometrika. 1986;73:751&#x2013;754.</Citation></Reference><Reference><Citation>Hong MG, Pawitan Y, Magnusson PK, Prince JA. Strategies and issues in the detection of pathway enrichment in genome-wide association studies. Hum Genet. 2009;126:289&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2865249</ArticleId><ArticleId IdType="pubmed">19408013</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Grenier-Boley B, Chouraki V, Heath S, Zelenika D, et al. Implication of the Immune System in Alzheimer's Disease: Evidence from Genome-Wide Pathway Analysis. J Alzheimers Dis 2010</Citation><ArticleIdList><ArticleId IdType="pubmed">20413860</ArticleId></ArticleIdList></Reference><Reference><Citation>Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719288</ArticleId><ArticleId IdType="pubmed">17554300</ArticleId></ArticleIdList></Reference><Reference><Citation>Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006:CD005593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006343</ArticleId><ArticleId IdType="pubmed">16437532</ArticleId></ArticleIdList></Reference><Reference><Citation>Camon EB, Barrell DG, Dimmer EC, Lee V, Magrane M, et al. An evaluation of GO annotation retrieval for BioCreAtIvE and GOA. BMC Bioinformatics. 2005;6(Suppl 1):S17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1869009</ArticleId><ArticleId IdType="pubmed">15960829</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CA, Hong MG, Eriksson UK, Blennow K, Wiklund F, et al. Analysis of lipid pathway genes indicates association of sequence variation near SREBF1/TOM1L2/ATPAF2 with dementia risk. Hum Mol Genet. 2010;19:2068&#x2013;2078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2860895</ArticleId><ArticleId IdType="pubmed">20167577</ArticleId></ArticleIdList></Reference><Reference><Citation>Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry. 2008;16:343&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">18448847</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006;12:1005&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pubmed">16960575</ArticleId></ArticleIdList></Reference><Reference><Citation>Duron E, Hanon O. Vascular risk factors, cognitive decline, and dementia. Vasc Health Risk Manag. 2008;4:363&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2496986</ArticleId><ArticleId IdType="pubmed">18561512</ArticleId></ArticleIdList></Reference><Reference><Citation>Weggen S, Rogers M, Eriksen J. NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development? Trends Pharmacol Sci. 2007;28:536&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pubmed">17900710</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci. 2009;10:333&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2908393</ArticleId><ArticleId IdType="pubmed">19339974</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, et al. ApoE promotes the proteolytic degradation of Abeta. Neuron. 2008;58:681&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493297</ArticleId><ArticleId IdType="pubmed">18549781</ArticleId></ArticleIdList></Reference><Reference><Citation>Koudinov AR, Berezov TT, Kumar A, Koudinova NV. Alzheimer's amyloid beta interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids. Clin Chim Acta. 1998;270:75&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">9544446</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer EG, McGeer PL. Innate immunity in Alzheimer's disease: a model for local inflammatory reactions. Mol Interv. 2001;1:22&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">14993335</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasko I, Stampfer-Kountchev M, Robatscher P, Veerhuis R, Eikelenboom P, et al. How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell. 2004;3:169&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">15268750</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007;10:1387&#x2013;1394.</Citation><ArticleIdList><ArticleId IdType="pubmed">17965659</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates KA, Verdile G, Li QX, Ames D, Hudson P, et al. Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry. 2009;14:469&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">18794889</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>